Tuberculosis surveillance and monitoring in Europe 2022 : 2020 data.
Date: 2022-06-08
Institutions: European Centre for Disease Prevention and Control
Subjects: Europe, disease prevention, disease surveillance, health statistics, infectious disease, public health, report

Tuberculosis surveillance 
and monitoring in Europe 

2022

2020 data

Tuberculosis surveillance 
and monitoring in Europe
2022

2020 data

Abstract

This report provides an overview of the latest tuberculosis (TB) epidemiological situation and is published jointly by the 
WHO Regional Office for Europe and the European Centre for Disease Prevention and Control (ECDC). It finds a sharp 24% 
drop in notified new and relapse TB cases between 2019 and 2020 which is due, in part, to decreased case detection and 
reporting as a result of the public health and social measures introduced by countries in response to the COVID-19 pandemic. 
Despite the potential issues of underdiagnosis and underreporting in 2020, 163 602 incident TB cases were notified in the 
European Region. The epidemic patterns and trends vary widely, with European Union/European Economic Area countries 
approaching the low incidence level of below 10 per 100 000 population, while the Region has nine of the 30 countries with 
the highest multidrug-resistant TB burden in the world.

Keywords
TUBERCULOSIS – EPIDEMIOLOGY
TB – EPIDEMIOLOGY
TB SURVEILLANCE

©  World  Health  Organization  and  the  European  Centre  for 
Disease Prevention and Control, 2022

Some rights reserved. This work is available under the Creative 
Commons Attribution- 3.0 IGO licence (CC BY-3.0 IGO; Creative 
Commons — Attribution 3.0 IGO — CC BY 3.0 IGO). 

Under the terms of this licence, you may copy, redistribute and 
adapt the work, even commercially, provided the work is appro-
priately cited, as indicated below. In any use of this work, there 
should be no suggestion that WHO or ECDC endorse any specific 
organization, products or services. The use of the WHO or ECDC 
logo is not permitted. If you adapt the work, then you must 
license your work under the same or equivalent Creative Commons 
licence. If you create a translation of this work, you should add 
the following disclaimer along with the suggested citation: “This 
translation was not created by the World Health Organization 
(WHO) or the European Centre for Disease Prevention and Control 
(ECDC). WHO and ECDC are not responsible for the content or 
accuracy of this translation. The original English edition shall 
be the binding and authentic edition”. 

Suggested citation. European Centre for Disease Prevention and 
Control, WHO Regional Office for Europe. Tuberculosis surveil-
lance and monitoring in Europe 2022 – 2020 data.  Copenhagen: 
WHO Regional Office for Europe and Stockholm: European Centre 
for Disease Prevention and Control; 2022. Licence: CC BY 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at 
http://apps.who.int/iris.

Sales, rights and licensing. To purchase WHO publications, see 
http://apps.who.int/bookorders. To submit requests for commer -
cial use and queries on rights and licensing, see http://www.
who.int/about/licensing. 

Third-party materials. If you wish to reuse material from this 
work that is attributed to a third party, such as tables, figures 
or images, it is your responsibility to determine whether permis-
sion is needed for that reuse and to obtain permission from the 
copyright holder. The risk of claims resulting from infringement 
of any third-party-owned component in the work rests solely 
with the user.

Maps. Except as otherwise stated, all maps included in this 
publication are WHO copyrighted. Reproduction or translation 
of  substantial  portions  of  the  maps  require  explicit,  prior 

authorization of WHO. To request permission to use the maps, 
please complete the permissions form available by this link: 
https://www.who.int/about/who-we-are/publishing-policies/
permissions 

WHO photographs. WHO photographs are copyrighted and are 
not to be reproduced in any medium without obtaining prior 
written permission. Requests for permission to reproduce WHO 
photographs should be addressed to: http://www.who.int/
about/licensing/copyright_form/en/ 

Cover picture: © Science Photo Library 

General disclaimers. The designations employed and the pres-
entation of the material in this publication do not imply the 
expression of any opinion whatsoever on the part of the World 
Health Organization and ECDC concerning the legal status of 
any  country,  territory,  area  or  city  or  of  its  authorities,  or 
concerning the delimitation of its frontiers or boundaries. Dotted 
lines on maps represent approximate border lines for which 
there may not yet be full agreement.

The mention of specific companies or of certain manufacturers’ 
products does not imply that they are endorsed or recommended 
by the World Health Organization and ECDC in preference to 
others of a similar nature that are not mentioned. Errors and 
omissions excepted, the names of proprietary products are 
distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health 
Organization and ECDC to verify the information contained in 
this publication. However, the published material is being distrib-
uted without warranty of any kind, either expressed or implied. 
The responsibility for the interpretation and use of the material 
lies  with  the  reader.  In  no  event  shall  the  World  Health 
Organization and ECDC be liable for damages arising from its 
use. 

The WHO Regional Office for Europe is responsible for the accu-
racy of the translation of the Russian summary.

This publication follows WHO institutional style guidelines which 
reflects the WHO Style Guide with regard to names and designa-
tion of countries, territories, areas or cities, or of their authori-
ties. The names and designations of countries, territories, areas 
and cities used in this publication should not be understood as 
an endorsement by ECDC of the terminology used. 

ECDC PDF  

ISBN 978-92-9498-567-5	

ISSN 2443-5538	

doi 10.2900/488579	

TQ-AO-22-001-EN-N		

WHO 

ISBN 978-92-890-5782-0

Contents

Acknowledgements ............................................................................................................................................................................................................................................. 

v

Abbreviations .........................................................................................................................................................................................................................................................    vi

Executive summary/Резюме .........................................................................................................................................................................................................   vii

 1. Main facts about tuberculosis ...........................................................................................................................................................................................  

1

References ..................................................................................................................................................................................................................................................................   2

2. Technical note ...............................................................................................................................................................................................................................................  
2.1 Data-reporting and analysis ..............................................................................................................................................................................................................  

5

7

2.2 Definitions .........................................................................................................................................................................................................................................................   9

References ..................................................................................................................................................................................................................................................................   11

3. Commentary ....................................................................................................................................................................................................................................................   13
3.1 The WHO European Region .................................................................................................................................................................................................................   15

3.2 EU/EEA countries.........................................................................................................................................................................................................................................   22

References ..................................................................................................................................................................................................................................................................   26

4. Commentary – monitoring  ......................................................................................................................................................................................................   29
4.1 WHO European Region ............................................................................................................................................................................................................................   31

4.2 European Union and European Economic Area countries ......................................................................................................................................   41

References ..................................................................................................................................................................................................................................................................   49

5. Annexes ..................................................................................................................................................................................................................................................................   51
Annex 1. Tuberculosis surveillance system overview, EU/EEA, 2020 ...................................................................................................................   53

Annex 2. List of variables for 2020 tuberculosis data collection ..............................................................................................................................   54

Annex 3. Completeness of data reported for 2020, EU/EEA ..........................................................................................................................................   55

Annex 4. Reporting completeness into Global TB Database, 2020.........................................................................................................................   56

Annex 5. Laboratory network capacity, European Region, 2020 ................................................................................................................................   57

Annex 6. Monitoring framework for follow up of the Tuberculosis Action Plan for  
the WHO European Region, 2016–2020 ...........................................................................................................................................................................................   58

6. Tables .........................................................................................................................................................................................................................................................................   61

7. Trend tables ......................................................................................................................................................................................................................................................   101

8. Country profiles ........................................................................................................................................................................................................................................   121

iii

Tables 
Summary table. Tuberculosis (TB) surveillance data by region, European Region, 2020  .................................................................................................................   63
Estimates of the TB disease burden, European Region, 2020...................................................................................................................................................   64
Table 1.  
Table 2.   Estimates for TB/HIV coinfection and RR-TB, European Region, 2020 ..................................................................................................................................   66
TB cases, notification rates per 100 000 population and mean annual change in rates, European Region, 2016–2020 ..........................   68
TB cases by history of previous TB treatment, European Region, 2020 ..............................................................................................................................   69
TB cases by site of disease, EU/EEA, 2020 .........................................................................................................................................................................................   70

Table 4.  

Table 3.  

Table 5.  

Table 6.  

 TB cases by history of previous TB treatment, site of disease and diagnostic method, according to WHO definitions, European 
Region, 2020 .......................................................................................................................................................................................................................................................   71
TB cases according to EU case definition, EU/EEA, 2020 ............................................................................................................................................................   72
Table 7.  
Table 8.   New and relapse TB cases, by age group and male-to-female ratio, European Region, 2020 .................................................................................   75
TB cases by origin, European Region, 2020 .......................................................................................................................................................................................   76
Table 9.  
Table 10.   Drug-resistance surveillance of bacteriologically confirmed pulmonary TB cases, European Region, 2020 ..................................................   78

Table 11.  

 Drug-resistance surveillance of bacteriologically confirmed pulmonary TB cases by previous TB treatment history, European 
Region, 2020 .......................................................................................................................................................................................................................................................   80
Table 12.   Pre-XDR-TB and XDR-TB cases among bacteriologically confirmed pulmonary RR/MDR-TB cases, European Region, 2020 ..................   82
Table 13.   RR/MDR-TB and pre-XDR/XDR-TB cases enrolled to treatment, European Region, 2020 ...........................................................................................   84
Table 14.   New and relapse TB cases with HIV infection, European Region, 2020 ...............................................................................................................................   85
Table 15.   TB in prisons, European Region, 2020...................................................................................................................................................................................................   86
Table 16.    Treatment outcome of new and relapse TB cases notified in 2019, European Region, 2020 ....................................................................................   87
Table 17.   Treatment outcome of previously treated TB cases notified in 2019, European Region, 2020 ................................................................................   88
Table 18.   Treatment outcome of new and relapse TB cases in children (0–14 years) notified in 2019, European Region, 2020 ................................   89
Table 19.    Treatment outcome of new and relapse TB cases of foreign origin notified in 2019, European Region, 2020 ................................................   90
Table 20.   Treatment outcome of HIV-positive new and relapse TB cases notified in 2019, European Region, 2020 ........................................................   91
Table 21.   Treatment outcome among new and relapse TB cases in prisons notified in 2019, European Region, 2020 ...................................................   92
Table 22.   Treatment outcome after 24 months of RR/MDR-TB cases started on second-line treatment in 2018, European Region, 2020 ...........   93
Table 23.   Treatment outcome after 24 months of pre-XDR-TB cases started on second-line treatment in 2018, European Region, 2020 ...........   94
Table 24.   Treatment outcome after 36 months of XDR-TB notified in 2017, EU/EEA, 2020 .............................................................................................................   95
Table 25.   Monitoring the WHO Roadmap to implement the tuberculosis action plan for the WHO European Region, 2016–2020, 2020..............   96

Trend tables 
Estimated tuberculosis (TB) mortality per 100 000 population, European Region, 2011–2020 ..............................................................................  102
Table I.  
Table II.   Estimated TB incidence per 100 000 population, European Region, 2011–2020 ............................................................................................................  104

Table III.  

 New and relapse TB cases,a notification rates per 100 000 population and mean annual change in rates, European Region, 
2011–2020 ............................................................................................................................................................................................................................................................  106
Table IV.   TB cases in children under 15 years, European Region, 2016–2020......................................................................................................................................  108

Table V.  

 RR/MDR-TB  notification among new bacteriologically confirmed pulmonary TB cases with available DST results, European 
Region, 2016–2020 ..........................................................................................................................................................................................................................................  109

Table VI.  

 RR/MDR-TB  notification  among  previously  treated  bacteriologically  confirmed  pulmonary  TB  cases  with  available  DST 
results, European Region, 2016–2020 ..................................................................................................................................................................................................  110
Table VII.   RR/MDR-TB notification among all bacteriologically confirmed TB cases with available DST results  EU/EEA  2016–2020 ...................   111
Table VIII.  Pre-XDR-TB notification among pulmonary RR/MDR-TB cases with DST results to fluoroquinolones, European Region, 2016–2020 112
Table IX.   TB cases with HIV infection, European Region, 2016–2020.......................................................................................................................................................  114
Treatment success after 12 months for new and relapse TB cases, European Region, 2015–2019 .......................................................................  116
Table X.  
Table XI.   Treatment success after 24 months of RR/MDR-TB cases started on treatment, European Region, 2014–2018 ...........................................   117
Table XII.   Treatment success after 24 months of pre-XDR-TB cases started on treatment, European Region, 2014–2018 ...........................................  118
Table XIII.  Treatment success after 36 months of XDR-TB cases notified in EU/EEA, 2013–2017 .................................................................................................  119

Table XIV.   New  and  relapsed  TB  cases  tested  using  WHO-recommended  rapid  diagnostics  such  as  Xpert  MTB/RIF,  European  Region, 

2016–2020 ...........................................................................................................................................................................................................................................................  120

iviv

Acknowledgements

This report has been published jointly by the European 
Centre for Disease Prevention and Control (ECDC) and the 
WHO Regional Office for Europe. The Regional Office devel-
oped the overview of the European Region as a whole and 
validated the figures of the non-member countries of the 
European Union (EU)/European Economic Area (EEA) and 
ECDC developed the overview of the EU/EEA countries and 
validated the EU/EEA figures.

Data collection, validation, analysis and overall prepara-
tion of the report was coordinated by Giorgi Kuchukhidze 
(WHO Regional Office for Europe) and Marlena Kaczmarek 
(ECDC).

Review and production support was provided by Andrei 
Dadu (WHO Regional Office for Europe), Soudeh Ehsani 
(WHO Regional Office for Europe), Ogtay Gozalov (WHO 
Regional Office for Europe), Arax Hovanesyan (freelance 
consultant), Emilia Lindquist (ECDC), Marieke J. van der 
Werf (ECDC) and Askar Yedilbayev (WHO Regional Office 
for Europe).

The report was sent for consultation and review to the 
operational contact points for epidemiology or national 
focal points for TB in the EU/EEA Member States and TB 
surveillance correspondents in the non-EU/EEA Member 
States and areas.

ECDC and the WHO Regional Office for Europe would like 
to thank the nominated operational contact points for TB 
surveillance from EU/EEA Member States and the TB surveil-
lance focal points from the non-EU/EEA Member States 
and areas of the WHO European Region for providing data 
and valuable comments on this report:

Albania: Donika Mema; Andorra: Clara Palma Jordana; 
Armenia: Anush Khachatryan; Austria: Bernhard Benka, 
Alexander Indra; Azerbaijan: Sevinj Taghiyeva; Belarus: 
Dzmitry Klimuk; Belgium: Wouter Arrozala  de Oñate, 
Vinciane	 Sizaire;	 Bosnia	 and	 Herzegovina:	 Snježana	
Brčkalo;	Bulgaria:	Elizabeta	Batchiiska,	Croatia:	Zvjezdana	

Lovrić,	Goranka	Petrović;	Cyprus:	Costas	Constantinou,	
Soteroulla	 Soteriou;	 Czechia:	 Věra	 Dvořáková,	 Jiří	
Wallenfels;  Denmark:  Peter  Henrik  Andersen,  Troels 
Lillebaek; Estonia: Vahur Hollo, Piret Viiklepp; Finland: 
Silja Mentula, Hanna Soini; France: Jean-Paul Guthmann, 
Isabelle Parent du Chatalet; Georgia: Mamuka Chincharauli, 
Nino Lomtadze; Germany: Walter Haas, Stefan Kroeger; 
Greece: Ourania Kalkouni; Hungary: Ágnes Bakos; Iceland: 
Kamilla Sigridur Josefsdottir; Ireland: Sarah Jackson, Paul 
McKeown; Israel: Yana Levin; Italy: Stefania D’Amato, 
Daniela  Maria  Cirillo;  Kazakhstan:  Elena  Arbuzova; 
Kyrgyzstan: Elmira Abdrahmanova; Latvia: Šarlote Konova, 
Ieva	 Rimšāne;	 Liechtenstein:	 Marina	 Jamnicki	 Abegg,	
Andrea	 Leibold;	 Lithuania:	 Giedrė	 Aleksienė,	 Edita	
Davidavičienė,	Kęstutis	Miškinis,	Alvyda	Naujokaitė,	Jurgita	
Pakalniškiene; Luxembourg: Irene Demuth; Malta: Analita 
Pace  Asciak,  Tanya  Melillo;  Monaco:  Jean  Lorenzi; 
Montenegro:	Stevan	Lučić;	Netherlands:	Erika	Slump,	Dick	
van Soolingen, Gerard de Vries; North Macedonia: Maja 
Zakoska;	Norway:	Trude	Margrete	Arnesen,	Einar	Heldal,	
Karin Rønning, Anne Torunn Mengshoel; Poland: Maria 
Korzeniewska-Koseła,	Stefan	Wesołowski;	Portugal:	Isabel	
Carvalho, Raquel Duarte, Marta Gomes, André Santos 
Silva; Republic of Moldova: Andrei Corloteanu; Romania: 
Nicoleta  Valentina  Cioran,  Odette  Popovici;  Russian 
Federation: Sergey Sterlikov; Serbia: Maja Stosic; Slovakia: 
Monika	Polanova,	Ivan	Solovič;	Slovenia:	Urska	Bidovec-
Stojkovic,	Petra	Svetina;	Spain:	Rosa	Cano	Portero,	María	
Vázquez	Torres;	Sweden:	Maria	Axelsson,	Sara	Byfors,	
Petra Edquist, Jerker Jonsson; Switzerland: Ekkehardt 
Altpeter; Tajikistan: Firuza Sharipova; Turkey: Aysegul 
Yildirim; Turkmenistan: Aisoltan Charyeva; Ukraine: Larissa 
Korinchuk;  United  Kingdom:  Colin  Campbell,  Michael 
Devine, Lisa Glaser, Jim McMenamin, Morris Muzyamba, 
Mark O’Doherty, Malorie Perry, Arlene Reynolds, Grace 
Smith, Lucy Thomas; Uzbekistan: Shahnoza Usmonova. 
Also Kosovo:1 Xhevat Kurhasani. 

1 All references to Kosovo in this document should be understood to be 
in the context of the United Nations Security Council resolution 1244 
(1999).

v

Abbreviations

ART 

CI 

DRS 

DST 

(E) 

ECDC 

EEA 

EQA 

antiretroviral therapy

confidence interval

drug-resistance surveillance

drug-susceptibility testing

European (indicator)

European Centre for Disease Prevention and Control

European Economic Area

external quality assessment

ERLTB-Net  

European Reference Laboratory Network for Tuberculosis

EU 

European Union

EU/EEA 

European Union/European Economic Area

(G) 

HPCs 

ICD 

LTBI 

MDR 

MDR-TB 

MTB/RIF 

PLHIV 

global (indicator)

 high-priority countries (Armenia, Azerbaijan, Belarus, Bulgaria, Estonia, 
Georgia, Kazakhstan, Kyrgyzstan, Latvia, Lithuania, the Republic of 
Moldova,  Romania,  the  Russian  Federation,  Tajikistan,  Turkey, 
Turkmenistan, Ukraine and Uzbekistan)

International Classification of Diseases 

latent tuberculosis infection

multidrug resistance

multidrug-resistant tuberculosis

Mycobacterium tuberculosis (MTB) and resistance to rifampin (RIF)

people living with HIV

pre-XDR 

pre-extensive drug resistance

pre-XDR-TB 

pre-extensively drug-resistant tuberculosis

RR 

RR-TB 

relative risk

rifampicin-resistant tuberculosis

RR/MDR      

rifampicin resistance/mutidrug resistance

RR/MDR-TB 

rifampicin-resistant or multidrug-resistant tuberculosis

TB 

TESSy 

TME 

WRD 

XDR 

tuberculosis

The European Surveillance System

(WHO) Tuberculosis Monitoring and Evaluation (platform)

WHO-recommended rapid diagnostics (tests)

extensive drug resistance

XDR-TB 

extensively drug-resistant tuberculosis

vi

 
Executive summary/Резюме

viivii

The WHO European Region
The data in this report present tuberculosis (TB) notifica-
tions through to the end of 2020, the period of the global 
COVID-19 pandemic. Although 2020 data are compared to 
those for previous years, the rates and trends should be 
interpreted with caution due to the potential impact of the 
public health and social measures introduced by countries 
in response to the COVID-19 pandemic on TB detection 
and reporting.

TB burden

The estimated number of TB cases in the WHO European 
Region has been decreasing consistently since 2000. 
During the period 2011–2020, the average annual decline 
in the TB incidence rate was 5.2%, with 6.4% achieved 
between 2019 and 2020, which is notably higher than the 
global rate of decline for TB incidence (1.9%) and the fastest 
decline in the world compared to other regions. The cumu-
lative reduction for the period 2015–2020 was 25%, indi-
cating that the Region exceeded the 2020 End TB Strategy 
milestone to reduce the TB incidence rate in 2020 by 20% 
against the 2015 baseline, and achieved the regional action 
plan target of a 25% reduction in the TB incidence rate (1).

An estimated 21 000 TB deaths occurred among HIV-negative 
people in the European Region in 2020, equivalent to 2.3 
deaths per 100 000 population (range 2.2–2.4). Between 
2011 and 2020, the TB mortality rate at regional level fell 
cumulatively by 54%, from 4.9 to 2.3 deaths per 100 000 
population, which on average is a decline of 8.3% per year. 
TB mortality in the Region plateaued for the first time over 
the last two decades between 2019 and 2020 as a conse-
quence of undiagnosed and untreated TB and associated 
increased death due to disruptions to TB services caused 
by the COVID-19 pandemic. As a result, the reduction in 
the absolute numbers of TB deaths in 2020 compared to 
2015 was only 26% versus the 35% target of the regional 
action plan. 

In 2020, there was an estimated 69 000 new cases of 
r i f a mp i c i n - r e si s t a n t  o r  m u l t i d r ug- r e si s t a n t  T B  
(RR/MDR-TB) in the Region, with 37 000 estimated among 
notified  bacteriologically  confirmed  pulmonar y  TB 
patients. The proportion of RR/MDR-TB among new and 
previously treated TB cases in the Region also significantly 
exceeds the global average, with 18% in new and 53% in 
previously treated cases compared to 4% and 21% respec-
tively (2). 

HIV prevalence in incident TB cases was estimated to be 
12% in 2020, another year of halted growth after an unprec-
edented  increase  from  4%  to  12%  during  the  period  
2007–2016. There was an estimated 29 000 HIV-positive 
TB cases in the Region, with almost 80% of cases estimated 
in the Russian Federation (55%) and Ukraine (24%).

TB disease notification and treatment outcomes

In 2020, 163 602 incident TB cases were notified in 51 of 
the 53 countries in the Region,2 amounting to 71% of the 
estimated new and relapse cases. A sharp 24% drop in 
notified new and relapse TB cases between 2019 and 2020 
represents clear discontinuity in the downward trend in 
TB notifications (reflecting an underlying decline in TB 
incidence) in the Region and is due to the impact of the 
COVID-19 pandemic on the detection and reporting of TB 
cases. 

The  impact  was  more  severe  in  the  early  days  of  the 
pandemic, when countries introduced strict public health 
and social measures in response to COVID-19. A survey 
conducted by the WHO Regional Office for Europe showed 
an average 36% decrease in TB notifications observed in 
April–June 2020 compared to the same period in 2019, 
with  a  correlation  between  the  level  of  stringency  of 
domestic movement restrictions implemented by countries 
and the decrease in TB notifications (3).

A total of 135 521 patients with pulmonary TB (82.8%) were 
notified among incident TB cases, 66.8% of which were 
laboratory-confirmed. Among bacteriologically confirmed 
pulmonary  TB  cases,  92%  were  tested  for  rifampicin 
resistance. 

Overall, 34.3% of pulmonary TB patients who were reported 
as having tested for drug susceptibility had RR/MDR-TB. 
Prevalence of RR/MDR-TB among new and previously treated 
bacteriologically confirmed pulmonary TB cases was 23.1% 
and 55.2% respectively.

Data on drug-susceptibility testing (DST) to fluoroqui-
nolones were available for 94.3% of all notified pulmonary 
RR-TB cases. Overall, 32.9% of pulmonary RR/MDR-TB 
cases  with  DST  results  to  fluoroquinolones  had  pre- 
extensively drug-resistant TB (pre-XDR-TB) in 2020.  Among 
pre-XDR-TB patients tested for any other Group A drugs, 
the prevalence of extensively drug-resistant TB (XDR-TB) 
was 6.5% at regional level. 

Of new and relapse TB patients notified from countries 
reporting HIV testing data, 92.6% were screened for HIV. 
A total of 19 663 TB cases were detected with HIV-positive 
status, which is 15% of those tested, representing an 
increase compared to 2019 (when it was 14.3%). 

A total of 14 351 (74.3%) HIV-positive patients are reported 
to have received antiretroviral therapy (ART). ART coverage 
has been increasing over the last five years but is still far 
below  the  WHO  target  of  universal  ART  coverage  for  
TB/HIV coinfected patients. 

2 Latvia and San Marino did not report any data.

ix

The treatment success rate in the Region remains below 
the respective regional targets of 85% and 75%. Successful 
treatment outcome for both incident TB and RR/MDR-TB 
cohorts were 76.5% and 55.9% respectively, which is 
comparable with the previous year’s results.

Conclusions

The remarkable progress in containing the burden of TB 
in the Region observed between 2015 and 2019 was halted 
in 2020 by the COVID-19 pandemic. As a result, in 2020, 
the downward trend in TB mortality and incidence slowed, 
far fewer people were diagnosed and treated for TB and, 
consequently, fewer people were tested for drug resistance 
and enrolled into RR/MDR-TB treatment. Despite these 
challenges, progress made before the pandemic was good 
enough to enable the regional action plan target of a 25% 
reduction in TB incidence rate in 2020 compared to 2015 
to be reached, meaning the Region overachieved the End 
TB Strategy milestone of a 20% reduction of TB incidence 
compared to the 2015 baseline. 

For the first time in over two decades, the downward trend 
in number of TB deaths was halted in 2020 as a consequence 
of delay in, or lack of, TB diagnosis due to disruption to 
TB services, leading to increased severity of disease and 
an associated increase in deaths. This compromised the 
achievement of the End TB Strategy milestone on reduction 
of number of TB deaths. The actual reduction in absolute 
number of TB deaths in 2020 compared to 2015 was only 
26% against the targeted 35%. Other noticeable impacts 
of the COVID-19 pandemic in the Region included a 17.7% 
reduction in the number of RR/MDR-TB patients detected 
and enrolled into treatment in 2020 compared to 2019. 
The treatment outcomes for new and relapse TB patients 
remained comparable with previous years, with no evidence 
of significant reduction in treatment success rates.  

Although slow improvement has been seen, the treatment 
success rates for new and relapse cases and RR/MDR-TB 
patients are still below regional and global targets. Despite 
the efforts made, the burden in relation to RR-TB and  
TB/HIV remains considerable, underlining the need to 
introduce more innovative and effective approaches to the 
diagnosis and treatment of TB and MDR-TB.  

European Union and European 
Economic Area countries
Epidemiology and treatment outcome

In 2020, 33 148 cases of TB were reported in 29 European 
Union and European Economic Area (EU/EEA) countries 
(Latvia did not report any case-based data), resulting in 
a notification rate of 7.3 per 100 000 population in the  
EU/EEA. The overall notification rate and the rates in most 
countries have been decreasing over the last five years. 
The rates for 2020 should be interpreted with caution due 
to the potential impact of measures implemented to mitigate 
the COVID-19 pandemic on data collection and access to 
health services. 

x

Of all notified TB cases, 24 139 (72.8%) were newly diag-
nosed and 22 301 (67.3%) were confirmed by culture, or 
smear and nucleic acid amplification test. In 2020, adults 
aged between 25 and 64 years accounted for 64.8% of all 
new and relapse TB cases, while children under 15 years 
made up 3.8%. Malta reported the highest notification 
rates among children, with 16.7 cases per 100 000 popula-
tion aged between 0 and 4 years. In 2020, new and relapse 
TB cases were more frequently reported in males than 
females, with a male-to-female ratio of 2 : 1. One third 
(33%) of TB cases reported in the EU/EEA in 2020 were of 
foreign origin.

Of 14 997 cases with DST results for at least rifampicin, 
649 (4.3%) were RR-TB and 566 (3.8%) had MDR-TB. The 
countries with the highest proportion of MDR-TB cases 
among those with DST results (excluding France) were 
Estonia (19.4%) and Lithuania (16.7%). Pre-XDR-TB was 
reported for 115 (27.6%) of the 417 RR/MDR-TB cases tested 
for fluoroquinolone susceptibility. Among pre-XDR cases, 
82 (71.3%) were tested for susceptibility to any other  
Group A drug and 37 (45.1%) met the XDR-TB definition. 

In 2020, 19 countries reported data on HIV coinfection. 
The number of countries reporting data on HIV coinfection 
peaked at 23 in 2016 and 2017, decreased to 21 in 2018 
and dropped again to 19 in 2019. Of the 12 327 TB cases 
with  known  HIV  status,  515  (4.2%)  were  reported  as 
HIV-positive.

TB in prisons remains poorly reported. For the 13 EU/EEA 
countries reporting data, the notification rate was 137 new 
and relapse TB cases per 100 000 prison population, and 
prisoners had a relative risk of 9.3 compared to the general 
population in the same countries.

Of all 28 985 TB cases notified in 2019 with a treatment 
outcome reported in 2020, 71.8% were treated success-
fully, 7.6% died and 0.8% experienced treatment failure. 
Of 927 RR/MDR-TB cases notified in 2018 with a treatment 
outcome reported in 2020, 52.4% were treated success-
fully, 14.5% died and 10.5% experienced treatment failure. 
Treatment success was reported only for 10 (38.5%) of the 
26 XDR-TB cases notified in 2017, while 15.4% of cases 
were reported to have died and 3.8% experienced treat-
ment failure.

Conclusions

In 2020, 29 of 30 EU/EEA countries reported TB notification 
data. There was a further decline in the overall TB notifica-
tion rate (7.3 per 100 000 population), continuing the trend 
observed since 2002, but the decline between 2019 and 
2020 data must be interpreted with caution due to the 
possible impact of measures implemented to mitigate 
COVID-19. Significant work needs to be done to achieve 
the United Nations Sustainable Development Goal 3 target 
notification rate at EU/EEA level of 2.4 per 100 000 popula-
tion by 2030. Reassuringly, the number of reported MDR-TB 
and XDR-TB cases continued to decline in EU/EEA countries 
in 2020 and accounted for a very small proportion of all 
reported TB cases in 2020.

Across all cohorts, reported treatment success remains 
well below WHO targets. Of all TB cases notified in 2019 
with a treatment outcome reported in 2020, only 71.8% 
were treated successfully. Treatment success was lower 
for RR/MDR-TB cases at 24 months (52.4%) and lower still 
among XDR-TB cases at 36 months (38.5%), while the 
proportion of deaths for these cohorts was 14.5% and 
15.4% respectively.

Across the EU/EEA, further efforts are needed to improve 
reporting of HIV coinfection and TB in prisons, and for 
treatment outcomes.

Monitoring progress towards TB 
elimination
The final year covered by the Tuberculosis action plan for 
the WHO European Region 2016–2020 (4) was 2020. Twenty 
of 26 WHO regional action plan indicators were effectively 
monitored and evaluated using routine surveillance data. 
Nine of the 20 targets monitored were achieved at regional 
level. Progress in reducing the TB incidence rate was 
particularly impressive, with most high-priority countries 
and the Region as a whole achieving the 2020 milestone 
of the global End TB Strategy and the regional action plan 
target. The Region was very close to reaching the target 
for reduction in number of TB deaths by 35% against the 
2015 baseline, but the existing downward trend in TB 
mortality halted in 2020 due to the COVID-19 pandemic, 
which ultimately compromised achievement of the target. 
Additional achievements include a substantial increase in 
HIV testing and ART coverage over the past few years and 
an increase in coverage with WHO-recommended rapid 
diagnostics. 

Unfortunately, the Region fell short of achieving 11 targets, 
including  those  for  the  TB  case-detection  rate,  the 
percentage  of  RR/MDR-TB  among  new  and  previously 
treated TB cases, prevalence of HIV among new and relapse 
TB cases, TB preventive treatment (TPT) coverage among 

children under 5 years, and treatment success rate among 
new  and  relapse  TB  patients  and  among  cohorts  of  
RR/MDR-TB and TB patients in prison. Despite the efforts 
made, the burden related to RR-TB and TB/HIV continues 
to increase, indicating the need to introduce more innova-
tive and effective approaches to address the issues.  The 
treatment success rate of new and relapse TB cases and 
RR/MDR-TB cases are still below the global and regional 
targets, but when data collected between 2016 and 2020 
are compared, a slow but sustainable increase can be seen 
among both cohorts. Prevention efforts, including contact 
tracing, coverage with TPT and ART among people living 
with HIV, need to be intensified.

References3
1.  Roadmap to implement the tuberculosis action plan 
for the WHO European Region 2016–2020. Towards 
ending tuberculosis and multidrug-resistant tubercu-
losis. Copenhagen: WHO Regional Office for Europe; 
2016 (https://apps.who.int/iris/handle/10665/329486).  

2.  Global tuberculosis report 2021. Geneva: World Health 
Organization;  2021  (ht tps://apps.who.int/iris/
handle/10665/346387).

3.  Dara M, Kuchukhidze G, Yedilbayev A, Perehinets I, 
Schmidt T, Leif Van Grieson W et al. Early COVID-19 
pandemic’s toll on tuberculosis services, WHO European 
Region,  Januar y  to  June  2020    Euro  Sur veill. 
2021;26(24):2100231.  doi:10.2807/1560 -7917.
ES.2021.26.24.2100231.

4.  Sixty-fifth Regional Committee for Europe: Vilnius, 
14–17 September 2015. Tuberculosis action plan for 
the WHO European Region 2016–2020. Copenhagen: 
WHO Regional Office for Europe; 2015 (EUR/RC65/17 
Rev.1; https://apps.who.int/iris/handle/10665/337750).

3 All references  were accessed on 12 February 2022. 

xi

Европейский регион ВОЗ
Данные,	 представленные	 в	 этом	 отчете,	 отражают	
ситуацию	с	регистрацией	случаев	туберкулеза	(ТБ)	за	
период	до	конца	2020	г.	–	время	глобальной	пандемии	
COVID-19.	 Хотя	 данные	 за	 2020	 г.	 сравниваются	 с	
данными	за	предыдущие	годы,	показатели	и	тенденции	
следует	 интерпретировать	 с	 осторожностью	 из-за	
потенциального	влияния	на	деятельность	по	выявлению	
и	 регис трации	 ТБ	 со	 с тоны	 мер	 общес твенного	
здравоохранения	 и	 социальных	 мер,	 введенных	
странами	в	ответ	на	пандемию	COVID-19.

Бремя туберкулеза

Расчетное	число	случаев	заболевания	ТБ	в	Европейском	
регионе	ВОЗ	последовательно	сокращается	с	2000	г.	В	
период	 с	 2011	 по	 2020	 гг.	 среднегодовое	 снижение	
уровня	заболеваемости	ТБ	составило	5,2%,	а	в	2019–
2020	гг.	–	6,4%,	что	значительно	превышает	глобальные	
темпы	снижения	заболеваемости	ТБ	(1,9%)	и	является	
примером	самых	быстрых	темпов	снижения	в	мире	по	
сравнению	 с	 другими	 регионами.	 	 Совок упное	
сокращение	за	период	2015	–	2020	гг.	составило	25%,	
что	 свидетельствует	 о	 том,	 что	 Регион	 превысил	
контрольный	показатель	Стратегии	по	ликвидации	
туберкулеза	2020	г.,	предусматривающий	снижение	
уровня	заболеваемости	туберкулезом	в	2020	г.	на	20%	
по	 сравнению	 с	 исходным	 уровнем	 2015	 г.,	 и	 достиг	
целевого	ориентира	Регионального	плана	действий	по	
снижению	уровня	заболеваемости	туберкулезом	на	
25% (1).

Согласно	оценкам,	в	2020	г.	в	Европейском	регионе	
ВОЗ	число	смертей	от	ТБ	среди	ВИЧ-отрицательных	
людей	составило	21	000,	что	соответствует	показателю	
в	2,3	смертей	на	100	000	населения	(диапазон	2,2–2,4).	
В	период	с	2011	по	2020	гг.	показатель	смертности	от	
ТБ	на	региональном	уровне	в	совокупности	снизился	
на	54,0%	–	с	4,9	до	2,3	смертей	на	100	000	населения,	
что	в	среднем	составляет	сокращение	на	8,3%	в	год.	
Смертность	от	ТБ	в	Регионе	впервые	за	последние	два	
десятилетия	 вышла	 на	 плато	 в	 период	 с	 2019	 по	 
2020	 гг.	 Такая	 ситуация	 стала	 результатом	 наличия	
недиагностированных	 и	 нелеченных	 случаев	 ТБ	 и	
связанного	с	этим	роста	смертности	из-за	перебоев	в	
работе	противотуберкулезных	служб	на	фоне	пандемии	
COVID-19.	Таким	образом,	снижение	абсолютного	числа	
смертей	от	ТБ	в	2020	г.	по	сравнению	с	2015	г.	составило	
всего	26%	против	35%,	предусмотренных	Региональным	
планом	действий.		

В	 2020	 г.	 в	 Регионе	 было	 зарегистрировано	 69	 000	
расчетных	 новых	 с лучаев	 ТБ	 с	 устойчивостью	 к	
рифампицину	 и	 множес твенной	 лекарс твенной	
устойчивостью	возбудителя		(РР/МЛУ-ТБ),	в	том	числе	
37	000	расчетных		случаев	среди	зарегистрированных		

xii

б о л ь н ы х	 л е г о ч н ы м	 Т Б	 с	 	 б а к т е р и о л о г и ч е с к и	
подтвержденным	диагнозом.	Доля	РР/МЛУ-ТБ	среди	
новых	и	ранее	леченных	случаев	ТБ	в	Регионе	также	
значительно	превышает	среднемировой	показатель:	
18%	среди	новых	и	53%	среди	ранее	леченных	случаев	
по	сравнению	с	4%	и	21%	соответственно	(2).

Распространенность	ВИЧ-инфекции	среди	больных	ТБ,	
по	оценкам,	составила	12%	в	2020	г.	–	это	еще	один	год	
приостановленного	роста	после	беспрецедентного	
увеличения	с	4%	до	12%	в	период	с	2007	по	2016	гг.	
Расчетное	 число	 ВИЧ-положительных	 случаев	 ТБ	 в	
Регионе	составило	29	000,	причем	почти	80%	случаев	
приходилось	на	Российскую	Федерацию	(55%)	и	Украину	
(24%).

Регистрация случаев и результаты лечения ТБ

В	2020	г.	было	зарегистрировано	163	602	новых	случая	
и	рецидивов	ТБ	в	51	из	53	стран	Региона4,	что	составляет	
71%	от	предполагаемых	новых	и	рецидивных	случаев.		
Резкое	сокращение	на	24%	числа	зарегистрированных	
новых	 случаев	 и	 рецидивов	 ТБ	 в	 период	 с	 2019	 по	 
2020	 гг.	 является	 явным	 отражением	 прерывания	
отрицательной	 динамики	 регистрации	 случаев	 ТБ	
(свидетельство	базового	снижения	заболеваемости	 
ТБ)	 в	 Регионе	 и	 объясняется	 влиянием	 пандемии	
COVID-19	на	деятельность	по	выявлению	и	регистрации	
случаев	ТБ.		

Это	воздействие	было	более	значительным	в	первые	
дни	 пандемии,	 когда	 страны	 ввели	 строгие	 меры	 в	
области	общественного	здравоохранения	и	социальной	
защиты	 в	 отве т	 на	 распрос транение	 COVID -19.	
Исследование,	проведенное	Европейским	региональным	
бюро	 ВОЗ,	 показало,	 что	 в	 апреле	 –	 июне	 2020	 г.	
наблюдалось	сокращение	регистрации	случаев	ТБ	в	
среднем	 на	 36%	 по	 сравнению	 с	 тем	 же	 периодом	 
2019	г.,	при	этом	прослеживалась	корреляция	между	
уровнем	 строгости	 ограничений	 на	 передвижение	
внутри	страны	и	сокращением	регистрации	случаев	 
ТБ	(3). 

С р е д и 	 н о в ы х 	 с л у ч а е в 	 и 	 р е ц и д и в о в 	 Т Б	 б ы л о	
зарегистрировано	в	общей	сложности	135	521	случай	
ТБ	легких	(82,8%),	из	которых	66,8%	имели	лабораторное	
подтверждение	диагноза.	Среди	бактериологически	
подтверж денных	 с лучаев	 ТБ	 легких	 92,0%	 были	
протестированы	на	устойчивость	к	рифампицину.		

В	 целом	 34,3%	 больных	 ТБ	 легких,	 у	 которых,	 по	
имеющимс я	 данным,	 были	 прове дены	 тес ты	 на	
лекарственную	чувствительность,	имели	РР/МЛУ-ТБ.	
Распространенность	РР/МЛУ-ТБ	среди	новых	и	ранее	

4	Латвия	и	Сан-Марино	не	предоставили	данных.

леченных	бактериологически	подтвержденных	случаев	
легочного	ТБ	составила	23,1%	и	55,2%	соответственно.

Д а н н ы е 	 о 	 т е с т и р о в а н и и 	 н а 	 л е к а р с т в е н н у ю	
чувствительность	(ТЛЧ)	к	фторхинолонам	были	в	наличии	
для	94,3%	всех	зарегистрированных	случаев	легочного	
РР-ТБ.	В	целом	32,9%	легочных	случаев	РР/МЛУ-ТБ	с	
результатами	ТЛЧ	к	фторхинолонам	имели	ТБ	с	пред-
широкой	лекарственной	устойчивостью	(пред-ШЛУ-ТБ)	
в	2020	г.		Среди	пациентов	с	пред-ШЛУ-ТБ,	прошедших	
тестирование	лекарственной	устойчивости	к	любым	
другим	 препаратам	группы	А,	распространенность	
ШЛУ-ТБ	на	региональном	уровне	составила	6,5%.	

С р е д и	 н о в ы х	 с л у ч а е в	 и	 р е ц и д и в о в	 Т Б ,	
зарегистрированных	 в	 странах,	 предоставивших	
данные	о	тестировании	на	ВИЧ,	92,6%	были	обследованы	
на	 ВИЧ.	 Всего	 было	 выявлено	 19	 663	 случая	 ТБ	 с	
ВИЧ-положительным	статусом,	что	составило	15,0%	от	
числа	 прошедших	 тестирование	 –	 это	 прирост	 по	
сравнению	с	2019	г.	(когда	эта	доля	составляла	14,3%).		

В	общей	сложности	14	351	(74,3%)	ВИЧ-положительных	
пациентов	получили	антиретровирусную	терапию	(АРТ).	
За	последние	пять	лет	охват	АРТ	увеличился,	но	еще	
остается	значительно	ниже	целевого	ориентира	ВОЗ	
по	всеобщему	охвату	пациентов	с	сочетанной	инфекцией	
ТБ/ВИЧ	антиретровирусной	терапией.		

Показатель	успешного	лечения	в	Регионе	остается	ниже	
соответствующих	региональных	целевых	ориентиров	
в	85%	и	75%.	Успешные	результаты	лечения	в	когортах	
новых	случаев	и	рецидивов	ТБ	и	РР/МЛУ-ТБ	составили	
76,5%	 и	 55,9%	 соответственно,	 что	 сопоставимо	 с	
результатами	предыдущего	года.

Выводы

Заметный	прогресс	в	сдерживании	роста	бремени	ТБ	
в	Регионе,	наблюдавшийся	в	период	с	2015	по	2019	гг.,	
был	приостановлен	в	2020	г.	пандемией	COVID-19.	В	
результате	в	2020	г.	тенденция	снижения	смертности	
и	заболеваемости	ТБ	замедлилась,	гораздо	меньшее	
число	людей	проходили	диагностику	и	лечение	ТБ	и,	
соответственно,	 меньшее	 число	 людей	 проходило	
тестирование	на	лекарственную	устойчивость	и	было	
включено	в	программу	лечения	РР/МЛУ-ТБ.	Несмотря	
на	эти	проблемы,	успехи,	достигнутые		до	пандемии,	
были	 достаточно	 значительными	 для	 достижения	
целевого	ориентира	Регионального	плана	действий	–	
снижения	уровня	заболеваемости	ТБ	на	25%	в	2020	г.	
по	 сравнению	 с	 2015	 г.,	 что	 означает,	 что	 Регион	
перевыполнил	 за дачу	 Стратегии	 по	 ликвидации	
туберкулеза	по	сокращению	заболеваемости	ТБ	на	20%	
по	сравнению	с	исходным	уровнем	2015	г.		

Впервые	 за	 более	 чем	 два	 десятилетия	 тенденция	
снижения	 чис ла	 смертей	 от	 ТБ	 приостановилась	 
в	 2020	 г.	 вс ле дс твие	 за держки	 или	 отс у тс твия	
д и а г н о с т и к и 	 Т Б 	 и з - з а 	 н а р у ш е н и я 	 р а б о т ы	
противотуберкулезных	служб,	что	привело	к	увеличению	
тяжести	заболевания	и	соответствующему	увеличению	

числа	смертей.	Это	поставило	под	угрозу	достижение	
важной	задачи	Стратегии	по	ликвидации	туберкулеза	
–	сокращения 	числа 	смертей 	от 	ТБ. 	 	Фактическое 	
снижение	абсолютного	числа	смертей	от	ТБ	в	2020	г.	
по	 сравнению	 с	 2015	 г.	 составило	 лишь	 26%	 против	
запланированных	35%.	Другие	заметные	последствия	
пандемии	COVID-19	в	Регионе	включают	сокращение	
на	17,7%	числа	пациентов	с	РР/МЛУ-ТБ,	выявленных	и	
вк люченных	 в	 программу	 лечения	 в	 2020	 г.,	 по	
сравнению	с	2019	г.	Результаты	лечения	новых	случаев	
и	 рец и дивов	 Т Б	 ос т ава лись	 сопос т авимыми	 с	
предыдущими	годами,	без	признаков	значительного	
снижения	показателей	успешного	лечения.				

Не с мо т ря	 на	 ме д ленное	 ул у чшение	 си т у ац ии,	
показатели	 успешного	 лечения	 новых	 случаев	 и	
рецидивов	ТБ,	а	также	случаев	с	РР/МЛУ-ТБ	все	еще	
ниже	региональных	и	глобальных	целевых	ориентиров.	
Несмотря	на	предпринимаемые	усилия,	бремя	РР-ТБ	и	
ТБ/ВИЧ	 остается	 значительным,	 что	 подчеркивает	
необходимость	внедрения	более	инновационных	и	
эффективных	подходов	в	сферу	диагностики	и	лечения	
ТБ	и	МЛУ-ТБ.				

Европейский Союз и страны 
Европейской экономической 
зоны
Эпидемиологическая ситуация и результаты 
лечения

В	2020	г.	в	29	странах	Европейского	союза	и	Европейской	
экономической	зоны	(ЕС/ЕЭЗ)	было	зарегистрировано	
33	148	случаев	заболевания	туберкулезом	(Латвия	не	
предоставила	данных	о	случаях	заболевания),	таким	
образом,	показатель	заболеваемости	составил	7,3	на	
100	000 	населения 	в 	ЕС/ЕЭЗ. 	 	Общий 	показатель 	
регистрации	 и	 показатели	 в	 большинстве	 стран	
снижались	в	течение	последних	пяти	лет.	Показатели	
за	2020	г.	следует	интерпретировать	с	осторожностью	
из-за	потенциального	влияния	мер,	предпринятых	для	
смягчения	последствий	пандемии	COVID-19,	на	процессы	
сбора	данных	и	доступность	услуг	здравоохранения.		

Из	всех	зарегистрированных	случаев	ТБ,	24	139	(72,8%)	
бы ли	 впервые	 диагнос т ированными	 с л у ча ями	
заболевания,	а	22	301	(67,3%)	имели	подтверждение	
диагноза	результатами	исследования	посева	или	мазка	
и	 теста	 на	 амплификацию	 нук леиновых	 кис лот.	 
В	2020	г.	взрослые	в	возрасте	от	25	до	64	лет	составили	
64,8%	всех	новых	случаев	и	рецидивов	ТБ,	а	дети	до	
15	лет 	– 	3,8%. 	 	Мальта 	сообщила 	о 	самых 	высоких 	
показателях	регистрации	среди	детей:	16,7	случаев	на	
100	000	населения	в	возрасте	от	0	до	4	лет.	В	2020	г.	
новые	случаи	и	рецидивы	ТБ	чаще	регистрировались	
среди	мужчин,	чем	у	женщин,	соотношение	мужчин	и	
женщин	составило	2,0.	Одна	треть	(33,0%)	случаев	ТБ,	
зарегис т рированны х	 в	 ЕС/Е ЭЗ	 в	 2020	 г.,	 бы ла	
иностранного	происхождения.

xiii

Из	14	997	случаев	с	результатами	ТЛЧ	как	минимум	к	
рифампицину,	649	(4,3%)	имели	РР-ТБ	и	566	(3,8%)	–	
МЛУ-ТБ.	 Странами	 с	 самой	 высокой	 долей	 случаев	
М ЛУ-Т Б	 сре ди	 больных	 с	 ре зультатами	 ТЛЧ	 (за	
исключением	Франции)	были	Эстония	(19,4%)	и	Литва	
(16,7%).		Пред-ШЛУ-ТБ	был	зарегистрирован	у	115	(27,6%)	
из	 417	 случаев	 РР/МЛУ-ТБ,	 протестированных	 на	
чувствительность	 к	 фторхинолонам.	 Среди	 случаев	
пред-ШЛУ-ТБ	 82	 (71,3%)	 были	 протестированы	 на	
чувствительность	к	любому	другому	препарату	группы	
А,	а	37	(45,1%)	соответствовали	определению	ШЛУ-ТБ.		

В	 2020	 г.	 данные	 о	 соче т анной	 инфекц ии	 ВИЧ	
предоставили	19	стран.	Число	стран,	предоставивших	
данные	 о	 	 сочетанной	 инфекции	 ВИЧ,	 дос тигло	
максимума	в	2016	и	2017	гг.	–	23,	за	которым	последовало	
снижение	 до	 21	 в	 2018	 г.	 ,	 а	 затем	 до	 19	 в	 2019	 г.	 Из	 
12	327	случаев	ТБ	с	известным	ВИЧ-статусом,	515	(4,2%)	
были	зарегистрированы	как	ВИЧ-положительные.

О	 туберкулезе	 в	 тюрьмах	 по-прежнему	 сообщается	
мало.	В	13	странах	ЕС/ЕЭЗ,	предоставивших	свои	данные,	
показатель	регистрации	составил	137	новых	случаев	и	
рецидивов	ТБ	на	100	000	заключенных,	а	относительный	
риск	для	заключенных	в	тех	же	странах	составил	9,3	
по	сравнению	с	населением	в	целом.

Из	 всех	 28	 982	 случаев	 ТБ,	 зарегистрированных	 
в	2019	г.	с	результатами	лечения,	полученными	в	2020	
г.,	71,8%	были	успешно	пролечены,	7,6%	умерли	и	0,8%	
имели	безуспешный	результат	лечения.	Из	927	случаев	 
РР/МЛУ-ТБ,	зарегистрированных	в	2018	г.,	о	результатах	
лечения	которых	было	сообщено	в	2020	г.,	52,4%	были	
пролечены	 успешно,	 14,5%	 умерли	 и	 10,5%	 имели	
безуспешный	результат	лечения.	Успешный	результат	
терапии	был	достигнут	лишь	у	10	(38,5%)	из	26	случаев	
ШЛУ-ТБ,	зарегистрированных	в	2017	г.,	в	то	время	как	
в	 15,4%	 случаев	 сообщалось	 о	 смерти,	 а	 в	 3,8%	 –	 о	
неудачном	лечении.

Выводы

В	2020	г.	29	из	30	стран	ЕС/ЕЭЗ	предоставили	данные	
о	регистрации	случаев	ТБ.	Наблюдалось	дальнейшее	
снижение	общего	показателя	регистрации	ТБ	(7,3	на	
100	 000	 населения)	 с	 продолжением	 тенденции,	
наблюдаемой	с	2002	г.,	однако	снижение,	отмеченное	
между	данными	2019	и	2020	гг.,	следует	интерпретировать	
с	 осторожностью	 из-за	 возможного	 влияния	 мер,	
принятых	 д ля	 смягчения	 пос ледствий	 COVID-19.		
Необходимо	проделать	значительную	работу,	чтобы	к	
2030	г.	достичь	целевого	ориентира	по	показателям	
регистрации,	 установленного	 ООН	 в	 рамках	 задачи	 
	3	Целей	в	области	устойчивого	развития,	на	уровне	 
ЕС/ЕЭЗ	–	2,4	на	100	000	населения.	Обнадеживает	то,	
что	в	2020	г.	число	зарегистрированных	случаев	МЛУ-ТБ	
и	ШЛУ-ТБ	в	странах	ЕС/ЕЭЗ	продолжало	снижаться	и	
с о с т а в и л о	 о ч е н ь	 н е б о л ь ш у ю	 д о л ю	 о т	 в с е х	
зарегистрированных	случаев	ТБ	в	2020	г.

Во	 всех	 когортах	 зарегистрированные	 результаты	
лечения	остаются	значительно	ниже	целевых	ориентиров	
ВОЗ.	 Из	 всех	 с лу чаев	 Т Б,	 зарегис трированных	 

xiv

в	2019	г.,	о	результатах	лечения	которых	было	сообщено	
в	2020	г.,	успех	в	лечении	был	достигнут	лишь	у	71,8%.	
Показатель	успешного	лечения	был	ниже	для	случаев	
РР/МЛУ-ТБ	на	24	месяце	(52,4%)	и	еще	ниже	для	случаев	
ШЛУ-ТБ	на	36	месяце	(38,5%),	а	доля	смертей	для	этих	
когорт	составила	15,2%	и	15,4%	соответственно.

Во	 всех	 странах	 ЕС/ЕЭЗ	 необходимы	 дальнейшие	
усилия	для	улучшения	отчетности	о	случаях	сочетанной	
инфекции	ВИЧ	и	ТБ	в	тюрьмах,	а	также	о	результатах	
лечения.

Мониторинг прогресса на пути 
к ликвидации ТБ
Последним	годом,	охваченным	мероприятиями	Плана 
действий по борьбе с туберкулезом для Европейского 
региона ВОЗ на 2016–2020 гг. (4),	был	2020	г.	Двадцать	
из	26	индикаторов	Регионального	плана	действий	ВОЗ	
б ы л и 	 э ф ф е к т и в н о 	 о т с л е ж е н ы 	 и 	 о ц е н е н ы 	 с	
использованием	данных	регулярного	эпиднадзора.	
Девять	из	20	отслеживаемых	целевых	ориентиров	были	
достигну ты	 на	 региональном	 уровне.	 	 Особенно	
впечатляющим	 был	 прогресс	 в	 снижении	 уровня	
заболеваемости	 ТБ:	 большинство	 стран	 высокого	
приоритета	в	отношении	ТБ	и	Регион	в	целом	достигли	
контрольного	уровня	2020	г.	глобальной	Стратегии	по	
ликвидации	 т уберк улеза	 и	 це левого	 ориентира	
Регионального	 плана	 действий.	 	 Регион	 был	 очень	
близок	к	достижению	целевого	ориентира	по	снижению	
числа	смертей	от	ТБ	на	35%	по	сравнению	с	базовым	
уровнем	 2015	 г.,	 однако	 существующая	 тенденция	
снижения	смертности	от	ТБ	остановилась	в	2020	г.	из-за	
пандемии	COVID-19,	что,	в	конечном	итоге,	поставило	
п о д 	 у г р о з у 	 д о с т и ж е н и е 	 п о с т а в л е н н о й 	 ц е л и .	
Дополнительные	достижения	включают	значительное	
увеличение	 охвата	 тестированием	 на	 ВИЧ	 и	 АРТ	 за	
последние	несколько	лет,	а	также	увеличение	охвата	
тестированием	с	использованием	быстрых	методов,	
рекомендованных	ВОЗ.		

К	сожалению,	Региону	не	удалось	достичь	11	целевых	
ориентиров,	 в	 том	 числе	 в	 отношении	 показателя	
выявления	случаев	ТБ,	процента	РР/МЛУ-ТБ	среди	новых	
и	ранее	лечившихся	больных	ТБ,	распространенности	
ВИЧ	 среди	 новых	 случаев	 и	 рецидивов	 ТБ,	 охвата	
профилактическим	лечением	ТБ	(ПЛТ)	детей	в	возрасте	
до	5	лет,	а	также	показателей	успешного	лечения	среди	
новых	 с лучаев	 и	 рецидивов	 ТБ,	 когорт	 больных	 
РР/МЛУ-ТБ	 и	 больных	 ТБ	 в	 тюрьмах.	 Несмотря	 на	
предпринимаемые	усилия,	бремя,	связанное	с	РР-ТБ	и	
Т Б/ВИЧ,	 пр о до л ж ае т	 рас т и,	 ч т о	 у к а зыв ае т	 на	
необходимость	внедрения	более	инновационных	и	
эффективных	подходов	для	решения	этих	проблем.		
Показатели	 успешного	 лечения	 новых	 случаев	 и	
рецидивов	 ТБ	 и	 случаев	 РР/МЛУ-ТБ	 остаются	 ниже	
глобальных	 и	 региональных	 целевых	 ориентиров,	
однако	при	сравнении	данных,	собранных	в	период	с	
2016	 по	 2020	 гг.,	 можно	 отметить	 медленный,	 но	
устойчивый	 рост	 в	 обеих	 когортах.	 Необходимо	
активизировать	усилия,	направленные	профилактику,	

в	том	числе	на	отслеживание	контактов,	увеличение	
охвата	ПЛТ	и	АРТ	среди	людей,	живущих	с	ВИЧ.

Библиография5
1.  Дорожная	карта	по	реализации	плана	действий	по	
борьбе	с	туберкулезом	для	Европейского	региона	
ВОЗ	 на	 2016–2020	 гг.	 На	 пу ти	 к	 ликвидации	
т уберкулеза	 и	 т уберкулеза	 с	 множественной	
лек арс твенной	 ус тойчивос тью.	 Копенгаген:	
Европейское	 региональное	 бюро	 ВОЗ;	 2016	 г.	
(https://apps.who.int/iris/handle/10665/329487).

5	Все	веб-ссылки	были	просмотрены	12	февраля	2022.	

2.  Global tuberculosis report 2021. Geneva: World Health 
Organization;  2021  (ht tps://apps.who.int/iris/
handle/10665/346387).

3.  Dara M, Kuchukhidze G, Yedilbayev A, Perehinets I, 
Schmidt T, Leif Van Grieson W et al. Early COVID-19 
pandemic’s toll on tuberculosis services, WHO European 
Region,  Januar y  to  June  2020    Euro  Sur veill. 
2021;26(24):2100231.  doi:10.2807/1560 -7917.
ES.2021.26.24.2100231. 

4.  Sixty-fifth Regional Committee for Europe: Vilnius, 
14–17 September 2015. Tuberculosis action plan for 
the WHO European Region 2016–2020. Copenhagen: 
WHO Regional Office for Europe; 2015 (EUR/RC65/17 
Rev.1; https://apps.who.int/iris/handle/10665/337754).

xv

1. Main facts  
about tuberculosis

11

Tuberculosis (TB) is an infectious disease caused by a 
group of Mycobacterium species called the Mycobacterium 
tuberculosis (M. tuberculosis) complex (1). Globally, TB is 
the leading cause of death by an infectious disease (2). 
Although TB typically affects the lungs (pulmonary TB), it 
can cause disease in any organ (extrapulmonary TB). TB 
is transmitted from person to person when, for example, 
an individual with pulmonary TB expels bacteria into the 
air by coughing. 

Approximately 25% of the world’s population is infected 
with M. tuberculosis (3), but only a small proportion of 
people	infected	with	TB	(≈	10%)	will	develop	TB	disease	
during their lifetime; the risk is much higher among immu-
nocompromised individuals (such as people infected with 
HIV). 

Sputum-smear microscopy has been the most common 
initial TB diagnostic method worldwide, but culture remains 
the gold standard, while the use of rapid molecular testing 
is increasing.

Standard treatment of non-resistant TB consists of a six-
month regimen of four first-line drugs (isoniazid, rifampicin, 
ethambutol and pyrazinamide), with success rates usually 
above 85% (4). Multidrug-resistant TB (MDR-TB), pre-
extensively drug-resistant TB (pre-XDR-TB) and extensively 
drug-resistant TB (XDR-TB) require longer treatments with 
more drugs and are associated with lower success rates. 

WHO estimated that 9.9 million people fell ill with TB in 
2020. Most cases were thought to have occurred in the 
WHO South-East Asia Region (43%), the WHO African 
Region (25%) and the WHO Western Pacific Region (18%). 
Smaller proportions of cases were estimated for the WHO 
Eastern Mediterranean Region (8%) and the WHO Region 
of the Americas (3%). The WHO European Region accounted 
for 2% of all cases (4).

Overall, this report shows that in countries of the European 
Union/European Economic Area (EU/EEA), TB remains a 
public health issue. Most EU/EEA countries, however, are 
low-incidence countries (with a notification rate below 10 
per 100 000) in which TB predominantly affects vulnerable 
populations such as migrants, prison inmates and people 
coinfected with HIV.

The overall aim of TB surveillance is to help inform public 
health action. The annual TB surveillance and monitoring 
report presents key figures and trends and provides an 
overview of the TB situation in the EU/EEA and the WHO 
European Region.

References6
1.  Lawn	 SD,	 Zumla	 AI.	 Tuberculosis.	 Lancet	 2011;	
3 7 8 ( 9 7 8 5 ) :5 7 –7 2 .  d o i: 1 0 .1 0 1 6/S 0 1 4 0 -  67 3 6 
(10)62173-3.

2.  The Global Health Observatory. Global Health Estimates 
2019: disease burden by cause, age, sex, by country 
and  by  region,  2000–2019.  Geneva:  World  Health 
Organization; 2019 (https://www.who.int/data/gho/
data/themes/mortality-and-global-health-estimates).

3.  Houben RMGJ, Dodd PJ. The global burden of latent 
tuberculosis infection: a re-estimation using mathe-
matical modelling. PLoS Med. 13(10):e1002152. https://
doi.org/10.1371/journal.pmed.1002152

4.  Global tuberculosis report 2021. Geneva: World Health 
Organization;  2021  (ht tps://apps.who.int/iris/
handle/10665/346387).

6 All references were accessed on 12 February 2022. 

3

Tuberculosis surveillance and monitoring in Europe 2022SURVEILLANCE REPORT2. Technical note

55

Between 1996 and 2007, TB surveillance data from the 
European Region were collected and analysed annually 
under the EuroTB project. 

Since 1 January 2008, the European Centre for Disease 
Prevention and Control (ECDC) and the WHO Regional Office 
for Europe have jointly coordinated the collection and 
analysis of TB surveillance data in Europe, aiming to ensure 
data standardization and high quality across the WHO 
European Region. The underlying standards and definitions 
have been agreed by leading European experts. The defini-
tions used in this report are in line with the latest WHO 
revised definitions (1,2). In the EU/EEA, reporting follows 
European Union (EU) case definitions (3). 

The report covers the 53 countries of the WHO European 
Region and Liechtenstein. These are collectively referred 
to as the European Region. Although the United Kingdom 
was part of the EU/EEA until 31 January 2020, for ease of 
reporting the 2020 United Kingdom data and historical 
data are shown in the non-EU/EEA section of the tables.

Data published in the report may differ from figures in 
national reports due to variations in reporting periods and 
the deadlines for data collection. The deadline for updating 
the data used in this report was 4 October 2020.

2.1 Data-reporting and analysis
Designated experts within national surveillance, infectious 
disease or public health institutes submitted TB surveil-
lance and control programme management data for 2020 
electronically to the ECDC/WHO Regional Office for Europe 
Joint TB Information System via a common portal (4). TB 
surveillance data from the EU/EEA countries were later 
submitted to The European Surveillance System (TESSy) 
platform hosted by ECDC (Annex 1). Surveillance data from 
non-EU/EEA countries and areas and programme manage-
ment data from the entire European Region were processed 
through the WHO Tuberculosis Monitoring and Evaluation 
(TME)  platform  in  aggregated  format.  In  all,  29  of  30  
EU/EEA Member States reported case-based data. All 
countries in the European Region were also asked to provide 
updates for 2017, 2018 and 2019 to allow for the exclusion 
of duplicate cases or those found later not to have TB, and 
for the reporting of treatment outcomes in previously 
notified cases.

The TESSy variable list for collection of the 2020 data 
(Annex 2) has not undergone changes compared to the 
previous year. 

Reporting completeness (Annexes 3 and 4) varied among 
countries and areas due to differences in legislation, 
specifics of national surveillance systems and TB case 
ascertainment. Readers should be cautious when making 
comparisons across countries and areas, even though the 

quality and comparability of reported data have improved 
in recent years and the reporting completeness is generally 
high in the EU/EEA, with a few exceptions, such as HIV 
status and drug-susceptibility testing (DST) data.

Estimates of TB disease burden presented in Tables 1, 2, 
I and II are provided by WHO using a methodology devel-
oped by the Global Task Force on TB Impact Measurement. 
Estimates are updated annually using the latest available 
data and analytical methods (5). Population denominators 
were obtained from United Nations Population Division 
statistics (6) for the calculation of rates in these tables. 

For the calculation of notification rates, country total 
population denominators by age group and gender were 
obtained from Eurostat (7) (9 April 2021) for the EU/EEA 
countries and from United Nations Population Division 
statistics for all other countries and areas. 

Reported data were analysed using the main epidemio-
logical (time, place, gender, age and patient origin) and 
case management (history of previous anti-TB treatment, 
localization of disease, laboratory results, HIV status and 
treatment outcome) variables. If indicated, associations 
between variables were quantified as relative risk (RR) 
and their 95% confidence intervals (CI), and results were 
considered significant if the CI did not include 1.

2.1.1 TB/HIV coinfection

Case-based HIV status for 2020 was reported by Belgium, 
Bulgaria, Croatia, Cyprus, Czechia, Denmark, Estonia, 
Greece, Hungary, Ireland, Lithuania, Luxembourg, the 
Netherlands, Norway, Portugal, Romania, Slovakia, Slovenia 
and  Spain.  The  proportion  of  TB/HIV  coinfection  was 
expressed as a percentage of reported TB cases with known 
HIV status. HIV status had to be available for more than 
50% of all TB cases to be considered complete in the 
country profiles. For the reported new and relapse TB cases 
with known HIV status in 2020, start or continuation on 
antiretroviral therapy (ART) was reported by six EU/EEA 
Member States.

2.1.2 Laboratory network performance and 
drug resistance

Results of DST from initial isolates of M. tuberculosis have 
been  collected  for  isoniazid  and  rifampicin  since  the 
reporting year 1998. EU/EEA countries have also reported 
susceptibility to ethambutol and streptomycin, with 79% 
of EU/EEA countries reporting the latter for the last six 
years (2015–2020). Data on second-line drug resistance 
to amikacin, capreomycin, kanamycin, ciprofloxacin and 
ofloxacin have been reported via TESSy since 2008 and 
via the Centralized Information System for Infectious 
Diseases/TME since 2009. Data on ciprofloxacin are no 
longer collected in TESSy (since 2017), as ciprofloxacin is 
no longer recommended for treatment of drug-susceptible 

7

Tuberculosis surveillance and monitoring in Europe 2022SURVEILLANCE REPORTor drug-resistant TB. Data on resistance to gatifloxacin, 
levofloxacin and moxifloxacin were added in 2013, bedaqui-
line and delamanid in 2016 and pyrazinamide in 2017. 
Case-based information on DST is collected in countries/
areas where DST results are linked to TB case notifications 
(28 of 29 countries in 2020). 

years earlier. As part of the 2021 data call, for 2020 data, 
outcome data were collected for TB cases reported in 2019, 
rifampicin-resistant, multidrug-resistant  and pre-XDR-TB 
cases in 2018 and XDR-TB cases in 2017. Non-EU/EEA 
countries and areas have reported aggregated treatment 
outcome data following the same principle since 2013.

Where individual DST data are not available, data have 
been obtained from WHO’s TME platform in aggregated 
format, when possible and deemed adequate. Information 
on the organization and laboratory practices for anti-TB 
DST in the country/area is collected using the TME module 
of the joint TB surveillance system. Since 2019, when 
collecting  data  to  report  resistance  to  anti-TB  drugs,  
EU/EEA Member States have been required to report the 
resistance pattern used on initiation of the treatment to 
TESSy, irrespective of the method used for DST or resist-
ance  prediction.  Drug-resistance  surveillance  (DRS) 
methods vary across countries and areas. Initial DST results 
may be collected routinely for all culture-positive TB cases 
notified, or only for cases included in specific surveys or 
diagnosed in/referred to selected laboratories. DRS data 
were considered complete if: 

•  they were collected nation-/area-wide; or

•  culture results were available for 90% or more of all 

cases; and

•  more than 50% of all cases were culture-positive; and

•  more than 75% of all culture-positive cases had DST 

results available for isoniazid and rifampicin; and

•  at	least	95%	of	the	external	quality	assessment	(EQA)	
results were confirmed by a supranational reference 
laboratory.

DRS data were not reported (or are considered incomplete) 
for  Albania,  Andorra,  Bosnia  and  Herzegovina,  Italy, 
Georgia, Latvia, Liechtenstein, Monaco, Serbia, Switzerland 
and Turkmenistan. France reported complete national DRS 
data only for rifampicin-resistant TB (RR-TB) cases.

EQA	systems	are	essential	for	ensuring	accurate	diagnosis	
of	TB	and	drug-resistant	TB.	Implementing	EQA	by	organ-
izing	regular	EQA	rounds	and	identifying	training	needs	
is one of the key activities of the European Reference 
Laboratory Network for Tuberculosis (ERLTB-Net) (8). The 
EQA	test	results	for	2020	are	published	in	Annex	5.

Percentages of laboratory-confirmed drug-resistant cases 
were calculated using cases with known DST results (for 
at least isoniazid and rifampicin) as the denominator. The 
results of DST for second-line drugs were analysed only 
for MDR-TB cases. 

2.1.3 Treatment outcome monitoring

EU/EEA countries have provided treatment outcome data 
since the reporting year 2002 through the submission of 
an updated dataset for cases notified one year prior to the 
year of reporting. The same applies to rifampicin-resistant 
or multidrug-resistant TB (RR/MDR-TB) and pre-XDR-TB 
treatment outcome for cases reported two years earlier 
and XDR-TB treatment outcome for cases reported three 

8

If enrolment for treatment is taken into account for treat-
ment outcome monitoring analysis, two types of TB cases 
are included: cases enrolled for treatment and cases with 
no indication of enrolment for treatment. For countries 
and areas reporting case-based data, the most recently 
updated information was used. This may result in denomi-
nators differing from the number of notified cases reported 
in the previous year’s report. For countries and areas 
reporting aggregate outcome data, completeness of cohorts 
is assessed by comparing the total number of cases included 
in treatment outcome monitoring cohorts with those initially 
notified as pulmonary and culture- or smear-positive, 
depending on the type of cohort.

2.1.4 Geographical areas

The following 30 EU/EEA countries are presented separately 
in tables and in Chapter 3: Austria, Belgium, Bulgaria, 
Croatia, Cyprus, Czechia, Denmark, Estonia, Finland, France, 
Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia 
(case-based data not reported for 2020), Luxembourg, 
Liechtenstein, Lithuania, Malta, the Netherlands, Norway, 
Poland, Portugal, Romania, Slovakia, Slovenia, Spain and 
Sweden.

The 24 remaining (non-EU/EEA) countries in the WHO 
European  Region  are  Albania,  Andorra,  Armenia, 
Azerbaijan, Belarus, Bosnia and Herzegovina, Georgia, 
Israel, Kazakhstan, Kyrgyzstan, the Republic of Moldova, 
Monaco, Montenegro, North Macedonia, the Russian 
Federation, San Marino, Serbia, Switzerland, Tajikistan, 
Turkey, Turkmenistan, Ukraine, the United Kingdom and 
Uzbekistan.

Data from Serbia include TB cases reported from Kosovo7 
and these are also stratified in tables to reflect United 
Nations Security Council Resolution 1244 (1999).

Data from the 18 high-priority countries (HPCs) identified 
in the Plan to stop TB in 18 high-priority countries in the 
WHO European Region, 2007–2015 (9) are presented in 
italics and as subtotals alongside the subtotals for the 
EU/EEA countries and non-EU/EEA countries and areas. 
The 18 HPCs in the WHO European Region are: Armenia, 
A zerbaijan,  Belarus,  Bulg aria,  E stonia,  Georgia, 
Kazakhstan, Kyrgyzstan, Latvia (did not report case-based 
data  for  2020),  Lithuania,  the  Republic  of  Moldova, 
Romania,  the  Russian  Federation,  Tajikistan,  Turkey, 
Turkmenistan, Ukraine and Uzbekistan.

TB notifications from France include overseas territories. 
TB notifications from Greenland are not included in the 
report.

7 All references to Kosovo in this document should be understood to be 
in the context of the United Nations Security Council resolution 1244 
(1999).

SURVEILLANCE REPORTTuberculosis surveillance and monitoring in Europe 20222.2 Definitions
2.2.1 TB case definition for surveillance

Information from EU/EEA countries was collected to enable 
the classification of cases according to the case definition 
approved by EU Member States and published by the 
European  Commission  (3).  This  classifies  cases  as 
“possible”, “probable” or “confirmed”. Possible cases 
meet clinical criteria only. Probable cases meet the clinical 
criteria as well as at least one of the laboratory criteria 
for a probable case: detection of acid-fast bacilli by micros-
copy; detection of M. tuberculosis complex by nucleic acid 
amplification testing; or histological appearance of granu-
lomata. In addition to meeting clinical criteria, confirmed 
cases require isolation of M. tuberculosis complex by 
culture or detection of both acid-fast bacilli by microscopy 
and M. tuberculosis complex by nucleic acid amplification 
testing. 

Data from all countries and areas in the European Region 
also follow the WHO-recommended definitions (2013 revi-
sion) (1). These define a “case of tuberculosis” as a patient 
in whom TB has been confirmed by bacteriology or diag-
nosed by a clinician. A “bacteriologically confirmed TB 
case” is one from whom a biological specimen is positive 
by smear microscopy, culture or WHO-recommended rapid 
diagnostics (WRD) such as Xpert MTB/RIF (Mycobacterium 
tuberculosis (MTB) and resistance to rifampin (RIF)). A 
“clinically diagnosed TB case” is one that does not fulfil 
the criteria for bacteriological confirmation but has been 
diagnosed with active TB by a clinician or other medical 
practitioner who has decided to give the patient a full 
course of TB treatment.

Cases discovered postmortem as having gross pathological 
findings consistent with active TB, which would have 
indicated anti-TB treatment had the patient been diagnosed 
before dying, also fit the clinical criteria and are included. 

2.2.2 Previous anti-TB treatment status

New cases have never been treated for TB or have taken 
anti-TB drugs for less than one month. For EU/EEA countries, 
cases diagnosed before 1951 are analysed as new cases.

Previously treated patients have received one month or 
more of anti-TB drugs in the past. They are further classi-
fied by the outcome of their most recent course of treatment 
as follows:

•  relapse: patients have previously been treated for TB, 
were declared cured or to have completed their treatment 
at the end of their most recent course of treatment, and 
are now diagnosed with a recurrent episode of TB (either 
a  true  relapse  or  a  new  episode  of  TB  caused  by 
reinfection);

•  treatment after failure: patients who have previously 
been treated for TB and whose treatment failed at the 
end of their most recent course of treatment;

•  treatment after loss to follow-up: patients who have 
previously been treated for TB and were declared lost 
to follow-up at the end of their most recent course of 

treatment (these were previously classified as “treat-
ment after default”); and

•  other  previous  treatment:  patient s  who  have  
previously been treated for TB but whose outcome after 
their most recent course of treatment is unknown or 
undocumented. 

Patients with an unknown previous TB treatment history 
do not fit any of the categories listed above.

New and relapse cases of TB are incident TB cases.

2.2.3 Site of disease

Pulmonary TB refers to any bacteriologically confirmed 
or  clinically  diagnosed  case  of  TB  involving  the  lung 
parenchyma  or  the  tracheobronchial  tree  (laryngeal  
TB  is  classified  as  pulmonar y).  A  patient  with  both  
pulmonary and extrapulmonary TB is classified as a case 
of pulmonary TB.

Extrapulmonary TB refers to any bacteriologically confirmed 
or clinically diagnosed case of TB involving organs or 
anatomical sites other than the lungs (such as pleura, 
lymph nodes, abdomen, genitourinary tract, skin, joints 
and bones, or meninges).

2.2.4 Notes on the definition

The above TB case definition and the definition of previous 
anti-TB treatment status and site of disease are in accord-
ance with the European Commission’s approved definitions 
for TB surveillance.

All possible, probable and confirmed cases are reported 
to the joint European surveillance database. For countries 
and areas with laboratory-based reporting where no clinical 
information is available, laboratory-confirmed cases should 
be reported.

Cases should be notified only once in a given 12-month 
period, but a case should be reported again if the diagnosis 
of confirmed TB is made following completion of anti-TB 
treatment (relapse), even if this occurs within 12 months 
of reporting the initial disease episode.

Cases that have never been treated are commonly referred 
to as new cases, although this term should not be consid-
ered to indicate incidence in the strict epidemiological 
sense.

Among re-treated cases, relapses are included in notifica-
tions from all countries, but cases re-treated after failure 
or loss to follow-up and chronic cases are not included, or 
further defined, by Belgium, Cyprus, Denmark, France, 
Luxembourg, Malta, Norway, Spain and the United Kingdom.

DST data were analysed for laboratory-confirmed cases.

2.2.5 Origin of cases

The geographical origin of a TB case is classified according 
to the place of birth of a person with TB disease (that is, 
born  in  the  country/born  outside  of  the  country)  for 
Bulgaria, Croatia, Cyprus, Czechia, Denmark, Estonia, 

9

Tuberculosis surveillance and monitoring in Europe 2022SURVEILLANCE REPORTFinland, France, Germany, Iceland, Ireland, Israel, Italy, 
Kyrgyzstan, Latvia (did not report case-based data for 
2020), Liechtenstein, Lithuania, Luxembourg, Malta, the 
Netherlands, North Macedonia, Norway, Portugal, Romania, 
Slovakia, Slovenia, Spain, Sweden, Tajikistan, Turkey, the 
United Kingdom and Uzbekistan. For Albania, Andorra, 
Ar menia,  Austria,  Belarus,  Belgium,  Bosnia  and 
Herzegovina, Georgia, Greece, Hungary, Kazakhstan, the 
Republic of Moldova, Montenegro, Poland, the Russian 
Federation, Serbia, Turkmenistan and Ukraine, origin is 
classified according to citizenship (citizen/non-citizen). 
Azerbaijan, Georgia, Kyrgyzstan, Monaco and Turkmenistan 
did not report information on origin. In Denmark, the 
birthplace of the parents is also used to classify origin 
(similarly, for cases born in the Netherlands the birthplace 
of parents is also notified for case management purposes). 
The country of origin is included in case-based data.

The term “native” as used in this report refers to cases 
born in or having citizenship (nationality) of the reporting 
country. “Foreign origin” refers to cases born in (or citizens 
of) a country different to the reporting country.

2.2.6 Drug resistance

Resistance among cases never treated (new TB cases) 
indicates primary drug resistance due to infection with 
resistant bacilli.

Resistance among cases previously treated usually indi-
cates acquired drug resistance emerging during treatment 
following selection of drug-resistant mutant bacilli. It can 
also result from exogenous reinfection with resistant 
bacilli.

Multidrug resistance (MDR) refers to resistance to at least 
isoniazid and rifampicin.

In accordance with the WHO treatment outcome definitions 
(1), this report distinguishes between two types of cases:

•  patients treated for drug-susceptible TB; and

•  patients treated for RR-TB – for non-EU/EEA countries 
and areas this includes those placed on second-line 
treatment (defined as combination chemotherapy for 
drug-resistant TB).

The two groups are mutually exclusive. For EU/EEA coun-
tries, the case types are based on DST results. Any patient 
reported as having RR-TB is assumed to be on second-line 
treatment and is excluded from the drug-susceptible TB 
outcome cohort.

2.2.7.2 Period of observation

All cases are observed until the first outcome assessment 
up to a maximum of 12 months after the start of treatment. 
For RR/MDR-TB and pre-XDR-TB cases in EU/EEA countries, 
treatment outcome after 24 months should be reported if 
treatment lasts longer than 12 months and the reported 
12-month outcome is coded as “still on treatment”.8 For 
XDR-TB cases in EU/EEA countries, treatment outcome 
after 36 months should be reported if treatment lasts 
longer than 24 months and the reported 12-month and 
24-month outcomes are coded as “still on treatment”.9 
Non-EU/EEA  countries  and  areas  evaluate  treatment 
outcomes according to the WHO definition.

2.2.7.3 Treatment outcome categories

All outcome categories but one apply to the entire Region 
and follow the WHO recommendations in Definitions and 
reporting framework for tuberculosis – 2013 revision (1). 
The additional category “still on treatment” applies only 
to EU/EEA Member States. The categories are as follows. 

Pre-extensive  drug  resistance  (pre-XDR)  refers  to  
resistance to: (i) at least rifampicin (that is, rifampicin 
resistance/mutidrug resistance (RR/MDR)) and (ii) any 
fluoroquinolone.

Cured – a pulmonary TB patient with bacteriologically 
confirmed TB at the beginning of treatment who was smear- 
or culture-negative in the last month of treatment and on 
at least one previous occasion.

Extensive drug resistance (XDR) refers to resistance to: 
(i) at least rifampicin (that is, rifampicin resistance/mutidrug 
resistance (RR/MDR)); (ii) a fluoroquinolone; and (iii) at 
least one additional Group A drug (1,2). The drugs currently 
included  in  Group  A  are  levofloxacin,  moxifloxacin,  
bedaquiline and linezolid.

Rifampicin resistance refers to resistance to rifampicin 
detected using phenotypic or genotypic methods, with or 
without resistance to other anti-TB drugs. This includes 
any resistance to rifampicin, whether monoresistance, 
MDR, polydrug resistance, pre-XDR or XDR.

2.2.7 Treatment outcome

2.2.7.1 Cohorts

A cohort is defined as all TB cases notified in the calendar 
year of interest, after exclusion of cases with a final diag-
nosis other than TB, or cases found to have been reported 
more than once. 

Cured of MDR-TB, pre-XDR-TB and XDR-TB – treatment 
completed, as recommended under national policy without 
evidence of failure AND three or more consecutive cultures 
taken at least 30 days apart are negative after the intensive 
phase.

Treatment completed – treatment completed but does not 
meet the criteria to be classified as cured or treatment 
failed.

Treatment failed – a TB patient whose sputum smear or 
culture  is  positive  at  month  f ive  or  later  during 
treatment.

Treatment failed for MDR-TB, pre-XDR-TB and XDR-TB case 
– treatment terminated or the need for permanent regimen 
change of at least two anti-TB drugs because of:

8 The degree of adherence to the 12-month limit is unknown, and a 
number of countries are known to exceed it.

9  The degree of adherence to the 24-month limit is unknown.

10

SURVEILLANCE REPORTTuberculosis surveillance and monitoring in Europe 2022•  lack of conversion by the end of the intensive phase; or

•  bacteriological reversion in the continuation phase after 

conversion to negative; or

•  evidence of additional acquired resistance to fluoroqui-

nolones or second-line injectable drugs; or

•  adverse drug reactions.

Died – a TB patient who dies for any reason before starting, 
or during the course of, treatment.

Lost to follow-up – a TB patient who did not start treatment 
or whose treatment was interrupted for two consecutive 
months or more (defined in previous reports as “defaulted”).

Still on treatment10 – a patient reported as still on treat-
ment at 12 months without any other outcome during 
treatment, or a patient reported as still on treatment at 12 
months and still on treatment at 24 months without any 
other outcome.

Not evaluated – a TB patient for whom no treatment outcome 
is assigned; this includes cases “transferred out” to another 
treatment unit and cases for whom the treatment outcome 
is unknown to the reporting unit. 

In this report, success is the sum of “cured” and “treat-
ment completed”.

References11
1.  Definitions and reporting framework for tuberculosis 
– 2013 revision. Geneva: World Health Organization; 
2013 (https://apps.who.int/iris/handle/10665/79199).

2.  Meeting report of the WHO expert consultation on the 
definition of extensively drug-resistant tuberculosis, 

10 This definition is applicable to EU/EEA countries only.

11 All references accessed on 16 February 2022. 

27–29  O c tober  2020.  Gene v a:  Wor ld  Health 
Organization;  2021  (ht tps://apps.who.int/iris/
handle/10665/338776).

3.  Commission Implementing Decision (EU) 2018/945  
of  22  June  2018  on  the  communicable  diseases  
and related special health issues to be covered by 
epidemiological surveillance as well as relevant case 
definitions. OJ L 170, 6.7.2018, p. 1–74 (https://eur-lex.
europa.eu/legal-content/EN/TXT/?uri=uriserv%3A
OJ.L_.2018.170.01.0001.01.ENG).

4.  ECDC  –  WHO/Europe  joint  surveillance  [website]. 
Stockholm, Copenhagen: ECDC, WHO Regional Office 
for Europe; 2022 (http://ecdcwhosurveillance.org/).

5.  Global tuberculosis report 2020. Geneva: World Health 
Organization;  2020  (https://apps.who.int/iris/
handle/10665/336069). 

6.  World population prospects: the 2019 revision, medium 
variant. In: United Nations DESA/Population Division 
[website].  New  York  (NY ):  United  Nations  DESA/
Population Division; 2019 (https://population.un.org/
wpp/).

7.  Eurostat [website]. Brussels: Eurostat; 2018 (https://

ec.europa.eu/eurostat/home).

8.  European  Reference  Laborator y  Network  for  TB 
(ERLT B -Net).  In:  European  Centre  for  Disease  
Prevention and Control [website]. Stockholm: ECDC; 
2019  (https://www.ecdc.europa.eu/en/about-us/
partnerships-and-networks/disease-and-laboratory-
networks/erltb-net).

9.  Plan to stop TB in 18 high-priority countries in the WHO 
European  Region,  2007–2015.  Copenhagen:  WHO 
Regional Office for Europe; 2007 (https://apps.who.
int/iris/handle/10665/345352).

11

Tuberculosis surveillance and monitoring in Europe 2022SURVEILLANCE REPORT3. Commentary

3.1 The WHO European Region
3.1.1 TB burden estimates (incidence and 
mortality, HIV and RR/MDR)

An estimated 231 000 new and relapse TB cases (range 
201 000–264 000) occurred in countries and areas of the 
WHO European Region in 2020, equivalent to an average 
incidence of 25 cases (range 22–28) per 100 000 popula-
tion. This represents about 2.3% of the total burden of TB 
in the world. 

The absolute number of incident TB cases in the WHO 
European Region fell by 16 000 in 2020 compared to the 
previous year. About 84% of the estimated TB cases in the 
Region occurred in the 18 HPCs, where estimated TB inci-
dence was 47 cases per 100 000 population, which is 
almost five times higher than the EU/EEA average. The six 
countries with the absolute highest number of incident TB 
cases over 10 000 were the Russian Federation (68 000), 
Ukraine  ( 32 000),  Uzbekistan  (22 000),  Turkey  and 
Kazakhstan (13 000 each), and Romania (12 000). The 
number relative to population (incidence rate) was highest 
in Kyrgyzstan (105 per 100 000 population), followed by 
Tajikistan (84 cases), the Republic of Moldova (74 cases). 
Ukraine (73 cases) and Georgia (70 cases) (Table II). 

The estimated number of TB cases in the Region has been 
decreasing consistently since 2000. During the period 
2011–2020, the average annual decline in the TB incidence 
rate was 5.2%, with 6.4% between 2019 and 2020, which 
is notably higher than the global rate of decline for TB 
incidence  (1.9%)  and  the  fastest  decline  in  the  world 
compared to other regions (1). The cumulative reduction 
for the period 2015–2020 was 25%, indicating that the 
Region exceeded the 2020 End TB Strategy milestone to 
reduce the TB incidence rate in 2020 by 20% against the 
2015 baseline, and also achieved the regional action plan 
target of a 25% reduction in the TB incidence rate. This 
was mostly driven by the decline in the Russian Federation, 
where incidence fell by 6% per year between 2011 and 
2020. It should nevertheless be emphasized that most of 
the HPCs in the Region have also experienced a decline 
in the TB incidence rate. During the period 2011–2020, the 
HPCs with the highest annual rate of decline were Estonia 
(−9.7%),	 Armenia	 (−9.2%),	 Belarus	 (−9.2%),	 Lithuania	
(−8.6%),	Azerbaijan	(−8.2%),	Latvia	(−7.6%)	and	Kazakhstan	
(−7.2%).

An estimated 21 000 TB deaths occurred among HIV-negative 
people in the European Region in 2020, equivalent to 2.3 
deaths per 100 000 population (range 2.2–2.4). Between 
2011 and 2020, the TB mortality rate at regional level fell 
cumulatively by 54%, from 4.9 to 2.3 deaths per 100 000 
population, which on average is a decline of 8.3% per year 
(Table I). TB mortality in the Region plateaued between 
2019 and 2020 for the first time in the last two decades. 

This was a consequence of undiagnosed and untreated TB 
and an associated increase in deaths due to disruptions 
to TB services caused by the COVID-19 pandemic. As a 
result, the reduction in the absolute numbers of TB deaths 
in 2020 compared to 2015 was only 26% versus the 35% 
target of the regional action plan and the End TB Strategy 
(1). Considerable variation was seen across the Region, 
ranging from fewer than one TB death per 100 000 popula-
tion in western European countries up to 10 per 100 000 
in HPCs. The TB mortality rate was highest in Turkmenistan 
(10  deaths per 100 000), followed by Tajikistan (9.6) and 
Ukraine (9.4). Together, the 18 HPCs accounted for over 
86% of TB deaths in the Region. 

An estimated 12% (range 9.2–16%) of incident TB cases 
in 2020 were coinfected with HIV (Table 2). The proportion 
of TB cases coinfected with HIV was highest in the Russian 
Federation (24%), Turkmenistan and Ukraine (22% each), 
followed by the Republic of Moldova (13%) and Armenia 
(11%). The top five countries with the highest absolute 
number of TB/HIV coinfection cases were the Russian 
Federation (16 000) and Ukraine (7000), representing 79% 
of the total number of cases, followed by Kazakhstan (850), 
Uzbekistan (690) and Turkmenistan (630).

Nine of the 30 countries with the highest RR/MDR-TB burden 
in the world are in the WHO European Region.12 In 2020, 
the WHO European Region had an estimated 37 000 incident 
cases of RR/MDR-TB among notified bacteriologically 
confirmed pulmonary TB cases, with MDR-TB accounting 
for 88% (Table 2). An estimated 18% (95% CI: 17–20%) of 
newly diagnosed patients and 53% (95% CI: 45–60%) of 
previously treated patients had RR/MDR-TB. Overall, an 
estimated 69 000 (range 54 000–86 000) incident cases 
of RR/MDR-TB occurred in the Region in 2020.

3.1.2 TB notification and trends

In 2020, 199 700 TB patients were reported from 51 coun-
tries and areas13 in the WHO European Region. Of these, 
163 602 were incident TB patients (Table 3, Table III). This 
represents an unprecedented 24.4% drop in the number 
of notified TB patients compared to 2019, due to the impact 
of the COVID-19 pandemic on access to TB diagnostic and 
treatment services. This translates into TB treatment 
coverage of 71% (95% CI: 62–81%) in 2020 (approximated 
as notifications divided by incidence), down from 88% 
(95% CI: 77–100%) in 2019. Among the HPCs, the sharpest 
drop was observed in Armenia and the Republic of Moldova 
(37% each), Romania (35%), Belarus (31%), Kyrgyzstan 

12 The nine countries from the WHO European Region included in the 
global list of 30 countries with highest RR/MDR-TB burden are (in 
alphabetical order): Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, the 
Republic of Moldova, the Russian Federation, Tajikistan, Ukraine and 
Uzbekistan.

13 Latvia and San Marino did not report, and Monaco reported zero cases 
in 2020.

15

Tuberculosis surveillance and monitoring in Europe 2022SURVEILLANCE REPORTand Lithuania (32% each), and Ukraine and Tajikistan (30% 
each).

The notification rate of new and relapse cases in 2020 
varies widely among countries, from zero (Monaco) to 65 
(Kyrgyzstan) per 100 000 population (Map 1 and Table III). 
Thirty-eight countries, mainly located in the western and 
central part of the Region, had low notification of new and 
relapse cases (fewer than 20 cases per 100 000) in 2020. 
Twelve reported new and relapse case rates of between 
20 and 50 per 100 000 population and two reported over 
50 cases per 100 000 population (Kyrgyzstan (65) and 
Kazakhstan (51.1)). The new and relapse case notifications 
from the 18 HPCs account for about 83% of the regional 
burden. Over a third of new and relapse cases (58 723) 
come from the Russian Federation, even though the Russian 
Federation  accounts  for  only  16%  of  the  Region’s 
population. 

The notification rate of new and relapse cases in the 18 
HPCs is almost twice as high as for the Region overall (33 
cases per 100 000, compared to 18 for the Region) and 
almost five times higher than the rate in the EU/EEA (seven 
cases per 100 000 population) (Fig. 3.1.1).

3.1.3 Previous treatment history

In 2020, previously treated cases represented 10.4% and 
34.3% in the EU/EEA and non-EU/EEA, respectively (Table 
4). The average in the 18 HPCs was 34.5%, which is above 

the pan-European average of 30.3%. Previously treated 
cases accounted for 15% or more of all TB cases in 13 
countries: Azerbaijan (48.7%), the Russian Federation 
(44.2%),  Turkmenistan  ( 38.6%),  Belarus  ( 34.1%), 
Kazakhstan (30.8%), Kyrgyzstan (27.7%), Ukraine (27.5%), 
the Republic of Moldova (27.3%), Uzbekistan (22.9%), 
Romania (21.8%), Georgia (19.4%), Lithuania (18.6%) and 
Armenia (16.9%). Reasons for the high percentage of previ-
ously treated cases include clinical failure or poor treatment 
adherence in previous treatment episodes, and possible 
reinfection and misclassification during the current treat-
ment episode.

3.1.4 Disease localization

Pulmonary localization was notified in 82.8% of the incident 
TB cases in the Region in 2020 (Table 6). The proportion 
of patients with pulmonary localization in the non-EU/EEA 
countries  and  areas  was  higher  than  in  the  EU/EEA. 
Extrapulmonary TB was notified on average for 17.2% of 
all incident TB cases in the Region. Thirteen countries 
reported more than 30% of their TB cases having extrapul-
monary localization: Andorra, Belgium, Finland, France, 
Lichtenstein, the Netherlands, Norway, Portugal, Sweden, 
Tajikistan, Turkey, the United Kingdom and Uzbekistan.

3.1.5 Bacteriological confirmation

Bacteriological confirmation of TB diagnosis was reported 
for 90 549 (66.8%) of all 135 521 new and relapse pulmonary 

Map 1. TB notification rates of new TB cases and relapses per 100 000 population, European Region, 2020

< 10
11–20
21–40
41–60
> 60
Not included or not reported

Non-visible countries

Andorra
Liechtenstein
Luxembourg
Malta
Monaco
San Marino

Sources: 2020 data from the European Surveillance System (TESSy) and 2020 data from the WHO global TB data-collection system. Map production: ©  WHO.

0

1000

2000 km

16

SURVEILLANCE REPORTTuberculosis surveillance and monitoring in Europe 2022Fig. 3.1.1. Trend of TB notification rate per 100 000 between 2016 and 2020 in countries below 10 cases per 100 000 
(upper panel) and 10 cases and over per 100 000 (lower panel) in the WHO European Region

2016
2020

0.0

2.0

4.0

6.0

8.0 10.0

12.0

14.0 16.0 18.0

Rate per 100 000

Monaco
Israel
Andorra
Norway
Slovakia
Sweden
Finland
Iceland
Czechia
Denmark
Netherlands
Greece
Slovenia
Italy
Cyprus
Hungary
Switzerland
Austria
Croatia
Ireland
Germany
Serbia
Luxembourg
Liechtenstein
United Kingdom
Spain
Montenegro
France
Belgium
North Macedonia
Poland
Albania
Estonia

Turkey
Bosnia and Herzegovina
Bulgaria
Armenia
Portugal
Belarus
Lithuania
Malta
Turkmenistan
Latvia
Uzbekistan
Azerbaijan
Romania
Ukraine
Russian Federation
Georgia
Tajikistan
Republic of Moldova
Kazakhstan

European Region
Subtotal 18 HPCs

0.0 10.0 20.0 30.0 40.0 50.0 60.0 70.0 80.0 90.0 100.0

Rate per 100 000

Note: Latvia did not report data in 2020 and is excluded.

17

Tuberculosis surveillance and monitoring in Europe 2022SURVEILLANCE REPORTcases in the Region (Table 6). Testing of patients using 
WRD  (such  as  Xpert  MTB/RIF)  was  much  lower  in  the  
EU/EEA countries (33.7%) than in the non-EU/EEA countries 
and areas (82.3%). The five-year trend nevertheless shows 
a continuing increase in usage of WRDs across the Region, 
from 55.5% in 2016 to 72.3% in 2020 (Fig. 3.1.2 and Table 
XIV). Testing also varied considerably among countries 
and areas, from 0.2% in Bulgaria to 96% in Kazakhstan. 
Bacteriological confirmation of new and relapse pulmonary 
cases was below 60% in seven countries, underlining the 
need  to  streng then  diag nostics:  Serbia  (45.7 %), 
Turkmenistan (46.9%), Malta (52.5%), Hungary (53%), the 
Russian Federation (53.4%), Iceland (55.6%) and Slovakia 
(56.9%). In 34 countries, bacteriological confirmation of 
new and relapse pulmonary cases was 75% and above. 

3.1.6 Age and sex

There is wide variation in the distribution of age- and sex-
specific notification rates across countries and areas (Table 
8). Notification rates in eastern European countries are 
highest in young adults (25–44 years) and subsequently 
decline with increasing age, while in central Asia and in 
Turkey, the notification rates either increase with age or 
are relatively constant across adult age groups. 

In the group of 18 HPCs, the rate of TB in children under 5 
years was lower than the notification rate among children 
aged 5–14 years, indicating that detection of TB remains 
particularly challenging in young children. 

In countries and areas with at least 100 new and relapse 
TB cases, the proportion of TB cases notified in children 
(0–14 years) varied from below 1% (Bosnia and Herzegovina, 
Belarus, Czechia and Estonia) to 22.9% (Slovakia) of all 
new and relapse cases. The difference in proportions of 
childhood TB cases across the countries and areas may 
reflect differences in case-finding practice (such as contact 
tracing), population age structure and under/overdiagnosis 
or reporting of childhood TB. The average percentage of 
new and relapse TB patients under 15 years in the Region 
is 4%. 

There were about twice as many males as females reported 
among  all  incident  TB  cases,  but  large  variation  was 

observed for male predominance in the sex distribution 
of TB cases, ranging from almost even distribution to over 
three times greater in Armenia and the Republic of Moldova. 
The exceptions were Norway and Serbia, where the number 
of female TB patients outnumbered those of males. In most 
countries and areas, gender differences in notification 
rates appear to be more significant among middle-aged 
and older adults. TB rates in males and females seem more 
similar in children and younger adults (0–14 and 15–24 
years). This gender difference in TB case notification most 
probably reflects the overrepresentation of males in the 
various TB risk groups, notably homeless people, prisoners, 
seasonal  migrant  workers  and  people  living  with  HIV 
(PLHIV).

3.1.7 Drug resistance

Fifty countries in the Region reported test results for 
rifampicin resistance in 2020. Overall, DST coverage in 
the Region, at least for rifampicin among bacteriologically 
confirmed pulmonary TB cases, was 92%, with 41 countries 
achieving coverage of 85% or higher. Only in two countries 
was the coverage less than 50% (Spain (46.8%) and France 
(3.4%)). The percentage of confirmed RR-TB cases among 
64 608 new pulmonary TB cases tested for rifampicin 
resistance in the Region was 23.1% (Map 2, Fig. 3.1.3, Table 
11 and Table V). While 18 countries reported no RR-TB or 
less than 1% among new TB cases, the rate was over 20% 
in eight countries (Table 11). Overall, for EU/EEA countries, 
the prevalence of RR-TB cases among all confirmed new 
pulmonary TB cases tested for rifampicin resistance was 
2.8%, but among previously treated pulmonary cases, the 
RR-TB proportion was higher at 12.8% (Fig. 3.1.4). 

Six HPCs had an RR/MDR-TB prevalence ranging from 10% 
to 19% among new cases tested for rifampicin resistance: 
Uzbekistan  (18.3%),  Estonia  (18%),  Armenia  (14.1%), 
Lithuania (12.4%), Azerbaijan (12%) and Georgia (10.7%). 
Four had 20–29% RR/MDR-TB among new cases (Ukraine 
(28.6%), Kyrgyzstan (28.3%), the Republic of Moldova 
(26%) and Tajikistan (24.2%)) and three had an RR/MDR-TB 
prevalence  over  30%  (Belarus  (39.5%),  the  Russian 
Federation  ( 36.3%)  and  Kazakhstan  ( 36.2%)).  The 
percentage of RR/MDR-TB reported for France is misleading, 
as DST results are documented for RR-TB cases only. 

Fig. 3.1.2. New and relapse TB cases tested using WRD such as Xpert MTB/RIF, European Region, 2016–2020

Notified

Tested

2016

2017

2018

2019

2020

s
e
s
a
C

250 000

200 000

150 000

100 000

50 000

0

Source: WHO (2).

18

SURVEILLANCE REPORTTuberculosis surveillance and monitoring in Europe 2022Map 2. Percentage of notified TB cases with MDR among new pulmonary laboratory-confirmed TB cases, European 
Region, 2020

< 2
12–6
7–14
15–30
> 30
Not included or not reported

Non-visible countries

Andorra
Liechtenstein
Luxembourg
Malta
Monaco
San Marino

0

1000

2000 km

Sources: 2020 data from the European Surveillance System (TESSy) and 2020 data from the WHO global TB data-collection system. Map production: ©  WHO.

The percentage of confirmed RR/MDR-TB cases among 
35 961 previously treated pulmonary bacteriologically 
confirmed TB cases whose isolates were tested for first-
line DST was 55.2% (Fig. 3.1.3, Table 11 and Table VI). 

Fourteen  countries/areas  had  between  15%  and  49%  
RR/MDR-TB among previously treated TB cases tested for 
first-line DST. The rate was even higher in some HPCs: 
Belarus (74.5%), the Russian Federation (68.4%), Kyrgyzstan 
(54%), the Republic of Moldova (53.1%) and Armenia (50%) 
(Fig. 3.1.5, Table 11). 

The rates of RR/MDR-TB notification among new and previ-
ously treated patients in 2020 at regional level was 1.6 
and 2.2 per 100 000 respectively (Table V, Table VI). A 
sharp decline in RR/MDR-TB notifications compared to the 
previous year is the result of the overall drop in TB notifica-
tions due to the COVID-19 pandemic. 

Trends in the rifampicin-resistant percentage among new 
bacteriologically confirmed pulmonary TB cases and trends 
in the notification rate per 100 000 population have differed 
by country in recent years (Table V). At subregional level, 
the proportion of rifampicin resistance among new pulmo-
nary TB cases remained stable in the EU/EEA over the last 
five years, ranging between 2.6% and 2.8%. Similarly, the 
rate of notified RR/MDR-TB cases remained stable at around 
0.1 case per 100 000 population. The rifampicin-resistant 

percentage among new bacteriologically confirmed pulmo-
nary TB cases in the non-EU/EEA countries and areas 
increased  slightly  from  25.7%  to  27.8%.  Before  the 
pandemic, the RR/MDR-TB notification rate among new TB 
patients ranged between 3.8 and 4.0 per 100 000 popula-
tion, with no sign of a decreasing trend. In 2020, the  
RR/MDR-TB  notification  rate  per  100 000  population 
declined to 3.1 per 100 000 population during the same 
period. 

Forty-four countries reported on DST data to fluoroqui-
nolones among pulmonary RR/MDR-TB patients in 2020. 
Data  on  DST  to  fluoroquinolones  were  available  for  
about 94.3% of all notified pulmonary RR/MDR-TB cases. 
Of the 32 851 pulmonary RR/MDR-TB cases subjected to 
DST to fluoroquinolones, 10 819 (32.9%) were pre-XDR-TB 
(Table 12).

Nineteen countries additionally reported DST results for 
any other Group A drugs among the pre-XDR-TB patients. 
Of 3898 pre-XDR-TB patients tested for resistance against 
any other Group A drugs, the prevalence of XDR-TB was 
6.5% at regional level (Table 12). In EU/EEA countries, 
where 71.3% of pre-XDR-TB cases were tested for Group A 
drugs, the prevalence of XDR among pre-XDR cases was 
45.1%, while in non-EU/EEA countries and areas where 
DST coverage to other Group A drugs was only 35.7%, the 
XDR prevalence among pre-XDR patients was 5.7%. Among 

19

Tuberculosis surveillance and monitoring in Europe 2022SURVEILLANCE REPORTFig. 3.1.3. Percentages of RR/MDR-TB among laboratory-confirmed pulmonary TB cases, European Region, 2016–2020 

e
g
a
t
n
e
c
r
e
P

60

50

40

30

20

10

0

New

Previously treated

2016

2017

2018

2019

2020

Fig. 3.1.4. Percentages of RR/MDR-TB among laboratory-confirmed pulmonary TB cases by previous treatment history, 
EU/EEA, 2016–2020

e
g
a
t
n
e
c
r
e
P

16

14

12

10

8

6

4

2

0

New

Previously treated

Unknown previous 
treatment history

2016

2017

2018

2019

2020

Fig. 3.1.5. Percentages of RR/MDR-TB among laboratory-confirmed pulmonary TB cases, 18 HPCs, 2016–2020

e
g
a
t
n
e
c
r
e
P

60

50

40

30

20

10

0

Notified

Tested

2016

2017

2018

2019

2020

countries and areas reporting at least 30 pre-XDR cases 
with Group A DST results, three reported over 20% XDR 
prevalence among pre-XDR-TB cases: Lithuania (35.3%), 
Georgia (28.6%) and Tajikistan (25.6%).

There is no clear trend in relation to pre-XDR-TB prevalence 
in countries and areas with a long history of DST surveil-
lance for fluoroquinolones among pulmonary RR/MDR-TB 
cases. In most, the pre-XDR percentage varies widely from 
year to year, but at regional level, pre-XDR prevalence 
among RR/MDR-TB cases slightly increased over the past 
four years, from 25.6 in 2017 to 32.9% (Table VIII). 

A total of 32 544 RR/MDR-TB and 11 979 pre-XDR-TB patients 
were enrolled in respective treatment programmes. The 
number of cases starting RR/MDR-TB treatment in 2020 
exceeded the total number of patients notified during the 
same period, as many of the HPCs have reported higher 
numbers of cases enrolled than detected. The reasons for 
such discrepancies include incomplete reporting, backlogs 
of RR/MDR-TB patients, frequent treatment failures and 
treatment interruptions leading to re-enrolment of the 
same patients in the same yearly cohort, and weakness 
of  surveillance.  Four  HPCs  reported  a  gap  of  over  5% 
between the number of RR/MDR-TB patients diagnosed 

20

SURVEILLANCE REPORTTuberculosis surveillance and monitoring in Europe 2022and the number enrolled in RR/MDR-TB treatment (treat-
ment coverage): Tajikistan (82%), Azerbaijan (89.3%), 
Kyrgyzstan (93.7%) and Belarus (94%) (Table 13). 

In 2020, access to XDR-TB treatment at regional level was 
83.5%. Seven HPCs (Azerbaijan, Belarus, Estonia, Georgia, 
Kyrgyzstan, the Russian Federation and Tajikistan) reported 
an over-5% gap in XDR-TB treatment coverage. 

3.1.8 TB/HIV coinfection

Thirty-nine countries/areas provided surveillance data  
on  TB/HIV  coinfection  (Table  14).  Of  the  141 960  new  
and  relapse  TB  patients  notif ied  in  the  repor ting  
countries/areas, 131 428 (92.6%) were screened for HIV. 
Twelve HPCs achieved a testing level above 90%: Armenia, 
Azerbaijan, Belarus, Estonia, Kazakhstan, Kyrgyzstan, 
Lithuania, the Republic of Moldova, the Russian Federation, 
Tajikistan, Ukraine and Uzbekistan. A total of 19 663 TB 
cases were detected with HIV-positive status, representing 
15% of those tested, compared with 14.3% recorded in 
2019. 

Among countries/areas reporting representative HIV testing 
(above 50% HIV testing coverage), four documented a 
significant overlap in the HIV and TB epidemics by exceeding 
10% HIV prevalence among new and relapse TB cases 
(Table 14): the Russian Federation (24.2%), Ukraine (21.8%), 
the Republic of Moldova (12.9%) and Armenia (10.6%). Six 
countries with representative routine surveillance had 
5–10% HIV prevalence among TB patients: Portugal (9.9%), 
Spain (9.7%), Estonia (9.7%), Israel (9.5%), Belarus (8.9%) 
and Kazakhstan (6.5%).

Twenty-six countries/areas in the Region provided informa-
tion on ART enrolment among TB cases with HIV-positive 
status in 2020. Of 19 312 HIV-positive TB cases, 14 351 
(74.3%) had received ART. This is slightly lower than in 
2019 (75.8%) and still below the WHO target of universal 
ART coverage. Eight HPCs achieved ART coverage of over 
90%: Azerbaijan, Belarus, Bulgaria, Estonia, Georgia, 
Kazakhstan, Tajikistan and Ukraine. 

3.1.9 Country of origin

TB patients of foreign origin represent 9.4% of all TB cases 
notified Region-wide: 33% in EU/EEA countries and 4.3% 

Fig. 3.1.6. TB cases of foreign origin, 2016–2020 

e
g
a
t
n
e
c
r
e
P

35

30

25

20

15

10

5

0

28.7

8.0

3.7
1.6

in non-EU/EEA countries and areas (Table 9, Fig. 3.1.6). TB 
patients of foreign origin represent a large majority in 
several countries: Liechtenstein (100%), Malta (97.9%), 
Iceland  (91.7%),  Sweden  (86.6%),  Cyprus  (86.1%), 
Luxembourg (85.3%), Israel (84.8%), Norway (81.3%), the 
Netherlands (72.4%), Denmark (72.1%), Switzerland (71.3%) 
and the United Kingdom (70.1%).

3.1.10 TB in prisons

Twenty-three countries/areas in the Region provided infor-
mation on TB case detection and treatment in prisons 
during 2020 (Table 15). Overall, 6887 (5.6%) of new and 
relapse TB cases in the Region were reported from prisons, 
with 6723 (97.6%) of these in the HPCs. The proportion of 
TB cases in prisons represented about 0.9% of the country 
total in EU/EEA countries; in non-EU/EEA countries and 
areas, the proportion was 6.2%. The notification rate in 
prisons in the non-EU/EEA countries and areas was 735 
new TB cases per 100 000 population, which is over five 
times higher than in the EU/EEA subregion (137 per 100 000). 
The overall notification rate for new TB cases in prisons 
in the WHO European Region was 628 per 100 000 popula-
tion. The TB notification rate exceeded 1000 cases per 
100 000 detainees in three countries: the Republic of 
Moldova, the Russian Federation and Ukraine. The highest 
TB-related risks in prison (relative to incidence in the 
general population) are calculated to be in Ukraine (RR 
27.6) followed by the Russian Federation (RR 27.1), the 
Republic of Moldova (RR 25.2) and Azerbaijan (RR 19.0). 

3.1.11 Treatment outcome

The treatment success rate among 162 955 new and relapse 
TB cases having started treatment with first-line drugs in 
2019 was 76.5% (Table 16). In the HPCs, the average rate 
of cases cured or for whom treatment was completed was 
78.2%.  The  treatment  success  rate  was  lower  in  the  
EU/EEA countries than in non-EU/EEA countries and areas 
(71.8% versus 77.5%), both showing results comparable 
with the previous year. Only 13 countries achieved an 85% 
treatment success rate in this treatment cohort. Another 
11 were close to the target, with success rates of 80–85%. 
Eight  countries  had  treatment  success  rates  below  
60%,  with  a  very  high  proportion  of  cases  not  being 
evaluated.

33.0

8.8

4.0
1.9

EU/EEA

Non-EU/EEA

European Region

18 HPCs

2016

2017

2018

2019

2020

Year of reporting

21

Tuberculosis surveillance and monitoring in Europe 2022SURVEILLANCE REPORTA total of 13 265 (8.1%) cases were reported to have died 
in the same cohort, 4.7% to have been lost to follow-up 
and 3.7% to have had treatment that failed. These unfa-
vourable outcomes were lower in the EU/EEA countries 
than in the rest of the Region, exemplified by the proportion 
of patients with failed treatment – 0.8% in the EU/EEA 
versus 4.3% in non-EU/EEA countries and areas (Table 16). 
Countries reporting fatal outcomes in excess of 10% were 
Slovenia (22.4%), Andorra (20%), Estonia (16.7%), Hungary 
(13.2%), Croatia (11.9%), Czechia (11.2%) and the Russian 
Federation (10.9%). 

The  treatment  success  rate  among  the  5007  child  TB  
cases (aged 0–14 years) in the 2019 cohort was 88.8% 
(Table 18). The treatment success rate in EU/EEA countries 
was remarkably lower than in the non-EU/EEA countries 
and areas (77% versus 92.8%). Among child TB cases in 
the Region, 1% died, another 1% failed and 1% were lost 
to follow-up. 

Of the 17 490 TB/HIV coinfected patients who started 
treatment throughout the Region in 2019, only 9587 (54.8%) 
had a successful treatment outcome (Table 20). 

In the 2018 cohort, treatment outcome was notified for 
47 707 laboratory-confirmed RR/MDR-TB cases reported 
by 42 countries (Table 22). The treatment success rate for 
the whole Region was 55.9%, which is slightly lower than 
the 58.6% rate reported for the 2017 RR/MDR-TB treatment 
cohort. The treatment success rate for RR/MDR-TB patients 
was higher in non-EU/EEA countries and areas than in the 
EU/EEA (56% versus 52.4%). In the Region as a whole, 
14.5% of RR/MDR-TB cases died, 12.8% failed and 11.3% 
were lost to follow-up. 

3.1.12 Conclusions for the WHO European 
Region

Analysis of 2020 routine surveillance data indicated that 
the remarkable progress in containing the burden of TB in 
the Region observed between 2015 and 2019 was halted 
in 2020 by the COVID-19 pandemic. As of December 2020, 
the WHO European Region has been the global epicentre 
of the COVID-19 pandemic, accounting for 31% of COVID-19 
cases and deaths (3). TB services were disrupted because 
diagnostic and clinical services were repurposed and 
health workers reallocated to COVID-19. In addition, there 
were changes in patients’ health-care-seeking behaviour 
influenced by the restrictions on movement imposed by 
authorities, concerns about the risks of going to health 
facilities during the pandemic and stigma associated with 
similarities in symptoms between TB and COVID-19. As a 
result, the pace of decline in TB mortality and TB incidence 
slowed, far fewer people were diagnosed and treated for 
TB and remarkably fewer people were tested for drug 
resistance and enrolled into RR/MDR-TB treatment. 

Despite these challenges, the progress made over the first 
four years of the action plan were sufficient for the Region 
to achieve the regional action plan target of reducing the 
TB incidence rate in 2020 by 25% and achieving the End 
TB Strategy milestone of reduction of TB incidence by 20% 
against the 2015 baseline (4). 

22

For the first time in over two decades, the downward trend 
in the number of TB deaths was halted in 2020 as a conse-
quence of delay in, or lack of, TB diagnosis due to disruption 
to TB services, leading to increased severity of disease and 
an associated increase in deaths. This compromised the 
achievement of the End TB Strategy milestone on reduction 
of number of TB deaths. The actual reduction in absolute 
number of TB deaths in 2020 compared to 2015 was only 
26% against the targeted 35%. Modelling projections suggest 
that the impact of disruptions caused by the pandemic on 
the number of people developing TB and dying from the 
disease could be much worse in 2021 and 2022 (5,6). Detailed 
analysis of the status of the action plan indicators against 
the target is provided in Chapter 4. 

Other impacts associated with the COVID-19 pandemic in 
the Region include a 17.7% reduction in the number of  
RR/MDR-TB patients detected and enrolled into treatment. 
On a more positive note, treatment outcome of new and 
relapse TB patients remained comparable in the 2019 
cohort compared to the 2018 cohort and there was no 
evidence of a significant reduction in treatment success. 
This was enhanced by adaptation of service delivery modes 
to  mitigate  the  pandemic  impact,  including  reducing 
frequency of outpatient visits for treatment monitoring or 
collection of anti-TB drugs, allowing TB patients to take a 
one-month  (or  longer)  supply  of  anti-TB  drugs  home, 
expanded use of remote advice and support, and home 
delivery of anti-TB drugs (7). 

There is a need to introduce and/or scale up innovative 
and adaptive models of care to address the challenges 
posed by the COVID-19 pandemic and ensure quality and 
timely  TB  services  are  provided  despite  the  ongoing 
pandemic. Actions and innovative solutions need to be 
implemented  to  reverse  the  impact  of  the  COVID-19 
pandemic to restore provision of diagnostic, treatment 
and preventive services to pre-pandemic levels. National 
health programmes and health authorities need to work 
with community representatives and partners to maintain 
TB diagnostic, treatment and preventive services and build 
synergies between COVID-19 and TB services. Revamping 
political commitment, allocating adequate national and 
international  resources  and  implementing  innovative 
approaches are crucial to avoiding losing the gains of the 
past decade. 

3.2 EU/EEA countries
3.2.1 Data completeness

TB notification data for 2020 were reported by 29 of 30 
countries (there were no data from Latvia for 2020). The 
reporting of non-mandatory variables in 2020 was complete 
or near complete (above 95%) for age, gender, TB site and 
variables defining the origin of a case (Annex 3). Overall, 
previous treatment history was available for 83.2% of 
cases reported in 2020, but completeness ranged from 
below 70% in six countries (Croatia 4.4%, France 54.2%, 
Iceland 0%, Ireland 52.1%, Liechtenstein 50% and Spain 
64.9%) to 100% in 12 countries (Annex 3).

SURVEILLANCE REPORTTuberculosis surveillance and monitoring in Europe 2022Among TB cases reported in 2020, 81% had culture results 
reported (Annex 3), which was a similar proportion to that 
reported in 2019 (81.1%). Eight countries had fewer than 
75% of cases with culture results reported: France (52.7%), 
Iceland (50%), Ireland (74.6%), Italy (66%), Liechtenstein 
(50%), Malta (30.7%), Portugal (65.3%) and Spain (72.5%). 
Reporting completeness for microscopy in 2020 (82.8%) 
was comparable to 2019 data (83%) and ranged from 36.3% 
in Ireland to 100% in Lithuania and Liechtenstein. For 2020, 
drug-susceptibility reporting completeness was 71.4% for 
first-line drugs (isoniazid and rifampicin). Completeness 
of DST reporting for at least one second-line drug (including 
bedaquiline, moxifloxacin and levofloxacin) was 100% for 
the 22 countries that reported at least one RR/MDR-TB 
case (Annex 3). 

The number of countries reporting HIV status remained 
constant, with only 19 (of 29) reporting HIV status in both 
2020 and 2019. This is a decline compared to 2018, when 
there were 21 (of 30) reporting and 2017, when there were 
23 (of 31). HIV status was available for only 39.3% of all 
TB cases reported in 2020, but 12 countries reported HIV 
status for more than 75% of their TB cases (Annex 3).

3.2.2 Time and place

In 2020, 33 148 cases of TB were reported in 29 EU/EEA 
countries  (Table  3).  The  number  of  cases  reported  in 
Romania  (7698)  accounted  for  23.2%  of  all  TB  cases 
reported in 2020.

The EU/EEA notification rate in 2020 was 7.3 per 100 000 
population  (Table  3),  continuing  the  downward  trend 
observed since the launch of European enhanced TB surveil-
lance	in	1996	(Fig.	3.2.1).	During	the	period	2016−2020,	
the average annual decline in the notification rate was 
11.6% (Table 3).

As reported for previous years, country-specific notifica-
tion rates differed considerably in 2020, ranging from 2.9 
per 100 000 population in Slovakia to 39.8 per 100 000 in 
Romania (Table 3). Rates were below 10 per 100 000 in 24 

countries, but above 25 per 100 000 in three: Lithuania 
26.0 per 100 000, Malta 27.2 and Romania 39.8.

Compared with 2016, notification rates have fallen in 26 
countries (Table 3). The annual rate of decrease exceeded 
10% in 16 countries, with the downward trend being particu-
larly  pronounced  in  Croatia,  Hungary,  Lithuania  and 
Sweden,  where  the  average  annual  rate  of  decrease 
exceeded 15%.

3.2.3 Previous treatment, laboratory 
confirmation and TB site

The distribution of cases by previous treatment history 
was similar in 2020 to that reported in previous years: 
24 139 (72.8%) of 33 148 TB cases reported in 2020 were 
newly diagnosed, 3451 (10.4%) had previously been treated 
for TB and 5558 (16.8%) had unknown previous treatment 
status (Table 4). The proportion of previously treated cases 
was over 10% in eight countries: Bulgaria, Estonia, Hungary, 
Lithuania, Norway, Poland, Romania and Slovakia.

Of all 33 148 TB cases reported in 2020, 23 640 (71.3%) 
were diagnosed with pulmonary TB, 7117 (21.5%) with 
extrapulmonary TB, 2116 (6.4%) with a combination and 
275 (0.8%) had no TB site reported (Table 5). The propor-
tion of extrapulmonary TB was above 30% in eight countries: 
Belgium  ( 30.8%),  Finland  ( 32.2%),  France  ( 30.9%), 
Liechtenstein (100%), the Netherlands (45.6%), Norway 
(38.1%), Portugal (30.2%) and Sweden (36.9%).

Of 24 618 new and relapse pulmonary TB cases reported 
in 2020, 20 191 (82%) were confirmed by culture and/or 
smear and nucleic acid amplification test (Table 6). Over 
30% of reported new and relapse pulmonary TB cases were 
diagnosed clinically in five countries: Bulgaria (38.1%), 
Hungary (47%), Iceland (44.4%), Malta (47.5%) and Slovakia 
(43.1%).

According to the EU case definition, 22 301 (67.3%) of 
33 148  TB  cases  reported  in  2020  are  classified  as 
confirmed, 3691 (11.1%) as probable and 7156 (21.6%) as 

Fig. 3.2.1. TB notification rate per 100 000 population by year of reporting, EU/EEA, 1995–2020

30

25

20

15

10

5

0

0
0
0
0
0
1

r
e
p
s
e
s
a
C

1995

1997

1999

2001

2003

2005

2007

2009

2011

2013

2015

2017

2019

Source: ECDC (3).

23

Tuberculosis surveillance and monitoring in Europe 2022SURVEILLANCE REPORT 
 
 
possible cases (Table 7). The proportion of laboratory-
confirmed TB cases remained stable in 2020 compared to 
2019 (67.1%) and 2018 (68.2%). Country-specific propor-
tions of laboratory-confirmed cases ranged from 30.7% 
in Malta to 94.8% in Slovenia, but over 75% of reported 
cases  were  laborator y-conf irmed  in  15  countries. 
Conversely, six countries reported over 40% of their TB 
cases as possible cases (that is, only clinically diagnosed): 
Bulgaria (43.1%), France (40.8%), Hungary (48.3%), Iceland 
(50%), Malta (51.4%) and Slovakia (41.1%). The high propor-
tion of clinically diagnosed cases may reflect underre-
porting  of  laboratory  results  to  national  surveillance 
systems in these countries, or could indicate that TB may 
be overdiagnosed in these countries.

3.2.4 Age and sex

Of 31 551 new and relapse TB cases reported in 2020, 
20 448  (64.8%)  were  aged  between  25  and  64  years  
and 6152 cases (19.5%) were in adults aged over 64 years 
(Table 8). Notification rates were similar among the 15–24 
and 45–64 years age groups (7.8 and 7.9 per 100 000 
population, respectively), slightly higher among the 25–44 
years age group (9.0 per 100 000 population) and slightly 
lower among those aged over 64 years (6.6 per 100 000 
population).

There was variation in the age distribution of cases between 
countries. In most, the cases were predominantly aged 
between 25 and 64 years, but cases were younger in Malta 
(42.9% were aged between 15 and 24 years) and older in 
Croatia, Estonia, Finland and Slovenia (where over 30% of 
cases were aged over 64 years (Table 8)).

Children under 15 years accounted for 1218 (3.8%) of 31 551 
new and relapse TB cases reported in 2020 (Table 8). 
Children aged between 5 and 14 years had the lowest 
notification rate of all age groups, at 1.5 per 100 000 popu-
lation. Malta reported the highest notification rates among 
children under 15 years: 16.7 cases per 100 000 children 
aged	0−4,	and	6.6	cases	per	100	000	aged	between	5	and	
14 (Table 8).

In 2020, the male-to-female ratio in new and relapse TB 
cases was 2 : 1. (Table 8), which was higher than the ratio 
reported in (male-to-female ratio was 1.8 : 1). In 26 of 29 
EU/EEA Member States, more new and relapse TB cases 
were reported among males than females. Norway reported 
slightly more female than male cases (male-to-female ratio 
was 0.8 : 1), while Liechtenstein and Iceland reported an 
equal ratio. For children under 15 years, the male-to-female 
ratio among new and relapse cases was almost equal.

3.2.5 Origin of cases

Of the 33 148 TB cases notified in 2020, 20 991 (63.3%) 
were born in, or were citizens of, the reporting country 
(referred to as “native”), 10 942 (33%) were of foreign 
origin and 1215 (3.7%) were of unknown origin (Table 9). 
Of the 10 942 cases of foreign origin in 2020, 71.6% (7839) 
were reported by only four countries (France, Germany, 
Italy and Spain). Country-specific proportions of foreign-
origin TB cases ranged from below 1% in three countries 
(Bulgaria, Croatia and Romania) to above 85% in six (Cyprus, 

24

Iceland, Liechtenstein, Luxembourg, Malta and Sweden). 
The overall proportion of native TB cases increased slightly 
from 62.8% in 2019 to 63.3% in 2020 (Table 9).

3.2.6 Drug resistance

Annex	5	displays	participation	and	performance	in	an	EQA	
scheme for DST by Member State.

Of 19 190 bacteriologically confirmed TB cases notified in 
2020, 14 997 (78.2%) had DST results reported for at least 
rifampicin (Table 10). The proportion of cases with DST 
results reported for at least rifampicin varied by country, 
ranging from 3.4% in France to 100% in nine countries 
(Cyprus, Denmark, Estonia, Iceland, Lithuania, Malta, 
Norway, Slovenia and Sweden). Among the pulmonary 
cases with rifampicin DST results, 649 (4.3%) were RR-TB 
and 566 (3.8%) were reported as MDR-TB. 

The  proportion  of  MDR-TB  cases  varied  by  countr y  
(Table 10). Eight countries reported no MDR-TB cases in 
2020, while a further 11 reported that the proportion of 
MDR-TB cases (among cases with DST results) was below 
2%. France reported 100% of cases with DST results as 
RR/MDR-TB,  but  DST  results  are  only  repor ted  for  
RR/MDR-TB cases in France. The highest proportion of 
MDR-TB cases (among cases with DST results) was reported 
by Estonia and Lithuania, with 19.4% and 16.7% reported 
as MDR-TB, respectively. 

The proportion of RR/MDR-TB among all bacteriologically 
confirmed  pulmonary  TB  cases  with  DST  results  for 
rifampicin was 4.2% (595 of 14 134 (Table 11)). When the 
data were analysed by previous treatment history, the 
proportion of RR/MDR-TB was higher among previously 
treated cases (12.8%, 260 of 2035) than new cases (2.8%, 
335 of 12 099). 

In 2020, 64.3% of RR/MDR-TB cases (417 of 649) had DST 
results for any fluoroquinolone (Table 12). Among these, 
115 (27.6%) met the definition for pre-XDR. Of all pre-XDR 
cases, the majority were reported by Lithuania (32.7%, 
34 cases) and Romania (28.1%, 27 cases). The majority 
(71.3%, 82 of 115) of pre-XDR cases had DST results reported 
for at least one other Group A drug (Table 12). Among these 
cases, 37 (45.1%) met the new XDR case definition. All 
XDR-TB cases were reported by only eight EU/EEA countries: 
Belgium (2.7%, one case), Czechia (10.8%, four), Estonia 
(16.2%, six), Germany (16.2%, six), Lithuania (32.4%, 12), 
Poland (10.8%, four), Romania (5.4%, two) and Sweden 
(5.4%, two). 

3.2.7 TB/HIV coinfection

HIV status was reported for 12 327 (73.4%) of 16 804  
TB cases reported from the 19 countries that reported HIV 
status of TB cases (Table IX). Of the cases with known HIV 
status, 515 (4.2%) were reported as HIV-positive. Among 
the 15 countries with at least 50% reporting completeness 
for HIV status, the proportion of coinfected cases was 
highest in Estonia (9.7%), Hungary (11.8%) and Portugal 
(9.9%). The trend in the proportion of HIV-coinfected TB 
cases decreased from 4.5% in 2016 to 4.2% in 2020, but 

SURVEILLANCE REPORTTuberculosis surveillance and monitoring in Europe 2022the proportion of coinfected cases in 2020 was higher 
than in 2019 (3.9% (Table IX)). 

3.2.8 TB in prisons

For 2020, 13 EU/EEA countries reported 266 new and relapse 
TB cases in prisons, resulting in a notification rate of 137 
per 100 000 prison population and a RR of 9.3 compared 
to the general population in the same countries (Table 15). 
Overall, TB cases in prisons accounted for 0.9% of all new 
and relapse cases notified in the 13 reporting EU/EEA 
countries, with the proportion being highest in Luxembourg 
(3.3%).

3.2.9 Treatment outcome

Of all 28 985 new and relapse TB cases notified in 2019 
with a treatment outcome reported in 2020, 20 797 (71.8%) 
were treated successfully, 2192 (7.6%) died, 230 (0.8%) 
experienced treatment failure, 1069 (3.7%) were lost to 
follow-up, 667 (2.3%) were still on treatment in 2020 and 
4030 cases (13.9%) were not evaluated (Table 16). Among 
the 23 countries that reported treatment outcome for the 
2019 cohort, eight reported successful treatment for over 
80% of cases: Belgium (80.8%), Bulgaria (81.8%), Iceland 
(100%), Lithuania (87.1%), the Netherlands (86.3%), Norway 
(84.6%),  Romania  (83.7%)  and  Slovakia  (93.8%).  In 
contrast, five countries reported death as the outcome for 
over 10% of cases: Croatia (11.9%), Czechia (11.2%), Estonia 
(16.7%), Hungary (13.2%), and Slovenia (22.4%) (Table 16). 

Treatment success among the 1021 previously treated TB 
cases notified in 2019 was 51.2% (Table 17), which was 
lower than the treatment success among new and relapse 
cases. A higher proportion of previously treated cases 
were reported to have treatment failure (7%) or to have 
died (8.8%) compared to new and relapse cases. 

Treatment outcome at 12 months was also reported for 
639  HIV-positive  TB  cases  who  were  notified  in  2019  
(Table 20). Of these, 352 (55.1%) were reported as success-
fully treated, 59 (9.2%) died, four (0.6%) experienced 
treatment failure, 44 (6.9%) were lost to follow-up, 51 (8%) 
were still on treatment in 2020 and 129 (20.2%) were not 
evaluated (Table 20).

Of 927 RR/MDR-TB cases notified in 2018 with a treatment 
outcome  reported  in  2020,  486  (52.4%)  were  treated 
successfully, 134 (14.5%) died, 97 (10.5%) experienced 
treatment failure, 109 (11.8%) were lost to follow-up, 51 
(5.5%) were still on treatment in 2020 and 66 (7.1%) were 
not evaluated (Table 22). Only five of the 18 countries that 
had reported RR/MDR-TB cases in 2018 and treatment 
outcomes in 2020 had treatment success above the target 
of 75%: Austria (83.3%), Belgium (77.8%), the Netherlands 
(83.3%), Norway (83.3%) and Sweden (100%). The 24-month 
treatment success rate for RR/MDR-TB was higher among 
the 2018 cohort (52.4%) than in previous cohorts: treat-
ment success was below 50% for cases reported between 
2014 and 2017 (Table XI).

Among the 211 cases categorized as pre-XDR-TB notified 
in 2018 with treatment outcome at 24 months reported in 
2020, 70 cases (33.2%) were reported as having treatment 

success, while 42 (19.9%) were reported to have died and 
43 (20.4%) had treatment failure (Table 23). Treatment 
success among the pre-XDR-TB cohort over the previous 
five years (2014–2018) had been below 35% each year 
(Table XII). 

In 2020, treatment outcome at 36 months for XDR-TB 
cases notified in 2017 was reported by seven countries, 
with  a  total  of  26  XDR-TB  cases.  Fourteen  countries 
reported zero XDR-TB cases in 2017. Among the 26 XDR-TB 
cases, 10 (38.5%) were treated successfully, four (15.4%) 
died,  one  (3.8%)  experienced  treatment  failure,  two 
(7.7%) were lost to follow-up and nine (34.6%) were not 
evaluated (Table 24). 

3.2.10 WHO disease burden estimates

According  to  WHO,  the  estimated  TB  incidence  in  the  
EU/EEA  overall  (excluding  Liechtenstein)  was  9.5  per 
100 000 population in 2020 (Table 1 and Table II). Of the 
29 countries with estimates, 22 had an estimated incidence 
of fewer than 10 per 100 000 population (Table 1 and Table 
II). The overall number of estimated TB deaths, excluding 
HIV deaths in people who were HIV-positive, was 3800 for 
the EU/EEA in 2020, the same as estimated for 2019 (3800) 
and a reduction of approximately 25% on the 5100 estimated 
for 2011 (Table I).

3.2.11 Conclusions for the European Union/
European Economic Area

In 2020, 29 of 30 EU/EEA countries reported TB notification 
data and a total of 33 148 TB cases. There was a further 
decline in the overall TB notification rate to 7.3 per 100 000 
population, which continued the decreasing trend observed 
since 2002. As in previous years, a few countries reported 
a large proportion of the total number of cases, including 
Romania, which reported almost a quarter of all TB cases 
in 2020.

The decline in total case numbers and notification rates 
in 2020 should be interpreted with caution, given the 
potential impact of measures put in place to mitigate the 
COVID-19 pandemic on TB clinical services and surveillance 
across the EU/EEA. A survey was conducted alongside the 
2020 TB data submission, asking EU/EEA Member States 
about the impact of the COVID-19 pandemic specifically 
on the 2020 TB surveillance data collection. Of the 26  
EU/EEA Member States that responded, five countries 
indicated that there was, or may have been, a change in 
the representativeness of 2020 surveillance data within 
their countries due to the impact of lockdowns and other 
measures on TB clinical services. A reduction in complete-
ness of TB data was reported by four countries in the 
survey. Three respondents indicated that TB data collection 
could not be prioritized over COVID-19 clinical work, which 
particularly impacted collection of treatment outcome 
variables. The analysis of data completeness (presented 
in Annex 3) indicated decreased completeness across 11 
of the 17 variables in 2020 compared with 2019, most 
notably for previous treatment history, diagnosis ante-
mortem, DST for first-line drugs, enrolment in treatment 
and outcome at 12 months. 

25

Tuberculosis surveillance and monitoring in Europe 2022SURVEILLANCE REPORTThe diversion of TB resources, whether clinical, laboratory 
or public health (including surveillance and contact tracing), 
to COVID-19 activities was the key issue identified in the 
survey when Member States were asked about the general 
impact of the pandemic on TB clinical services and surveil-
lance data collection. It was suggested by some Member 
States  that  difficulties  in  patients  accessing  clinical 
services, either due to lockdown/movement restrictions 
or  overburdened  health  ser vices,  alongside  fear  of 
contracting COVID-19, may have resulted in delayed pres-
entation and/or diagnosis of some TB cases during 2020. 
Delayed diagnosis may have resulted in more severe illness 
at time of diagnosis for some cases. In addition, delayed 
treatment  of  pulmonary  cases,  along  with  decreased 
contact-tracing resources for TB, may have led to more TB 
transmission. As such, it is hypothesized that there may 
be an increase in the number and clinical severity of cases 
in the coming years.

If the decline in TB incidence during 2020 was real and not 
just an artefact of the COVID-19 pandemic, it would indicate 
ongoing progress towards reaching the United Nations 
Sustainable Development Goal 3 target of an 80% reduc-
tion in the TB incidence rate in 2030 compared to 2015. 
The target at EU/EEA level is a notification rate of 2.4 per 
100 000 population (based on an 80% reduction of the 
2015 TB notification rate of 11.9 per 100 000 population). 
The decline observed in 2020 would indicate progress is 
being  made,  but  at  the  current  rate  of  decline,  most  
EU/EEA countries are still not on track to reach the 80% 
reduction target by 2030 or the elimination target by 2050 
(8). Additional resources may be required to accelerate 
progress towards achieving these goals and to counteract 
any increase in TB cases resulting from the impact of the 
COVID-19 pandemic on TB services. 

The  number of drug-resistant TB cases  in  the EU/EEA 
continued to decrease in 2020, despite the high number 
of drug-resistant TB cases in the European Region HPCs 
bordering the EU/EEA. DST results for first-line drugs were 
only  reported  for  approximately  70%  of  laboratory-
confirmed TB cases in 2020. This shows a decline from 
almost 75% of laboratory-confirmed TB cases in 2019, 
indicating considerable room for improvement in DST 
testing. The definitions of “drug-resistant TB” changed in 
2020, with the introduction of a “pre-XDR-TB” definition 
and a change to that for “XDR-TB”, although “MDR-TB” 
remained unchanged (9). Pre-XDR-TB is defined as TB that 
fulfils the definition of RR/MDR-TB (resistance to at least 
rifampicin) and which is also resistant to any fluoroqui-
nolone. The new definition for XDR-TB includes cases that 
meet the definition for pre-XDR-TB (resistance to rifampicin 
and any fluoroquinolone) as well as having resistance to 
any other Group A drug. Changes to these definitions, 
along with the updated WHO treatment guidelines for 
drug-resistant TB (10), emphasize the need for DST against 
second-line drugs, particularly fluoroquinolones, bedaqui-
line and linezolid. 

Overall, it is reassuring that TB incidence continued to 
decline across the EU/EEA in 2020 and that a low propor-
tion of drug-resistant cases was reported, but there is still 

26

considerable work ahead to achieve the United Nations 
Sustainable Development Goals target. With the disruption 
caused by the COVID-19 pandemic during 2020, it is now 
critical that TB services are prioritized and appropriately 
resourced to support intensified public health measures 
against TB. ECDC remains committed to supporting EU/
EEA countries in ending the TB epidemic.

References14
1.  Sixty-fifth Regional Committee for Europe: Vilnius, 
14–17 September 2015. Tuberculosis action plan for 
the WHO European Region 2016–2020. Copenhagen: 
WHO Regional Office for Europe; 2015 (EUR/RC65/17 
Rev.1; https://apps.who.int/iris/handle/10665/337750).

2.  Automated real-time nucleic acid amplification tech-
nology for rapid and simultaneous detection of tuber-
culosis and rifampicin resistance. Xpert MTB/RIF assay 
for the diagnosis of pulmonary and extrapulmonary 
TB in adults and children: policy update. Geneva: World 
Health Organization; 2013 (WHOWHO/HTM/TB/2013.16; 
https://apps.who.int/iris/handle/10665/112472).

3.  COVID-19 weekly epidemiological update, 29 December 
2020.  Geneva:  World  Health  Organization;  2020 
(https://apps.who.int/iris/handle/10665/338325).

4.  Global strategy and targets for tuberculosis prevention, 
care and control after 2015. In: Sixty-seventh World 
Health Assembly, Geneva, 19–24 May 2014. Resolutions 
and  decisions,  annexes.  Geneva:  World  Health 
Organization; 2014 (WHA67.1; https://apps.who.int/
iris/handle/10665/162760).

5.  The potential impact of the COVID-19 response on 
tuberculosis in high-burden countries: a modelling 
analysis. Geneva: Stop TB Partnership in collaboration 
with Imperial College, Avenir Health, Johns Hopkins 
University and USAID; 2020 (http://stoptb.org/assets/
documents/news/Modeling%20Report_1%20May%20
2020_FINAL.pdf). 

6.  Glaziou  P.  P redic ted  impac t  of  the  COV ID -19  
pandemic  on  global  tuberculosis  deaths  in  2020. 
medRxiv 2020;2020.04.28.20079582. https://doi.
org/10.1101/2020.04.28.20079582

7.  Dara M, Kuchukhidze G, Yedilbayev A, Perehinets I, 
Schmidt T, Leif Van Grieson W et al. Early COVID-19 
pandemic’s toll on tuberculosis services, WHO European 
Reg ion,  Januar y  to  June  2020.  Euro  Sur veill. 
2021;26(24):2100231.  doi:10.2807/1560 -7917.
ES.2021.26.24.2100231. 

8.  Tow ards  tuberculosis  elimination:  an  ac tion  
framework in low-incidence countries. Geneva: World 
Health Organization; 2014 (https://apps.who.int/iris/
handle/10665/132231). 

9.  Meeting report of the WHO expert consultation on  
t he  def init ion  of  e x tensi vel y  dr ug- re sis t ant  

14 All references accessed on 16 February 2022. 

SURVEILLANCE REPORTTuberculosis surveillance and monitoring in Europe 2022tuberculosis, 27–29 October 2020. Geneva: World 
Health Organization; 2021 (https://apps.who.int/iris/
handle/10665/338776).

10.  WHO consolidated guidelines on tuberculosis. Module 
4. Treatment. Drug-resistant treatment. Geneva: World 
Health Organization; 2020 (https://apps.who.int/iris/
handle/10665/332397). 

27

Tuberculosis surveillance and monitoring in Europe 2022SURVEILLANCE REPORT4. Commentary 
– monitoring 

4.1 WHO European Region
The final year covered by the Tuberculosis action plan for 
the WHO European Region 2016–2020 was 2020. The plan 
was developed by the WHO Regional Office for Europe in 
close consultation with representatives from countries, 
experts and communities and was endorsed at the 65th 
meeting of the WHO Regional Committee for Europe through 
resolution EUR/RC65/17 (1). The monitoring report summa-
rizes the status of the indicators of the action plan according 
to the targets set by the monitoring and evaluation frame-
work that was established to monitor the performance of 
the action plan’s areas of intervention. A selection of 
indicators was harmonized with the End TB Strategy’s 
recommended top 10 global indicators. The action plan 
will be superseded by the new TB action plan for the WHO 
European Region 2023–2030 that will be submitted to the 
72nd session of the WHO Regional Committee for Europe 
in 2022. 

4.1.1 Monitoring of indicators

Indicator 1.A.1 Coverage of population at risk with 
systematic screening for active TB and latent TB 
infection 

The WHO global TB database collects information only on 
coverage of TB screening outcomes among the household 
contacts of bacteriologically confirmed TB cases. In 2020, 
19 countries reported on coverage of TB screening among 
household contacts. Overall, 98% of household contacts 
were  screened  for  TB.  All  10  HPCs  that  provided  data 
achieved the targeted 80% of screening coverage. 

Indicator 1.B.1 Percentage of newly notified TB 
patients diagnosed using WHO-recommended rapid 
tests (G)15

No baseline data were available. The target was first set 
to 30% and later updated to 90%, based on the global 
targets for the End TB Strategy. In 2020, 45 countries 
reported data on the proportion of newly notified patients 
diagnosed using WRD. As is shown in Fig. 4.1.1, the target 
at regional level has not been achieved: only 72% of new 
and relapse cases were diagnosed using WRD. This figure 
was higher for the 18 HPCs, reaching 81%. Of these, five 
met the target, 11 did not meet the target and two (Latvia 
and Turkey) did not provide information. At EU/EEA subre-
gional level, only 34% of cases were diagnosed using rapid 
tests (Fig. 4.1.1). 

Indicator 1.B.2 First-line DST coverage (%) among all 
bacteriologically confirmed TB cases (G)

The  action  plan  aimed  to  ensure  provision  of  DST  for  
all  bacteriologically  confirmed  TB  cases.  In  2020,  50  
countries/areas reported routine surveillance data on DST. 

Coverage of DST among all bacteriologically confirmed TB 
cases was 92%. In all, 14 of 16 HPCs had DST coverage 
above 90% (Fig. 4.1.2). Latvia and Turkmenistan did not 
report complete routine drug-resistance surveillance data. 

Indicator 1.B.3 RR/MDR-TB case-detection rate (%) (G)

In 2020, 34 832 RR/MDR-TB cases were detected among 
bacteriologically confirmed pulmonary TB patients notified 
in the WHO European Region. This is 94% of all estimated 
cases, indicating comprehensive RR/MDR case detection 
among notified patients at regional level. However, consid-
ering that on average 45 000 RR-TB/MDR-TB patients were 
enrolled in treatment annually in the WHO European Region 
between 2015 and 2019 without any sign of a decreasing 
trend, the substantial drop in the number of RR/MDR-TB 
patients is one of most worrying impacts of the COVID-19 
pandemic on overall TB detection in the Region. 

Indicator 1.B.4 TB notification rate per 100 000 
population (E)16

The regional action plan aims to reduce the TB incidence 
rate by 25% by 2020 against the 2015 baseline. Before 
2020, the trend in TB notification rates was considered a 
good proxy of TB incidence in the Region. During the period 
2015–2019, notification of new and relapse TB cases in 
the Region declined by 5.1% per year on average. This 
trend was in line with the annual decrease in the WHO 
estimated TB incidence for the Region (5.1%), resulting in 
a 19% reduction in the TB incidence rate between 2015 
and 2019, which was the highest decline observed among 
all WHO regions and on target to meet the 2020 End TB 
Strategy milestone. 

Due to severe disruption to health services caused by the 
COVID-19 pandemic, however, TB notifications at regional 
level dropped by 24.6% in 2020 compared to 2019, meaning 
that many people with TB were not detected by health 
systems or reported by surveillance systems. Among HPCs, 
the highest drop was observed in Armenia and the Republic 
of  Moldova  (37%  each),  followed  by  Romania  (34.7%)  
(Fig. 4.1.3). In this context, the observed decline in TB noti-
fications is no longer relevant for the assessment of perfor-
mance against the target for this indicator. The impact of 
COVID-19 resulted in a slowing of the annual decline of TB 
burden and modelling studies suggested that negative 
impacts would become much worse in 2021 and beyond (2).

Indicator 1.B.5 TB case-detection rate (%)

In 2020, 163 602 incident TB cases were notified in 52 
countries/areas across the WHO European Region, compared 
with an estimated 231 000 cases (range: 201 000–264 000). 
T his  r e p r e s e n t s  a  c a s e - d e te c t i o n  r a te  o f  7 1%  
(95% CI: 62–81%), which is remarkably lower than the 87% 

15 G (Global) indicates that this indicator belongs to the End TB 
Strategy’s recommended top 10 global indicators.

16  (E) represents a European-level indicator. 

31

Tuberculosis surveillance and monitoring in Europe 2022SURVEILLANCE REPORTFig. 4.1.1. Percentage of new and relapse TB patients notified in 2020 who were diagnosed using WRD in 18 HPCs and 
WHO European Region, 2020 

Target = 90%

y
r
t
n
u
o
C

Kazakhstan

Ukraine

      Republic of Moldova

Belarus

Uzbekistan

Georgia

Estonia

Tajikistan

Armenia

Azerbaijan

Russian Federation

Kyrgyzstan

Turkmenistan

Romania

Bulgaria

Turkey

Lithuania

Latvia

European Region

18 HPCs

0

10

20

30

40

50

60

70

80

90

100

Note: Latvia and Turkey did not report data.

Percentage

Figure 4.1.2. First-line DST coverage (%) among all bacteriologically confirmed TB cases (G) by 18 HPCs and WHO 
European Region, 2020

Target = 100%

y
r
t
n
u
o
C

Belarus

Uzbekistan

Tajikistan

Lithuania

Estonia

Kazakhstan

Georgia

Armenia

Ukraine

Azerbaijan

    Republic of Moldova

  Russian Federation

Kyrgyzstan

Turkey

Romania

Bulgaria

Turkmenistan

Latvia

European Region

18 HPCs

0

20

40

60

80

100

Percentage

(G): global indicator.

Note: Latvia and Turkmenistan did not report data.

32

SURVEILLANCE REPORTTuberculosis surveillance and monitoring in Europe 2022Fig. 4.1.3. Trend in new and relapse TB notification rate per 100 000 population (E) for 18 HPCs and WHO European 
Region, 2014–2020

Armenia

Azerbaijan

Belarus

Bulgaria

50

40

30

20

10

0

20

15

10

5

0

80

60

40

20

0

50

40

30

20

10

0

30

20

10

0

2014

2016

2018

2020

2014

2016

2018

2020

2014

2016

2018

2020

2014

2016

2018

2020

Estonia

Georgia 

100

50

0

Kazakhstan

Kyrgyzstan

100

50

0

150

100

50

0

2014

2016

2018

2020

2014

2016

2018

2020

2014

2016

2018

2020

2014

2016

2018

2020

Latvia

Lithuania

Republic of Moldova

Romania

40

30

20

10

0

80

60

40

20

0

60

40

20

0

150

100

50

0

80

60

40

20

0

2014

2016

2018

2020

2014

2016

2018

2020

2014

2016

2018

2020

2014

2016

2018

2020

Russian Federation

Tajikistan

Turkey

Turkmenistan

80

60

40

20

0

20

15

10

5

0

60

40

20

0

2014

2016

2018

2020

2014

2016

2018

2020

2014

2016

2018

2020

2014

2016

2018

2020

Ukraine

Uzbekistan

18 HPCs

80

60

40

20

0

80

60

40

20

0

80

60

40

20

0

European Region

40

30

20

10

0

2014

2016

2018

2020

2014

2016

2018

2020

2014

2016

2018

2020

2014

2016

2018

2020

  Trend for new and relapse TB notification rates
  The 2020 milestone target of 25% reduction in TB incidence against the 2015 baseline, assuming that notification is the proxy of TB estimated 

incidence

(E): European indicator.

(95% CI: 72–100%) baseline measured in 2014. Before the 
COVID-19 pandemic, most of the countries had successfully 
improved case detection and were on track to increase the 
number of TB cases detected, but in 2020, the case-detec-
tion rate was above 75% in only three of the 18 HPCs. 

Indicator 1.B.6 Percentage of RR/MDR-TB among 
new TB patients (E)

The regional action plan aims to reduce RR/MDR prevalence 
among new TB cases. At regional level, the prevalence of 
RR/MDR-TB among 64 608 new pulmonary TB cases tested 
with DST results to rifampicin was 23.1%. This is higher 
than the 18.8% observed in 2015, suggesting that rifampicin 
resistance is still increasing in the Region. The Region 
therefore  is  not  on  track  to  reduce  the  percentage  of 
rifampicin resistance among new TB patients. 

In 12 of the 16 HPCs reporting DST data, RR/MDR prevalence 
among new pulmonary TB cases was higher than, or compa-
rable to, 2015 data. Armenia, Azerbaijan, Romania and 
Turkey have shown a declining trend in RR/MDR percentage 
over the past five years. Large year-to-year variation and 
missing data in several countries indicated that routine 
drug-resistance surveillance in these countries is chal-
lenging and that additional efforts are required to produce 
quality data (Fig. 4.1.4). 

Indicator 1.B.7 Percentage of RR/MDR-TB among 
previously treated TB patients

In 2020, the percentage of confirmed RR/MDR-TB cases 
among previously treated TB patients tested at least for 
rifampicin was 55.2%, which is higher than the 2015 rate 

33

Tuberculosis surveillance and monitoring in Europe 2022SURVEILLANCE REPORT   
   
   
   
   
Fig. 4.1.4. Trend in RR/MDR percentage among new pulmonary TB cases (E) for 18 HPCs and WHO European Region, 
2014–2020

Armenia

Azerbaĳan

Belarus

Bulgaria

60

40

20

0

4

2

2014

2016

2018

2020

2014

2016

2018

2020

2014

2016

2018

2020

Georgia 

Kazakhstan

Kyrgyzstan

30

20

10

0

30

20

10

0

2014

2016

2018

2020

Estonia

20

10

0

15

10

5

0

20

10

100

50

40

20

0

6

4

2

0

2014

2016

2018

2020

2014

2016

2018

2020

2014

2016

2018

2020

Latvia

10

Lithuania

Republic of Moldova

5

0

40

20

0

40

20

0

2014

2016

2018

2020

2014

2016

2018

2020

Russian Federation

Tajikistan

30

20

10

0

2014

2016

2018

2020

2014

2016

2018

2020

2014

2016

2018

2020

Ukraine

Uzbekistan

100

50

0

18 HPCs

30

20

10

0

40

20

0

3

2

1

0

2014

2016

2018

2020

Romania

15

10

5

0

30

20

10

0

2014

2016

2018

2020

European Region

2014

2016

2018

2020

2014

2016

2018

2020

Turkey

Turkmenistan

2014

2016

2018

2020

2014

2016

2018

2020

2014

2016

2018

2020

2014

2016

2018

2020

(E): European indicator.

(46.3%), indicating that the Region is not on track to reduce 
the RR/MDR-TB burden among previously treated patients. 

Indicator 1.C.2 Percentage of detected  
RR/MDR-TB enrolled in treatment (G)

Indicator 1.C.1 Percentage of hospitalization among 
new TB patients (E)

In  2020,  32  countries  provided  information  on  the 
percentage of hospitalization among TB patients enrolled 
in first- and second-line treatment. Hospitalization rates 
for first-line TB treatment ranged from 22% (Georgia) to 
90% (Bulgaria and Uzbekistan). These data suggest that 
hospitalization remains high in most countries/areas in 
the Region and additional efforts are required to change 
the model of care (Fig. 4.1.5). 

Achieving universal second-line treatment coverage for 
all detected RR/MDR-TB patients is a fundamental require-
ment for reducing TB transmission in the community and 
TB-related deaths. The number of cases starting RR/MDR-TB 
treatment in 2020 was computed to be above 100%, as 
many HPCs reported higher numbers of cases enrolled in 
treatment than detected. The reasons for such discrepan-
cies include incomplete reporting, backlogs of RR/MDR-TB 
patients, frequent treatment failures and treatment inter-
ruptions leading to re-enrolment of the same patients in 
the same yearly cohort, and weakness of TB surveillance. 
At country level, only four HPCs reported a gap of over 5% 
between the number of patients enrolled and the number 
diagnosed: Azerbaijan (89.3%), Belarus (94%), Kyrgyzstan 

34

SURVEILLANCE REPORTTuberculosis surveillance and monitoring in Europe 2022   
   
   
   
   
Fig. 4.1.5. Proportion of TB patients hospitalized (%) (E) for 18 HPCs, 2020

Uzbekistan

Bulgaria

Kyrgyzstan

Lithuania

Tajikistan

Turkmenistan

Belarus

Kazakhstan

y
r
t
n
u
o
C

Russian Federation

Armenia

Ukraine

Romania

Estonia

Republic of Moldova

Turkey

Azerbaijan

Georgia

Latvia

0

10

20

30

40

50

60

70

80

90

100

(E): European indicator.

Note: Latvia did not report data.

Percentage 

(93.7%) and Tajikistan (82%). The other 13 demonstrated 
universal treatment coverage. 

Indicator 1.C.5 TB mortality rate (International 
Classification of Diseases (ICD) A15-19) (G) (E)

Indicator 1.C.3 Treatment success rate (%) among all 
new and relapsed TB patients (G)

Effective TB treatment is essential to prevent death and 
cut transmission. The treatment success rate serves as a 
key indicator for monitoring progress towards the End TB 
Strategy. According to the action plan, the WHO European 
Region needs to increase the treatment success rate for 
new and relapse TB cases to at least 85%. 

In 2019, the treatment success rate for new and relapse 
patients enrolled in treatment at regional level was 76.5%, 
compared to the baseline rate of 73%. Only six of the 17 
HPCs reporting data achieved the targeted level of an 85% 
treatment success rate. Another six HPCs showed a trend 
towards improvement in treatment success (Fig. 4.1.6).

Indicator 1.C.4 Treatment success rate (%) in the 
MDR-TB treatment cohort (G) (E)

Treatment success rate is an indicator of high-quality TB 
care. Despite the treatment success rate having increased 
from 48.7 to 55.9% over the past five years, it remains far 
below the 75% target set in the action plan. Of the 18 HPCs, 
only Kazakhstan and Estonia achieved the benchmark of 
having  a  treatment  success  rate  of  at  least  75%  for  
RR/MDR-TB patients (Fig. 4.1.7.). Another 10 HPCs increased 
their RR/MDR-TB treatment success rate significantly but 
did not achieve the 2020 target (75% treatment success 
rate for RR/MDR-TB cases) (Fig. 4.1.7).

The TB action plan for the WHO European Region aimed to 
reduce the number of TB deaths in 2020 by 35% compared 
to 2015. As shown in Fig. 4.1.8, with the exception of 
Azerbaijan and Turkmenistan, the HPCs showed a rapid 
decline in TB mortality between 2015 and 2019. However, 
for the first time in recent decades, Georgia, Tajikistan 
and Ukraine reported an increase in TB mortality between 
2019 and 2020, which was a consequence of the large drop 
in the number of people diagnosed with TB due to the 
COVID-19 pandemic. The sharp decline in TB mortality 
observed in the rest of the countries before the pandemic 
in 2020 either slowed or plateaued. 

Despite the challenges in 2020, overall, the regional target 
has  been  achieved.  In  eight  HPCs  (Armenia,  Belarus, 
Estonia, Kazakhstan, Kyrgyzstan, the Republic of Moldova, 
the Russian Federation and Uzbekistan), the action plan 
target set for 2020 of reducing the TB mortality rate by 
35% has been achieved (Fig. 4.1.8). In another five coun-
tries, mortality was significantly reduced, but the target 
was not met. 

Indicator 1.D.1 Percentage of detected cases among 
estimated incident TB/HIV coinfected cases 

Consistent improvement has been observed over the past 
five years in detecting TB/HIV coinfected people, reaching 
over 84% at regional level. In 2020, however, only 67.8% 
of the estimated number of TB/HIV coinfected people were 

35

Tuberculosis surveillance and monitoring in Europe 2022SURVEILLANCE REPORTFig. 4.1.6. Trend in treatment success rate for new and relapse TB cases enrolled into treatment 2013–2019 (G) in each 
of the HPCs and total for 18 HPCs and WHO European Region (percentage), 2013–2019

Armenia

100

50

0

100

50

0

Azerbaĳan

Belarus

100

Bulgaria

100

50

0

50

0

2013

2015

2017

2019

2013

2015

2017

2019

2013

2015

2017

2019

2013

2015

2017

2019

Estonia

100

Georgia 

100

50

0

50

0

100

50

0

Kazakhstan

Kyrgyzstan

100

50

0

2013

2015

2017

2019

2013

2015

2017

2019

2013

2015

2017

2019

2013

2015

2017

2019

Latvia

100

Lithuania

100

Republic of Moldova

Romania

100

50

0

100

50

0

50

0

2013

2015

2017

2019

2013

2015

2017

2019

2013

2015

2017

2019

2013

2015

2017

2019

Russian Federation

Tajikistan

100

Turkey

100

50

0

50

0

Turkmenistan

100

50

0

50

0

100

50

2013

2015

2017

2019

2013

2015

2017

2019

2013

2015

2017

2019

2013

2015

2017

2019

Ukraine

100

50

Uzbekistan

100

18 HPCs

100

50

0

50

European Region

100

50

2013

2015

2017

2019

2013

2015

2017

2019

2013

2015

2017

2019

2013

2015

2017

2019

  Treatment success rate by year
  Regional target of 85% treatment success rate

(G) Global indicator.

detected by health systems in the Region, comparable to  
the 64% achieved in 2015. None of the 18 HPCs achieved 
a detection rate of over 90%. 

Indicator 1.D.2 HIV testing coverage (G) (E)

The aim of the action plan was for countries to achieve HIV 
testing coverage of close to 100%. In 2020, HIV testing 
coverage at regional level was 92.6%, which is a notable 
improvement on the 67.6% testing coverage at baseline. 
Twelve HPCs reported HIV testing coverage of over 90% 
(Fig. 4.1.9). 

36

Indicator 1.D.3 Percentage of HIV coinfection among 
all TB (new and relapse TB cases)

In 2020, fifteen per cent of new TB patients with known 
HIV status were HIV-positive, compared to the 8.9% base-
line in 2015. This rapid change is partially due to improve-
ment of the surveillance system in the Russian Federation. 
An increase in TB/HIV coinfection was recorded in six of 
the 16 HPCs reporting TB/HIV status: Armenia, Azerbaijan, 
Belarus, Kazakhstan, the Republic of Moldova and the 
Russian Federation. Although Estonia, Georgia, Lithuania, 
Romania and Uzbekistan reported a lower percentage of 
TB/HIV cases in 2020 than in 2015, there is no clear trend 
towards reversion. The rapid increase in six of the HPCs 
is an indication that HIV transmission is continuing apace 

SURVEILLANCE REPORTTuberculosis surveillance and monitoring in Europe 2022   
   
   
   
   
   
Fig. 4.1.7. Trend in treatment success rate in the RR/MDR-TB cohort enrolled in treatment (G) (E) between 2013 and 2018 
for each of the 18 HPCs and as a total for the 18 HPCs and WHO European Region (percentage), 2013–2018

Armenia

100

50

0

100

50

0

Azerbaĳan

Belarus

100

Bulgaria

100

50

0

50

0

2013

2014

2015

2016 2017 2018

2013

2014

2015

2016 2017 2018

2013

2014

2015

2016 2017 2018

2013

2014

2015

2016 2017 2018

Estonia

100

Georgia 

100

50

0

50

0

100

50

0

Kazakhstan

Kyrgyzstan

100

50

0

2013

2014

2015

2016 2017 2018

2013

2014

2015

2016 2017 2018

2013

2014

2015

2016 2017 2018

2013

2014

2015

2016 2017 2018

Latvia

100

Lithuania

100

Republic of Moldova

Romania

100

50

0

100

50

0

50

0

2013

2014

2015

2016 2017 2018

2013

2014

2015

2016 2017 2018

2013

2014

2015

2016 2017 2018

2013

2014

2015

2016 2017 2018

Russian Federation

Tajikistan

100

Turkey

100

50

0

50

0

Turkmenistan

100

50

0

50

0

100

50

0

2013

2014

2015

2016 2017 2018

2013

2014

2015

2016 2017 2018

2013

2014

2015

2016 2017 2018

2013

2014

2015

2016 2017 2018

Ukraine

100

Uzbekistan

100

18 HPCs

100

50

0

50

0

50

0

European Region

100

50

0

2013

2014

2015

2016 2017 2018

2013

2014

2015

2016 2017 2018

2013

2014

2015

2016 2017 2018

2013

2014

2015

2016 2017 2018

  Treatment success rate by year
  Regional target of 85% treatment success rate

(E) European indicator. (G) Global indicator. 

in most eastern European and central Asian countries and 
that efforts towards the early identification of PLHIV and 
the  administration  of  preventive  TB  treatment  are 
inadequate.

coverage targeted by the action plan. Eight of the HPCs 
attained  coverage  above  90%  (Azerbaijan,  Belarus, 
Bulgaria, Estonia, Georgia, Kazakhstan, Tajikistan and 
Ukraine). 

Indicator 1.D.4 Percentage of TB/HIV coinfected 
patients enrolled in ART

Indicator 1.D.5 TB preventive treatment coverage 
among people living with HIV/AIDS (G)

The TB action plan aims to achieve full coverage with ART 
for all patients detected with TB/HIV coinfection, as per 
WHO recommendations. In 2020, 26 countries/areas in 
the Region provided information on ART enrolment among 
TB cases with positive HIV status, with ART coverage at 
74.3% among those reporting. This is a remarkable improve-
ment on the baseline of 53.8%, but far below the universal 

In 2020, five countries in the Region provided information 
on TB preventive treatment among PLHIV to the reporting 
system of the Joint United Nations Programme on HIV and 
AIDS. Overall, of 18 273 PLHIV newly enrolled in HIV care, 
80% received treatment for latent TB infection (LTBI), which 
is a much higher figure than the 30% target (Fig. 4.1.10). 

37

Tuberculosis surveillance and monitoring in Europe 2022SURVEILLANCE REPORT   
   
   
   
   
Fig. 4.1.8. Trend in TB mortality rate (G) (E) for the 18 HPCs and WHO European Region, per 100 000 population, 
2015–2020

Armenia

Azerbaĳan

Belarus

Bulgaria

3

2

1

0

3

2

1

0

6

4

2

0

15

10

5

0

15

10

5

0

2015

2016

2017

2018 2019 2020

Estonia

8

6

4

2

0

6

4

2

0

2015

2016

2017

2018 2019 2020

Georgia 

6

4

2

0

6

4

2

0

2

1

0

2015

2016

2017

2018 2019 2020

2015

2016

2017

2018 2019 2020

Kazakhstan

Kyrgyzstan

10

2015

2016

2017

2018 2019 2020

Romania

5

0

6

4

2

0

2015

2016

2017

2018 2019 2020

2015

2016

2017

2018 2019 2020

2015

2016

2017

2018 2019 2020

Latvia

Lithuania

Republic of Moldova

10

5

0

10

5

0

2015

2016

2017

2018 2019 2020

2015

2016

2017

2018 2019 2020

2015

2016

2017

2018 2019 2020

2015

2016

2017

2018 2019 2020

Russian Federation

Tajikistan

Turkey

Turkmenistan

2015

2016

2017

2018 2019 2020

Ukraine

15

10

5

0

8

6

4

2

0

1.0

0.5

0.0

2015

2016

2017

2018 2019 2020

2015

2016

2017

2018 2019 2020

Uzbekistan

18 HPCs

8

6

4

2

0

15

10

5

0

4

3

2

1

0

2015

2016

2017

2018 2019 2020

European Region

2015

2016

2017

2018 2019 2020

2015

2016

2017

2018 2019 2020

2015

2016

2017

2018 2019 2020

2015

2016

2017

2018 2019 2020

  Trend of TB mortality rates per 100 000 population
  Regional milestone of 35% reduction in TB deaths by 2020 compared to 2015

(E) European indicator. (G) Global indicator. 

Indicator 1.E.1 Contact investigation coverage (G) (E)

Contact  tracing is a key component of TB prevention, 
especially in children. Contact investigation may result in 
earlier identification of people who are ill or infected with 
TB, possibly decreasing disease severity and reducing 
transmission of M. tuberculosis. WHO recommends that 
all contacts of bacteriologically confirmed TB patients be 
followed-up and screened for TB.

This indicator is calculated as the number of contacts of 
people with bacteriologically confirmed TB evaluated for 
TB, divided by the number eligible. Only 19 countries in 
the Region reported data on contact tracing to WHO, and 
98% of all contacts with TB cases were investigated for 

TB/LTBI in 2020. The target of 90% was achieved by eight 
of nine HPCs reporting data on contact-tracing coverage 
(Fig. 4.1.11).

Indicator 1.E.2 TB preventive treatment coverage of 
childhood TB contacts aged under 5 years (G) (E)

WHO recommends that children under 5 years who are 
household or close contacts of people with TB and who, 
after an appropriate clinical evaluation, are found not to 
have active TB should start TB preventive treatment in 
accordance with WHO guidelines. The regional action plan 
aims to achieve at least 90% coverage with TB preventive 
treatment of childhood TB contacts under 5 years. This 
indicator is calculated as the number of children aged 

38

SURVEILLANCE REPORTTuberculosis surveillance and monitoring in Europe 2022   
   
   
Fig. 4.1.9. HIV testing coverage among new and relapse TB patients (G) (E) for the 18 HPCs and WHO European Region, 
2020

Target = 100%

Azerbaijan

Belarus

Uzbekistan

Ukraine

Kazakhstan

Lithuania

Tajikistan

y
r
t
n
u
o
C

Republic of Moldova

Russian Federation

Kyrgyzstan

Estonia

Armenia

Georgia

Romania

Bulgaria

Turkey

Turkmenistan

Latvia

European Region

18 HPCs

0

20

40

60

80

100

(E) European indicator. (G) Global indicator. 
Note: Latvia and Turkmenistan did not report data.

Percentage 

Fig. 4.1.10. TB preventive treatment coverage among PLHIV (G) for the 18 HPCs and WHO European Region, 2020

Target = 30%

y
r
t
n
u
o
C

Tajikistan

Kazakhstan

Ukraine

Kyrgyzstan

Republic of Moldova

European Region

18 HPC

0

20

40

60

80

100

Percentage 

(E) European indicator. (G) Global indicator. 
Note: Armenia, Azerbaijan, Belarus, Bulgaria, Estonia, Georgia, Latvia, Lithuania, Romania, the Russian Federation, Turkey, Turkmenistan and Uzbekistan 
did not report data.

under 5 who are household contacts of bacteriologically 
confirmed pulmonary TB cases and have started on TB 
preventive treatment, divided by the number of children 
under 5 who are household contacts of bacteriologically 
confirmed pulmonary TB patients. In 2020, 11 countries 
provided information to the global TB database on TB 
preventive treatment among children under 5 years. At 

regional level, TB preventive treatment coverage of child-
hood TB contacts aged under 5 years was 29.6%. Ukraine 
was the only country among the six HPCs reporting data 
on LTBI treatment that achieved the 90% target (Fig. 4.1.12).

39

Tuberculosis surveillance and monitoring in Europe 2022SURVEILLANCE REPORTFig. 4.1.11. Contact investigation coverage (G) (E) for the 18 HPCs and WHO European Region, 2020

Target = 90%

y
r
t
n
u
o
C

Turkmenistan

Kyrgyzstan

Belarus

Kazakhstan
Romania

Ukraine

Bulgaria

Republic of Moldova
Turkey

European Region

18 HPCs

0

20

40

60

80

100

Percentage 

(E) European indicator. (G) Global indicator. 
Note: Armenia, Azerbaijan, Estonia, Georgia, Latvia, Lithuania, the Russian Federation, Tajikistan and Uzbekistan did not report data.

Fig. 4.1.12. LTBI treatment coverage in childhood TB contacts aged under 5 years (G) (E) for the 18 HPCs and WHO 
European Region, 2020

Target = 90%

Ukraine

Turkey

Republic of Moldova

Kazakhstan

Kyrgyzstan

Belarus

y
r
t
n
u
o
C

European Region

18 HPCs

0

20

40

60

80

100

Percentage 

(E) European indicator. (G) Global indicator. 
Note: Armenia, Azerbaijan, Bulgaria, Estonia, Georgia, Latvia, Lithuania, Romania, the Russian Federation, Tajikistan, Turkmenistan and Uzbekistan did 
not report data.

Indicator 2.E.1 Treatment success rate (%) among 
new and relapse TB cases among prisoners

In 2020, 23 countries in the Region provided data on treat-
ment outcome of prison TB cases enrolled in treatment in 
2019. Overall, the treatment success rate of new and relapse 
TB cases at regional level was 60.4%, which is much lower 
than the 76.5% treatment success rate in the general 
population and the 63.2% baseline. The regional indicator 
is largely influenced by results for the Russian Federation, 
which accounts for around 79% of prison TB cases with 
available treatment outcomes. Six of the 15 HPCs achieved 
the target treatment success rate of 85%. 

4.1.2 Conclusions and monitoring 
recommendations

evaluated using routine surveillance data. Achievement 
of the action plan targets has been affected by the COVID-19 
pandemic. In the last year of the action plan, the decline 
in mortality and incidence slowed, far fewer people were 
diagnosed and treated for TB, and remarkably few people 
were  tested  for  drug  resistance  and  enrolled  into  
RR/MDR-TB treatment. Despite these challenges, nine of 
20 targets set by the regional action plan were achieved 
at regional level.

The Region achieved the 2020 regional action plan target 
to reduce the TB incidence rate in 2020 by 25% and was 
very close to achieving the target of reducing TB deaths 
by 35% against the 2015 baseline. Good progress was also 
observed in increasing HIV testing and ART coverage. 

In 2020, 20 of 26 indicators in the TB action plan for the 
WHO European Region were effectively monitored and 

Although 11 targets set by the regional action plan were 
not achieved, improvement has been noted against the 

40

SURVEILLANCE REPORTTuberculosis surveillance and monitoring in Europe 2022baseline values. Treatment success rates for new and 
relapse TB cases and RR/MDR-TB cases were not achieved, 
but  when  data  collected  between  2016  and  2020  are 
compared, a slow but sustainable increase can be seen 
among both incident TB and RR/MDR-TB cohorts. A substan-
tial increase in testing coverage using WRD has also been 
documented.

The Region was not successful in reaching the targets for 
six indicators, including TB treatment coverage, percentage 
of RR/MDR-TB among new and previously TB cases, the 
prevalence of HIV among new and relapse TB cases, TB 
preventive treatment coverage among children under 5 
years and the treatment success rate among TB patients 
in prison. Despite the efforts made, the burden related to 
RR-TB and TB/HIV over the past five years continued to 
increase, indicating the need to introduce more innovative 
and effective approaches to address these issues. 

Completeness and quality of data related to screening, 
contact tracing and preventive TB treatment needs to be 
improved. Prevention efforts, including contact tracing, 
TB preventive treatment coverage and ART coverage among 
PLHIV, need to be intensified. However, priority should be 
given to actions to restore access to and provision of TB 
services to ensure the level of TB detection and treatment 
returns to that of 2019. 

4.2 European Union and 
European Economic Area 
countries
A summary of findings by EU/EEA Member State and indi-
cator is provided below and in Table 25, while indicator 
definitions and targets can be found in Annex 6.

4.2.1 Integrated patient-centred care and 
prevention

1.A Systematic screening of contacts and high-risk 
groups

Indicator 1.A.1 Coverage of population at risk with 
systematic screening for active TB and LTBI

Screening for active TB and LTBI should be promoted to 
contribute to the detection of active and latent cases of 
TB, especially in at-risk populations. The less generalized 
the epidemic becomes, the more emphasis needs to be 
placed on this activity. This indicator is a direct measure 
of the level of screening in the community. Strategies for 
screening should be developed and/or revised taking into 
account WHO recommendations (5,6) and ECDC guidance 
(7,8). Of the six countries reporting these data (Bulgaria, 
Norway, Portugal, Romania, Slovakia and Slovenia), four 
reported screening coverage of over 80% for the popula-
tion at risk (Table 25).

1.B Early diagnosis of all forms of TB and universal 
access to DST, including the use of rapid tests

Indicator 1.B.1 Percentage of TB patients diagnosed 
using WRD (G)

Twenty-nine EU/EEA Member States reported on the propor-
tion of patients notified with new and relapse TB in 2020 
who were diagnosed using WRD (Table XIV). Overall, 33.7% 
of cases reported in the EU/EEA are diagnosed using these 
tests. The target for 2020 was 30%, which was met by 18 
Member States (Fig. 4.2.1).

Indicator 1.B.2 First-line DST coverage (%) among all 
bacteriologically confirmed TB cases (G)

In 2020, 19 190 incident TB cases were bacteriologically 
confirmed in 29 EU/EEA Member States. DST results for 
rifampicin and isoniazid were provided for 14 997 (78.2%) 
of them (Table 10). The target (100%) was achieved by nine 
countries (Cyprus, Denmark, Estonia, Iceland, Lithuania, 
Malta, Norway, Slovenia and Sweden) and an additional 
seven achieved above 95% (Finland, Slovakia, Austria, 
Greece, Belgium, Luxembourg and Ireland) (Fig. 4.2.2).

Indicator 1.B.3 RR/MDR-TB case detection rate (%) 

In 2016, WHO started replacing MDR-TB estimates with 
RR-TB estimates, since the latter provide a good proxy of 
the former and the recommended management is identical 
for both. The RR/MDR-TB case-detection rate is calculated 
by dividing the number of notified cases with RR/MDR-TB 
by the estimated number of such cases. In 2020, seven 
EU/EEA countries achieved an RR/MDR-TB detection rate 
of 85% or more (Table 25). 

Indicator 1.B.4 TB notification rate per 100 0000 
population (E)

The regional action plan aims to reduce the TB incidence 
rate by 25% by 2020 against the 2015 baseline. To achieve 
this, countries in the Region should have at least a 5.5% 
annual reduction in the notification of new and relapse TB 
cases.

In 2020, country-specific notification rates in EU/EEA 
Member States differed considerably, ranging from 2.7 
per 100 000 in Norway to 37.2 in Romania (Table III). Rates 
were below the regional target (24.6 per 100 000) in 26 of 
29 reporting countries. Only Lithuania, Malta and Romania 
reported rates above the regional target, but both Lithuania 
and Romania have had an average annual decrease of over 
−5.5%	since	2015	(−9%	and	−12.9%,	respectively	(Table	
III)), so they are on track to meet the 2020 reduction target 
(Fig. 4.2.3, Table 25).

Indicator 1.B.5 TB case-detection rate (%)

In 2020, 31 551 new and relapse TB cases (Table III) were 
notified in 29 countries compared to an estimated 42 600 
TB cases (Table II), representing a case-detection rate of 
74.1%. Twenty-two EU/EEA Member States reported a 
case-detection rate of 75% or above (Table 25), but only 
12 achieved the target of an increase in case-detection 
rate against 2016.

41

Tuberculosis surveillance and monitoring in Europe 2022SURVEILLANCE REPORTFig. 4.2.1. Percentage of TB patients diagnosed using WRD (G), EU/EEA, 2020

Target = 30%

y
r
t
n
u
o
C

Liechtenstein
Denmark
Estonia
Sweden
Germany
Norway
Slovenia
Netherlands
Ireland
Czechia
Austria
Belgium
Finland
Iceland
Cyprus
Spain
Portugal
Romania
Slovakia
Poland
Greece
Bulgaria
Croatia
France
Hungary
Italy
Lithuania
Luxembourg
Malta
Total EU/EEA
0

10

20

30

40

50

60

70

80

90

100

(G) Global indicator. 

Percentage 

Fig. 4.2.2. First-line DST coverage among all bacteriologically confirmed TB patients (G), EU/EEA, 2020

Target = 100%

y
r
t
n
u
o
C

Cyprus
Denmark
Estonia
Iceland
Lithuania
Malta
Norway
Slovenia
Sweden
Finland
Slovakia
Austria
Greece
Belgium
Luxembourg
Ireland
Netherlands
Czechia
Poland
Hungary
Germany
Romania
Croatia
Italy
Portugal
Bulgaria
Spain
France
Subtotal EU/EEA

0

10

20

30

40

50

60

70

80

90

100

(G) Global indicator. 

Percentage 

42

SURVEILLANCE REPORTTuberculosis surveillance and monitoring in Europe 2022Indicator 1.B.6 Percentage of RR/MDR-TB among 
new TB patients (E)

percentage of hospitalizations was observed for six of the 
13 countries. 

In 2020, 29 EU/EEA countries reported DST results for 
first-line drugs. The prevalence of RR/MDR-TB among 
12 099 new pulmonary TB cases with first-line DST results 
was 2.8% (Table 11), which was higher than in 2018 (2.6%) 
and the same as 2016 (2.8% (Table V)). The target of a 
decreasing percentage was met by 17 EU/EEA countries 
(Fig. 4.2.4, Table V).

Indicator 1.B.7 Percentage of RR/MDR-TB among 
previously treated TB patients

In 2020, the prevalence of RR/MDR-TB among 2035 previ-
ously treated pulmonary TB cases tested for first-line DST 
was 12.8% (Table 11), which is lower than in 2018 and 2016 
(15% and 14.5%, respectively (Table VI)). The target of a 
decreasing percentage was met by 17 EU/EEA countries 
(Table VI).

1.C Equitable access to quality treatment and 
continuity of care for all people with TB, including 
drug-resistant TB, and patient support to facilitate 
treatment adherence

Indicator 1.C.1 Percentage of hospitalizations of new 
TB patients (E)

Thirteen EU/EEA Member States reported on hospitaliza-
tion of new TB patients in 2020 (Fig. 4.2.5). When 2020 
data were compared with 2016 data, a decrease in the 

Indicator 1.C.2 Percentage of detected RR/MDR-TB 
enrolled in treatment (G)

Twenty-eight Member States reported on treatment enrol-
ment of RR/MDR-TB patients in 2020 (Table 13). The target 
of 100% treatment enrolment of RR/MDR-TB patients was 
met by 19 countries. Four countries did not diagnose any 
RR/MDR-TB cases in 2020. Overall, 97.6% of RR/MDR-TB 
cases reported in the EU/EEA started treatment with second-
line anti-TB drugs, in accordance with WHO guidelines 
(Fig. 4.2.6).

Indicator 1.C.3 TB treatment success rate (%) among 
all new and relapsed TB patients (G)

Of the 28 985 new and relapse TB cases notified in 2019 
with a treatment outcome reported in 2020, 20 797 (71.8%) 
were treated successfully (Table 16). France, Greece, Italy, 
Lat via  (did  not  repor t  case-based  data  for  2020), 
Liechtenstein, Malta and Poland did not report treatment 
outcome data. Only four countries (Iceland, Lithuania, the 
Netherlands and Slovakia) met the treatment success 
target of 85% (Fig. 4.2.7).

Fig. 4.2.3. TB notification rate per 100 000 population (E), EU/EEA, 2020

Target = 24.6%

y
r
t
n
u
o
C

Romania
Malta
Lithuania
Portugal
Bulgaria
Estonia
Poland
Belgium
France
Spain
Luxembourg
Liechtenstein
Germany
Ireland
Croatia
Austria
Hungary
Cyprus
Italy
Denmark
Greece
Slovenia
Netherlands
Czechia
Iceland
Sweden
Finland
Norway
Slovakia
Subtotal EU/EEA

0

5

10

15

20

25

30

35

40

45

(E) European indicator. 

Percentage 

43

Tuberculosis surveillance and monitoring in Europe 2022SURVEILLANCE REPORTFig. 4.2.4. Percentage of RR/MDR-TB among new TB patients (E), 2016 and 2020, EU/EEA, 2020

y
r
t
n
u
o
C

Lithuania
Estonia
Latvia
Norway
Hungary
Sweden
Italy
Greece
Ireland
Austria
Romania
Germany
Spain
Denmark
Slovakia
Netherlands
Finland
Portugal
     Belgium
France
 Czechia
Bulgaria
Poland
Croatia
Cyprus
Liechtenstein
Luxembourg
Malta
Slovenia
Iceland
Subtotal EU/EEA

Percentage of rifampicin resistance in new TB cases 2016

Percentage of rifampicin resistance in new TB cases 2020

0

4

8

12

16

20

(E) European indicator. 

Percentage 

reporting data (numerator, not available for 11 countries) 
and  WHO  estimates  (denominator,  not  available  for 
Liechtenstein). The target HIV case-detection rate of close 
to 100% was almost reached by Belgium (93.9%) and two 
countries (Czechia and Slovakia) had more reported than 
estimated cases, thereby exceeding the 100% target.

Indicator 1.D.2 HIV testing coverage (%) (G) (E)

Nineteen EU/EEA countries provided information on the 
HIV status of their TB cases and 73.7% of cases had known 
HIV status (Table IX). The target testing coverage of close 
to 100% was achieved only by Greece (Fig. 4.2.10).

Indicator 1.D.3 Percentage of HIV among all TB

In 2020, 19 EU/EEA Member States reported 554 TB cases 
with HIV infection (Table IX). Country-specific proportions 
ranged from 0% in Croatia, Luxembourg and Slovenia to 
just over 11% in Estonia and Hungary (Table IX). Among 
the 15 countries with at least 50% reporting completeness 
for  HIV  in  2020,  nine  (Denmark,  Estonia,  Lithuania, 
Luxembourg, the Netherlands, Norway, Portugal, Romania 
and Slovenia) reached the target of a decrease in the 
percentage of HIV among all TB cases reported (compared 
with 2016).

Indicator 1.C.4 TB treatment success rate (%) among 
the RR/MDR-TB treatment cohort (G) (E)

Of the 927 RR/MDR-TB cases notified in 2018 with a treat-
ment outcome reported in 2020, 486 (52.4%) were treated 
successfully (Table 22). Of 18 Member States reporting 
treatment success for RR/MDR-TB cases diagnosed in 2018, 
only five (Austria, Belgium, the Netherlands, Norway and 
Sweden) met the treatment success target of 75%. Treatment 
success ranged from 0% in two countries (Croatia and 
Denmark) to 100% in Sweden (Fig. 4.2.8).

Indicator 1.C.5 TB mortality rate per 100 000 
population (ICD A15-19) (G) (E)

WHO estimated 3750 TB deaths among HIV-negative people 
in the EU/EEA for 2020 (Table 1). The estimated mortality 
for the EU/EEA was 0.8 deaths per 100 000 population, 
ranging from 0.2 in the Netherlands to over four in Lithuania 
and Romania. The regional target of below 2.7 cases per 
100 000 was met by all EU/EEA Member States except 
Romania, Lithuania and Latvia (Fig. 4.2.9).

1.D Collaborative TB/HIV activities and management 
of comorbidities

Indicator 1.D.1 TB/HIV case-detection rate (%)

In 2020, 19 EU/EEA Member States reported on new and 
relapse TB patients with HIV infection (Table 14). The 
detection rate of TB/HIV coinfected cases is based on 

44

SURVEILLANCE REPORTTuberculosis surveillance and monitoring in Europe 2022Fig. 4.2.5. Percentage of hospitalizations for new TB patients (E), EU/EEA, 2020

Romania

Bulgaria

Norway

Finland

France

Lithuania

y
r
t
n
u
o
C

Luxembourg

Estonia

Hungary

Sweden

Ireland

Netherlands

Portugal

0

10

20

30

40

50

60

70

80

90

100

(E) European indicator. 

Percentage 

Fig. 4.2.6. Percentage of detected RR/MDR-TB enrolled into treatment (G) (E), EU/EEA, 2020

Target = 100%

y
r
t
n
u
o
C

Austria
Belgium
Bulgaria
Croatia
Czechia
Estonia
France
Greece
Ireland
Lithuania
Malta
Netherlands
Norway
Poland
Portugal
Slovakia
Slovenia
Spain
Sweden
Romania
Germany
Hungary
Denmark
Finland
Subtotal EU/EEA

0

10

20

30

40

50

60

70

80

90

100

(E) European indicator. (G) Global indicator. 

Percentage 

45

Tuberculosis surveillance and monitoring in Europe 2022SURVEILLANCE REPORTFig. 4.2.7. TB treatment success rate among all new and relapse cases (G), EU/EEA, 2020

Target = 85%

y
r
t
n
u
o
C

Iceland

Slovakia

Lithuania

Netherlands

Norway

Romania

Bulgaria

Belgium

Estonia

Austria

Czechia

Portugal

Slovenia

Germany

Hungary

Sweden

Spain

Denmark

Finland

Luxembourg

Cyprus

Croatia

Ireland

Subtotal EU/EEA

0

10

20

30

40

50

60

70

80

90

100

(G) Global indicator. 

Percentage 

Fig. 4.2.8. TB treatment success rate among the RR/MDR-TB cohort (G) (E), EU/EEA, 2020

Target = 75%

y
r
t
n
u
o
C

Sweden

Austria

Netherlands

Norway

Belgium

Estonia

Finland

Slovakia

Portugal

Germany

Bulgaria

Lithuania

Hungary

Romania

Czechia

Ireland

Croatia

Denmark

Subtotal EU/EEA

0

10

20

30

40

50

60

70

80

90

100

(E) European indicator. (G) Global indicator.  

Percentage 

46

SURVEILLANCE REPORTTuberculosis surveillance and monitoring in Europe 2022Fig. 4.2.9. TB mortality rate (ICD A15-19) (G) (E), EU/EEA, 2020

Target = 2.7%

y
r
t
n
u
o
C

Romania
Lithuania
Latvia
Portugal
Croatia
Poland
Bulgaria
Estonia
Slovenia
France
Hungary
Slovakia
Iceland
Finland
Spain
Italy
Greece
Austria
Cyprus
Ireland
Luxembourg
Norway
Germany
Belgium
Malta
Sweden
Czechia
Denmark
Netherlands
Liechtenstein
Subtotal EU/EEA

0

1

2

3

4

5

(E) European indicator. (G) Global indicator. 

Percentage 

Fig. 4.2.10. HIV testing coverage (%) (G) (E), EU/EEA, 2018

Target = 100%

y
r
t
n
u
o
C

Greece

Lithuania

Estonia

Romania

Bulgaria

Cyprus

Luxembourg

Netherlands

Norway

Denmark

Slovenia

Portugal

Spain

Czechia

Slovakia

Belgium

Ireland

Hungary

Croatia

Subtotal EU/EEA

0

10

20

30

40

50

60

70

80

90

100

(E) European indicator. (G) Global indicator.  

Percentage 

47

Tuberculosis surveillance and monitoring in Europe 2022SURVEILLANCE REPORTIndicator 1.D.4 ART coverage (%) among TB/HIV 
coinfected 

Six EU/EEA Member States reported ART enrolment to the 
WHO global TB database (Table 14). In these countries, 
84.1% of HIV-coinfected TB cases had started ART in 2020. 
The target for enrolment coverage of close to 100% was 
achieved by three EU/EEA Member States (Bulgaria, Estonia 
and Slovakia).

2.C Regulatory frameworks for case-based 
surveillance, strengthening vital registration, 
quality and rational use of medicines and 
pharmacovigilance

Indicator 2.C.1 Treatment coverage with new TB 
drugs (%)

The target is 20% treatment coverage with new TB drugs, 
but data for this are not available for 2020.

Indicator 1.D.5 LTBI treatment coverage (%) among 
PLHIV (G)

2.D Community systems and civil society 
engagement

The target for LTBI treatment coverage among PLHIV is 
30%. No relevant data were available in the WHO global 
TB database for any EU/EEA Member State in 2020, so this 
indicator could not be monitored (Fig. 4.2.11).

1.E Management of LTBI and preventive treatment of 
persons at high risk, and vaccination against TB

Indicator 1.E.1 Contact investigation coverage (%) 
(G) (E)

Only three EU/EEA Member States reported contact inves-
tigation data for the percentage of all eligible contacts of 
bacteriologically confirmed TB cases who had been inves-
tigated for TB/LTBI in 2020 (Table 25). The target of 90% 
was achieved by two reporting Member States (Slovakia 
and Slovenia, both 100%) and was almost reached by a 
third country (Norway, 89.6%).

Indicator 1.E.2 LTBI treatment coverage (%) in 
childhood TB contacts aged under 5 years (G) (E)

Six EU/EEA Member States reported LTBI treatment coverage 
data for childhood TB contacts aged under 5 years, with 
100% of these contacts reported to have started LTBI 
treatment in 2020 (Table 25). 

4.2.2 Bold policies and supportive systems

2.A Political commitment with adequate resources, 
including universal health coverage policy

Indicator 2.A.1 Number of Member States that have 
a regular TB control/elimination performance 
publication every five years (E)

The target is for 30 countries to produce a regular TB 
control/elimination performance publication every five 
years, but data on this are not available for 2020.

2.B Health system strengthening in all functions, 
including well aligned functioning mechanisms for 
TB and human resources

Indicator 2.B.1 Percentage of TB patients and their 
households that experience catastrophic financial 
consequences due to TB (G) (E) 

The target for this is close to zero, but data are not avail-
able for 2020.

48

Indicator 2.D.1 Number of Member States with 
functioning multistakeholder coalitions advocating 
for TB care and resources 

The target is for 30 countries to have such coalitions in 
place, but data are not available for 2020.

2.E Social protection, poverty alleviation and 
actions on other determinants of TB, such as 
migration and prisons

Indicator 2.E.1 Treatment success rate (%) of new 
and relapse TB cases among prisoners

Of the 263 TB cases notified in prisons across 10 EU/EEA 
Member States in 2019 for whom treatment outcome data 
are available, 176 (66.9%) were treated successfully (Table 
21). Luxembourg reported no TB cases among prisoners. 
Among the 10 Member States reporting, treatment success 
ranged from 41.2% in the Netherlands to 100% in Estonia 
and Slovakia. Only two countries (Estonia and Slovakia) 
met the treatment success target of 85% for TB cases 
diagnosed in prisons.

4.2.3 Intensified research and innovation

3.A Discovery, development and rapid uptake of new 
tools, interventions and strategies

Indicator 3.A.1 European TB research initiative 
established by mid-2016

The target is for the European TB research initiative to be 
established, but country-specific indicators are not defined 
for 2020.

4.2.4 Conclusions and monitoring 
recommendations

In 2020, 19 of 26 WHO targets were monitored, based on 
the data available from EU/EEA Member States. For many 
of the indicators where data were reported by Member 
States, most of the targets either were met or close to 
being met. The most significant indicator is the TB notifica-
tion rate, with a target incidence below 24.6 cases per 
100 000  population.  This  target  was  met  by  26  of  29 
reporting countries. Most reporting EU/EEA Member States 
also met or were close to meeting the targets on use of 
WRD for diagnosis (30% of new cases and relapses) and 
first-line DST coverage among bacteriologically confirmed 
cases (target 100% of cases).

There is difficulty in monitoring progress against WHO 
targets due to limited or no reporting against some of the 
indicators. A reduction was seen across several indicators 

SURVEILLANCE REPORTTuberculosis surveillance and monitoring in Europe 2022Fig. 4.2.11. LTBI treatment coverage among PLHIV (G), EU/EEA, 2020

Target = 90%

y
r
t
n
u
o
C

Slovenia

Slovakia

Norway

Subtotal EU/EEA

0

10

20

30

40

50

60

70

80

90

100

(G) Global indicator.  

Percentage 

in the number of Member States reporting data in 2020 
compared with 2018 and/or 2016. This may reflect the 
impact  of  the  COVID-19  pandemic  on  public  health 
resources. 

Although  TB  seems  well  under  control  in  most  of  the  
EU/EEA Member States, these monitoring figures indicate 
that certain aspects could be improved from the TB clinical 
service delivery perspective (to meet the indicator targets) 
and from the surveillance/data-reporting perspective (to 
have data for indicators). 

References17
1.  Sixty-fifth Regional Committee for Europe: Vilnius, 
14–17 September 2015. Tuberculosis action plan for 
the WHO European Region 2016–2020. Copenhagen: 
WHO Regional Office for Europe; 2015 (EUR/RC65/17 
Rev.1; https://apps.who.int/iris/handle/10665/337750).

2.  Global tuberculosis report 2021. Geneva: World Health 
Organization;  2021  (ht tps://apps.who.int/iris/
handle/10665/346387).

3.  Roadmap to implement the tuberculosis action plan 
for the WHO European Region 2016–2020: towards 
ending tuberculosis and multidrug-resistant tubercu-
losis. Copenhagen: WHO Regional Office for Europe; 
2016 (https://apps.who.int/iris/handle/10665/329486).

17 All references accessed 16 February 2022.

4.  Sixty-first Regional Committee for Europe: Baku, 12–15 
September 2011. Consolidated action plan to prevent 
and combat multidrug- and extensively drug-resistant 
tuberculosis in the WHO European Region 2011–2015. 
Copenhagen:  WHO  Regional  Of f ice  for  Europe;  
2011  (EUR/RC61/15;  ht tps://apps.who.int/iris/
handle/10665/335846). 

5.  Systematic screening for active tuberculosis: principles 
and  recommendations.  Geneva:  World  Health 
Organization;  2013  (ht tps://apps.who.int/iris/
handle/10665/84971). 

6.  Latent tuberculosis infection. Updated and consolidated 
guidelines for programmatic management. Geneva: 
World Health Organization; 2018 (https://apps.who.
int/iris/handle/10665/260233).

7.  Public health guidance on screening and vaccination 
for infectious diseases in newly arrived migrants within 
the EU/EEA. In: European Centre for Disease Prevention 
and  Control  [website].  Stockholm:  ECDC;  2019  
(https://www.ecdc.europa.eu/en/publications-data/
public-health-guidance-screening-and-vaccination-
infectious-diseases-newly).

8.  Management  of  latent  tuberculosis  infection.  In: 
European Centre for Disease Prevention and Control 
[website]. Stockholm: ECDC; 2019 (https://www.ecdc.
europa.eu/en/tuberculosis/prevention-and-control/
management-latent-tuberculosis-infection).

49

Tuberculosis surveillance and monitoring in Europe 2022SURVEILLANCE REPORT 
5. Annexes

Annex 1. Tuberculosis surveillance system overview, European Union/European Economic Area, 2020

Country

Data source

Legal 
character

Comprehensiveness 

Type

National 
coverage

Austria
Belgium
Bulgaria
Croatiab
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden

AT-TUBERKULOSEGESETZ
BE-TUBERCULOSIS
BG-MOH
HR-CNIPH
CY-NOTIFIED_DISEASES
CZ-TUBERCULOSIS
DK-MIS
EE-TBC
FI-NIDR
FR-MANDATORY_INFECTIOUS_DISEASES
DE-SURVNET@RKI-7.1/6
EL-NOTIFIABLE_DISEASES
HU-TUBERCULOSIS
IS-TUBERCULOSIS
IE-CIDR
IT-NRS
LV-TB
CH-SFOPH-LI
LT-TB_REGISTER
LU-SYSTEM1
MT-DISEASE_SURVEILLANCE
NL-NTR
NO-MSIS_A
PL_CR
PT-TUBERCULOSIS
RO-NTBSy
SK-NRT
SI-TUBERCULOSIS
ES-STATUTORY_DISEASES
SE-SweTBReg

Cp
Cp
Cp
Cp
Cp
Cp
Cp
Cp
Cp
Cp
Cp
Cp
Cp
Cp
Cp
Cp
Cp
Cp
Cp
Cp
Cp
Cp
Cp
Cp
Cp
Cp
Cp
Cp
Cp
Cp

Co
Co
Co
Co
Co
Co
Co
Co
Co
Co
Co
Co
Co
Co
Co
Co
Co
Co
Co
Co
Co
Co
Co
Co
Co
Co
Co
Co
Co
Co

C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C

Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y

Data available

EuroTB 
aggregated data
–
–
1995–2006
1995–2007
1995–2001
–
–
–
–
–
1995–2000
1995–2001
1995–1998
–
1995–1997
–
1995–2000
–
1995–2002
–
–
–
–
1995–1999
1995–1999
–
1995
–
1995–2006
–

TESSy 
case-based dataa
1995–2020
1995–2020
2007–2020
2012–2020
2002–2020
1995–2020
1995–2020
1995–2020
1995–2020
1995–2020
2001–2020
2002–2020
1999–2020
1995–2020
1998–2020
1995–2020
2001–2017
1995–2020
2003–2020
1995–2020
1995–2020
1995–2020
1995–2020
2000–2020
2000–2020
1995–2020
1996–2020
1995–2020
2007–2020
1995–2020

Cp: compulsory reporting.
Co: comprehensive.
C: case-based.
TESSy: The European Surveillance System. 
Y: yes.
a For some years, data from France, Spain and Italy related to drug-susceptibility testing have been collected in aggregated format from the WHO TB Monitoring 
and Evaluation data.
b Data reported since 2012 to TESSy, historical data extracted from WHO TB Monitoring and Evaluation data.

53

Tuberculosis surveillance and monitoring in Europe 2022SURVEILLANCE REPORTAnnex 2. List of variables for 2020 tuberculosis data collectiona

List

Description

Common set of variables

1 RecordId
2 RecordType
3 RecordTypeVersion
4 Subject
5 Status
6 DataSource
7 ReportingCountry
8 PlaceOfNotification
9 PlaceOfResidence
10 Age
11 Gender
12 DateOfDiagnosis
13 DateOfNotification
14 DateUsedForStatistics
Disease-specific variables
15 BornReportingCountry
16 CountryOfBirth
17 CountryOfNationality
18 DateOfEntryToCountry
19 NationalityReportingCountry
20 MajorSiteOfTB
21 MinorSiteOfTB
22 PrevDiagnosis
23 PrevDiagnosisYear
24 PrevTreatment
25 PrevTreatmentCompletion
26 DiagnosedAnteMortem
27 EnrolledToTreatment
28 Outcome12Months
29 Outcome24Months
30 Outcome36Months
31 ResultCulture
32 ResultMicroscopy
33 ResultOtherTest
34 Pathogen
35 HIVStatus
36 SIR_AMK
37 SIR_BDQ
38 SIR_CAP
39 SIR_DLM
40 SIR_ETH
41 SIR_GAT
42 SIR_INH
43 SIR_KAN
44 SIR_LVX
45 SIR_MFX
46 SIR_OFX
47 SIR_PZA
48 SIR_RIF
49 SIR_STR
50 IsolateID

51 ECDCIsolateID

52 SpoligoCodeb
53 MiruCodeb
54 BeijingGenotypeb

Unique identifier for each record generated by the national surveillance system
Structure and format of the data
Indicates which version the sender uses when generating the data for upload
Disease to report
Status of reporting NEW/UPDATE or DELETE (inactivate)
The data source (surveillance system) that the record originates from
The country reporting the record
Place of the first notification of the case to a regional authority
Place of residence of patient at the time of disease onset
Age of patient in years as reported in the national system
Gender of the reported case
First date of clinical or laboratory diagnosis
Date when the case is first reported to public health authorities
The reference date used for standard reports; usually one of the above

The patient was born in the country of report
Country of birth of patient
Country of nationality of patient
Date of entry to country – for TB cases not born in the reporting country
Origin of the patient (based on citizenship)
Major site of the disease
Minor site of the disease
Previous diagnosis of tuberculosis in the past
Year of previous diagnosis
Previous anti-tuberculosis drug treatment (at least one month of drug combination)
Completion of the previous anti-tuberculosis drug treatment
Vital status of the patient at the time of diagnosis
Patient started appropriate tuberculosis treatment according to international recommendations
Patient first outcome at 12 months from the start of the treatment
The first outcome observed 13 to 24 months from the start of treatment
The first outcome observed 25 to 36 months from the start of treatment
The result of the culture test for Mycobacterium tuberculosis complex
The result of the microscopy test performed
Additional laboratory test results
Species and gene (Mycobacterium tuberculosis complex) of the pathogen which is the cause of the reported disease 
Result of the last HIV test
Susceptibility to amikacin 
Susceptibility to bedaquiline
Susceptibility to capreomycin
Susceptibility to delamanid
Susceptibility to ethambutol
Susceptibility to gatifloxacin
Susceptibility to isoniazid
Susceptibility to kanamycin
Susceptibility to levofloxacin
Susceptibility to moxifloxacin
Susceptibility to ofloxacin
Susceptibility to pyrazinamide
Susceptibility to rifampicin
Susceptibility to streptomycin
Unique identifier for each isolate within the data source/laboratory system related to the case
Identifier for each isolate record that is guaranteed to be unique across countries/laboratories/pathogens and not contain 
additional encoded information
Spoligo pattern code
MIRU pattern code
Beijing genotype identification

a Notification of tuberculosis cases for 2020, treatment outcome data updated for cohort 2019 and rifampicin-resitance/multidrug-resistance 
treatment outcome data updated for cohort 2018 and pre-extensive drug resistance treatment outcome data updated for cohort 2018 and 
extensively drug-resistant tuberculosis treatment outcome data updated for cohort 2017. 
b Optional variable. No need to be reported if the ”IsolateID” or “ECDCIsolateID” is provided. 

54

SURVEILLANCE REPORTTuberculosis surveillance and monitoring in Europe 2022–

–

)
0
.
0
(

–

–

–

–

)
0
.
0
0
1
(

–

–

–

–

–

–

–

–

–

–

–

–

–

)
0
.
0
0
1
(

–

–

–

–

–

–

–

–

)
7
.

6
6
(

–

–

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

–

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

–

)
0
.
0
0
1
(

–

–

)
0
.
0
(

)
0
.
0
0
1
(

–

–

–

)
9
.
3
9
(

)
9
.

8
9
(

)
0
.
0
0
1
(

)
3
.
1
4
(

)
6
.
3
5
(

)
9
.
7
4
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
2
4
(

)
7
.
4
1
(

)
6
.
5
8
(

)
0
.
0
(

)
4
.

8
9
(

)
0
.
0
0
1
(

)
0
.
6
(

)
0
.
0
(

–

–

)
0
.
0
0
1
(

)
0
.
0
0
1
(

–

–

–

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

–

)
0
.
0
(

)
0
.
0
0
1
(

)
3
.

8
9
(

)
0
.
4
5
(

)
0
.
0
(

)
3
.
7
9
(

)
1
.
5
9
(

)
0
.
0
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
2
.
7
9
(

)
0
.
0
0
1
(

)
3
.
4
5
(

)
0
.
7
6
(

)
6

.
1
6
(

)
0
.
0
(

)
1
.
8
9
(

)
4
.
7
5
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
3
.
0
4
(

)
0
.
0
0
1
(

)
0
.
0
(

)
7
.

8
7
(

)
4
.
7
9
(

)
7
.
4
9
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
2
.
3
5
(

–

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
3
.
7
9
(

)
4
.
9
9
(

)
0
.
0
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
(

)
1
.
1
6
(

)
0
.
0
0
1
(

)
0
.
0
(

)
9
.
6
4
(

)
0
.
4
8
(

)
2
.
2
(

)
3
.
3
8
(

)
8

.
4
5
(

)
0
.
6
7
(

)
5
.
3
9
(

)
0
.
0
(

)
0
.
0
(

)
0
.
0
(

)
0
.
0
0
1
(

)
4
.
4
(

)
0
.
0
(

)
0
.
5
3
(

)
0
.
0
(

–

)
0
.
0
(

)
3
.
8
9
(

)
4
.
2
8
(

)
0
.
0
(

)
5
.

8
7
(

)
3
.
6
7
(

)
0
.
0
(

)
2
.
5
7
(

)
6
.
4
8
(

)
9
.
1
5
(

)
3
.
5
7
(

)
8
.
7
5
(

)
0
.
0
(

)
3
.
9
3
(

–

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

–

)
0
.
0
0
1
(

–

–

–

–

–

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

–

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
7
.
5
9
(

)
2
.
6
9
(

)
8
.
6
5
(

)
7
.
9
8
(

)
0
.
0
0
1
(

)
2
.
0
9
(

)
4
.
9
9
(

)
1
.
8
9
(

)
9
.
7
9
(

)
6
.
3
(

)
9
.
7
8
(

)
4
.
6
9
(

)
8
.
9
8
(

–

)
0
.
0
0
1
(

)
4
.
9
5
(

)
0
.
0
(

)
0
.
0
(

)
0
.
0
0
1
(

)
4
.
6
9
(

)
0
.
3
9
(

)
0
.
3
9
(

)
2
.
9
9
(

)
2
.
1
9
(

)
3
.
2
6
(

)
0
.
7
8
(

)
5
.

8
9
(

)
0
.
0
0
1
(

)
5
.
6
4
(

)
0
.
0
0
1
(

)
4
.
1
7
(

)
9
.
2
7
(

)
8

.
5
7
(

)
0
.
7
(

)
0
.
0
(

)
4
.
4
4
(

)
7
.
3
8
(

)
9
.
5
9
(

)
3
.
0
9
(

)
0
.
9
6
(

)
0
.
0
(

)
5
.
5
8
(

)
5
.
5
2
(

)
0
.
0
(

)
7
.
1
4
(

)
4
.
0
8
(

)
0
.
0
(

–

)
0
.
0
0
1
(

)
8
.
0
(

)
0
.
0
(

)
0
.
0
(

)
4
.
6
8
(

)
8

.
3
9
(

)
0
.
7
2
(

)
5
.
2
4
(

)
6
.
6
3
(

)
2
.
4
3
(

)
7
.

8
9
(

)
6
.

8
3
(

)
3
.
9
8
(

)
8

.

6
3
(

)
5
.
7
6
(

)
2
.

8
3
(

)
2
.
8
8
(

)
8

.
2
6
(

)
7
.
1
9
(

)
8

.

8
8
(

)
7
.
7
9
(

)
4
.
8
9
(

)
4
.
9
4
(

)
5
.
1
8
(

)
4
.
0
9
(

)
2
.
9
6
(

)
4
.
0
9
(

)
0
.
0
5
(

)
3
.
6
3
(

)
0
.
5
4
(

–

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
6
.
7
6
(

)
1
.
2
6
(

)
1
.
9
7
(

)
5
.
2
7
(

)
4
.
5
9
(

)
1
.
3
7
(

)
7
.
5
9
(

)
4
.
5
8
(

)
0
.
7
8
(

)
8

.

8
7
(

)
0
.
4
6
(

)
8

.
2
8
(

)
5
.
2
9
(

)
5
.
5
9
(

)
6
.
6
8
(

)
3
.
0
8
(

)
3
.
3
8
(

)
6
.

8
9
(

)
7
.
7
9
(

)
6
.
7
9
(

)
0
.
1
8
(

)
7
.
2
5
(

)
1
.
6
8
(

)
9
.
1
9
(

)
4
.

8
8
(

)
0
.
0
5
(

)
6
.
4
7
(

)
0
.
6
6
(

–

)
0
.
0
5
(

)
0
.
0
0
1
(

)
2
.
1
9
(

)
7
.
0
3
(

)
5
.
2
8
(

)
1
.
3
9
(

)
1
.
0
9
(

)
3
.
5
6
(

)
7
.
4
9
(

)
8
.
7
7
(

)
1
.
6
9
(

)
5
.
2
7
(

)
0
.
0
0
1
(

)
0
.
1
8
(

)
5
.
9
9
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
6
.
9
5
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
2
(

)
3
.
7
9
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
(

–

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
(

)
0
.
7
9
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
(

)
0
.
0
0
1
(

)
3
.
9
6
(

e
m
o
c
t
u
O

e
m
o
c
t
u
O

e
m
o
c
t
u
O

d
e
l
l
o
r
n
E

6
3

e
s
h
t
n
o
m

)

%

(

4
2

d
s
h
t
n
o
m

)

%

(

2
1

c
s
h
t
n
o
m

)

%

(

t
n
e
m
t
a
e
r
t

)

%

(

)

%

(

)

%

(

n
i

s
u
t
a
t
s
V
I

H

D
L
S
T
S
D

D
L
F
T
S
D

)

%

(

t
l
u
s
e
R

t
l
u
s
e
R

t
s
e
t

r
e
h
t
o

y
p
o
c
s
o
r
c
i
m

)

%

(

)

%

(

t
l
u
s
e
R

e
r
u
t
l
u
c

)

%

(

d
e
s
o
n
g
a
i

D

m
e
t
r
o
m
e
t
n
a

)

%

(

)
2
.
1
8
(

)
4
.
9
7
(

)
4
.
4
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
4
.
9
9
(

)
2
.
4
5
(

)
5
.
1
7
(

)
7
.
0
9
(

)
0
.
0
0
1
(

–

)
0
.
0
(

)
1
.
2
5
(

)
3
.
5
7
(

)
0
.
0
5
(

)
0
.
0
0
1
(

)
2
.

8
8
(

)
0
.
0
7
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
5
.
7
9
(

)
7
.

8
9
(

)
9
.
4
6
(

)
7
.
9
9
(

)
2
.
3
8
(

)

%

(

s
u
o
i
v
e
r
P

t
n
e
m
t
a
e
r
t

b
y
r
o
t
s
i

h

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
9
.
7
5
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
1
.
9
9
(

)
5
.

8
9
(

)
4
.
4
9
(

)
0
.
0
0
1
(

)
7
.
1
9
(

)
4
.
5
7
(

)
0
.
0
0
1
(

–

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
2
.
9
9
(

)
1
.
8
9
(

)
0
.
0
0
1
(

)
9
.
9
9
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
2
.
9
9
(

)
7
.
9
9
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
7
.
7
9
(

)
0
.
0
0
1
(

)
1
.
7
9
(

)
8

.
3
9
(

)
1
.
6
9
(

)
7
.
4
9
(

)
0
.
0
0
1
(

)
3
.
3
8
(

)
7
.
1
7
(

)
6
.
7
9
(

–

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
1
.
7
9
(

)
7
.
5
6
(

)
5
.
9
9
(

)
0
.
0
0
1
(

)
8
.
9
9
(

)
6
.

8
7
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
3
.
1
8
(

)
0
.
0
0
1
(

)
4
.
5
9
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
9
.

8
9
(

)
9
.

8
8
(

)
7
.
5
9
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
3
.
3
7
(

)
0
.
9
9
(

–

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
7
.

8
9
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
9
.
9
9
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
9
.
5
8
(

)
0
.
0
0
1
(

)
3
.

6
9
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
8
.
9
9
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
6
.
9
9
(

)
0
.
0
0
1
(

–

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
9
.
9
9
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
7
.

8
9
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
9
.
9
9
(

–

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
9
.
2
9
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
9
.
9
9
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
0
.
0
0
1
(

)
9
.
9
9
(

)
0
.
0
0
1
(

)
9
.
9
9
(

e
t
i

S

)

%

(

y
r
t
n
u
o
C

n
i
g
i
r
o
f
o

)

%

(

a
n
i
g
i
r
O

)

%

(

r
e
d
n
e
G

)

%

(

e
g
A

)

%

(

y
r
t
n
u
o
C

m
u

i
g
l
e
B

a
i
r
a
g

l

u
B

a
i
r
t
s
u
A

a
i
t
a
o
r
C

s
u
r
p
y
C

a
i

h
c
e
z
C

k
r
a
m
n
e
D

a
i

n
o
t
s
E

d
n
a
l

n

i
F

e
c
n
a
r
F

y
n
a
m

r
e
G

y
r
a
g
n
u
H

e
c
e
e
r
G

d
n
a
l
e
c
I

d
n
a
l
e
r
I

a
i
v
t
a
L

y
l
a
t
I

n

i
e
t
s
n
e
t
h
c
e
i
L

g
r
u
o
b
m
e
x
u
L

a
i

n
a
u
h
t
i
L

s
d
n
a
l
r
e
h
t
e
N

a
t
l
a
M

y
a
w

r
o
N

d
n
a
l
o
P

l
a
g
u
t
r
o
P

a
i

n
a
m
o
R

a
i
k
a
v
o
l

S

a
i

n
e
v
o
l

S

n
e
d
e
w
S

n

i
a
p
S

A
E
E
/
U
E
l
a
t
o
T

.
n

i
c
a
x
o
l
f
o
v
e
l

d
n
a
n

i
c
a
x
o
l
f
i
x
o
m

,
e
n

i
l
i

u
q
a
d
e
b
:
e
r
a
n
o
i
t
a
l

u
c
l
a
c
n

i

d
e
d
u

l
c
n

i

D
L
S

.
s
e
s
a
c

s
i
s
o
l

u
c
r
e
b
u
t

t
n
a
t
s
i
s
e
r
-
g
u
r
d

i
t
l

u
m

r
o
f

y
l

n
o
d
e
t
a
l

u
c
l
a
c

,
s
g
u
r
d
s
i
s
o
l

u
c
r
e
b
u
t
-
i
t
n
a

e
n

i
l
-
d
n
o
c
e
s

.
n

i
c
a
p
m
a
f
i
r
d
n
a
d

i
z
a
i

n
o
s
i

:
e
r
a
n
o
i
t
a
l

u
c
l
a
c
n

i

d
e
d
u

l
c
n

i

D
L
F

.
s
e
s
a
c

s
i
s
o
l

u
c
r
e
b
u
t
d
e
m

r
i
f
n
o
c

r
o
f
d
e
t
a
l

u
c
l
a
c

,
s
g
u
r
d
s
i
s
o
l

u
c
r
e
b
u
t
-
i
t
n
a

e
n

i
l
-
t
s
r
i
f

r
o
f
g
n

i
t
s
e
t

r
o
f
g
n

i
t
s
e
t

y
t
i
l
i

b

i
t
p
e
c
s
u
s
-
g
u
r
d
:

D
L
F

T
S
D

y
t
i
l
i

b

i
t
p
e
c
s
u
s
-
g
u
r
d
:

D
L
S
T
S
D

.
s
c
i
l
a
t
i

n

i

d
e
t
n
e
s
e
r
p
s
e
i
r
t
n
u
o
c

y
t
i
r
o
i
r
p
-
h
g
i

h
s
i
s
o
l

u
c
r
e
b
u
t
8
1
n
o
i
g
e
R
n
a
e
p
o
r
u
E
O
H
W

:
e
t
o
N

a
e
r
A
c
i
m
o
n
o
c
E
n
a
e
p
o
r
u
E
/
n
o
i
n
U
n
a
e
p
o
r
u
E
,
0
2
0
2
r
o
f
d
e
t
r
o
p
e
r
a
t
a
d
f
o
s
s
e
n
e
t
e
l
p
m
o
C

.
3
x
e
n
n
A

.

m
o
d
g
n

i

K
d
e
t
i

n
U
e
h
t
d
n
a

y
a
w

r
o
N

,
d
n
a
l
e
r
I

,
k
r
a
m
n
e
D

,

m
u

i
g
l
e
B
y
b
d
e
t
r
o
p
e
r

s
e
s
a
c

r
o
f

s
i
s
o
l

u
c
r
e
b
u
t

f
o
s
i
s
o
n
g
a
i

d
s
u
o
i
v
e
r
p
y
b
d
e
n

i
f
e
d
t
n
e
m
t
a
e
r
t

s
u
o
i
v
e
r
p
f
o
y
r
o
t
s
i
H
b

.
e
c
n
e
r
e
f
e
r
p
y
r
t
n
u
o
c
n
o
g
n

i

d
n
e
p
e
d
,
y
r
t
n
u
o
C
g
n

i
t
r
o
p
e
R
y
t
i
l
a
n
o
i
t
a
N
d
n
a

y
r
t
n
u
o
C
g
n

i
t
r
o
p
e
R
n
r
o
B
:
d
e
g
r
e
m
s
e
l

b
a
i
r
a
v
o
w

t

,
n

i
g
i
r
o
e
h
t
g
n

i

i

n
m

r
e
t
e
d
r
o
F
a

.
s
h
t
n
o
m
4
2
d
n
a

s
h
t
n
o
m
2
1

t
a

"
t
n
e
m
t
a
e
r
t
n
o
l
l
i
t
s
"

s
a
d
e
t
r
o
p
e
r

e
r
a

t
a
h
t

s
e
s
a
c

t
r
o
h
o
c
8
1
0
2
s
i
s
o
l

u
c
r
e
b
u
t

t
n
a
t
s
i
s
e
r
-
g
u
r
d
y
l
e
v
i
s
n
e
t
x
e

e
h
t

.
s
h
t
n
o
m
2
1

t
a

"
t
n
e
m
t
a
e
r
t
n
o
l
l
i
t
s
"

s
a
d
e
t
r
o
p
e
r

e
r
a

t
a
h
t

s
e
s
a
c

t
r
o
h
o
c
9
1
0
2
s
i
s
o
l

u
c
r
e
b
u
t

t
n
a
t
s
i
s
e
r
-
g
u
r
d

i
t
l

u
m
e
h
t

.
t
r
o
h
o
c
9
1
0
2
e
h
t

r
o
f

r
o
f

r
o
f

a
t
a
D

c

a
t
a
D
d

a
t
a
D

e

.
a
e
r
A
c
i
m
o
n
o
c
E
n
a
e
p
o
r
u
E
/
n
o
i

n
U
n
a
e
p
o
r
u
E

:
A
E
E
/
U
E

55

Tuberculosis surveillance and monitoring in Europe 2022SURVEILLANCE REPORT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Annex 4. Reporting completeness into Global TB Database, 2020

Country/area

Identification (%) 
(17 fields)

Notification (%) 
(54 fields)

Anti-tuberculosis 
drug resistance 
surveillance (%)

Treatment outcome 
of TB cases by risk 
categories (%) 
(80 fields)

Implementing End TB 
Strategy (%)  
(100 fields)

Budget and 
expenditure (%)  
(49 fields)

EU/EEA
Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
Subtotal EU/EEA
Non-EU/EEA
Albania
Andorra
Armenia
Azerbaijan
Belarus
Bosnia and Herzegovina
Georgia
Israel
Kazakhstan
Kyrgyzstan
Republic of Moldova
Monaco
Montenegro
North Macedonia
Russian Federation
San Marino
Serbia

Serbia excluding Kosovo1
Kosovo1
Switzerland
Tajikistan
Turkey
Turkmenistan
Ukraine
United Kingdom
Uzbekistan
Subtotal non-EU/EEA
Total European Region
Subtotal 18 HPCs

(0.0)
(0.0)
(100.0)
(0.0)
(0.0)
(94.1)
(0.0)
(100.0)
(70.6)
(94.1)
(76.5)
(0.0)
(0.0)
(0.0)
(94.1)
(35.3)
(100.0)
–
(70.6)
(100.0)
(70.6)
(100.0)
(0.0)
(94.1)
(70.6)
(100.0)
(64.7)
(100.0)
(0.0)
(70.6)
(53.5)

(100.0)
(64.7)
(100.0)
(88.2)
(100.0)
(100.0)
(100.0)
(100.0)
(100.0)
(100.0)
(100.0)
(29.4)
(100.0)
(100.0)
(64.7)
(0.0)
(100.0)
(100.0)
(100.0)
(100.0)
(100.0)
(100.0)
(88.2)
(100.0)
(29.4)
(100.0)
(86.0)
(68.0)
(95.1)

(77.8)
(92.6)
(87.0)
(77.8)
(77.8)
(96.3)
(72.2)
(98.1)
(87.0)
(83.3)
(79.6)
(77.8)
(77.8)
(77.8)
(74.1)
(70.4)
(3.7)
–
(92.6)
(94.4)
(88.9)
(90.7)
(81.5)
(83.3)
(92.6)
(94.4)
(98.1)
(90.7)
(77.8)
(83.3)
(79.3)

(94.4)
(48.1)
(92.6)
(85.2)
(96.3)
(83.3)
(98.1)
(90.7)
(87.0)
(87.0)
(100.0)
(75.9)
(85.2)
(83.3)
(87.0)
(0.0)
(75.9)
(0.0)
(75.9)
(79.6)
(87.0)
(90.7)
(74.1)
(92.6)
(61.1)
(83.3)
(80.8)
(80.0)
(85.4)

(71.4)
(71.4)
(71.4)
(71.4)
(71.4)
(71.4)
(71.4)
(71.4)
(71.4)
(71.4)
(71.4)
(71.4)
(71.4)
(71.4)
(71.4)
(95.2)
(0.0)
–
(71.4)
(71.4)
(71.4)
(71.4)
(71.4)
(71.4)
(71.4)
(71.4)
(71.4)
(71.4)
(71.4)
(71.4)
(67.5)

(19.0)
(40.5)
(45.2)
(28.6)
(78.6)
(33.3)
(81.0)
(54.8)
(59.5)
(47.6)
(95.2)
(7.1)
(54.8)
(95.2)
(76.2)
(0.0)
(7.1)
(0.0)
(7.1)
(95.2)
(85.7)
(95.2)
(21.4)
(85.7)
(54.8)
(92.9)
(56.4)
(62.6)
(65.5)

(46.3)
(100.0)
(92.5)
(53.8)
(38.8)
(100.0)
(38.8)
(86.3)
(46.3)
(46.3)
(60.0)
(0.0)
(53.8)
(38.8)
(53.8)
(0.0)
(0.0)
–
(100.0)
(56.3)
(1.3)
(85.0)
(58.8)
(0.0)
(77.5)
(100.0)
(92.5)
(40.0)
(53.8)
(61.3)
(52.7)

(96.3)
(73.8)
(100.0)
(50.0)
(92.5)
(20.0)
(92.5)
(62.5)
(100.0)
(70.0)
(100.0)
(0.0)
(52.5)
(100.0)
(92.5)
(0.0)
(31.3)
(0.0)
(31.3)
(61.3)
(100.0)
(100.0)
(31.3)
(100.0)
(46.3)
(38.8)
(67.1)
(59.1)
(80.3)

(0.0)
(9.6)
(75.5)
(37.2)
(0.0)
(54.3)
(1.1)
(79.8)
(47.9)
(35.1)
(11.7)
(0.0)
(0.0)
(0.0)
(54.3)
(22.3)
(0.0)
–
(72.3)
(46.8)
(22.3)
(44.7)
(24.5)
(29.8)
(66.0)
(80.9)
(73.4)
(77.7)
(0.0)
(46.8)
(33.8)

(75.5)
(53.2)
(69.1)
(53.2)
(77.7)
(45.7)
(84.0)
(22.3)
(84.0)
(83.0)
(92.6)
(0.0)
(67.0)
(76.6)
(47.9)
(0.0)
(78.7)
(0.0)
(78.7)
(56.4)
(62.8)
(87.2)
(52.1)
(93.6)
(0.0)
(63.8)
(59.4)
(45.2)
(70.0)

(0.0)
(0.0)
(100.0)
(0.0)
(0.0)
(0.0)
(0.0)
(2.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
–
(0.0)
(0.0)
(0.0)
(2.0)
(0.0)
(0.0)
(0.0)
(2.0)
(2.0)
(0.0)
(0.0)
(0.0)
(3.6)

(2.0)
(2.0)
(63.3)
(79.6)
(98.0)
(16.3)
(100.0)
(0.0)
(98.0)
(93.9)
(100.0)
(0.0)
(2.0)
(0.0)
(95.9)
(0.0)
(0.0)
(0.0)
(0.0)
(2.0)
(98.0)
(0.0)
(16.3)
(100.0)
(0.0)
(0.0)
(40.3)
(19.9)
(58.2)

Note: European Region comprises the 53 countries of the WHO European Region and Liechtenstein. WHO European Region 18 tuberculosis HPCs presented in 
italics. 
EU/EEA: European Union/European Economic Area.
HPCs: high-priority countries. 
 1 All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999).

56

SURVEILLANCE REPORTTuberculosis surveillance and monitoring in Europe 2022Annex 5. Laboratory network capacity, European Region, 2020a

Country/area laboratory network

International proficiency testing of 
national reference laboratory

Microscopy

Culture

DST for isoniazid 
and rifampicin

f
o
r
e
b
m
u
N

s
e
i
r
o
t
a
r
o
b
a
l

g
n
i
m

r
o
f
r
e
p

d
e
s
s
a
p
A
Q
E

f
o
r
e
b
m
u
N

s
e
i
r
o
t
a
r
o
b
a
l

g
n
i
m

r
o
f
r
e
p

f
o
r
e
b
m
u
N

s
e
i
r
o
t
a
r
o
b
a
l

g
n
i
m

r
o
f
r
e
p

d
e
s
s
a
p
A
Q
E

Line 
probe 
assay 
(N)

Xpert 
MTB/RIF 
(N)

Year

Percentage 
agreement of 
results for:

d
i
z
a
i
n
o
s
i

n
i
c
i
p
m
a
f
i
r

b
e
c
n
a
m

r
o
f
r
e
p
e
l
b
a
t
p
e
c
c
A

–
–
33
13
–
38
–
2
9
140
–
–
–
–
10
45
–
–
11
1
1
–
–
54
46
94
7
2
–
5
  511

12
7
18
38
96
14
11
13
245
108
57
–
1
7
 5 277
–
33
30
3
32
76
165
67
758
–
290
 7 325
 7 836
 7 346

–
–
33
1
–
38
–
2
9
–
–
–
–
–
10
–
–
–
11
1
–
–
–
–
46
87
7
2
–
5
  252

0
–
18
20
81
7
0
–
140
108
57
–
1
7
652
–
–
–
0
32
70
114
–
742
–
254
 2 303
 2 555
 2 389

–
–
30
13
–
38
–
2
9
140
–
–
–
–
10
45
–
–
5
1
1
30
–
54
42
87
3
2
–
5
  517

1
7
1
7
15
11
2
13
20
7
4
–
1
3
349
–
29
29
0
20
6
85
6
52
–
8
  647
 1 164
  686

–
–
10
5
–
17
–
2
1
50
–
–
–
–
3
45
–
–
5
1
1
7
–
40
19
87
1
1
–
5
  300

1
3
1
3
8
5
1
1
20
1
4
–
1
0
198
–
4
4
0
9
1
46
6
34
–
8
  355
  655
  435

–
–
10
5
–
17
–
2
1
–
–
–
–
–
3
–
–
–
5
1
–
–
–
–
10
45
1
1
–
4
  105

0
–
0
3
8
0
1
–
20
1
4
–
1
0
79
–
4
4
0
9
0
46
–
34
–
8
  218
  323
  266

–
–
3
1
–
–
–
1
2
38
–
–
–
–
1
25
–
–
1
1
0
–
–
1
20
8
1
1
–
5
  109

1
4
1
2
8
3
2
1
17
1
4
–
0
0
4
–
1
1
0
5
6
5
6
4
–
12
  87
  196
  85

–
–
4
1
–
–
–
6
5
75
–
–
–
–
6
45
–
–
4
0
1
–
–
25
10
30
1
2
–
5
  220

–

1
3
8
16
24
0
28
1
119
24
4
–
1
1
1
–
–
–
0
55
52
26
7
159
–
52
  762
  982
  744

–
–
2020
2020
–
2020
–
2020
2020
2020
–
–
–
–
2020
2019
–
–
2020
2020
–
2020
–
2020
2020
2020
2020
2020
–
2020
–

2016
–
2018
2020
2020
–
2020
–
2020
2020
2020
–
2020
2017
–
–
–
–
–
2020
2019
2020
2019
–
–
2020
–
–
–

–
–
100
100
–
100
–
100
100
100
–
–
–
–
100
100
–
–
100
100
–
100
–
100
100
100
100
100
–
100
–

100
–
100
–
100
–
100
–
95
100
100
–
100
100
–
–
–
–
–
100
100
100
–
100
–
100
–
–
–

–
–
100
100
–
100
–
100
100
100
–
–
–
–
100
100
–
–
100
100
–
100
–
100
100
100
100
100
–
100
–

100
–
100
–
100
–
100
–
95
100
100
–
100
100
–
–
–
–
–
100
100
100
–
100
–
100
–
–
–

–
–
Y
–
–
Y
–
Y
Y
–
–
–
–
–
Y
Y
–
–
–
Y
–
Y
–
Y
Y
Y
Y
–
–
Y
–

N
–
N
Y
Y
–
Y
–
N
Y
Y
–
Y
N
–
–
–
–
–
Y
Y
Y
–
–
–
Y
–
–
–

Country/area

EU/EEA
Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
Subtotal EU/EEA
Non-EU/EEA
Albania
Andorra
Armenia
Azerbaijan
Belarus
Bosnia and Herzegovina
Georgia
Israel
Kazakhstan
Kyrgyzstan
Republic of Moldova
Monaco
Montenegro
North Macedonia
Russian Federation
San Marino
Serbia

Serbia excluding Kosovo1
Kosovo1
Switzerland
Tajikistan
Turkey
Turkmenistan
Ukraine
United Kingdom
Uzbekistan
Subtotal non-EU/EEA
Total European Region
Subtotal 18 HPCs

Note: European Region comprises the 53 countries of the WHO European Region and Liechtenstein. WHO European Region 18 tuberculosis HPCs 
presented in italics.
EQA:	external	quality	assessment.
EU/EEA: European Union/European Economic Area.
DST: drug-susceptibility testing.
HPCs: high-priority countries. 
N: no.
Y: yes.
a Data obtained from WHO Tuberculosis Monitoring and Evaluation database.
b Acceptable performance defined as reference laboratory achieving 95% performance (smear and drug-susceptibility testing).
1 All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999).

57

Tuberculosis surveillance and monitoring in Europe 2022SURVEILLANCE REPORT 
 
 
 
 
 
 
 
 
 
 
 
Annex 6. Monitoring framework for follow up of the Tuberculosis Action Plan for the WHO European Region, 2016–2020

Area of 
intervention

Indicator

Baseline for WHO 
European Region 
(2014)

Target

Frequency 
of 
assessment

Data 
source

Monitoring 
mechanism

Indicator definition

Indicator 
level

1.C Equitable access to quality treatment and continuity of care for all people with TB, including drug-resistant TB, and patient support to facilitate treatment adherence

Percentage of hospitalization 
of new TB patients (E)

NA

Decrease

01–2016 
01–2021

NTP

Desk 
review

1.B.1

1.B.2

1.B.3

1.B.4

1.B.5

1.B.6

1.B.7

1.C.1

1.C.2

1.C.3

1.C.4

1.C.5

1. Integrated patient-centred care and prevention
1.A Systematic screening of contacts and high-risk groups

1.A.1

Coverage of population 
at risk with systematic 
screening for active TB 
and LTBI

NA

Full 
coverage

01–2016 
01–2021

NTP

Desk 
review

1.B Early diagnosis of all forms of TB and universal access to DST, including the use of rapid tests 

Percentage of TB 
patients diagnosed using 
WHO-recommended rapid 
tests (G)

NA

≥	90% Annually

NTP

Desk 
review

First-line DST coverage (%) 
among all bacteriologically 
confirmed TB cases (G)

91.9%

Close to 
100%

Annually

WHO 
global TB 
database

Routine 
reporting

RR/MDR-TB case detection 
rate (%) (G)

TB notification rate per  
100 000 population (E)

46.5%

85% Annually

30.4

24.6 Annually

TB case-detection rate (%)

88.2%

Increase Annually

Percentage of RR/MDR-TB 
among new TB patients (E)

Percentage of RR/MDR-TB 
among previously treated TB 
patients

16.9%

Decrease Annually

48.0%

Decrease Annually

WHO 
global TB 
database

WHO 
global TB 
database
WHO 
global TB 
database

WHO 
global TB 
database

WHO 
global TB 
database

WHO 
global TB 
database

WHO 
global TB 
database

WHO 
global TB 
database

WHO 
global TB 
database

WHO 
global TB 
database

WHO 
global TB 
database

WHO 
global TB 
database

WHO 
global TB 
database

WHO 
global TB 
database

Percentage of detected  
RR/MDR-TB enrolled in 
treatment (G)

Treatment success rate (%) 
among all new and relapse TB 
patients (G)

Treatment success rate 
(%) among the RR/MDR-TB 
treatment cohort (G) (E)

TB mortality rate (ICD A15-19) 
per 100 000 population 
(G) (E)

61.9%

Close to 
100%

Annually

77.2%

85% Annually

54.8%

75% Annually

3.7

2.7 Annually

1.D Collaborative TB/HIV activities and management of comorbidities

TB/HIV case-detection 
rate (%)

84.8%

Close to 
100%

Annually

HIV testing coverage (%) 
(G) (E)

67.6%

Close to 
100%

Annually

Percentage of HIV among 
all TB

7.8%

Decrease Annually

ART coverage (%) among  
TB/HIV cases

53.8%

Close to 
100%

Annually

LTBI treatment enrolment rate 
(%) among PLHIV (G)

4.8%

30% Annually

1.D.1

1.D.2

1.D.3

1.D.4

1.D.5

58

Total number of people screened for TB and/
or LTBI in a defined period over  the total 
number of people at risk according to the 
national guidelines, in the same period

Number of newly notified TB patients 
diagnosed with WHO-recommended rapid 
tests, divided by the total number of  newly 
notified TB patients
Number of TB patients with DST results 
divided by the number of notified cases in the 
same year, expressed as a percentage.  
DST coverage includes results from 
molecular (such as Xpert MTB/RIF) as well as 
conventional phenotypic DST results.
Total number of notified RR/MDR-TB cases 
over total number of estimated RR/MDR-TB 
cases among notified bacteriologically 
confirmed pulmonary TB patients

Routine 
reporting

Routine 
reporting

Total number of new and relapse TB cases 
notified per 100 000 population

Routine 
reporting

Routine 
reporting

Routine 
reporting

Total number of notified TB cases over total 
number of estimated TB cases expressed as 
percentage
Total number of laboratory-confirmed new 
RR/MDR-TB cases over total number of new 
TB cases with DST results expressed as 
percentage
Total number of laboratory-confirmed 
previously treated RR/MDR-TB cases over 
total number of previously treated TB cases 
with DST results expressed as percentage

Total number of new TB cases hospitalized 
in a specified period over total number of 
new TB cases registered in the same period 
expressed as percentage
Total number of laboratory-confirmed  
RR/MDR-TB cases enrolled into SLD treatment 
in line with WHO recommendations over total 
number of laboratory-confirmed RR/MDR-TB 
cases notified expressed as percentage
New and relapse TB cases  registered in 
a specified period that were successfully 
treated 
Number of confirmed RR/MDR-TB cases 
during the specified period that were 
successfully treated over number of 
confirmed RR/MDR-TB cases that started on a 
prescribed MDR-TB treatment regimen during 
the specified period

Routine 
reporting

Routine 
reporting

Routine 
reporting

Routine 
reporting

Estimated number of TB deaths (from vital 
registration system) per 100 000 population

Routine 
reporting

Routine 
reporting

Routine 
reporting

Routine 
reporting

Routine 
reporting

Total number of registered HIV coinfected 
TB patients in a specified period over total 
number of estimated TB/HIV coinfected 
patients
Number of new and relapse TB patients 
with documented HIV status divided by 
the number of new and relapse TB patients 
notified in the same year, expressed as  
percentage
Total number of registered TB patients in a 
specified period who are HIV-positive over 
total number of registered TB patients in 
the same period with documented HIV test 
results
Total number of registered HIV/TB patients 
in a specified period who are enrolled in ART 
over total number of registered TB patients in 
the same period who are HIV-positive
Total number of new HIV cases enrolled in 
LTBI treatment  in a specified period; total 
number of new HIV cases eligible for  LTBI 
treatment in the same period

98.2%

72.3%

92.0%

93.8%

17.5

70.7%

23.1%

55.2%

NA

125.4%

76.5%

55.9%

2.3

67.8%

92.6%

15.0%

74.3%

79.5%

SURVEILLANCE REPORTTuberculosis surveillance and monitoring in Europe 2022Annex 6 contd

Area of 
intervention

Indicator

Baseline for WHO 
European Region 
(2014)

Target

Frequency of 
assessment

Data 
source

Monitoring 
mechanism

Indicator definition

Indicator 
level

1.E Management of LTBI and preventive treatment of people at high risk, and vaccination against TB

1.E.1

1.E.2

Contact investigation 
coverage (%) (G) (E)

NA

90%

01–2016 
01–2021

NTP

LTBI treatment coverage 
(%) in childhood TB contact 
persons aged under 5 
years (G)

N/A

90% 01–2016

NTP

2. Bold policies and supportive systems
2.A Political commitment with adequate resources, including universal health coverage policy

Desk 
review

Desk 
review

Number of contacts of people with 
bacteriologically confirmed TB who were 
investigated for TB/LTBI in a defined period 
over the number of contacts eligible for 
contact investigation in the same period
Total number of child TB contacts age < 5 
years enrolled in LTBI treatment in a defined 
period over number of child TB contact cases 
eligible for  LTBI treatment in the same period

98.2%

29.6%

2.A.1

Number of Member States 
that have a regular TB 
control/elimination 
performance publication 
every five years (E)

NA

53

Cumulative 
2016–2020

NTP

Desk 
review

–

2.B Health system strengthening in all functions, including well aligned functioning mechanisms for TB and human resources

2.B.1

Percentage of TB patients 
and their households that 
experience catastrophic 
financial consequences due 
to TB (G) (E)

NA

Close to	0 Annually

NTP

Desk 
review

Number of people treated for TB (and their 
households) who incur catastrophic costs 
(direct and indirect combined) divided by the 
total number of people treated for TB

2.C Regulatory frameworks for case-based surveillance, strengthening vital registration, quality and rational use of medicines and pharmacovigilance

2.C.1

Treatment coverage (%) with 
new TB drugs

2.D Community systems and civil society engagement

2.D.1

Number of Member 
States with functioning 
multistakeholder coalitions 
advocating for TB care and 
resources

NA

NA

20%

Cumulative 
2016–2020

NTP

Desk 
review

Number of TB patients treated with regimens 
that include new TB drugs divided by the 
number of notified patients eligible for 
treatment with new TB drugs, expressed as 
a percentage

53

Cumulative 
2016–2020

NTP

Desk 
review

–

2.E Social protection, poverty alleviation and actions on other determinants of TB, such as migration and prisons

2.E.1

Treatment success rate (%) 
of new and relapse TB cases 
among prisoners

63.2%

85% Annually

WHO 
global TB 
database

Routine 
reporting

New and relapse prison TB cases registered 
in a specified period that were  successfully 
treated

3. Intensified research and innovation
3.A Discovery, development and rapid uptake of new tools, interventions and strategies

3.A.1

European TB research 
initiative established by 
mid-2016

– Established

Cumulative 
2016–2020

NTP

Desk 
review

–

–

–

–

–

60.4%

–

ART: antiretroviral therapy. DST: drug-susceptibility testing. (E): European (indicator). (G): global (indicator). LTBI: latent tuberculosis infection. NA: not available. 
NTP: national tuberculosis programme. PLHIV: people living with HIV. RR/MDR-TB: rifampicin-resistant/multidrug-resistant tuberculosis. SLD: second-line drug.  
TB: tuberculosis.

59

Tuberculosis surveillance and monitoring in Europe 2022SURVEILLANCE REPORT6. Tables

  
  
Summary table. Tuberculosis (TB) surveillance data by region, European Region, 2020 

Data item

Total population (millions)
Estimates of TB disease burden, 2020c 
Estimated TB mortality rate (excluding HIV-related deaths) per  
100 000 population
Estimated TB incidence rate per 100 000 population
Estimated RR-TB cases among notified bacteriologically confirmed 
pulmonary TB patients
Estimated percentage of HIV infection among incident TB cases 
(new and relapse)
Notifications of TB cases, 2020
Total number of TB cases
All TB cases per 100 000 population
Mean annual percentage change of notification rate (2016–2020)
Number of new and relapse TB cases
New and relapse TB cases per 100 000 population
Mean annual percentage change of notification rate of new and 
relapse TB cases (2016–2020)
Percentage of new cases among all TB cases
Percentage of retreatment cases among all TB cases
Percentage of pulmonary TB among all TB cases
Percentage of laboratory-confirmed TB cases among all TB cases
Male-to-female ratio of new and relapse TB cases
Percentage of foreign TB cases among all TB cases
TB case laboratory confirmation, RR/MDR and XDR, 2020
Percentage of laboratory-confirmed cases among new pulmonary 
TB casesd
Percentage of DST results reported among new bacteriologically 
confirmed pulmonary TB cases
Percentage of RR/MDR-TB among new pulmonary TB cases
Percentage of RR/MDR-TB among previously treated pulmonary 
TB cases
Percentage of pre-XDR-TB among all RR/MDR-TB cases with DST for 
fluoroquinolone
Percentage of XDR-TB among all pre-XDR-TB cases with DST for any 
other Group A drugs
Percentage of XDR-TB among all MDR-TB cases with DST for SLD
TB/HIV coinfection, 2020
Percentage of new and relapse TB cases with known HIV status
Percentage of HIV-positive cases among new and relapse TB cases 
with known HIV status
Percentage of HIV-positive new and relapse TB cases started on 
ART
Treatment outcome
Treatment success rate among new and relapse TB cases notified 
in 2019 
Treatment success rate among previously treated TB cases 
reported in 2019e 
Treatment success rate among childhood TB cases notified in 2019 
Treatment success rate among TB/HIV cases notified in 2019
Treatment	success	rate	among	RR/MDR-TB	cases	enrolled in	SLD	
treatment in 2018 
Teatment success rate among all pre-XDR-TB cases notified in 
2018 
Treatment success rate among all XDR-TB cases notified in 2017 

y
b
a
t
a
d
g
n
i
w
o
h
s
e
l
b
a
T

a
e
r
a
/
y
r
t
n
u
o
c

–

1

1

2

2

3
3
3
III
III

III

4
4
5
8
8
9

11

11

11

11

12

12

14

14

14

14

16

17

18
20

22

23

24

EU/EEA

Non-EU/EEA

Total

18 high-priority 
countriesa

Region

g
n
i
t
r
o
p
e
r

f
o
r
e
b
m
u
N

b
s
a
e
r
a
/
s
e
i
r
t
n
u
o
c

e
u
l
a
V

g
n
i
t
r
o
p
e
r

f
o
r
e
b
m
u
N

b
s
a
e
r
a
/
s
e
i
r
t
n
u
o
c

e
u
l
a
V

g
n
i
t
r
o
p
e
r

f
o
r
e
b
m
u
N

b
s
a
e
r
a
/
s
e
i
r
t
n
u
o
c

29

518.1

24

481.9

30

29

28

27

29
29
29
29
29

28

29
29
29
29
29
29

29

29

29

29

29

29

29

19

19

6

23

22

23
19

21

21

21

0.8

9.5

810

3.6

		33	148
7.3
–11.6%
		31	551
7.0

–11.1%

72.8%
10.4%
77.7%
67.3%
2.0
33.0%

76.7%

84.3%

2.8%

12.8%

27.6%

45.1%

22.4%

73.4%

4.2%

84.1%

71.8%

51.2%

77.0%
55.1%

52.4%

33.2%

52.1%

21

24

22

21

23
23
23
23
23

23

23
23
–
–
23
20

21

21

21

21

15

8

18

20

20

20

23

22

18
15

21

19

–

3.5

39.2

		35	800

14.2

		166	552
34.6
–9.7%
		132	051
27.4

–10.7%

65.7%
34.3%
–
–
1.8
4.3%

62.8%

94.9%

27.8%

57.7%

27.0%

5.7%

22.5%

95.2%

16.1%

74.2%

77.5%

61.7%

92.8%
54.8%

56.0%

52.1%

–

53

51

53

50

48

52
52
52
52
52

51

52
52
–
–
52
50

50

50

50

50

44

37

47

39

39

26

46

44

41
34

42

40

–

e
u
l
a
V

932.9

2.3

25.0

		37	000

12.0

		199	700
21.4
–9.8%
		163	602
17.5

–10.7%

66.9%
30.3%
–
–
1.8
9.4%

65.2%

92.7%

23.1%

55.2%

33.0%

6.5%

22.5%

92.6%

15.0%

74.3%

76.5%

61.1%

88.8%
54.8%

55.9%

50.9%

–

g
n
i
t
r
o
p
e
r

f
o
r
e
b
m
u
N

b
s
a
e
r
a
/
s
e
i
r
t
n
u
o
c

18

18

18

17

18

17
17
17
17
17

17

17
17
–
–
17
14

16

16

16

16

16

11

15

16

16

14

17

17

13
14

17

17

–

e
u
l
a
V

411.0

4.4

47.4

36	200

13.8

		169	799
41.5
–9.7%
		135	024
32.8

–10.9%

65.5%
34.5%
–
–
1.9
2.0%

63.5%

94.3%

26.9%

56.2%

32.9%

6.1%

22.6%

94.8%

15.3%

74.3%

78.2%

61.0%

93.5%
54.9%

55.9%

50.9%

–

Note: European Region comprises the 53 countries of the WHO European Region and Liechtenstein.  
ART: antiretroviral therapy. 
DST: drug-susceptibility testing. 
MDR: multidrug-resistant.  
RR: rifampicin-resistant. 
SLD: second-line anti-TB drugs. 
XDR: extensively drug-resistant. 
a High-priority countries: the 18 high-priority countries in the WHO European Region are: Armenia, Azerbaijan, Belarus, Bulgaria, Estonia, Georgia, Kazakhstan, 
Kyrgyzstan, Latvia, Lithuania, the Republic of Moldova, Romania, the Russian Federation, Tajikistan, Turkey, Turkmenistan, Ukraine and Uzbekistan. 
b Number of countries/areas with available data included in the statistics.  
c WHO estimates, as published in Global tuberculosis report 2020 (Geneva: World Health Organization; 2020 [will be replaced by a reference number]).
d Laboratory-confirmed cases – cases with positive identification for Mycobacterium tuberculosis complex confirmed by culture and/or line probe assay for  
non-EU/EEA countries and areas. For EU/EEA countries: culture-positive OR microscopy-positive and nucleic acid amplification test-positive cases. 
e Excluding relapse TB cases. 

63

Tuberculosis surveillance and monitoring in Europe 2022SURVEILLANCE REPORT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Estimates of the TB disease burden, European Region, 2020

Country

Populationa

Estimated number of deaths from TB 
(all forms, excluding HIV)

Estimated number of incident cases (all forms)

Estimated incidence of child TB cases

Estimated incidence of TB among females

Number
Low

Best

Per 100 000

Number

High

Best

Low

High

Best

Low

High

Per 100 000
Low

Best

High

Number

Per 100 000

Number

Per 100 000

Best

Low

High

Best

Low

High

Best

Low

High

Best

Low

High

EU/EEA
Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
Subtotal EU/EEA
Non-EU/EEA
Albania
Andorra
Armenia
Azerbaijan
Belarus
Bosnia and Herzegovina
Georgia
Israel
Kazakhstan
Kyrgyzstan
Monaco
Montenegro
North Macedonia
Republic of Moldova
Russian Federation
San Marino
Serbia
Switzerland
Tajikistan
Turkey
Turkmenistan
Ukraine
United Kingdom
Uzbekistan
Subtotal non-EU/EEA
Total European Region
Subtotal 18 HPCs

–

9	006	400
11	589	616
6 948 445
4	105	268
1	207	361
10	708	982
5	792	203
1 326 539
5	540	718
65	273	512
83	783	945
10	423	056
9	660	350
	341	250
4	937	796
60	461	828
1 886 202

2 722 291
	625	976
	441	539
17	134	873
5	421	242
37	846	605
10	196	707
19 237 682
5	459	643
2	078	932
46	754	783
10	099	270
 451 013 014

2	877	800
	77	265
2 963 234
10 139 175
9 449 321
3	280	815
3 989 175
8	655	541
18 776 707
6 524 191
	39	244
	628	062
2	083	380
4 033 963
145 934 460
	33	938
8	737	370
8	654	618
9 537 642
84 339 067
6 031 187
43 733 759
67	886	004
33 469 199
481 875 117
932 888 131
411 042 239

		41
		33
  97
		60
		5
		23
		10
  16
		30
		440
		270
		52
		62
		2
		18
		310
  64
–
  120
		2
		1
		28
		19
		570
		240
  920
		35
		14
		250
		22
  3 800

11
1
30
740
260
110
190
21
610
300
0
1
25
210
7 300
0
93
17
920
420
620
4 100
		310
1 100
 17 000
 21 000
 18 017

40
32
95
59
4
22
10
16
30
420
260
49
62
2
18
300
62
–
110
2
1
28
18
540
230
910
34
14
250
22
  3 700

6
1
29
660
250
96
170
20
580
290
0
1
21
200
7  100
0
85
17
790
410
520
3 500
310
1 000
  16 000
 20 000
 17 000

42
34
99
60
5
23
11
16
31
460
270
54
62
2
18
310
65
–
130
2
1
29
19
600
250
930
35
15
260
22
  3 800

18
2
30
830
270
130
220
21
630
300
0
2
28
230
7 600
0
100
18
1100
440
720
4 800
320
1 100
  18 000
 22 000
 19 000

0.46
0.29
1.40
1.50
0.39
0.21
0.17
1.20
0.55
0.68
0.32
0.50
0.64
0.62
0.37
0.51
3.40
–
4.40
0.35
0.23
0.16
0.34
1.50
2.40
4.80
0.64
0.69
0.54
0.22
0.8

0.40
1.40
1.00
7.30
2.80
3.50
4.80
0.24
3.20
4.60
0.00
0.23
1.20
5.30
5.00
0.00
1.10
0.20
9.60
0.50
10.00
9.40
0.46
3.20
3.5
2.3
4.4

0.45
0.27
1.40
1.40
0.36
0.21
0.16
1.20
0.55
0.64
0.31
0.47
0.64
0.60
0.37
0.50
3.30
–
4.20
0.34
0.23
0.16
0.33
1.40
2.30
4.80
0.63
0.68
0.53
0.21
0.8

0.22
0.85
0.99
6.50
2.70
2.90
4.20
0.23
3.10
4.50
0.00
0.16
1.00
4.90
4.80
0.00
0.97
0.19
8.30
0.48
8.60
7.90
0.45
3.00
3.3
2.2
4.1

0.47
0.30
1.40
1.50
0.42
0.21
0.18
1.20
0.55
0.71
0.33
0.52
0.64
0.64
0.37
0.51
3.50
–
4.70
0.36
0.23
0.17
0.35
1.60
2.40
4.80
0.65
0.70
0.55
0.22
0.8

0.63
2.10
1.00
8.20
2.90
4.10
5.50
0.25
3.40
4.70
0.00
0.32
1.40
5.60
5.20
0.00
1.20
0.21
11.00
0.52
12.00
11.00
0.48
3.30
3.7
2.4
4.6

			440
			890
  1 300
			270
			69
			410
			280
   140
			200
		5	300
		4	600
			470
			440
			10
			260
		4	000
   430
–
   790
			37
			160
			710
			170
		3	600
		1	600
  12 000
			180
			86
		3	400
			360
  43 000

			430
			2
   680
  5 900
  2 500
			850
  2 800
			180
  13 000
  6 900
			0
			99
			250
  3 000
  68 000
			0
		1	200
			400
  8 000
  13 000
  2 800
  32 000
		4	700
  22 000
 189 000
 231 000
 195 000

			380
			770
  1 000
			230
			59
			350
			240
   120
			170
		4	700
		3	900
			400
			380
			8
			230
		3	400
   370
–
   680
			31
			140
			600
			140
		3	100
		1	400
  10 000
			150
			74
		2	900
			310
  41 000

			370
			2
   520
  4 500
  1 900
			650
  2 300
			160
  8 400
  5 800
			0
			84
			190
  2 500
  43 000
			0
			980
			350
  6 100
  11 000
  2 200
  21 000
		4	200
  15 000
  158 000
 201 000
  164 000

			510
		1	000
  1 700
			310
			80
			480
			320
   160
			230
		6	000
		5	300
			550
			510
			11
			300
		4	600
   500
–
   910
			43
			190
			820
			190
		4	200
		1	800
  14 000
			200
			100
		3	900
			420
  45 000

			500
			3
   870
  7 500
  3 100
		1	100
  3 300
			210
  19 000
  8 000
			0
			120
			310
  3 500
  98 000
			0
		1	300
			470
  10 000
  15 000
  3 600
  45 000
		5	200
  30 000
  220 000
 264 000
  226 000

4.9
7.7
19
6.6
5.7
3.9
4.9
10
3.6
8.2
5.5
4.5
4.6
2.8
5.3
6.6
23
–
29
5.9
36
4.1
3.1
9.6
16
64
3.2
4.1
7.3
3.6
9.5

			15
			3
   23
   58
   26
			26
   70
			2
   69
   105
			0
			16
			12
   74
   46
			0
			13
			5
   84
   15
   47
   73
			7
   66
39
25
47

4.2
6.6
14
5.7
4.9
3.3
4.2
8.9
3.1
7.2
4.7
3.9
3.9
2.4
4.6
5.7
20
–
25
5
31
3.5
2.6
8.2
13
54
2.8
3.5
6.2
3.1
9.1

			13
			3
   18
   44
   20
			20
   58
			2
   45
   89
			0
			13
			9
   63
   30
			0
			11
			4
   64
   13
   36
   49
			6
   46
33
22
40

5.6
8.9
24
7.6
6.6
4.5
5.6
12
4.2
9.2
6.4
5.2
5.3
3.3
6.2
7.6
26
–
34
6.8
42
4.8
3.5
11
18
74
3.7
4.8
8.4
4.2
10.0

			17
			3
   29
   74
   33
			33
   83
			2
   99
   122
			0
			18
			15
   86
   67
			0
			15
			5
   106
   18
   60
   102
			8
   90
46
28
55

Note: European Region comprises the 53 countries of the WHO European Region and Liechtenstein. WHO European Region 18 TB HPCs are presented in italics.
HPCs: high-priority countries.
a Population estimate 2020 by United Nations Statistical Database for all countries.   

64

			220

180

250

			14

			55

   110

			1

			2

			2

			17

			1

			6

			280

			190

			17

			6

			0

			6

   8

–

   15

			0

			9

			22

			13

			44

			47

   590

			40

			0

			220

			18

			5

			0

   40

   360

   81

			2

			150

			5

   730

   500

			0

			0

			17

   140

  1 900

			0

			29

			18

   510

   830

   160

  1 300

			170

  3 200

 10 000

 12 000

 11 000

12

46

79

1

2

2

1

5

15

250

160

15

5

0

5

7

–

0

7

13

18

11

37

40

490

33

0

180

15

			5

			0

   29

   260

   60

			2

			120

			4

   420

   410

			0

			0

			13

   120

  1 100

			0

			24

			16

   370

   690

   120

   790

			150

16

64

140

20

320

220

20

1

2

3

1

7

7

0

7

9

–

17

0

10

25

15

50

54

690

48

0

250

21

			6

			0

   51

   450

   100

			3

			170

			5

  1 000

   580

			0

			0

			22

   160

  2 700

			0

			34

			21

   640

   970

   200

  1 800

			190

  4 400

  2 000

  8 000

 10 000

  9 000

  12 000

 14 000

  13 000

1.1

2.8

10.8

0.2

1.0

0.1

1.8

0.5

0.7

2.4

1.6

1.2

0.4

0.0

0.6

2.8

2.6

–

3.6

0.0

14.2

0.8

1.4

0.8

3.5

19.8

4.7

0.0

3.3

1.0

2.9

1.0

0.0

6.5

15.1

5.0

0.4

18.6

0.2

13.3

23.5

0.0

0.0

5.0

21.8

7.1

0.0

2.2

1.4

14.3

4.1

8.6

18.6

1.4

33.2

9.9

7.1

12.5

0.9

2.3

7.7

0.2

1.0

0.1

1.6

0.5

0.6

2.2

1.4

1.1

0.4

0.0

0.5

2.3

2.3

–

3.1

0.0

11.0

0.7

1.2

0.6

3.0

16.4

3.9

0.0

2.7

0.8

2.7

1.0

0.0

4.7

10.9

3.7

0.4

14.9

0.2

7.7

19.2

0.0

0.0

3.8

18.7

4.1

0.0

1.8

1.2

10.4

3.4

6.5

11.3

1.2

20.7

7.9

5.9

10.3

23.1

  3 800

  3 000

1.2

3.2

13.7

0.2

1.0

0.2

2.1

0.5

0.8

2.8

1.9

1.4

0.5

0.0

0.7

3.2

2.9

–

4.0

0.0

15.8

0.9

1.6

0.9

4.1

5.7

0.0

3.7

1.2

3.0

1.2

0.0

8.3

18.9

6.1

0.6

21.1

0.2

18.3

27.2

0.0

0.0

6.5

25.0

10.1

0.0

2.5

1.6

18.0

4.8

10.8

25.7

1.6

45.6

11.9

8.3

14.8

			150

			310

   450

			110

			32

			130

			100

			36

			84

		2	000

		1	600

			120

			170

			4

			100

		2	400

   130

–

   190

			2

			30

			310

			93

			970

			560

			71

			34

		1	300

			170

			110

			1

   170

  2 100

   740

			330

			960

			68

  6 100

  2 900

			0

			27

			83

			0

			640

			170

  3 600

  5 500

  1 200

  10 000

		1	900

  10 000

 67 000

 84 000

 69 000

			120

			250

   300

			84

			25

			100

			82

			29

			66

		1	700

		1	300

			96

			140

			4

			80

		1	900

   110

–

   150

			2

			24

			240

			74

			780

			440

			56

			27

		1	000

			130

			88

			1

   110

  1 400

   490

			210

			730

			54

  2 700

  2 300

			0

			22

			55

			0

			500

			140

  2 300

  4 300

   770

  5 200

		1	700

  5 400

			180

			370

   600

			130

			38

			150

			130

			42

			100

		2	300

		2	000

			140

			210

			5

			120

		2	900

   160

–

   230

			3

			35

			370

			110

		1	200

			670

  4 700

			86

			42

		1	500

			210

			130

			1

   220

  2 800

   980

			440

		1	200

			82

  9 500

  3 600

			0

			33

			110

			0

			780

			210

  4 800

  6 800

  1 600

  15 000

		2	200

  15 000

  54 000

  80 000

 68 000

 99 000

  56 000

  82 000

   860

   690

  1 000

  20 000

  9 600

  31 000

3.3

5.3

12.6

5.2

5.3

2.4

3.4

5.2

3.0

5.9

3.8

2.3

3.4

2.4

4.0

7.7

12.8

–

13.0

0.6

13.6

3.6

3.5

5.0

10.4

38.4

2.5

3.3

5.5

3.4

6.5

7.8

2.5

10.8

41.4

14.7

19.7

46.0

1.6

63.1

88.0

0.0

8.5

8.0

40.9

25.5

0.0

14.4

3.9

76.1

12.9

39.2

42.6

5.5

59.6

26.8

17.5

32.2

  1 950

  1 830

  2 070

  15 000

  14 000

  16 000

Country

EU/EEA

3.9 Austria

6.3 Belgium

16.8 Bulgaria

6.1 Croatia

6.3 Cyprus

2.8 Czechia

4.5 Denmark

6.0 Estonia

3.6 Finland

6.8 France

4.7 Germany

2.6 Greece

4.1 Hungary

2.9 Iceland

4.8 Ireland

9.3 Italy

15.7 Latvia

– Liechtenstein

15.7 Lithuania

1.0 Luxembourg

15.9 Malta

4.3 Netherlands

4.1 Norway

6.2 Poland

12.5 Portugal

47.6 Romania

3.1 Slovakia

4.0 Slovenia

6.3 Spain

4.2 Sweden

6.9 Subtotal EU/EEA

Non-EU/EEA

9.2 Albania

2.5 Andorra

14.0 Armenia

55.2 Azerbaijan

19.4 Belarus

26.3 Bosnia and Herzegovina

57.5 Georgia

1.9 Israel

98.3 Kazakhstan

109.2 Kyrgyzstan

0.0 Monaco

10.4 Montenegro

10.6 North Macedonia

47.6 Republic of Moldova

39.6 Russian Federation

0.0 San Marino

17.5 Serbia

4.8 Switzerland

101.4 Tajikistan

15.9 Turkey

52.3 Turkmenistan

63.9 Ukraine

6.4 United Kingdom

89.4 Uzbekistan

32.0 Subtotal non-EU/EEA

20.6 Total European Region

38.2 Subtotal 18 HPCs

2.6

4.3

8.4

4.0

4.1

1.8

2.8

4.2

2.4

5.0

3.1

1.8

2.8

2.4

3.2

6.1

10.8

–

10.3

0.6

10.9

30.4

2.8

2.8

4.0

8.2

2.0

2.6

4.2

2.6

6.1

6.2

2.5

7.0

27.6

9.7

12.5

35.0

1.2

27.9

69.8

0.0

6.9

5.3

32.8

12.3

0.0

11.2

3.2

48.6

10.1

25.1

22.2

4.9

32.2

21.6

14.2

26.1

SURVEILLANCE REPORTTuberculosis surveillance and monitoring in Europe 2022  
Country

EU/EEA

Austria

Belgium

Bulgaria

Croatia

Cyprus

Czechia

Denmark

Estonia

Finland

France

Germany

Greece

Hungary

Iceland

Ireland

Italy

Latvia

Liechtenstein

Lithuania

Luxembourg

Malta

Netherlands

Norway

Poland

Portugal

Romania

Slovakia

Slovenia

Spain

Sweden

Albania

Andorra

Armenia

Azerbaijan

Belarus

Georgia

Israel

Kazakhstan

Kyrgyzstan

Monaco

Montenegro

Subtotal EU/EEA

Non-EU/EEA

Bosnia and Herzegovina

North Macedonia

Republic of Moldova

Russian Federation

San Marino

Serbia

Switzerland

Tajikistan

Turkey

Turkmenistan

Ukraine

United Kingdom

Uzbekistan

Subtotal non-EU/EEA

Total European Region

Subtotal 18 HPCs

		41

		33

  97

		60

		5

		23

		10

  16

		30

		440

		270

		52

		62

		2

		18

		310

  64

–

  120

		2

		1

		28

		19

		570

		240

  920

		35

		14

		250

		22

11

1

30

740

260

110

190

21

610

300

0

1

25

210

0

93

17

920

420

620

–

9	006	400

11	589	616

6 948 445

4	105	268

1	207	361

10	708	982

5	792	203

1 326 539

5	540	718

65	273	512

83	783	945

10	423	056

9	660	350

	341	250

4	937	796

60	461	828

1 886 202

2 722 291

	625	976

	441	539

17	134	873

5	421	242

37	846	605

10	196	707

19 237 682

5	459	643

2	078	932

46	754	783

10	099	270

2	877	800

	77	265

2 963 234

10 139 175

9 449 321

3	280	815

3 989 175

8	655	541

18 776 707

6 524 191

	39	244

	628	062

2	083	380

4 033 963

	33	938

8	737	370

8	654	618

9 537 642

84 339 067

6 031 187

43 733 759

67	886	004

33 469 199

481 875 117

932 888 131

411 042 239

40

32

95

59

4

22

10

16

30

420

260

49

62

2

18

300

62

–

110

2

1

28

18

540

230

910

34

14

250

22

6

1

29

660

250

96

170

20

580

290

0

1

21

0

85

17

790

410

520

42

34

99

60

5

23

11

16

31

460

270

54

62

2

18

310

65

–

130

2

1

29

19

600

250

930

35

15

260

22

18

2

30

830

270

130

220

21

630

300

0

2

28

230

7 600

0

100

18

1100

440

720

4 800

320

1 100

0.46

0.29

1.40

1.50

0.39

0.21

0.17

1.20

0.55

0.68

0.32

0.50

0.64

0.62

0.37

0.51

3.40

–

4.40

0.35

0.23

0.16

0.34

1.50

2.40

4.80

0.64

0.69

0.54

0.22

0.8

0.40

1.40

1.00

7.30

2.80

3.50

4.80

0.24

3.20

4.60

0.00

0.23

1.20

5.30

5.00

0.00

1.10

0.20

9.60

0.50

10.00

9.40

0.46

3.20

3.5

2.3

4.4

0.45

0.27

1.40

1.40

0.36

0.21

0.16

1.20

0.55

0.64

0.31

0.47

0.64

0.60

0.37

0.50

3.30

–

4.20

0.34

0.23

0.16

0.33

1.40

2.30

4.80

0.63

0.68

0.53

0.21

0.8

0.22

0.85

0.99

6.50

2.70

2.90

4.20

0.23

3.10

4.50

0.00

0.16

1.00

4.90

4.80

0.00

0.97

0.19

8.30

0.48

8.60

7.90

0.45

3.00

3.3

2.2

4.1

0.47

0.30

1.40

1.50

0.42

0.21

0.18

1.20

0.55

0.71

0.33

0.52

0.64

0.64

0.37

0.51

3.50

–

4.70

0.36

0.23

0.17

0.35

1.60

2.40

4.80

0.65

0.70

0.55

0.22

0.8

0.63

2.10

1.00

8.20

2.90

4.10

5.50

0.25

3.40

4.70

0.00

0.32

1.40

5.60

5.20

0.00

1.20

0.21

11.00

0.52

12.00

11.00

0.48

3.30

3.7

2.4

4.6

			440

			890

  1 300

			270

			69

			410

			280

   140

			200

		5	300

		4	600

			470

			440

			10

			260

		4	000

   430

–

   790

			37

			160

			710

			170

		3	600

		1	600

  12 000

			180

			86

		3	400

			360

			430

			2

   680

  5 900

  2 500

			850

  2 800

			180

  13 000

  6 900

			0

			99

			250

  3 000

  68 000

			0

		1	200

			400

  8 000

  13 000

  2 800

  32 000

		4	700

  22 000

 189 000

 231 000

 195 000

			380

			770

  1 000

			230

			59

			350

			240

   120

			170

		4	700

		3	900

			400

			380

			8

			230

		3	400

   370

–

   680

			31

			140

			600

			140

		3	100

		1	400

  10 000

			150

			74

		2	900

			310

			370

			2

   520

  4 500

  1 900

			650

  2 300

			160

  8 400

  5 800

			0

			84

			190

  2 500

  43 000

			0

			980

			350

  6 100

  11 000

  2 200

  21 000

		4	200

  15 000

			510

		1	000

  1 700

			310

			80

			480

			320

   160

			230

		6	000

		5	300

			550

			510

			11

			300

		4	600

   500

–

   910

			43

			190

			820

			190

		4	200

		1	800

  14 000

			200

			100

		3	900

			420

			500

			3

   870

  7 500

  3 100

		1	100

  3 300

			210

  19 000

  8 000

			0

			120

			310

  3 500

  98 000

			0

		1	300

			470

  10 000

  15 000

  3 600

  45 000

		5	200

  30 000

  158 000

  220 000

 201 000

 264 000

  164 000

  226 000

4.9

7.7

19

6.6

5.7

3.9

4.9

10

3.6

8.2

5.5

4.5

4.6

2.8

5.3

6.6

23

–

29

5.9

36

4.1

3.1

9.6

16

64

3.2

4.1

7.3

3.6

9.5

			15

			3

   23

   58

   26

			26

   70

			2

   69

   105

			0

			16

			12

   74

   46

			0

			13

			5

   84

   15

   47

   73

			7

   66

39

25

47

4.2

6.6

14

5.7

4.9

3.3

4.2

8.9

3.1

7.2

4.7

3.9

3.9

2.4

4.6

5.7

20

–

25

5

31

3.5

2.6

8.2

13

54

2.8

3.5

6.2

3.1

9.1

			13

			3

   18

   44

   20

			20

   58

			2

   45

   89

			0

			13

			9

   63

   30

			0

			11

			4

   64

   13

   36

   49

			6

   46

33

22

40

5.6

8.9

24

7.6

6.6

4.5

5.6

12

4.2

9.2

6.4

5.2

5.3

3.3

6.2

7.6

26

–

34

6.8

42

4.8

3.5

11

18

74

3.7

4.8

8.4

4.2

10.0

			17

			3

   29

   74

   33

			33

   83

			2

   99

   122

			0

			18

			15

   86

   67

			0

			15

			5

   106

   18

   60

   102

			8

   90

46

28

55

4 100

		310

1 100

 17 000

 21 000

 18 017

3 500

310

1 000

  16 000

 20 000

 17 000

  18 000

 22 000

 19 000

 451 013 014

  3 800

  3 700

  3 800

  43 000

  41 000

  45 000

145 934 460

7 300

200

7  100

Note: European Region comprises the 53 countries of the WHO European Region and Liechtenstein. WHO European Region 18 TB HPCs are presented in italics.

HPCs: high-priority countries.

a Population estimate 2020 by United Nations Statistical Database for all countries.   

Table 1. Estimates of the TB disease burden, European Region, 2020

Populationa

Estimated number of deaths from TB 

(all forms, excluding HIV)

Number

Per 100 000

Estimated number of incident cases (all forms)

Number

Per 100 000

Best

Low

High

Best

Low

High

Best

Low

High

Best

Low

High

Estimated incidence of child TB cases

Estimated incidence of TB among females

Number
Low

Best

Per 100 000

High

Best

Low

High

Best

Number
Low

Per 100 000

Country

High

Best

Low

High

			14
			55
   110
			1
			2
			2
			17
			1
			6
			280
			190
			17
			6
			0
			6
			220
   8
–
   15
			0
			9
			22
			13
			44
			47
   590
			40
			0
			220
			18
  1 950

			5
			0
   40
   360
   81
			2
			150
			5
   730
   500
			0
			0
			17
   140
  1 900
			0
			29
			18
   510
   830
   160
  1 300
			170
  3 200
 10 000
 12 000
 11 000

12
46
79
1
2
2
15
1
5
250
160
15
5
0
5
180
7
–
13
0
7
18
11
37
40
490
33
0
180
15
  1 830

			5
			0
   29
   260
   60
			2
			120
			4
   420
   410
			0
			0
			13
   120
  1 100
			0
			24
			16
   370
   690
   120
   790
			150
  2 000
  8 000
 10 000
  9 000

16
64
140
1
2
3
20
1
7
320
220
20
7
0
7
250
9
–
17
0
10
25
15
50
54
690
48
0
250
21
  2 070

			6
			0
   51
   450
   100
			3
			170
			5
  1 000
   580
			0
			0
			22
   160
  2 700
			0
			34
			21
   640
   970
   200
  1 800
			190
  4 400
  12 000
 14 000
  13 000

1.1
2.8
10.8
0.2
1.0
0.1
1.8
0.5
0.7
2.4
1.6
1.2
0.4
0.0
0.6
2.8
2.6
–
3.6
0.0
14.2
0.8
1.4
0.8
3.5
19.8
4.7
0.0
3.3
1.0
2.9

1.0
0.0
6.5
15.1
5.0
0.4
18.6
0.2
13.3
23.5
0.0
0.0
5.0
21.8
7.1
0.0
2.2
1.4
14.3
4.1
8.6
18.6
1.4
33.2
9.9
7.1
12.5

0.9
2.3
7.7
0.2
1.0
0.1
1.6
0.5
0.6
2.2
1.4
1.1
0.4
0.0
0.5
2.3
2.3
–
3.1
0.0
11.0
0.7
1.2
0.6
3.0
16.4
3.9
0.0
2.7
0.8
2.7

1.0
0.0
4.7
10.9
3.7
0.4
14.9
0.2
7.7
19.2
0.0
0.0
3.8
18.7
4.1
0.0
1.8
1.2
10.4
3.4
6.5
11.3
1.2
20.7
7.9
5.9
10.3

1.2
3.2
13.7
0.2
1.0
0.2
2.1
0.5
0.8
2.8
1.9
1.4
0.5
0.0
0.7
3.2
2.9
–
4.0
0.0
15.8
0.9
1.6
0.9
4.1
23.1
5.7
0.0
3.7
1.2
3.0

1.2
0.0
8.3
18.9
6.1
0.6
21.1
0.2
18.3
27.2
0.0
0.0
6.5
25.0
10.1
0.0
2.5
1.6
18.0
4.8
10.8
25.7
1.6
45.6
11.9
8.3
14.8

			150
			310
   450
			110
			32
			130
			100
			36
			84
		2	000
		1	600
			120
			170
			4
			100
		2	400
   130
–
   190
			2
			30
			310
			93
			970
			560
  3 800
			71
			34
		1	300
			170
  15 000

			110
			1
   170
  2 100
   740
			330
			960
			68
  6 100
  2 900
			0
			27
			83
   860
  20 000
			0
			640
			170
  3 600
  5 500
  1 200
  10 000
		1	900
  10 000
 67 000
 84 000
 69 000

			120
			250
   300
			84
			25
			100
			82
			29
			66
		1	700
		1	300
			96
			140
			4
			80
		1	900
   110
–
   150
			2
			24
			240
			74
			780
			440
  3 000
			56
			27
		1	000
			130
  14 000

			88
			1
   110
  1 400
   490
			210
			730
			54
  2 700
  2 300
			0
			22
			55
   690
  9 600
			0
			500
			140
  2 300
  4 300
   770
  5 200
		1	700
  5 400
  54 000
 68 000
  56 000

			180
			370
   600
			130
			38
			150
			130
			42
			100
		2	300
		2	000
			140
			210
			5
			120
		2	900
   160
–
   230
			3
			35
			370
			110
		1	200
			670
  4 700
			86
			42
		1	500
			210
  16 000

			130
			1
   220
  2 800
   980
			440
		1	200
			82
  9 500
  3 600
			0
			33
			110
  1 000
  31 000
			0
			780
			210
  4 800
  6 800
  1 600
  15 000
		2	200
  15 000
  80 000
 99 000
  82 000

3.3
5.3
12.6
5.2
5.3
2.4
3.4
5.2
3.0
5.9
3.8
2.3
3.4
2.4
4.0
7.7
12.8
–
13.0
0.6
13.6
3.6
3.5
5.0
10.4
38.4
2.5
3.3
5.5
3.4
6.5

7.8
2.5
10.8
41.4
14.7
19.7
46.0
1.6
63.1
88.0
0.0
8.5
8.0
40.9
25.5
0.0
14.4
3.9
76.1
12.9
39.2
42.6
5.5
59.6
26.8
17.5
32.2

EU/EEA
3.9 Austria
6.3 Belgium
16.8 Bulgaria
6.1 Croatia
6.3 Cyprus
2.8 Czechia
4.5 Denmark
6.0 Estonia
3.6 Finland
6.8 France
4.7 Germany
2.6 Greece
4.1 Hungary
2.9 Iceland
4.8 Ireland
9.3 Italy
15.7 Latvia

– Liechtenstein

15.7 Lithuania
1.0 Luxembourg
15.9 Malta
4.3 Netherlands
4.1 Norway
6.2 Poland
12.5 Portugal
47.6 Romania
3.1 Slovakia
4.0 Slovenia
6.3 Spain
4.2 Sweden
6.9 Subtotal EU/EEA
Non-EU/EEA

9.2 Albania
2.5 Andorra
14.0 Armenia
55.2 Azerbaijan
19.4 Belarus
26.3 Bosnia and Herzegovina
57.5 Georgia
1.9 Israel

98.3 Kazakhstan
109.2 Kyrgyzstan
0.0 Monaco
10.4 Montenegro
10.6 North Macedonia
47.6 Republic of Moldova
39.6 Russian Federation
0.0 San Marino
17.5 Serbia
4.8 Switzerland

101.4 Tajikistan
15.9 Turkey
52.3 Turkmenistan
63.9 Ukraine
6.4 United Kingdom
89.4 Uzbekistan
32.0 Subtotal non-EU/EEA
20.6 Total European Region
38.2 Subtotal 18 HPCs

2.6
4.3
8.4
4.0
4.1
1.8
2.8
4.2
2.4
5.0
3.1
1.8
2.8
2.4
3.2
6.1
10.8
–
10.3
0.6
10.9
2.8
2.8
4.0
8.2
30.4
2.0
2.6
4.2
2.6
6.1

6.2
2.5
7.0
27.6
9.7
12.5
35.0
1.2
27.9
69.8
0.0
6.9
5.3
32.8
12.3
0.0
11.2
3.2
48.6
10.1
25.1
22.2
4.9
32.2
21.6
14.2
26.1

65

Tuberculosis surveillance and monitoring in Europe 2022SURVEILLANCE REPORT  
Table 2. Estimates for TB/HIV coinfection and RR-TB, European Region, 2020

Country

EU/EEA
Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
Subtotal EU/EEA
Non-EU/EEA
Albania
Andorra
Armenia
Azerbaijan
Belarus
Bosnia and Herzegovina
Georgia
Israel
Kazakhstan
Kyrgyzstan
Monaco
Montenegro
North Macedonia
Republic of Moldova
Russian Federation
San Marino
Serbia
Switzerland
Tajikistan
Turkey
Turkmenistan
Ukraine
United Kingdom
Uzbekistan
Subtotal non-EU/EEA
Total European Region
Subtotal 18 HPCs

Estimated HIV infection among incident TB cases (new and relapse)

Estimated percentage of RR-TB 
cases among new TB cases

Best

			9
			33
   14
			3
			3
			3
			7
   13
			3
			270
			120
			17
			5
			0
			10
			210
   35
–
   23
			0
			3
			22
			4
			43
			160
   280
			1
			0
			230
			8
  1 530

			4
–
   72
   110
   220
			2
   55
			17
   850
   220
–
			0
   1
   390
  16 000
–
			4
			18
   230
   150
   630
  7 000
			160
   690
  26 800
  29 000
  27 000

Number
Low

High

Best

Low

High

Best

Low

High

%

%

			5
			12
   5
			1
			2
			2
			3
   7
			2
			210
			63
			10
			3
			0
			5
			120
   12
–
   13
			0
			0
			13
			1
			23
			120
   220
			0
			0
			88
			4
  1 000

			0
–
   47
   75
   160
			1
   35
			9
   540
   180
–
			0
   0
   310
  10 000
–
			2
			10
   170
   120
   340
  4 600
			60
   470
  19 000
  22 000
  20 000

			15
			64
   28
			4
			5
			5
			14
   23
			5
			340
			190
			27
			8
			0
			15
			320
   70
–
   36
			2
			8
			34
			7
			67
			190
   340
			2
			2
			440
			13
  2 000

			12
–
   100
   150
   290
			3
   78
			28
  1 200
   280
–
			4
   2
   470
  24 000
–
			6
			29
   310
   190
  1 000
  9 800
			310
   950
  34 000
  36 000
  39 300

	2.2	
	3.7	
 1.1 
	1.0	
	4.7	
	0.8	
	2.5	
 9.7 
	1.5	
	5.1	
	2.6	
	3.6	
	1.1	
	2.1	
	3.6	
	5.2	
 8.1 
–
 2.9 
			0
	1.7	
	3.1	
	2.1	
	1.2	
	9.8	
 2.2 
	0.5	
–
	6.8	
	2.2	
 3.6 

	1.0	
–
 11.0 
 1.9 
 8.9 
	0.2	
 1.9 
	9.5	
 6.5 
 3.3 
–
			0
 0.5 
 13.0 
 24.0 
–
	0.3	
	4.5	
 2.9 
 1.2 
 22.0 
 22.0 
	3.4	
 3.1 
 14.2 
 12.0 
 13.8 

	1.2	
	1.4	
 0.4 
	0.5	
	2.5	
	0.4	
	0.9	
 4.8 
	0.8	
	4.1	
	1.4	
	2.1	
	0.6	
	0.8	
	2.0	
	3.0	
 2.8 
–
 1.7 
			0
	0.2	
	1.9	
	0.8	
	0.7	
	8.3	
 1.9 
	0.2	
–
	2.6	
	1.2	
 2.2 

	0.1	
–
 7.6 
 1.4 
 7.5 
	0.1	
 1.3 
	5.2	
 6.0 
 2.7 
–
			0
 0.2 
 11.0 
 24.0 
–
	0.2	
	2.5	
 2.4 
 1.0 
 13.0 
 21.0 
	1.3	
 2.8 
 8.6 
 9.2 
 8.8 

	3.3	
	7.1	
 2.1 
	1.5	
	7.6	
	1.2	
	4.9	
 16.0 
	2.4	
	6.2	
	4.1	
	5.5	
	1.7	
	4.1	
	5.7	
	7.9	
 16.0 
–
 4.4 
	5.4	
	4.9	
	4.8	
	4.1	
	1.8	
	11.0	
 2.6 
	0.9	
	2.4	
	13.0	
	3.5	
 4.9 

	2.9	
–
 14.0 
 2.3 
 10.0 
	0.4	
 2.7 
	15.0	
 7.0 
 3.8 
–
	4.4	
 1.0 
 15.0 
 25.0 
–
	0.5	
	7.0	
 3.5 
 1.4 
 34.0 
 22.0 
	6.6	
 3.5 
 21.5 
 16.0 
 24.0 

2.3
2.1
2.5
0.4
0.0
3.6
1.8
19.0
0.0
1.0
2.2
1.5
3.8
0.0
1.1
2.4
8.0
–
13.0
0.0
0.0
1.6
2.5
1.4
1.0
2.3
0.0
1.8
4.2
2.4
2.7

0.8
0.0
14.0
12.0
40.0
0.0
11.0
5.6
36.0
28.0
2.3
0.0
1.2
26.0
36.0
2.3
1.1
1.1
24.0
2.5
23.0
29.0
2.0
18.0
   21.0
 18.0 
 22.0

0.8
1.0
1.3
0.0
0.0
1.6
0.4
11.0
0.0
0.7
0.8
0.0
1.4
0.0
0.0
1.7
5.4
–
9.8
0.0
0.0
0.5
0.3
1.0
0.5
1.8
0.0
0.0
2.9
0.7
1.9

0.0
0.0
9.6
10.0
36.0
0.0
8.9
1.8
35.0
26.0
1.1
0.0
0.0
23.0
36.0
1.1
0.5
0.2
22.0
2.0
21.0
28.0
1.4
17.0
   20.0
17.2 
 21.0 

4.9
3.9
4.4
2.5
7.6
6.9
5.0
28.0
3.6
1.5
4.8
8.0
8.2
60.0
5.8
3.2
11.0
–
16.0
19.0
9.5
4.1
8.6
2.1
1.7
2.9
7.0
9.4
5.8
5.9
3.7

4.4
98.0
20.0
14.0
43.0
1.8
13.0
13.0
38.0
30.0
4.0
12.0
6.7
29.0
37.0
4.0
2.2
3.3
26.0
3.0
26.0
30.0
2.8
20.0
   23.0
 20.0 
 23.0 

Note: European Region comprises the 53 countries of the WHO European Region and Liechtenstein. WHO European Region 18 TB HPCs are presented in italics. 
HPCs: high-priority countries. 
RR-TB: rifampicin-resistant tuberculosis.        

66

Estimated percentage of RR-TB 

cases among retreated TB 

Estimated RR-TB cases among 

notified bacteriologically 

confirmed pulmonary TB 

Estimated number of incident 

RR-TB cases

patients

%

patients

Number

Number

Best

High

Best

High

Best

High

Low

3.8

1.9

13.0

0.2

0.0

6.7

0.0

9.1

9.4

7.1

0.2

8.2

0.0

0.0

7.7

16.0

19.0

–

24.0

0.0

7.2

0.0

0.0

1.5

2.8

12.0

0.2

0.0

9.4

0.3

46.0

5.0

7.2

35.0

23.0

71.0

0.0

21.0

0.0

48.0

50.0

7.2

0.0

0.3

48.0

68.0

7.2

1.3

9.1

38.0

7.8

48.0

40.0

0.9

36.0

18.0

8.8

21.0

6.3

0.0

30.0

0.0

31.0

67.0

10.0

23.0

9.1

24.0

0.0

0.0

13.0

31.0

–

32.0

0.0

11.0

0.0

0.0

3.0

6.9

13.0

9.1

0.0

18.0

10.0

53.0

23.0

11.0

50.0

24.0

75.0

0.0

26.0

0.0

50.0

54.0

11.0

0.0

10.0

53.0

68.0

11.0

4.7

26.0

43.0

11.0

54.0

41.0

3.3

38.0

43.0

24.0

32.0

30.0

98.0

65.0

20.0

61.0

99.0

15.0

30.0

41.0

47.0

98.0

46.0

21.0

44.0

–

41.0

98.0

16.0

25.0

34.0

5.5

14.0

15.0

41.0

60.0

30.0

45.0

60.0

54.0

16.0

65.0

26.0

78.0

15.0

32.0

98.0

52.0

58.0

16.0

85.0

45.0

58.0

69.0

16.0

11.0

51.0

49.0

15.0

60.0

43.0

8.1

41.0

   53.0

   53.0

53.0

   46.0

   45.0

46.0

   60.0

   60.0

60.0

Country

EU/EEA

			24 Austria

			43 Belgium 

   90 Bulgaria

			5 Croatia

			0 Cyprus

			34 Czechia

			11 Denmark 

   42 Estonia

			3 Finland

			130 France

			250 Germany

			31 Greece

			47 Hungary

			0 Iceland

			4 Ireland

			190 Italy

 68.0  Latvia

– Liechtenstein

   170 Lithuania

			0 Luxembourg

			1 Malta

			25 Netherlands

			11 Norway

			83 Poland

			34 Portugal

   730 Romania

			1 Slovakia

			2 Slovenia

			250 Spain

			21 Sweden

Non-EU/EEA

			19 Albania

			0 Andorra

   230 Armenia

  1 500 Azerbaijan

  1 600 Belarus

   530 Georgia

			20 Israel

   100

   86

   120

			8

			13

   24

			1

			0

			13

			2

   22

			2

			32

			92

			6

			13

			0

			1

			42

–

–

			0

			0

			5

			2

			44

			12

   290

			1

			1

			77

			5

			4

			0

   54

   720

   820

			0

   190

			5

			0

			0

			2

Low

			3

			6

   16

			0

			0

			6

			0

   14

			0

			23

			46

			0

			6

			0

			0

			31

–

–

			0

			0

			0

			0

			30

			7

   260

			0

			0

			54

			1

			0

			0

   42

   670

   790

			0

   170

			1

			0

			0

			0

			0

			1

			4

			140

			140

			13

			20

   32

			3

			1

			20

			5

   30

			4

			41

			16

			21

			3

			5

			53

–

–

			2

			5

			9

			5

			58

			18

   330

			4

			3

			100

			10

   880

			8

			1

   66

   760

   860

			3

   220

			9

			0

			2

			5

			13

			26

   57

			2

			0

			19

			4

   28

			2

			95

			10

			27

			0

			2

			140

 48.0 

–

   130

			0

			1

			11

			3

			60

			21

   570

			1

			1

			180

			10

  1 600

			8

			0

   150

  1 200

  1 300

			0

   420

			10

  5 200

  2 500

			0

			0

			4

			0

			17

			14

Low

			5

			13

   31

			0

			0

			9

			1

   17

			1

			66

			66

			1

			12

			0

			1

			98

 32.0 

–

   99

			0

			0

			3

			0

			40

			12

   430

			0

			1

			120

			3

			2

			0

   95

   850

   930

			0

   320

			3

			0

			0

			0

			0

			7

			6

   810

   740

  1 400

  1 800 Subtotal EU/EEA

			0 Bosnia and Herzegovina

			0 Monaco

			0 Montenegro

			16 North Macedonia

  2 900

   940

  2 800

   890

  2 900

   990

  3 300

  2 100

  7 600 Kazakhstan

  3 000 Kyrgyzstan

   430

   400

   460

  1 100

   850

  1 300 Republic of Moldova

  23 000

  23 000

  24 000

  37 000

  23 000

  53 000 Russian Federation

			0

			2

			10

   560

   140

   290

  4 300

			40

  1 400

  35 800

  37 000

  36 200

			0

			3

			16

   590

   170

   310

  4 400

			53

  1 500

  36 000

  37 000

  37 000

   520

   120

   260

  4 200

			27

  1 300

  35 000

  37 000

  36 000

			0 San Marino

			30 Serbia

			25 Switzerland

  2 800 Tajikistan

   510 Turkey

  1 300 Turkmenistan

  2 200

   400

   960

  11 000

			100

  5 200

  68 800

  69 000

  69 500

  1 600

   310

   650

			70

  3 600

  53 000

  54 000

  54 000

  6 900

  15 000 Ukraine

			140 United Kingdom

  7 100 Uzbekistan

  84 000 Subtotal non-EU/EEA

  86 000 Total European Region

  85 000 Subtotal 18 HPCs

SURVEILLANCE REPORTTuberculosis surveillance and monitoring in Europe 2022Table 2. Estimates for TB/HIV coinfection and RR-TB, European Region, 2020

Estimated HIV infection among incident TB cases (new and relapse)

Estimated percentage of RR-TB 

cases among new TB cases

Number

%

%

High

Best

Low

High

Best

Low

High

Estimated percentage of RR-TB 
cases among retreated TB 
patients

%

Best

Low

High

Estimated RR-TB cases among 
notified bacteriologically 
confirmed pulmonary TB 
patients
Number
Low

Best

High

18.0
8.8
21.0
6.3
0.0
30.0
0.0
31.0
67.0
10.0
23.0
9.1
24.0
0.0
0.0
13.0
31.0
–
32.0
0.0
11.0
0.0
0.0
3.0
6.9
13.0
9.1
0.0
18.0
10.0
53.0

23.0
11.0
50.0
24.0
75.0
0.0
26.0
0.0
50.0
54.0
11.0
0.0
10.0
53.0
68.0
11.0
4.7
26.0
43.0
11.0
54.0
41.0
3.3
38.0
   53.0
   53.0
53.0

3.8
1.9
13.0
0.2
0.0
6.7
0.0
9.1
9.4
7.1
16.0
0.2
8.2
0.0
0.0
7.7
19.0
–
24.0
0.0
7.2
0.0
0.0
1.5
2.8
12.0
0.2
0.0
9.4
0.3
46.0

5.0
7.2
35.0
23.0
71.0
0.0
21.0
0.0
48.0
50.0
7.2
0.0
0.3
48.0
68.0
7.2
1.3
9.1
38.0
7.8
48.0
40.0
0.9
36.0
   46.0
   45.0
46.0

43.0
24.0
32.0
30.0
98.0
65.0
20.0
61.0
99.0
15.0
30.0
41.0
47.0
98.0
46.0
21.0
44.0
–
41.0
98.0
16.0
25.0
34.0
5.5
14.0
15.0
41.0
60.0
30.0
45.0
60.0

54.0
16.0
65.0
26.0
78.0
15.0
32.0
98.0
52.0
58.0
16.0
85.0
45.0
58.0
69.0
16.0
11.0
51.0
49.0
15.0
60.0
43.0
8.1
41.0
   60.0
   60.0
60.0

			8
			13
   24
			1
			0
			13
			2
   22
			2
			32
			92
			6
			13
			0
			1
			42
–
–
   100
			0
			0
			5
			2
			44
			12
   290
			1
			1
			77
			5
   810

			4
			0
   54
   720
   820
			0
   190
			5
  2 900
   940
			0
			0
			2
   430
  23 000
			0
			2
			10
   560
   140
   290
  4 300
			40
  1 400
  35 800
  37 000
  36 200

			3
			6
   16
			0
			0
			6
			0
   14
			0
			23
			46
			0
			6
			0
			0
			31
–
–
   86
			0
			0
			0
			0
			30
			7
   260
			0
			0
			54
			1
   740

			0
			0
   42
   670
   790
			0
   170
			1
  2 800
   890
			0
			0
			0
   400
  23 000
			0
			1
			4
   520
   120
   260
  4 200
			27
  1 300
  35 000
  37 000
  36 000

			13
			20
   32
			3
			1
			20
			5
   30
			4
			41
			140
			16
			21
			3
			5
			53
–
–
   120
			2
			5
			9
			5
			58
			18
   330
			4
			3
			100
			10
   880

			8
			1
   66
   760
   860
			3
   220
			9
  2 900
   990
			0
			2
			5
   460
  24 000
			0
			3
			16
   590
   170
   310
  4 400
			53
  1 500
  36 000
  37 000
  37 000

Country

EU/EEA

Austria

Belgium

Bulgaria

Croatia

Cyprus

Czechia

Denmark

Estonia

Finland

France

Germany

Greece

Hungary

Iceland

Ireland

Italy

Latvia

Liechtenstein

Lithuania

Luxembourg

Malta

Netherlands

Norway

Poland

Portugal

Romania

Slovakia

Slovenia

Spain

Sweden

Albania

Andorra

Armenia

Azerbaijan

Belarus

Georgia

Israel

Kazakhstan

Kyrgyzstan

Monaco

Montenegro

Subtotal EU/EEA

Non-EU/EEA

North Macedonia

Republic of Moldova

Russian Federation

San Marino

Serbia

Switzerland

Tajikistan

Turkey

Turkmenistan

Ukraine

United Kingdom

Uzbekistan

Bosnia and Herzegovina

Best

			9

			33

   14

			3

			3

			3

			7

   13

			3

			270

			120

			17

			5

			0

			10

			210

   35

–

   23

			0

			3

			22

			4

			43

			160

   280

			1

			0

			230

			8

  1 530

			4

–

   72

   110

   220

			2

   55

			17

   850

   220

–

			0

   1

–

			4

			18

   230

   150

   630

  7 000

			160

   690

Low

			5

			12

   5

			1

			2

			2

			3

   7

			2

			210

			63

			10

			3

			0

			5

			120

   12

–

   13

			0

			0

			13

			1

			23

			120

   220

			0

			0

			88

			4

			0

–

   47

   75

   160

			1

   35

			9

   540

   180

–

			0

   0

  1 000

–

			2

			10

   170

   120

   340

  4 600

			60

   470

			15

			64

   28

			4

			5

			5

			14

   23

			5

			340

			190

			27

			8

			0

			15

			320

   70

–

   36

			2

			8

			34

			7

			67

			190

   340

			2

			2

			440

			13

  2 000

			12

–

   100

   150

   290

			3

   78

			28

  1 200

   280

–

			4

   2

–

			6

			29

   310

   190

  1 000

  9 800

			310

   950

  34 000

  36 000

  39 300

   390

   310

   470

  16 000

  10 000

  24 000

	2.2	

	3.7	

 1.1 

	1.0	

	4.7	

	0.8	

	2.5	

 9.7 

	1.5	

	5.1	

	2.6	

	3.6	

	1.1	

	2.1	

	3.6	

	5.2	

 8.1 

–

 2.9 

			0

	1.7	

	3.1	

	2.1	

	1.2	

	9.8	

 2.2 

	0.5	

–

	6.8	

	2.2	

 3.6 

	1.0	

–

 11.0 

 1.9 

 8.9 

	0.2	

 1.9 

	9.5	

 6.5 

 3.3 

–

			0

 0.5 

 13.0 

 24.0 

–

	0.3	

	4.5	

 2.9 

 1.2 

 22.0 

 22.0 

	3.4	

 3.1 

 14.2 

 12.0 

 13.8 

	1.2	

	1.4	

 0.4 

	0.5	

	2.5	

	0.4	

	0.9	

 4.8 

	0.8	

	4.1	

	1.4	

	2.1	

	0.6	

	0.8	

	2.0	

	3.0	

 2.8 

–

 1.7 

			0

	0.2	

	1.9	

	0.8	

	0.7	

	8.3	

 1.9 

	0.2	

–

	2.6	

	1.2	

 2.2 

	0.1	

–

 7.6 

 1.4 

 7.5 

	0.1	

 1.3 

	5.2	

 6.0 

 2.7 

–

			0

 0.2 

 11.0 

 24.0 

–

	0.2	

	2.5	

 2.4 

 1.0 

 13.0 

 21.0 

	1.3	

 2.8 

 8.6 

 9.2 

 8.8 

	3.3	

	7.1	

 2.1 

	1.5	

	7.6	

	1.2	

	4.9	

 16.0 

	2.4	

	6.2	

	4.1	

	5.5	

	1.7	

	4.1	

	5.7	

	7.9	

–

 4.4 

	5.4	

	4.9	

	4.8	

	4.1	

	1.8	

 16.0 

	11.0	

 2.6 

	0.9	

	2.4	

	13.0	

	3.5	

 4.9 

	2.9	

–

 14.0 

 2.3 

 10.0 

	0.4	

 2.7 

	15.0	

 7.0 

 3.8 

–

	4.4	

 1.0 

 15.0 

 25.0 

–

	0.5	

	7.0	

 3.5 

 1.4 

 34.0 

 22.0 

	6.6	

 3.5 

 21.5 

 16.0 

 24.0 

19.0

2.3

2.1

2.5

0.4

0.0

3.6

1.8

0.0

1.0

2.2

1.5

3.8

0.0

1.1

2.4

8.0

–

0.0

0.0

1.6

2.5

1.4

1.0

2.3

0.0

1.8

4.2

2.4

2.7

13.0

0.8

0.0

14.0

12.0

40.0

0.0

11.0

5.6

36.0

28.0

2.3

0.0

1.2

26.0

36.0

2.3

1.1

1.1

24.0

2.5

23.0

29.0

2.0

18.0

0.8

1.0

1.3

0.0

0.0

1.6

0.4

11.0

0.0

0.7

0.8

0.0

1.4

0.0

0.0

1.7

5.4

–

9.8

0.0

0.0

0.5

0.3

1.0

0.5

1.8

0.0

0.0

2.9

0.7

1.9

0.0

0.0

9.6

10.0

36.0

0.0

8.9

1.8

35.0

26.0

1.1

0.0

0.0

23.0

36.0

1.1

0.5

0.2

22.0

2.0

21.0

28.0

1.4

17.0

4.9

3.9

4.4

2.5

7.6

6.9

5.0

3.6

1.5

4.8

8.0

8.2

28.0

60.0

5.8

3.2

11.0

–

16.0

19.0

9.5

4.1

8.6

2.1

1.7

2.9

7.0

9.4

5.8

5.9

3.7

4.4

98.0

20.0

14.0

43.0

1.8

13.0

13.0

38.0

30.0

4.0

12.0

6.7

29.0

37.0

4.0

2.2

3.3

26.0

3.0

26.0

30.0

2.8

20.0

Subtotal non-EU/EEA

Total European Region

Subtotal 18 HPCs

  26 800

  29 000

  27 000

  19 000

  22 000

  20 000

HPCs: high-priority countries. 

RR-TB: rifampicin-resistant tuberculosis.        

   21.0

 18.0 

 22.0

   20.0

17.2 

 21.0 

   23.0

 20.0 

 23.0 

Note: European Region comprises the 53 countries of the WHO European Region and Liechtenstein. WHO European Region 18 TB HPCs are presented in italics. 

Estimated number of incident 
RR-TB cases

Country

Number
Low

Best

			13
			26
   57
			2
			0
			19
			4
   28
			2
			95
			140
			10
			27
			0
			2
			140
 48.0 
–
   130
			0
			1
			11
			3
			60
			21
   570
			1
			1
			180
			10
  1 600

			8
			0
   150
  1 200
  1 300
			0
   420
			10
  5 200
  2 500
			0
			0
			4
  1 100
  37 000
			0
			17
			14
  2 200
   400
   960
  11 000
			100
  5 200
  68 800
  69 000
  69 500

			5
			13
   31
			0
			0
			9
			1
   17
			1
			66
			66
			1
			12
			0
			1
			98
 32.0 
–
   99
			0
			0
			3
			0
			40
			12
   430
			0
			1
			120
			3
  1 400

			2
			0
   95
   850
   930
			0
   320
			3
  3 300
  2 100
			0
			0
			0
   850
  23 000
			0
			7
			6
  1 600
   310
   650
  6 900
			70
  3 600
  53 000
  54 000
  54 000

High

EU/EEA
			24 Austria
			43 Belgium 
   90 Bulgaria
			5 Croatia
			0 Cyprus
			34 Czechia
			11 Denmark 
   42 Estonia
			3 Finland
			130 France
			250 Germany
			31 Greece
			47 Hungary
			0 Iceland
			4 Ireland

			190 Italy
 68.0  Latvia

– Liechtenstein

   170 Lithuania

			0 Luxembourg
			1 Malta

			25 Netherlands
			11 Norway
			83 Poland
			34 Portugal
   730 Romania
			1 Slovakia
			2 Slovenia

			250 Spain

			21 Sweden

  1 800 Subtotal EU/EEA

Non-EU/EEA

			19 Albania
			0 Andorra
   230 Armenia
  1 500 Azerbaijan
  1 600 Belarus

			0 Bosnia and Herzegovina

   530 Georgia
			20 Israel

  7 600 Kazakhstan
  3 000 Kyrgyzstan
			0 Monaco
			0 Montenegro
			16 North Macedonia
  1 300 Republic of Moldova
  53 000 Russian Federation
			0 San Marino
			30 Serbia
			25 Switzerland

  2 800 Tajikistan
   510 Turkey
  1 300 Turkmenistan
  15 000 Ukraine

			140 United Kingdom
  7 100 Uzbekistan

  84 000 Subtotal non-EU/EEA
  86 000 Total European Region
  85 000 Subtotal 18 HPCs

67

Tuberculosis surveillance and monitoring in Europe 2022SURVEILLANCE REPORTTable 3. TB cases, notification rates per 100 000 population and mean annual change in rates, European Region, 
2016–2020

Country/area

EU/EEA
Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
Subtotal EU/EEA
Non-EU/EEA
Albania
Andorra
Armenia
Azerbaijan
Belarus
Bosnia and Herzegovina
Georgia
Israel
Kazakhstan
Kyrgyzstan
Monaco
Montenegro
North Macedonia
Republic of Moldova
Russian Federation
San Marino
Serbia

Serbia excluding Kosovo1
Kosovo1
Switzerland
Tajikistan
Turkey
Turkmenistan
Ukraine
United Kingdom
Uzbekistan
Subtotal non-EU/EEA
Total European Region
Subtotal 18 HPCs

2016

N

		634
	1	042
 1 603
		464
		60
		516
		330
  192
		234
	5	735
	5	925
		440
		786
		6
		315
	4	032
  660
		2
 1 442
		29
		50
		887
		295
	6	444
	1	936
 13 601
		296
		118
	5	070
		714
 53 858

		415
		4
 1 080
 6 707
	3	598
		907
 3 330
		250
 12 658
 7 995
		2
		87
		267
 4 134
 121 046
0
	1	488
		767
		721
		609
 6 241
 12 417
 2 340
 34 088
	6	175
 18 441
 244 279
 298 137
 251 573

2017

N

		569
		967
 1 463
		378
		53
		501
		275
  176
		245
	5	015
	5	518
		467
		685
		14
		300
	3	944
  552
		1
 1 387
		32
		42
		783
		261
	5	787
	1	914
 12 997
		249
		112
	5	660
		519
 50 866

		503
		1
  926
 7 129
	3	052
		768
 2 927
		234
 12 942
 7 695
–
		77
		219
 3 858
 114 187
0
	1	466
		745
		721
		555
 6 279
 12 046
 2 232
 31 584
	5	567
 19 329
 233 576
 284 442
 240 761

Rate

7.3
9.2
22.4
11.1
7.1
4.9
5.8
14.6
4.3
8.6
7.2
4.1
8.0
1.8
6.7
6.6
33.5
5.3
49.9
5.0
11.1
5.2
5.7
17.0
18.7
68.8
5.5
5.7
10.9
7.2
12.0

14.4
5.2
36.8
68.9
38.1
26.8
82.9
3.1
71.0
131.6
5.3
13.9
12.8
101.7
83.3
0.0
16.8
10.8
40.6
7.3
72.0
15.6
41.3
76.2
9.3
58.7
51.9
32.4
62.5

Rate

6.5
8.5
20.6
9.1
6.2
4.7
4.8
13.4
4.5
7.5
6.7
4.3
7.0
4.1
6.3
6.5
28.3
2.6
48.7
5.4
9.1
4.6
5.0
15.2
18.6
66.2
4.6
5.4
12.2
5.2
11.3

17.4
1.3
31.4
72.4
32.3
22.9
73.0
2.8
71.6
124.3
–
12.3
10.5
95.0
78.5
0.0
16.6
10.6
40.4
6.6
70.7
14.9
38.8
71.0
8.3
60.5
49.3
30.8
59.4

2018

N

Rate

2019

N

Rate

2020

N

Rate

Mean annual % 
change in rate,  
2016–2020

		482
		977
 1 358
		372
		52
		443
		291
  147
		227
	5	092
	5	489
		432
		640
		8
		310
	3	912
–
		1
 1 142
		42
		55
		795
		208
	5	487
	1	936
 12 199
		281
		99
	4	766
		488
 47 731

		440
		2
  796
 6 896
	2	542
		669
 2 590
		292
 13 361
 7 585
1
  84
		217
 3 465
 106 913
		0
	1	358
		656
		702
		516
 5 975
 11 786
 2 636
 30 378
	5	075
 18 496
 222 073
 269 804
 228 265

5.5
8.6
19.3
9.1
6.0
4.2
5.0
11.1
4.1
15.1
6.6
4.0
6.5
2.3
6.4
6.5
–
2.6
40.7
7.0
11.6
4.6
3.9
14.4
18.8
62.5
5.2
4.8
10.2
4.8
10.6

15.3
2.6
27.0
69.3
26.9
20.1
64.7
3.5
72.9
120.3
2.6
13.4
10.4
85.5
73.4
0.0
15.4
9.4
39.2
6.1
65.7
14.3
45.1
68.7
7.6
57.0
46.6
29.1
56.3

		474
		963
 1 344
		305
		69
		461
		281
  150
		226
	5	116
	4	812
		459
		552
		13
		266
	3	346
–
–
 1 058
		50
		98
		754
		162
	5	321
	1	932
 11 618
		214
		101
	4	543
		479
 45 167

		412
		5
  670
 6 533
	2	615
		580
 2 451
		217
 12 990
 7 039
–
  82
		199
 3 255
 103 979
		0
	1	179
		567
		612
		435
 5 976
 11 401
 2 863
 28 539
	5	132
 18 774
 215 326
 260 493
 221 255

5.4
8.4
19.2
7.5
7.9
4.3
4.8
11.3
4.1
7.6
5.8
4.3
5.6
3.6
5.4
5.6
–
–
37.9
8.1
19.9
4.4
3.0
14.0
18.8
59.8
3.9
4.9
9.7
4.7
10.0

14.3
6.5
22.7
65.0
27.7
17.6
61.3
2.5
70.0
109.7
–
13.1
9.6
80.5
71.3
0.0
13.4
8.2
34.4
5.1
64.1
13.7
48.2
64.9
7.6
56.9
44.9
28.0
54.3

		388
		830
  930
		183
		36
		367
		219
  124
		174
	4	606
	4	127
		396
		406
		12
		240
	2	287
–
		2
  726
		34
		140
		623
		160
	3	388
	1	445
 7 698
		158
		77
	3	044
		328
 33 148

		240
		2
  444
 4 991
	1	778
		357
 1 842
		158
 10 020
 4 885
0
  40
		148
 1 906
 84 956
–
		441
–
		441
		387
 4 316
 8 925
 2 610
 19 521
	4	458
 14 127
 166 552
 199 700
 169 799

4.4
7.2
13.4
4.5
4.1
3.4
3.8
9.3
3.1
6.8
5.0
3.7
4.2
3.3
4.8
3.8
–
5.2
26.0
5.4
27.2
3.6
3.0
8.9
14.0
39.8
2.9
3.7
6.4
3.2
7.3

8.3
2.6
15.0
49.2
18.8
10.9
46.2
1.8
53.4
74.9
0.0
6.4
7.1
47.2
58.2
–
5.0
–
24.8
4.5
45.3
10.6
43.3
44.6
6.6
42.2
34.6
21.4
41.5

–12.1%
–6.0%
–12.1%
–20.1%
–13.0%
–8.5%
–10.2%
–10.6%
–7.3%
–5.6%
–8.9%
–2.5%
–15.1%
16.3%
–7.7%
–12.8%
–
–0.7%
–15.1%
1.9%
25.1%
–9.0%
–14.8%
–14.8%
–6.9%
–12.8%
–14.6%
–10.5%
–12.4%
–18.6%
–11.6%

–12.7%
–15.9%
–20.1%
–8.1%
–16.2%
–20.2%
–13.6%
–12.3%
–6.9%
–13.2%
–100.0%
–17.7%
–13.7%
–17.4%
–8.6%
–
–26.0%
–
–11.6%
–11.4%
–11.0%
–9.2%
1.2%
–12.5%
–8.4%
–7.9%
–9.7%
–9.8%
–9.7%

Note: European Region comprises the 53 countries of the WHO European Region and Liechtenstein. WHO European Region 18 TB HPCs are presented in italics. The 
data published in this report might differ from figures in national reports due to different times of reporting. The deadline for correcting and updating the data used 
in this report in the joint database was 4 October 2021.
HPCs: high-priority countries.
1 All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999). 

68

SURVEILLANCE REPORTTuberculosis surveillance and monitoring in Europe 2022 
 
 
       
Table 4. TB cases by history of previous TB treatment, European Region, 2020

Country/area

EU/EEA
Austria
Belgiumd
Bulgaria
Croatia
Cyprus
Czechia
Denmarkd
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Irelandd
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norwayd
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
Subtotal EU/EEA
Non-EU/EEA
Albania
Andorra
Armenia
Azerbaijan
Belarus
Bosnia and Herzegovina
Georgia
Israel
Kazakhstan
Kyrgyzstan
Monaco
Montenegro
North Macedonia
Republic of Moldova
Russian Federation
San Marino
Serbia

Serbia excluding Kosovo1
Kosovo1
Switzerland
Tajikistan
Turkey
Turkmenistan
Ukraine
United Kingdomd
Uzbekistan
Subtotal non-EU/EEA
Total European Region
Subtotal 18 HPCs

Newa

Unknown 
previous TB 
history

Previously treated

Previous 
treatment 
completed

Other  
previously 
treated

All TB cases

N

(%)b

N

(%)b

N

(%)c

N

(%)c

N

		296
		607
  820
		1
		34
		351
		205
  109
		169
	2	288
	2	725
		338
		359
		0
		114
	1	597
–
		1
  591
		28
		98
		593
		144
	2	912
	1	351
 6 019
		133
		70
	1	880
		306
24 139

		223
		2
  369
 2 558
 1 171
		322
 1 484
		156
 6 934
 3 534
0
		38
		130
 1 386
 47 399
–
		412
–
		412
		351
 3 759
 8 358
 1 603
 14 156
	4	185
 10 893
 109 423
 133 562
 111 143

(76.3)
(73.1)
(88.2)
(0.5)
(94.4)
(95.6)
(93.6)
(87.9)
(97.1)
(49.7)
(66.0)
(85.4)
(88.4)
(0.0)
(47.5)
(69.8)
–
(50.0)
(81.4)
(82.4)
(70.0)
(95.2)
(90.0)
(86.0)
(93.5)
(78.2)
(84.2)
(90.9)
(61.8)
(93.3)
(72.8)

(92.9)
(100.0)
(83.1)
(51.3)
(65.9)
(90.2)
(80.6)
(98.7)
(69.2)
(72.3)
–
(95.0)
(87.8)
(72.7)
(55.8)
–
(93.4)
–
(93.4)
(90.7)
(87.1)
(93.6)
(61.4)
(72.5)
(93.9)
(77.1)
(65.7)
(66.9)
(65.5)

		73
		171
  0
		175
		0
		0
		0
  0
		1
	2	110
	1	176
		37
		0
		12
		115
		566
–
		1
  0
		4
		42
		0
		0
		0
		0
  0
		4
		1
	1	069
		1
 5 558

–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
  0
 5 558
  0

(18.8)
(20.6)
(0.0)
(95.6)
(0.0)
(0.0)
(0.0)
(0.0)
(0.6)
(45.8)
(28.5)
(9.3)
(0.0)
(100.0)
(47.9)
(24.7)
–
(50.0)
(0.0)
(11.8)
(30.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(2.5)
(1.3)
(35.1)
(0.3)
(16.8)

–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
(0.0)
(2.8)
(0.0)

		13
		0
  67
		1
		0
		9
		0
  11
		4
		0
		109
		5
		25
		0
		0
		0
–
		0
  97
		0
		0
		21
		0
		238
		51
 1 174
		16
		4
		0
		9
 1 854

			17
			0
   25
  1 125
   343
			35
   187
			2
  2 669
   707
–
			2
			13
   381
  11 324
–
			27
–
			27
			0
   389
   472
   315
  3 377
			0
  1 218
 22 628
 24 482
 23 881

(3.4)
(0.0)
(7.2)
(0.5)
(0.0)
(2.5)
(0.0)
(8.9)
(2.3)
(0.0)
(2.6)
(1.3)
(6.2)
(0.0)
(0.0)
(0.0)
–
(0.0)
(13.4)
(0.0)
(0.0)
(3.4)
(0.0)
(7.0)
(3.5)
(15.3)
(10.1)
(5.2)
(0.0)
(2.7)
(5.6)

(7.1)
(0.0)
(5.6)
(22.5)
(19.3)
(9.8)
(10.2)
(1.3)
(26.6)
(14.5)
–
(5.0)
(8.8)
(20.0)
(13.3)
–
(6.1)
–
(6.1)
(0.0)
(9.0)
(5.3)
(12.1)
(17.3)
(0.0)
(8.6)
(13.6)
(12.3)
(14.1)

		6
		52
  43
		6
		2
		7
		14
  4
		0
		208
		117
		16
		22
		0
		11
		124
–
		0
  38
		2
		0
		9
		16
		238
		43
  505
		5
		2
		95
		12
 1 597

			0
			0
   50
  1 308
   264
			0
   171
			0
   417
   644
–
			0
			5
   139
  26 233
–
			2
–
			2
			36
   168
   95
   692
  1 988
			273
  2 016
 34 501
 36 098
 34 775

(1.5)
(6.3)
(4.6)
(3.3)
(5.6)
(1.9)
(6.4)
(3.2)
(0.0)
(4.5)
(2.8)
(4.0)
(5.4)
(0.0)
(4.6)
(5.4)
–
(0.0)
(5.2)
(5.9)
(0.0)
(1.4)
(10.0)
(7.0)
(3.0)
(6.6)
(3.2)
(2.6)
(3.1)
(3.7)
(4.8)

(0.0)
(0.0)
(11.3)
(26.2)
(14.8)
(0.0)
(9.3)
(0.0)
(4.2)
(13.2)
–
(0.0)
(3.4)
(7.3)
(30.9)
–
(0.5)
–
(0.5)
(9.3)
(3.9)
(1.1)
(26.5)
(10.2)
(6.1)
(14.3)
(20.7)
(18.1)
(20.5)

		388
		830
  930
		183
		36
		367
		219
  124
		174
	4	606
	4	127
		396
		406
		12
		240
	2	287
–
		2
  726
		34
		140
		623
		160
	3	388
	1	445
 7 698
		158
		77
	3	044
		328
 33 148

		240
		2
  444
 4 991
 1 778
		357
 1 842
		158
 10 020
 4 885
–
		40
		148
 1 906
 84 956
–
		441
–
		441
		387
 4 316
 8 925
 2 610
 19 521
	4	458
 14 127
 166 552
 199 700
 169 799

Note: European Region comprises the 53 countries of the WHO European Region and Liechtenstein. WHO European 
Region 18 TB HPCs are presented in italics. 
HPCs: high-priority countries.
a For non-EU/EEA countries and areas, cases with unknown previous TB history are included among new TB cases.
b Proportion of all TB cases.
c Proportion of all previously treated TB cases.
d Previous TB history is defined by previous diagnosis. Treatment completion is not analysed for these countries.
1 All references to Kosovo in this document should be understood to be in the context of the United Nations Security 
Council resolution 1244 (1999).

69

Tuberculosis surveillance and monitoring in Europe 2022SURVEILLANCE REPORT  
Table 5. TB cases by site of disease, EU/EEA, 2020

Country

Pulmonary only

Pulmonary and 
extrapulmonary

Pulmonary

Extrapulmonary

No site reported

Total 

EU/EEA
Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
Total EU/EEA

N

(%)

N

(%)

N

(%)

		251
		439
  696
		96
		28
		294
		148
  96
		118
	3	140
	2	341
		264
		375
		8
		97
	1	574
–
		0
  676
		25
		79
		248
		76
	3	220
		841
 6 169
		101
		44
	2	014
		182
 23 640

(64.7)
(52.9)
(74.8)
(52.5)
(77.8)
(80.1)
(67.6)
(77.4)
(67.8)
(68.2)
(56.7)
(66.7)
(92.4)
(66.7)
(40.4)
(68.8)
–
(0.0)
(93.1)
(73.5)
(56.4)
(39.8)
(47.5)
(95.0)
(58.2)
(80.1)
(63.9)
(57.1)
(66.2)
(55.5)
(71.3)

44
135
50
8
2
27
10
  19
		0
		0
		562
		60
		13
		0
		29
		69
–
		0
  0
		1
		20
		86
		20
		17
		166
  486
		34
		22
		211
		25
 2 116

(11.3)
(16.3)
(5.4)
(4.4)
(5.6)
(7.4)
(4.6)
(15.3)
(0.0)
(0.0)
(13.6)
(15.2)
(3.2)
(0.0)
(12.1)
(3.0)
–
(0.0)
(0.0)
(2.9)
(14.3)
(13.8)
(12.5)
(0.5)
(11.5)
(6.3)
(21.5)
(28.6)
(6.9)
(7.6)
(6.4)

		93
		256
  184
		2
		6
		46
		61
  9
		56
	1	423
	1	161
		50
		18
		3
		55
		644
–
		2
  50
		8
		41
		284
		61
		151
		436
 1 043
		23
		11
		819
		121
 7 117

(24.0)
(30.8)
(19.8)
(1.1)
(16.7)
(12.5)
(27.9)
(7.3)
(32.2)
(30.9)
(28.1)
(12.6)
(4.4)
(25.0)
(22.9)
(28.2)
–
100
(6.9)
(23.5)
(29.3)
(45.6)
(38.1)
(4.5)
(30.2)
(13.5)
(14.6)
(14.3)
(26.9)
(36.9)
(21.5)

N

0
0
0
77
0
0
0
0
0
43
63
22
0
1
59
0
–
0
0
0
0
5
3
0
2
0
0
0
0
0
275

(%)

N

(0.0)
(0.0)
(0.0)
(42.1)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.9)
(1.5)
(5.6)
(0.0)
(8.3)
(24.6)
(0.0)
–
(0.0)
(0.0)
(0.0)
(0.0)
(0.8)
(1.9)
(0.0)
(0.1)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.8)

		388
		830
  930
		183
		36
		367
		219
  124
		174
	4	606
	4	127
		396
		406
		12
		240
	2	287
–
		2
  726
		34
		140
		623
		160
	3	388
	1	445
 7 698
		158
		77
	3	044
		328
 33 148

Note: WHO European Region five TB high-priority countries are presented in italics.

70

SURVEILLANCE REPORTTuberculosis surveillance and monitoring in Europe 2022Table 6. TB cases by history of previous TB treatment, site of disease and diagnostic method, according to WHO 
definitions,a European Region, 2020

N

(%)c  

N

Newb and relapse TB cases
Pulmonaryd
Laboratory-
confirmedf

(%)e  

Clinically 
diagnosed

Extrapulmonary

Previously treated 
cases

All TB cases

N

(%)g

N

(%)g

N

(%)e

N

(%)c

N

Country/area

EU/EEA
Austria
Belgiumh
Bulgaria
Croatia
Cyprus
Czechia
Denmarkh
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Irelandh
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norwayh
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
Subtotal EU/EEA 
Non-EU/EEA
Albania
Andorra
Armenia
Azerbaijan
Belarus
Bosnia and Herzegovina
Georgia
Israel
Kazakhstan
Kyrgyzstan
Monaco
Montenegro
North Macedonia
Republic of Moldova
Russian Federation
San Marino
Serbia

Serbia excluding Kosovo1
Kosovo1
Switzerland
Tajikistan
Turkey
Turkmenistan
Ukraine
United Kingdomh
Uzbekistan
Subtotal non-EU/EEA
Total European Region
Subtotal 18 HPCs

		382
		778
  887
		177
		34
		360
		205
  120
		174
	4	398
	4	010
		380
		384
		12
		229
	2	163
–
		2
  688
		32
		140
		614
		144
	3	150
	1	402
 7 193
		153
		75
	2	949
		316
 31 551

		240
		2
		394
 3 683
 1 514
		357
 1 671
		158
 9 603
 4 241
  0
		40
		143
 1 767
 58 723
–
  439
–
		439
		351
 4 148
 8 830
 1 918
 17 533
	4	185
 12 111
 132 051
 163 602
 135 024

(98.5)
(93.7)
(95.4)
(96.7)
(94.4)
(98.1)
(93.6)
(96.8)
(100.0)
(95.5)
(97.2)
(96.0)
(94.6)
(100.0)
(95.4)
(94.6)
–
(100.0)
(94.8)
(94.1)
(100.0)
(98.6)
(90.0)
(93.0)
(97.0)
(93.4)
(96.8)
(97.4)
(96.9)
(96.3)
(95.2)

(100.0)
(100.0)
(88.7)
(73.8)
(85.2)
(100.0)
(90.7)
(100.0)
(95.8)
(86.8)
–
(100.0)
(96.6)
(92.7)
(69.1)
–
(99.5)
–
(99.5)
(90.7)
(96.1)
(98.9)
(73.5)
(89.8)
(93.9)
(85.7)
(79.3)
(81.9)
(79.5)

		289
		539
  708
		175
		28
		314
		148
  112
		118
	3	029
	2	867
		333
		366
		9
		178
	1	539
–
		0
  638
		24
		99
		333
		89
	3	006
		976
 6 159
		130
		64
	2	149
		199
 24 618

		201
		1
		285
 3 016
 1 417
		319
 1 319
		113
 8 634
 3 369
–
  38
  121
 1 633
 54 109
–
  317
–
		317
		260
 2 788
 5 724
 1 516
 15 983
	2	253
 7 487
 110 903
 135 521
 114 897

(75.7)
(69.3)
(79.8)
(98.9)
(82.4)
(87.2)
(72.2)
(93.3)
(67.8)
(68.9)
(71.5)
(87.6)
(95.3)
(75.0)
(77.7)
(71.2)
–
(0.0)
(92.7)
(75.0)
(70.7)
(54.2)
(61.8)
(95.4)
(69.6)
(85.6)
(85.0)
(85.3)
(72.9)
(63.0)
(78.0)

(83.8)
(50.0)
(72.3)
(81.9)
(93.6)
(89.4)
(78.9)
(71.5)
(89.9)
(79.4)
–
(95.0)
(84.6)
(92.4)
(92.1)
–
(72.2)
–
(72.2)
(74.1)
(67.2)
(64.8)
(79.0)
(91.2)
(53.8)
(61.8)
(84.0)
(82.8)
(85.1)

		259
		482
  438
		139
		25
		269
		132
  106
		107
	2	133
	2	619
		317
		194
		5
		139
	1	310
–
		0
  579
		23
		52
		286
		82
	2	427
		864
 5 295
		74
		62
	1	592
		181
 20 191

		147
		1
		216
 2 309
 1 345
		240
 1 219
		90
 6 725
 2 252
–
  31
  105
 1 122
 28 919
–
		145
–
		145
		244
 1 902
 4 478
  711
 11 569
	1	809
 4 779
 70 358
 90 549
 73 964

(89.6)
(89.4)
(61.9)
(79.4)
(89.3)
(85.7)
(89.2)
(94.6)
(90.7)
(70.4)
(91.3)
(95.2)
(53.0)
(55.6)
(78.1)
(85.1)
–
(0.0)
(90.8)
(95.8)
(52.5)
(85.9)
(92.1)
(80.7)
(88.5)
(86.0)
(56.9)
(96.9)
(74.1)
(91.0)
(82.0)

(73.1)
(100.0)
(75.8)
(76.6)
(94.9)
(75.2)
(92.4)
(79.6)
(77.9)
(66.8)
–
(81.6)
(86.8)
(68.7)
(53.4)
–
(45.7)
–
(45.7)
(93.8)
(68.2)
(78.2)
(46.9)
(72.4)
(80.3)
(63.8)
(63.4)
(66.8)
(64.4)

		30
		57
  270
		36
		3
		45
		16
  6
		11
		896
		248
		16
		172
		4
		39
		229
–
		0
  59
		1
		47
		47
		7
		579
		112
  864
		56
		2
		557
		18
 4 427

		54
		0
		69
  707
  72
		79
  100
		23
 1 909
 1 117
–
  7
  16
  511
 25 190
–
		172
–
		172
		16
  886
 1 246
  805
 4 414
		444
 2 708
 40 545
 44 972
 40 933

(10.4)
(10.6)
(38.1)
(20.6)
(10.7)
(14.3)
(10.8)
(5.4)
(9.3)
(29.6)
(8.7)
(4.8)
(47.0)
(44.4)
(21.9)
(14.9)
–
(0.0)
(9.2)
(4.2)
(47.5)
(14.1)
(7.9)
(19.3)
(11.5)
(14.0)
(43.1)
(3.1)
(25.9)
(9.0)
(18.0)

(26.9)
(0.0)
(24.2)
(23.4)
(5.1)
(24.8)
(7.6)
(20.4)
(22.1)
(33.2)
–
(18.4)
(13.2)
(31.3)
(46.6)
–
(54.3)
–
(54.3)
(6.2)
(31.8)
(21.8)
(53.1)
(27.6)
(19.7)
(36.2)
(36.6)
(33.2)
(35.6)

		93
		239
  179
		2
		6
		46
		57
  8
		56
	1	369
	1	143
		47
		18
		3
		51
		624
–
		2
  50
		8
		41
		281
		55
		144
		426
 1 034
		23
		11
		800
		117
 6 933

		39
		1
  109
  667
  97
		38
  352
  45
  969
  872
–
  2
  22
  134
 4 614
–
		122
–
		122
		91
 1 360
 3 106
  402
 1 550
 1 932
 4 624
 21 148
 28 081
 20 127

(24.3)
(30.7)
(20.2)
(1.1)
(17.6)
(12.8)
(27.8)
(6.7)
(32.2)
(31.1)
(28.5)
(12.4)
(4.7)
(25.0)
(22.3)
(28.8)
–
(100.0)
(7.3)
(25.0)
(29.3)
(45.8)
(38.2)
(4.6)
(30.4)
(14.4)
(15.0)
(14.7)
(27.1)
(37.0)
(22.0)

(16.3)
(50.0)
(27.7)
(18.1)
(6.4)
(10.6)
(21.1)
(28.5)
(10.1)
(20.6)
–
(5.0)
(15.4)
(7.6)
(7.9)
–
(27.8)
–
(27.8)
(25.9)
(32.8)
(35.2)
(21.0)
(8.8)
(46.2)
(38.2)
(16.0)
(17.2)
(14.9)

		6
		52
  43
		6
		2
		7
		14
  4
		0
		208
		117
		16
		22
		0
		11
		124
–
		0
  38
		2
		0
		9
		16
		238
		43
  505
		5
		2
		95
		12
 1 597

		0
		0
		50
 1 308
  264
		0
  171
		0
  417
  644
–
  0
  5
  139
 26 233
–
		2
–
		2
		36
  168
  95
  692
 1 988
		273
 2 016
 34 501
 36 098
 34 775

(1.5)
(6.3)
(4.6)
(3.3)
(5.6)
(1.9)
(6.4)
(3.2)
(0.0)
(4.5)
(2.8)
(4.0)
(5.4)
(0.0)
(4.6)
(5.4)
–
(0.0)
(5.2)
(5.9)
(0.0)
(1.4)
(10.0)
(7.0)
(3.0)
(6.6)
(3.2)
(2.6)
(3.1)
(3.7)
(4.8)

(0.0)
(0.0)
(11.3)
(26.2)
(14.8)
(0.0)
(9.3)
(0.0)
(4.2)
(13.2)
–
(0.0)
(3.4)
(7.3)
(30.9)
–
(0.5)
–
(0.5)
(9.3)
(3.9)
(1.1)
(26.5)
(10.2)
(6.1)
(14.3)
(20.7)
(18.1)
(20.5)

Note: European Region comprises the 53 countries of the WHO European Region and Liechtenstein. WHO European Region 18 TB HPCs are presented in italics. 
HPCs: high-priority countries.
a WHO (2013). Definitions and reporting framework for tuberculosis – 2013 revision. Updated December 2014 and January 2020. Geneva: World Health Organization 
(WHO/HTM/TB/ 2013.2; https://apps.who.int/iris/handle/10665/79199, accessed 16 February 2022).
b Cases with unknown previous TB history are included among new TB ases.
c Proportion of all TB cases.
d For the EU/EEA countries, cases with no disease site reported are included among pulmonary TB cases.
e Proportion of all new and relapse TB cases.
f Confirmed by culture, smear and/or nucleic acid amplification test. Microscopy results from any specimen are included for EU/EEA countries.
g Proportion of all new and relapse pulmonary TB cases.
h Previous TB history is defined by previous diagnosis.
1 All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999).

		388
		830
  930
		183
		36
		367
		219
  124
		174
	4	606
	4	127
		396
		406
		12
		240
	2	287
–
		2
  726
		34
		140
		623
		160
	3	388
	1	445
 7 698
		158
		77
	3	044
		328
 33 148

		240
		2
		444
 4 991
 1 778
		357
 1 842
		158
 10 020
 4 885
		0
  40
  148
 1 906
 84 956
–
		441
–
		441
		387
 4 316
 8 925
 2 610
 19 521
	4	458
 14 127
 166 552
 199 700
 169 799

71

Tuberculosis surveillance and monitoring in Europe 2022SURVEILLANCE REPORTTable 7. TB cases according to EU case definition, EU/EEA, 2020

All laboratory-confirmed casesa

Country

Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
Total EU/EEA

Meeting only the 
smear-positive and 
nucleic acid test-
positive criterion
(%)c
(2.1)
(1.4)
(0.2)
(0.0)
(0.0)
(1.4)
(0.0)
(0.9)
(0.0)
(0.0)
(3.5)
(0.0)
(0.0)
(0.0)
(0.6)
(0.0)
–
(0.0)
(0.0)
(0.0)
(0.0)
(1.9)
(0.8)
(0.0)
(4.6)
(0.7)
(1.5)
(0.0)
(3.7)
(0.0)
(1.3)

N
6
9
1
0
0
4
0
1
0
0
115
0
0
0
1
0
–
0
0
0
0
8
1
0
40
42
1
0
67
0
296

Meeting only the 
culture-positive 
criterion

Meeting both 
criteria

Confirmed casesb

Probable cases

Possible cases

All TB cases

N
		219
		382
  432
		146
		22
		161
		102
  58
		117
	1	879
	1	682
		321
		197
		4
		119
	1	490
–
		1
  635
		28
		43
		252
		91
	2	017
		701
 4 172
		52
		49
	1	290
		199
 16 861

(%)c
(77.9)
(60.0)
(99.8)
(100.0)
(78.6)
(56.5)
(56.7)
(54.2)
(83.0)
(100.0)
(51.6)
(88.9)
(100.0)
(66.7)
(70.0)
(100.0)
–
(100.0)
(100.0)
(100.0)
(100.0)
(58.5)
(68.4)
(76.0)
(81.1)
(73.2)
(77.6)
(67.1)
(71.3)
(75.4)
(75.6)

N
		56
		246
  0
		0
		6
		120
		78
  48
		24
		0
	1	462
		40
		0
		2
		50
		0
–
		0
  0
		0
		0
		171
		41
		638
		123
 1 483
		14
		24
		453
		65
 5 144

(%)c
(19.9)
(38.6)
(0.0)
(0.0)
(21.4)
(42.1)
(43.3)
(44.9)
(17.0)
(0.0)
(44.9)
(11.1)
(0.0)
(33.3)
(29.4)
(0.0)
–
(0.0)
(0.0)
(0.0)
(0.0)
(39.7)
(30.8)
(24.0)
(14.2)
(26.0)
(20.9)
(32.9)
(25.0)
(24.6)
(23.1)

N
		281
		637
  433
		146
		28
		285
		180
  107
		141
	1	879
	3	259
		361
		197
		6
		170
	1	490
–
		1
  635
		28
		43
		431
		133
	2	655
		864
 5 697
		67
		73
	1	810
		264
 22 301

(%)d
(72.4)
(76.7)
(46.6)
(79.8)
(77.8)
(77.7)
(82.2)
(86.3)
(81.0)
(40.8)
(79.0)
(91.2)
(48.5)
(50.0)
(70.8)
(65.2)
–
(50.0)
(87.5)
(82.4)
(30.7)
(69.2)
(83.1)
(78.4)
(59.8)
(74.0)
(42.4)
(94.8)
(59.5)
(80.5)
(67.3)

N
		55
		112
  96
		1
		3
		56
		6
  13
		23
		850
		404
		13
		13
		0
		21
		343
–
		1
  0
		1
		25
		77
		13
		50
		311
  699
		26
		3
		447
		29
 3 691

(%)d
(14.2)
(13.5)
(10.3)
(0.5)
(8.3)
(15.3)
(2.7)
(10.5)
(13.2)
(18.5)
(9.8)
(3.3)
(3.2)
(0.0)
(8.8)
(15.0)
–
(50.0)
(0.0)
(2.9)
(17.9)
(12.4)
(8.1)
(1.5)
(21.5)
(9.1)
(16.5)
(3.9)
(14.7)
(8.8)
(11.1)

N
52
		81
  401
		36
		5
		26
		33
  4
		10
	1	877
		464
		22
		196
		6
		49
		454
–
		0
  91
		5
		72
		115
		14
		683
		270
 1 302
		65
		1
		787
		35
 7 156

(%)d
(13.4)
(9.8)
(43.1)
(19.7)
(13.9)
(7.1)
(15.1)
(3.2)
(5.7)
(40.8)
(11.2)
(5.6)
(48.3)
(50.0)
(20.4)
(19.9)
–
(0.0)
(12.5)
(14.7)
(51.4)
(18.5)
(8.8)
(20.2)
(18.7)
(16.9)
(41.1)
(1.3)
(25.9)
(10.7)
(21.6)

N
		388
		830
  930
		183
		36
		367
		219
  124
		174
	4	606
	4	127
		396
		406
		12
		240
	2	287
–
		2
  726
		34
		140
		623
		160
	3	388
	1	445
 7 698
		158
		77
	3	044
		328
 33 148

Note: WHO European Region 18 TB high-priority countries are presented in italics.
a Laboratory-confirmed TB cases according to the EU case definition.
b Culture-positive OR microscopy-positive and nucleic acid amplification test-positive.
c Proportion of all laboratory-confirmed TB cases.
d Proportion of all TB cases. 

72

SURVEILLANCE REPORTTuberculosis surveillance and monitoring in Europe 2022 
 
Table 8. New and relapse TB cases, by age group and male-to-female ratio, European Region, 2020a

Country/area

EU/EEA
Austria
Belgiumb
Bulgaria
Croatia
Cyprus
Czechia
Denmarkb
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Irelandb
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norwayb
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
Subtotal EU/EEA
Non-EU/EEA
Albania
Andorra
Armenia
Azerbaijan
Belarus
Bosnia and Herzegovina
Georgia
Israel
Kazakhstan
Kyrgyzstan
Monaco
Montenegro
North Macedonia
Republic of Moldova
Russian Federation
San Marino
Serbia

Serbia excluding Kosovo1
Kosovo1
Switzerland
Tajikistan
Turkey
Turkmenistan
Ukraine
United Kingdomb
Uzbekistan
Subtotal non-EU/EEA
Total European Region
Subtotal 18 HPCs

0–4

5–14

15–24

25–44

N

(%)

Rate per 
100 000

M/F 
ratio

N

(%)

Rate per 
100 000

M/F 
ratio

N

(%)

Rate per 
100 000

M/F 
ratio

N

(%)

Rate per 
100 000

M/F 
ratio

45–64

N

(%)

Rate per 

100 000

M/F 

ratio

> 64

Rate per 

100 000

N

(%)

M/F ratio

N

(%)

Unknown

Total

Rate per 

100 000

N

M/F 

ratio

Country/area

7
22
8
1
0
1
3
0
2
88
84
4
0
2
3
40
–
0
3
0
4
6
6
12
24
100
23
0
67
4
514

			0
			0
   18
   20
   1
			0
   6
			2
   64
   41
			0
   0
			4
   19
   575
–
			5
–
			5
			8
   65
   150
   25
   87
			56
   239
 1 385
 1 899
 1 477

(1.8)
(2.8)
(0.9)
(0.6)
(0.0)
(0.3)
(1.5)
(0.0)
(1.1)
(2.0)
(2.1)
(1.1)
(0.0)
(16.7)
(1.3)
(1.8)
–
(0.0)
(0.4)
(0.0)
(2.9)
(1.0)
(4.2)
(0.4)
(1.7)
(1.4)
(15.0)
(0.0)
(2.3)
(1.3)
(1.6)

(0.0)
(0.0)
(4.6)
(0.8)
(0.1)
(0.0)
(0.4)
(1.3)
(0.7)
(1.0)
–
(0.0)
(2.8)
(1.1)
(1.0)
–
(1.1)
–
(1.1)
(2.3)
(1.6)
(1.7)
(1.3)
(0.5)
(1.3)
(2.0)
(1.1)
(1.2)
(1.1)

1.6
3.6
2.5
0.5
0.0
0.2
1.0
0.0
0.8
2.4
2.1
0.9
0.0
9.4
1.0
1.8
–
0.0
2.1
0.0
16.7
0.7
2.1
0.6
5.5
10.0
7.8
0.0
3.3
0.7
2.4

0.0
0.0
8.8
2.4
0.2
0.0
2.2
0.2
3.3
5.4
–
0.0
3.6
9.4
6.2
–
1.2
–
0.1
1.8
4.8
2.3
3.8
4.1
1.4
7.0
4.0
3.4
5.0

0.8
1.4
0.6
N/F
–
N/M
0.5
–
N/F
1.0
1.2
3.0
–
1.0
N/M
0.7
–
–
2.0
–
3.0
1.0
1.0
1.0
1.4
1.2
1.9
–
1.2
3.0
1.1

–
–
8.0
1.0
0.0
–
0.5
1.0
0.7
1.4
–
–
1.0
1.1
1.0
–
0.7
–
0.7
0.6
1.4
1.0
1.0
1.4
1.0
1.2
1.1
1.1
1.1

5
26
16
1
0
1
7
1
3
103
79
13
5
0
3
60
–
0
10
0
3
13
5
26
18
161
12
0
121
12
704

			3
			0
   5
   71
   3
			1
   42
			2
   239
   139
			0
   0
			6
   37
  1 052
–
			6
–
			6
			8
   175
   241
   25
   295
			97
  1 494
 3 941
 4 645
 4 103

(1.3)
(3.3)
(1.8)
(0.6)
(0.0)
(0.3)
(3.4)
(0.8)
(1.7)
(2.3)
(2.0)
(3.4)
(1.3)
(0.0)
(1.3)
(2.8)
–
(0.0)
(1.5)
(0.0)
(2.1)
(2.1)
(3.5)
(0.8)
(1.3)
(2.2)
(7.8)
(0.0)
(4.1)
(3.8)
(2.2)

(1.3)
(0.0)
(1.3)
(2.8)
(0.2)
(0.3)
(2.5)
(1.3)
(2.5)
(3.3)
–
(0.0)
(4.2)
(2.1)
(1.8)
–
(1.4)
–
(1.4)
(2.3)
(4.2)
(2.7)
(1.3)
(1.7)
(2.3)
(12.3)
(3.0)
(2.9)
(3.0)

0.6
2.0
2.3
0.3
0.0
0.1
1.1
0.7
0.5
1.2
1.1
1.2
0.5
0.0
0.4
1.1
–
0.0
3.6
0.0
6.6
0.7
0.8
0.7
1.9
7.9
2.1
0.0
2.5
1.0
1.5

0.9
0.0
1.2
4.6
0.3
0.3
7.8
0.1
6.7
10.1
–
0.0
2.6
8.4
6.0
–
0.6
–
0.1
0.9
8.0
1.8
2.1
6.0
1.2
24.1
5.9
4.1
7.1

0.3
1.6
1.3
N/F
–
N/F
2.5
N/M
0.5
0.9
0.9
5.5
1.5
–
1.0
1.6
–
–
0.7
–
2.0
0.1
1.5
2.3
3.5
1.1
2.0
–
1.5
0.7
1.2

2.0
–
4.0
1.0
0.5
0.0
0.8
1.0
0.7
1.1
–
–
0.5
1.3
0.9
–
1.0
–
1.0
1.7
1.0
0.7
1.0
0.9
1.0
1.1
1.0
1.0
1.0

		44
		140
  37
		8
		10
		16
		24
  3
		10
		838
		691
		74
		23
		2
		18
		330
–
		0
  22
		7
		60
		89
		26
		134
		133
  612
		3
		3
		288
		67
 3 712

			42
			0
   39
   588
   48
			43
   222
			8
  1 104
   801
			0
   6
			17
   110
  3 058
–
			70
–
			70
			53
  1 014
  1 518
   274
   919
			507
  1 306
 11 747
 15 459
 12 182

(11.5)
(18.0)
(4.2)
(4.5)
(29.4)
(4.4)
(11.7)
(2.5)
(5.7)
(19.1)
(17.2)
(19.5)
(6.0)
(16.7)
(7.9)
(15.3)
–
(0.0)
(3.2)
(21.9)
(42.9)
(14.5)
(18.1)
(4.3)
(9.5)
(8.5)
(2.0)
(4.0)
(9.8)
(21.2)
(11.8)

(17.5)
(0.0)
(9.9)
(23.0)
(3.2)
(12.0)
(13.3)
(5.1)
(11.5)
(18.9)
–
(15.0)
(11.9)
(6.2)
(5.2)
–
(15.9)
–
(15.9)
(15.1)
(24.4)
(17.2)
(14.3)
(5.2)
(12.1)
(10.8)
(9.0)
(9.5)
(8.8)

4.6
10.7
6.0
1.8
8.8
1.7
3.3
2.4
1.6
10.5
8.1
6.7
2.2
4.2
2.9
5.7
–
0.0
7.7
9.7
109.2
4.2
3.9
3.5
12.1
30.2
0.5
1.5
6.1
5.8
7.8

9.8
0.0
11.2
43.4
5.5
11.3
49.2
0.6
49.8
79.0
–
7.5
6.8
24.8
22.3
–
6.7
–
0.8
5.8
61.6
11.2
29.0
22.3
6.5
24.6
20.2
14.6
24.8

2.4
2.2
0.6
3.0
1.5
1.3
2.0
N/F
4.0
2.0
2.1
9.6
0.8
1.0
3.5
2.5
–
–
1.2
N/F
6.5
1.4
1.0
1.5
1.3
1.2
0.5
2.0
1.5
2.7
1.8

3.2
–
2.0
1.7
1.1
1.4
1.6
1.0
1.0
1.3
–
5.0
0.9
1.6
1.3
–
1.1
–
1.1
1.8
1.3
1.2
1.0
1.4
1.4
1.1
1.3
1.4
1.2

		122
		304
  247
		34
		13
		121
		76
  22
		38
	1	744
	1	502
		136
		94
		4
		106
		802
–
		1
  192
		17
		51
		278
		59
		784
		383
 2 226
		26
		12
		982
		128
 10 504

			75
			2
   133
   933
   567
			78
   653
			79
  3 987
  1 403
			0
   12
			48
   753
  31 043
–
			121
–
			121
			145
  1 496
  2 656
   844
  8 658
		1	779
  3 728
 59 193
 69 697
 61 320

(31.9)
(39.1)
(27.8)
(19.2)
(38.2)
(33.6)
(37.1)
(18.3)
(21.8)
(39.7)
(37.5)
(35.8)
(24.5)
(33.3)
(46.3)
(37.1)
–
(50.0)
(27.9)
(53.1)
(36.4)
(45.3)
(41.0)
(24.9)
(27.3)
(30.9)
(17.0)
(16.0)
(33.3)
(40.5)
(33.3)

(31.3)
(100.0)
(33.8)
(36.5)
(37.5)
(21.8)
(39.1)
(50.0)
(41.5)
(33.1)
–
(30.0)
(33.6)
(42.6)
(52.9)
–
(27.4)
–
(27.4)
(41.3)
(36.1)
(30.1)
(44.0)
(49.4)
(42.5)
(30.8)
(45.2)
(42.9)
(44.4)

5.1
10.2
13.1
3.2
4.7
4.0
5.2
6.0
2.7
10.8
7.2
5.0
3.4
3.7
7.6
5.7
–
10.2
26.7
8.8
29.5
6.5
4.1
6.8
14.9
42.1
1.6
2.1
7.8
4.7
9.0

9.5
10.3
14.3
28.1
20.0
9.0
59.6
3.5
70.6
72.1
–
6.9
7.6
53.6
70.4
–
5.0
–
28.9
6.2
55.9
10.5
44.8
65.1
9.8
34.4
41.5
26.8
49.6

1.7
1.7
1.6
2.1
1.6
2.2
1.1
2.7
0.9
2.1
1.7
3.5
1.2
0.3
1.4
1.7
–
N/F
2.5
16.0
2.6
1.2
0.5
2.6
1.7
2.2
1.4
1.0
1.4
0.9
1.9

3.7
1.0
2.1
2.0
2.7
1.6
1.8
1.9
1.1
1.3
–
1.4
3.0
3.2
2.4
–
0.8
–
0.8
1.0
1.2
1.2
1.4
2.4
1.4
1.2
1.9
1.9
2.0

		113

		168

  352

		63

		10

		127

		73

  56

		35

		886

		858

		72

		160

		4

		56

		525

–

		0

  342

		5

		11

		139

		34

	1	370

		523

 2 990

		46

		22

		844

		60

 9 944

			64

			0

   144

   761

   695

			118

   544

			31

  3 064

  1 276

			0

   11

			48

   704

  18 090

–

–

			133

			87

   991

  2 629

   604

  6 170

		1	133

  3 557

 40 854

 50 798

 44 102

(29.6)

(21.6)

(39.7)

(35.6)

(29.4)

(35.3)

(35.6)

(46.7)

(20.1)

(20.1)

(21.4)

(18.9)

(41.7)

(33.3)

(24.5)

(24.3)

–

(0.0)

(49.7)

(15.6)

(7.9)

(22.6)

(23.6)

(43.5)

(37.3)

(41.6)

(30.1)

(29.3)

(28.6)

(19.0)

(31.5)

(26.7)

(0.0)

(36.5)

(29.7)

(45.9)

(33.1)

(32.6)

(19.6)

(31.9)

(30.1)

–

(27.5)

(33.6)

(39.8)

(30.8)

–

–

(30.2)

(24.8)

(23.9)

(29.8)

(31.5)

(35.2)

(27.1)

(29.4)

(31.2)

(31.3)

(31.9)

4.4

5.4

18.0

5.6

4.8

4.5

4.8

16.0

2.5

5.1

3.5

2.4

6.1

4.6

4.6

2.9

–

0.0

42.2

2.9

9.0

2.9

2.5

13.8

17.7

56.2

3.1

3.7

6.1

2.4

7.9

8.6

0.0

19.9

31.8

26.3

12.2

53.0

1.9

77.5

113.3

–

6.8

8.6

67.7

46.7

5.8

–

–

14.4

3.5

73.0

14.8

57.2

51.8

6.5

58.7

35.2

21.0

44.9

N/M

2.4

2.2

2.7

2.0

4.0

3.7

1.2

4.6

1.9

1.7

2.4

3.5

2.5

3.0

1.5

2.0

–

5.1

4.0

N/F

1.5

0.7

4.8

2.2

4.7

3.6

4.5

2.3

0.8

3.0

2.6

N/F

5.9

2.2

4.9

2.4

3.5

1.6

1.1

1.8

–

3.4

4.3

3.2

0.7

–

–

0.7

2.1

1.0

1.8

2.1

3.3

1.6

1.4

10.0

		91

		118

  227

		70

		1

		94

		22

  38

		86

		739

		795

		76

		102

		0

		43

		404

–

		1

  119

		3

		1

		89

		14

		824

		320

 1 104

		43

		38

		645

		45

 6 152

			56

			0

   55

   185

   200

			117

   204

			36

  1 145

   581

			0

   11

			20

   144

  4 500

–

–

			106

			50

   407

  1 636

   146

  1 404

			613

  1 787

(23.8)

(15.2)

(25.6)

(39.5)

(2.9)

(26.1)

(10.7)

(31.7)

(49.4)

(16.8)

(19.8)

(20.0)

(26.6)

(0.0)

(18.8)

(18.7)

–

(50.0)

(17.3)

(9.4)

(0.7)

(14.5)

(9.7)

(26.2)

(22.8)

(15.3)

(28.1)

(50.7)

(21.9)

(14.2)

(19.5)

(23.3)

(0.0)

(14.0)

(7.2)

(13.2)

(32.8)

(12.2)

(22.8)

(11.9)

(13.7)

–

(27.5)

(14.0)

(8.1)

(7.7)

–

–

(24.0)

(14.2)

(9.8)

(18.5)

(7.6)

(8.0)

(14.6)

(14.8)

(10.2)

(12.0)

(10.5)

5.4

5.4

15.1

8.2

0.7

4.4

1.9

14.3

7.0

5.4

4.4

3.2

5.3

0.0

6.0

2.9

–

14.1

21.4

3.3

1.1

2.6

1.5

11.9

14.0

30.1

4.8

9.0

7.0

2.2

6.6

13.2

0.0

15.7

27.1

13.6

19.9

33.5

3.4

77.2

188.4

–

11.1

6.6

28.6

19.9

6.4

–

–

10.2

3.0

134.2

21.6

50.8

18.9

4.8

111.5

21.0

12.6

28.4

			133

(30.2)

			106

(24.0)

1.8

1.9

1.6

0.8

N/M

1.5

3.4

1.7

1.3

1.5

1.5

1.5

1.2

–

2.3

1.5

–

–

2.1

N/F

N/F

1.8

2.5

1.6

1.9

1.7

0.6

1.0

1.9

1.3

1.6

2.5

–

2.7

1.2

1.1

1.3

1.2

1.6

0.9

1.1

–

1.8

1.0

2.2

1.2

0.9

–

–

0.9

1.1

0.9

1.4

0.9

1.2

1.3

1.0

1.2

1.3

1.2

0

0

0

0

0

0

0

0

0

0

1

5

0

0

0

2

–

0

0

0

0

0

0

1

0

0

0

2

0

10

21

			0

			0

   0

   0

   0

			0

   0

			0

   0

   0

			0

   0

			0

   0

			0

–

–

			0

			0

   0

   0

   0

   0

			0

   0

(0.0)

(0.0)

(0.0)

(0.0)

(0.0)

(0.0)

(0.0)

(0.0)

(0.0)

(0.0)

(0.0)

(1.3)

(0.0)

(0.0)

(0.0)

(0.1)

–

(0.0)

(0.0)

(0.0)

(7.1)

(0.0)

(0.0)

(0.0)

(0.1)

(0.0)

(0.0)

(0.0)

(0.1)

(0.0)

(0.1)

(0.0)

(0.0)

(0.0)

(0.0)

(0.0)

(0.0)

(0.0)

(0.0)

(0.0)

(0.0)

–

(0.0)

(0.0)

(0.0)

(0.7)

(0.0)

–

–

(0.0)

(0.0)

(0.0)

(0.0)

(0.0)

(0.0)

(0.0)

(0.0)

(0.3)

(0.3)

(0.3)

1.5

1.0

N/F

N/F

N/F

5.3

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

  382

		778

  887

		177

		34

		360

		205

  120

		174

	4	398

	4	010

		380

		384

		12

		229

	2	163

–

		2

  688

		32

		140

		614

		144

	3	150

	1	402

 7 193

		153

		75

	2	949

		316

 31 551

			240

			2

   394

  2 558

  1 514

			357

  1 671

			158

  9 603

  4 241

0

   40

			143

  1 767

–

–

			441

			351

  4 148

  8 830

  1 918

  17 533

		4	185

  12 111

EU/EEA

1.9 Austria

1.9 Belgiumb

1.9 Bulgaria

1.5 Croatia

1.8 Cyprus

2.3 Czechia

1.4 Denmarkb

2.9 Estonia

1.4 Finland

1.8 France

1.8 Germany

3.3 Greece

1.6 Hungary

1.0 Iceland

1.6 Irelandb

1.8 Italy

– Latvia

1.0 Liechtenstein

3.1 Lithuania

15.0 Luxembourg

4.8 Malta

1.3 Netherlands

0.8 Norwayb

2.7 Poland

1.9 Portugal

2.6 Romania

1.5 Slovakia

1.5 Slovenia

1.7 Spain

1.1 Sweden

2.0 Subtotal EU/EEA

Non-EU/EEA

2.9 Albania

1.0 Andorra

3.1 Armenia

1.8 Azerbaijan

2.9 Belarus

2.0 Georgia

1.7 Israel

1.0 Kazakhstan

1.4 Kyrgyzstan

– Monaco

2.6 Montenegro

–

0.8

Kosovo1

1.3 Switzerland

1.1 Tajikistan

1.3 Turkey

1.5 Turkmenistan

2.4 Ukraine

1.4 United Kingdomb

1.2 Uzbekistan

1.6 Bosnia and Herzegovina

2.4  13 403

2.5

 19 555

2.6  14 495

  405

  426

  405

3.7

3.5

3.7

 130 928

 162 479

 138 084

1.8 Subtotal non-EU/EEA

1.8 Total European Region

1.9 Subtotal 18 HPCs

   405

3.7

  58 723

2.3 Russian Federation

2.0 North Macedonia

3.1 Republic of Moldova

– San Marino

			441

0.8 Serbia

Serbia excluding Kosovo1

Note: European Region comprises the 53 countries of the WHO European Region and Liechtenstein. WHO European Region 18 TB HPCs are presented in italics. 
HPCs: high-priority countries.
F: female.
M: male
N/F: no female in the subgroup.
N/M: no male in the subgroup.
a Cases with unknown previous TB history are included among new TB cases.
b Previous TB history is defined by previous diagnosis.
1 All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999). 

74

SURVEILLANCE REPORTTuberculosis surveillance and monitoring in Europe 2022 
 
 
 
 
 
 
 
 
 
 
  
Country/area

EU/EEA

Austria

Belgiumb

Bulgaria

Croatia

Cyprus

Czechia

Denmarkb

Estonia

Finland

France

Germany

Greece

Hungary

Iceland

Irelandb

Italy

Latvia

Liechtenstein

Lithuania

Luxembourg

Malta

Netherlands

Norwayb

Poland

Portugal

Romania

Slovakia

Slovenia

Spain

Sweden

Albania

Andorra

Armenia

Azerbaijan

Belarus

Georgia

Israel

Kazakhstan

Kyrgyzstan

Monaco

Montenegro

San Marino

Serbia

Kosovo1

Switzerland

Tajikistan

Turkey

Turkmenistan

Ukraine

Subtotal EU/EEA

Non-EU/EEA

Bosnia and Herzegovina

North Macedonia

Republic of Moldova

Russian Federation

Serbia excluding Kosovo1

United Kingdomb

Uzbekistan

Subtotal non-EU/EEA

Total European Region

Subtotal 18 HPCs

HPCs: high-priority countries.

F: female.

M: male

N/F: no female in the subgroup.

N/M: no male in the subgroup.

7

22

88

84

40

8

1

0

1

3

0

2

4

0

2

3

–

0

3

0

4

6

6

12

24

100

23

0

67

4

514

			0

			0

   18

   20

   1

			0

   6

			2

   64

   41

			0

   0

			4

   19

   575

			5

–

–

			5

			8

   65

   150

   25

   87

			56

   239

 1 385

 1 899

 1 477

(1.8)

(2.8)

(0.9)

(0.6)

(0.0)

(0.3)

(1.5)

(0.0)

(1.1)

(2.0)

(2.1)

(1.1)

(0.0)

(1.3)

(1.8)

–

(0.0)

(0.4)

(0.0)

(2.9)

(1.0)

(4.2)

(0.4)

(1.7)

(1.4)

(16.7)

(15.0)

(0.0)

(2.3)

(1.3)

(1.6)

(0.0)

(0.0)

(4.6)

(0.8)

(0.1)

(0.0)

(0.4)

(1.3)

(0.7)

(1.0)

–

(0.0)

(2.8)

(1.1)

(1.0)

(1.1)

–

–

(1.1)

(2.3)

(1.6)

(1.7)

(1.3)

(0.5)

(1.3)

(2.0)

(1.1)

(1.2)

(1.1)

1.6

3.6

2.5

0.5

0.0

0.2

1.0

0.0

0.8

2.4

2.1

0.9

0.0

9.4

1.0

1.8

–

0.0

2.1

0.0

16.7

0.7

2.1

0.6

5.5

10.0

7.8

0.0

3.3

0.7

2.4

0.0

0.0

8.8

2.4

0.2

0.0

2.2

0.2

3.3

5.4

–

0.0

3.6

9.4

6.2

1.2

–

–

0.1

1.8

4.8

2.3

3.8

4.1

1.4

7.0

4.0

3.4

5.0

0.8

1.4

0.6

N/F

–

N/M

0.5

–

N/F

1.0

1.2

3.0

–

1.0

N/M

0.7

–

–

–

2.0

3.0

1.0

1.0

1.0

1.4

1.2

1.9

–

1.2

3.0

1.1

–

–

8.0

1.0

0.0

–

0.5

1.0

0.7

1.4

–

–

1.0

1.1

1.0

0.7

–

–

0.7

0.6

1.4

1.0

1.0

1.4

1.0

1.2

1.1

1.1

1.1

103

79

13

5

26

16

1

0

1

7

1

3

5

0

3

–

0

0

3

60

10

13

5

26

18

161

12

0

121

12

704

			3

			0

   5

   71

   3

			1

   42

			2

			0

   0

			6

			6

–

–

			6

			8

   239

   139

   37

  1 052

   175

   241

   25

   295

			97

  1 494

 3 941

 4 645

 4 103

(1.3)

(3.3)

(1.8)

(0.6)

(0.0)

(0.3)

(3.4)

(0.8)

(1.7)

(2.3)

(2.0)

(3.4)

(1.3)

(0.0)

(1.3)

(2.8)

–

(0.0)

(1.5)

(0.0)

(2.1)

(2.1)

(3.5)

(0.8)

(1.3)

(2.2)

(7.8)

(0.0)

(4.1)

(3.8)

(2.2)

(1.3)

(0.0)

(1.3)

(2.8)

(0.2)

(0.3)

(2.5)

(1.3)

(2.5)

(3.3)

–

(0.0)

(4.2)

(2.1)

(1.8)

(1.4)

–

–

(1.4)

(2.3)

(4.2)

(2.7)

(1.3)

(1.7)

(2.3)

(12.3)

(3.0)

(2.9)

(3.0)

0.6

2.0

2.3

0.3

0.0

0.1

1.1

0.7

0.5

1.2

1.1

1.2

0.5

0.0

0.4

1.1

–

0.0

3.6

0.0

6.6

0.7

0.8

0.7

1.9

7.9

2.1

0.0

2.5

1.0

1.5

0.9

0.0

1.2

4.6

0.3

0.3

7.8

0.1

6.7

–

0.0

2.6

8.4

6.0

0.6

–

–

0.1

0.9

8.0

1.8

2.1

6.0

1.2

10.1

24.1

5.9

4.1

7.1

0.3

1.6

1.3

N/F

–

N/F

2.5

N/M

0.5

0.9

0.9

5.5

1.5

–

1.0

1.6

–

–

–

0.7

2.0

0.1

1.5

2.3

3.5

1.1

2.0

–

1.5

0.7

1.2

2.0

–

4.0

1.0

0.5

0.0

0.8

1.0

0.7

1.1

–

–

0.5

1.3

0.9

1.0

–

–

1.0

1.7

1.0

0.7

1.0

0.9

1.0

1.1

1.0

1.0

1.0

		44

		140

  37

		8

		10

		16

		24

  3

		10

		838

		691

		330

		74

		23

		2

		18

–

		0

  22

		7

		60

		89

		26

		134

		133

  612

		3

		3

		288

		67

 3 712

			42

			0

   39

   48

			43

   222

			8

  1 104

   801

			0

   6

			17

   110

  3 058

–

–

			70

			53

  1 014

  1 518

   274

   919

			507

  1 306

 11 747

 15 459

 12 182

(11.5)

(18.0)

(4.2)

(4.5)

(29.4)

(4.4)

(11.7)

(2.5)

(5.7)

(19.1)

(17.2)

(19.5)

(6.0)

(16.7)

(7.9)

(15.3)

–

(0.0)

(3.2)

(21.9)

(42.9)

(14.5)

(18.1)

(4.3)

(9.5)

(8.5)

(2.0)

(4.0)

(9.8)

(21.2)

(11.8)

(17.5)

(0.0)

(9.9)

(3.2)

(12.0)

(13.3)

(5.1)

(11.5)

(18.9)

–

(15.0)

(11.9)

(6.2)

(5.2)

–

–

(15.9)

(15.1)

(24.4)

(17.2)

(14.3)

(5.2)

(12.1)

(10.8)

(9.0)

(9.5)

(8.8)

   588

(23.0)

109.2

4.6

10.7

10.5

6.0

1.8

8.8

1.7

3.3

2.4

1.6

8.1

6.7

2.2

4.2

2.9

5.7

–

0.0

7.7

9.7

4.2

3.9

3.5

12.1

30.2

0.5

1.5

6.1

5.8

7.8

9.8

0.0

11.2

43.4

5.5

11.3

49.2

0.6

49.8

79.0

–

7.5

6.8

24.8

22.3

6.7

–

–

0.8

5.8

61.6

11.2

29.0

22.3

6.5

24.6

20.2

14.6

24.8

2.4

2.2

0.6

3.0

1.5

1.3

2.0

N/F

4.0

2.0

2.1

9.6

0.8

1.0

3.5

2.5

–

–

1.2

N/F

6.5

1.4

1.0

1.5

1.3

1.2

0.5

2.0

1.5

2.7

1.8

3.2

–

2.0

1.7

1.1

1.4

1.6

1.0

1.0

1.3

–

5.0

0.9

1.6

1.3

–

1.1

–

1.1

1.8

1.3

1.2

1.0

1.4

1.4

1.1

1.3

1.4

1.2

		122

		304

  247

		34

		13

		121

		76

  22

		38

	1	744

	1	502

		136

		94

		4

		106

		802

–

		1

  192

		17

		51

		278

		59

		784

		383

 2 226

		26

		12

		982

		128

			75

			2

   133

   933

   567

			78

   653

			79

  3 987

  1 403

			0

   12

			48

   753

  31 043

–

–

			121

			145

  1 496

  2 656

   844

  8 658

		1	779

  3 728

 59 193

 69 697

 61 320

(31.9)

(39.1)

(27.8)

(19.2)

(38.2)

(33.6)

(37.1)

(18.3)

(21.8)

(39.7)

(37.5)

(35.8)

(24.5)

(33.3)

(46.3)

(37.1)

–

(50.0)

(27.9)

(53.1)

(36.4)

(45.3)

(41.0)

(24.9)

(27.3)

(30.9)

(17.0)

(16.0)

(33.3)

(40.5)

(31.3)

(100.0)

(33.8)

(36.5)

(37.5)

(21.8)

(39.1)

(50.0)

(41.5)

(33.1)

–

(30.0)

(33.6)

(42.6)

(52.9)

–

–

(27.4)

(41.3)

(36.1)

(30.1)

(44.0)

(49.4)

(42.5)

(30.8)

(45.2)

(42.9)

(44.4)

 10 504

(33.3)

5.1

10.2

13.1

10.8

3.2

4.7

4.0

5.2

6.0

2.7

7.2

5.0

3.4

3.7

7.6

5.7

–

10.2

26.7

8.8

29.5

6.5

4.1

6.8

14.9

42.1

1.6

2.1

7.8

4.7

9.0

9.5

10.3

14.3

28.1

20.0

9.0

59.6

3.5

70.6

72.1

–

6.9

7.6

53.6

70.4

5.0

–

–

28.9

6.2

55.9

10.5

44.8

65.1

9.8

34.4

41.5

26.8

49.6

N/F

2.5

16.0

1.7

1.7

1.6

2.1

1.6

2.2

1.1

2.7

0.9

2.1

1.7

3.5

1.2

0.3

1.4

1.7

–

2.6

1.2

0.5

2.6

1.7

2.2

1.4

1.0

1.4

0.9

1.9

3.7

1.0

2.1

2.0

2.7

1.6

1.8

1.9

1.1

1.3

–

1.4

3.0

3.2

2.4

0.8

–

–

0.8

1.0

1.2

1.2

1.4

2.4

1.4

1.2

1.9

1.9

2.0

			70

(15.9)

			121

(27.4)

Table 8. New and relapse TB cases, by age group and male-to-female ratio, European Region, 2020a

0–4

5–14

15–24

25–44

45–64

> 64

Unknown

Total

N

(%)

Rate per 

100 000

M/F 

ratio

N

(%)

Rate per 

100 000

M/F 

ratio

N

(%)

Rate per 

100 000

M/F 

ratio

N

(%)

Rate per 

100 000

M/F 

ratio

N

(%)

Rate per 
100 000

M/F 
ratio

N

(%)

Rate per 
100 000

M/F ratio

N

(%)

Rate per 
100 000

N

M/F 
ratio

Country/area

		113
		168
  352
		63
		10
		127
		73
  56
		35
		886
		858
		72
		160
		4
		56
		525
–
		0
  342
		5
		11
		139
		34
	1	370
		523
 2 990
		46
		22
		844
		60
 9 944

			64
			0
   144
   761
   695
			118
   544
			31
  3 064
  1 276
			0
   11
			48
   704
  18 090
–
			133
–
			133
			87
   991
  2 629
   604
  6 170
		1	133
  3 557
 40 854
 50 798
 44 102

(29.6)
(21.6)
(39.7)
(35.6)
(29.4)
(35.3)
(35.6)
(46.7)
(20.1)
(20.1)
(21.4)
(18.9)
(41.7)
(33.3)
(24.5)
(24.3)
–
(0.0)
(49.7)
(15.6)
(7.9)
(22.6)
(23.6)
(43.5)
(37.3)
(41.6)
(30.1)
(29.3)
(28.6)
(19.0)
(31.5)

(26.7)
(0.0)
(36.5)
(29.7)
(45.9)
(33.1)
(32.6)
(19.6)
(31.9)
(30.1)
–
(27.5)
(33.6)
(39.8)
(30.8)
–
(30.2)
–
(30.2)
(24.8)
(23.9)
(29.8)
(31.5)
(35.2)
(27.1)
(29.4)
(31.2)
(31.3)
(31.9)

4.4
5.4
18.0
5.6
4.8
4.5
4.8
16.0
2.5
5.1
3.5
2.4
6.1
4.6
4.6
2.9
–
0.0
42.2
2.9
9.0
2.9
2.5
13.8
17.7
56.2
3.1
3.7
6.1
2.4
7.9

8.6
0.0
19.9
31.8
26.3
12.2
53.0
1.9
77.5
113.3
–
6.8
8.6
67.7
46.7
–
5.8
–
14.4
3.5
73.0
14.8
57.2
51.8
6.5
58.7
35.2
21.0
44.9

2.4
2.2
2.7
2.0
4.0
3.7
1.2
4.6
1.9
1.7
2.4
3.5
2.5
3.0
1.5
2.0
–
N/M
5.1
4.0
N/F
1.5
0.7
4.8
2.2
4.7
3.6
4.5
2.3
0.8
3.0

		91
		118
  227
		70
		1
		94
		22
  38
		86
		739
		795
		76
		102
		0
		43
		404
–
		1
  119
		3
		1
		89
		14
		824
		320
 1 104
		43
		38
		645
		45
 6 152

			56
2.6
			0
N/F
   55
5.9
   185
2.2
   200
4.9
			117
2.4
   204
3.5
			36
1.6
  1 145
1.1
   581
1.8
			0
–
   11
10.0
			20
3.4
   144
4.3
  4 500
3.2
–
–
			106
0.7
–
–
			106
0.7
			50
2.1
   407
1.0
  1 636
1.8
   146
2.1
  1 404
3.3
			613
1.6
1.4
  1 787
2.4  13 403
2.5
 19 555
2.6  14 495

(23.8)
(15.2)
(25.6)
(39.5)
(2.9)
(26.1)
(10.7)
(31.7)
(49.4)
(16.8)
(19.8)
(20.0)
(26.6)
(0.0)
(18.8)
(18.7)
–
(50.0)
(17.3)
(9.4)
(0.7)
(14.5)
(9.7)
(26.2)
(22.8)
(15.3)
(28.1)
(50.7)
(21.9)
(14.2)
(19.5)

(23.3)
(0.0)
(14.0)
(7.2)
(13.2)
(32.8)
(12.2)
(22.8)
(11.9)
(13.7)
–
(27.5)
(14.0)
(8.1)
(7.7)
–
(24.0)
–
(24.0)
(14.2)
(9.8)
(18.5)
(7.6)
(8.0)
(14.6)
(14.8)
(10.2)
(12.0)
(10.5)

5.4
5.4
15.1
8.2
0.7
4.4
1.9
14.3
7.0
5.4
4.4
3.2
5.3
0.0
6.0
2.9
–
14.1
21.4
3.3
1.1
2.6
1.5
11.9
14.0
30.1
4.8
9.0
7.0
2.2
6.6

13.2
0.0
15.7
27.1
13.6
19.9
33.5
3.4
77.2
188.4
–
11.1
6.6
28.6
19.9
–
6.4
–
10.2
3.0
134.2
21.6
50.8
18.9
4.8
111.5
21.0
12.6
28.4

–

1.8
1.9
1.6
0.8
N/M
1.5
3.4
1.7
1.3
1.5
1.5
1.5
1.2
–
2.3
1.5
–
–
2.1
N/F
N/F
1.8
2.5
1.6
1.9
1.7
0.6
1.0
1.9
1.3
1.6

2.5
–
2.7
1.2
1.1
1.3
1.2
1.6
0.9
1.1
–
1.8
1.0
2.2
1.2
–
0.9
–
0.9
1.1
0.9
1.4
0.9
1.2
1.3
1.0
1.2
1.3
1.2

0
0
0
0
0
0
0
0
0
0
1
5
0
0
0
2
–
0
0
0
10
0
0
0
1
0
0
0
2
0
21

			0
			0
   0
   0
   0
			0
   0
			0
   0
   0
			0
   0
			0
   0
   405
–
			0
–
			0
			0
   0
   0
   0
   0
			0
   0
  405
  426
  405

(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(1.3)
(0.0)
(0.0)
(0.0)
(0.1)
–
(0.0)
(0.0)
(0.0)
(7.1)
(0.0)
(0.0)
(0.0)
(0.1)
(0.0)
(0.0)
(0.0)
(0.1)
(0.0)
(0.1)

(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
–
(0.0)
(0.0)
(0.0)
(0.7)
–
(0.0)
–
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.3)
(0.3)
(0.3)

–
–
–
–
–
–
–
–
–
–
–
1.5
–
–
–
1.0
–
–
–
–
N/F
–
–
–
N/F
–
–
–
N/F
–
5.3

–
–
–
–
–
–
–
–
–
–
–
–
–
–
3.7
–
–
–
–
–
–
–
–
–
–
–
3.7
3.5
3.7

  382
		778
  887
		177
		34
		360
		205
  120
		174
	4	398
	4	010
		380
		384
		12
		229
	2	163
–
		2
  688
		32
		140
		614
		144
	3	150
	1	402
 7 193
		153
		75
	2	949
		316
 31 551

			240
			2
   394
  2 558
  1 514
			357
  1 671
			158
  9 603
  4 241
0
   40
			143
  1 767
  58 723
–
			441
–
			441
			351
  4 148
  8 830
  1 918
  17 533
		4	185
  12 111
 130 928
 162 479
 138 084

EU/EEA
1.9 Austria
1.9 Belgiumb
1.9 Bulgaria
1.5 Croatia
1.8 Cyprus
2.3 Czechia
1.4 Denmarkb
2.9 Estonia
1.4 Finland
1.8 France
1.8 Germany
3.3 Greece
1.6 Hungary
1.0 Iceland
1.6 Irelandb
1.8 Italy

– Latvia

1.0 Liechtenstein
3.1 Lithuania
15.0 Luxembourg
4.8 Malta
1.3 Netherlands
0.8 Norwayb
2.7 Poland
1.9 Portugal
2.6 Romania
1.5 Slovakia
1.5 Slovenia
1.7 Spain
1.1 Sweden
2.0 Subtotal EU/EEA
Non-EU/EEA

2.9 Albania
1.0 Andorra
3.1 Armenia
1.8 Azerbaijan
2.9 Belarus
1.6 Bosnia and Herzegovina
2.0 Georgia
1.7 Israel
1.0 Kazakhstan
1.4 Kyrgyzstan
– Monaco
2.6 Montenegro
2.0 North Macedonia
3.1 Republic of Moldova
2.3 Russian Federation

– San Marino

0.8 Serbia

Serbia excluding Kosovo1
Kosovo1

–
0.8
1.3 Switzerland
1.1 Tajikistan
1.3 Turkey
1.5 Turkmenistan
2.4 Ukraine
1.4 United Kingdomb
1.2 Uzbekistan
1.8 Subtotal non-EU/EEA
1.8 Total European Region
1.9 Subtotal 18 HPCs

Note: European Region comprises the 53 countries of the WHO European Region and Liechtenstein. WHO European Region 18 TB HPCs are presented in italics. 

1 All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999).

a Cases with unknown previous TB history are included among new TB cases.

b Previous TB history is defined by previous diagnosis.

1 All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999). 

75

Tuberculosis surveillance and monitoring in Europe 2022SURVEILLANCE REPORT 
 
 
 
 
 
 
 
 
 
 
  
Table 9. TB cases by origin, European Region, 2020

Native
N

Foreign

Unknown origin

All TB cases

(%)

N

(%)

N

(%)

Country/area

EU/EEA
Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
Subtotal EU/EEA
Non-EU/EEA
Albania
Andorra
Armenia
Azerbaijan
Belarus
Bosnia and Herzegovina
Georgia
Israel
Kazakhstan
Kyrgyzstan
Monaco
Montenegro
North Macedonia
Republic of Moldova
Russian Federation
San Marino
Serbia

Serbia excluding Kosovo1
Kosovo1
Switzerland
Tajikistan
Turkey
Turkmenistan
Ukraine
United Kingdom
Uzbekistan
Subtotal non-EU/EEA
Total European Region
Subtotal 18 HPCs

Origin 
criterion

Citizenship
Citizenship
Birthplace
Birthplace
Birthplace
Birthplace
Birthplace
Birthplace
Birthplace
Birthplace
Birthplace
Citizenship
Citizenship
Birthplace
Birthplace
Birthplace
–
Birthplace
Birthplace
Birthplace
Birthplace
Birthplace
Birthplace
Citizenship
Birthplace
Birthplace
Birthplace
Birthplace
Birthplace
Birthplace
–

Citizenship
Citizenship
Citizenship
–
Citizenship
Birthplace
–
Birthplace
Citizenship
Birthplace
–
Citizenship
Birthplace
Citizenship
Citizenship
Birthplace
–
–
Birthplace
Birthplace
–
Birthplace
Citizenship
Citizenship
Birthplace
Birthplace
–
–
–

	173
	358
 928
	183
	5
	241
	61
 88
	106
1	377
1	132
	156
	387
	1
	68
	992
–
	0
 713
	5
	3
	164
	30
3	272
1	051
7 666
	152
	51
1	584
	44
20 991

		240
  2
  440
–
	1	778
  352
–
  24
 9 842
	4	885
0
		36
  141
 1 898
	83	453
–
		440
–
		440
  111
–
 7 505
 2 610
 19 490
 1 335
 14 127
 148 709
 169 700
 155 423

(44.6)
(43.1)
(99.8)
(100.0)
(13.9)
(65.7)
(27.9)
(71.0)
(60.9)
(29.9)
(27.4)
(39.4)
(95.3)
(8.3)
(28.3)
(43.4)
–
(0.0)
(98.2)
(14.7)
(2.1)
(26.3)
(18.8)
(96.6)
(72.7)
(99.6)
(96.2)
(66.2)
(52.0)
(13.4)
(63.3)

(100.0)
(100.0)
(99.1)
–
(100.0)
(98.6)
–
(15.2)
(98.2)
(100.0)
–
(90.0)
(95.3)
(99.6)
(98.2)
–
(99.8)
–
(99.8)
(28.7)
–
(84.1)
(100.0)
(99.8)
(29.9)
(100.0)
(95.7)
(90.0)
(98.0)

	215
	472
 2
	0
	31
	126
	158
 36
	66
2	719
2	817
	240
	19
	11
	108
1	273
–
	2
 13
	29
	137
	451
	130
	116
	393
 32
	6
	26
1	030
	284
10 942

		0
  0
  4
–
		0
  5
–
  134
  178
		0
0
		4
  7
  8
	1	503
–
		1
–
		1
  276
–
 1 420
0
  31
3 123
  0
 6 694
 17 636
 3 227

(55.4)
(56.9)
(0.2)
(0.0)
(86.1)
(34.3)
(72.1)
(29.0)
(37.9)
(59.0)
(68.3)
(60.6)
(4.7)
(91.7)
(45.0)
(55.7)
–
(100.0)
(1.8)
(85.3)
(97.9)
(72.4)
(81.3)
(3.4)
(27.2)
(0.4)
(3.8)
(33.8)
(33.8)
(86.6)
(33.0)

(0.0)
(0.0)
(0.9)
–
(0.0)
(1.4)
–
(84.8)
(1.8)
(0.0)
–
(10.0)
(4.7)
(0.4)
(1.8)
–
(0.2)
–
(0.2)
(71.3)
–
(15.9)
(0.0)
(0.2)
(70.1)
(0.0)
(4.3)
(9.4)
(2.0)

	0
	0
 0
	0
	0
	0
	0
 0
	2
	510
	178
	0
	0
	0
	64
	22
–
	0
 0
	0
	0
	8
	0
	0
	1
 0
	0
	0
	430
	0
1 215

–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
  0
 1 215
  0

(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(1.1)
(11.1)
(4.3)
(0.0)
(0.0)
(0.0)
(26.7)
(1.0)
–
(0.0)
(0.0)
(0.0)
(0.0)
(1.3)
(0.0)
(0.0)
(0.1)
(0.0)
(0.0)
(0.0)
(14.1)
(0.0)
(3.7)

–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
(0.0)
(0.6)
(0.0)

N

	388
	830
 930
	183
	36
	367
	219
 124
	174
4	606
4	127
	396
	406
	12
	240
2	287
–
	2
 726
	34
	140
	623
	160
3	388
1	445
7 698
	158
	77
3	044
	328
33 148

		240
  2
  444
–
	1	778
  357
–
  158
 10 020
	4	885
0
		40
  148
 1 906
	84	956
–
		441
–
		441
  387
–
 8 925
 2 610
 19 521
4 458
 14 127
 155 403
 188 551
 158 650

Note: European Region comprises the 53 countries of the WHO European Region and Liechtenstein. WHO European Region 
18 TB HPCs are presented in italics. 
HPCs: high-priority countries.
1 All references to Kosovo in this document should be understood to be in the context of the United Nations Security 
Council resolution 1244 (1999).

76

SURVEILLANCE REPORTTuberculosis surveillance and monitoring in Europe 2022Table 10. Drug-resistance surveillance of bacteriologically confirmeda pulmonary TB cases, European Region, 2020

Country/area

Source of data 

Coverage

Bacteriologically confirmed 
casesa
N

(%)

EU/EEA
Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
Subtotal EU/EEA
Non-EU/EEA
Albania
Andorra
Armenia
Azerbaijan
Belarus
Bosnia and Herzegovina
Georgia
Israel
Kazakhstan
Kyrgyzstan
Monaco
Montenegro
North Macedonia
Republic of Moldova
Russian Federation
San Marino
Serbia

Serbia excluding Kosovo1
Kosovo1
Switzerland
Tajikistan
Turkey
Turkmenistan
Ukraine
United Kingdom
Uzbekistan
Subtotal non-EU/EEA
Total European Region
Subtotal 18 HPCs

TESSy
TESSy
TESSy
TESSy
TESSy
TESSy
TESSy
TESSy
TESSy
TESSy
TESSy
TESSy
TESSy
TESSy
TESSy
NRL–TMEd
–
TESSy
TESSy
TESSy
TESSy
TESSy
TESSy
TESSy
TESSy
TESSy
TESSy
TESSy
TESSy
TESSy
–

NRL–TME
NRL–TME
NRL–TME
NRL–TME
NRL–TME
NRL–TME
NRL–TME
NRL–TME
NRL–TME
NRL–TME
–
NRL–TME
NRL–TME
NRL–TME
NRL–TME
–
NRL–TME
NRL–TME
NRL–TME
NRL–TME
NRL–TME
NRL–TME
–
NRL–TME
TESSy
NRL–TME
–
–
–

National
National
National
National
National
National
National
National
National
National
National
National
National
National
National
Partial
–
National
National
National
National
National
National
National
National
National
National
National
National
National
–

National
National
National
National
National
National
National
National
National
National
–
National
National
National
National
National
National
National
National
Subnational
National
National
–
National
National
National
–
–
–

		227
		461
  424
		99
		27
		254
		134
  100
		103
	1	388
	2	468
		299
		196
		5
		103
	1	390
	–	
0
  617
		23
		27
		264
		84
	2	573
		724
 5 473
		65
		62
	1	420
		180
 19 190

147
		1
  251
 3 617
 1 584
		240
 1 370
		90
 7 084
 2 635
		0
		31
		105
 1 261
 45 055
–
–
–
–
		271
 2 023
 4 523
–
 13 177
	1	927
 5 713
 91 105
 110 295
 94 907

(76.9)
(80.3)
(56.8)
(95.2)
(90.0)
(79.1)
(83.8)
(87.0)
(87.3)
(44.2)
(85.0)
(92.3)
(50.5)
(62.5)
(81.7)
(84.6)
–
–
(91.3)
(88.5)
(27.3)
(79.0)
(87.5)
(79.5)
(71.9)
(82.2)
(48.1)
(93.9)
(63.8)
(87.0)
(74.5)

(73.1)
(100.0)
(74.5)
(82.6)
(95.5)
(72.3)
(92.9)
(79.6)
(78.3)
(66.0)
–
(81.6)
(83.3)
(69.3)
(56.3)
–
–
–
–
(86.3)
(69.2)
(78.0)
–
(73.6)
(79.7)
(60.1)
(64.0)
(65.6)
(64.6)

Cases with DST results at 
least for  RIF

N

220
441
243
		84
		27
		233
		134
  100
		102
		47
	2	197
		289
		177
		5
		98
	1	009
–
		0
  617
		22
		27
		250
		84
	2	350
		467
 4 803
		64
		62
		665
		180
 14 997

138
		1
  246
 3 505
 1 584
		231
 1 355
		90
 7 074
 2 439
–
		31
		91
 1 207
 42 022
–
–
–
–
		171
 2 023
 4 074
–
 12 818
	1	622
 5 713
 86 435
 101 432
 89 823

(%)

(96.9)
(95.7)
(57.3)
(84.8)
(100.0)
(91.7)
(100.0)
(100.0)
(99.0)
(3.4)
(89.0)
(96.7)
(90.3)
(100.0)
(95.1)
(72.6)
–
–
(100.0)
(95.7)
(100.0)
(94.7)
(100.0)
(91.3)
(64.5)
(87.8)
(98.5)
(100.0)
(46.8)
(100.0)
(78.2)

(93.9)
(100.0)
(98.0)
(96.9)
(100.0)
(96.3)
(98.9)
(100.0)
(99.9)
(92.6)
–
(100.0)
(86.7)
(95.7)
(93.3)
–
–
–
–
(63.1)
(100.0)
(90.1)
–
(97.3)
(84.2)
(100.0)
(94.9)
(92.0)
(94.6)

Note: European Region comprises the 53 countries of the WHO European Region and Liechtenstein. WHO European Region 18 TB HPCs are presented in italics. The resistance pattern at the 
initiation of treatment is reported to TESSy irrespective of the method used for drug-susceptibility testing or resistance prediction.
DST: drug-susceptibility testing. 
HPCs: high-priority countries. 
MDR-TB: multidrug-resistant tuberculosis. 
N: no.
NRL: national reference laboratory.
RIF: rifampicin.
TESSy: The European Surveillance System. 
TME: WHO global TB data-collection system.
Y: yes.
1 All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999). 

78

Cases resistant to RIF   

MDR-TB casesb

All pulmonary  

TB cases

Reporting 

completenessc

104

(16.9)

N

12

2

9

1

0

11

2

19

0

47

69

7

11

0

0

39

–

0

0

0

4

2

40

7

244

1

1

12

5

 649 

4

		0

  52

  701

  825

		0

  191

		5

 2 859

  870

  413

 21 963

–

		0

		2

–

–

–

–

		4

  555

  127

–

 4 177

35

 1 400

 34 183

 34 832

 34 512

(19.0)

(0.0)

(100.0)

(%)

(0.9)

(2.0)

(4.9)

(1.2)

(0.0)

(4.7)

(1.5)

(3.1)

(2.4)

(6.2)

(0.0)

(0.0)

(3.9)

–

–

(0.0)

(0.0)

(1.6)

(2.4)

(1.7)

(1.5)

(5.1)

(1.6)

(1.6)

(1.8)

(2.8)

(4.3)

(2.9)

(0.0)

(21.1)

(20.0)

(52.1)

(0.0)

(14.1)

(5.6)

(40.4)

(35.7)

–

(0.0)

(2.2)

(34.2)

(52.3)

–

–

–

–

–

(2.3)

(27.4)

(3.1)

(32.6)

(2.2)

(24.5)

(39.5)

(34.3)

(38.4)

N

1	

7	

9 

1	

0	

11	

2	

19 

0	

47	

57	

34	

103 

36	

6	

203 

5	

7	

0	

0	

–

0	

0	

0	

3	

1	

1	

0	

8	

5	

 566 

–

  0

  49

  122

  787

  0

  165

		5

 2 328

  715

  275

 20 569

–

		0

		0

–

–

–

–

  0

  324

  108

–

 3 076

25	

 1 394

 29 942

 30 508

 30 246

(%)

(0.5)

(1.6)

(3.8)

(1.2)

(0.0)

(4.7)

(1.5)

(19.4)

(0.0)

(100.0)

(2.6)

(1.7)

(4.0)

(0.0)

(0.0)

(3.4)

–

–

(16.7)

(0.0)

(0.0)

(1.2)

(1.2)

(1.5)

(1.3)

(4.2)

(1.6)

(0.0)

(1.2)

(2.8)

(3.8)

–

(0.0)

(21.5)

(10.5)

(49.7)

(0.0)

(14.0)

(5.6)

(32.9)

(29.3)

–

(0.0)

(0.0)

(30.8)

(48.9)

–

–

–

–

–

(0.0)

(19.7)

(2.7)

(24.0)

(1.5)

(25.6)

(36.2)

(31.2)

(35.1)

N

	295	

	574	

 746 

		104

		30

		321

		160

  115

		118

	3	140

	2	903

		324

		388

		8

		126

	1	643

–

		0

  676

		26

		99

		334

		96

	3	237

	1	007

 6 655

		135

		66

	2	225

		207

  201

  1

  337

 4 380

 1 658

  332

 1 475

		113

 9 051

 3 992

–

		38

		126

 1 819

 25 758

 79 963

–

–

–

–

–

  314

 2 925

 5 802

 17 915

	2	419

 9 503

 142 364

 168 122

 147 012

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

N

N

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

–

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

–

Y

Y

Y

Y

–

N

N

N

N

Y

Y

N

Y

Y

Y

–

–

–

EU/EEA

Austria

Belgium

Bulgaria

Croatia

Cyprus

Czechia

Denmark

Estonia

Finland

France

Germany

Greece

Hungary

Iceland

Ireland

Italy

Latvia

Liechtenstein

Lithuania

Luxembourg

Malta

Netherlands

Norway

Poland

Portugal

Romania

Slovakia

Slovenia

Spain

Sweden

Albania

Andorra

Armenia

Azerbaijan

Belarus

Georgia

Israel

Kazakhstan

Kyrgyzstan

Monaco

Montenegro

Subtotal EU/EEA

Non-EU/EEA

Bosnia and Herzegovina

Serbia excluding Kosovo1

North Macedonia

Republic of Moldova

Russian Federation

San Marino

Serbia

Kosovo1

Switzerland

Tajikistan

Turkey

Turkmenistan

Ukraine

United Kingdom

Uzbekistan

Subtotal non-EU/EEA

Total European Region

Subtotal 18 HPCs

SURVEILLANCE REPORTTuberculosis surveillance and monitoring in Europe 2022 
Table 10. Drug-resistance surveillance of bacteriologically confirmeda pulmonary TB cases, European Region, 2020

Country/area

Source of data 

Coverage

Bacteriologically confirmed 

Cases with DST results at 

least for  RIF

casesa

N

EU/EEA

Austria

Belgium

Bulgaria

Croatia

Cyprus

Czechia

Denmark

Estonia

Finland

France

Germany

Greece

Hungary

Iceland

Ireland

Italy

Latvia

Liechtenstein

Lithuania

Luxembourg

Malta

Netherlands

Norway

Poland

Portugal

Romania

Slovakia

Slovenia

Spain

Sweden

Albania

Andorra

Armenia

Azerbaijan

Belarus

Georgia

Israel

Kazakhstan

Kyrgyzstan

Monaco

Montenegro

Subtotal EU/EEA

Non-EU/EEA

Bosnia and Herzegovina

Serbia excluding Kosovo1

North Macedonia

Republic of Moldova

Russian Federation

San Marino

Serbia

Kosovo1

Switzerland

Tajikistan

Turkey

Turkmenistan

Ukraine

United Kingdom

Uzbekistan

Subtotal non-EU/EEA

Total European Region

Subtotal 18 HPCs

NRL–TMEd

TESSy

TESSy

TESSy

TESSy

TESSy

TESSy

TESSy

TESSy

TESSy

TESSy

TESSy

TESSy

TESSy

TESSy

TESSy

–

TESSy

TESSy

TESSy

TESSy

TESSy

TESSy

TESSy

TESSy

TESSy

TESSy

TESSy

TESSy

TESSy

–

NRL–TME

NRL–TME

NRL–TME

NRL–TME

NRL–TME

NRL–TME

NRL–TME

NRL–TME

NRL–TME

NRL–TME

NRL–TME

NRL–TME

NRL–TME

NRL–TME

NRL–TME

NRL–TME

NRL–TME

NRL–TME

NRL–TME

NRL–TME

NRL–TME

TESSy

NRL–TME

–

–

–

–

–

–

National

National

National

National

National

National

National

National

National

National

National

National

National

National

National

Partial

–

National

National

National

National

National

National

National

National

National

National

National

National

National

–

National

National

National

National

National

National

National

National

National

National

–

National

National

National

National

National

National

National

National

Subnational

National

National

National

National

National

–

–

–

–

(%)

(76.9)

(80.3)

(56.8)

(95.2)

(90.0)

(79.1)

(83.8)

(87.0)

(87.3)

(44.2)

(85.0)

(92.3)

(50.5)

(62.5)

(81.7)

(84.6)

–

–

(91.3)

(88.5)

(27.3)

(79.0)

(87.5)

(79.5)

(71.9)

(82.2)

(48.1)

(93.9)

(63.8)

(87.0)

(74.5)

(73.1)

(100.0)

(74.5)

(82.6)

(95.5)

(72.3)

(92.9)

(79.6)

(78.3)

(66.0)

–

(81.6)

(83.3)

(69.3)

(56.3)

–

–

–

–

–

(86.3)

(69.2)

(78.0)

(73.6)

(79.7)

(60.1)

(64.0)

(65.6)

(64.6)

		227

		461

  424

		99

		27

		254

		134

  100

		103

	1	388

	2	468

		299

		196

		5

		103

	1	390

	–	

0

  617

		23

		27

		264

		84

	2	573

		724

 5 473

		65

		62

	1	420

		180

 19 190

147

		1

  251

 3 617

 1 584

		240

 1 370

		90

 7 084

 2 635

		0

		31

		105

 1 261

 45 055

–

–

–

–

–

		271

 2 023

 4 523

 13 177

	1	927

 5 713

 91 105

 110 295

 94 907

N

220

441

243

		84

		27

		233

		134

  100

		102

		47

	2	197

		289

		177

		5

		98

	1	009

–

		0

  617

		22

		27

		250

		84

	2	350

		467

 4 803

		64

		62

		665

		180

138

		1

  246

 3 505

 1 584

		231

 1 355

		90

 7 074

 2 439

–

		31

		91

 14 997

 1 207

 42 022

–

–

–

–

–

		171

 2 023

 4 074

 12 818

	1	622

 5 713

 86 435

 101 432

 89 823

(%)

(96.9)

(95.7)

(57.3)

(84.8)

(100.0)

(91.7)

(100.0)

(100.0)

(99.0)

(3.4)

(89.0)

(96.7)

(90.3)

(100.0)

(95.1)

(72.6)

–

–

(100.0)

(95.7)

(100.0)

(94.7)

(100.0)

(91.3)

(64.5)

(87.8)

(98.5)

(100.0)

(46.8)

(100.0)

(78.2)

(93.9)

(100.0)

(98.0)

(96.9)

(100.0)

(96.3)

(98.9)

(100.0)

(99.9)

(92.6)

(100.0)

(86.7)

(95.7)

(93.3)

–

–

–

–

–

–

(63.1)

(100.0)

(90.1)

(97.3)

(84.2)

(100.0)

(94.9)

(92.0)

(94.6)

Cases resistant to RIF   

MDR-TB casesb

All pulmonary  
TB cases

N

2
9
12
1
0
11
2
19
0
47
69
7
11
0
0
39
–
0
104
0
0
4
2
40
7
244
1
1
12
5
 649 

4
		0
  52
  701
  825
		0
  191
		5
 2 859
  870
–
		0
		2
  413
 21 963
–
–
–
–
		4
  555
  127
–
 4 177
35
 1 400
 34 183
 34 832
 34 512

(%)

(0.9)
(2.0)
(4.9)
(1.2)
(0.0)
(4.7)
(1.5)
(19.0)
(0.0)
(100.0)
(3.1)
(2.4)
(6.2)
(0.0)
(0.0)
(3.9)
–
–
(16.9)
(0.0)
(0.0)
(1.6)
(2.4)
(1.7)
(1.5)
(5.1)
(1.6)
(1.6)
(1.8)
(2.8)
(4.3)

(2.9)
(0.0)
(21.1)
(20.0)
(52.1)
(0.0)
(14.1)
(5.6)
(40.4)
(35.7)
–
(0.0)
(2.2)
(34.2)
(52.3)
–
–
–
–
(2.3)
(27.4)
(3.1)
–
(32.6)
(2.2)
(24.5)
(39.5)
(34.3)
(38.4)

N

1	
7	
9 
1	
0	
11	
2	
19 
0	
47	
57	
5	
7	
0	
0	
34	
–
0	
103 
0	
0	
3	
1	
36	
6	
203 
1	
0	
8	
5	
 566 

–
  0
  49
  122
  787
  0
  165
		5
 2 328
  715
–
		0
		0
  275
 20 569
–
–
–
–
  0
  324
  108
–
 3 076
25	
 1 394
 29 942
 30 508
 30 246

(%)

(0.5)
(1.6)
(3.8)
(1.2)
(0.0)
(4.7)
(1.5)
(19.4)
(0.0)
(100.0)
(2.6)
(1.7)
(4.0)
(0.0)
(0.0)
(3.4)
–
–
(16.7)
(0.0)
(0.0)
(1.2)
(1.2)
(1.5)
(1.3)
(4.2)
(1.6)
(0.0)
(1.2)
(2.8)
(3.8)

–
(0.0)
(21.5)
(10.5)
(49.7)
(0.0)
(14.0)
(5.6)
(32.9)
(29.3)
–
(0.0)
(0.0)
(30.8)
(48.9)
–
–
–
–
(0.0)
(19.7)
(2.7)
–
(24.0)
(1.5)
(25.6)
(36.2)
(31.2)
(35.1)

N

	295	
	574	
 746 
		104
		30
		321
		160
  115
		118
	3	140
	2	903
		324
		388
		8
		126
	1	643
–
		0
  676
		26
		99
		334
		96
	3	237
	1	007
 6 655
		135
		66
	2	225
		207
 25 758

  201
  1
  337
 4 380
 1 658
  332
 1 475
		113
 9 051
 3 992
–
		38
		126
 1 819
 79 963
–
–
–
–
  314
 2 925
 5 802
–
 17 915
	2	419
 9 503
 142 364
 168 122
 147 012

Reporting 
completenessc

Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
N
N
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
–

Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
–
Y
Y
Y
Y
–
N
N
N
N
Y
Y
N
Y
Y
Y
–
–
–

EU/EEA
Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
Subtotal EU/EEA
Non-EU/EEA
Albania
Andorra
Armenia
Azerbaijan
Belarus
Bosnia and Herzegovina
Georgia
Israel
Kazakhstan
Kyrgyzstan
Monaco
Montenegro
North Macedonia
Republic of Moldova
Russian Federation
San Marino
Serbia

Serbia excluding Kosovo1
Kosovo1
Switzerland
Tajikistan
Turkey
Turkmenistan
Ukraine
United Kingdom
Uzbekistan
Subtotal non-EU/EEA
Total European Region
Subtotal 18 HPCs

a Bacteriologically confirmed cases – cases with positive identification for Mycobacterium tuberculosis complex confirmed by culture and/or line probe assay for non-EU/EEA countries and 
areas. For EU/EEA countries: cases with positive identification for Mycobacterium tuberculosis complex confirmed by culture and/or line probe assay.  
b Includes cases that are MDR but that also meet the pre-XDR or XDR case definitions (pre-XDR and XDR cases have not been excluded).
c Data are considered complete when national coverage is 100% OR culture results are available for 90% of all cases, and 50% of all cases are culture-positive, and 75% of them have DST 
results, and external quality-assessment results have been accurate in 95% of samples of reported year.  
d Laboratory-related data from Italy are reported by the NRL and may differ from data shown elsewhere in this report. 
1 All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999). 

79

Tuberculosis surveillance and monitoring in Europe 2022SURVEILLANCE REPORT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 11. Drug-resistance surveillance of bacteriologically confirmeda pulmonary TB cases by previous TB treatment history, 
European Region, 2020

New cases with 
DST results to RIF 

New RR/MDR-TB 
casesc

 New 
bacteriologically 
confirmed 
pulmonary TB 
cases

New pulmonary TB 
cases

Previously treated 
cases with DST 
results to RIF 

Previously treated 
RR/MDR-TB casesc

Previously 
treated 
bacteriologically 
confirmed 
pulmonary TB 
cases

Previously 
treated 
pulmonary TB 
cases

Total cases with 

DST results to RIF 

Total RR/MDR-TB cases

Total pulmonary 

TB cases

  Total 

bacteriologically 

confirmed 

pulmonary TB 

cases

N

(%) d

N

(%)e

N

(%) f

N

(%) g

N

(%) d

N

(%)e

N

(%) f

N

(%) g

N

(%) h

(%)i

N

(%) g

N

(%) j

EU/EEA
Austria
Belgiumk
Bulgaria
Croatia
Cyprus
Czechia
Denmarkk
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Irelandk
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norwayk 
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
Subtotal EU/EEA 
Non-EU/EEA
Albania
Andorra
Armenia
Azerbaijan
Belarus
Bosnia and Herzegovina
Georgia
Israel
Kazakhstan
Kyrgyzstan
Monaco
Montenegro
North Macedonia
Republic of Moldova
Russian Federation
San Marino
Serbia

Serbia excluding Kosovo1
Kosovo1
Switzerland
Tajikistan
Turkey
Turkmenistan
Ukraine
United Kingdomk
Uzbekistan
Subtotal non-EU/EEA 
Total European Region
Subtotal 18 HPCs 

			173
			320
   207
			0
			25
			223
			127
   89
			100
			20
		1	553
			251
			156
			0
			66
			983
–
   0
   483
   18
			18
			243
			76
		2	017
			439
  3 608
			51
			57
			627
			169
  12 099

		125
		1
		198
	1	245
 1 015
		208
 1 064
		89
 4 858
 1 741
–
  29
		81
  840
 21 099
–
–
–
–
		171
 1 683
 3 777
–
	8	793
1	546
 3 946
 52 509
 64 608
 54 646

(97.2)
(96.4)
(56.1)
(0.0)
(100.0)
(91.8)
(100.0)
(100.0)
(99.0)
(2.9)
(90.9)
(96.9)
(90.7)
(0.0)
(98.5)
(100.0)
–
(0.0)
(100.0)
(94.7)
(100.0)
(95.3)
(100.0)
(92.0)
(64.8)
(87.8)
(98.1)
(100.0)
(68.9)
(100.0)
(84.3)

(93.3)
(100.0)
(99.5)
(93.5)
(100.0)
(97.7)
(99.8)
(100.0)
(99.9)
(92.0)
–
(100.0)
(85.3)
(95.3)
(92.5)
–
–
–
–
(90.5)
(100.0)
(90.5)
–
(97.2)
(99.1)
(100.0)
(94.9)
(92.7)
(94.3)

0
2
5
0
0
8
1
16
0
20
33
5
6
0
0
33
–
0
61
0
0
4
2
29
4
85
0
1
11
4
335

		1
		0
		28
		149
  401
		0
  114
		5
 1 758
  493
–
  0
		1
  218
 7 657
–
–
–
–
		4
  408
  94
0
	2	515
31
  721
 14 598
 14 933
 14 723

(0.0)
(0.6)
(2.4)
(0.0)
(0.0)
(3.6)
(0.8)
(18.0)
(0.0)
(100.0)
(2.1)
(2.0)
(3.8)
(0.0)
(0.0)
(3.4)
–
(0.0)
(12.6)
(0.0)
(0.0)
(1.6)
(2.6)
(1.4)
(0.9)
(2.4)
(0.0)
(1.8)
(1.8)
(2.4)
(2.8)

(0.8)
(0.0)
(14.1)
(12.0)
(39.5)
(0.0)
(10.7)
(5.6)
(36.2)
(28.3)
–
(0.0)
(1.2)
(26.0)
(36.3)
–
–
–
–
(2.3)
(24.2)
(2.5)
–
(28.6)
(1.2)
(18.3)
(27.8)
(23.1)
(26.9)

		178
		332
  369
		1
		25
		243
		127
  89
		101
		685
	1	708
		259
		172
		0
		67
		983
–
		0
  483
  19
		18
		255
		76
	2	192
		677
 4 109
		52
		57
		910
		169
 14 356

		134
		1
		199
	1	331
 1 015
		213
 1 066
		89
 4 862
 1 892
–
  29
		95
  881
 22 811
–
–
–
–
		189
 1 683
 4 172
–
	9	042
	1	693
 3 946
 55 343
 69 699
 57 950

(80.2)
(79.6)
(57.2)
(100.0)
(89.3)
(78.9)
(84.7)
(88.1)
(88.6)
(45.5)
(87.0)
(91.8)
(50.3)
–
(82.7)
(90.5)
–
–
(89.1)
(90.5)
(25.4)
(79.4)
(88.4)
(79.1)
(72.1)
(81.6)
(46.8)
(96.6)
(68.9)
(87.6)
(76.7)

(72.4)
(100.0)
(75.7)
(68.1)
(93.6)
(75.0)
(92.2)
(80.2)
(80.4)
(69.4)
–
(80.6)
(85.6)
(69.7)
(52.6)
–
–
–
–
(72.7)
(67.6)
(78.0)
–
(70.6)
(75.9)
(61.2)
(62.8)
(65.2)
(63.5)

		222
		417
  645
		1
		28
		308
		150
  101
		114
	1	507
	1	964
		282
		342
		0
		81
	1	086
–
		0
  542
  21
		71
		321
		86
	2	770
		939
 5 038
		111
		59
	1	320
		193
 18 719

		185
		1
		263
	1	954
 1 084
		284
 1 156
		111
 6 051
 2 725
–
  36
		111
 1 264
 43 357
–
–
–
–
		260
 2 488
 5 346
–
	12	813
	2	253
 6 451
 88 193
 106 912
 91 278

(92.5)
(92.3)
(86.5)
(12.5)
(93.3)
(96.0)
(93.8)
(87.8)
(96.6)
(90.8)
(91.6)
(94.9)
(88.1)
(0.0)
(92.0)
(91.3)
–
(0.0)
(80.2)
(91.3)
(100.0)
(96.1)
(89.6)
(85.6)
(93.2)
(75.7)
(84.7)
(90.8)
(94.6)
(93.7)
(85.7)

(92.0)
(100.0)
(78.0)
(44.6)
(65.4)
(85.5)
(78.3)
(98.2)
(66.9)
(68.3)
–
(94.7)
(88.1)
(69.5)
(54.2)
–
–
–
–
(82.8)
(85.1)
(92.1)
–
(71.5)
(92.7)
(67.9)
(61.9)
(65.1)
(62.1)

5
22
  36
		6
		2
		10
		7
  11
		2
		11
		95
		14
		21
		0
		6
		26
–
		0
  134
  1
		0
		7
		8
		333
		28
 1 195
		11
		4
		30
		10
 2 035

		13
		0
		48
	2	260
  569
		23
  291
		1
 2 216
  698
–
  2
		10
  367
 20 923
–
–
–
–
		0
  340
  297
–
	4	025
		76
 1 767
 33 926
 35 961
 35 177

(100.0)
(91.7)
(65.5)
(85.7)
(100.0)
(90.9)
(100.0)
(100.0)
(100.0)
(16.2)
(80.5)
(93.3)
(87.5)
(0.0)
(100.0)
(32.5)
–
(0.0)
(100.0)
(100.0)
(0.0)
(77.8)
(100.0)
(87.4)
(59.6)
(87.6)
(100.0)
(100.0)
(58.8)
(100.0)
(82.9)

(100.0)
–
(92.3)
(98.9)
(100.0)
(85.2)
(95.7)
–
(99.7)
(93.9)
–
(100.0)
(100.0)
(96.6)
(94.1)
–
–
–
–
(0.0)
(100.0)
(84.6)
–
(97.3)
(96.8)
(100.0)
(95.3)
(94.5)
(95.2)

1
0
4
1
0
3
1
3
0
11
5
1
5
0
0
6
–
0
43
0
0
0
0
11
3
159
1
0
1
1
260

		3
		0
		24
		552
  424
		0
  77
		0
 1 101
  377
–
  0
		1
  195
 14 306
–
–
–
–
0
  147
  33
–
	1	662
4
  679
 19 585
 19 845
 19 786

(20.0)
(0.0)
(11.1)
(16.7)
(0.0)
(30.0)
(14.3)
(27.3)
(0.0)
(100.0)
(5.3)
(7.1)
(23.8)
(0.0)
(0.0)
(23.1)
–
(0.0)
(32.1)
(0.0)
(0.0)
(0.0)
(0.0)
(3.3)
(10.7)
(13.3)
(9.1)
(0.0)
(3.3)
(10.0)
(12.8)

(23.1)
–
(50.0)
(24.4)
(74.5)
(0.0)
(26.5)
–
(49.7)
(54.0)
–
(0.0)
(10.0)
(53.1)
(68.4)
–
–
–
–
–
(43.2)
(11.1)
–
(41.3)
(2.5)
(38.4)
(57.7)
(55.2)
(56.2)

5
		24
  55
		7
		2
		11
		7
  11
		2
		68
		118
		15
		24
		0
		6
		80
–
		0
  134
  1
		0
		9
		8
		381
		47
 1 364
		11
		4
		51
		10
 2 455

		13
		0
		52
	2	286
  569
		27
  304
		1
 2 222
  743
–
  2
		10
  380
 22 244
–
–
–
–
		27
  340
  351
–
	4	135
		118
 1 767
 35 591
 38 046
 36 957

(27.8)
(68.6)
(54.5)
(100.0)
(100.0)
(84.6)
(70.0)
(78.6)
(50.0)
(44.4)
(65.2)
(100.0)
(52.2)
(0.0)
(85.7)
(76.9)
–
(0.0)
(100.0)
(50.0)
(0.0)
(69.2)
(80.0)
(81.6)
(69.1)
(84.4)
(55.0)
(66.7)
(67.1)
(76.9)
(78.3)

(81.3)
–
(70.3)
(94.2)
(99.1)
(56.3)
(95.0)
–
(74.1)
(58.6)
–
(100.0)
(66.7)
(68.5)
(60.8)
–
–
–
–
(50.0)
(77.8)
(77.0)
–
(81.0)
(62.7)
(57.9)
(65.7)
(66.4)
(66.3)

		18
		35
  101
		7
		2
		13
		10
  14
		4
		153
		181
		15
		46
		0
		7
		104
–
		0
  134
  2
		0
		13
		10
		467
		68
 1 617
		20
		6
		76
		13
 3 136

		16
		0
		74
	2	426
  574
		48
  320
		2
 3 000
 1 267
–
  2
		15
  555
 36 606
–
–
–
–
		54
  437
  456
–
	5	102
		166
 3 052
 54 172
 57 308
 55 735

(7.5)
(7.7)
(13.5)
(87.5)
(6.7)
(4.0)
(6.3)
(12.2)
(3.4)
(9.2)
(8.4)
(5.1)
(11.9)
(0.0)
(8.0)
(8.7)
–
(0.0)
(19.8)
(8.7)
(0.0)
(3.9)
(10.4)
(14.4)
(6.8)
(24.3)
(15.3)
(9.2)
(5.4)
(6.3)
(14.4)

(8.0)
–
(22.0)
(55.4)
(34.6)
(14.5)
(21.7)
(1.8)
(33.1)
(31.7)
–
(5.3)
(11.9)
(30.5)
(45.8)
–
–
–
–
(17.2)
(14.9)
(7.9)
–
(28.5)
(7.3)
(32.1)
(38.1)
(34.9)
(37.9)

Note: European Region comprises the 53 countries of the WHO European Region and Liechtenstein. WHO European Region 18 TB HPCs are presented in italics. The resistance pattern at 
the initiation of treatment is reported to TESSy irrespective of the method used for DST or resistance prediction.
DST: drug-susceptibility testing.
HPCs: high-priority countries.
RIF: rifampicin.
RR/MDR: rifampicin-resitant and multidrug-resistant (tuberculosis).
TESSy: The European Surveillance System.
a Bacteriologically confirmed cases – cases with positive identification for Mycobacterium tuberculosis complex confirmed by culture and/or line probe assay for non-EU/EEA countries 
and areas. For EU/EEA countries: culture-positive OR microscopy-positive and nucleic acid amplification test-positive cases. 
b Pulmonary TB cases with unknown previous TB treatment history are excluded.
1 All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999).
80

N

12

2

3

1

0

11

2

19

0

31

38

6

11

0

0

39

–

0

0

0

4

2

104

40

7

244

1

1

12

5

595

		4

		0

		52

		701

  825

		0

  191

		5

 2 859

  870

  413

 21 963

–

		0

		2

–

–

–

–

		4

  555

  127

–

 4 177

  35

 1 400

 34 183

 34 778

 34 512

178

342

  243

		6

		27

		233

		134

  100

		102

		31

	1	648

		265

		177

		0

		72

	1	009

–

		0

  617

  19

		18

		250

		84

	2	350

		467

 4 803

		62

		61

		657

		179

 14 134

		138

		1

		246

	3	505

 1 584

		231

 1 355

		90

 7 074

 2 439

–

		31

		91

 1 207

 42 022

–

–

–

–

–

		171

 2 023

 4 074

 12 818

 1 622

 5 713

 86 435

 100 569

 89 823

(97.3)

(96.1)

(57.3)

(75.0)

(100.0)

(91.7)

(100.0)

(100.0)

(99.0)

(4.1)

(90.3)

(96.7)

(90.3)

(0.0)

(98.6)

(94.9)

–

(0.0)

(100.0)

(95.0)

(100.0)

(94.7)

(100.0)

(91.3)

(64.5)

(87.8)

(98.4)

(100.0)

(68.4)

(100.0)

(84.1)

(93.9)

(100.0)

(98.0)

(96.9)

(100.0)

(96.3)

(98.9)

(100.0)

(99.9)

(92.6)

(100.0)

(86.7)

(95.7)

(93.3)

–

–

–

–

–

–

(79.2)

(100.0)

(90.1)

(97.3)

(98.9)

(100.0)

(95.1)

(93.3)

(94.6)

	1	190

(52.0)

Italy

EU/EEA

(61.9) Austria

(54.5) Belgiumk

(80.2) Bulgaria

(4.4) Croatia

(83.3) Cyprus

(87.5) Czechia

(73.1) Denmarkk

(92.7) Estonia

(67.8) Finland

(36.0) France

(52.0) Germany

(75.0) Greece

(95.6) Hungary

(0.0)

Iceland

(36.7)

Irelandk

– Latvia

(0.0) Liechtenstein

(93.1) Lithuania

(67.6) Luxembourg

(50.7) Malta

(53.6) Netherlands

(60.0) Norwayk 

(95.5) Poland

(69.7) Portugal

(86.5) Romania

(82.9) Slovakia

(84.4) Slovenia

(45.9) Spain

(62.8) Sweden

Non-EU/EEA

(83.8) Albania

(50.0) Andorra

(75.9) Armenia

(87.8) Azerbaijan

(93.3) Belarus

(80.2) Georgia

(71.5)

Israel

(90.3) Kazakhstan

(81.7) Kyrgyzstan

– Monaco

240

		452

  746

		8

		30

		321

		160

  115

		118

	1	660

	2	145

		297

		388

		0

		88

–

		0

  676

  23

		71

		334

		96

	3	237

	1	007

 6 655

		131

		65

	1	396

		206

		201

		1

		337

	4	380

 1 658

		332

 1 476

		113

 9 051

 3 992

		0

		38

		126

–

–

–

–

–

(100.0)

(0.6)

(0.6)

(3.7)

(16.7)

(0.0)

(4.7)

(1.5)

(19.0)

(0.0)

(2.3)

(2.3)

(6.2)

(0.0)

(0.0)

(3.9)

–

(0.0)

(16.9)

(0.0)

(0.0)

(1.6)

(2.4)

(1.7)

(1.5)

(5.1)

(1.6)

(1.6)

(1.8)

(2.8)

(4.2)

(2.9)

(0.0)

(21.1)

(20.0)

(52.1)

(0.0)

(14.1)

(5.6)

(40.4)

(35.7)

–

(0.0)

(2.2)

(34.2)

(52.3)

–

–

–

–

–

(2.3)

(27.4)

(3.1)

(32.6)

(1.2)

(24.5)

(39.5)

(34.6)

(38.4)

		183

		356

  424

		8

		27

		254

		134

  100

		103

		753

	1	826

		274

		196

		0

		73

	1	063

–

		0

  617

  20

		18

		264

		84

	2	573

		724

 5 473

		63

		61

		961

		179

 16 811

		251

	3	617

 1 584

		240

 1 370

		90

 7 084

 2 635

–

		31

		105

 1 261

 45 055

–

–

–

–

–

		216

 2 023

 4 523

 13 177

 1 811

 5 713

 90 934

 107 745

 94 907

(76.3)

(78.8)

(56.8)

(100.0)

(90.0)

(79.1)

(83.8)

(87.0)

(87.3)

(45.4)

(85.1)

(92.3)

(50.5)

(0.0)

(83.0)

(89.3)

–

(0.0)

(91.3)

(87.0)

(25.4)

(79.0)

(87.5)

(79.5)

(71.9)

(82.2)

(48.1)

(93.8)

(68.8)

(86.9)

(76.9)

(74.5)

(82.6)

(95.5)

(72.3)

(92.8)

(79.6)

(78.3)

(66.0)

–

(81.6)

(83.3)

(69.3)

(56.3)

–

–

–

–

–

(68.8)

(69.2)

(78.0)

(73.6)

(74.9)

(60.1)

(63.9)

(65.6)

(64.6)

(95.0) Montenegro

(85.1) North Macedonia

 1 819

 79 963

(95.4) Republic of Moldova

(94.1) Russian Federation

– San Marino

– Serbia

–

–

Kosovo1

Serbia excluding Kosovo1

		314

 2 925

 5 802

(81.1) Switzerland

(67.8) Tajikistan

(65.0) Turkey

 17 915

 2 419

 9 503

 142 365

 164 220

 147 013

– Turkmenistan

(91.8) Ukraine

(53.3) United Kingdomk

(67.3) Uzbekistan

(87.1) Subtotal non-EU/EEA 

(83.5) Total European Region

(85.6) Subtotal 18 HPCs 

 21 855

(66.0) Subtotal EU/EEA 

		147

(73.1)

		1

(100.0)

(93.0) Bosnia and Herzegovina

SURVEILLANCE REPORTTuberculosis surveillance and monitoring in Europe 2022Table 11. Drug-resistance surveillance of bacteriologically confirmeda pulmonary TB cases by previous TB treatment history, 

European Region, 2020

New cases with 

DST results to RIF 

New RR/MDR-TB 

casesc

New pulmonary TB 

cases

Previously treated 

cases with DST 

results to RIF 

Previously treated 

RR/MDR-TB casesc

 New 

bacteriologically 

confirmed 

pulmonary TB 

cases

Previously 

treated 

bacteriologically 

confirmed 

pulmonary TB 

cases

Previously 

treated 

pulmonary TB 

cases

Total cases with 
DST results to RIF 

Total RR/MDR-TB cases

  Total 
bacteriologically 
confirmed 
pulmonary TB 
cases

Total pulmonary 
TB cases

11

(100.0)

43

  134

(100.0)

  134

EU/EEA

Austria

Belgiumk

Bulgaria

Croatia

Cyprus

Czechia

Denmarkk

Estonia

Finland

France

Germany

Greece

Hungary

Iceland

Irelandk

Italy

Latvia

Liechtenstein

Lithuania

Luxembourg

Malta

Netherlands

Norwayk 

Poland

Portugal

Romania

Slovakia

Slovenia

Spain

Sweden

Albania

Andorra

Armenia

Azerbaijan

Belarus

Georgia

Israel

Kazakhstan

Kyrgyzstan

Monaco

Montenegro

San Marino

Serbia

Kosovo1

Switzerland

Tajikistan

Turkey

Turkmenistan

Ukraine

Subtotal EU/EEA 

Non-EU/EEA

Bosnia and Herzegovina

North Macedonia

Republic of Moldova

Russian Federation

Serbia excluding Kosovo1

United Kingdomk

Uzbekistan

Subtotal non-EU/EEA 

Total European Region

Subtotal 18 HPCs 

			173

			320

   207

			0

			25

			223

			127

   89

			100

			20

		1	553

			251

			156

			0

			66

			983

–

   0

   483

   18

			18

			243

			76

		2	017

			439

  3 608

			51

			57

			627

			169

  12 099

		125

		1

		198

	1	245

 1 015

		208

 1 064

		89

 4 858

 1 741

–

  29

		81

  840

 21 099

–

–

–

–

–

		171

 1 683

 3 777

	8	793

1	546

 3 946

 52 509

 64 608

 54 646

(97.2)

(96.4)

(56.1)

(0.0)

(100.0)

(91.8)

(100.0)

(100.0)

(99.0)

(2.9)

(90.9)

(96.9)

(90.7)

(0.0)

(98.5)

(100.0)

–

(0.0)

(100.0)

(94.7)

(100.0)

(95.3)

(100.0)

(92.0)

(64.8)

(87.8)

(98.1)

(100.0)

(68.9)

(100.0)

(84.3)

(93.3)

(100.0)

(99.5)

(93.5)

(100.0)

(97.7)

(99.8)

(100.0)

(99.9)

(92.0)

(100.0)

(85.3)

(95.3)

(92.5)

–

–

–

–

–

–

(90.5)

(100.0)

(90.5)

(97.2)

(99.1)

(100.0)

(94.9)

(92.7)

(94.3)

N

0

2

5

0

0

8

1

16

0

20

33

33

61

5

6

0

0

–

0

0

0

4

2

29

4

85

0

1

11

4

335

		1

		0

		28

		149

  401

		0

  114

		5

 1 758

  493

  218

 7 657

–

  0

		1

–

–

–

–

		4

  408

  94

0

	2	515

31

  721

 14 598

 14 933

 14 723

(%)e

(0.0)

(0.6)

(2.4)

(0.0)

(0.0)

(3.6)

(0.8)

(18.0)

(0.0)

(100.0)

(2.1)

(2.0)

(3.8)

(0.0)

(0.0)

(3.4)

–

(0.0)

(12.6)

(0.0)

(0.0)

(1.6)

(2.6)

(1.4)

(0.9)

(2.4)

(0.0)

(1.8)

(1.8)

(2.4)

(2.8)

(0.8)

(0.0)

(14.1)

(12.0)

(39.5)

(0.0)

(10.7)

(5.6)

(36.2)

(28.3)

–

(0.0)

(1.2)

(26.0)

(36.3)

–

–

–

–

–

(2.3)

(24.2)

(2.5)

(28.6)

(1.2)

(18.3)

(27.8)

(23.1)

(26.9)

		178

		332

  369

		1

		25

		243

		127

  89

		101

		685

	1	708

		259

		172

		0

		67

		983

–

		0

  483

  19

		18

		255

		76

	2	192

		677

 4 109

		52

		57

		910

		169

 14 356

		134

		1

		199

	1	331

 1 015

		213

 1 066

		89

 4 862

 1 892

–

  29

		95

  881

 22 811

–

–

–

–

–

		189

 1 683

 4 172

	9	042

	1	693

 3 946

 55 343

 69 699

 57 950

(80.2)

(79.6)

(57.2)

(100.0)

(89.3)

(78.9)

(84.7)

(88.1)

(88.6)

(45.5)

(87.0)

(91.8)

(50.3)

(82.7)

(90.5)

–

–

–

(89.1)

(90.5)

(25.4)

(79.4)

(88.4)

(79.1)

(72.1)

(81.6)

(46.8)

(96.6)

(68.9)

(87.6)

(76.7)

(72.4)

(100.0)

(75.7)

(68.1)

(93.6)

(75.0)

(92.2)

(80.2)

(80.4)

(69.4)

–

(80.6)

(85.6)

(69.7)

(52.6)

–

–

–

–

–

(72.7)

(67.6)

(78.0)

(70.6)

(75.9)

(61.2)

(62.8)

(65.2)

(63.5)

		222

		417

  645

		1

		28

		308

		150

  101

		114

	1	507

	1	964

		282

		342

		0

		81

	1	086

–

		0

  542

  21

		71

		321

		86

	2	770

		939

 5 038

		111

		59

	1	320

		193

 18 719

		185

		1

		263

	1	954

 1 084

		284

 1 156

		111

 6 051

 2 725

–

  36

		111

 1 264

 43 357

–

–

–

–

–

		260

 2 488

 5 346

	12	813

	2	253

 6 451

 88 193

 106 912

 91 278

(92.5)

(92.3)

(86.5)

(12.5)

(93.3)

(96.0)

(93.8)

(87.8)

(96.6)

(90.8)

(91.6)

(94.9)

(88.1)

(0.0)

(92.0)

(91.3)

–

(0.0)

(80.2)

(91.3)

(100.0)

(96.1)

(89.6)

(85.6)

(93.2)

(75.7)

(84.7)

(90.8)

(94.6)

(93.7)

(85.7)

(92.0)

(100.0)

(78.0)

(44.6)

(65.4)

(85.5)

(78.3)

(98.2)

(66.9)

(68.3)

–

(94.7)

(88.1)

(69.5)

(54.2)

–

–

–

–

–

(82.8)

(85.1)

(92.1)

(71.5)

(92.7)

(67.9)

(61.9)

(65.1)

(62.1)

5

22

  36

		6

		2

		10

		7

  11

		2

		11

		95

		14

		21

		0

		6

		26

–

		0

  134

  1

		0

		7

		8

		333

		28

 1 195

		11

		4

		30

		10

 2 035

		13

		0

		48

	2	260

  569

		23

  291

		1

 2 216

  698

–

  2

		10

  367

–

–

–

–

		0

  340

  297

–

	4	025

		76

 1 767

 33 926

 35 961

 35 177

(100.0)

(91.7)

(65.5)

(85.7)

(100.0)

(90.9)

(100.0)

(100.0)

(100.0)

(16.2)

(80.5)

(93.3)

(87.5)

(0.0)

(100.0)

(32.5)

–

(0.0)

(100.0)

(100.0)

(0.0)

(77.8)

(100.0)

(87.4)

(59.6)

(87.6)

(100.0)

(100.0)

(58.8)

(100.0)

(82.9)

(100.0)

–

(92.3)

(98.9)

(100.0)

(85.2)

(95.7)

(99.7)

(93.9)

(100.0)

(100.0)

(96.6)

(94.1)

–

–

–

–

–

–

–

(0.0)

(100.0)

(84.6)

(97.3)

(96.8)

(100.0)

(95.3)

(94.5)

(95.2)

1

0

4

1

0

3

1

3

0

5

1

5

0

0

6

–

0

0

0

0

0

1

0

1

1

11

3

159

260

		3

		0

		24

		552

  424

		0

  77

		0

 1 101

  377

–

  0

		1

  195

 14 306

–

–

–

–

0

–

4

  147

  33

	1	662

  679

 19 585

 19 845

 19 786

N

5

		24

  55

		7

		2

		11

		7

  11

		2

		68

		118

		15

		24

		80

		0

		6

–

		0

  1

		0

		9

		8

		11

		4

		51

		10

		13

		0

		52

		381

		47

 1 364

	2	286

  569

		27

  304

		1

 2 222

  743

–

  2

		10

  380

–

–

–

–

		27

  340

  351

–

	4	135

		118

 1 767

 35 591

 38 046

 36 957

(20.0)

(0.0)

(11.1)

(16.7)

(0.0)

(30.0)

(14.3)

(27.3)

(0.0)

(5.3)

(7.1)

(23.8)

(0.0)

(0.0)

(23.1)

–

(0.0)

(32.1)

(0.0)

(0.0)

(0.0)

(0.0)

(3.3)

(10.7)

(13.3)

(9.1)

(0.0)

(3.3)

(10.0)

(12.8)

(23.1)

–

(50.0)

(24.4)

(74.5)

(0.0)

(26.5)

(49.7)

(54.0)

(0.0)

(10.0)

(53.1)

–

–

–

–

–

–

–

–

(43.2)

(11.1)

(41.3)

(2.5)

(38.4)

(57.7)

(55.2)

(56.2)

(27.8)

(68.6)

(54.5)

(100.0)

(100.0)

(84.6)

(70.0)

(78.6)

(50.0)

(44.4)

(65.2)

(100.0)

(52.2)

(0.0)

(85.7)

(76.9)

–

(0.0)

(50.0)

(0.0)

(69.2)

(80.0)

(81.6)

(69.1)

(84.4)

(55.0)

(66.7)

(67.1)

(76.9)

(81.3)

–

(70.3)

(94.2)

(99.1)

(56.3)

(95.0)

(74.1)

(58.6)

(100.0)

(66.7)

(68.5)

(60.8)

–

–

–

–

–

–

–

(50.0)

(77.8)

(77.0)

(81.0)

(62.7)

(57.9)

(65.7)

(66.4)

(66.3)

		18

		35

  101

		7

		2

		13

		10

  14

		4

		153

		181

		15

		46

		104

		0

		7

–

		0

  2

		0

		13

		10

		467

		68

 1 617

		20

		6

		76

		13

		16

		0

		74

	2	426

  574

		48

  320

		2

 3 000

 1 267

–

  2

		15

  555

–

–

–

–

		54

  437

  456

–

	5	102

		166

 3 052

 54 172

 57 308

 55 735

(7.5)

(7.7)

(13.5)

(87.5)

(6.7)

(4.0)

(6.3)

(12.2)

(3.4)

(9.2)

(8.4)

(5.1)

(11.9)

(0.0)

(8.0)

(8.7)

–

(0.0)

(19.8)

(8.7)

(0.0)

(3.9)

(10.4)

(14.4)

(6.8)

(24.3)

(15.3)

(9.2)

(5.4)

(6.3)

(8.0)

–

(22.0)

(55.4)

(34.6)

(14.5)

(21.7)

(1.8)

(33.1)

(31.7)

–

(5.3)

(11.9)

(30.5)

(45.8)

–

–

–

–

–

(17.2)

(14.9)

(7.9)

(28.5)

(7.3)

(32.1)

(38.1)

(34.9)

(37.9)

 2 455

(78.3)

 3 136

(14.4)

 20 923

(68.4)

 22 244

 36 606

N

(%) d

N

(%) f

N

(%) g

N

(%) d

N

(%)e

(%) f

N

(%) g

N

(%) h

178
342
  243
		6
		27
		233
		134
  100
		102
		31
	1	648
		265
		177
		0
		72
	1	009
–
		0
  617
  19
		18
		250
		84
	2	350
		467
 4 803
		62
		61
		657
		179
 14 134

		138
		1
		246
	3	505
 1 584
		231
 1 355
		90
 7 074
 2 439
–
		31
		91
 1 207
 42 022
–
–
–
–
		171
 2 023
 4 074
–
 12 818
 1 622
 5 713
 86 435
 100 569
 89 823

(97.3)
(96.1)
(57.3)
(75.0)
(100.0)
(91.7)
(100.0)
(100.0)
(99.0)
(4.1)
(90.3)
(96.7)
(90.3)
(0.0)
(98.6)
(94.9)
–
(0.0)
(100.0)
(95.0)
(100.0)
(94.7)
(100.0)
(91.3)
(64.5)
(87.8)
(98.4)
(100.0)
(68.4)
(100.0)
(84.1)

(93.9)
(100.0)
(98.0)
(96.9)
(100.0)
(96.3)
(98.9)
(100.0)
(99.9)
(92.6)
–
(100.0)
(86.7)
(95.7)
(93.3)
–
–
–
–
(79.2)
(100.0)
(90.1)
–
(97.3)
(98.9)
(100.0)
(95.1)
(93.3)
(94.6)

N

2
3
12
1
0
11
2
19
0
31
38
6
11
0
0
39
–
0
104
0
0
4
2
40
7
244
1
1
12
5
595

		4
		0
		52
		701
  825
		0
  191
		5
 2 859
  870
–
		0
		2
  413
 21 963
–
–
–
–
		4
  555
  127
–
 4 177
  35
 1 400
 34 183
 34 778
 34 512

(%)i

N

(%) g

N

(%) j

(0.6)
(0.6)
(3.7)
(16.7)
(0.0)
(4.7)
(1.5)
(19.0)
(0.0)
(100.0)
(2.3)
(2.3)
(6.2)
(0.0)
(0.0)
(3.9)
–
(0.0)
(16.9)
(0.0)
(0.0)
(1.6)
(2.4)
(1.7)
(1.5)
(5.1)
(1.6)
(1.6)
(1.8)
(2.8)
(4.2)

(2.9)
(0.0)
(21.1)
(20.0)
(52.1)
(0.0)
(14.1)
(5.6)
(40.4)
(35.7)
–
(0.0)
(2.2)
(34.2)
(52.3)
–
–
–
–
(2.3)
(27.4)
(3.1)
–
(32.6)
(1.2)
(24.5)
(39.5)
(34.6)
(38.4)

		183
		356
  424
		8
		27
		254
		134
  100
		103
		753
	1	826
		274
		196
		0
		73
	1	063
–
		0
  617
  20
		18
		264
		84
	2	573
		724
 5 473
		63
		61
		961
		179
 16 811

		147
		1
		251
	3	617
 1 584
		240
 1 370
		90
 7 084
 2 635
–
		31
		105
 1 261
 45 055
–
–
–
–
		216
 2 023
 4 523
–
 13 177
 1 811
 5 713
 90 934
 107 745
 94 907

(76.3)
(78.8)
(56.8)
(100.0)
(90.0)
(79.1)
(83.8)
(87.0)
(87.3)
(45.4)
(85.1)
(92.3)
(50.5)
(0.0)
(83.0)
(89.3)
–
(0.0)
(91.3)
(87.0)
(25.4)
(79.0)
(87.5)
(79.5)
(71.9)
(82.2)
(48.1)
(93.8)
(68.8)
(86.9)
(76.9)

(73.1)
(100.0)
(74.5)
(82.6)
(95.5)
(72.3)
(92.8)
(79.6)
(78.3)
(66.0)
–
(81.6)
(83.3)
(69.3)
(56.3)
–
–
–
–
(68.8)
(69.2)
(78.0)
–
(73.6)
(74.9)
(60.1)
(63.9)
(65.6)
(64.6)

240
		452
  746
		8
		30
		321
		160
  115
		118
	1	660
	2	145
		297
		388
		0
		88
	1	190
–
		0
  676
  23
		71
		334
		96
	3	237
	1	007
 6 655
		131
		65
	1	396
		206
 21 855

		201
		1
		337
	4	380
 1 658
		332
 1 476
		113
 9 051
 3 992
		0
		38
		126
 1 819
 79 963
–
–
–
–
		314
 2 925
 5 802
–
 17 915
 2 419
 9 503
 142 365
 164 220
 147 013

EU/EEA
(61.9) Austria
(54.5) Belgiumk
(80.2) Bulgaria
(4.4) Croatia
(83.3) Cyprus
(87.5) Czechia
(73.1) Denmarkk
(92.7) Estonia
(67.8) Finland
(36.0) France
(52.0) Germany
(75.0) Greece
(95.6) Hungary
Iceland
(0.0)
Irelandk
(36.7)
Italy
(52.0)
– Latvia

(0.0) Liechtenstein
(93.1) Lithuania
(67.6) Luxembourg
(50.7) Malta
(53.6) Netherlands
(60.0) Norwayk 
(95.5) Poland
(69.7) Portugal
(86.5) Romania
(82.9) Slovakia
(84.4) Slovenia
(45.9) Spain
(62.8) Sweden
(66.0) Subtotal EU/EEA 

Non-EU/EEA

(83.8) Albania
(50.0) Andorra
(75.9) Armenia
(87.8) Azerbaijan
(93.3) Belarus
(93.0) Bosnia and Herzegovina
(80.2) Georgia
Israel
(71.5)
(90.3) Kazakhstan
(81.7) Kyrgyzstan
– Monaco
(95.0) Montenegro
(85.1) North Macedonia
(95.4) Republic of Moldova
(94.1) Russian Federation

– San Marino
– Serbia
–
–

Serbia excluding Kosovo1
Kosovo1

(81.1) Switzerland
(67.8) Tajikistan
(65.0) Turkey

– Turkmenistan

(91.8) Ukraine
(53.3) United Kingdomk
(67.3) Uzbekistan
(87.1) Subtotal non-EU/EEA 
(83.5) Total European Region
(85.6) Subtotal 18 HPCs 

c Includes cases that are RR/MDR but that also meet the pre-XDR or XDR case definitions (pre-XDR and XDR cases have not been excluded).
d Proportion of bacteriologically confirmed pulmonary TB cases with DST results with the respective previous TB treatment history.
e Proportion of bacteriologically confirmed pulmonary RR/MDR-TB cases with DST results and the respective previous TB treatment history.
f Proportion of all pulmonary TB cases with the respective previous TB treatment history.
g Proportion of all pulmonary TB cases. For EU/EEA, excluding the cases with unknown previous TB treatment history.
h Proportion of all bacteriologically confirmed pulmonary TB cases with DST results. For EU/EEA, excluding the cases with unknown previous TB treatment history.
i Proportion of all bacteriologically confirmed pulmonary RR/MDR-TB cases with DST results. For EU/EEA, excluding the cases with unknown previous TB treatment 
history.
j Proportion of all TB cases. 
k Previous TB history is defined by previous diagnosis.
1 All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999).

81

Tuberculosis surveillance and monitoring in Europe 2022SURVEILLANCE REPORTTable 12. Pre-XDR-TB and XDR-TB cases among bacteriologically confirmeda pulmonary RR/MDR-TB cases, European Region, 2020

Country/area

Source of data

Coverage

Bacteriologically 
confirmed pulmonary 
RR/MDR-TB casesb
N

(%)

Cases with DST results 
for any 
fluoroquinolone 

N

(%)

EU/EEA
Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
Subtotal EU/EEA
Non-EU/EEA
Albania
Andorra
Armenia
Azerbaijan
Belarus
Bosnia and Herzegovina
Georgia
Israel
Kazakhstan
Kyrgyzstan
Monaco
Montenegro
North Macedonia
Republic of Moldova
Russian Federation
San Marino
Serbia

Serbia excluding Kosovo1
Kosovo1
Switzerland
Tajikistan
Turkey
Turkmenistan
Ukraine
United Kingdom
Uzbekistan
Subtotal non-EU/EEA
Total European Region
Subtotal 18 HPCs

TESSy
TESSy
TESSy
TESSy
TESSy
TESSy
TESSy
TESSy
TESSy
TESSy
TESSy
TESSy
TESSy
TESSy
TESSy
NRL–TME
–
TESSy
TESSy
TESSy
TESSy
TESSy
TESSy
TESSy
TESSy
TESSy
TESSy
TESSy
TESSy
TESSy
–

NRL–TME
NRL–TME
NRL–TME
NRL–TME
NRL–TME
–
NRL–TME
NRL–TME
–
NRL–TME
–
NRL–TME
NRL–TME
NRL–TME
NRL–TME
–
–
–
–
NRL–TME
NRL–TME
NRL–TME
–
NRL–TME

NRL–TME
–
–
–

National
National
National
National
National
National
National
National
National
National
National
National
National
National
National
Partial
–
National
National
National
National
National
National
National
National
National
National
National
National
National
–

National
National
National
National
National
–
National
National
–
National
–
National
National
National
National
National
–
–
–
National
National
National
–
National
National
National
–
–
–

2	
9	
12 
1	
0	
11	
2	
19 
0	
47	
69	
7	
11	
0	
0	
39	
–
0	
104 
0	
0	
4	
2	
40	
7	
244 
1	
1	
12	
5	
 649 

			4
			0
   52
   701
   825
			0
   191
			5
  2 859
   870
0	
			0
			2
   413
  21 963
–
–
–
–
			4
   555
   127
–
  4 177
35	
  1 400
 34 183
 34 832
 34 512

(0.9)
(2.0)
(5.0)
(1.2)
(0.0)
(4.7)
(1.5)
(19.4)
(0.0)
(100.0)
(3.1)
(2.4)
(6.3)
(0.0)
(0.0)
(3.9)
–
(0.0)
(16.9)
(0.0)
(0.0)
(1.6)
(2.4)
(1.7)
(1.5)
(5.1)
(1.6)
(1.6)
(1.8)
(2.8)
(4.6)

(2.9)
(0.0)
(21.1)
(20.0)
(52.1)
(0.0)
(14.1)
(5.6)
(40.4)
(35.7)
–
(0.0)
(2.2)
(34.2)
(52.3)
–
–
–
–
(2.3)
(27.4)
(3.1)
–
(32.6)
(2.2)
(24.5)
(39.5)
(34.6)
(38.4)

2	
5	
10 
0	
0	
7	
2	
19 
0	
41	
51	
3	
10	
0	
0	
34	
–
0	
104 
0	
0	
4	
2	
14	
3	
96 
1	
1	
3	
5	
 417 

			0
–
   52
   576
   825
–
   173
			5
  2 848
   869
–
–
			0
   413
  20 449
–
–
–
–
			4
   512
   99
–
  4 177
32	
  1 400
 32 434
 32 851
 32 622

(100.0)
(55.6)
(83.3)
(0.0)
(0.0)
(63.6)
(100.0)
(100.0)
(0.0)
(87.2)
(73.9)
(42.9)
(90.9)
(0.0)
(0.0)
(87.2)
–
(0.0)
(100.0)
(0.0)
(0.0)
(100.0)
(100.0)
(35.0)
(42.9)
(39.3)
(100.0)
(100.0)
(25.0)
(100.0)
(64.3)

(0.0)
–
(100.0)
(82.2)
(100.0)
–
(90.6)
(100.0)
(99.6)
(99.9)
–
–
(0.0)
(100.0)
(93.1)
–
–
–
–
(100.0)
(92.3)
(78.0)
–
(100.0)
(91.4)
(100.0)
(94.9)
(94.3)
(94.5)

Pre-XDR-TB casesc

N

0	
1	
2 
0	
0	
4	
0	
6 
0	
8	
10	
0	
0	
0	
0	
8	
–
0	
34 
0	
0	
0	
0	
12	
0	
27 
0	
0	
1	
2	
 115 

–
–
   11
   87
   354
–
   50
			1
   399
   149
–
–
–
   188
  7 822
–
–
–
–
			2
   121
   14
–
  1 120
8	
   378
 10 704
 10 819
 10 762

(%)

(0.0)
(20.0)
(20.0)
(0.0)
(0.0)
(57.1)
(0.0)
(31.6)
(0.0)
(19.5)
(19.6)
(0.0)
(0.0)
(0.0)
(0.0)
(23.5)
–
(0.0)
(32.7)
(0.0)
(0.0)
(0.0)
(0.0)
(85.7)
(0.0)
(28.1)
(0.0)
(0.0)
(33.3)
(40.0)
(27.6)

–
–
(21.2)
(15.1)
(42.9)
–
(28.9)
(20.0)
(14.0)
(17.1)
–
–
–
(45.5)
(38.3)
–
–
–
–
(50.0)
(23.6)
(14.1)
–
(26.8)
(25.0)
(27.0)
(33.0)
(32.9)
(33.0)

Note: WHO European Region 18 TB HPCs are presented in italics. The resistance pattern at the initiation of treatment is reported to TESSy irrespective of the method used for DST or 
resistance prediction. 
DST: drug-susceptibility testing.
HPCs: high-priority countries.
MDR-TB: multidrug-resistant tuberculosis.
N: no. 
NRL: national reference laboratory.
TESSy: The European surveillance system.
TME: WHO global TB data-collection system.
XDR-TB: extensively drug-resistant tuberculosis. 
Y: yes.
1 All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999). 

82

Cases with DST results 

for any other  

Group A drugs

XDR-TB casesd

Reporting 

completenesse Country/area

N

(%)

N

(%)

10

34

10

82

0

1

2

0

0

4

0

6

0

8

0

0

0

0

–

–

0

0

0

0

0

0

4

0

0

1

2

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

2

(0.0)

(100.0)

(100.0)

(0.0)

(0.0)

(100.0)

(0.0)

(100.0)

(0.0)

(100.0)

(100.0)

(0.0)

(0.0)

(0.0)

(0.0)

–

–

(0.0)

(100.0)

(0.0)

(0.0)

(0.0)

(0.0)

(83.3)

(0.0)

(14.8)

(0.0)

(0.0)

(100.0)

(100.0)

(71.3)

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

188

2  474

(100.0)

(31.6)

121

13

–

591

–

378

 3 816

 3 898

 3 860

(100.0)

(100.0)

(92.9)

(52.8)

(100.0)

(35.7)

(36.0)

(35.9)

(100.0)

(45.1)

37

12

0

1

0

0

0

4

0

6

0

0

6

0

0

0

0

–

–

0

0

0

0

0

4

0

2

0

0

0

2

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

1

3

–

–

9

19

87

31

52

  216

  253

  235

(0.0)

(100.0)

(0.0)

(0.0)

(0.0)

(100.0)

(0.0)

(100.0)

(0.0)

(0.0)

(60.0)

(0.0)

(0.0)

(0.0)

(0.0)

–

–

(0.0)

(35.3)

(0.0)

(0.0)

(0.0)

(0.0)

(40.0)

(0.0)

(50.0)

(0.0)

(0.0)

(0.0)

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

(10.1)

(3.5)

(50.0)

(25.6)

(23.1)

(8.8)

(2.4)

(5.7)

(6.5)

(6.1)

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

N

N

–

–

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

–

Y

Y

Y

Y

–

N

N

N

N

Y

Y

N

Y

Y

Y

–

–

–

Austria

Belgium

Bulgaria

Croatia

Cyprus

Czechia

Denmark

Estonia

Finland

France

Germany

Greece

Hungary

Iceland

Ireland

Italy

Latvia

Liechtenstein

Lithuania

Luxembourg

Malta

Netherlands

Norway

Poland

Portugal

Romania

Slovakia

Slovenia

Spain

Sweden

Albania

Andorra

Armenia

Azerbaijan

Belarus

Georgia

Israel

Kazakhstan

Kyrgyzstan

Monaco

Montenegro

Subtotal EU/EEA

Non-EU/EEA

Serbia excluding Kosovo1

North Macedonia

Republic of Moldova

Russian Federation

San Marino

Serbia

Kosovo1

Switzerland

Tajikistan

Turkey

Turkmenistan

Ukraine

United Kingdom

Uzbekistan

Subtotal non-EU/EEA

Total European Region

Subtotal 18 HPCs

49

(98.0)

14

(28.6)

Bosnia and Herzegovina

SURVEILLANCE REPORTTuberculosis surveillance and monitoring in Europe 2022 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 12. Pre-XDR-TB and XDR-TB cases among bacteriologically confirmeda pulmonary RR/MDR-TB cases, European Region, 2020

Country/area

Source of data

Coverage

Bacteriologically 

confirmed pulmonary 

RR/MDR-TB casesb

Cases with DST results 

for any 

fluoroquinolone 

Pre-XDR-TB casesc

Cases with DST results 
for any other  
Group A drugs

XDR-TB casesd

Reporting 

completenesse Country/area

EU/EEA

Austria

Belgium

Bulgaria

Croatia

Cyprus

Czechia

Denmark

Estonia

Finland

France

Germany

Greece

Hungary

Iceland

Ireland

Italy

Latvia

Liechtenstein

Lithuania

Luxembourg

Malta

Netherlands

Norway

Poland

Portugal

Romania

Slovakia

Slovenia

Spain

Sweden

Albania

Andorra

Armenia

Azerbaijan

Belarus

Georgia

Israel

Kazakhstan

Kyrgyzstan

Monaco

Montenegro

Subtotal EU/EEA

Non-EU/EEA

Bosnia and Herzegovina

Serbia excluding Kosovo1

North Macedonia

Republic of Moldova

Russian Federation

San Marino

Serbia

Kosovo1

Switzerland

Tajikistan

Turkey

Turkmenistan

Ukraine

United Kingdom

Uzbekistan

Subtotal non-EU/EEA

Total European Region

Subtotal 18 HPCs

NRL–TME

TESSy

TESSy

TESSy

TESSy

TESSy

TESSy

TESSy

TESSy

TESSy

TESSy

TESSy

TESSy

TESSy

TESSy

TESSy

–

TESSy

TESSy

TESSy

TESSy

TESSy

TESSy

TESSy

TESSy

TESSy

TESSy

TESSy

TESSy

TESSy

–

NRL–TME

NRL–TME

NRL–TME

NRL–TME

NRL–TME

NRL–TME

NRL–TME

NRL–TME

NRL–TME

NRL–TME

NRL–TME

NRL–TME

NRL–TME

NRL–TME

NRL–TME

NRL–TME

NRL–TME

–

–

–

–

–

–

–

–

–

–

–

National

National

National

National

National

National

National

National

National

National

National

National

National

National

National

Partial

–

National

National

National

National

National

National

National

National

National

National

National

National

National

–

National

National

National

National

National

National

National

National

National

National

National

National

National

National

National

National

National

National

National

–

–

–

–

–

–

–

–

–

–

104 

104 

N

2	

9	

12 

1	

0	

11	

2	

19 

0	

47	

69	

7	

11	

0	

0	

39	

–

0	

0	

0	

4	

2	

40	

7	

244 

1	

1	

12	

5	

 649 

			4

			0

   52

   701

   825

			0

   191

			5

  2 859

   870

0	

			0

			2

   413

  21 963

–

–

–

–

			4

   555

   127

–

  4 177

35	

  1 400

 34 183

 34 832

 34 512

(%)

(0.9)

(2.0)

(5.0)

(1.2)

(0.0)

(4.7)

(1.5)

(19.4)

(0.0)

(100.0)

(3.1)

(2.4)

(6.3)

(0.0)

(0.0)

(3.9)

–

(0.0)

(16.9)

(0.0)

(0.0)

(1.6)

(2.4)

(1.7)

(1.5)

(5.1)

(1.6)

(1.6)

(1.8)

(2.8)

(4.6)

(2.9)

(0.0)

(21.1)

(20.0)

(52.1)

(0.0)

(14.1)

(5.6)

(40.4)

(35.7)

–

(0.0)

(2.2)

(34.2)

(52.3)

–

–

–

–

–

(2.3)

(27.4)

(3.1)

(32.6)

(2.2)

(24.5)

(39.5)

(34.6)

(38.4)

N

2	

5	

10 

0	

0	

7	

2	

19 

0	

41	

51	

3	

10	

0	

0	

34	

–

0	

0	

0	

4	

2	

14	

3	

96 

1	

1	

3	

5	

–

–

–

–

–

–

 417 

			0

–

   52

   576

   825

–

   173

			5

  2 848

   869

(%)

(100.0)

(55.6)

(83.3)

(0.0)

(0.0)

(63.6)

(100.0)

(100.0)

(0.0)

(87.2)

(73.9)

(42.9)

(90.9)

(0.0)

(0.0)

(87.2)

–

(0.0)

(100.0)

(0.0)

(0.0)

(100.0)

(100.0)

(35.0)

(42.9)

(39.3)

(100.0)

(100.0)

(25.0)

(100.0)

(64.3)

(0.0)

–

(100.0)

(82.2)

(100.0)

(90.6)

(100.0)

(99.6)

(99.9)

–

–

–

–

–

–

–

–

			4

   512

   99

–

  4 177

32	

  1 400

 32 434

 32 851

 32 622

(100.0)

(92.3)

(78.0)

(100.0)

(91.4)

(100.0)

(94.9)

(94.3)

(94.5)

10	

N

0	

1	

2 

0	

0	

4	

0	

6 

0	

8	

0	

0	

0	

0	

8	

–

0	

0	

0	

0	

0	

34 

12	

0	

27 

0	

0	

1	

2	

 115 

–

–

   11

   87

   354

–

   50

			1

   399

   149

–

–

–

–

–

–

–

			2

   121

   14

  1 120

–

8	

   378

 10 704

 10 819

 10 762

(%)

(0.0)

(20.0)

(20.0)

(0.0)

(0.0)

(57.1)

(0.0)

(31.6)

(0.0)

(19.5)

(19.6)

(0.0)

(0.0)

(0.0)

(0.0)

(23.5)

–

(0.0)

(32.7)

(0.0)

(0.0)

(0.0)

(0.0)

(85.7)

(0.0)

(28.1)

(0.0)

(0.0)

(33.3)

(40.0)

(27.6)

(21.2)

(15.1)

(42.9)

(28.9)

(20.0)

(14.0)

(17.1)

–

–

–

–

–

–

–

–

–

–

–

(50.0)

(23.6)

(14.1)

(26.8)

(25.0)

(27.0)

(33.0)

(32.9)

(33.0)

			0

   413

  20 449

(0.0)

(100.0)

(93.1)

   188

  7 822

(45.5)

(38.3)

N

0
1
2
0
0
4
0
6
0
8
10
0
0
0
0
–
–
0
34
0
0
0
0
10
0
4
0
0
1
2
82

–
–
–
–
–
–
49
–
–
–
–
–
–
188
2  474
–
–
–
–
2
121
13
–
591
–
378
 3 816
 3 898
 3 860

(%)

(0.0)
(100.0)
(100.0)
(0.0)
(0.0)
(100.0)
(0.0)
(100.0)
(0.0)
(100.0)
(100.0)
(0.0)
(0.0)
(0.0)
(0.0)
–
–
(0.0)
(100.0)
(0.0)
(0.0)
(0.0)
(0.0)
(83.3)
(0.0)
(14.8)
(0.0)
(0.0)
(100.0)
(100.0)
(71.3)

–
–
–
–
–
–
(98.0)
–
–
–
–
–
–
(100.0)
(31.6)
–
–
–
–
(100.0)
(100.0)
(92.9)
–
(52.8)
–
(100.0)
(35.7)
(36.0)
(35.9)

N

0
1
0
0
0
4
0
6
0
0
6
0
0
0
0
–
–
0
12
0
0
0
0
4
0
2
0
0
0
2
37

–
–
–
–
–
–
14
–
–
–
–
–
–
19
87
–
–
–
–
1
31
3
–
52
–
9
  216
  253
  235

(%)

(0.0)
(100.0)
(0.0)
(0.0)
(0.0)
(100.0)
(0.0)
(100.0)
(0.0)
(0.0)
(60.0)
(0.0)
(0.0)
(0.0)
(0.0)
–
–
(0.0)
(35.3)
(0.0)
(0.0)
(0.0)
(0.0)
(40.0)
(0.0)
(50.0)
(0.0)
(0.0)
(0.0)
(100.0)
(45.1)

–
–
–
–
–
–
(28.6)
–
–
–
–
–
–
(10.1)
(3.5)
–
–
–
–
(50.0)
(25.6)
(23.1)
–
(8.8)
–
(2.4)
(5.7)
(6.5)
(6.1)

Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
N
N
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
–
–
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
–
Y
Y
Y
Y
–
N
N
N
N
Y
Y
N
Y
Y
Y
–
–
–

Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
Subtotal EU/EEA
Non-EU/EEA
Albania
Andorra
Armenia
Azerbaijan
Belarus
Bosnia and Herzegovina
Georgia
Israel
Kazakhstan
Kyrgyzstan
Monaco
Montenegro
North Macedonia
Republic of Moldova
Russian Federation
San Marino
Serbia

Serbia excluding Kosovo1
Kosovo1
Switzerland
Tajikistan
Turkey
Turkmenistan
Ukraine
United Kingdom
Uzbekistan
Subtotal non-EU/EEA
Total European Region
Subtotal 18 HPCs

Note: WHO European Region 18 TB HPCs are presented in italics. The resistance pattern at the initiation of treatment is reported to TESSy irrespective of the method used for DST or 

resistance prediction. 

DST: drug-susceptibility testing.

HPCs: high-priority countries.

MDR-TB: multidrug-resistant tuberculosis.

N: no. 

Y: yes.

NRL: national reference laboratory.

TESSy: The European surveillance system.

TME: WHO global TB data-collection system.

XDR-TB: extensively drug-resistant tuberculosis. 

1 All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999). 

a For EU/EEA countries, bacteriologically confirmed cases are culture-positive OR microscopy-positive and nucleic 
acid amplification test-positive cases. For non-EU/EEA countries and areas, cases with positive identification for 
Mycobacterium tuberculosis complex confirmed by culture and/or line probe assay.  
b RR/MDR-TB defined as resistance to at least rifampicin. Includes cases that are RR/MDR but that also meet the  
pre-XDR or XDR case definitions (pre-XDR and XDR cases have not been excluded). 
c Pre-XDR-TB defined as RR/MDR-TB as well as resistance to any fluoroquinolone.
d XDR-TB defined as resistance to rifampicin and resistance to at least one fluoroquinolone (pre-XDR-TB) as well as 
resistance to at least one additional Group A drug. Group A drugs include: levofloxacin, moxifloxacin, bedaquiline 
and linezolid. For EU/EEA countries, linezolid resistance is not yet reported to TESSy, therefore XDR-TB is assessed 
on resistance to levofloxacin, moxifloxacin and/or bedaquiline.  
e Data	considered	complete	when	collected	nationwide	OR	culture	results	available	for	≥	90%	of	all	cases,	and	>	
50%	of	all	cases	culture-positive,	and	>	75%	of	them	with	DST	results	for	isoniazid	and	rifampicin,	and	≥	95%	of	the	
external quality-assessment results confirmed by a supranational reference laboratory.  
1 All references to Kosovo in this document should be understood to be in the context of the United Nations Security 
Council resolution 1244 (1999). 

83

Tuberculosis surveillance and monitoring in Europe 2022SURVEILLANCE REPORT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 13. RR/MDR-TB and pre-XDR/XDR-TB cases enrolled to treatment, European Region, 2020

Country/area

EU/EEA
Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark 
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
Subtotal EU/EEA 
Non-EU/EEA
Albania
Andorra
Armenia
Azerbaijan
Belarus
Bosnia and Herzegovina
Georgia
Israel
Kazakhstan
Kyrgyzstan
Monaco
Montenegro
North Macedonia
Republic of Moldova
Russian Federation
San Marino
Serbia

Serbia excluding Kosovo1
Kosovo1
Switzerland
Tajikistan
Turkey
Turkmenistan
Ukraine
United Kingdom
Uzbekistan
Subtotal non-EU/EEA
Total European Region
Subtotal 18 HPCs

Total number of 
RR/MDR-TB cases 
detecteda

RR/MDR-TB cases enrolled to 
treatmentbc

Total number of 
pre-XDRd/XDR-TBe 
cases detected

Pre-XDRd/XDR-TBe cases enrolled to 
treatmentbc

N

		2
		14
  10
		1
		0
		7
		2
  13
		1
		59
		81
		12
		11
		0
		1
		39
–
		0
  71
		0
		2
		12
		2
		29
		9
  224
		1
		1
		14
		4
  622

		4
		0
  45
  656
  520
		0
  150
		4
 3 114
  889
		0
		0
		2
  225
 14 141
–
–
–
–
		4
  434
  135
  519
 3 085
–
 1 400
 25 327
 25 949
 25 631

N

		2
		14
  10
		1
–
		7
		0
  13
		0
		59
		74
		12
		10
–
		1
–
–
–
  71
–
		2
		12
		2
		29
		9
  221
		1
		1
		14
		4
  569

		4
		0
  45
  586
  489
		0
  149
		4
 3 400
  833
		0
		0
		2
  483
 20 045
–
–
–
–
		1
  356
  132
  519
 3 527
–
 1 400
 31 975
 32 544
 32 279

(%)

(100.0)
(100.0)
(100.0)
(100.0)
–
(100.0)
(0.0)
(100.0)
(0.0)
(100.0)
(91.4)
(100.0)
(90.9)
–
(100.0)
–
–
–
(100.0)
–
(100.0)
(100.0)
(100.0)
(100.0)
(100.0)
(98.7)
(100.0)
(100.0)
(100.0)
(100.0)
(97.6)

(100.0)
–
(100.0)
(89.3)
(94.0)
–
(99.3)
(100.0)
(109.2)
(93.7)
–
–
(100.0)
(214.7)
(141.8)
–
–
–
–
(25.0)
(82.0)
(97.8)
(100.0)
(114.3)
–
(100.0)
(126.2)
(125.4)
(125.9)

N

		0
		3
  2
		0
		0
		4
		0
  6
		0
		8
		13
		0
		0
		0
		0
		8
–
		0
  34
		0
		0
		0
		0
		13
		0
  28
		0
		0
		1
		2
  122

		0
		0
  7
  108
  354
		0
  52
		1
 1 193
  149
		0
		0
		0
  219
 7 822
–
–
–
–
		1
  123
  14
  264
 1 172
–
  378
 11 857
 11 979
 11 925

N

		0
		3
  2
		0
		0
		4
		0
  5
		0
		8
		13
		0
		0
		0
		0
–
–
		0
  34
		0
		0
		0
		0
		13
		0
  28
		0
		0
		1
		2
  113

		0
		0
  7
  69
  321
		0
  44
		1
 1 178
  67
		0
		0
		0
  209
 6 097
–
–
–
–
		1
  103
  14
  0
 1 350
–
  427
 9 888
 10 001
 9 955

(%)

–
(100.0)
(100.0)
–
–
(100.0)
–
(83.3)
–
(100.0)
(100.0)
–
–
–
–
–
–
–
(100.0)
–
–
–
–
(100.0)
–
(100.0)
–
–
(100.0)
(100.0)
(92.6)

–
–
(100.0)
(63.9)
(90.7)
–
(84.6)
(100.0)
(98.7)
(45.0)
–
–
–
(95.4)
(77.9)
–
–
–
–
(100.0)
(83.7)
(100.0)
(0.0)
(115.2)
–
(113.0)
(83.4)
(83.5)
(83.5)

Note: European Region comprises the 53 countries of the WHO European Region and Liechtenstein. WHO European Region 18 TB HPCs are presented in italics. The 
resistance pattern at the initiation of treatment is reported to TESSy irrespective of the method used for drug-susceptibility testing or resistance prediction. 
HPCs: high-priority countries.
RR/MDR-TB: rifampicin-resitant and multidrug-resistant TB.
TESSy: The European Surveillance System.
XDR-TB: extensively drug-resistant tuberculosis. 
a Excluding pre-XDR and XDR-TB cases. 
b For countries that do not provide information on treatment start, all reported cases are used as proxy.
c For some non-EU/EEA countries and areas, patients who were diagnosed before 2018 but started on treatment in 2018 are included, resulting in over 100% 
coverage. 
d Pre-XDR-TB defined as resistance to rifampicin (RR/MDR-TB) as well as resistance to any fluoroquinolone.
e XDR-TB defined as resistance to rifampicin and to at least one fluoroquinolone (pre-XDR-TB) as well as resistance to at least one additional Group A drug.  
Group A drugs include: levofloxacin, moxifloxacin, bedaquiline and linezolid. For EU/EEA countries, linezolid resistance is not yet reported to TESSy, therefore XDR-TB 
is assessed on resistance to levofloxacin, moxifloxacin and/or bedaquiline (in addition to meeting pre-XDR-TB criteria).  
1 All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999). 

84

SURVEILLANCE REPORTTuberculosis surveillance and monitoring in Europe 2022 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 14. New and relapsea TB cases with HIV infection, European Region, 2020

Country/area

EU/EEA
Austria
Belgiumd
Bulgaria
Croatia
Cyprus
Czechia
Denmarkd
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Irelandd
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norwayd
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
Subtotal EU/EEA
Non-EU/EEA
Albania
Andorra
Armenia
Azerbaijan
Belarus
Bosnia and Herzegovina
Georgia
Israel
Kazakhstan
Kyrgyzstan
Monaco
Montenegro
North Macedonia
Republic of Moldova
Russian Federation
San Marino
Serbia

Serbia excluding Kosovo1
Kosovo1
Switzerland
Tajikistan
Turkey
Turkmenistan
Ukraine
United Kingdomd
Uzbekistan
Subtotal non-EU/EEA
Total European Region
Subtotal 18 HPCs

New and relapse TB 
casesb

TB cases with known HIV status

HIV-positive TB cases

HIV-positive cases started ARTc

N

–
		778
  887
		177
		34
		360
		205
  120
–
–
–
		380
		384
–
		229
–
–
–
  688
		32
–
		614
		144
–
	1	402
 7 193
		153
		75
	2	949
–
 16 804

		240
		2
  394
 3 683
 1 514
		357
 1 669
		158
 9 603
 4 241
0
		40
		143
 1 767
 58 723
–
–
–
–
–
 4 148
 8 830
–
 17 533
–
 12 111
 125 156
 141 960
 133 104

N

–
		359
  747
		4
		29
		195
		154
  113
–
–
–
		380
		17
–
		80
–
–
–
  676
		26
–
		483
		114
–
	1	053
 6 077
		81
		56
	1	683
–
 12 327

		199
		0
  369
 3 683
 1 514
15
 1 490
		158
 9 440
 4 007
–
		35
		69
 1 693
 55 838
–
–
–
–
–
 4 043
 7 062
–
 17 375
–
 12 111
 119 101
 131 428
 126 238

(%)

–
(46.1)
(84.2)
(2.3)
(85.3)
(54.2)
(75.1)
(94.2)
–
–
–
(100.0)
(4.4)
–
(34.9)
–
–
–
(98.3)
(81.3)
–
(78.7)
(79.2)
–
(75.1)
(84.5)
(52.9)
(74.7)
(57.1)
–
(73.4)

(82.9)
(0.0)
(93.7)
(100.0)
(100.0)
(4.2)
(89.3)
(100.0)
(98.3)
(94.5)
–
(87.5)
(48.3)
(95.8)
(95.1)
–
–
–
–
–
(97.5)
(80.0)
–
(99.1)
–
(100.0)
(95.2)
(92.6)
(94.8)

N

–
31
1
0
2
7
4
11
–
–
–
15
2
–
3
–
–
–
18
0
–
14
2
–
104
136
2
0
163
–
515

		2
–
  39
  83
  135
0
  29
		15
  614
  131
–
		0
		1
  219
 13 506
–
–
–
–
–
  118
  83
–
 3 794
–
  379
 19 148
 19 663
 19 296

(%)

–
(8.6)
(0.1)
(0.0)
(6.9)
(3.6)
(2.6)
(9.7)
–
–
–
(3.9)
(11.8)
–
(3.8)
–
–
–
(2.7)
(0.0)
–
(2.9)
(1.8)
–
(9.9)
(2.2)
(2.5)
(0.0)
(9.7)
–
(4.2)

(1.0)
–
(10.6)
(2.3)
(8.9)
–
(1.9)
(9.5)
(6.5)
(3.3)
–
(0.0)
(1.4)
(12.9)
(24.2)
–
–
–
–
–
(2.9)
(1.2)
–
(21.8)
–
(3.1)
(16.1)
(15.0)
(15.3)

N

–
–
1
–
–
–
–
11
–
–
–
–
–
–
–
–
–
–
–
0
–
11
–
–
–
113
2
–
–
–
138

		2
–
–
  77
  124
–
  29
  15
  592
  88
–
–
  1
  170
 9 190
–
–
–
–
–
  116
  62
–
 3 460
–
  287
 14 213
 14 351
 14 320

(%)

–
–
(100.0)
–
–
–
–
(100.0)
–
–
–
–
–
–
–
–
–
–
–
–
–
(78.6)
–
–
–
(83.1)
(100.0)
–
–
–
(84.1)

(100.0)
–
–
(92.8)
(91.9)
–
(100.0)
(100.0)
(96.4)
(67.2)
–
–
(100.0)
(77.6)
(68.0)
–
–
–
–
–
(98.3)
(74.7)
–
(91.2)
–
(75.7)
(74.2)
(74.3)
(74.3)

Note: European Region comprises the 53 countries of the WHO European Region and Liechtenstein. WHO European Region 18 TB HPCs are presented in italics. 
ART: antiretroviral therapy. 
HPCs: high-priority countries. 
a Cases with unknown previous TB history are included among new TB cases. 
b Countries are only included in this analysis if total number of cases tested for HIV and test results are provided. For EU/EEA countries, countries are only included in 
this analysis if the total number of cases tested for HIV is more than zero. 
c Data from the WHO Global TB Database. 
d Previous TB history is defined by previous diagnosis. 
1 All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999). 

85

Tuberculosis surveillance and monitoring in Europe 2022SURVEILLANCE REPORT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 15. TB in prisons, European Region, 2020a

Country/area

EU/EEA
Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
Subtotal EU/EEAc
Non EU/EEA
Albania
Andorra
Armenia
Azerbaijan
Belarus
Bosnia and Herzegovina
Georgia
Israel
Kazakhstan
Kyrgyzstan
Monaco
Montenegro
North Macedonia
Republic of Moldova
Russian Federation
San Marino
Serbia

Serbia excluding Kosovo1
Kosovo1
Switzerland
Tajikistan
Turkey
Turkmenistan
Ukraine
United Kingdom
Uzbekistan
Subtotal non-EU/EEA
Total European Region
Subtotal 18 HPCs

Prison populationb

New and relapse TB cases (all forms) 
notified in prisons

Proportion of new and relapse TB cases in 
prisons out of the country total

TB relative risk in 
prisonsc

N

N

Rate per 100 000 prisoners

–
	10	559
 6 436
–
–
	19	286
–
 2 500
–
–
–
–
–
–
	6	490
–
–
–
 5 121
		750
–
	24	092
–
	70	716
	11	412
 22 700
	10	372
	3	571
–
–
 194 005

–
–
	2	003
 19 377
–
–
 9 143
–
 32 000
–
–
–
	2	600
 6 429
 499 659
–
–
–
–
–
 13 000
 266 831
–
 50 183
–
–
 901 225
1 095 230
 935 382

–
		11
  6
–
–
		4
–
  3
–
–
–
–
–
–
		0
–
–
–
  22
		1
–
		6
–
		112
		24
  74
		3
		0
–
–
  266

–
–
3
134
–
–
28
–
199
–
–
–
3
71
 5 442
–
–
–
–
–
68
118
–
555
–
–
 6 621
 6 887
 6 723

–
		104
  93
–
–
		21
–
  120
–
–
–
–
–
–
		0
–
–
–
  430
		133
–
		25
–
		158
		210
  326
		29
		0
–
–
  137

–
–
149.8
691.5
–
–
306.2
–
621.9
–
–
–
115.4
1 104.0
 1 089.0
–
–
–
–
–
523.1
44.2
–
1 106.0
–
–
734.7
628.8
718.7

%

–
(1.2)
(0.4)
–
–
(0.8)
–
(1.5)
–
–
–
–
–
–
(0.0)
–
–
–
(1.6)
(3.3)
–
(0.7)
–
(1.8)
(1.1)
(0.5)
(1.0)
(0.0)
–
–
(0.9)

–
–
(0.8)
(3.6)
–
–
(1.7)
–
(2.1)
–
–
–
(2.1)
(4.0)
(9.3)
–
–
–
–
–
(1.6)
(1.3)
–
(3.2)
–
–
(6.2)
(5.6)
(5.8)

–
13.3
5.1
–
–
4.8
–
10.8
–
–
–
–
–
–
0.0
–
–
–
11.9
17.1
–
5.8
–
12.1
12.6
5.7
7.4
0.0
–
–
9.3

–
–
11.3
19.0
–
–
7.3
–
12.2
–
–
–
16.8
25.2
27.1
–
–
–
–
–
12.0
4.2
–
27.6
–
–
22.5
23.5
22.1

Note: European Region comprises the 53 countries of the WHO European Region and Liechtenstein. WHO European Region 18 TB HPCs are presented in italics. 
HPCs: high-priority countries.
a Data from the WHO Global TB Database.
b Belarus, Kazakhstan, Montenegro and Kosovo1 prison population data are from prisonstudies.org.
c In the calculation of summary results, only countries/areas reporting data on prison population and TB notification in prisons are included.
1 All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999).

86

SURVEILLANCE REPORTTuberculosis surveillance and monitoring in Europe 2022Table 16.  Treatment outcome of new and relapse TB casesa notified in 2019, European Region, 2020

Country/area

EU/EEA
Austria
Belgiume
Bulgaria
Croatia
Cyprus
Czechia
Denmarke
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Irelande
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norwaye
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
Subtotal EU/EEA
Non-EU/EEA 
Albania
Andorra
Armenia
Azerbaijan
Belarus
Bosnia and Herzegovina
Georgia
Israel
Kazakhstan
Kyrgyzstan
Monaco
Montenegro
North Macedonia
Republic of Moldova
Russian Federation
San Marino
Serbia

Serbia excluding Kosovo1
Kosovo1
Switzerland
Tajikistan
Turkey
Turkmenistan
Ukraine
United Kingdome
Uzbekistan
Subtotal non-EU/EEA
Total European Region
Subtotal 18 HPCs

New and 
relapse TB 
cases notified 
in 2019b

Success

Died

Failed

Lost to follow-upc

Still on treatment

Not evaluatedd

N

(%)

N

(%)

N

(%)

N

(%)

N

(%)

N

(%)

		459
		877
 1 278
		295
		65
		447
		259
  120
		222
–
	4	566
–
		517
		13
		243
–
–
–
  866
		47
–
		730
		149
–
	1	859
 10 812
		209
		98
	4	386
		468
 28 985

			412
			5
   485
  1 702
  1 302
			580
  1 947
			217
  7 429
  5 110
0
			82
			199
  2 215
  54 589
–
			602
–
			602
			391
  5 114
  11 095
  2 117
  19 414
	4	739
  14 224
 133 970
 162 955
 139 819

		341
		709
 1 045
		72
		18
		330
		117
  91
		85
–
	3	130
–
		336
		13
		9
–
–
–
  754
		17
–
		630
		126
–
	1	327
 9 051
		196
		69
	2	045
		286
 20 797

			364
			3
   399
  1 429
  1 153
			185
  1 657
			182
  6 704
  4 155
–
			78
			177
  1 854
  37 208
–
			513
–
			513
			267
  4 643
  9 231
  1 749
  15 381
	3	675
  12 820
 103 827
 124 624
 109 324

(74.3)
(80.8)
(81.8)
(24.4)
(27.7)
(73.8)
(45.2)
(75.8)
(38.3)
–
(68.6)
–
(65.0)
(100.0)
(3.7)
–
–
–
(87.1)
(36.2)
–
(86.3)
(84.6)
–
(71.4)
(83.7)
(93.8)
(70.4)
(46.6)
(61.1)
(71.8)

(88.3)
(60.0)
(82.3)
(84.0)
(88.6)
(31.9)
(85.1)
(83.9)
(90.2)
(81.3)
–
(95.1)
(88.9)
(83.7)
(68.2)
–
(85.2)
–
(85.2)
(68.3)
(90.8)
(83.2)
(82.6)
(79.2)
(77.5)
(90.1)
(77.5)
(76.5)
(78.2)

	42
	63
 95
	35
	1
	50
	2
 20
	0
–
	355
–
	68
	0
	5
–
–
–
 74
	0
–
	32
	4
–
	107
1 016
	7
	22
	179
	15
2 192

			19
			1
   36
   66
   93
			28
   74
			14
   432
   328
–
			4
			9
   164
  5 936
–
			24
–
			24
			10
   179
   973
   90
  1 816
	229
   548
 11 073
 13 265
 11 940

(9.2)
(7.2)
(7.4)
(11.9)
(1.5)
(11.2)
(0.8)
(16.7)
(0.0)
–
(7.8)
–
(13.2)
(0.0)
(2.1)
–
–
–
(8.5)
(0.0)
–
(4.4)
(2.7)
–
(5.8)
(9.4)
(3.3)
(22.4)
(4.1)
(3.2)
(7.6)

(4.6)
(20.0)
(7.4)
(3.9)
(7.1)
(4.8)
(3.8)
(6.5)
(5.8)
(6.4)
–
(4.9)
(4.5)
(7.4)
(10.9)
–
(4.0)
–
(4.0)
(2.6)
(3.5)
(8.8)
(4.3)
(9.4)
(4.8)
(3.9)
(8.3)
(8.1)
(8.5)

0
5
12
1
0
1
0
1
0
–
3
–
16
0
1
–
–
–
14
0
–
1
3
–
2
168
0
0
1
1
230

			0
			0
   19
   53
   28
			10
   46
			2
   186
   112
–
			0
			2
   69
  3 567
–
			3
–
			3
			0
   60
   22
   135
  1 180
0
   227
 5 721
 5 951
 5 899

(0.0)
(0.6)
(0.9)
(0.3)
(0.0)
(0.2)
(0.0)
(0.8)
(0.0)
–
(0.1)
–
(3.1)
(0.0)
(0.4)
–
–
–
(1.6)
(0.0)
–
(0.1)
(2.0)
–
(0.1)
(1.6)
(0.0)
(0.0)
(0.0)
(0.2)
(0.8)

(0.0)
(0.0)
(3.9)
(3.1)
(2.2)
(1.7)
(2.4)
(0.9)
(2.5)
(2.2)
–
(0.0)
(1.0)
(3.1)
(6.5)
–
(0.5)
–
(0.5)
(0.0)
(1.2)
(0.2)
(6.4)
(6.1)
(0.0)
(1.6)
(4.3)
(3.7)
(4.2)

	3
	74
 101
	6
	6
	50
	1
 4
	5
–
	125
–
	52
	0
	0
–
–
–
 20
	7
–
	26
	3
–
	68
 497
	0
	3
	18
	0
1 069

			18
			1
   29
   134
   28
			3
   97
			6
   107
   481
–
			0
			11
   116
  3 471
–
			57
–
			57
			0
   190
   200
   84
  1 023
	208
   353
 6 617
 7 686
 6 935

(0.7)
(8.4)
(7.9)
(2.0)
(9.2)
(11.2)
(0.4)
(3.3)
(2.3)
–
(2.7)
–
(10.1)
(0.0)
(0.0)
–
–
–
(2.3)
(14.9)
–
(3.6)
(2.0)
–
(3.7)
(4.6)
(0.0)
(3.1)
(0.4)
(0.0)
(3.7)

(4.4)
(20.0)
(6.0)
(7.9)
(2.2)
(0.5)
(5.0)
(2.8)
(1.4)
(9.4)
–
(0.0)
(5.5)
(5.2)
(6.4)
–
(9.5)
–
(9.5)
(0.0)
(3.7)
(1.8)
(4.0)
(5.3)
(4.4)
(2.5)
(4.9)
(4.7)
(5.0)

	44
	12
 1
	6
	9
	9
	3
 1
	3
–
	122
–
	20
	0
	0
–
–
–
 4
	0
–
	8
	0
–
	291
 79
	0
	3
	51
	1
 667

–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
  0
  667
  85

(9.6)
(1.4)
(0.1)
(2.0)
(13.8)
(2.0)
(1.2)
(0.8)
(1.4)
–
(2.7)
–
(3.9)
(0.0)
(0.0)
–
–
–
(0.5)
(0.0)
–
(1.1)
(0.0)
–
(15.7)
(0.7)
(0.0)
(3.1)
(1.2)
(0.2)
(2.3)

–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
(0.0)
(0.4)
(0.1)

	29
	14
 24
	175
	31
	7
	136
 3
	129
–
	831
–
	25
	0
	228
–
–
–
 0
	23
–
	33
	13
–
	64
 1
	6
	1
2	092
	165
4 030

			11
			0
   2
   20
   0
			354
   73
			13
   0
   34
–
			0
			0
   12
  4 407
–
			5
–
			5
			114
   42
   669
   59
   14
			627
   276
 6 732
 10 762
 5 636

(6.3)
(1.6)
(1.9)
(59.3)
(47.7)
(1.6)
(52.5)
(2.5)
(58.1)
–
(18.2)
–
(4.8)
(0.0)
(93.8)
–
–
–
(0.0)
(48.9)
–
(4.5)
(8.7)
–
(3.4)
(0.0)
(2.9)
(1.0)
(47.7)
(35.3)
(13.9)

(2.7)
(0.0)
(0.4)
(1.2)
(0.0)
(61.0)
(3.7)
(6.0)
(0.0)
(0.7)
–
(0.0)
(0.0)
(0.5)
(8.1)
–
(0.8)
–
(0.8)
(29.2)
(0.8)
(6.0)
(2.8)
(0.1)
(13.2)
(1.9)
(5.0)
(6.6)
(4.0)

Note: European Region comprises the 53 countries of the WHO European Region and Liechtenstein. WHO European Region 18 TB HPCs are presented in italics. EU/EEA: 
country data are shown as missing (–) when data on treatment outcome are not reported. For inclusion in the cohort, drug-susceptibility data are also required.
HPCs: high-priority countries.
a Cases with unknown previous TB history are included among new TB cases.
b For non-EU/EEA countries and areas: patients started on second-line treatment are excluded. For EU/EEA countries: rifampicin-resistant TB cases are excluded. 
c In previous reports defined as "defaulted".
d In previous reports defined as "transferred out and unknown".
e Previous TB history is defined by previous diagnosis.
1 All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999).

87

Tuberculosis surveillance and monitoring in Europe 2022SURVEILLANCE REPORTTable 17. Treatment outcome of previously treated TB cases notified in 2019, European Region, 2020

Country/area

EU/EEA
Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
Subtotal EU/EEA
Non-EU/EEA 
Albania
Andorra
Armenia
Azerbaijan
Belarus
Bosnia and Herzegovina
Georgia
Israel
Kazakhstan
Kyrgyzstan
Monaco
Montenegro
North Macedonia
Republic of Moldova
Russian Federation
San Marino
Serbia

Serbia excluding Kosovo1
Kosovo1
Switzerland
Tajikistan
Turkey
Turkmenistan
Ukraine
United Kingdom
Uzbekistan
Subtotal non-EU/EEA
Total European Region
Subtotal 18 HPCs

New and 
relapse TB 
cases notified 
in 2019a

Success

Died

Failed

Lost to follow-upb

Still on treatment

Not evaluated c

N

(%)

	9
	69
 52
	8
	3
	6
	21
 1
	1
–
	145
–
	22
	0
	17
–
–
–
 19
–
–
	15
	11
–
	58
 422
	0
	3
	136
	1
1 021

			0
			0
   17
  2 401
   60
–
   197
			0
   94
   626
			0
			0
			0
   137
  7 851
–
			7
–
			7
			41
   144
   154
   746
  2 462
	322
  1 550
 16 809
 17 830
 16 933

	5
	53
 38
	3
	0
	2
	8
 1
	1
–
	70
–
	9
	0
	1
–
–
–
 16
–
–
	9
	8
–
	34
 179
	0
	2
	81
	1
 523

			0
			0
   6
  1 788
   43
–
   121
			0
   66
   351
			0
			0
			0
   82
  3 980
–
			4
–
			4
			22
   115
   83
   584
  1 576
	235
  1 308
 10 364
 10 887
 10 337

(55.6)
(76.8)
(73.1)
(37.5)
(0.0)
(33.3)
(38.1)
(100.0)
(100.0)
–
(48.3)
–
(40.9)
–
(5.9)
–
–
–
(84.2)
–
–
(60.0)
(72.7)
–
(58.6)
(42.4)
–
(66.7)
(59.6)
(100.0)
(51.2)

–
–
(35.3)
(74.5)
(71.7)
–
(61.4)
–
(70.2)
(56.1)
–
–
–
(59.9)
(50.7)
–
(57.1)
–
(57.1)
(53.7)
(79.9)
(53.9)
(78.3)
(64.0)
(73.0)
(84.4)
(61.7)
(61.1)
(61.0)

N

	1
	3
 3
	1
	0
	1
	0
 0
	0
–
	10
–
	4
	0
	0
–
–
–
 0
–
–
	2
	1
–
	4
 55
	0
	0
	5
	0
 90

			0
			0
   2
   154
   7
–
   17
			0
   14
   57
			0
			0
			0
   18
   763
–
			2
–
			2
			1
   16
   6
   54
   280
	16
   98
 1 505
 1 595
 1 544

(%)

(11.1)
(4.3)
(5.8)
(12.5)
(0.0)
(16.7)
(0.0)
(0.0)
(0.0)
–
(6.9)
–
(18.2)
–
(0.0)
–
–
–
(0.0)
–
–
(13.3)
(9.1)
–
(6.9)
(13.0)
–
(0.0)
(3.7)
(0.0)
(8.8)

–
–
(11.8)
(6.4)
(11.7)
–
(8.6)
–
(14.9)
(9.1)
–
–
–
(13.1)
(9.7)
–
(28.6)
–
(28.6)
(2.4)
(11.1)
(3.9)
(7.2)
(11.4)
(5.0)
(6.3)
(9.0)
(8.9)
(9.1)

N

0
2
2
0
0
0
0
0
0
–
1
–
0
0
0
–
–
–
1
–
–
0
0
–
0
63
0
0
2
0
71

			0
			0
   3
   129
   2
–
   8
			0
   6
   14
			0
			0
			0
   15
  1 091
–
			0
–
			0
			0
   2
   3
   43
   259
0
   16
 1 591
 1 662
 1 657

(%)

N

(%)

(0.0)
(2.9)
(3.8)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
–
(0.7)
–
(0.0)
–
(0.0)
–
–
–
(5.3)
–
–
(0.0)
(0.0)
–
(0.0)
(14.9)
–
(0.0)
(1.5)
(0.0)
(7.0)

–
–
(17.6)
(5.4)
(3.3)
–
(4.1)
–
(6.4)
(2.2)
–
–
–
(10.9)
(13.9)
–
(0.0)
–
(0.0)
(0.0)
(1.4)
(1.9)
(5.8)
(10.5)
(0.0)
(1.0)
(9.5)
(9.3)
(9.8)

2
9
 9
	0
	2
	2
	0
 0
	0
–
	13
–
	6
	0
	0
–
–
–
 2
–
–
	1
	0
–
	7
 120
	0
	1
	0
	0
 174

			0
			0
   6
   266
   8
–
   39
			0
   8
   198
			0
			0
			0
   21
   859
–
			1
–
			1
			0
   9
   23
   44
   346
	17
   68
 1 913
 2 087
 2 026

(22.2)
(13.0)
(17.3)
(0.0)
(66.7)
(33.3)
(0.0)
(0.0)
(0.0)
–
(9.0)
–
(27.3)
–
(0.0)
–
–
–
(10.5)
–
–
(6.7)
(0.0)
–
(12.1)
(28.4)
–
(33.3)
(0.0)
(0.0)
(17.0)

–
–
(35.3)
(11.1)
(13.3)
–
(19.8)
–
(8.5)
(31.6)
–
–
–
(15.3)
(10.9)
–
(14.3)
–
(14.3)
(0.0)
(6.3)
(14.9)
(5.9)
(14.1)
(5.3)
(4.4)
(11.4)
(11.7)
(12.0)

N

	1
	2
 0
	0
	0
	0
	2
 0
	0
–
	7
–
	1
	0
	0
–
–
–
 0
–
–
	1
	0
–
	10
 5
	0
	0
	2
	0
 31

			0
			0
–
–
–
–
–
–
–
–
			0
			0
			0
–
–
–
–
–
–
–
–
–
–
–
–
–
  0
  31
  5

(%)

(11.1)
(2.9)
(0.0)
(0.0)
(0.0)
(0.0)
(9.5)
(0.0)
(0.0)
–
(4.8)
–
(4.5)
–
(0.0)
–
–
–
(0.0)
–
–
(6.7)
(0.0)
–
(17.2)
(1.2)
–
(0.0)
(1.5)
(0.0)
(3.0)

–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
(0.0)
(0.2)
(0.0)

N

(%)

	0
	0
 0
	4
	1
	1
	11
 0
	0
–
	44
–
	2
	0
	16
–
–
–
 0
–
–
	2
	2
–
	3
 0
	0
	0
	46
	0
 132

			0
			0
   0
   64
   0
–
   12
			0
   0
   6
			0
			0
			0
   1
  1 158
–
			0
–
			0
			18
   2
   39
   21
   1
			54
   60
 1 436
 1 568
 1 364

(0.0)
(0.0)
(0.0)
(50.0)
(33.3)
(16.7)
(52.4)
(0.0)
(0.0)
–
(30.3)
–
(9.1)
–
(94.1)
–
–
–
(0.0)
–
–
(13.3)
(18.2)
–
(5.2)
(0.0)
–
(0.0)
(33.8)
(0.0)
(12.9)

–
–
(0.0)
(2.7)
(0.0)
–
(6.1)
–
(0.0)
(1.0)
–
–
–
(0.7)
(14.7)
–
(0.0)
–
(0.0)
(43.9)
(1.4)
(25.3)
(2.8)
(0.0)
(16.8)
(3.9)
(8.5)
(8.8)
(8.1)

Note: European Region comprises the 53 countries of the WHO European Region and Liechtenstein. WHO European Region 18 TB HPCs are presented in italics. EU/EEA: 
country data are shown as missing (–) when data on treatment outcome are not reported.
HPCs: high-priority countries.
a Excluding relapsed TB cases
b In previous reports defined as "defaulted".
c In previous reports defined as "transferred out and unknown".
1 All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999).

88

SURVEILLANCE REPORTTuberculosis surveillance and monitoring in Europe 2022Table 18. Treatment outcome of new and relapsea TB cases in children (0–14 years) notified in 2019, European 
Region, 2020

Success

Died

Failed

Lost to follow-upc

Still on treatment

Not evaluatedd

New and 
relapse 
TB cases 
reported in 
2019b

Country/area

EU/EEA
Austria
Belgiume
Bulgaria
Croatia
Cyprus
Czechia
Denmarke
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Irelande
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norwaye
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
Subtotal EU/EEA
Non-EU/EEA 
Albania
Andorra
Armenia
Azerbaijan
Belarus
Bosnia and Herzegovina
Georgia
Israel
Kazakhstan
Kyrgyzstan
Monaco
Montenegro
North Macedonia
Republic of Moldova
Russian Federation
San Marino
Serbia

Serbia excluding Kosovo1
Kosovo1
Switzerland
Tajikistan
Turkey
Turkmenistan
Ukraine
United Kingdome
Uzbekistan
Subtotal non-EU/EEA
Total European Region
Subtotal 18 HPCs

N

(%)

N

(%)

N

(%)

	22
	48
 54
	1
	2
	4
	16
 1
	9
–
	192
–
	10
	0
	10
–
–
–
 26
	0
–
	47
	4
–
	71
 388
	35
	2
	316
	18
1 276

			11
		0
  29
–
  8
		3
  65
		7
  274
–
 0
  1
		12
		103
 1 753
–
–
–
–
		15
  350
  490
–
  428
 182
–
 3 731
 5 007
 3 969

	19
	45
 47
	1
	0
	4
	0
 1
	0
–
	152
–
	8
	0
	1
–
–
–
 26
	0
–
	43
	4
–
	44
 372
	34
	2
	169
	11
 983

			11
–
  26
–
  8
		0
  62
		7
  271
–
–
1
		12
		103
 1 652
–
–
–
–
		11
  332
  397
–
  414
	154
–
 3 461
 4 444
 3 711

(86.4)
(93.8)
(87.0)
(100.0)
(0.0)
(100.0)
(0.0)
(100.0)
(0.0)
–
(79.2)
–
(80.0)
–
(10.0)
–
–
–
(100.0)
–
–
(91.5)
(100.0)
–
(62.0)
(95.9)
(97.1)
(100.0)
(53.5)
(61.1)
(77.0)

(100.0)
–
(89.7)
–
(100.0)
(0.0)
(95.4)
(100.0)
(98.9)
–
–
(100.0)
(100.0)
(100.0)
(94.2)
–
–
–
–
(73.3)
(94.9)
(81.0)
–
(96.7)
(84.6)
–
(92.8)
(88.8)
(93.5)

0
0
1
0
0
0
0
0
0
–
1
–
0
0
0
–
–
–
0
0
–
0
0
–
1
5
0
0
1
0
9

			0
–
  0
–
  0
		0
  0
		0
  1
–
–
0
		0
		0
  10
–
–
–
–
		0
  3
  21
–
  8
0
–
  43
  52
  49

(0.0)
(0.0)
(1.9)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
–
(0.5)
–
(0.0)
–
(0.0)
–
–
–
(0.0)
–
–
(0.0)
(0.0)
–
(1.4)
(1.3)
(0.0)
(0.0)
(0.3)
(0.0)
(0.7)

(0.0)
–
(0.0)
–
(0.0)
(0.0)
(0.0)
(0.0)
(0.4)
–
–
(0.0)
(0.0)
(0.0)
(0.6)
–
–
–
–
(0.0)
(0.9)
(4.3)
–
(1.9)
(0.0)
–
(1.2)
(1.0)
(1.2)

0
0
0
0
0
0
0
0
0
–
0
–
0
0
0
–
–
–
0
0
–
0
0
–
0
2
0
0
0
0
2

			0
–
  0
–
  0
		0
  1
		0
  2
–
–
0
		0
		0
  39
–
–
–
–
		0
  1
  0
–
  5
0
–
  48
  50
  50

(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
–
(0.0)
–
(0.0)
–
(0.0)
–
–
–
(0.0)
–
–
(0.0)
(0.0)
–
(0.0)
(0.5)
(0.0)
(0.0)
(0.0)
(0.0)
(0.2)

(0.0)
–
(0.0)
–
(0.0)
(0.0)
(1.5)
(0.0)
(0.7)
–
–
(0.0)
(0.0)
(0.0)
(2.2)
–
–
–
–
(0.0)
(0.3)
(0.0)
–
(1.2)
(0.0)
–
(1.3)
(1.0)
(1.3)

N

0
1
3
0
0
0
0
0
0
–
3
–
0
0
0
–
–
–
0
0
–
2
0
–
0
7
0
0
0
0
16

			0
–
  3
–
  0
		0
  2
		0
  0
–
–
0
		0
		0
  6
–
–
–
–
		0
  11
  8
–
  1
3
–
  34
  50
  41

(%)

(0.0)
(2.1)
(5.6)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
–
(1.6)
–
(0.0)
–
(0.0)
–
–
–
(0.0)
–
–
(4.3)
(0.0)
–
(0.0)
(1.8)
(0.0)
(0.0)
(0.0)
(0.0)
(1.3)

(0.0)
–
(10.3)
–
(0.0)
(0.0)
(3.1)
(0.0)
(0.0)
–
–
(0.0)
(0.0)
(0.0)
(0.3)
–
–
–
–
(0.0)
(3.1)
(1.6)
–
(0.2)
(1.6)
–
(0.9)
(1.0)
(1.0)

N

2
2
0
0
0
0
0
0
0
–
5
–
1
0
0
–
–
–
0
0
–
1
0
–
24
2
0
0
3
0
40

–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
  0
  40
  2

(%)

N

(%)

(9.1)
(4.2)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
–
(2.6)
–
(10.0)
–
(0.0)
–
–
–
(0.0)
–
–
(2.1)
(0.0)
–
(33.8)
(0.5)
(0.0)
(0.0)
(0.9)
(0.0)
(3.1)

–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
(0.0)
(0.8)
(0.1)

1
0
3
0
2
0
16
0
9
–
31
–
1
0
9
–
–
–
0
0
–
1
0
–
2
0
1
0
143
7
226

			0
–
   0
–
   0
			3
   0
			0
   0
–
–
			0
			0
			0
   46
–
–
–
–
			4
   3
   64
–
   0
			25
–
  145
  371
  116

(4.5)
(0.0)
(5.6)
(0.0)
(100.0)
(0.0)
(100.0)
(0.0)
(100.0)
–
(16.1)
–
(10.0)
–
(90.0)
–
–
–
(0.0)
–
–
(2.1)
(0.0)
–
(2.8)
(0.0)
(2.9)
(0.0)
(45.3)
(38.9)
(17.7)

(0.0)
–
(0.0)
–
(0.0)
(100.0)
(0.0)
(0.0)
(0.0)
–
–
(0.0)
(0.0)
(0.0)
(2.6)
–
–
–
–
(26.7)
(0.9)
(13.1)
–
(0.0)
(13.7)
–
(3.9)
(7.4)
(2.9)

Note: European Region comprises the 53 countries of the WHO European Region and Liechtenstein. WHO European Region 18 TB HPCs are presented in italics. EU/EEA: 
country data are shown as missing (–) when data on treatment outcome are not reported. For inclusion in the cohort, drug-susceptibility data are also required.
HPCs: high-priority countries.
a Cases with unknown previous TB history are included among new TB cases.
b For non-EU/EEA countries and areas: patients started on second-line treatment are excluded. For EU/EEA countries: rifampicin-resistant TB cases are excluded. 
c In previous reports defined as "defaulted".
d In previous reports defined as "transferred out and unknown".
e Previous TB history is defined by previous diagnosis.
1 All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999). 

89

Tuberculosis surveillance and monitoring in Europe 2022SURVEILLANCE REPORT 
 
 
 
 
 
Table 19.  Treatment outcome of new and relapsea TB cases of foreign origin notified in 2019, European Region, 2020

Country/area

EU/EEA
Austriae
Belgiumef
Bulgaria
Croatia
Cyprus
Czechia
Denmarkf
Estonia
Finland
France
Germany
Greecee
Hungarye
Iceland
Irelandf
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norwayf
Polande
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
Subtotal EU/EEA
Non-EU/EEA 
Albania
Andorra
Armenia
Azerbaijan
Belarus
Bosnia and Herzegovina
Georgia
Israel
Kazakhstan
Kyrgyzstan
Monaco
Montenegro
North Macedonia
Republic of Moldova
Russian Federation
San Marino
Serbia

Serbia excluding Kosovo1
Kosovo1
Switzerland
Tajikistan
Turkey
Turkmenistan
Ukraine
United Kingdomf
Uzbekistan
Subtotal non-EU/EEA
Total European Region
Subtotal 18 HPCs

New and 
relapse TB 
cases of 
foreign origin 
notified in 
2019b

Success

Died

Failed

Lost to follow-upc

Still on treatment

Not evaluatedd

N

(%)

N

(%)

N

(%)

N

(%)

N

(%)

N

(%)

		250
		483
  0
		4
		58
		128
		184
  27
		91
–
	3	193
–
		38
		11
		105
–
–
–
  11
		43
–
		548
		135
–
		454
  40
		5
		35
	1	682
		406
 7 931

0
1
		9
–
0
–
–
		188
  90
–
–
		3
		2
  19
 1 880
–
–
–
–
		292
0
 1 453
–
  31
	3	375
0
 7 343
 15 274
 3 560

		185
		402
  0
		0
		16
		86
		83
  21
		42
–
	2	255
–
		16
		11
		5
–
–
–
  10
		16
–
		473
		115
–
		309
  31
		5
		30
		771
		256
 5 138

		0
1
3
–
		0
–
–
		159
  79
–
–
		1
		2
  13
 1 603
–
–
–
–
		204
		0
 1 038
–
  21
	2	708
		0
 5 832
 10 970
 2 819

(74.0)
(83.2)
–
(0.0)
(27.6)
(67.2)
(45.1)
(77.8)
(46.2)
–
(70.6)
–
(42.1)
(100.0)
(4.8)
–
–
–
(90.9)
(37.2)
–
(86.3)
(85.2)
–
(68.1)
(77.5)
(100.0)
(85.7)
(45.8)
(63.1)
(64.8)

–
–
(33.3)
–
–
–
–
(84.6)
(87.8)
–
–
(33.3)
(100.0)
(68.4)
(85.3)
–
–
–
–
(69.9)
–
(71.4)
–
(67.7)
(80.2)
–
(79.4)
(71.8)
(79.2)

7
11
0
1
1
7
1
4
0
–
133
–
0
0
0
–
–
–
1
0
–
18
1
–
8
3
0
2
22
8
228

0
0
1
–
0
–
–
  11
  8
–
–
		0
  0
  2
  10
–
–
–
–
  4
0
  94
–
  1
108
0
  239
  467
  124

(2.8)
(2.3)
–
(25.0)
(1.7)
(5.5)
(0.5)
(14.8)
(0.0)
–
(4.2)
–
(0.0)
(0.0)
(0.0)
–
–
–
(9.1)
(0.0)
–
(3.3)
(0.7)
–
(1.8)
(7.5)
(0.0)
(5.7)
(1.3)
(2.0)
(2.9)

–
–
(11.1)
–
–
–
–
(5.9)
(8.9)
–
–
(0.0)
(0.0)
(10.5)
(0.5)
–
–
–
–
(1.4)
–
(6.5)
–
(3.2)
(3.2)
–
(3.3)
(3.1)
(3.5)

0
2
0
0
0
0
0
0
0
–
1
–
0
0
0
–
–
–
0
0
–
1
3
–
1
1
0
0
1
0
10

0
0
0
–
0
–
–
  2
  1
–
–
		0
  0
  0
  56
–
–
–
–
  0
0
  6
–
  2
0
0
  67
  77
  66

(0.0)
(0.4)
–
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
–
(0.0)
–
(0.0)
(0.0)
(0.0)
–
–
–
(0.0)
(0.0)
–
(0.2)
(2.2)
–
(0.2)
(2.5)
(0.0)
(0.0)
(0.1)
(0.0)
(0.1)

–
–
(0.0)
–
–
–
–
(1.1)
(1.1)
–
–
(0.0)
(0.0)
(0.0)
(3.0)
–
–
–
–
(0.0)
–
(0.4)
–
(6.5)
(0.0)
–
(0.9)
(0.5)
(1.9)

0
51
0
0
6
27
1
0
2
–
86
–
5
0
0
–
–
–
0
6
–
19
3
–
23
4
0
2
9
0
244

0
0
3
–
0
–
–
  4
  2
–
–
		1
  0
  2
  0
–
–
–
–
  6
0
  93
–
  6
154
0
  271
  515
  110

(0.0)
(10.6)
–
(0.0)
(10.3)
(21.1)
(0.5)
(0.0)
(2.2)
–
(2.7)
–
(13.2)
(0.0)
(0.0)
–
–
–
(0.0)
(14.0)
–
(3.5)
(2.2)
–
(5.1)
(10.0)
(0.0)
(5.7)
(0.5)
(0.0)
(3.1)

–
–
(33.3)
–
–
–
–
(2.1)
(2.2)
–
–
(33.3)
(0.0)
(10.5)
(0.0)
–
–
–
–
(2.1)
–
(6.4)
–
(19.4)
(4.6)
–
(3.7)
(3.4)
(3.1)

30
9
0
0
6
4
1
0
0
–
87
–
1
0
0
–
–
–
0
0
–
6
0
–
89
1
0
0
26
1
261

–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
  0
  261
  1

(12.0)
(1.9)
–
(0.0)
(10.3)
(3.1)
(0.5)
(0.0)
(0.0)
–
(2.7)
–
(2.6)
(0.0)
(0.0)
–
–
–
(0.0)
(0.0)
–
(1.1)
(0.0)
–
(19.6)
(2.5)
(0.0)
(0.0)
(1.5)
(0.2)
(3.3)

–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
(0.0)
(1.7)
(0.0)

	28
	8
 0
	3
	29
	4
	98
 2
	47
–
	631
–
	16
	0
	100
–
–
–
 0
	21
–
	31
	13
–
	24
 0
	0
	1
	853
	141
2 050

	0
0
2
–
	0
–
–
  12
  0
–
–
		1
  0
  2
  211
–
–
–
–
  78
 0
  222
–
  1
	405
	0
  934
 2 984
  440

(11.2)
(1.7)
–
(75.0)
(50.0)
(3.1)
(53.3)
(7.4)
(51.6)
–
(19.8)
–
(42.1)
(0.0)
(95.2)
–
–
–
(0.0)
(48.8)
–
(5.7)
(9.6)
–
(5.3)
(0.0)
(0.0)
(2.9)
(50.7)
(34.7)
(25.8)

–
–
(22.2)
–
–
–
–
(6.4)
(0.0)
–
–
(33.3)
(0.0)
(10.5)
(11.2)
–
–
–
–
(26.7)
–
(15.3)
–
(3.2)
(12.0)
–
(12.7)
(19.5)
(12.4)

Note: European Region comprises the 53 countries of the WHO European Region and Liechtenstein. WHO European Region 18 TB HPCs are presented in italics. EU/EEA: 
country data are shown as missing (–) when data on treatment outcome are not reported. For inclusion in the cohort, drug-susceptibility data are also required.
HPCs: high-priority countries.
a Cases with unknown previous TB history are included among new TB cases.
b For non-EU/EEA countries and areas: patients started on second-line treatment are excluded. For EU/EEA countries: rifampicin-resistant TB cases are excluded. 
c In previous reports defined as "defaulted".
d In previous reports defined as "transferred out and unknown".
e Origin is based on nationality.
f Previous TB history is defined by previous diagnosis.
1 All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999). 

90

SURVEILLANCE REPORTTuberculosis surveillance and monitoring in Europe 2022 
 
 
 
 
 
 
 
 
 
Table 20. Treatment outcome of HIV-positive new and relapsea TB cases notified in 2019, European Region, 2020

Country/area

EU/EEA
Austria
Belgiume
Bulgaria
Croatia
Cyprus
Czechia
Denmarke
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Irelande
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norwaye
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
Subtotal EU/EEA
Non-EU/EEA 
Albania
Andorra
Armenia
Azerbaijan
Belarus
Bosnia and Herzegovina
Georgia
Israel
Kazakhstan
Kyrgyzstan
Monaco
Montenegro
North Macedonia
Republic of Moldova
Russian Federation
San Marino
Serbia

Serbia excluding Kosovo1
Kosovo1
Switzerland
Tajikistan
Turkey
Turkmenistan
Ukraine
United Kingdome
Uzbekistan
Subtotal non-EU/EEA
Total European Region
Subtotal 18 HPCs

HIV-positive 
TB cases 
notified in 
2019b

–
34
1
0
1
7
4
11
–
–
–
–
3
0
9
–
–
–
20
0
–
19
4
–
143
171
4
1
207
–
639

		8
0
  43
–
  69
–
  28
		8
258
  103
0
–
  1
		201
 11 568
–
–
–
–
–
  136
  103
–
 4 325
–
–
 16 851
 17 490
 17 037

Success

Died

Failed

Lost to follow–upc

Still on treatment

Not evaluatedd

N

–
27
1
0
1
3
1
6
–
–
–
–
1
0
0
–
–
–
18
0
–
13
3
–
81
110
4
1
82
–
352

		4
0
  28
–
  56
–
  19
		6
190
  65
0
–
0
129
 5 501
–
–
–
–
–
  97
  63
–
 3 077
–
–
 9 235
 9 587
 9 360

(%)

–
(79.4)
(100.0)
–
(100.0)
(42.9)
(25.0)
(54.5)
–
–
–
–
(33.3)
–
(0.0)
–
–
–
(90.0)
–
–
(68.4)
(75.0)
–
(56.6)
(64.3)
(100.0)
(100.0)
(39.6)
–
(55.1)

(50.0)
–
(65.1)
–
(81.2)
–
(67.9)
(75.0)
(73.6)
(63.1)
–
–
(0.0)
(64.2)
(47.6)
–
–
–
–
–
(71.3)
(61.2)
–
(71.1)
–
–
(54.8)
(54.8)
(54.9)

N

–
2
0
0
0
1
0
4
–
–
–
–
1
0
0
–
–
–
2
0
–
1
0
–
9
26
0
0
13
–
59

		3
0
  10
–
  6
–
  1
		0
46
  24
0
–
1
37
 2 712
–
–
–
–
–
  28
  17
–
  785
–
–
 3 670
 3 729
 3 698

(%)

–
(5.9)
(0.0)
–
(0.0)
(14.3)
(0.0)
(36.4)
–
–
–
–
(33.3)
–
(0.0)
–
–
–
(10.0)
–
–
(5.3)
(0.0)
–
(6.3)
(15.2)
(0.0)
(0.0)
(6.3)
–
(9.2)

(37.5)
–
(23.3)
–
(8.7)
–
(3.6)
(0.0)
(17.8)
(23.3)
–
–
(100.0)
(18.4)
(23.4)
–
–
–
–
–
(20.6)
(16.5)
–
(18.2)
–
–
(21.8)
(21.3)
(21.7)

N

–
1
0
0
0
0
0
1
–
–
–
–
0
0
0
–
–
–
0
0
–
0
0
–
1
1
0
0
0
–
4

		0
0
  4
–
  5
–
  2
		0
7
  2
0
–
0
13
 1 277
–
–
–
–
–
  2
  1
–
  180
–
–
 1 493
 1 497
 1 495

(%)

–
(2.9)
(0.0)
–
(0.0)
(0.0)
(0.0)
(9.1)
–
–
–
–
(0.0)
–
(0.0)
–
–
–
(0.0)
–
–
(0.0)
(0.0)
–
(0.7)
(0.6)
(0.0)
(0.0)
(0.0)
–
(0.6)

(0.0)
–
(9.3)
–
(7.2)
–
(7.1)
(0.0)
(2.7)
(1.9)
–
–
(0.0)
(6.5)
(11.0)
–
–
–
–
–
(1.5)
(1.0)
–
(4.2)
–
–
(8.9)
(8.6)
(8.8)

N

–
3
0
0
0
2
0
0
–
–
–
–
1
0
0
–
–
–
0
0
–
2
0
–
7
28
0
0
1
–
44

		1
0
  1
–
  2
–
  3
		0
15
  12
0
–
0
21
 1 145
–
–
–
–
–
  9
  2
–
  282
–
–
 1 493
 1 537
 1 520

(%)

–
(8.8)
(0.0)
–
(0.0)
(28.6)
(0.0)
(0.0)
–
–
–
–
(33.3)
–
(0.0)
–
–
–
(0.0)
–
–
(10.5)
(0.0)
–
(4.9)
(16.4)
(0.0)
(0.0)
(0.5)
–
(6.9)

(12.5)
–
(2.3)
–
(2.9)
–
(10.7)
(0.0)
(5.8)
(11.7)
–
–
(0.0)
(10.4)
(9.9)
–
–
–
–
–
(6.6)
(1.9)
–
(6.5)
–
–
(8.9)
(8.8)
(8.9)

N

–
1
0
0
0
1
0
0
–
–
–
–
0
0
0
–
–
–
0
0
–
2
0
–
36
6
0
0
5
–
51

–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
  0
  51
  6

(%)

–
(2.9)
(0.0)
–
(0.0)
(14.3)
(0.0)
(0.0)
–
–
–
–
(0.0)
–
(0.0)
–
–
–
(0.0)
–
–
(10.5)
(0.0)
–
(25.2)
(3.5)
(0.0)
(0.0)
(2.4)
–
(8.0)

–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
(0.0)
(0.3)
(0.0)

N

–
0
0
0
0
0
3
0
–
–
–
–
0
0
9
–
–
–
0
0
–
1
1
–
9
0
0
0
106
–
129

			0
			0
   0
–
   0
–
   3
			2
			0
   0
0
–
   0
			1
   933
–
–
–
–
–
   0
   20
–
   1
–
–
  960
 1 089
  958

(%)

–
(0.0)
(0.0)
–
(0.0)
(0.0)
(75.0)
(0.0)
–
–
–
–
(0.0)
–
(100.0)
–
–
–
(0.0)
–
–
(5.3)
(25.0)
–
(6.3)
(0.0)
(0.0)
(0.0)
(51.2)
–
(20.2)

(0.0)
–
(0.0)
–
(0.0)
–
(10.7)
(25.0)
(0.0)
(0.0)
–
–
(0.0)
(0.5)
(8.1)
–
–
–
–
–
(0.0)
(19.4)
–
(0.0)
–
–
(5.7)
(6.2)
(5.6)

Note: European Region comprises the 53 countries of the WHO European Region and Liechtenstein. WHO European Region 18 TB HPCs are presented in italics. EU/EEA: 
country data are shown as missing (–) when data on treatment outcome are not reported. For inclusion in the cohort, drug-susceptibility data are also required.
HPCs: high-priority countries.
a Cases with unknown previous TB history are included among new TB cases.
b Rifampicin-resistant TB cases are excluded.
c In previous reports defined as "defaulted".
d In previous reports defined as "transferred out and unknown".
e Previous TB history is defined by previous diagnosis.
1 All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999). 

91

Tuberculosis surveillance and monitoring in Europe 2022SURVEILLANCE REPORT 
 
 
 
 
 
 
 
 
 
 
Table 21. Treatment outcome among new and relapsea TB cases in prisons notified in 2019, European Region, 2020

Country/area

EU/EEA
Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
Subtotal EU/EEA
Non-EU/EEA
Albania
Andorra
Armenia
Azerbaijan
Belarus
Bosnia and Herzegovina
Georgia
Israel
Kazakhstan
Kyrgyzstan
Monaco
Montenegro
North Macedonia
Republic of Moldova
Russian Federation
San Marino
Serbia

Serbia excluding Kosovo1
Kosovo1
Switzerland
Tajikistan
Turkey
Turkmenistan
Ukraine
United Kingdom
Uzbekistan
Subtotal non-EU/EEA
Total European Region
Subtotal 18 HPCs

New and relapse TB 
cases in prisons notified 
in 2019b

–
13
7
–
–
6
–
2
–
–
44
–
–
–
–
–
–
–
18
0
–
17
–
–
42
108
6
–
–
–
263

		6
0
  2
  116
  23
–
  22
0
  77
  95
0
1
		2
  84
 5 611
–
–
–
–
–
  79
  188
–
  453
–
–
 6 759
 7 022
 6 885

Success

Died

Failed

Lost to follow-upc

Not evaluatedd

N

–
11
4
–
–
5
–
2
–
–
20
–
–
–
–
–
–
–
10
–
–
7
–
–
25
86
6
–
–
–
176

6
0
  0
  112
  20
–
  22
0
  67
  77
0
1
		2
  66
 3 133
–
–
–
–
–
  70
  146
–
  343
–
–
 4 065
 4 241
 4 158

(%)

–
(84.6)
(57.1)
–
–
(83.3)
–
(100.0)
–
–
(45.5)
–
–
–
–
–
–
–
(55.6)
–
–
(41.2)
–
–
(59.5)
(79.6)
(100.0)
–
–
–
(66.9)

(100.0)
–
(0.0)
(96.6)
(87.0)
–
(100.0)
–
(87.0)
(81.1)
–
–
(100.0)
(78.6)
(55.8)
–
–
–
–
–
(88.6)
(77.7)
–
(75.7)
–
–
(60.1)
(60.4)
(60.4)

N

–
0
1
–
–
0
–
0
–
–
1
–
–
–
–
–
–
–
0
0
–
0
–
–
2
2
0
–
–
–
6

0
0
  0
  2
  1
–
  0
0
  1
  3
0
0
		0
  4
  160
–
–
–
–
–
  4
  16
–
  26
–
–
  217
  223
  220

(%)

–
(0.0)
(14.3)
–
–
(0.0)
–
(0.0)
–
–
(2.3)
–
–
–
–
–
–
–
(0.0)
–
–
(0.0)
–
–
(4.8)
(1.9)
(0.0)
–
–
–
(2.3)

(0.0)
–
(0.0)
(1.7)
(4.3)
–
(0.0)
–
(1.3)
(3.2)
–
–
(0.0)
(4.8)
(2.9)
–
–
–
–
–
(5.1)
(8.5)
–
(5.7)
–
–
(3.2)
(3.2)
(3.2)

N

–
0
0
–
–
0
–
0
–
–
0
–
–
–
–
–
–
–
0
0
–
0
–
–
0
1
0
–
–
–
1

0
0
  1
  1
  1
–
  0
0
  4
  3
0
0
		0
  6
  470
–
–
–
–
–
  2
		3
–
		34
–
–
  525
  526
  526

(%)

–
(0.0)
(0.0)
–
–
(0.0)
–
(0.0)
–
–
(0.0)
–
–
–
–
–
–
–
(0.0)
–
–
(0.0)
–
–
(0.0)
(0.9)
(0.0)
–
–
–
(0.4)

(0.0)
–
(50.0)
(0.9)
(4.3)
–
(0.0)
–
(5.2)
(3.2)
–
–
(0.0)
(7.1)
(8.4)
–
–
–
–
–
(2.5)
(1.6)
–
(7.5)
–
–
(7.8)
(7.5)
(7.6)

N

–
2
1
–
–
1
–
0
–
–
12
–
–
–
–
–
–
–
0
0
–
5
–
–
2
8
0
–
–
–
31

0
0
  1
  0
  1
–
  0
0
  5
  12
0
0
		0
  4
  232
–
–
–
–
–
  2
  10
–
  50
–
–
  317
  348
  326

(%)

–
(15.4)
(14.3)
–
–
(16.7)
–
(0.0)
–
–
(27.3)
–
–
–
–
–
–
–
(0.0)
–
–
(29.4)
–
–
(4.8)
(7.4)
(0.0)
–
–
–
(11.8)

(0.0)
–
(50.0)
(0.0)
(4.3)
–
(0.0)
–
(6.5)
(12.6)
–
–
(0.0)
(4.8)
(4.1)
–
–
–
–
–
(2.5)
(5.3)
–
(11.0)
–
–
(4.7)
(5.0)
(4.7)

N

–
0
1
–
–
0
–
0
–
–
11
–
–
–
–
–
–
–
8
0
–
5
–
–
13
11
0
–
–
–
49

		0
0
  0
  1
  0
–
  0
0
  0
  0
0
0
		0
  4
 1 616
–
–
–
–
–
  1
  13
–
  0
–
–
 1 635
 1 684
 1 655

(%)

–
(0.0)
(14.3)
–
–
(0.0)
–
(0.0)
–
–
(25.0)
–
–
–
–
–
–
–
(44.4)
–
–
(29.4)
–
–
(31.0)
(10.2)
(0.0)
–
–
–
(18.6)

(0.0)
–
(0.0)
(0.9)
(0.0)
–
(0.0)
–
(0.0)
(0.0)
–
–
(0.0)
(4.8)
(28.8)
–
–
–
–
–
(1.3)
(6.9)
–
(0.0)
–
–
(24.2)
(24.0)
(24.0)

Note: European Region comprises the 53 countries of the WHO European Region and Liechtenstein. WHO European Region 18 TB HPCs are presented in italics. EU/EEA: 
country data are shown as missing (–) when data on treatment outcome are not reported. For inclusion in the cohort, drug-susceptibility data are also required.
HPCs: high-priority countries.
a Cases with unknown previous TB history are included among new TB cases.
b Rifampicin-resistant TB cases are excluded.
c In previous reports defined as "defaulted".
d In previous reports defined as "transferred out and unknown".
1 All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999). 

92

SURVEILLANCE REPORTTuberculosis surveillance and monitoring in Europe 2022 
 
 
 
 
 
 
 
 
 
 
 
Table 22. Treatment outcome after 24 months of RR/MDR-TB cases started on second-line treatment in 2018, 
European Region, 2020

Country/area

EU/EEA
Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
Subtotal EU/EEA
Non-EU/EEA
Albania
Andorra
Armenia
Azerbaijan
Belarus
Bosnia and Herzegovina
Georgia
Israel
Kazakhstan
Kyrgyzstan
Monaco
Montenegro
North Macedonia
Republic of Moldova
Russian Federation
San Marino
Serbia

Serbia excluding Kosovo1
Kosovo1
Switzerland
Tajikistan
Turkey
Turkmenistan
Ukraine
United Kingdom
Uzbekistan
Subtotal non-EU/EEA
Total European Region
Subtotal 18 HPCs

RR/MDR-TBa 
cases 
started on 
second-line 
treatmentb in 
2018

Success

Died

Failed

Lost to follow upc

Still on treatment

Not evaluatedd

N

(%)

N

(%)

18
9
28
2
0
12
4
31
3
–
131
–
13
0
8
–
–
–
189
–
–
6
6
–
11
439
3
0
–
14
927

15
7
17
0
–
4
0
23
2
–
83
–
6
–
1
–
–
–
103
–
–
5
5
–
7
192
2
–
–
14
486

4
0
  85
  821
  919
–
  230
		14
 4 336
 1 244
0
1
		2
		921
 28 706
–
–
–
–
		9
  727
  180
  549
 5 953
40
 2 039
 46 780
 47 707
 47 397

3
0
  39
  471
  670
–
  155
		9
 3 499
  775
0
1
		1
		541
 14 757
–
–
–
–
		6
  510
  99
  248
 3 006
30
 1 375
 26 195
 26 681
 26 480

(83.3)
(77.8)
(60.7)
(0.0)
–
(33.3)
(0.0)
(74.2)
(66.7)
–
(63.4)
–
(46.2)
–
(12.5)
–
–
–
(54.5)
–
–
(83.3)
(83.3)
–
(63.6)
(43.7)
(66.7)
–
–
(100.0)
(52.4)

(75.0)
–
(45.9)
(57.4)
(72.9)
–
(67.4)
(64.3)
(80.7)
(62.3)
–
(100.0)
(50.0)
(58.7)
(51.4)
–
–
–
–
(66.7)
(70.2)
(55.0)
(45.2)
(50.5)
(75.0)
(67.4)
(56.0)
(55.9)
(55.9)

1
1
4
1
–
1
0
4
0
–
4
–
3
–
1
–
–
–
31
–
–
1
0
–
0
81
1
–
–
0
134

1
0
  13
  94
  87
–
  13
		2
  408
  122
0
0
		0
		98
 4 488
–
–
–
–
		0
  95
  20
  92
  970
2
  278
 6 783
 6 917
 6 898

(5.6)
(11.1)
(14.3)
(50.0)
–
(8.3)
(0.0)
(12.9)
(0.0)
–
(3.1)
–
(23.1)
–
(12.5)
–
–
–
(16.4)
–
–
(16.7)
(0.0)
–
(0.0)
(18.5)
(33.3)
–
–
(0.0)
(14.5)

(25.0)
–
(15.3)
(11.4)
(9.5)
–
(5.7)
(14.3)
(9.4)
(9.8)
–
(0.0)
(0.0)
(10.6)
(15.6)
–
–
–
–
(0.0)
(13.1)
(11.1)
(16.8)
(16.3)
(5.0)
(13.6)
(14.5)
(14.5)
(14.6)

N

0
0
1
0
–
0
0
0
0
–
2
–
0
–
0
–
–
–
12
–
–
0
1
–
0
81
0
–
–
0
97

0
0
  11
  142
  60
–
  13
		0
  182
  97
0
0
		0
		111
 4 133
–
–
–
–
		0
  23
  2
  98
 1 033
0
  120
 6 025
 6 122
 6 119

(%)

N

(%)

(0.0)
(0.0)
(3.6)
(0.0)
–
(0.0)
(0.0)
(0.0)
(0.0)
–
(1.5)
–
(0.0)
–
(0.0)
–
–
–
(6.3)
–
–
(0.0)
(16.7)
–
(0.0)
(18.5)
(0.0)
–
–
(0.0)
(10.5)

(0.0)
–
(12.9)
(17.3)
(6.5)
–
(5.7)
(0.0)
(4.2)
(7.8)
–
(0.0)
(0.0)
(12.1)
(14.4)
–
–
–
–
(0.0)
(3.2)
(1.1)
(17.9)
(17.4)
(0.0)
(5.9)
(12.9)
(12.8)
(12.9)

0
1
5
0
–
4
0
1
0
–
4
–
0
–
1
–
–
–
20
–
–
0
0
–
0
73
0
–
–
0
109

0
0
  22
  114
  95
–
  34
		2
  216
  249
0
0
		1
		169
 3 081
–
–
–
–
		0
  88
  9
  92
  926
4
  173
 5 275
 5 384
 5 367

(0.0)
(11.1)
(17.9)
(0.0)
–
(33.3)
(0.0)
(3.2)
(0.0)
–
(3.1)
–
(0.0)
–
(12.5)
–
–
–
(10.6)
–
–
(0.0)
(0.0)
–
(0.0)
(16.6)
(0.0)
–
–
(0.0)
(11.8)

(0.0)
–
(25.9)
(13.9)
(10.3)
–
(14.8)
(14.3)
(5.0)
(20.0)
–
(0.0)
(50.0)
(18.3)
(10.7)
–
–
–
–
(0.0)
(12.1)
(5.0)
(16.8)
(15.6)
(10.0)
(8.5)
(11.3)
(11.3)
(11.3)

N

1
0
0
0
–
1
0
1
0
–
10
–
1
–
0
–
–
–
23
–
–
0
0
–
2
12
0
–
–
0
51

–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
  0
  51
  36

(%)

N

(%)

(5.6)
(0.0)
(0.0)
(0.0)
–
(8.3)
(0.0)
(3.2)
(0.0)
–
(7.6)
–
(7.7)
–
(0.0)
–
–
–
(12.2)
–
–
(0.0)
(0.0)
–
(18.2)
(2.7)
(0.0)
–
–
(0.0)
(5.5)

–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
(0.0)
(0.1)
(0.1)

1
0
1
1
–
2
4
2
1
–
44
–
3
–
5
–
–
–
0
–
–
0
0
–
2
0
0
–
–
0
66

			0
0
   0
   0
   7
–
   15
			1
   31
   1
0
			0
			0
			2
  2 247
–
–
–
–
			3
   11
   50
   19
   18
			4
   93
 2 502
 2 568
 2 497

(5.6)
(0.0)
(3.6)
(50.0)
–
(16.7)
(100.0)
(6.5)
(33.3)
–
(33.6)
–
(23.1)
–
(62.5)
–
–
–
(0.0)
–
–
(0.0)
(0.0)
–
(18.2)
(0.0)
(0.0)
–
–
(0.0)
(7.1)

(0.0)
–
(0.0)
(0.0)
(0.8)
–
(6.5)
(7.1)
(0.7)
(0.1)
–
(0.0)
(0.0)
(0.2)
(7.8)
–
–
–
–
(33.3)
(1.5)
(27.8)
(3.5)
(0.3)
(10.0)
(4.6)
(5.3)
(5.4)
(5.3)

Note: European Region comprises the 53 countries of the WHO European Region and Liechtenstein. WHO European Region 18 TB HPCs are presented in italics. EU/EEA: 
country data are shown as missing (–) when data on treatment outcome are not reported. For inclusion in the cohort, drug-susceptibility data are also required.
HPCs: high-priority countries.
RR/MDR-TB: rifampicin-resistant or multidrug-resistant tuberculosis.
a Includes cases that are RR/MDR but that also meet the pre-XDR or XDR case definitions (pre-XDR and XDR cases have not been excluded).
b For EU/EEA countries, cases diagnosed postmortem are excluded, and cases with no treatment enrolment data reported are assumed to be enrolled in treatment.
c In previous reports defined as "defaulted".
d In previous reports defined as "transferred out and unknown".
1 All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999). 

93

Tuberculosis surveillance and monitoring in Europe 2022SURVEILLANCE REPORT 
 
 
 
 
 
 
 
 
 
Table 23. Treatment outcome after 24 months of pre-XDR-TB cases started on second-line treatment in 2018, 
European Region, 2020

Country/area

EU/EEA
Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
Subtotal EU/EEA
Non–EU/EEA
Albania
Andorra
Armenia
Azerbaijan
Belarus
Bosnia and Herzegovina
Georgia
Israel
Kazakhstan
Kyrgyzstan
Monaco
Montenegro
North Macedonia
Republic of Moldova
Russian Federation
San Marino
Serbia

Serbia excluding Kosovo1
Kosovo1
Switzerland
Tajikistan
Turkey
Turkmenistan
Ukraine
United Kingdom
Uzbekistan
Subtotal non-EU/EEA
Total European Region
Subtotal 18 HPCs

Pre–XDR–TBa 
cases started 
on second–
line treatment 
in 2018b

5
5
5
0
0
3
0
10
1
–
27
–
6
0
0
–
–
–
76
–
–
2
1
–
0
69
1
0
–
0
211

0
0
  14
189
  383
–
  54
		2
  386
  105
0
–
0
		62
  27
–
–
–
–
1
  63
  8
28
 1 479
5
  404
 3 210
 3 421
 3 362

Success

Died

Failed

Lost to follow-upc

Still on treatment

Not evaluatedd

N

3
4
2
0
0
0
0
9
1
–
14
–
1
0
0
–
–
–
23
–
–
2
1
–
0
10
0
0
–
0
70

0
0
  3
116
  293
–
  29
		1
  293
  55
0
–
0
32
  11
–
–
–
–
1
  42
  1
8
  505
2
  280
 1 672
 1 742
 1 712

(%)

(60.0)
(80.0)
(40.0)
–
–
(0.0)
–
(90.0)
(100.0)
–
(51.9)
–
(16.7)
–
–
–
–
–
(30.3)
–
–
(100.0)
(100.0)
–
–
(14.5)
(0.0)
–
–
–
(33.2)

–
–
(21.4)
(61.4)
(76.5)
–
(53.7)
(50.0)
(75.9)
(52.4)
–
–
–
(51.6)
(40.7)
–
–
–
–
(100.0)
(66.7)
(12.5)
(28.6)
(34.1)
(40.0)
(69.3)
(52.1)
(50.9)
(50.9)

N

1
1
1
0
0
1
0
0
0
–
2
–
1
0
0
–
–
–
13
–
–
0
0
–
0
21
1
0
–
0
42

0
0
  4
15
  32
–
  3
		0
  35
  19
0
–
0
19
  6
–
–
–
–
0
  10
  1
8
  195
0
  62
  409
  451
  444

(%)

(20.0)
(20.0)
(20.0)
–
–
(33.3)
–
(0.0)
(0.0)
–
(7.4)
–
(16.7)
–
–
–
–
–
(17.1)
–
–
(0.0)
(0.0)
–
–
(30.4)
(100.0)
–
–
–
(19.9)

–
–
(28.6)
(7.9)
(8.4)
–
(5.6)
(0.0)
(9.1)
(18.1)
–
–
–
(30.6)
(22.2)
–
–
–
–
(0.0)
(15.9)
(12.5)
(28.6)
(13.2)
(0.0)
(15.3)
(12.7)
(13.2)
(13.2)

N

0
0
1
0
0
0
0
0
0
–
2
–
0
0
0
–
–
–
10
–
–
0
0
–
0
30
0
0
–
0
43

0
0
  3
27
  33
–
  11
		1
  34
  10
0
–
0
2
  6
–
–
–
–
0
  5
  0
10
  622
0
  27
  791
  834
  831

(%)

(0.0)
(0.0)
(20.0)
–
–
(0.0)
–
(0.0)
(0.0)
–
(7.4)
–
(0.0)
–
–
–
–
–
(13.2)
–
–
(0.0)
(0.0)
–
–
(43.5)
(0.0)
–
–
–
(20.4)

–
–
(21.4)
(14.3)
(8.6)
–
(20.4)
(50.0)
(8.8)
(9.5)
–
–
–
(3.2)
(22.2)
–
–
–
–
(0.0)
(7.9)
(0.0)
(35.7)
(42.1)
(0.0)
(6.7)
(24.6)
(24.4)
(24.7)

N

0
0
0
0
0
1
0
0
0
–
0
–
0
0
0
–
–
–
7
–
–
0
0
–
0
2
0
0
–
0
10

0
0
  4
31
  25
–
  7
		0
  21
  21
0
–
0
2
  1
–
–
–
–
0
  6
  0
2
  157
0
  20
  297
  307
  306

(%)

(0.0)
(0.0)
(0.0)
–
–
(33.3)
–
(0.0)
(0.0)
–
(0.0)
–
(0.0)
–
–
–
–
–
(9.2)
–
–
(0.0)
(0.0)
–
–
(2.9)
(0.0)
–
–
–
(4.7)

–
–
(28.6)
(16.4)
(6.5)
–
(13.0)
(0.0)
(5.4)
(20.0)
–
–
–
(3.2)
(3.7)
–
–
–
–
(0.0)
(9.5)
(0.0)
(7.1)
(10.6)
(0.0)
(5.0)
(9.3)
(9.0)
(9.1)

N

1
0
0
0
0
0
0
1
0
–
2
–
1
0
0
–
–
–
23
–
–
0
0
–
0
6
0
0
–
0
34

–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
  0
  34
  30

(%)

(20.0)
(0.0)
(0.0)
–
–
(0.0)
–
(10.0)
(0.0)
–
(7.4)
–
(16.7)
–
–
–
–
–
(30.3)
–
–
(0.0)
(0.0)
–
–
(8.7)
(0.0)
–
–
–
(16.1)

–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
(0.0)
(1.0)
(0.9)

N

0
0
1
0
0
1
0
0
0
–
7
–
3
0
0
–
–
–
0
–
–
0
0
–
0
0
0
0
–
0
12

0
0
   0
			0
   0
–
   4
			0
   3
   0
0
–
0
			7
   3
–
–
–
–
			0
   0
   6
			0
   0
			3
   15
  41
  53
  39

(%)

(0.0)
(0.0)
(20.0)
–
–
(33.3)
–
(0.0)
(0.0)
–
(25.9)
–
(50.0)
–
–
–
–
–
(0.0)
–
–
(0.0)
(0.0)
–
–
(0.0)
(0.0)
–
–
–
(5.7)

–
–
(0.0)
(0.0)
(0.0)
–
(7.4)
(0.0)
(0.8)
(0.0)
–
–
–
(11.3)
(11.1)
–
–
–
–
(0.0)
(0.0)
(75.0)
(0.0)
(0.0)
(60.0)
(3.7)
(1.3)
(1.5)
(1.2)

Note: European Region comprises the 53 countries of the WHO European Region and Liechtenstein. WHO European Region 18 TB HPCs are presented in italics. EU/EEA: 
country data are shown as missing (–) when data on treatment outcome are not reported. For inclusion in the cohort, drug-susceptibility data are also required.
HPCs: high-priority countries. 
Pre-XDR-TB: pre-extensively drug-resistant tuberculosis. 
a Pre-XDR-TB defined as resistance to rifampicin (RR/MDR-TB) as well as resistance to any fluoroquinolone. Includes cases that are pre-XDR but that also meet the XDR 
case definitions (XDR cases have not been excluded).
b For EU/EEA countries, cases diagnosed postmortem are excluded, and cases with no treatment enrolment data reported are assumed to be enrolled in treatment.
c In previous reports defined as "defaulted".
d In previous reports defined as "transferred out and unknown". 
1 All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999).

94

SURVEILLANCE REPORTTuberculosis surveillance and monitoring in Europe 2022 
Table 24. Treatment outcome after 36 months of XDR-TB notified in 2017, EU/EEA, 2020

Country

EU/EEA
Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
Total EU/EEA

XDR-TBa cases 
reported in 
2017

2
0
4
0
0
0
0
3
0
–
13
0
0
0
–
–
–
–
1
–
–
0
0
–
2
1
0
0
–
0
26

Success

Died

Failed

Lost to follow-upb

Not evaluatedc

N

0
0
2
0
0
0
0
1
0
–
5
0
0
0
–
–
–
–
0
–
–
0
0
–
2
0
0
0
–
0
10

(%)

(0.0)
–
(50.0)
–
–
–
–
(33.3)
–
–
(38.5)
–
–
–
–
–
–
–
(0.0)
–
–
–
–
–
(100.0)
(0.0)
–
–
–
–
(38.5)

N

1
0
1
0
0
0
0
1
0
–
0
0
0
0
–
–
–
–
0
–
–
0
0
–
0
1
0
0
–
0
4

(%)

(50.0)
–
(25.0)
–
–
–
–
(33.3)
–
–
(0.0)
–
–
–
–
–
–
–
(0.0)
–
–
–
–
–
(0.0)
(100.0)
–
–
–
–
(15.4)

N

0
0
0
0
0
0
0
1
0
–
0
0
0
0
–
–
–
–
0
–
–
0
0
–
0
0
0
0
–
0
1

(%)

(0.0)
–
(0.0)
–
–
–
–
(33.3)
–
–
(0.0)
–
–
–
–
–
–
–
(0.0)
–
–
–
–
–
(0.0)
(0.0)
–
–
–
–
(3.8)

N

0
0
0
0
0
0
0
0
0
–
1
0
0
0
–
–
–
–
1
–
–
0
0
–
0
0
0
0
–
0
2

(%)

(0.0)
–
(0.0)
–
–
–
–
(0.0)
–
–
(7.7)
–
–
–
–
–
–
–
(100.0)
–
–
–
–
–
(0.0)
(0.0)
–
–
–
–
(7.7)

N

1
0
1
0
0
0
0
0
0
–
7
0
0
0
–
–
–
–
0
–
–
0
0
–
0
0
0
0
–
0
9

(%)

(50.0)
–
(25.0)
–
–
–
–
(0.0)
–
–
(53.8)
–
–
–
–
–
–
–
(0.0)
–
–
–
–
–
(0.0)
(0.0)
–
–
–
–
(34.6)

Note: WHO European Region 18 TB high-priority countries are presented in italics. Country data are shown as missing (–) when data on treatment 
outcome are not reported. For inclusion in the cohort, drug-susceptibility data are also required.
TESSy: The European Surveillance System.
XDR-TB: extensively drug-resistant tuberculosis. 
a XDR-TB defined as resistance to rifampicin and to at least one fluoroquinolone (pre-XDR-TB) as well as resistance to at least one additional Group A 
drug. Group A drugs include: levofloxacin, moxifloxacin, bedaquiline and linezolid. For EU/EEA countries, linezolid resistance is not yet reported to 
TESSy, therefore XDR-TB is assessed on resistance to levofloxacin, moxifloxacin and/or bedaquiline (in addition to meeting pre-XDR-TB criteria). 
b In previous reports defined as "defaulted".
c In previous reports defined as "transferred out and unknown". 

95

Tuberculosis surveillance and monitoring in Europe 2022SURVEILLANCE REPORT 
Management 

of LTBI and 

preventive 

treatment of 

persons at 

high risk, and 

vaccination 

against TB

e

g

a

r

e

v

o

c

n

o

i

t

a

g

i

t

s

e

v

n

i

t

c

a

t

n

o

C

1

.

E

.

1

%

0

9

=

t

e

g

r

a

T

.

)

E

(

)

G

(

5

r

e

d

n

u

d

e

g

a

s

t

c

a

t

n

o

c

B

T

n

i

e

g

a

r

e

v

o

c

t

n

e

m

t

a

e

r

t

I

B

T

L

2

.

E

.

1

d

o

o

h

d

l

i

h

c

%

0

9

=

t

e

g

r

a

T

.

)

E

(

)

G

(

s

r

a

e

y

Political 

with 

adequate 

resources, 

including 

universal 

health 

coverage 

policy

n

o

i

t

a

n

i

m

i

l

e

/

l

o

r

t

n

o

c

B

T

a

e

v

a

h

t

a

h

t

.

)

E

(

e

l

b

a

l

i

a

v

a

y

l

c

i

l

b

u

p

e

c

n

a

m

r

o

f

r

e

p

s

e

t

a

t

S

r

e

b

m

e

M

f

o

r

e

b

m

u

N

1

.

A

.

2

3

5

=

t

e

g

r

a

T

g

n

o

m

a

)

%

(

e

t

a

r

t

n

e

m

l

o

r

n

e

T

R

A

4

.

D

.

1

.

d

e

t

c

e

f

n

i

o

c

V

I

H

/

B

T

%

0

0

1

=

t

e

g

r

a

T

g

n

o

m

a

e

g

a

r

e

v

o

c

t

n

e

m

t

a

e

r

t

I

B

T

L

5

.

D

.

1

%

0

3

=

t

e

g

r

a

T

.

)

G

(

V

I

H

L

P

commitment 

strengthening 

2. Bold policies and supportive systems

Health 

systems 

in all 

functions, 

including 

financing 

mechanisms 

for TB and 

human 

resources

Regulatory 

frameworks 

for case-based 

surveillance, 

strengthening 

quality and 

rational use of 

medicines, and 

pharmacovigilance

well-aligned 

vital registration, 

Community 

systems and 

civil society 

engagement

Social 

protection, 

poverty 

alleviation 

and actions 

on other 

determinants 

of TB, such 

as migration 

and prisons

3. Intensified 

research and 

innovation

Discovery, 

development 

and rapid 

uptake of 

new tools, 

interventions 

and strategies

c

i

h

p

o

r

t

s

a

t

a

c

e

c

n

e

i

r

e

p

x

e

t

a

h

t

s

d

l

o

h

e

s

u

o

0

o

t

e

s

o

l

c

:

t

e

g

r

a

T

.

)

E

(

)

G

(

B

T

o

t

e

u

d

s

t

s

o

c

d

e

t

c

e

f

f

a

-

B

T

f

o

e

g

a

t

n

e

c

r

e

P

1

.

B

.

2

h

Country

w

e

n

h

t

i

w

)

%

(

e

g

a

r

e

v

o

c

t

n

e

m

t

a

e

r

T

1

.

C

.

2

%

0

3

=

t

e

g

r

a

T

.

)

E

(

)

G

(

s

g

u

r

d

B

T

s

n

o

i

t

i

l

a

o

c

r

e

d

l

o

h

e

k

a

t

s

i

t

l

u

m

g

n

i

n

o

i

t

c

n

u

f

h

t

i

w

s

e

t

a

t

S

r

e

b

m

e

M

f

o

r

e

b

m

u

N

1

.

D

.

2

.

e

c

r

u

o

s

e

r

d

n

a

e

r

a

c

B

T

r

o

f

g

n

i

t

a

c

o

v

d

a

3

5

=

t

e

g

r

a

T

w

e

n

f

o

)

%

(

e

t

a

r

s

s

e

c

c

u

s

t

n

e

m

t

a

e

r

T

1

.

E

.

2

.

s

r

e

n

o

s

i

r

p

g

n

o

m

a

s

e

s

a

c

B

T

e

s

p

a

l

e

r

d

n

a

%

5

8

=

t

e

g

r

a

T

e

v

i

t

a

i

t

i

n

i

h

c

r

a

e

s

e

r

B

T

n

a

e

p

o

r

u

E

1

.

A

.

.

6

1

0

2

-

d

i

m

y

b

d

e

h

s

i

l

b

a

t

s

d

e

h

s

i

l

b

a

t

s

e

:

t

e

g

r

a

T

3

e

.

)

%

(

e

t

a

r

n

o

i

t

c

e

t

e

d

-

e

s

a

c

V

I

H

/

B

T

1

.

D

.

1

%

0

9

=

t

e

g

r

a

T

–

(93.9)

(7.1)

(0.0)

(66.7)

(233.3)

(57.1)

(84.6)

–

–

–

–

–

–

–

–

–

–

–

–

(78.3)

(63.6)

(50.0)

(65.0)

(48.6)

(200.0)

(70.9)

.

)

E

(

)

G

(

)

%

(

e

g

a

r

e

v

o

c

g

n

i

t

s

e

t

V

I

H

2

.

D

.

1

%

0

0

1

=

t

e

g

r

a

T

–

(46.1)

(84.2)

(2.3)

(85.3)

(54.2)

(75.1)

(94.2)

–

–

–

–

–

–

–

–

–

(98.3)

(81.3)

(78.7)

(79.2)

(75.1)

(84.5)

(52.9)

(74.7)

(57.1)

–

.

B

T

l

l

a

g

n

o

m

a

V

I

H

f

o

b

e

g

a

t

n

e

c

r

e

P

3

.

D

.

1

e

s

a

e

r

c

e

d

:

t

e

g

r

a

T

–

(8.5)

(0.1)

(0.0)

(6.7)

(3.5)

(2.4)

–

–

–

–

–

–

–

–

–

(2.8)

(0.0)

(2.9)

(1.6)

(10.2)

(2.3)

(2.4)

(0.0)

(9.8)

–

(88.2)

(40.0)

(100.0)

(4.4)

(4.3)

(11.1)

(30.0)

(34.9)

(3.6)

(100.0)

(95.1)

(11.2)

(100.0)

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

(78.6)

(83.1)

(100.0)

(80.7)

(14.3)

(70.6)

(99.0)

(100.0)

(27.3)

(0.0)

(91.3)

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

(84.6)

(57.1)

(83.3)

(100.0)

(45.5)

(55.6)

(41.2)

(59.5)

(79.6)

(100.0)

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

EU/EEA

– Austria

– Belgium

– Bulgaria

– Croatia

– Cyprus

– Czechia

– Denmark

– Estonia

– Finland

– France

– Germany

– Greece

– Hungary

– Iceland

– Ireland

– Italy

– Latvia

– Liechtenstein

– Lithuania

– Luxembourg

– Malta

– Netherlands

– Norway

– Poland

– Portugal

– Romania

– Slovakia

– Slovenia

– Spain

– Sweden

(33.7)

(73.4)

(4.2)

(84.1)

(95.7)

(14.3)

(66.9)

– Subtotal EU/EEA

Table 25. Monitoring the WHO Roadmap to implement the tuberculosis action plan for the WHO European Region, 2016–2020, 2020

1. Integrated, patient-centred care and prevention

Systematic 
screening 
of contacts 
and 
high-risk 
groups

Early diagnosis of all forms of TB and universal access to DST, including the 
use of rapid tests

Equitable access to quality treatment and 
continuum of care for all people with TB, including 
drug-resistant TB; and patient support to facilitate 
treatment adherence

Collaborative TB/HIV activities, and 

management of relevant comorbidities

Country

EU/EEA
Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
Subtotal EU/EEA

k
s
i
r

t
a
n
o
i
t
a
l
u
p
o
p
f
o
e
g
a
r
e
v
o
C
1
.

A

.
1

e
v
i
t
c
a
r
o
f
g
n
i
n
e
e
r
c
s
c
i
t
a
m
e
t
s
y
s
h
t
i
w

%
0
8
=
t
e
g
r
a
T
.
I
B
T
L
d
n
a
B
T

d
n
a
w
e
n
d
e
i
f
i
t
o
n
f
o
e
g
a
t
n
e
c
r
e
P
1
.

B

.
1

g
n
i
s
u
d
e
s
o
n
g
a
i
d
s
t
n
e
i
t
a
p
B
T
e
s
p
a
l
e
r

.
)
G
(
s
t
s
e
t
d
i
p
a
r
d
e
d
n
e
m
m
o
c
e
r
-
O
H
W

%
0
9
≥

t
e
g
r
a
T

d
e
m

r
i
f
n
o
c
y
l
l
a
c
i
g
o
l
o
i
r
e
t
c
a
b
l
l
a
g
n
o
m
a

%
0
0
1
=
t
e
g
r
a
T
a
.
)
G
(
s
e
s
a
c
B
T

)

%

(
e
g
a
r
e
v
o
c
T
S
D
e
n
i
l
-
t
s
r
i
F
2
.

B

.
1

e
t
a
r
n
o
i
t
c
e
t
e
d
-
e
s
a
c
B
T
-
R
D
M
/
R
R
3
.
B

.
1

%
5
8
=
t
e
g
r
a
T
a
.
)

%

(

–
–
(95.1)
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
(80.7)
–
(70.6)
(99.0)
(100.0)
(27.3)
–
–
(95.7)

(68.8)
(68.5)
(0.2)
(0.0)
(35.3)
(71.4)
(96.1)
(87.5)
(61.5)
(0.0)
(85.5)
(25.3)
(0.0)
(41.7)
(76.9)
(0.0)
–
(100.0)
(0.0)
(0.0)
(0.0)
(80.5)
(85.4)
(27.8)
(31.0)
(30.7)
(29.4)
(82.7)
(31.9)
(86.7)
(33.7)

(96.9)
(95.7)
(57.3)
(84.8)
(100.0)
(91.7)
(100.0)
(100.0)
(99.0)
(3.4)
(89.0)
(96.7)
(90.3)
(100.0)
(95.1)
(72.6)
–
–
(100.0)
(95.7)
(100.0)
(94.7)
(100.0)
(91.3)
(64.5)
(87.8)
(98.5)
(100.0)
(46.8)
(100.0)
(78.2)

(12.5)
(15.4)
(37.5)
(100.0)
–
(84.6)
(100.0)
(86.4)
(0.0)
(96.9)
(35.9)
(66.7)
(53.8)
–
(0.0)
(81.0)
–
–
(103.0)
–
–
(60.0)
(50.0)
(81.8)
(50.0)
(70.0)
(100.0)
(0.0)
(10.4)
(100.0)
(64.4)

0
0
0
0
0
1

r
e
p
e
t
a
r
n
o
i
t
a
c
i
f
i
t
o
n
B
T
4
.

B

.
1

r
e
p
6

.
4
2
=
t
e
g
r
a
T
.
)
E
(
n
o
i
t
a
l
u
p
o
p

n
o
i
t
a
l
u
p
o
p
0
0
0
0
0
1

(4.4)
(7.2)
(13.4)
(4.5)
(4.1)
(3.4)
(3.8)
(9.3)
(3.1)
(6.8)
(5.0)
(3.7)
(4.2)
(3.3)
(4.8)
(3.8)
–
(5.2)
(26.0)
(5.4)
(27.2)
(3.6)
(3.0)
(8.9)
(14.0)
(39.8)
(2.9)
(3.7)
(6.4)
(3.2)
(7.3)

.
)

%

(
e
t
a
r
n
o
i
t
c
e
t
e
d
-
e
s
a
c
B
T
5
.

B

.
1

e
s
a
e
r
c
n
i

:
t
e
g
r
a
T

(86.8)
(87.4)
(68.2)
(65.6)
(49.3)
(87.8)
(73.2)
(85.7)
(87.0)
(83.0)
(87.2)
(80.9)
(87.3)
(120.0)
(88.1)
(54.1)
–
–
(87.1)
(86.5)
(87.5)
(86.5)
(84.7)
(87.5)
(87.6)
(59.9)
(85.0)
(87.2)
(86.7)
(87.8)
(74.1)

:
t
e
g
r
a
T
a
.
)
E
(
s
t
n
e
i
t
a
p
B
T
w
e
n
g
n
o
m
a

B
T
-
R
D
M
/
R
R
f
o
e
g
a
t
n
e
c
r
e
P
6

.

B

.
1

B
T
-
R
D
M
/
R
R
f
o
e
g
a
t
n
e
c
r
e
P
7
.

B

.
1

B
T
d
e
t
a
e
r
t
y
l
s
u
o
i
v
e
r
p
g
n
o
m
a

e
s
a
e
r
c
e
d
:
t
e
g
r
a
T
a
.
s
t
n
e
i
t
a
p

e
s
a
e
r
c
e
d

(0.6)
(0.9)
(3.9)
(0.0)
(0.0)
(3.6)
(0.8)
(18.0)
(0.0)
(100.0)
(2.1)
(2.0)
(3.8)
–
(0.0)
(3.4)
–
–
(12.6)
(0.0)
(0.0)
(1.6)
(2.6)
(1.4)
(0.9)
(2.4)
(0.0)
(1.8)
(1.8)
(2.4)
(2.8)

(20.0)
(0.0)
(11.1)
(16.7)
(0.0)
(30.0)
(14.3)
(27.3)
(0.0)
(100.0)
(5.3)
(7.1)
(23.8)
–
(0.0)
(23.1)
–
(0.0)
(32.1)
(0.0)
(0.0)
(0.0)
(0.0)
(3.3)
(10.7)
(13.3)
(9.1)
(0.0)
(3.3)
(10.0)
(12.8)

f
o
n
o
i
t
a
z
i
l
a
t
i
p
s
o
h
f
o
e
g
a
t
n
e
c
r
e
P
1
.
C
.
1

e
s
a
e
r
c
e
d
:
t
e
g
r
a
T
.
)
E
(
s
t
n
e
i
t
a
p
B
T
w
e
n

–
–
(90.0)
–
–
(95.0)
–
(60.0)
(80.0)
–
–
–
–
–
(50.0)

–
–
(80.0)
(80.0)

(30.0)
–
–
(30.0)
(60.0)
(80.0)
(95.0)
–
(50.0)
–

.
)
G
(

t
n
e
m

t
a
e
r
t
n
i
d
e
l
l
o
r
n
e
B
T
-
R
D
M

/
R
R
d
e
t
c
e
t
e
d
f
o
e
g
a
t
n
e
c
r
e
P
2
.
C
.
1

%
0
0
1
=
t
e
g
r
a
T

)

%

(
e
t
a
r
s
s
e
c
c
u
s
t
n
e
m

t
a
e
r
T
3
.
C
.
1

B
T
e
s
p
a
l
e
r
d
n
a
w
e
n
l
l
a
g
n
o
m
a

%
5
8
=
t
e
g
r
a
T
.
)
G
(
s
t
n
e
i
t
a
p

%
5
7
=
t
e
g
r
a
T
.
)
E
(

)
G
(

t
r
o
h
o
c

t
n
e
m

t
a
e
r
t

)

%

(
e
t
a
r
s
s
e
c
c
u
s
t
n
e
m

t
a
e
r
T
4
.
C
.
1

B
T
-
R
D
M
/
R
R
e
h
t
g
n
o
m
a

)
9
1
–
5
1
A
D
C
I
(
e
t
a
r
y
t
i
l
a
t
r
o
m
B
T
5
.
C
.
1

r
e
p
7
.
2
=
t
e
g
r
a
T
.
)
E
(

)
G
(

n
o
i
t
a
l
u
p
o
p
0
0
0
0
0
1

(100.0)
(100.0)
(100.0)
(100.0)
–
(100.0)
(0.0)
(100.0)
(0.0)
(100.0)
(91.4)
(100.0)
(90.9)
–
(100.0)
–
–
–
(100.0)
–
–
(100.0)
(100.0)
(100.0)
(100.0)
(98.7)
(100.0)
–
(100.0)
(100.0)
(97.6)

(74.3)
(80.8)
(81.8)
(24.4)
(27.7)
(73.8)
(44.9)
(75.8)
(38.3)
–
(68.6)
–
(65.0)
(100.0)
(3.7)
–
–
–
(87.1)
(36.2)
–
(86.3)
(84.6)
–
(71.4)
(83.7)
(93.8)
(70.4)
(46.6)
(61.1)
(71.8)

(83.3)
(77.8)
(60.7)
(0.0)
–
(33.3)
(0.0)
(74.2)
(66.7)
–
(63.4)
–
(46.2)
–
(12.5)
–
–
–
(54.5)
–
–
(83.3)
(83.3)
–
(63.6)
(43.7)
(66.7)
–
–
(100.0)
(52.4)

(0.5)
(0.3)
(1.4)
(1.5)
(0.4)
(0.2)
(0.2)
(1.2)
(0.6)
(0.7)
(0.3)
(0.5)
(0.6)
(0.6)
(0.4)
(0.5)
(3.4)
(0.0)
(4.4)
(0.4)
(0.2)
(0.2)
(0.3)
(1.5)
(2.4)
(4.8)
(0.6)
(0.7)
(0.5)
(0.2)
(0.8)

Note: European Region comprises the 53 countries of the WHO European Region and Liechtenstein. WHO European Region 18 TB HPCs are presented in italics. 
Numbers in red indicate that the target is not met; numbers in green that the target is met. Black text indicates that the target cannot be assessed. For indicators 
1.B.4 and 1.C.5, number in green indicates also that the country/area/(sub)region is on track to meet the 2020 target.
DST: drug-susceptibility testing.
E: WHO European Region indicator.
G: End TB Strategy global indicator.
HPCs: high-priority countries.
LTBI: latent tuberculosis infection.
PLHIV: people living with HIV.
RR/MDR: rifampicin-resistant or multidrug-resistant.
a Only pulmonary cases included.
b Target not assessed for countries with less than 50% reporting completeness for HIV.

96

SURVEILLANCE REPORTTuberculosis surveillance and monitoring in Europe 2022 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Table 25. Monitoring the WHO Roadmap to implement the tuberculosis action plan for the WHO European Region, 2016–2020, 2020

1. Integrated, patient-centred care and prevention

Early diagnosis of all forms of TB and universal access to DST, including the 

use of rapid tests

Equitable access to quality treatment and 

continuum of care for all people with TB, including 

drug-resistant TB; and patient support to facilitate 

treatment adherence

Collaborative TB/HIV activities, and 
management of relevant comorbidities

.
)

%

(
e
t
a
r
n
o
i
t
c
e
t
e
d
-
e
s
a
c
V
I

H
/
B
T
1
.

D

.
1

%
0
9
=
t
e
g
r
a
T

–
(93.9)
(7.1)
(0.0)
(66.7)
(233.3)
(57.1)
(84.6)
–
–
–
(88.2)
(40.0)
–
(30.0)
–
–
–
(78.3)
–
–
(63.6)
(50.0)
–
(65.0)
(48.6)
(200.0)
–
(70.9)
–
(33.7)

.
)
E
(

)
G
(

)

%

(
e
g
a
r
e
v
o
c
g
n
i
t
s
e
t
V
I

H
2
.

D

.
1

%
0
0
1
=
t
e
g
r
a
T

–
(46.1)
(84.2)
(2.3)
(85.3)
(54.2)
(75.1)
(94.2)
–
–
–
(100.0)
(4.4)
–
(34.9)
–
–
–
(98.3)
(81.3)
–
(78.7)
(79.2)
–
(75.1)
(84.5)
(52.9)
(74.7)
(57.1)
–
(73.4)

.

B
T
l
l
a
g
n
o
m
a
V
I

H
f
o
e
g
a
t
n
e
c
r
e
P
3
.
D

.
1

b
e
s
a
e
r
c
e
d
:
t
e
g
r
a
T

g
n
o
m
a
)

%

(
e
t
a
r

t
n
e
m
l
o
r
n
e
T
R
A
4
.

D

.
1

.
d
e
t
c
e
f
n
i
o
c
V
I

H
/
B
T

%
0
0
1
=
t
e
g
r
a
T

g
n
o
m
a
e
g
a
r
e
v
o
c

t
n
e
m

t
a
e
r
t

I
B
T
L
5
.
D

.
1

%
0
3
=
t
e
g
r
a
T
.
)
G
(
V
I

H
L
P

–
(8.5)
(0.1)
(0.0)
(6.7)
(3.5)
(2.4)
(11.2)
–
–
–
(4.3)
(11.1)
–
(3.6)
–
–
–
(2.8)
(0.0)
–
(2.9)
(1.6)
–
(10.2)
(2.3)
(2.4)
(0.0)
(9.8)
–
(4.2)

–
–
(100.0)
–
–
–
–
(100.0)
–
–
–
–
–
–
–
–
–
–
–
–
–
(78.6)
–
–
–
(83.1)
(100.0)
–
–
–
(84.1)

–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–

Systematic 

screening 

of contacts 

and 

high-risk 

groups

k

s

i

r

t

a

n

o

i

t

a

l

u

p

o

p

f

o

e

g

a

r

e

v

o

C

e

v

i

t

c

a

r

o

f

g

n

i

n

e

e

r

c

s

c

i

t

a

m

e

t

s

y

s

1

.

A

.

1

h

t

i

w

%

0

8

=

t

e

g

r

a

T

.

I

B

T

L

d

n

a

B

T

(95.1)

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

(80.7)

(70.6)

(99.0)

(100.0)

(27.3)

Country

EU/EEA

Austria

Belgium

Bulgaria

Croatia

Cyprus

Czechia

Denmark

Estonia

Finland

France

Germany

Greece

Hungary

Iceland

Ireland

Italy

Latvia

Liechtenstein

Lithuania

Luxembourg

Malta

Netherlands

Norway

Poland

Portugal

Romania

Slovakia

Slovenia

Spain

Sweden

d

n

a

w

e

n

d

e

i

f

i

t

o

n

f

o

e

g

a

t

n

e

c

r

e

P

1

.

B

.

1

g

n

i

s

u

d

e

s

o

n

g

a

i

d

s

t

n

e

i

t

a

p

B

T

e

s

p

a

l

e

r

.

)

G

(

s

t

s

e

t

d

i

p

a

r

d

e

d

n

e

m

m

o

c

e

r

-

O

H

W

%

0

9

≥

t

e

g

r

a

T

d

e

m

r

i

f

n

o

c

y

l

l

a

c

i

g

o

l

o

i

r

e

t

c

a

b

l

l

a

g

n

o

m

)

%

(

e

g

a

r

e

v

o

c

T

S

D

e

n

i

l

-

t

s

r

i

F

2

.

B

.

1

%

0

0

1

=

t

e

g

r

a

T

a

.

)

G

(

s

e

s

a

c

B

a

T

(96.9)

(95.7)

(57.3)

(84.8)

(100.0)

(91.7)

(100.0)

(100.0)

(99.0)

(3.4)

(89.0)

(96.7)

(90.3)

(100.0)

(95.1)

(72.6)

–

–

(95.7)

(100.0)

(94.7)

(100.0)

(91.3)

(64.5)

(87.8)

(98.5)

(100.0)

(46.8)

(68.8)

(68.5)

(0.2)

(0.0)

(35.3)

(71.4)

(96.1)

(87.5)

(61.5)

(0.0)

(85.5)

(25.3)

(0.0)

(41.7)

(76.9)

(0.0)

–

(0.0)

(0.0)

(0.0)

(80.5)

(85.4)

(27.8)

(31.0)

(30.7)

(29.4)

(82.7)

(31.9)

(86.7)

(33.7)

(100.0)

e

t

a

r

n

o

i

t

c

e

t

e

d

-

e

s

a

c

B

T

-

R

D

M

/

R

R

3

.

B

.

1

%

5

8

=

t

e

g

r

a

T

a

.

)

%

(

(12.5)

(15.4)

(37.5)

(100.0)

–

(84.6)

(100.0)

(86.4)

(0.0)

(96.9)

(35.9)

(66.7)

(53.8)

(0.0)

(81.0)

–

–

–

–

–

(60.0)

(50.0)

(81.8)

(50.0)

(70.0)

(100.0)

(0.0)

(10.4)

0

0

0

0

0

1

r

e

p

r

e

6

.

p

4

e

t

a

r

n

o

i

t

a

c

i

f

i

t

o

n

B

T

4

.

B

.

1

2

=

t

e

g

r

a

T

.

)

E

(

n

o

i

t

a

l

u

p

o

p

n

o

i

t

a

l

u

p

o

p

0

0

0

0

0

1

(4.4)

(7.2)

(13.4)

(4.5)

(4.1)

(3.4)

(3.8)

(9.3)

(3.1)

(6.8)

(5.0)

(3.7)

(4.2)

(3.3)

(4.8)

(3.8)

–

(5.2)

(26.0)

(5.4)

(27.2)

(3.6)

(3.0)

(8.9)

(14.0)

(39.8)

(2.9)

(3.7)

(6.4)

(3.2)

(7.3)

.

)

%

(

e

t

a

r

n

o

i

t

c

e

t

e

d

-

e

s

a

c

B

T

5

.

B

.

1

e

s

a

e

r

c

n

i

:

t

e

g

r

a

T

(86.8)

(87.4)

(68.2)

(65.6)

(49.3)

(87.8)

(73.2)

(85.7)

(87.0)

(83.0)

(87.2)

(80.9)

(87.3)

(120.0)

(88.1)

(54.1)

–

–

(87.1)

(86.5)

(87.5)

(86.5)

(84.7)

(87.5)

(87.6)

(59.9)

(85.0)

(87.2)

(86.7)

(87.8)

(74.1)

a

:

t

e

g

r

a

T

.

)

E

(

s

t

n

e

i

t

a

p

B

T

w

e

n

g

n

o

m

a

B

T

-

R

D

M

/

R

R

f

o

e

g

a

t

n

e

c

r

e

P

6

.

B

.

1

B

T

-

R

D

M

/

R

R

f

o

e

g

a

t

n

e

c

r

e

P

7

.

B

.

1

B

T

d

e

t

a

e

r

t

y

l

s

u

o

i

v

e

r

p

g

n

o

m

a

e

s

a

e

r

c

e

d

:

t

e

g

r

a

T

a

.

s

t

n

e

i

t

a

p

(100.0)

(100.0)

e

s

a

e

r

c

e

d

(0.6)

(0.9)

(3.9)

(0.0)

(0.0)

(3.6)

(0.8)

(18.0)

(0.0)

(2.1)

(2.0)

(3.8)

(0.0)

(3.4)

–

–

–

(12.6)

(0.0)

(0.0)

(1.6)

(2.6)

(1.4)

(0.9)

(2.4)

(0.0)

(1.8)

(1.8)

(2.4)

(2.8)

(20.0)

(0.0)

(11.1)

(16.7)

(0.0)

(30.0)

(14.3)

(27.3)

(0.0)

(5.3)

(7.1)

(23.8)

(0.0)

(23.1)

–

–

(0.0)

(32.1)

(0.0)

(0.0)

(0.0)

(0.0)

(3.3)

(10.7)

(13.3)

(9.1)

(0.0)

(3.3)

(10.0)

(12.8)

(95.0)

(100.0)

f

o

n

o

i

t

a

z

i

l

a

t

i

p

s

o

h

f

o

e

g

a

t

n

e

c

r

e

P

1

.

C

.

1

e

s

a

e

r

c

e

d

:

t

e

g

r

a

T

.

)

E

(

s

t

n

e

i

t

a

p

B

T

w

e

n

(90.0)

(60.0)

(80.0)

(80.0)

(80.0)

(30.0)

(30.0)

(60.0)

(80.0)

(95.0)

(50.0)

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

.

)

G

(

t

n

e

m

t

a

e

r

t

/

R

R

d

e

t

c

e

t

e

d

f

o

n

i

e

g

a

t

n

e

c

r

e

P

2

.

C

.

1

d

e

l

l

o

r

n

e

B

T

-

R

D

M

%

0

0

1

=

t

e

g

r

a

T

(100.0)

(100.0)

(100.0)

(100.0)

–

(0.0)

(100.0)

(0.0)

(100.0)

(91.4)

(100.0)

(90.9)

–

–

–

–

–

–

(100.0)

(100.0)

(100.0)

(100.0)

(98.7)

(100.0)

–

(100.0)

(100.0)

(97.6)

%

5

7

=

t

e

g

r

a

T

.

)

E

(

)

G

(

t

r

o

h

o

c

t

n

e

m

t

a

e

r

t

)

%

(

e

t

a

r

s

s

e

c

c

u

s

t

n

e

m

t

a

e

r

T

4

.

C

.

1

B

T

-

R

D

M

/

R

R

e

h

t

g

n

o

m

a

(83.3)

(77.8)

(60.7)

(0.0)

–

(33.3)

(0.0)

(74.2)

(66.7)

–

–

–

–

–

–

–

–

–

–

–

(83.3)

(83.3)

(63.6)

(43.7)

(66.7)

(100.0)

(52.4)

)

%

(

e

t

B

T

a

e

r

s

s

e

c

c

u

s

t

n

e

m

t

a

e

r

T

3

.

C

.

1

s

p

a

l

e

r

d

n

a

w

e

n

l

l

a

g

n

o

m

a

%

5

8

=

t

e

g

r

a

T

.

)

G

(

s

t

n

e

i

t

a

p

(74.3)

(80.8)

(81.8)

(24.4)

(27.7)

(73.8)

(44.9)

(75.8)

(38.3)

–

–

–

–

–

–

–

(87.1)

(36.2)

(86.3)

(84.6)

(71.4)

(83.7)

(93.8)

(70.4)

(46.6)

(61.1)

(71.8)

(68.6)

(63.4)

(65.0)

(100.0)

(3.7)

(46.2)

(12.5)

(50.0)

(100.0)

)

9

1

–

5

1

A

D

C

I

(

e

t

a

r

y

t

i

l

a

t

r

o

m

B

T

5

.

C

.

1

r

e

p

7

.

2

=

t

e

g

r

a

T

.

)

E

(

)

G

(

n

o

i

t

a

l

u

p

o

p

0

0

0

0

0

1

(0.5)

(0.3)

(1.4)

(1.5)

(0.4)

(0.2)

(0.2)

(1.2)

(0.6)

(0.7)

(0.3)

(0.5)

(0.6)

(0.6)

(0.4)

(0.5)

(3.4)

(0.0)

(4.4)

(0.4)

(0.2)

(0.2)

(0.3)

(1.5)

(2.4)

(4.8)

(0.6)

(0.7)

(0.5)

(0.2)

(0.8)

(100.0)

(103.0)

(100.0)

(54.5)

Subtotal EU/EEA

(95.7)

(100.0)

(100.0)

(78.2)

(64.4)

2. Bold policies and supportive systems

Management 
of LTBI and 
preventive 
treatment of 
persons at 
high risk, and 
vaccination 
against TB

Political 
commitment 
with 
adequate 
resources, 
including 
universal 
health 
coverage 
policy

Health 
systems 
strengthening 
in all 
functions, 
including 
well-aligned 
financing 
mechanisms 
for TB and 
human 
resources

Regulatory 
frameworks 
for case-based 
surveillance, 
strengthening 
vital registration, 
quality and 
rational use of 
medicines, and 
pharmacovigilance

Community 
systems and 
civil society 
engagement

Social 
protection, 
poverty 
alleviation 
and actions 
on other 
determinants 
of TB, such 
as migration 
and prisons

3. Intensified 
research and 
innovation

Discovery, 
development 
and rapid 
uptake of 
new tools, 
interventions 
and strategies

e
g
a
r
e
v
o
c
n
o
i
t
a
g
i
t
s
e
v
n
i

t
c
a
t
n
o
C
1
.
E
.
1

%
0
9
=
t
e
g
r
a
T
.
)
E
(

)
G
(

–
–
(95.1)
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
(80.7)
–
(70.6)
(99.0)
(100.0)
(27.3)
–
–
(95.7)

5
r
e
d
n
u
d
e
g
a
s
t
c
a
t
n
o
c
B
T
d
o
o
h
d
l
i
h
c

n
i
e
g
a
r
e
v
o
c

t
n
e
m

t
a
e
r
t

I
B
T
L
2
.
E
.
1

%
0
9
=
t
e
g
r
a
T
.
)
E
(

)
G
(
s
r
a
e
y

n
o
i
t
a
n
i
m

i
l
e
/
l
o
r
t
n
o
c
B
T
a
e
v
a
h
t
a
h
t

.
)
E
(
e
l
b
a
l
i
a
v
a
y
l
c
i
l
b
u
p
e
c
n
a
m

r
o
f
r
e
p

s
e
t
a
t
S
r
e
b
m
e
M

f
o
r
e
b
m
u
N
1
.

A

.
2

3
5
=
t
e
g
r
a
T

c
i
h
p
o
r
t
s
a
t
a
c
e
c
n
e
i
r
e
p
x
e
t
a
h
t
s
d
l
o
h
e
s
u
o
h

0
o
t
e
s
o
l
c

:
t
e
g
r
a
T
.
)
E
(

)
G
(
B
T
o
t
e
u
d
s
t
s
o
c

d
e
t
c
e
f
f
a
-
B
T
f
o
e
g
a
t
n
e
c
r
e
P
1
.

B

.
2

Country

w
e
n
h
t
i
w

)

%

(
e
g
a
r
e
v
o
c

t
n
e
m

t
a
e
r
T
1
.
C
.
2

%
0
3
=
t
e
g
r
a
T
.
)
E
(

)
G
(
s
g
u
r
d
B
T

s
n
o
i
t
i
l
a
o
c

r
e
d
l
o
h
e
k
a
t
s
i
t
l
u
m
g
n
i
n
o
i
t
c
n
u
f

h
t
i
w
s
e
t
a
t
S
r
e
b
m
e
M

f
o
r
e
b
m
u
N
1
.

D

.
2

.
e
c
r
u
o
s
e
r
d
n
a
e
r
a
c
B
T
r
o
f
g
n
i
t
a
c
o
v
d
a

3
5
=
t
e
g
r
a
T

w
e
n
f
o
)

%

(
e
t
a
r
s
s
e
c
c
u
s
t
n
e
m

t
a
e
r
T
1
.
E
.
2

.
s
r
e
n
o
s
i
r
p
g
n
o
m
a
s
e
s
a
c
B
T
e
s
p
a
l
e
r
d
n
a

%
5
8
=
t
e
g
r
a
T

e
v
i
t
a
i
t
i
n
i
h
c
r
a
e
s
e
r
B
T
n
a
e
p
o
r
u
E
1
.

A

.
3

.

6
1
0
2
-
d
i
m
y
b
d
e
h
s
i
l
b
a
t
s
e

d
e
h
s
i
l
b
a
t
s
e
:
t
e
g
r
a
T

–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
(14.3)
–
–
–
(0.0)
(91.3)
–
–
(14.3)

–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–

–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–

–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–

–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–

–
(84.6)
(57.1)
–
–
(83.3)
–
(100.0)
–
–
(45.5)
–
–
–
–
–
–
–
(55.6)
–
–
(41.2)
–
–
(59.5)
(79.6)
(100.0)
–
–
–
(66.9)

EU/EEA
– Austria
– Belgium
– Bulgaria
– Croatia
– Cyprus
– Czechia
– Denmark
– Estonia
– Finland
– France
– Germany
– Greece
– Hungary
– Iceland
– Ireland
– Italy
– Latvia
– Liechtenstein
– Lithuania
– Luxembourg
– Malta
– Netherlands
– Norway
– Poland
– Portugal
– Romania
– Slovakia
– Slovenia
– Spain
– Sweden
– Subtotal EU/EEA

97

Tuberculosis surveillance and monitoring in Europe 2022SURVEILLANCE REPORT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Political 

Political 

with 

with 

adequate 

adequate 

resources, 

resources, 

including 

including 

universal 

universal 

health 

health 

coverage 

coverage 

policy

policy

n

n

o

o

i

i

t

t

a

a

n

n

i

i

m

m

i

i

l

l

e

e

/

/

l

l

o

o

r

r

t

t

n

n

o

o

c

c

B

B

T

T

a

a

e

e

v

v

a

a

h

h

t

t

a

a

h

h

t

t

.

.

)

)

E

E

(

(

e

e

l

l

b

b

a

a

l

l

i

i

a

a

v

v

a

a

y

y

l

l

c

c

i

i

l

l

b

b

u

u

p

p

e

e

c

c

n

n

a

a

m

m

r

r

o

o

f

f

r

r

e

e

p

p

s

s

e

e

t

t

a

a

t

t

S

S

r

r

e

e

b

b

m

m

e

e

M

M

f

f

o

o

r

r

e

e

b

b

m

m

u

u

N

N

1

1

.

.

A

A

.

.

2

2

3

3

5

5

=

=

t

t

e

e

g

g

r

r

a

a

T

T

Management 

Management 

of LTBI and 

of LTBI and 

preventive 

preventive 

treatment of 

treatment of 

persons at 

persons at 

high risk, and 

high risk, and 

vaccination 

vaccination 

against TB

against TB

5

5

r

r

e

e

d

d

n

n

u

u

d

d

e

e

g

g

a

a

s

s

t

t

c

c

a

a

t

t

n

n

o

o

c

c

B

B

T

T

d

d

o

o

o

o

h

h

d

d

l

l

i

i

h

h

c

c

n

n

i

i

e

e

g

g

a

a

r

r

e

e

v

v

o

o

c

c

t

t

n

n

e

e

m

m

t

t

a

a

e

e

r

r

t

t

I

I

B

B

T

T

L

L

2

2

.

.

E

E

.

.

1

1

%

%

0

0

9

9

=

=

t

t

e

e

g

g

r

r

a

a

T

T

.

.

)

)

E

E

(

(

)

)

G

G

(

(

s

s

r

r

a

a

e

e

y

y

e

e

g

g

a

a

r

r

e

e

v

v

o

o

c

c

n

n

o

o

i

i

t

t

a

a

g

g

i

i

t

t

s

s

e

e

v

v

n

n

i

i

t

t

c

c

a

a

t

t

n

n

o

o

C

C

1

1

.

.

E

E

.

.

1

1

%

%

0

0

9

9

=

=

t

t

e

e

g

g

r

r

a

a

T

T

.

.

)

)

E

E

(

(

)

)

G

G

(

(

(29.3)

(29.3)

(100.0)

(100.0)

(89.1)

(89.1)

(100.0)

(100.0)

(2.1)

(2.1)

Collaborative TB/HIV activities, and 

Collaborative TB/HIV activities, and 

management of relevant comorbidities

management of relevant comorbidities

g

g

n

n

o

o

m

m

a

a

)

)

%

%

(

(

e

e

t

t

a

a

r

r

t

t

n

n

e

e

m

m

l

l

o

o

r

r

n

n

e

e

T

T

R

R

A

A

4

4

.

.

D

D

.

.

1

1

.

.

d

d

e

e

t

t

c

c

e

e

f

f

n

n

i

i

o

o

c

c

V

V

I

I

H

H

/

/

B

B

T

T

%

%

0

0

0

0

1

1

=

=

t

t

e

e

g

g

r

r

a

a

T

T

g

g

n

n

o

o

m

m

a

a

e

e

g

g

a

a

r

r

e

e

v

v

o

o

c

c

t

t

n

n

e

e

m

m

t

t

a

a

e

e

r

r

t

t

I

I

B

B

T

T

L

L

5

5

.

.

D

D

.

.

1

1

%

%

0

0

3

3

=

=

t

t

e

e

g

g

r

r

a

a

T

T

.

.

)

)

G

G

(

(

V

V

I

I

H

H

L

L

P

P

(1.0)

(1.0)

(100.0)

(100.0)

.

.

)

)

%

%

(

(

e

e

t

t

a

a

r

r

n

n

o

o

i

i

t

t

c

c

e

e

t

t

e

e

d

d

-

-

e

e

s

s

a

a

c

c

V

V

I

I

H

H

/

/

B

B

T

T

1

1

.

.

D

D

.

.

1

1

%

%

0

0

9

9

=

=

t

t

e

e

g

g

r

r

a

a

T

T

(50.0)

(50.0)

–

–

(54.2)

(54.2)

(75.5)

(75.5)

(61.4)

(61.4)

(0.0)

(0.0)

(52.7)

(52.7)

(88.2)

(88.2)

(72.2)

(72.2)

(59.5)

(59.5)

(100.0)

(100.0)

(56.2)

(56.2)

(84.4)

(84.4)

–

–

–

–

 – 

 – 

 – 

 – 

 – 

 – 

 – 

 – 

 – 

 – 

–

–

–

–

.

.

)

)

E

E

(

(

)

)

G

G

(

(

)

)

%

%

(

(

e

e

g

g

a

a

r

r

e

e

v

v

o

o

c

c

g

g

n

n

i

i

t

t

s

s

e

e

t

t

V

V

I

I

H

H

2

2

.

.

D

D

.

.

1

1

%

%

0

0

0

0

1

1

=

=

t

t

e

e

g

g

r

r

a

a

T

T

(82.9)

(82.9)

(0.0)

(0.0)

(93.7)

(93.7)

(120.9)

(120.9)

(100.0)

(100.0)

(4.2)

(4.2)

(89.3)

(89.3)

(100.0)

(100.0)

(98.3)

(98.3)

(94.5)

(94.5)

–

–

(87.5)

(87.5)

(48.3)

(48.3)

(95.8)

(95.8)

(95.1)

(95.1)

 – 

 – 

 – 

 – 

 – 

 – 

 – 

 – 

 – 

 – 

–

–

–

–

.

.

B

B

T

T

l

l

l

l

a

a

g

g

n

n

o

o

m

m

a

a

V

V

I

I

H

H

f

f

o

o

b

b

e

e

g

g

a

a

t

t

n

n

e

e

c

c

r

r

e

e

P

P

3

3

.

.

D

D

.

.

1

1

e

e

s

s

a

a

e

e

r

r

c

c

e

e

d

d

:

:

t

t

e

e

g

g

r

r

a

a

T

T

–

–

(10.6)

(10.6)

(1.9)

(1.9)

(8.9)

(8.9)

–

–

(1.9)

(1.9)

(9.5)

(9.5)

(6.5)

(6.5)

(3.3)

(3.3)

–

–

(0.0)

(0.0)

(1.4)

(1.4)

(12.9)

(12.9)

(24.2)

(24.2)

 – 

 – 

 – 

 – 

 – 

 – 

 – 

 – 

 – 

 – 

–

–

–

–

(0.0)

(0.0)

(92.8)

(92.8)

(91.9)

(91.9)

–

–

–

–

(100.0)

(100.0)

(100.0)

(100.0)

(96.4)

(96.4)

(67.2)

(67.2)

(100.0)

(100.0)

(77.6)

(77.6)

(68.0)

(68.0)

–

–

–

–

 – 

 – 

 – 

 – 

 – 

 – 

 – 

 – 

 – 

 – 

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

(91.2)

(91.2)

(47.9)

(47.9)

(100.0)

(100.0)

(100.0)

(100.0)

(19.7)

(19.7)

(13.8)

(13.8)

(14.5)

(14.5)

(100.0)

(100.0)

(91.8)

(91.8)

(0.0)

(0.0)

(27.0)

(27.0)

(26.9)

(26.9)

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

(51.3)

(51.3)

(55.3)

(55.3)

(97.5)

(97.5)

(80.0)

(80.0)

(2.9)

(2.9)

(1.2)

(1.2)

(98.3)

(98.3)

(74.7)

(74.7)

(93.4)

(93.4)

(54.2)

(54.2)

(99.1)

(99.1)

(21.8)

(21.8)

(91.2)

(91.2)

(73.5)

(73.5)

(100.0)

(100.0)

(47.1)

(47.1)

(86.7)

(86.7)

(100.0)

(100.0)

(95.7)

(95.7)

(49.6)

(49.6)

(93.2)

(93.2)

(54.9)

(54.9)

(71.4)

(71.4)

(67.8)

(67.8)

(71.5)

(71.5)

(100.0)

(100.0)

(95.2)

(95.2)

(92.6)

(92.6)

(94.8)

(94.8)

(3.1)

(3.1)

(16.1)

(16.1)

(15.0)

(15.0)

(15.3)

(15.3)

(75.7)

(75.7)

(74.2)

(74.2)

(74.3)

(74.3)

(74.3)

(74.3)

(79.5)

(79.5)

(79.5)

(79.5)

(79.5)

(79.5)

(99.1)

(99.1)

(98.2)

(98.2)

(99.1)

(99.1)

(30.1)

(30.1)

(29.6)

(29.6)

(30.1)

(30.1)

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

 –   

 –   

 –   

 –   

 –   

 –   

commitment 

commitment 

strengthening 

strengthening 

2. Bold policies and supportive systems

2. Bold policies and supportive systems

Health 

Health 

systems 

systems 

in all 

in all 

functions, 

functions, 

including 

including 

financing 

financing 

mechanisms 

mechanisms 

for TB and 

for TB and 

human 

human 

resources

resources

Regulatory 

Regulatory 

frameworks 

frameworks 

for case-based 

for case-based 

surveillance, 

surveillance, 

strengthening 

strengthening 

quality and 

quality and 

rational use of 

rational use of 

medicines, and 

medicines, and 

pharmacovigilance

pharmacovigilance

well-aligned 

well-aligned 

vital registration, 

vital registration, 

Community 

Community 

systems and 

systems and 

civil society 

civil society 

engagement

engagement

Social 

Social 

protection, 

protection, 

poverty 

poverty 

alleviation 

alleviation 

and actions 

and actions 

on other 

on other 

determinants 

determinants 

of TB, such 

of TB, such 

as migration 

as migration 

and prisons

and prisons

3. Intensified 

3. Intensified 

research and 

research and 

innovation

innovation

Discovery, 

Discovery, 

development 

development 

and rapid 

and rapid 

uptake of 

uptake of 

new tools, 

new tools, 

interventions 

interventions 

and strategies

and strategies

c

c

i

i

h

h

p

p

o

o

r

r

t

t

s

s

a

a

t

t

a

a

c

c

e

e

c

c

n

n

e

e

i

i

r

r

e

e

p

p

x

x

e

e

t

t

a

a

h

h

t

t

s

s

d

d

l

l

o

o

h

h

e

e

s

s

u

u

o

o

0

0

o

o

t

t

e

e

s

s

o

o

l

l

c

c

:

:

t

t

e

e

g

g

r

r

a

a

T

T

.

.

)

)

E

E

(

(

)

)

G

G

(

(

B

B

T

T

o

o

t

t

e

e

u

u

d

d

s

s

t

t

s

s

o

o

c

c

d

d

e

e

t

t

c

c

e

e

f

f

f

f

a

a

-

-

B

B

T

T

f

f

o

o

e

e

g

g

a

a

t

t

n

n

e

e

c

c

r

r

e

e

P

P

1

1

.

.

B

B

.

.

2

2

h

h

w

w

e

e

n

n

h

h

t

t

i

i

w

w

)

)

%

%

(

(

e

e

g

g

a

a

r

r

e

e

v

v

o

o

c

c

t

t

n

n

e

e

m

m

t

t

a

a

e

e

r

r

T

T

1

1

.

.

C

C

.

.

2

2

%

%

0

0

3

3

=

=

t

t

e

e

g

g

r

r

a

a

T

T

.

.

)

)

E

E

(

(

)

)

G

G

(

(

s

s

g

g

u

u

r

r

d

d

B

B

T

T

s

s

n

n

o

o

i

i

t

t

i

i

l

l

a

a

o

o

c

c

r

r

e

e

d

d

l

l

o

o

h

h

e

e

k

k

a

a

t

t

s

s

i

i

t

t

l

l

u

u

m

m

g

g

n

n

i

i

n

n

o

o

i

i

t

t

c

c

n

n

u

u

f

f

h

h

t

t

i

i

w

w

s

s

e

e

t

t

a

a

t

t

S

S

r

r

e

e

b

b

m

m

e

e

M

M

f

f

o

o

r

r

e

e

b

b

m

m

u

u

N

N

1

1

.

.

D

D

.

.

2

2

.

.

e

e

c

c

r

r

u

u

o

o

s

s

e

e

r

r

d

d

n

n

a

a

e

e

r

r

a

a

c

c

B

B

T

T

r

r

o

o

f

f

g

g

n

n

i

i

t

t

a

a

c

c

o

o

v

v

d

d

a

a

3

3

5

5

=

=

t

t

e

e

g

g

r

r

a

a

T

T

w

w

e

e

n

n

f

f

o

o

)

)

%

%

(

(

e

e

t

t

a

a

r

r

s

s

s

s

e

e

c

c

c

c

u

u

s

s

t

t

n

n

e

e

m

m

t

t

a

a

e

e

r

r

T

T

1

1

.

.

E

E

.

.

2

2

.

.

s

s

r

r

e

e

n

n

o

o

s

s

i

i

r

r

p

p

g

g

n

n

o

o

m

m

a

a

s

s

e

e

s

s

a

a

c

c

B

B

T

T

e

e

s

s

p

p

a

a

l

l

e

e

r

r

d

d

n

n

a

a

%

%

5

5

8

8

=

=

t

t

e

e

g

g

r

r

a

a

T

T

:

:

t

t

e

e

g

g

r

r

a

a

T

T

.

.

6

6

1

1

0

0

2

2

-

-

d

d

i

i

m

m

y

y

b

b

e

e

v

v

i

i

t

t

a

a

i

i

t

t

i

i

n

n

i

i

h

h

c

c

r

r

a

a

e

e

s

s

e

e

r

r

B

B

T

T

n

n

a

a

e

e

p

p

o

o

r

r

u

u

E

E

1

1

.

.

A

A

.

.

d

d

d

d

e

e

e

e

h

h

h

h

s

s

s

s

i

i

i

i

l

l

l

l

b

b

b

b

a

a

a

a

t

t

t

t

s

s

s

s

3

3

e

e

e

e

Country/area

Country/area

– Bosnia and Herzegovina

– Bosnia and Herzegovina

Non-EU/EEA

Non-EU/EEA

– Albania

– Albania

– Andorra

– Andorra

– Armenia

– Armenia

– Azerbaijan

– Azerbaijan

– Belarus

– Belarus

– Georgia

– Georgia

– Israel

– Israel

– Kazakhstan

– Kazakhstan

– Kyrgyzstan

– Kyrgyzstan

– Monaco

– Monaco

– Montenegro

– Montenegro

Serbia excluding Kosovo1

Serbia excluding Kosovo1

– North Macedonia

– North Macedonia

– Republic of Moldova

– Republic of Moldova

– Russian Federation

– Russian Federation

– San Marino

– San Marino

– Serbia

– Serbia

–

–

–

–

Kosovo1

Kosovo1

– Switzerland

– Switzerland

– Tajikistan

– Tajikistan

– Turkey

– Turkey

– Turkmenistan

– Turkmenistan

– Ukraine

– Ukraine

– United Kingdom

– United Kingdom

– Uzbekistan

– Uzbekistan

 –    Subtotal non-EU/EEA

 –    Subtotal non-EU/EEA

 –    Total European Region

 –    Total European Region

 –    Subtotal 18 HPCs

 –    Subtotal 18 HPCs

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

 –   

 –   

 –   

 –   

 –   

 –   

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

 –   

 –   

 –   

 –   

 –   

 –   

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

 –   

 –   

 –   

 –   

 –   

 –   

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

(100.0)

(100.0)

(0.0)

(0.0)

(96.6)

(96.6)

(87.0)

(87.0)

(100.0)

(100.0)

(87.0)

(87.0)

(81.1)

(81.1)

(100.0)

(100.0)

(78.6)

(78.6)

(55.8)

(55.8)

(88.6)

(88.6)

(77.7)

(77.7)

(75.7)

(75.7)

(60.1)

(60.1)

(60.4)

(60.4)

(60.4)

(60.4)

Table 25 contd
Table 25 contd

Country/area
Country/area

1. Integrated, patient-centred care and prevention
1. Integrated, patient-centred care and prevention

Systematic 
Systematic 
screening 
screening 
of contacts 
of contacts 
and 
and 
high-risk 
high-risk 
groups
groups

Early diagnosis of all forms of TB and universal access to DST, including the 
Early diagnosis of all forms of TB and universal access to DST, including the 
use of rapid tests
use of rapid tests

Equitable access to quality treatment and 
Equitable access to quality treatment and 
continuum of care for all people with TB, including 
continuum of care for all people with TB, including 
drug-resistant TB; and patient support to facilitate 
drug-resistant TB; and patient support to facilitate 
treatment adherence
treatment adherence

k
k
s
s
i
i
r
r

t
t
a
a
n
n
o
o
i
i
t
t
a
a
l
l
u
u
p
p
o
o
p
p
f
f
o
o
e
e
g
g
a
a
r
r
e
e
v
v
o
o
C
C
1
1
.
.

A
A

.
.
1
1

e
e
v
v
i
i
t
t
c
c
a
a
r
r
o
o
f
f
g
g
n
n
i
i
n
n
e
e
e
e
r
r
c
c
s
s
c
c
i
i
t
t
a
a
m
m
e
e
t
t
s
s
y
y
s
s
h
h
t
t
i
i
w
w

%
%
0
0
8
8
=
=
t
t
e
e
g
g
r
r
a
a
T
T
.
.
I
I
B
B
T
T
L
L
d
d
n
n
a
a
B
B
T
T

d
d
n
n
a
a
w
w
e
e
n
n
d
d
e
e
i
i
f
f
i
i
t
t
o
o
n
n
f
f
o
o
e
e
g
g
a
a
t
t
n
n
e
e
c
c
r
r
e
e
P
P
1
1
.
.

B
B

.
.
1
1

g
g
n
n
i
i
s
s
u
u
d
d
e
e
s
s
o
o
n
n
g
g
a
a
i
i
d
d
s
s
t
t
n
n
e
e
i
i
t
t
a
a
p
p
B
B
T
T
e
e
s
s
p
p
a
a
l
l
e
e
r
r

.
.
)
)
G
G
(
(
s
s
t
t
s
s
e
e
t
t
d
d
i
i
p
p
a
a
r
r
d
d
e
e
d
d
n
n
e
e
m
m
m
m
o
o
c
c
e
e
r
r
-
-
O
O
H
H
W
W

%
%
0
0
9
9
≥
≥

t
t
e
e
g
g
r
r
a
a
T
T

d
d
e
e
m
m

r
r
i
i
f
f
n
n
o
o
c
c
y
y
l
l
l
l
a
a
c
c
i
i
g
g
o
o
l
l
o
o
i
i
r
r
e
e
t
t
c
c
a
a
b
b
l
l
l
l
a
a
g
g
n
n
o
o
m
m
a
a

%
%
0
0
0
0
1
1
=
=
t
t
e
e
g
g
r
r
a
a
T
T
a
a
.
.
)
)
G
G
(
(
s
s
e
e
s
s
a
a
c
c
B
B
T
T

)
)

%
%

(
(
e
e
g
g
a
a
r
r
e
e
v
v
o
o
c
c
T
T
S
S
D
D
e
e
n
n
i
i
l
l
-
-
t
t
s
s
r
r
i
i
F
F
2
2
.
.

B
B

.
.
1
1

e
e
t
t
a
a
r
r
n
n
o
o
i
i
t
t
c
c
e
e
t
t
e
e
d
d
-
-
e
e
s
s
a
a
c
c
B
B
T
T
-
-
R
R
D
D
M
M
/
/
R
R
R
R
3
3
.
.
B
B

.
.
1
1

%
%
5
5
8
8
=
=
t
t
e
e
g
g
r
r
a
a
T
T
a
a
.
.
)
)

%
%

(
(

Non-EU/EEA
Non-EU/EEA
Albania
Albania
Andorra
Andorra
Armenia
Armenia
Azerbaijan
Azerbaijan
Belarus
Belarus
Bosnia and Herzegovina
Bosnia and Herzegovina
Georgia
Georgia
Israel
Israel
Kazakhstan
Kazakhstan
Kyrgyzstan
Kyrgyzstan
Monaco
Monaco
Montenegro
Montenegro
North Macedonia
North Macedonia
Republic of Moldova
Republic of Moldova
Russian Federation
Russian Federation
San Marino
San Marino
Serbia
Serbia

Serbia excluding Kosovo1
Serbia excluding Kosovo1
Kosovo1
Kosovo1
Switzerland
Switzerland
Tajikistan
Tajikistan
Turkey
Turkey
Turkmenistan
Turkmenistan
Ukraine
Ukraine
United Kingdom
United Kingdom
Uzbekistan
Uzbekistan
Subtotal non-EU/EEA
Subtotal non-EU/EEA
Total European Region
Total European Region
Subtotal 18 HPCs
Subtotal 18 HPCs

(29.3)
(29.3)
(100.0)
(100.0)
(89.1)
(89.1)
–
–
(100.0)
(100.0)
–
–
–
–
–
–
(100.0)
(100.0)
(100.0)
(100.0)
–
–
(14.5)
(14.5)
(100.0)
(100.0)
(91.8)
(91.8)
–
–
–
–
–
–
–
–
–
–
(100.0)
(100.0)
–
–
(86.7)
(86.7)
(100.0)
(100.0)
(95.7)
(95.7)
–
–
–
–
(99.1)
(99.1)
(98.2)
(98.2)
(99.1)
(99.1)

(57.5)
(57.5)
(100.0)
(100.0)
(82.7)
(82.7)
(82.4)
(82.4)
(94.2)
(94.2)
–
–
(87.7)
(87.7)
–
–
(96.0)
(96.0)
(58.8)
(58.8)
–
–
(87.5)
(87.5)
–
–
(94.2)
(94.2)
(81.6)
(81.6)
	–	
	–	
	–	
	–	
	–	
	–	
	–	
	–	
	–	
	–	
(84.4)
(84.4)
–
–
(37.1)
(37.1)
(95.7)
(95.7)
(11.4)
(11.4)
(91.3)
(91.3)
(82.3)
(82.3)
(72.3)
(72.3)
(80.7)
(80.7)

(93.9)
(93.9)
(100.0)
(100.0)
(98.0)
(98.0)
(96.9)
(96.9)
(100.0)
(100.0)
(96.3)
(96.3)
(98.9)
(98.9)
(100.0)
(100.0)
(99.9)
(99.9)
(92.6)
(92.6)
–
–
(100.0)
(100.0)
(86.7)
(86.7)
(95.7)
(95.7)
(93.3)
(93.3)
 – 
 – 
 – 
 – 
 – 
 – 
 – 
 – 
(63.1)
(63.1)
(100.0)
(100.0)
(90.1)
(90.1)
–
–
(97.3)
(97.3)
(84.2)
(84.2)
(100.0)
(100.0)
(94.9)
(94.9)
(92.0)
(92.0)
(94.6)
(94.6)

(100.0)
(100.0)
–
–
(96.3)
(96.3)
(97.4)
(97.4)
(100.6)
(100.6)
–
–
(100.5)
(100.5)
(100.0)
(100.0)
(98.6)
(98.6)
(92.6)
(92.6)
–
–
–
–
(100.0)
(100.0)
(96.0)
(96.0)
(95.5)
(95.5)
–
–
–
–
–
–
–
–
(40.0)
(40.0)
(99.1)
(99.1)
(90.7)
(90.7)
–
–
(97.1)
(97.1)
(87.5)
(87.5)
(100.0)
(100.0)
(95.5)
(95.5)
(93.8)
(93.8)
(95.2)
(95.2)

0
0
0
0
0
0
0
0
0
0
1
1

r
r
e
e
p
p
e
e
t
t
a
a
r
r
n
n
o
o
i
i
t
t
a
a
c
c
i
i
f
f
i
i
t
t
o
o
n
n
B
B
T
T
4
4
.
.

B
B

.
.
1
1

r
r
e
e
p
p
6
6

.
.
4
4
2
2
=
=
t
t
e
e
g
g
r
r
a
a
T
T
.
.
)
)
E
E
(
(
n
n
o
o
i
i
t
t
a
a
l
l
u
u
p
p
o
o
p
p

n
n
o
o
i
i
t
t
a
a
l
l
u
u
p
p
o
o
p
p
0
0
0
0
0
0
0
0
0
0
1
1

(8.3)
(8.3)
(2.6)
(2.6)
(13.3)
(13.3)
(36.3)
(36.3)
(16.0)
(16.0)
(10.9)
(10.9)
(41.8)
(41.8)
(1.8)
(1.8)
(51.1)
(51.1)
(65.0)
(65.0)
(0.0)
(0.0)
(6.4)
(6.4)
(6.9)
(6.9)
(43.8)
(43.8)
(40.2)
(40.2)
(0.0)
(0.0)
(5.0)
(5.0)
–
–
 – 
 – 
(4.1)
(4.1)
(43.5)
(43.5)
(10.5)
(10.5)
(31.8)
(31.8)
(40.1)
(40.1)
(6.2)
(6.2)
(36.2)
(36.2)
(27.4)
(27.4)
(17.5)
(17.5)
(32.8)
(32.8)

.
.
)
)

%
%

(
(
e
e
t
t
a
a
r
r
n
n
o
o
i
i
t
t
c
c
e
e
t
t
e
e
d
d
-
-
e
e
s
s
a
a
c
c
B
B
T
T
5
5
.
.

B
B

.
.
1
1

e
e
s
s
a
a
e
e
r
r
c
c
n
n
i
i

:
:
t
t
e
e
g
g
r
r
a
a
T
T

(55.8)
(55.8)
(100.0)
(100.0)
(57.9)
(57.9)
(62.4)
(62.4)
(60.6)
(60.6)
(42.0)
(42.0)
(59.6)
(59.6)
(87.8)
(87.8)
(73.9)
(73.9)
(61.5)
(61.5)
 – 
 – 
(40.4)
(40.4)
(57.2)
(57.2)
(58.9)
(58.9)
(86.4)
(86.4)
 – 
 – 
(36.6)
(36.6)
 – 
 – 
 – 
 – 
(87.8)
(87.8)
(51.9)
(51.9)
(67.9)
(67.9)
(68.5)
(68.5)
(54.8)
(54.8)
(89.0)
(89.0)
(55.1)
(55.1)
(70.0)
(70.0)
(70.7)
(70.7)
(69.2)
(69.2)

:
:
t
t
e
e
g
g
r
r
a
a
T
T
a
a
.
.
)
)
E
E
(
(
s
s
t
t
n
n
e
e
i
i
t
t
a
a
p
p
B
B
T
T
w
w
e
e
n
n
g
g
n
n
o
o
m
m
a
a

B
B
T
T
-
-
R
R
D
D
M
M
/
/
R
R
R
R
f
f
o
o
e
e
g
g
a
a
t
t
n
n
e
e
c
c
r
r
e
e
P
P
6
6

.
.

B
B

.
.
1
1

B
B
T
T
-
-
R
R
D
D
M
M
/
/
R
R
R
R
f
f
o
o
e
e
g
g
a
a
t
t
n
n
e
e
c
c
r
r
e
e
P
P
7
7
.
.

B
B

.
.
1
1

B
B
T
T
d
d
e
e
t
t
a
a
e
e
r
r
t
t
y
y
l
l
s
s
u
u
o
o
i
i
v
v
e
e
r
r
p
p
g
g
n
n
o
o
m
m
a
a

e
e
s
s
a
a
e
e
r
r
c
c
e
e
d
d
:
:
t
t
e
e
g
g
r
r
a
a
T
T
a
a
.
.
s
s
t
t
n
n
e
e
i
i
t
t
a
a
p
p

e
e
s
s
a
a
e
e
r
r
c
c
e
e
d
d

(0.8)
(0.8)
(0.0)
(0.0)
(14.1)
(14.1)
(12.0)
(12.0)
(39.5)
(39.5)
(0.0)
(0.0)
(10.7)
(10.7)
(5.6)
(5.6)
(36.2)
(36.2)
(28.3)
(28.3)
 – 
 – 
(0.0)
(0.0)
(1.2)
(1.2)
(26.0)
(26.0)
(36.3)
(36.3)
 – 
 – 
 – 
 – 
 – 
 – 
 – 
 – 
(2.3)
(2.3)
(24.2)
(24.2)
(2.5)
(2.5)
–
–
(28.6)
(28.6)
(2.0)
(2.0)
(18.3)
(18.3)
(27.8)
(27.8)
(23.1)
(23.1)
(26.9)
(26.9)

(23.1)
(23.1)
(0.0)
(0.0)
(50.0)
(50.0)
(24.4)
(24.4)
(74.5)
(74.5)
(0.0)
(0.0)
(26.5)
(26.5)
(0.0)
(0.0)
(49.7)
(49.7)
(54.0)
(54.0)
 – 
 – 
(0.0)
(0.0)
(10.0)
(10.0)
(53.1)
(53.1)
(68.4)
(68.4)
 – 
 – 
 – 
 – 
 – 
 – 
 – 
 – 
(0.0)
(0.0)
(43.2)
(43.2)
(11.1)
(11.1)
–
–
(41.3)
(41.3)
(5.3)
(5.3)
(38.4)
(38.4)
(57.7)
(57.7)
(55.2)
(55.2)
(56.2)
(56.2)

f
f
o
o
n
n
o
o
i
i
t
t
a
a
z
z
i
i
l
l
a
a
t
t
i
i
p
p
s
s
o
o
h
h
f
f
o
o
e
e
g
g
a
a
t
t
n
n
e
e
c
c
r
r
e
e
P
P
1
1
.
.
C
C
.
.
1
1

e
e
s
s
a
a
e
e
r
r
c
c
e
e
d
d
:
:
t
t
e
e
g
g
r
r
a
a
T
T
.
.
)
)
E
E
(
(
s
s
t
t
n
n
e
e
i
i
t
t
a
a
p
p
B
B
T
T
w
w
e
e
n
n

(20.0)
(20.0)
(100.0)
(100.0)
(63.0)
(63.0)
(27.0)
(27.0)
(68.0)
(68.0)
–
–
(22.0)
(22.0)

(64.0)
(64.0)
(86.0)
(86.0)
	–	
	–	
(93.0)
(93.0)
(50.0)
(50.0)
(58.0)
(58.0)
(63.0)
(63.0)
–
–
(75.0)
(75.0)
	–	
	–	
	–	
	–	
(80.0)
(80.0)
(73.0)
(73.0)
(55.0)
(55.0)
(72.0)
(72.0)
(61.0)
(61.0)
–
–
(90.0)
(90.0)
 –   
 –   
 –   
 –   
 –   
 –   

.
.
)
)
G
G
(
(

t
t
n
n
e
e
m
m

t
t
a
a
e
e
r
r
t
t
n
n
i
i
d
d
e
e
l
l
l
l
o
o
r
r
n
n
e
e
B
B
T
T
-
-
R
R
D
D
M
M

/
/
R
R
R
R
d
d
e
e
t
t
c
c
e
e
t
t
e
e
d
d
f
f
o
o
e
e
g
g
a
a
t
t
n
n
e
e
c
c
r
r
e
e
P
P
2
2
.
.
C
C
.
.
1
1

%
%
0
0
0
0
1
1
=
=
t
t
e
e
g
g
r
r
a
a
T
T

)
)

%
%

(
(
e
e
t
t
a
a
r
r
s
s
s
s
e
e
c
c
c
c
u
u
s
s
t
t
n
n
e
e
m
m

t
t
a
a
e
e
r
r
T
T
3
3
.
.
C
C
.
.
1
1

B
B
T
T
e
e
s
s
p
p
a
a
l
l
e
e
r
r
d
d
n
n
a
a
w
w
e
e
n
n
l
l
l
l
a
a
g
g
n
n
o
o
m
m
a
a

%
%
5
5
8
8
=
=
t
t
e
e
g
g
r
r
a
a
T
T
.
.
)
)
G
G
(
(
s
s
t
t
n
n
e
e
i
i
t
t
a
a
p
p

%
%
5
5
7
7
=
=
t
t
e
e
g
g
r
r
a
a
T
T
.
.
)
)
E
E
(
(

)
)
G
G
(
(

t
t
r
r
o
o
h
h
o
o
c
c

t
t
n
n
e
e
m
m

t
t
a
a
e
e
r
r
t
t

)
)

%
%

(
(
e
e
t
t
a
a
r
r
s
s
s
s
e
e
c
c
c
c
u
u
s
s
t
t
n
n
e
e
m
m

t
t
a
a
e
e
r
r
T
T
4
4
.
.
C
C
.
.
1
1

B
B
T
T
-
-
R
R
D
D
M
M
/
/
R
R
R
R
e
e
h
h
t
t
g
g
n
n
o
o
m
m
a
a

)
)
9
9
1
1
–
–
5
5
1
1
A
A
D
D
C
C
I
I
(
(
e
e
t
t
a
a
r
r
y
y
t
t
i
i
l
l
a
a
t
t
r
r
o
o
m
m
B
B
T
T
5
5
.
.
C
C
.
.
1
1

r
r
e
e
p
p
7
7
.
.
2
2
=
=
t
t
e
e
g
g
r
r
a
a
T
T
.
.
)
)
E
E
(
(

)
)
G
G
(
(

n
n
o
o
i
i
t
t
a
a
l
l
u
u
p
p
o
o
p
p
0
0
0
0
0
0
0
0
0
0
1
1

(100.0)
(100.0)
–
–
(100.0)
(100.0)
(89.3)
(89.3)
(94.0)
(94.0)
–
–
(99.3)
(99.3)
(100.0)
(100.0)
(109.2)
(109.2)
(93.7)
(93.7)
	–	
	–	
–
–
(100.0)
(100.0)
(214.7)
(214.7)
(141.8)
(141.8)
–
–
–
–
–
–
–
–
(25.0)
(25.0)
(82.0)
(82.0)
(97.8)
(97.8)
(100.0)
(100.0)
(114.3)
(114.3)
–
–
(100.0)
(100.0)
(126.2)
(126.2)
(125.4)
(125.4)
(125.9)
(125.9)

(88.3)
(88.3)
(60.0)
(60.0)
(82.3)
(82.3)
(84.0)
(84.0)
(88.6)
(88.6)
(31.9)
(31.9)
(85.1)
(85.1)
(83.9)
(83.9)
(90.2)
(90.2)
(81.3)
(81.3)
–
–
(95.1)
(95.1)
(88.9)
(88.9)
(83.7)
(83.7)
(68.2)
(68.2)
–
–
(85.2)
(85.2)
	–	
	–	
	–	
	–	
(68.3)
(68.3)
(90.8)
(90.8)
(83.2)
(83.2)
(82.6)
(82.6)
(79.2)
(79.2)
(77.5)
(77.5)
(90.1)
(90.1)
(77.5)
(77.5)
(76.5)
(76.5)
(78.2)
(78.2)

(75.0)
(75.0)
–
–
(45.9)
(45.9)
(57.4)
(57.4)
(72.9)
(72.9)
–
–
(67.4)
(67.4)
(64.3)
(64.3)
(80.7)
(80.7)
(62.3)
(62.3)
–
–
100.0
100.0
(50.0)
(50.0)
(58.7)
(58.7)
(51.4)
(51.4)
–
–
–
–
–
–
–
–
(66.7)
(66.7)
(70.2)
(70.2)
(55.0)
(55.0)
(45.2)
(45.2)
(50.5)
(50.5)
(75.0)
(75.0)
(67.4)
(67.4)
(56.0)
(56.0)
(55.9)
(55.9)
(55.9)
(55.9)

(0.4)
(0.4)
(1.4)
(1.4)
(1.0)
(1.0)
(7.3)
(7.3)
(2.8)
(2.8)
(3.5)
(3.5)
(4.8)
(4.8)
(0.2)
(0.2)
(3.2)
(3.2)
(4.6)
(4.6)
(0.0)
(0.0)
(0.2)
(0.2)
(1.2)
(1.2)
(5.3)
(5.3)
(5.0)
(5.0)
(0.0)
(0.0)
(1.1)
(1.1)
 – 
 – 
 – 
 – 
(0.2)
(0.2)
(9.6)
(9.6)
(0.5)
(0.5)
(10.0)
(10.0)
(9.4)
(9.4)
(0.5)
(0.5)
(3.2)
(3.2)
(3.5)
(3.5)
(2.3)
(2.3)
(4.4)
(4.4)

 1 All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999).  

98

SURVEILLANCE REPORTTuberculosis surveillance and monitoring in Europe 2022 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. Integrated, patient-centred care and prevention

1. Integrated, patient-centred care and prevention

Table 25 contd

Table 25 contd

Country/area

Country/area

Systematic 

Systematic 

screening 

screening 

of contacts 

of contacts 

and 

and 

high-risk 

high-risk 

groups

groups

k

k

s

s

i

i

r

r

t

t

a

a

n

n

o

o

i

i

t

t

a

a

l

l

u

u

p

p

o

o

p

p

f

f

o

o

e

e

g

g

a

a

r

r

e

e

v

v

o

o

C

C

e

e

v

v

i

i

t

t

c

c

a

a

r

r

o

o

f

f

g

g

n

n

i

i

n

n

e

e

e

e

r

r

c

c

s

s

c

c

i

i

t

t

a

a

m

m

e

e

t

t

s

s

y

y

s

s

1

1

.

.

A

A

.

.

1

1

h

h

t

t

i

i

w

w

%

%

0

0

8

8

=

=

t

t

e

e

g

g

r

r

a

a

T

T

.

.

I

I

B

B

T

T

L

L

d

d

n

n

a

a

B

B

T

T

d

d

n

n

a

a

w

w

e

e

n

n

d

d

e

e

i

i

f

f

i

i

t

t

o

o

n

n

f

f

o

o

e

e

g

g

a

a

t

t

n

n

e

e

c

c

r

r

e

e

P

P

1

1

.

.

B

B

.

.

1

1

g

g

n

n

i

i

s

s

u

u

d

d

e

e

s

s

o

o

n

n

g

g

a

a

i

i

d

d

s

s

t

t

n

n

e

e

i

i

t

t

a

a

p

p

B

B

T

T

e

e

s

s

p

p

a

a

l

l

e

e

r

r

.

.

)

)

G

G

(

(

s

s

t

t

s

s

e

e

t

t

d

d

i

i

p

p

a

a

r

r

d

d

e

e

d

d

n

n

e

e

m

m

m

m

o

o

c

c

e

e

r

r

-

-

O

O

H

H

W

W

%

%

0

0

9

9

≥

≥

t

t

e

e

g

g

r

r

a

a

T

T

d

d

e

e

m

m

r

r

i

i

f

f

n

n

o

o

c

c

y

y

l

l

l

l

a

a

c

c

i

i

g

g

o

o

l

l

o

o

i

i

r

r

e

e

t

t

c

c

a

a

b

b

l

l

l

l

a

a

g

g

n

n

o

o

m

m

)

)

%

%

(

(

e

e

g

g

a

a

r

r

e

e

v

v

o

o

c

c

T

T

S

S

D

D

e

e

n

n

i

i

l

l

-

-

t

t

s

s

r

r

i

i

F

F

2

2

.

.

B

B

.

.

1

1

%

%

0

0

0

0

1

1

=

=

t

t

e

e

g

g

r

r

a

a

T

T

a

a

.

.

)

)

G

G

(

(

s

s

e

e

s

s

a

a

c

c

B

B

a

a

T

T

a

a

:

:

t

t

e

e

g

g

r

r

a

a

T

T

.

.

)

)

E

E

(

(

s

s

t

t

n

n

e

e

i

i

t

t

a

a

p

p

B

B

T

T

w

w

e

e

n

n

g

g

n

n

o

o

m

m

a

a

B

B

T

T

-

-

R

R

D

D

M

M

/

/

R

R

R

R

f

f

o

o

e

e

g

g

a

a

t

t

n

n

e

e

c

c

r

r

e

e

P

P

6

6

.

.

B

B

.

.

1

1

B

B

T

T

-

-

R

R

D

D

M

M

/

/

R

R

R

R

f

f

o

o

e

e

g

g

a

a

t

t

n

n

e

e

c

c

r

r

e

e

P

P

7

7

.

.

B

B

.

.

1

1

B

B

T

T

d

d

e

e

t

t

a

a

e

e

r

r

t

t

y

y

l

l

s

s

u

u

o

o

i

i

v

v

e

e

r

r

p

p

g

g

n

n

o

o

m

m

a

a

e

e

s

s

a

a

e

e

r

r

c

c

e

e

d

d

:

:

t

t

e

e

g

g

r

r

a

a

T

T

a

a

.

.

s

s

t

t

n

n

e

e

i

i

t

t

a

a

p

p

.

.

)

)

G

G

(

(

t

t

n

n

e

e

m

m

t

t

a

a

e

e

r

r

t

t

/

/

R

R

R

R

d

d

e

e

t

t

c

c

e

e

t

t

e

e

d

d

f

f

o

o

n

n

i

i

e

e

g

g

a

a

t

t

n

n

e

e

c

c

r

r

e

e

P

P

2

2

.

.

C

C

.

.

1

1

d

d

e

e

l

l

l

l

o

o

r

r

n

n

e

e

B

B

T

T

-

-

R

R

D

D

M

M

%

%

0

0

0

0

1

1

=

=

t

t

e

e

g

g

r

r

a

a

T

T

)

)

%

%

(

(

e

e

t

t

B

B

T

T

a

a

e

e

r

r

s

s

s

s

e

e

c

c

c

c

u

u

s

s

t

t

n

n

e

e

m

m

t

t

a

a

e

e

r

r

T

T

3

3

.

.

C

C

.

.

1

1

s

s

p

p

a

a

l

l

e

e

r

r

d

d

n

n

a

a

w

w

e

e

n

n

l

l

l

l

a

a

g

g

n

n

o

o

m

m

a

a

%

%

5

5

8

8

=

=

t

t

e

e

g

g

r

r

a

a

T

T

.

.

)

)

G

G

(

(

s

s

t

t

n

n

e

e

i

i

t

t

a

a

p

p

%

%

5

5

7

7

=

=

t

t

e

e

g

g

r

r

a

a

T

T

.

.

)

)

E

E

(

(

)

)

G

G

(

(

t

t

r

r

o

o

h

h

o

o

c

c

t

t

n

n

e

e

m

m

t

t

a

a

e

e

r

r

t

t

)

)

%

%

(

(

e

e

t

t

a

a

r

r

s

s

s

s

e

e

c

c

c

c

u

u

s

s

t

t

n

n

e

e

m

m

t

t

a

a

e

e

r

r

T

T

4

4

.

.

C

C

.

.

1

1

B

B

T

T

-

-

R

R

D

D

M

M

/

/

R

R

R

R

e

e

h

h

t

t

g

g

n

n

o

o

m

m

a

a

)

)

9

9

1

1

–

–

5

5

1

1

A

A

D

D

C

C

I

I

(

(

e

e

t

t

a

a

r

r

y

y

t

t

i

i

l

l

a

a

t

t

r

r

o

o

m

m

B

B

T

T

5

5

.

.

C

C

.

.

1

1

r

r

e

e

p

p

7

7

.

.

2

2

=

=

t

t

e

e

g

g

r

r

a

a

T

T

.

.

)

)

E

E

(

(

)

)

G

G

(

(

n

n

o

o

i

i

t

t

a

a

l

l

u

u

p

p

o

o

p

p

0

0

0

0

0

0

0

0

0

0

1

1

(93.9)

(93.9)

(100.0)

(100.0)

(8.3)

(8.3)

(2.6)

(2.6)

(55.8)

(55.8)

(100.0)

(100.0)

(100.0)

(100.0)

(100.6)

(100.6)

e

e

t

t

a

a

r

r

n

n

o

o

i

i

t

t

c

c

e

e

t

t

e

e

d

d

-

-

e

e

s

s

a

a

c

c

B

B

T

T

-

-

R

R

D

D

M

M

/

/

R

R

R

R

3

3

.

.

B

B

.

.

1

1

%

%

5

5

8

8

=

=

t

t

e

e

g

g

r

r

a

a

T

T

a

a

.

.

)

)

%

%

(

(

(96.3)

(96.3)

(97.4)

(97.4)

(100.5)

(100.5)

(100.0)

(100.0)

(98.6)

(98.6)

(92.6)

(92.6)

(100.0)

(100.0)

(96.0)

(96.0)

(95.5)

(95.5)

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

(40.0)

(40.0)

(99.1)

(99.1)

(90.7)

(90.7)

(97.1)

(97.1)

(87.5)

(87.5)

(95.5)

(95.5)

(93.8)

(93.8)

(95.2)

(95.2)

0

0

0

0

0

0

0

0

0

0

1

1

r

r

e

e

p

p

r

r

e

e

6

6

.

.

p

p

4

4

e

e

t

t

a

a

r

r

n

n

o

o

i

i

t

t

a

a

c

c

i

i

f

f

i

i

t

t

o

o

n

n

B

B

T

T

4

4

.

.

B

B

.

.

1

1

2

2

=

=

t

t

e

e

g

g

r

r

a

a

T

T

.

.

)

)

E

E

(

(

n

n

o

o

i

i

t

t

a

a

l

l

u

u

p

p

o

o

p

p

n

n

o

o

i

i

t

t

a

a

l

l

u

u

p

p

o

o

p

p

0

0

0

0

0

0

0

0

0

0

1

1

(13.3)

(13.3)

(36.3)

(36.3)

(16.0)

(16.0)

(10.9)

(10.9)

(41.8)

(41.8)

(1.8)

(1.8)

(51.1)

(51.1)

(65.0)

(65.0)

(0.0)

(0.0)

(6.4)

(6.4)

(6.9)

(6.9)

(43.8)

(43.8)

(40.2)

(40.2)

(0.0)

(0.0)

(5.0)

(5.0)

–

–

 – 

 – 

(4.1)

(4.1)

(43.5)

(43.5)

(10.5)

(10.5)

(31.8)

(31.8)

(40.1)

(40.1)

(6.2)

(6.2)

(36.2)

(36.2)

(27.4)

(27.4)

(17.5)

(17.5)

(32.8)

(32.8)

.

.

)

)

%

%

(

(

e

e

t

t

a

a

r

r

n

n

o

o

i

i

t

t

c

c

e

e

t

t

e

e

d

d

-

-

e

e

s

s

a

a

c

c

B

B

T

T

5

5

.

.

B

B

.

.

1

1

e

e

s

s

a

a

e

e

r

r

c

c

n

n

i

i

:

:

t

t

e

e

g

g

r

r

a

a

T

T

(57.9)

(57.9)

(62.4)

(62.4)

(60.6)

(60.6)

(42.0)

(42.0)

(59.6)

(59.6)

(87.8)

(87.8)

(73.9)

(73.9)

(61.5)

(61.5)

 – 

 – 

(40.4)

(40.4)

(57.2)

(57.2)

(58.9)

(58.9)

(86.4)

(86.4)

(36.6)

(36.6)

 – 

 – 

 – 

 – 

 – 

 – 

(87.8)

(87.8)

(51.9)

(51.9)

(67.9)

(67.9)

(68.5)

(68.5)

(54.8)

(54.8)

(89.0)

(89.0)

(55.1)

(55.1)

(70.0)

(70.0)

(70.7)

(70.7)

(69.2)

(69.2)

(57.5)

(57.5)

(100.0)

(100.0)

(82.7)

(82.7)

(82.4)

(82.4)

(94.2)

(94.2)

(87.7)

(87.7)

–

–

–

–

–

–

–

–

(96.0)

(96.0)

(58.8)

(58.8)

(87.5)

(87.5)

(94.2)

(94.2)

(81.6)

(81.6)

	–	

	–	

	–	

	–	

	–	

	–	

	–	

	–	

	–	

	–	

–

–

(84.4)

(84.4)

(37.1)

(37.1)

(95.7)

(95.7)

(11.4)

(11.4)

(91.3)

(91.3)

(82.3)

(82.3)

(72.3)

(72.3)

(80.7)

(80.7)

(100.0)

(100.0)

(98.0)

(98.0)

(96.9)

(96.9)

(96.3)

(96.3)

(98.9)

(98.9)

(100.0)

(100.0)

(99.9)

(99.9)

(92.6)

(92.6)

–

–

(100.0)

(100.0)

(86.7)

(86.7)

(95.7)

(95.7)

(93.3)

(93.3)

 – 

 – 

 – 

 – 

 – 

 – 

 – 

 – 

(63.1)

(63.1)

(100.0)

(100.0)

(90.1)

(90.1)

–

–

(97.3)

(97.3)

(84.2)

(84.2)

(94.9)

(94.9)

(92.0)

(92.0)

(94.6)

(94.6)

(100.0)

(100.0)

(100.0)

(100.0)

f

f

o

o

n

n

o

o

i

i

t

t

a

a

z

z

i

i

l

l

a

a

t

t

i

i

p

p

s

s

o

o

h

h

f

f

o

o

e

e

g

g

a

a

t

t

n

n

e

e

c

c

r

r

e

e

P

P

1

1

.

.

C

C

.

.

1

1

e

e

s

s

a

a

e

e

r

r

c

c

e

e

d

d

:

:

t

t

e

e

g

g

r

r

a

a

T

T

.

.

)

)

E

E

(

(

s

s

t

t

n

n

e

e

i

i

t

t

a

a

p

p

B

B

T

T

w

w

e

e

n

n

(20.0)

(20.0)

(100.0)

(100.0)

(63.0)

(63.0)

(27.0)

(27.0)

(68.0)

(68.0)

–

–

(22.0)

(22.0)

(64.0)

(64.0)

(86.0)

(86.0)

	–	

	–	

(93.0)

(93.0)

(50.0)

(50.0)

(58.0)

(58.0)

(63.0)

(63.0)

(75.0)

(75.0)

–

–

	–	

	–	

	–	

	–	

(80.0)

(80.0)

(73.0)

(73.0)

(55.0)

(55.0)

(72.0)

(72.0)

(61.0)

(61.0)

(90.0)

(90.0)

–

–

 –   

 –   

 –   

 –   

 –   

 –   

e

e

s

s

a

a

e

e

r

r

c

c

e

e

d

d

(0.8)

(0.8)

(0.0)

(0.0)

(14.1)

(14.1)

(12.0)

(12.0)

(39.5)

(39.5)

(0.0)

(0.0)

(10.7)

(10.7)

(5.6)

(5.6)

(36.2)

(36.2)

(28.3)

(28.3)

 – 

 – 

(0.0)

(0.0)

(1.2)

(1.2)

(26.0)

(26.0)

(36.3)

(36.3)

 – 

 – 

 – 

 – 

 – 

 – 

 – 

 – 

(2.3)

(2.3)

(24.2)

(24.2)

(2.5)

(2.5)

–

–

(28.6)

(28.6)

(2.0)

(2.0)

(18.3)

(18.3)

(27.8)

(27.8)

(23.1)

(23.1)

(26.9)

(26.9)

(23.1)

(23.1)

(0.0)

(0.0)

(50.0)

(50.0)

(24.4)

(24.4)

(74.5)

(74.5)

(0.0)

(0.0)

(26.5)

(26.5)

(0.0)

(0.0)

(49.7)

(49.7)

(54.0)

(54.0)

 – 

 – 

(0.0)

(0.0)

(10.0)

(10.0)

(53.1)

(53.1)

(68.4)

(68.4)

 – 

 – 

 – 

 – 

 – 

 – 

 – 

 – 

(0.0)

(0.0)

(43.2)

(43.2)

(11.1)

(11.1)

–

–

(41.3)

(41.3)

(5.3)

(5.3)

(38.4)

(38.4)

(57.7)

(57.7)

(55.2)

(55.2)

(56.2)

(56.2)

(100.0)

(100.0)

(100.0)

(100.0)

(89.3)

(89.3)

(94.0)

(94.0)

–

–

–

–

(99.3)

(99.3)

(100.0)

(100.0)

(109.2)

(109.2)

(93.7)

(93.7)

(100.0)

(100.0)

(214.7)

(214.7)

(141.8)

(141.8)

	–	

	–	

–

–

–

–

–

–

–

–

–

–

(25.0)

(25.0)

(82.0)

(82.0)

(97.8)

(97.8)

(100.0)

(100.0)

(114.3)

(114.3)

–

–

(100.0)

(100.0)

(126.2)

(126.2)

(125.4)

(125.4)

(125.9)

(125.9)

(88.3)

(88.3)

(60.0)

(60.0)

(82.3)

(82.3)

(84.0)

(84.0)

(88.6)

(88.6)

(31.9)

(31.9)

(85.1)

(85.1)

(83.9)

(83.9)

(90.2)

(90.2)

(81.3)

(81.3)

–

–

(95.1)

(95.1)

(88.9)

(88.9)

(83.7)

(83.7)

(68.2)

(68.2)

(85.2)

(85.2)

–

–

	–	

	–	

	–	

	–	

(68.3)

(68.3)

(90.8)

(90.8)

(83.2)

(83.2)

(82.6)

(82.6)

(79.2)

(79.2)

(77.5)

(77.5)

(90.1)

(90.1)

(77.5)

(77.5)

(76.5)

(76.5)

(78.2)

(78.2)

(75.0)

(75.0)

(45.9)

(45.9)

(57.4)

(57.4)

(72.9)

(72.9)

–

–

–

–

(67.4)

(67.4)

(64.3)

(64.3)

(80.7)

(80.7)

(62.3)

(62.3)

–

–

100.0

100.0

(50.0)

(50.0)

(58.7)

(58.7)

(51.4)

(51.4)

–

–

–

–

–

–

–

–

(66.7)

(66.7)

(70.2)

(70.2)

(55.0)

(55.0)

(45.2)

(45.2)

(50.5)

(50.5)

(75.0)

(75.0)

(67.4)

(67.4)

(56.0)

(56.0)

(55.9)

(55.9)

(55.9)

(55.9)

(0.4)

(0.4)

(1.4)

(1.4)

(1.0)

(1.0)

(7.3)

(7.3)

(2.8)

(2.8)

(3.5)

(3.5)

(4.8)

(4.8)

(0.2)

(0.2)

(3.2)

(3.2)

(4.6)

(4.6)

(0.0)

(0.0)

(0.2)

(0.2)

(1.2)

(1.2)

(5.3)

(5.3)

(5.0)

(5.0)

(0.0)

(0.0)

(1.1)

(1.1)

 – 

 – 

 – 

 – 

(0.2)

(0.2)

(9.6)

(9.6)

(0.5)

(0.5)

(10.0)

(10.0)

(9.4)

(9.4)

(0.5)

(0.5)

(3.2)

(3.2)

(3.5)

(3.5)

(2.3)

(2.3)

(4.4)

(4.4)

Bosnia and Herzegovina

Bosnia and Herzegovina

Non-EU/EEA

Non-EU/EEA

Albania

Albania

Andorra

Andorra

Armenia

Armenia

Azerbaijan

Azerbaijan

Belarus

Belarus

Georgia

Georgia

Israel

Israel

Kazakhstan

Kazakhstan

Kyrgyzstan

Kyrgyzstan

Monaco

Monaco

Montenegro

Montenegro

Serbia excluding Kosovo1

Serbia excluding Kosovo1

North Macedonia

North Macedonia

Republic of Moldova

Republic of Moldova

Russian Federation

Russian Federation

San Marino

San Marino

Serbia

Serbia

Kosovo1

Kosovo1

Switzerland

Switzerland

Tajikistan

Tajikistan

Turkey

Turkey

Turkmenistan

Turkmenistan

Ukraine

Ukraine

United Kingdom

United Kingdom

Uzbekistan

Uzbekistan

Subtotal non-EU/EEA

Subtotal non-EU/EEA

Total European Region

Total European Region

Subtotal 18 HPCs

Subtotal 18 HPCs

(29.3)

(29.3)

(100.0)

(100.0)

(89.1)

(89.1)

(100.0)

(100.0)

(100.0)

(100.0)

(100.0)

(100.0)

(14.5)

(14.5)

(100.0)

(100.0)

(91.8)

(91.8)

(100.0)

(100.0)

(86.7)

(86.7)

(100.0)

(100.0)

(95.7)

(95.7)

(99.1)

(99.1)

(98.2)

(98.2)

(99.1)

(99.1)

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

Early diagnosis of all forms of TB and universal access to DST, including the 

Early diagnosis of all forms of TB and universal access to DST, including the 

use of rapid tests

use of rapid tests

Equitable access to quality treatment and 

Equitable access to quality treatment and 

continuum of care for all people with TB, including 

continuum of care for all people with TB, including 

drug-resistant TB; and patient support to facilitate 

drug-resistant TB; and patient support to facilitate 

treatment adherence

treatment adherence

Collaborative TB/HIV activities, and 
Collaborative TB/HIV activities, and 
management of relevant comorbidities
management of relevant comorbidities

2. Bold policies and supportive systems
2. Bold policies and supportive systems

Management 
Management 
of LTBI and 
of LTBI and 
preventive 
preventive 
treatment of 
treatment of 
persons at 
persons at 
high risk, and 
high risk, and 
vaccination 
vaccination 
against TB
against TB

Political 
Political 
commitment 
commitment 
with 
with 
adequate 
adequate 
resources, 
resources, 
including 
including 
universal 
universal 
health 
health 
coverage 
coverage 
policy
policy

Health 
Health 
systems 
systems 
strengthening 
strengthening 
in all 
in all 
functions, 
functions, 
including 
including 
well-aligned 
well-aligned 
financing 
financing 
mechanisms 
mechanisms 
for TB and 
for TB and 
human 
human 
resources
resources

Regulatory 
Regulatory 
frameworks 
frameworks 
for case-based 
for case-based 
surveillance, 
surveillance, 
strengthening 
strengthening 
vital registration, 
vital registration, 
quality and 
quality and 
rational use of 
rational use of 
medicines, and 
medicines, and 
pharmacovigilance
pharmacovigilance

Community 
Community 
systems and 
systems and 
civil society 
civil society 
engagement
engagement

Social 
Social 
protection, 
protection, 
poverty 
poverty 
alleviation 
alleviation 
and actions 
and actions 
on other 
on other 
determinants 
determinants 
of TB, such 
of TB, such 
as migration 
as migration 
and prisons
and prisons

3. Intensified 
3. Intensified 
research and 
research and 
innovation
innovation

Discovery, 
Discovery, 
development 
development 
and rapid 
and rapid 
uptake of 
uptake of 
new tools, 
new tools, 
interventions 
interventions 
and strategies
and strategies

.
.
)
)

%
%

(
(
e
e
t
t
a
a
r
r
n
n
o
o
i
i
t
t
c
c
e
e
t
t
e
e
d
d
-
-
e
e
s
s
a
a
c
c
V
V
I
I

H
H
/
/
B
B
T
T
1
1
.
.

D
D

.
.
1
1

%
%
0
0
9
9
=
=
t
t
e
e
g
g
r
r
a
a
T
T

(50.0)
(50.0)
–
–
(54.2)
(54.2)
(75.5)
(75.5)
(61.4)
(61.4)
(0.0)
(0.0)
(52.7)
(52.7)
(88.2)
(88.2)
(72.2)
(72.2)
(59.5)
(59.5)
–
–
–
–
(100.0)
(100.0)
(56.2)
(56.2)
(84.4)
(84.4)
 – 
 – 
 – 
 – 
 – 
 – 
 – 
 – 
 – 
 – 
(51.3)
(51.3)
(55.3)
(55.3)
–
–
(54.2)
(54.2)
–
–
(54.9)
(54.9)
(71.4)
(71.4)
(67.8)
(67.8)
(71.5)
(71.5)

.
.
)
)
E
E
(
(

)
)
G
G
(
(

)
)

%
%

(
(
e
e
g
g
a
a
r
r
e
e
v
v
o
o
c
c
g
g
n
n
i
i
t
t
s
s
e
e
t
t
V
V
I
I

H
H
2
2
.
.

D
D

.
.
1
1

%
%
0
0
0
0
1
1
=
=
t
t
e
e
g
g
r
r
a
a
T
T

(82.9)
(82.9)
(0.0)
(0.0)
(93.7)
(93.7)
(120.9)
(120.9)
(100.0)
(100.0)
(4.2)
(4.2)
(89.3)
(89.3)
(100.0)
(100.0)
(98.3)
(98.3)
(94.5)
(94.5)
–
–
(87.5)
(87.5)
(48.3)
(48.3)
(95.8)
(95.8)
(95.1)
(95.1)
 – 
 – 
 – 
 – 
 – 
 – 
 – 
 – 
 – 
 – 
(97.5)
(97.5)
(80.0)
(80.0)
–
–
(99.1)
(99.1)
–
–
(100.0)
(100.0)
(95.2)
(95.2)
(92.6)
(92.6)
(94.8)
(94.8)

.
.

B
B
T
T
l
l
l
l
a
a
g
g
n
n
o
o
m
m
a
a
V
V
I
I

H
H
f
f
o
o
e
e
g
g
a
a
t
t
n
n
e
e
c
c
r
r
e
e
P
P
3
3
.
.
D
D

.
.
1
1

b
b
e
e
s
s
a
a
e
e
r
r
c
c
e
e
d
d
:
:
t
t
e
e
g
g
r
r
a
a
T
T

(1.0)
(1.0)
–
–
(10.6)
(10.6)
(1.9)
(1.9)
(8.9)
(8.9)
–
–
(1.9)
(1.9)
(9.5)
(9.5)
(6.5)
(6.5)
(3.3)
(3.3)
–
–
(0.0)
(0.0)
(1.4)
(1.4)
(12.9)
(12.9)
(24.2)
(24.2)
 – 
 – 
 – 
 – 
 – 
 – 
 – 
 – 
 – 
 – 
(2.9)
(2.9)
(1.2)
(1.2)
–
–
(21.8)
(21.8)
–
–
(3.1)
(3.1)
(16.1)
(16.1)
(15.0)
(15.0)
(15.3)
(15.3)

g
g
n
n
o
o
m
m
a
a
)
)

%
%

(
(
e
e
t
t
a
a
r
r

t
t
n
n
e
e
m
m
l
l
o
o
r
r
n
n
e
e
T
T
R
R
A
A
4
4
.
.

D
D

.
.
1
1

.
.
d
d
e
e
t
t
c
c
e
e
f
f
n
n
i
i
o
o
c
c
V
V
I
I

H
H
/
/
B
B
T
T

%
%
0
0
0
0
1
1
=
=
t
t
e
e
g
g
r
r
a
a
T
T

(100.0)
(100.0)
–
–
(0.0)
(0.0)
(92.8)
(92.8)
(91.9)
(91.9)
–
–
(100.0)
(100.0)
(100.0)
(100.0)
(96.4)
(96.4)
(67.2)
(67.2)
–
–
–
–
(100.0)
(100.0)
(77.6)
(77.6)
(68.0)
(68.0)
 – 
 – 
 – 
 – 
 – 
 – 
 – 
 – 
 – 
 – 
(98.3)
(98.3)
(74.7)
(74.7)
–
–
(91.2)
(91.2)
–
–
(75.7)
(75.7)
(74.2)
(74.2)
(74.3)
(74.3)
(74.3)
(74.3)

g
g
n
n
o
o
m
m
a
a
e
e
g
g
a
a
r
r
e
e
v
v
o
o
c
c

t
t
n
n
e
e
m
m

t
t
a
a
e
e
r
r
t
t

I
I
B
B
T
T
L
L
5
5
.
.
D
D

.
.
1
1

%
%
0
0
3
3
=
=
t
t
e
e
g
g
r
r
a
a
T
T
.
.
)
)
G
G
(
(
V
V
I
I

H
H
L
L
P
P

–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
(91.2)
(91.2)
(47.9)
(47.9)
–
–
–
–
–
–
(26.9)
(26.9)
–
–
–
–
–
–
–
–
–
–
–
–
(93.4)
(93.4)
–
–
–
–
(73.5)
(73.5)
–
–
–
–
(79.5)
(79.5)
(79.5)
(79.5)
(79.5)
(79.5)

e
e
g
g
a
a
r
r
e
e
v
v
o
o
c
c
n
n
o
o
i
i
t
t
a
a
g
g
i
i
t
t
s
s
e
e
v
v
n
n
i
i

t
t
c
c
a
a
t
t
n
n
o
o
C
C
1
1
.
.
E
E
.
.
1
1

%
%
0
0
9
9
=
=
t
t
e
e
g
g
r
r
a
a
T
T
.
.
)
)
E
E
(
(

)
)
G
G
(
(

(29.3)
(29.3)
(100.0)
(100.0)
(89.1)
(89.1)
–
–
(100.0)
(100.0)
–
–
–
–
–
–
(100.0)
(100.0)
(100.0)
(100.0)
–
–
(14.5)
(14.5)
(100.0)
(100.0)
(91.8)
(91.8)
–
–
–
–
–
–
–
–
–
–
(100.0)
(100.0)
–
–
(86.7)
(86.7)
(100.0)
(100.0)
(95.7)
(95.7)
–
–
–
–
(99.1)
(99.1)
(98.2)
(98.2)
(99.1)
(99.1)

5
5
r
r
e
e
d
d
n
n
u
u
d
d
e
e
g
g
a
a
s
s
t
t
c
c
a
a
t
t
n
n
o
o
c
c
B
B
T
T
d
d
o
o
o
o
h
h
d
d
l
l
i
i
h
h
c
c

n
n
i
i
e
e
g
g
a
a
r
r
e
e
v
v
o
o
c
c

t
t
n
n
e
e
m
m

t
t
a
a
e
e
r
r
t
t

I
I
B
B
T
T
L
L
2
2
.
.
E
E
.
.
1
1

%
%
0
0
9
9
=
=
t
t
e
e
g
g
r
r
a
a
T
T
.
.
)
)
E
E
(
(

)
)
G
G
(
(
s
s
r
r
a
a
e
e
y
y

n
n
o
o
i
i
t
t
a
a
n
n
i
i
m
m

i
i
l
l
e
e
/
/
l
l
o
o
r
r
t
t
n
n
o
o
c
c
B
B
T
T
a
a
e
e
v
v
a
a
h
h
t
t
a
a
h
h
t
t

.
.
)
)
E
E
(
(
e
e
l
l
b
b
a
a
l
l
i
i
a
a
v
v
a
a
y
y
l
l
c
c
i
i
l
l
b
b
u
u
p
p
e
e
c
c
n
n
a
a
m
m

r
r
o
o
f
f
r
r
e
e
p
p

s
s
e
e
t
t
a
a
t
t
S
S
r
r
e
e
b
b
m
m
e
e
M
M

f
f
o
o
r
r
e
e
b
b
m
m
u
u
N
N
1
1
.
.

A
A

.
.
2
2

3
3
5
5
=
=
t
t
e
e
g
g
r
r
a
a
T
T

c
c
i
i
h
h
p
p
o
o
r
r
t
t
s
s
a
a
t
t
a
a
c
c
e
e
c
c
n
n
e
e
i
i
r
r
e
e
p
p
x
x
e
e
t
t
a
a
h
h
t
t
s
s
d
d
l
l
o
o
h
h
e
e
s
s
u
u
o
o
h
h

0
0
o
o
t
t
e
e
s
s
o
o
l
l
c
c

:
:
t
t
e
e
g
g
r
r
a
a
T
T
.
.
)
)
E
E
(
(

)
)
G
G
(
(
B
B
T
T
o
o
t
t
e
e
u
u
d
d
s
s
t
t
s
s
o
o
c
c

d
d
e
e
t
t
c
c
e
e
f
f
f
f
a
a
-
-
B
B
T
T
f
f
o
o
e
e
g
g
a
a
t
t
n
n
e
e
c
c
r
r
e
e
P
P
1
1
.
.

B
B

.
.
2
2

w
w
e
e
n
n
h
h
t
t
i
i
w
w

)
)

%
%

(
(
e
e
g
g
a
a
r
r
e
e
v
v
o
o
c
c

t
t
n
n
e
e
m
m

t
t
a
a
e
e
r
r
T
T
1
1
.
.
C
C
.
.
2
2

%
%
0
0
3
3
=
=
t
t
e
e
g
g
r
r
a
a
T
T
.
.
)
)
E
E
(
(

)
)
G
G
(
(
s
s
g
g
u
u
r
r
d
d
B
B
T
T

s
s
n
n
o
o
i
i
t
t
i
i
l
l
a
a
o
o
c
c

r
r
e
e
d
d
l
l
o
o
h
h
e
e
k
k
a
a
t
t
s
s
i
i
t
t
l
l
u
u
m
m
g
g
n
n
i
i
n
n
o
o
i
i
t
t
c
c
n
n
u
u
f
f

h
h
t
t
i
i
w
w
s
s
e
e
t
t
a
a
t
t
S
S
r
r
e
e
b
b
m
m
e
e
M
M

f
f
o
o
r
r
e
e
b
b
m
m
u
u
N
N
1
1
.
.

D
D

.
.
2
2

.
.
e
e
c
c
r
r
u
u
o
o
s
s
e
e
r
r
d
d
n
n
a
a
e
e
r
r
a
a
c
c
B
B
T
T
r
r
o
o
f
f
g
g
n
n
i
i
t
t
a
a
c
c
o
o
v
v
d
d
a
a

3
3
5
5
=
=
t
t
e
e
g
g
r
r
a
a
T
T

w
w
e
e
n
n
f
f
o
o
)
)

%
%

(
(
e
e
t
t
a
a
r
r
s
s
s
s
e
e
c
c
c
c
u
u
s
s
t
t
n
n
e
e
m
m

t
t
a
a
e
e
r
r
T
T
1
1
.
.
E
E
.
.
2
2

.
.
s
s
r
r
e
e
n
n
o
o
s
s
i
i
r
r
p
p
g
g
n
n
o
o
m
m
a
a
s
s
e
e
s
s
a
a
c
c
B
B
T
T
e
e
s
s
p
p
a
a
l
l
e
e
r
r
d
d
n
n
a
a

%
%
5
5
8
8
=
=
t
t
e
e
g
g
r
r
a
a
T
T

e
e
v
v
i
i
t
t
a
a
i
i
t
t
i
i
n
n
i
i
h
h
c
c
r
r
a
a
e
e
s
s
e
e
r
r
B
B
T
T
n
n
a
a
e
e
p
p
o
o
r
r
u
u
E
E
1
1
.
.

A
A

.
.
3
3

:
:
t
t
e
e
g
g
r
r
a
a
T
T
.
.

6
6
1
1
0
0
2
2
-
-
d
d
i
i
m
m
y
y
b
b
d
d
e
e
h
h
s
s
i
i
l
l
b
b
a
a
t
t
s
s
e
e

d
d
e
e
h
h
s
s
i
i
l
l
b
b
a
a
t
t
s
s
e
e

Country/area
Country/area

–
–
–
–
–
–
–
–
(2.1)
(2.1)
–
–
–
–
–
–
(19.7)
(19.7)
(13.8)
(13.8)
–
–
–
–
(0.0)
(0.0)
(27.0)
(27.0)
–
–
–
–
–
–
–
–
–
–
(47.1)
(47.1)
–
–
(49.6)
(49.6)
–
–
(93.2)
(93.2)
–
–
–
–
(30.1)
(30.1)
(29.6)
(29.6)
(30.1)
(30.1)

–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
 –   
 –   
 –   
 –   
 –   
 –   

–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
 –   
 –   
 –   
 –   
 –   
 –   

–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
 –   
 –   
 –   
 –   
 –   
 –   

–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
 –   
 –   
 –   
 –   
 –   
 –   

(100.0)
(100.0)
–
–
(0.0)
(0.0)
(96.6)
(96.6)
(87.0)
(87.0)
–
–
(100.0)
(100.0)
–
–
(87.0)
(87.0)
(81.1)
(81.1)
–
–
–
–
(100.0)
(100.0)
(78.6)
(78.6)
(55.8)
(55.8)
–
–
–
–
–
–
–
–
–
–
(88.6)
(88.6)
(77.7)
(77.7)
–
–
(75.7)
(75.7)
–
–
–
–
(60.1)
(60.1)
(60.4)
(60.4)
(60.4)
(60.4)

Non-EU/EEA
Non-EU/EEA

– Albania
– Albania
– Andorra
– Andorra
– Armenia
– Armenia
– Azerbaijan
– Azerbaijan
– Belarus
– Belarus
– Bosnia and Herzegovina
– Bosnia and Herzegovina
– Georgia
– Georgia
– Israel
– Israel
– Kazakhstan
– Kazakhstan
– Kyrgyzstan
– Kyrgyzstan
– Monaco
– Monaco
– Montenegro
– Montenegro
– North Macedonia
– North Macedonia
– Republic of Moldova
– Republic of Moldova
– Russian Federation
– Russian Federation
– San Marino
– San Marino
– Serbia
– Serbia
–
–
–
–
– Switzerland
– Switzerland
– Tajikistan
– Tajikistan
– Turkey
– Turkey
– Turkmenistan
– Turkmenistan
– Ukraine
– Ukraine
– United Kingdom
– United Kingdom
– Uzbekistan
– Uzbekistan
 –    Subtotal non-EU/EEA
 –    Subtotal non-EU/EEA
 –    Total European Region
 –    Total European Region
 –    Subtotal 18 HPCs
 –    Subtotal 18 HPCs

Serbia excluding Kosovo1
Serbia excluding Kosovo1
Kosovo1
Kosovo1

1 All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999).

99

Tuberculosis surveillance and monitoring in Europe 2022SURVEILLANCE REPORT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7. Trend tables

Table I. Estimated tuberculosis (TB) mortality per 100 000 population, European Region, 2011–2020a

Country

EU/EEA
Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
Subtotal EU/EEA 
Non-EU/EEA 
Albania
Andorra
Armenia
Azerbaijan
Belarus
Bosnia and Herzegovina
Georgia
Israel
Kazakhstan
Kyrgyzstan
Monaco
Montenegro
North Macedonia
Republic of Moldova
Russian Federation
San Marino
Serbia
Switzerland
Tajikistan
Turkey
Turkmenistan
Ukraine
United Kingdom
Uzbekistan
Subtotal non-EU/EEA
Total European Region
Subtotal 18 HPCs

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

N

Rate per 
100 000

N

Rate per 
100 000

N

Rate per 
100 000

N

Rate per 
100 000

N

Rate per 
100 000

N

Rate per 
100 000

N

Rate per 

100 000

N

Rate per 

100 000

N

Rate per 

100 000

N

Rate per 

100 000

Mean annual 

Mean annual 

% change 

in rate,  

2016–2020

% change 

in rate,  

2011–2020

Country

		56
		54
  180
		66
		4
		56
		17
  46
		62
		640
		340
		75
		120
		3
		29
		390
  81
−
  220
		2
		3
		37
		30
		690
		230
 1 300
		26
		14
		300
		47
 5 100

		9
		0
  120
  660
  850
		180
  230
		22
 1 700
  660
		0
		1
		32
  540
 22 000
		0
		150
		25
		800
  850
  730
 7 200
		340
 2 500
 40 000
 44 000
 41 000

(0.7)
(0.5)
(2.4)
(1.5)
(0.3)
(0.5)
(0.3)
(3.5)
(1.1)
(1.0)
(0.4)
(0.7)
(1.2)
(0.8)
(0.6)
(0.7)
(3.9)
–
(7.0)
(0.4)
(0.7)
(0.2)
(0.6)
(1.8)
(2.2)
(6.5)
(0.5)
(0.7)
(0.6)
(0.5)
(1.1)

(0.3)
(0.3)
(4.2)
(7.2)
(9.0)
(5.0)
(5.6)
(0.3)
(10.0)
(12.0)
(0.2)
(0.2)
(1.6)
(13.0)
(15.0)
(0.0)
(1.7)
(0.3)
(10.0)
(1.2)
(14.0)
(16.0)
(0.5)
(8.7)
(8.8)
(4.9)
(10.5)

		43
		61
  170
		60
		5
		31
		23
  36
		50
		560
		360
		110
		130
		3
		26
		340
  64
–
  260
		1
		1
		35
		22
		680
		230
 1 300
		18
		11
		330
		40
 5 000

		9
		1
  140
  420
  750
		170
  230
		22
 1 600
  630
		0
		1
		28
  510
 19 000
		0
		160
		23
		790
  740
  590
 7 100
		340
 2 200
 35 000
 41 000
 37 000

(0.5)
(0.6)
(2.4)
(1.4)
(0.4)
(0.3)
(0.4)
(2.7)
(0.9)
(0.9)
(0.4)
(1.0)
(1.3)
(0.9)
(0.6)
(0.6)
(3.1)
–
(8.5)
(0.2)
(0.2)
(0.2)
(0.5)
(1.8)
(2.2)
(6.3)
(0.3)
(0.6)
(0.7)
(0.4)
(1.1)

(0.3)
(1.0)
(4.8)
(4.6)
(7.9)
(4.6)
(5.7)
(0.3)
(9.7)
(11.0)
(0.1)
(0.2)
(1.4)
(13.0)
(13.0)
(0.0)
(1.8)
(0.3)
(10.0)
(1.0)
(11.0)
(16.0)
(0.5)
(7.5)
(7.7)
(4.5)
(9.4)

		70
		57
  160
		54
		1
		68
		17
  26
		32
		560
		380
		78
		95
		2
		22
		270
  110
–
  210
		1
		3
		40
		21
		580
		230
 1 200
		21
		9
		300
		44
 4 700

		8
		0
  110
  440
  650
		150
  210
		15
 1 100
  630
		0
		1
		25
  370
 18 000
		0
		150
		20
		780
  620
  530
 6 400
		360
 2 200
 33 000
 37 000
 34 000

(0.8)
(0.5)
(2.1)
(1.3)
(0.1)
(0.6)
(0.3)
(1.9)
(0.6)
(0.9)
(0.5)
(0.7)
(1.0)
(0.5)
(0.5)
(0.5)
(5.2)
–
(7.1)
(0.2)
(0.7)
(0.2)
(0.4)
(1.5)
(2.2)
(5.7)
(0.4)
(0.5)
(0.6)
(0.5)
(1.1)

(0.3)
(0.6)
(3.6)
(4.7)
(6.9)
(4.2)
(5.1)
(0.2)
(6.2)
(11.0)
(0.1)
(0.2)
(1.2)
(9.1)
(12.0)
(0.0)
(1.6)
(0.3)
(9.7)
(0.8)
(9.9)
(14.0)
(0.6)
(7.2)
(7.2)
(4.1)
(8.6)

		72
		42
  130
		40
		5
		40
		13
  29
		41
		480
		320
		55
		84
		2
		24
		290
  69
–
  230
		1
		1
		35
		13
		580
		220
 1 100
		35
		22
		290
		30
 4 300

		8
		1
  81
  430
  510
		130
  190
		15
  930
  520
		0
		1
		25
  370
 16 000
		0
		120
		13
		780
  590
  640
 5 800
		370
 2 200
 30 000
 34 000
 31 000

(0.8)
(0.4)
(1.8)
(1.0)
(0.4)
(0.4)
(0.2)
(2.2)
(0.8)
(0.8)
(0.4)
(0.5)
(0.9)
(0.6)
(0.5)
(0.5)
(3.4)
–
(7.8)
(0.2)
(0.2)
(0.2)
(0.3)
(1.5)
(2.1)
(5.7)
(0.6)
(1.0)
(0.6)
(0.3)
(1.0)

(0.3)
(0.7)
(2.8)
(4.5)
(5.4)
(3.8)
(4.6)
(0.2)
(5.4)
(8.9)
(0.0)
(0.2)
(1.2)
(9.0)
(11.0)
(0.0)
(1.3)
(0.2)
(9.5)
(0.8)
(12.0)
(13.0)
(0.6)
(7.1)
(6.5)
(3.7)
(7.8)

		65
		61
  120
		46
		2
		57
		17
  22
		33
		470
		320
		45
		100
		2
		17
		340
  99
–
  190
		1
		2
		37
		12
		580
		220
 1 100
		35
		11
		250
		25
 4 300

		8
		0
  68
  570
  450
		120
  160
		15
  720
  460
		0
		1
		25
  310
 14 000
		0
		88
		17
		760
  540
  570
 5 000
		350
 2 000
 26 000
 31 000
 27 000

(0.8)
(0.4)
(1.8)
(1.0)
(0.4)
(0.4)
(0.2)
(2.2)
(0.8)
(0.8)
(0.4)
(0.5)
(0.9)
(0.6)
(0.5)
(0.5)
(3.4)
–
(7.8)
(0.2)
(0.2)
(0.2)
(0.3)
(1.5)
(2.1)
(5.7)
(0.6)
(1.0)
(0.6)
(0.3)
(1.0)

(0.3)
(0.5)
(2.3)
(5.9)
(4.7)
(3.6)
(4.0)
(0.2)
(4.1)
(7.8)
(0.0)
(0.2)
(1.2)
(7.7)
(9.9)
(0.0)
(1.0)
(0.2)
(9.0)
(0.7)
(10.0)
(11.0)
(0.5)
(6.6)
(5.6)
(3.4)
(6.7)

		39
		32
  120
		58
		3
		43
		23
  28
		26
		440
		300
		48
		64
		2
		17
		310
  80
–
  180
		1
		3
		30
		18
		600
		210
  990
		35
		7
		260
		26
 4 000

		8
		0
  56
  580
  390
		120
  180
		15
  660
  420
		0
		1
		25
  280
 12 000
		0
		100
		25
		760
  540
  580
 4 500
		310
 1 900
 23 000
 28 000
 24 000

(0.5)
(0.3)
(1.6)
(1.4)
(0.2)
(0.4)
(0.4)
(2.1)
(0.5)
(0.7)
(0.4)
(0.5)
(0.7)
(0.6)
(0.4)
(0.5)
(4.1)
–
(6.2)
(0.2)
(0.7)
(0.2)
(0.3)
(1.6)
(2.0)
(5.0)
(0.6)
(0.4)
(0.6)
(0.3)
(0.9)

(0.3)
(0.5)
(1.9)
(5.9)
(4.1)
(3.5)
(4.4)
(0.2)
(3.7)
(6.9)
(0.0)
(0.2)
(1.2)
(6.9)
(8.4)
(0.0)
(1.1)
(0.3)
(8.8)
(0.7)
(10.0)
(10.0)
(0.5)
(6.1)
(4.9)
(3.0)
(6.0)

		36

		33

  98

		61

		3

		38

		14

  23

		35

		440

		300

		58

		63

		2

		18

		310

  75

–

  160

		3

		1

		24

		18

		560

		200

  950

		35

		7

		250

		23

		8

		0

  45

  580

  320

		110

  170

		13

  580

  380

		0

		1

		25

  220

		0

		94

		17

		750

  500

  590

 10 000

 4 000

		310

 1 600

 20 000

 25 000

 21 000

(0.4)

(0.3)

(1.4)

(1.5)

(0.3)

(0.4)

(0.3)

(1.8)

(0.6)

(0.7)

(0.4)

(0.6)

(0.7)

(0.6)

(0.4)

(0.5)

(3.8)

–

(5.7)

(0.5)

(0.2)

(0.1)

(0.3)

(1.5)

(2.0)

(4.8)

(0.6)

(0.4)

(0.5)

(0.2)

(0.3)

(0.1)

(1.5)

(5.9)

(3.4)

(3.2)

(4.2)

(0.2)

(3.2)

(6.1)

(0.0)

(0.2)

(1.2)

(5.5)

(7.1)

(0.0)

(1.1)

(0.2)

(8.5)

(0.6)

(10.0)

(9.1)

(0.5)

(5.0)

(4.2)

(2.7)

(5.2)

		49

		33

  98

		60

		5

		39

		10

  13

		30

		440

		310

		52

		84

		2

		18

		310

  65

–

  120

		2

		1

		28

		18

		570

		240

  940

		35

		6

		250

		22

		8

		0

  30

  590

  260

		100

  160

		20

  590

  360

		0

		1

		25

  210

 9 200

		0

		94

		17

		740

  460

  600

 4 000

		310

 1 300

 19 000

 23 000

 20 000

(0.6)

(0.3)

(1.4)

(1.5)

(0.4)

(0.4)

(0.2)

(1.0)

(0.6)

(0.7)

(0.4)

(0.5)

(0.9)

(0.6)

(0.4)

(0.5)

(3.4)

–

(4.3)

(0.4)

(0.2)

(0.2)

(0.3)

(1.5)

(2.4)

(4.8)

(0.6)

(0.3)

(0.5)

(0.2)

(0.9)

(0.3)

(0.3)

(1.0)

(5.9)

(2.8)

(3.0)

(4.0)

(0.2)

(3.2)

(5.7)

(0.0)

(0.2)

(1.2)

(5.3)

(6.3)

(0.0)

(1.1)

(0.2)

(8.2)

(0.6)

(10.0)

(9.0)

(0.5)

(4.0)

(4.0)

(2.5)

(4.9)

		41

		33

  98

		60

		5

		23

		10

  16

		30

		440

		270

		52

		62

		2

		18

		310

  64

–

  120

		2

		1

		28

		18

		570

		240

  930

		35

		14

		250

		22

		8

		0

  30

  590

  260

		93

  150

		20

  600

  290

		0

		1

		25

  210

 8 000

		0

		94

		17

		730

  420

  610

 3 700

		310

 1 000

 17 000

 21 000

 18 000

(0.5)

(0.3)

(1.4)

(1.5)

(0.4)

(0.2)

(0.2)

(1.2)

(0.6)

(0.7)

(0.3)

(0.5)

(0.6)

(0.6)

(0.4)

(0.5)

(3.4)

–

(4.4)

(0.4)

(0.2)

(0.2)

(0.3)

(1.5)

(2.4)

(4.8)

(0.6)

(0.7)

(0.5)

(0.2)

(0.3)

(0.6)

(1.0)

(5.9)

(2.8)

(2.8)

(3.8)

(0.2)

(3.2)

(4.6)

(0.0)

(0.2)

(1.2)

(5.3)

(5.5)

(0.0)

(1.1)

(0.2)

(7.9)

(0.5)

(10.0)

(8.3)

(0.5)

(3.2)

(3.5)

(2.3)

(4.4)

		41

		33

  97

		60

		5

		23

		10

  16

		30

		440

		270

		52

		62

		2

		18

		310

  64

–

  120

		2

		1

		28

		19

		570

		240

  920

		35

		14

		250

		22

		11

		1

  30

  740

  260

		110

  190

		21

  610

  300

		0

		1

		25

  210

 7 300

		0

		93

		17

		920

  420

  620

 4 100

		310

 1 100

 17 000

 21 000

 18 000

(0.5)

(0.3)

(1.4)

(1.5)

(0.4)

(0.2)

(0.2)

(1.2)

(0.6)

(0.7)

(0.3)

(0.5)

(0.6)

(0.6)

(0.4)

(0.5)

(3.4)

–

(4.4)

(0.4)

(0.2)

(0.2)

(0.3)

(1.5)

(2.4)

(4.8)

(0.6)

(0.7)

(0.5)

(0.2)

(0.8)

(0.4)

(1.4)

(1.0)

(7.3)

(2.8)

(3.5)

(4.8)

(0.2)

(3.2)

(4.6)

(0.0)

(0.2)

(1.2)

(5.3)

(5.0)

(0.0)

(1.1)

(0.2)

(9.6)

(0.5)

(10.0)

(9.4)

(0.5)

(3.2)

(3.5)

(2.3)

(4.4)

 3 800

(0.8)

 3 900

 3 800

(0.8)

 3 800

0.6

0.0

−3.3

1.7

15.4

−15.4

−19.8

−13.1

3.5

0.0

−2.9

2.7

−0.8

1.2

0.0

0.0

−4.6

–

−8.2

18.1

−25.1

−2.9

0.0

−1.6

4.7

−1.0

0.0

18.5

−0.5

−4.1

−1.4

8.4

30.0

−14.8

5.5

−9.1

0.0

2.2

7.5

−3.6

−9.6

3.6

0.0

−6.4

−12.2

0.0

−9.6

2.2

−7.4

0.0

−1.5

0.0

−14.9

−7.8

−7.3

−7.4

EU/EEA

−4.1 Austria

−5.7 Belgium

−5.8 Bulgaria

0.0 Croatia

1.5 Cyprus

−9.8 Czechia

−6.1 Denmark

−11.2 Estonia

−7.4 Finland

−4.2 France

−3.0 Germany

−3.5 Greece

−6.7 Hungary

−2.8 Iceland

−5.6 Ireland

−2.8 Italy

−1.5 Latvia

– Liechtenstein

−5.0 Lithuania

−1.5 Luxembourg

−12.0 Malta

−3.5 Netherlands

−6.1 Norway

−2.0 Poland

1.0 Portugal

−3.3 Romania

3.0 Slovakia

0.0 Slovenia

−1.9 Spain

−8.7 Sweden

−3.4 Subtotal EU/EEA 

Non-EU/EEA 

3.6 Albania

17.0 Andorra

−14.7 Armenia

0.2 Azerbaijan

−12.2 Belarus

−3.9 Bosnia and Herzegovina

−1.7 Georgia

−2.1

Israel

−11.9 Kazakhstan

−10.1 Kyrgyzstan

−100.0 Monaco

1.6 Montenegro

−3.1 North Macedonia

−9.5 Republic of Moldova

−11.5 Russian Federation

San Marino

−4.7 Serbia

−5.1 Switzerland

−0.5 Tajikistan

−9.3 Turkey

−3.7 Turkmenistan

−5.7 Ukraine

−1.6 United Kingdom

−10.5 Uzbekistan

−9.7 Subtotal non-EU/EEA

−8.3 Total European Region

−9.3 Subtotal 18 HPCs

Note: European Region comprises the 53 countries of the WHO European Region and Liechtenstein. WHO European Region 18 TB HPCs are presented in italics.
HPCs: high-priority countries.
a Excludes HIV coinfected cases.

102

SURVEILLANCE REPORTTuberculosis surveillance and monitoring in Europe 2022 
  
   
Country

EU/EEA

Austria

Belgium

Bulgaria

Croatia

Cyprus

Czechia

Denmark

Estonia

Finland

France

Germany

Greece

Hungary

Iceland

Ireland

Italy

Latvia

Bosnia and Herzegovina

Liechtenstein

Lithuania

Luxembourg

Malta

Netherlands

Norway

Poland

Portugal

Romania

Slovakia

Slovenia

Spain

Sweden

Albania

Andorra

Armenia

Azerbaijan

Belarus

Georgia

Israel

Kazakhstan

Kyrgyzstan

Monaco

Montenegro

Subtotal EU/EEA 

Non-EU/EEA 

North Macedonia

Republic of Moldova

Russian Federation

San Marino

Serbia

Switzerland

Tajikistan

Turkey

Turkmenistan

Ukraine

United Kingdom

Uzbekistan

Subtotal non-EU/EEA

Total European Region

Subtotal 18 HPCs

		56

		54

  180

		66

		4

		56

		17

  46

		62

		640

		340

		75

		120

		3

		29

		390

  81

−

  220

		2

		3

		37

		30

		690

		230

 1 300

		26

		14

		300

		47

 5 100

		9

		0

  120

  660

  850

		180

  230

		22

 1 700

  660

		0

		1

		32

  540

		0

		150

		25

		800

  850

  730

 7 200

		340

 2 500

 40 000

 44 000

 41 000

(0.7)

(0.5)

(2.4)

(1.5)

(0.3)

(0.5)

(0.3)

(3.5)

(1.1)

(1.0)

(0.4)

(0.7)

(1.2)

(0.8)

(0.6)

(0.7)

(3.9)

–

(7.0)

(0.4)

(0.7)

(0.2)

(0.6)

(1.8)

(2.2)

(6.5)

(0.5)

(0.7)

(0.6)

(0.5)

(1.1)

(0.3)

(0.3)

(4.2)

(7.2)

(9.0)

(5.0)

(5.6)

(0.3)

(10.0)

(12.0)

(0.2)

(0.2)

(1.6)

(13.0)

(15.0)

(0.0)

(1.7)

(0.3)

(10.0)

(1.2)

(14.0)

(16.0)

(0.5)

(8.7)

(8.8)

(4.9)

(10.5)

		43

		61

  170

		60

		5

		31

		23

  36

		50

		560

		360

		110

		130

		3

		26

		340

  64

–

  260

		1

		1

		35

		22

		680

		230

 1 300

		18

		11

		330

		40

 5 000

		9

		1

  140

  420

  750

		170

  230

		22

 1 600

  630

		0

		1

		28

  510

 19 000

		0

		160

		23

		790

  740

  590

 7 100

		340

 2 200

 35 000

 41 000

 37 000

(0.5)

(0.6)

(2.4)

(1.4)

(0.4)

(0.3)

(0.4)

(2.7)

(0.9)

(0.9)

(0.4)

(1.0)

(1.3)

(0.9)

(0.6)

(0.6)

(3.1)

–

(8.5)

(0.2)

(0.2)

(0.2)

(0.5)

(1.8)

(2.2)

(6.3)

(0.3)

(0.6)

(0.7)

(0.4)

(1.1)

(0.3)

(1.0)

(4.8)

(4.6)

(7.9)

(4.6)

(5.7)

(0.3)

(9.7)

(11.0)

(0.1)

(0.2)

(1.4)

(13.0)

(13.0)

(0.0)

(1.8)

(0.3)

(10.0)

(1.0)

(11.0)

(16.0)

(0.5)

(7.5)

(7.7)

(4.5)

(9.4)

		70

		57

  160

		54

		1

		68

		17

  26

		32

		560

		380

		78

		95

		2

		22

		270

  110

–

  210

		1

		3

		40

		21

		580

		230

 1 200

		21

		9

		300

		44

 4 700

		8

		0

  110

  440

  650

		150

  210

		15

 1 100

  630

		0

		1

		25

  370

		0

		150

		20

		780

  620

  530

 6 400

		360

 2 200

 33 000

 37 000

 34 000

(0.8)

(0.5)

(2.1)

(1.3)

(0.1)

(0.6)

(0.3)

(1.9)

(0.6)

(0.9)

(0.5)

(0.7)

(1.0)

(0.5)

(0.5)

(0.5)

(5.2)

–

(7.1)

(0.2)

(0.7)

(0.2)

(0.4)

(1.5)

(2.2)

(5.7)

(0.4)

(0.5)

(0.6)

(0.5)

(1.1)

(0.3)

(0.6)

(3.6)

(4.7)

(6.9)

(4.2)

(5.1)

(0.2)

(6.2)

(11.0)

(0.1)

(0.2)

(1.2)

(9.1)

(12.0)

(0.0)

(1.6)

(0.3)

(9.7)

(0.8)

(9.9)

(14.0)

(0.6)

(7.2)

(7.2)

(4.1)

(8.6)

		72

		42

  130

		40

		5

		40

		13

  29

		41

		480

		320

		55

		84

		2

		24

		290

  69

–

  230

		1

		1

		35

		13

		580

		220

 1 100

		35

		22

		290

		30

 4 300

		8

		1

  81

  430

  510

		130

  190

		15

  930

  520

		0

		1

		25

  370

		0

		120

		13

		780

  590

  640

 5 800

		370

 2 200

 30 000

 34 000

 31 000

		65

		61

  120

		46

		2

		57

		17

  22

		33

		470

		320

		45

		100

		2

		17

		340

  99

–

  190

		1

		2

		37

		12

		580

		220

 1 100

		35

		11

		250

		25

 4 300

		8

		0

  68

  570

  450

		120

  160

		15

  720

  460

		0

		1

		25

  310

		0

		88

		17

		760

  540

  570

(0.8)

(0.4)

(1.8)

(1.0)

(0.4)

(0.4)

(0.2)

(2.2)

(0.8)

(0.8)

(0.4)

(0.5)

(0.9)

(0.6)

(0.5)

(0.5)

(3.4)

–

(7.8)

(0.2)

(0.2)

(0.2)

(0.3)

(1.5)

(2.1)

(5.7)

(0.6)

(1.0)

(0.6)

(0.3)

(1.0)

(0.3)

(0.7)

(2.8)

(4.5)

(5.4)

(3.8)

(4.6)

(0.2)

(5.4)

(8.9)

(0.0)

(0.2)

(1.2)

(9.0)

(0.0)

(1.3)

(0.2)

(9.5)

(0.8)

(12.0)

(13.0)

(0.6)

(7.1)

(6.5)

(3.7)

(7.8)

(0.8)

(0.4)

(1.8)

(1.0)

(0.4)

(0.4)

(0.2)

(2.2)

(0.8)

(0.8)

(0.4)

(0.5)

(0.9)

(0.6)

(0.5)

(0.5)

(3.4)

–

(7.8)

(0.2)

(0.2)

(0.2)

(0.3)

(1.5)

(2.1)

(5.7)

(0.6)

(1.0)

(0.6)

(0.3)

(1.0)

(0.3)

(0.5)

(2.3)

(5.9)

(4.7)

(3.6)

(4.0)

(0.2)

(4.1)

(7.8)

(0.0)

(0.2)

(1.2)

(7.7)

(9.9)

(0.0)

(1.0)

(0.2)

(9.0)

(0.7)

		39

		32

  120

		58

		3

		43

		23

  28

		26

		440

		300

		48

		64

		2

		17

		310

  80

–

  180

		1

		3

		30

		18

		600

		210

  990

		35

		7

		260

		26

		8

		0

  56

  580

  390

		120

  180

		15

  660

  420

		0

		1

		25

  280

		0

		100

		25

		760

  540

  580

 4 000

(0.5)

(0.3)

(1.6)

(1.4)

(0.2)

(0.4)

(0.4)

(2.1)

(0.5)

(0.7)

(0.4)

(0.5)

(0.7)

(0.6)

(0.4)

(0.5)

(4.1)

–

(6.2)

(0.2)

(0.7)

(0.2)

(0.3)

(1.6)

(2.0)

(5.0)

(0.6)

(0.4)

(0.6)

(0.3)

(0.9)

(0.3)

(0.5)

(1.9)

(5.9)

(4.1)

(3.5)

(4.4)

(0.2)

(3.7)

(6.9)

(0.0)

(0.2)

(1.2)

(6.9)

(8.4)

(0.0)

(1.1)

(0.3)

(8.8)

(0.7)

 5 000

		350

 2 000

 26 000

 31 000

 27 000

(10.0)

(11.0)

(0.5)

(6.6)

(5.6)

(3.4)

(6.7)

 4 500

		310

 1 900

 23 000

 28 000

 24 000

(10.0)

(10.0)

(0.5)

(6.1)

(4.9)

(3.0)

(6.0)

 22 000

 18 000

 16 000

(11.0)

 14 000

 12 000

Note: European Region comprises the 53 countries of the WHO European Region and Liechtenstein. WHO European Region 18 TB HPCs are presented in italics.

HPCs: high-priority countries.

a Excludes HIV coinfected cases.

Table I. Estimated tuberculosis (TB) mortality per 100 000 population, European Region, 2011–2020a

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

N

Rate per 

100 000

N

Rate per 

100 000

N

Rate per 

100 000

N

Rate per 

100 000

N

Rate per 

100 000

N

Rate per 

100 000

N

Rate per 
100 000

N

Rate per 
100 000

N

Rate per 
100 000

N

Rate per 
100 000

Mean annual 
% change 
in rate,  
2016–2020

Mean annual 
% change 
in rate,  
2011–2020

Country

		36
		33
  98
		61
		3
		38
		14
  23
		35
		440
		300
		58
		63
		2
		18
		310
  75
–
  160
		3
		1
		24
		18
		560
		200
  950
		35
		7
		250
		23
 3 800

		8
		0
  45
  580
  320
		110
  170
		13
  580
  380
		0
		1
		25
  220
 10 000
		0
		94
		17
		750
  500
  590
 4 000
		310
 1 600
 20 000
 25 000
 21 000

(0.4)
(0.3)
(1.4)
(1.5)
(0.3)
(0.4)
(0.3)
(1.8)
(0.6)
(0.7)
(0.4)
(0.6)
(0.7)
(0.6)
(0.4)
(0.5)
(3.8)
–
(5.7)
(0.5)
(0.2)
(0.1)
(0.3)
(1.5)
(2.0)
(4.8)
(0.6)
(0.4)
(0.5)
(0.2)
(0.8)

(0.3)
(0.1)
(1.5)
(5.9)
(3.4)
(3.2)
(4.2)
(0.2)
(3.2)
(6.1)
(0.0)
(0.2)
(1.2)
(5.5)
(7.1)
(0.0)
(1.1)
(0.2)
(8.5)
(0.6)
(10.0)
(9.1)
(0.5)
(5.0)
(4.2)
(2.7)
(5.2)

		49
		33
  98
		60
		5
		39
		10
  13
		30
		440
		310
		52
		84
		2
		18
		310
  65
–
  120
		2
		1
		28
		18
		570
		240
  940
		35
		6
		250
		22
 3 900

		8
		0
  30
  590
  260
		100
  160
		20
  590
  360
		0
		1
		25
  210
 9 200
		0
		94
		17
		740
  460
  600
 4 000
		310
 1 300
 19 000
 23 000
 20 000

(0.6)
(0.3)
(1.4)
(1.5)
(0.4)
(0.4)
(0.2)
(1.0)
(0.6)
(0.7)
(0.4)
(0.5)
(0.9)
(0.6)
(0.4)
(0.5)
(3.4)
–
(4.3)
(0.4)
(0.2)
(0.2)
(0.3)
(1.5)
(2.4)
(4.8)
(0.6)
(0.3)
(0.5)
(0.2)
(0.9)

(0.3)
(0.3)
(1.0)
(5.9)
(2.8)
(3.0)
(4.0)
(0.2)
(3.2)
(5.7)
(0.0)
(0.2)
(1.2)
(5.3)
(6.3)
(0.0)
(1.1)
(0.2)
(8.2)
(0.6)
(10.0)
(9.0)
(0.5)
(4.0)
(4.0)
(2.5)
(4.9)

		41
		33
  98
		60
		5
		23
		10
  16
		30
		440
		270
		52
		62
		2
		18
		310
  64
–
  120
		2
		1
		28
		18
		570
		240
  930
		35
		14
		250
		22
 3 800

		8
		0
  30
  590
  260
		93
  150
		20
  600
  290
		0
		1
		25
  210
 8 000
		0
		94
		17
		730
  420
  610
 3 700
		310
 1 000
 17 000
 21 000
 18 000

(0.5)
(0.3)
(1.4)
(1.5)
(0.4)
(0.2)
(0.2)
(1.2)
(0.6)
(0.7)
(0.3)
(0.5)
(0.6)
(0.6)
(0.4)
(0.5)
(3.4)
–
(4.4)
(0.4)
(0.2)
(0.2)
(0.3)
(1.5)
(2.4)
(4.8)
(0.6)
(0.7)
(0.5)
(0.2)
(0.8)

(0.3)
(0.6)
(1.0)
(5.9)
(2.8)
(2.8)
(3.8)
(0.2)
(3.2)
(4.6)
(0.0)
(0.2)
(1.2)
(5.3)
(5.5)
(0.0)
(1.1)
(0.2)
(7.9)
(0.5)
(10.0)
(8.3)
(0.5)
(3.2)
(3.5)
(2.3)
(4.4)

		41
		33
  97
		60
		5
		23
		10
  16
		30
		440
		270
		52
		62
		2
		18
		310
  64
–
  120
		2
		1
		28
		19
		570
		240
  920
		35
		14
		250
		22
 3 800

		11
		1
  30
  740
  260
		110
  190
		21
  610
  300
		0
		1
		25
  210
 7 300
		0
		93
		17
		920
  420
  620
 4 100
		310
 1 100
 17 000
 21 000
 18 000

(0.5)
(0.3)
(1.4)
(1.5)
(0.4)
(0.2)
(0.2)
(1.2)
(0.6)
(0.7)
(0.3)
(0.5)
(0.6)
(0.6)
(0.4)
(0.5)
(3.4)
–
(4.4)
(0.4)
(0.2)
(0.2)
(0.3)
(1.5)
(2.4)
(4.8)
(0.6)
(0.7)
(0.5)
(0.2)
(0.8)

(0.4)
(1.4)
(1.0)
(7.3)
(2.8)
(3.5)
(4.8)
(0.2)
(3.2)
(4.6)
(0.0)
(0.2)
(1.2)
(5.3)
(5.0)
(0.0)
(1.1)
(0.2)
(9.6)
(0.5)
(10.0)
(9.4)
(0.5)
(3.2)
(3.5)
(2.3)
(4.4)

0.6
0.0
−3.3
1.7
15.4
−15.4
−19.8
−13.1
3.5
0.0
−2.9
2.7
−0.8
1.2
0.0
0.0
−4.6
–
−8.2
18.1
−25.1
−2.9
0.0
−1.6
4.7
−1.0
0.0
18.5
−0.5
−4.1
−1.4

8.4
30.0
−14.8
5.5
−9.1
0.0
2.2
7.5
−3.6
−9.6

3.6
0.0
−6.4
−12.2

0.0
−9.6
2.2
−7.4
0.0
−1.5
0.0
−14.9
−7.8
−7.3
−7.4

EU/EEA
−4.1 Austria
−5.7 Belgium
−5.8 Bulgaria
0.0 Croatia
1.5 Cyprus
−9.8 Czechia
−6.1 Denmark
−11.2 Estonia
−7.4 Finland
−4.2 France
−3.0 Germany
−3.5 Greece
−6.7 Hungary
−2.8 Iceland
−5.6 Ireland
−2.8 Italy
−1.5 Latvia

– Liechtenstein

−5.0 Lithuania
−1.5 Luxembourg
−12.0 Malta
−3.5 Netherlands
−6.1 Norway
−2.0 Poland

1.0 Portugal
−3.3 Romania
3.0 Slovakia
0.0 Slovenia
−1.9 Spain
−8.7 Sweden
−3.4 Subtotal EU/EEA 
Non-EU/EEA 

3.6 Albania
17.0 Andorra
−14.7 Armenia

0.2 Azerbaijan

−12.2 Belarus
−3.9 Bosnia and Herzegovina
−1.7 Georgia
−2.1
Israel
−11.9 Kazakhstan
−10.1 Kyrgyzstan

−100.0 Monaco

1.6 Montenegro
−3.1 North Macedonia
−9.5 Republic of Moldova
−11.5 Russian Federation
San Marino

−4.7 Serbia
−5.1 Switzerland
−0.5 Tajikistan
−9.3 Turkey
−3.7 Turkmenistan
−5.7 Ukraine
−1.6 United Kingdom
−10.5 Uzbekistan
−9.7 Subtotal non-EU/EEA
−8.3 Total European Region
−9.3 Subtotal 18 HPCs

103

Tuberculosis surveillance and monitoring in Europe 2022SURVEILLANCE REPORT 
  
   
Table II. Estimated TB incidence per 100 000 population, European Region, 2011–2020

Country

EU/EEA
Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
Subtotal EU/EEA 
Non-EU/EEA 
Albania
Andorra
Armenia
Azerbaijan
Belarus
Bosnia and Herzegovina
Georgia
Israel
Kazakhstan
Kyrgyzstan
Monaco
Montenegro
North Macedonia
Republic of Moldova
Russian Federation
San Marino
Serbia
Switzerland
Tajikistan
Turkey
Turkmenistan
Ukraine
United Kingdom
Uzbekistan
Subtotal non-EU/EEA
Total European Region
Subtotal 18 HPCs

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

N

Rate per 
100 000

N

Rate per 
100 000

N

Rate per 
100 000

N

Rate per 
100 000

N

Rate per 
100 000

N

Rate per 
100 000

N

Rate per 

100 000

N

Rate per 

100 000

N

Rate per 

100 000

N

Rate per 

100 000

Mean annual 

Mean annual 

% change 

in rate,  

2016–2020

% change 

in rate,  

2011–2020

Country

		770
	1	100
 2 700
		710
		59
		650
		410
  340
		360
	5	700
	4	700
		520
	1	500
		9
		450
	3	900
  990
–
 2 000
		29
		34
	1	100
		370
	9	100
	2	900
 20 000
		430
		210
	7	400
		620
 69 100

		490
		3
 1 600
 11 000
 5 900
	1	700
 5 000
		470
 22 000
 6 900
		0
		130
		420
 4 900
 116 000
		0
	2	500
		600
 9 000
 17 000
 3 400
 48 000
	9	500
 27 000
 294 000
 363 000
 304 000

(9.2)
(10.0)
(37.0)
(17.0)
(5.2)
(6.2)
(7.4)
(25.0)
(6.7)
(9.0)
(5.8)
(4.8)
(15.0)
(2.8)
(9.7)
(6.6)
(47.0)
–
(65.0)
(5.5)
(8.3)
(6.7)
(7.4)
(24.0)
(27.0)
(96.0)
(8.0)
(10.0)
(16.0)
(6.5)
(15.5)

(17.0)
(4.1)
(55.0)
(125.0)
(62.0)
(46.0)
(122.0)
(6.3)
(135.0)
(125.0)
(1.0)
(20.0)
(20.0)
(119.0)
(81.0)
(0.0)
(28.0)
(7.6)
(117.0)
(24.0)
(66.0)
(105.0)
(15.0)
(93.0)
(64.8)
(40.4)
(77.8)

		710
	1	000
 2 600
		620
		72
		650
		390
  300
		300
	5	700
	4	600
		600
	1	300
		12
		390
	3	600
 1 100
–
 1 900
		52
		48
	1	100
		390
	8	100
	2	900
 19 000
		370
		150
	6	500
		680
 65 100

		470
		10
 1 500
 8 000
 6 000
	1	800
 4 800
		580
 20 000
 7 100
		0
		110
		430
 5 100
 110 000
		0
	2	200
		480
 8 500
 16 000
 3 700
 46 000
	9	300
 26 000
 278 000
 343 000
 288 000

(8.4)
(9.4)
(35.0)
(14.0)
(6.4)
(6.1)
(7.0)
(23.0)
(5.5)
(9.0)
(5.7)
(5.5)
(14.0)
(3.5)
(8.5)
(5.9)
(53.0)
–
(62.0)
(9.7)
(11.0)
(6.3)
(7.9)
(21.0)
(27.0)
(92.0)
(6.8)
(7.5)
(14.0)
(7.1)
(14.6)

(16.0)
(13.0)
(53.0)
(86.0)
(63.0)
(49.0)
(119.0)
(7.6)
(122.0)
(127.0)
(1.1)
(18.0)
(21.0)
(124.0)
(77.0)
(0.0)
(24.0)
(6.0)
(108.0)
(22.0)
(70.0)
(101.0)
(14.0)
(89.0)
(60.8)
(38.0)
(73.3)

		720
	1	000
 2 400
		590
		47
		540
		380
  300
		310
	5	700
	4	800
		570
	1	200
		13
		410
	3	500
 1 000
–	
 1 800
		44
		58
		960
		420
	8	100
	2	700
 18 000
		460
		160
	6	000
		700
 62 900

		550
		6
 1 700
 7 300
 5 600
	1	600
 4 700
		350
 18 000
 8 100
		0
		140
		400
 5 200
 106 000
		0
	2	400
		540
 8 000
 15 000
 3 800
 44 000
	8	300
 26 000
 268 000
 331 000
 277 000

(8.4)
(9.3)
(33.0)
(14.0)
(4.1)
(5.1)
(6.7)
(23.0)
(5.6)
(8.9)
(5.9)
(5.3)
(12.0)
(3.9)
(8.9)
(5.8)
(49.0)
–
(60.0)
(8.1)
(13.0)
(5.7)
(8.2)
(21.0)
(26.0)
(89.0)
(8.4)
(7.7)
(13.0)
(7.3)
(14.1)

(19.0)
(7.1)
(60.0)
(78.0)
(59.0)
(44.0)
(116.0)
(4.6)
(106.0)
(142.0)
(1.1)
(22.0)
(19.0)
(127.0)
(73.0)
(0.0)
(27.0)
(6.6)
(100.0)
(20.0)
(71.0)
(96.0)
(13.0)
(86.0)
(58.2)
(36.5)
(70.0)

		650
	1	000
 2 300
		570
		45
		550
		340
  270
		290
	5	500
	5	000
		560
		920
		9
		340
	4	000
  850
–
 1 700
		28
		52
		940
		350
	7	500
	2	500
 17 000
		370
		160
	5	500
		730
 60 000

		470
		7
 1 700
 7 200
 4 800
	1	500
 4 300
		420
 16 000
 7 300
		0
		130
		350
 4 700
 101 000
		0
	2	100
		490
 7 500
 15 000
 3 200
 43 000
	7	400
 25 000
 254 000
 314 000
 263 000

(7.5)
(9.1)
(31.0)
(13.0)
(3.9)
(5.1)
(5.9)
(21.0)
(5.3)
(8.5)
(6.1)
(5.2)
(9.4)
(2.8)
(7.4)
(6.6)
(42.0)
–
(57.0)
(5.0)
(12.0)
(5.5)
(6.8)
(20.0)
(24.0)
(85.0)
(6.8)
(7.9)
(12.0)
(7.5)
(13.4)

(16.0)
(8.7)
(57.0)
(76.0)
(51.0)
(43.0)
(106.0)
(5.3)
(91.0)
(126.0)
(0.0)
(21.0)
(17.0)
(115.0)
(70.0)
(0.0)
(23.0)
(5.9)
(91.0)
(20.0)
(58.0)
(94.0)
(11.0)
(82.0)
(54.8)
(34.5)
(66.1)

		650
	1	100
 2 000
		560
		72
		580
		370
  240
		310
	5	400
	6	500
		500
		990
		8
		340
	4	000
  800
–
 1 600
		34
		37
		980
		330
	7	200
	2	400
 16 000
		350
		150
	4	600
		900
 59 000

		480
		5
 1 500
 6 800
 4 700
	1	400
 4 000
		320
 14 000
 8 100
		0
		92
		350
 4 100
 97 000
		0
	1	900
		610
 7 300
 14 000
 2 700
 41 000
	6	600
 25 000
 242 000
 301 000
 251 000

(7.5)
(9.5)
(28.0)
(13.0)
(6.2)
(5.5)
(6.5)
(18.0)
(5.6)
(8.4)
(8.0)
(4.7)
(10.0)
(2.4)
(7.3)
(6.6)
(40.0)
–
(55.0)
(6.1)
(8.5)
(5.8)
(6.3)
(19.0)
(23.0)
(82.0)
(6.5)
(7.2)
(9.9)
(9.2)
(13.2)

(17.0)
(5.9)
(50.0)
(71.0)
(50.0)
(40.0)
(99.0)
(4.0)
(81.0)
(136.0)
(0.0)
(15.0)
(17.0)
(102.0)
(67.0)
(0.0)
(21.0)
(7.4)
(86.0)
(18.0)
(49.0)
(91.0)
(10.0)
(79.0)
(51.8)
(32.9)
(62.7)

		710
	1	100
 1 900
		520
		66
		590
		340
  220
		260
	5	700
	6	600
		470
		850
		7
		340
	4	300
  740
–
 1 500
		33
		58
	1	000
		320
	7	100
	2	100
 15 000
		320
		140
	5	400
		810
 58 500

		480
		5
 1 300
 6 400
 4 000
	1	100
 3 700
		290
 13 000
 8 100
		2
		100
		330
 4 100
 91 000
		0
	1	700
		660
 7 400
 14 000
 2 600
 39 000
	6	500
 24 000
 230 000
 289 000
 238 000

(8.1)
(10.0)
(27.0)
(12.0)
(5.6)
(5.5)
(5.9)
(16.0)
(4.7)
(8.7)
(8.0)
(4.4)
(8.7)
(2.1)
(7.2)
(7.2)
(37.0)
–
(54.0)
(5.8)
(13.0)
(5.9)
(6.1)
(19.0)
(20.0)
(74.0)
(5.9)
(6.5)
(12.0)
(8.2)
(13.1)

(17.0)
(6.0)
(44.0)
(66.0)
(42.0)
(33.0)
(92.0)
(3.5)
(73.0)
(133.0)
(6.0)
(16.0)
(16.0)
(101.0)
(63.0)
(0.0)
(19.0)
(7.9)
(85.0)
(18.0)
(46.0)
(87.0)
(9.8)
(76.0)
(48.9)
(31.5)
(59.0)

		650

	1	100

 1 800

		420

		60

		570

		290

  200

		270

	5	900

	6	200

		500

		750

		15

		350

	4	400

  620

–

 1 500

		37

		48

		890

		270

	6	400

	2	000

 14 000

		260

		130

	5	000

		560

 55 200

		580

		1

 1 100

 6 500

 3 500

		960

 3 400

		270

 12 000

 7 700

		0

		86

		270

 3 900

 86 000

		0

	1	700

		610

 7 500

 14 000

 2 500

 37 000

	5	900

 23 000

		540

	1	000

 1 600

		420

		59

		500

		310

  170

		260

	5	800

	6	100

		470

		690

		9

		340

	4	300

  560

–

 1 200

		48

		63

		910

		220

	6	000

	2	100

 13 000

		310

		110

	5	200

		550

 52 800

		510

		2

  920

 6 300

 2 900

		830

 3 200

		340

 12 000

 7 300

		1

		97

		270

 3 500

 79 000

		0

	1	500

		540

 7 600

 13 000

 2 700

 36 000

	5	400

 23 000

(7.3)

(9.2)

(25.0)

(10.0)

(5.1)

(5.4)

(5.1)

(15.0)

(4.9)

(9.0)

(7.4)

(4.7)

(7.7)

(4.5)

(7.3)

(7.3)

(32.0)

–

(51.0)

(6.2)

(11.0)

(5.2)

(5.1)

(17.0)

(20.0)

(72.0)

(4.8)

(6.2)

(11.0)

(5.7)

(12.3)

(20.0)

(1.5)

(36.0)

(66.0)

(37.0)

(29.0)

(86.0)

(3.3)

(69.0)

(124.0)

(0.0)

(14.0)

(13.0)

(95.0)

(59.0)

(0.0)

(19.0)

(7.2)

(85.0)

(17.0)

(43.0)

(84.0)

(8.8)

(73.0)

(46.0)

(29.6)

(55.7)

		530

	1	000

 1 400

		340

		76

		530

		300

  170

		260

	5	900

	5	300

		500

		610

		15

		280

	3	700

  490

–

 1 200

		55

		110

		860

		180

	5	700

	2	000

 13 000

		250

		110

	4	700

		550

 50 100

		470

		6

  780

 6 000

 2 800

		900

 3 000

		250

 13 000

 7 100

		0

		92

		250

 3 200

 73 000

		0

	1	300

		460

 7 700

 13 000

 2 600

 34 000

	5	400

 22 000

(6.1)

(9.1)

(23.0)

(10.0)

(4.9)

(4.7)

(5.4)

(13.0)

(4.8)

(8.9)

(7.3)

(4.4)

(7.1)

(2.7)

(7.0)

(7.2)

(29.0)

–

(44.0)

(8.0)

(14.0)

(5.3)

(4.1)

(16.0)

(21.0)

(68.0)

(5.8)

(5.4)

(11.0)

(5.5)

(11.7)

(18.0)

(3.0)

(31.0)

(63.0)

(31.0)

(25.0)

(80.0)

(4.0)

(67.0)

(116.0)

(3.0)

(15.0)

(13.0)

(86.0)

(54.0)

(0.0)

(17.0)

(6.4)

(84.0)

(16.0)

(46.0)

(80.0)

(8.0)

(70.0)

(43.4)

(28.1)

(52.5)

		440

		890

 1 300

		270

		69

		410

		280

  140

		200

	5	300

	4	600

		470

		440

		10

		260

	4	000

  430

–

  790

		37

		160

		710

		170

	3	600

	1	600

 12 000

		180

		86

	3	400

		360

 42 600

		430

		2

  680

 5 900

 2 500

		850

 2 800

		180

 13 000

 6 900

		0

		99

		250

 3 000

 68 000

		0

	1	200

		400

 8 000

 13 000

 2 800

 32 000

	4	700

 22 000

(6.0)

(8.9)

(21.0)

(8.3)

(6.3)

(4.9)

(5.2)

(13.0)

(4.7)

(9.0)

(6.4)

(4.8)

(6.3)

(4.4)

(5.8)

(6.0)

(26.0)

–

(42.0)

(9.0)

(26.0)

(5.0)

(3.3)

(15.0)

(19.0)

(66.0)

(4.5)

(5.4)

(10.0)

(5.5)

(11.1)

(16.0)

(7.5)

(26.0)

(60.0)

(29.0)

(27.0)

(74.0)

(2.9)

(68.0)

(110.0)

(0.0)

(15.0)

(12.0)

(80.0)

(50.0)

(0.0)

(14.0)

(5.4)

(83.0)

(16.0)

(45.0)

(77.0)

(8.0)

(67.0)

(41.1)

(26.6)

(49.8)

(4.9)

(7.7)

(19.0)

(6.6)

(5.7)

(3.9)

(4.9)

(10.0)

(3.6)

(8.2)

(5.5)

(4.5)

(4.6)

(2.8)

(5.3)

(6.6)

(23.0)

–

(29.0)

(5.9)

(36.0)

(4.1)

(3.1)

(9.6)

(16.0)

(64.0)

(3.2)

(4.1)

(7.3)

(3.6)

(9.5)

(15.0)

(3.0)

(23.0)

(58.0)

(26.0)

(26.0)

(70.0)

(2.1)

(69.0)

(105.0)

(0.0)

(16.0)

(12.0)

(74.0)

(46.0)

(0.0)

(13.0)

(4.7)

(84.0)

(15.0)

(47.0)

(73.0)

(6.9)

(66.0)

(39.2)

(24.9)

(47.4)

 218 000

 273 000

 226 000

 207 000

 260 000

 214 000

 197 000

 247 000

 204 000

 189 000

 232 000

 195 000

−11.8

−6.3

−8.4

−13.9

0.4

−8.2

−4.5

−11.1

−6.4

−1.5

−8.9

0.6

−14.7

7.5

−7.4

−2.2

−11.2

–

−14.4

0.4

29.0

−8.7

−15.6

−15.7

−5.4

−3.6

−14.2

−10.9

−11.7

−18.6

−7.8

−3.1

−15.9

−15.0

−3.2

−11.3

−5.8

−6.6

−12.0

−12.2

−1.4

−5.7

0.0

0.0

−6.9

−7.5

−7.6

0.0

−9.1

−0.3

−4.5

0.5

−4.3

−8.4

−3.5

−5.4

−5.7

−5.3

EU/EEA

−6.8 Austria

−2.9 Belgium

−7.1 Bulgaria

−10.0 Croatia

1.0 Cyprus

−5.0 Czechia

−4.5 Denmark

−9.7 Estonia

−6.7 Finland

−1.0 France

−0.6 Germany

−0.7 Greece

−12.3 Hungary

0.0 Iceland

−6.5 Ireland

0.0 Italy

−7.6 Latvia

– Liechtenstein

−8.6 Lithuania

0.8 Luxembourg

17.7 Malta

−5.3 Netherlands

−9.2 Norway

−9.7 Poland

−5.6 Portugal

−4.4 Romania

−9.7 Slovakia

−9.4 Slovenia

−8.3 Spain

−6.4 Sweden

−5.4 Subtotal EU/EEA 

Non-EU/EEA 

−1.4 Albania

−3.4 Andorra

−9.2 Armenia

−8.2 Azerbaijan

−9.2 Belarus

−6.1 Bosnia and Herzegovina

−6.0 Georgia

−11.5 Israel

−7.2 Kazakhstan

−1.9 Kyrgyzstan

−100.0 Monaco

−2.4 Montenegro

−5.5 North Macedonia

−5.1 Republic of Moldova

−6.1 Russian Federation

0.0 San Marino

−8.2 Serbia

−5.2 Switzerland

−3.6 Tajikistan

−5.1 Turkey

−3.7 Turkmenistan

−4.0 Ukraine

−8.3 United Kingdom

−3.7 Uzbekistan

−5.4 Subtotal non-EU/EEA

−5.2 Total European Region

−5.4 Subtotal 18 HPCs

Note: European Region comprises the 53 countries of the WHO European Region and Liechtenstein. WHO European Region 18 TB HPCs are presented in italics.
HPCs: high-priority countries. 

104

SURVEILLANCE REPORTTuberculosis surveillance and monitoring in Europe 2022 
 
 
 
 
 
Country

EU/EEA

Austria

Belgium

Bulgaria

Croatia

Cyprus

Czechia

Denmark

Estonia

Finland

France

Germany

Greece

Hungary

Iceland

Ireland

Italy

Latvia

Bosnia and Herzegovina

Liechtenstein

Lithuania

Luxembourg

Malta

Netherlands

Norway

Poland

Portugal

Romania

Slovakia

Slovenia

Spain

Sweden

Albania

Andorra

Armenia

Azerbaijan

Belarus

Georgia

Israel

Kazakhstan

Kyrgyzstan

Monaco

Montenegro

Subtotal EU/EEA 

Non-EU/EEA 

North Macedonia

Republic of Moldova

Russian Federation

San Marino

Serbia

Switzerland

Tajikistan

Turkey

Turkmenistan

Ukraine

United Kingdom

Uzbekistan

Subtotal non-EU/EEA

Total European Region

Subtotal 18 HPCs

		770

	1	100

 2 700

		710

		59

		650

		410

  340

		360

	5	700

	4	700

		520

	1	500

		9

		450

	3	900

  990

–

 2 000

		29

		34

	1	100

		370

	9	100

	2	900

 20 000

		430

		210

	7	400

		620

 69 100

		490

		3

 1 600

 11 000

 5 900

	1	700

 5 000

		470

 22 000

 6 900

		0

		130

		420

 4 900

 116 000

		0

	2	500

		600

 9 000

 17 000

 3 400

 48 000

	9	500

 27 000

 294 000

 363 000

 304 000

(9.2)

(10.0)

(37.0)

(17.0)

(5.2)

(6.2)

(7.4)

(25.0)

(6.7)

(9.0)

(5.8)

(4.8)

(15.0)

(2.8)

(9.7)

(6.6)

(47.0)

–

(65.0)

(5.5)

(8.3)

(6.7)

(7.4)

(24.0)

(27.0)

(96.0)

(8.0)

(10.0)

(16.0)

(6.5)

(15.5)

(17.0)

(4.1)

(55.0)

(125.0)

(62.0)

(46.0)

(122.0)

(6.3)

(135.0)

(125.0)

(1.0)

(20.0)

(20.0)

(119.0)

(81.0)

(0.0)

(28.0)

(7.6)

(117.0)

(24.0)

(66.0)

(105.0)

(15.0)

(93.0)

(64.8)

(40.4)

(77.8)

		710

	1	000

 2 600

		620

		72

		650

		390

  300

		300

	5	700

	4	600

		600

	1	300

		12

		390

	3	600

 1 100

–

 1 900

		52

		48

	1	100

		390

	8	100

	2	900

 19 000

		370

		150

	6	500

		680

 65 100

		470

		10

 1 500

 8 000

 6 000

	1	800

 4 800

		580

 20 000

 7 100

		0

		110

		430

 5 100

 110 000

		0

	2	200

		480

 8 500

 16 000

 3 700

 46 000

	9	300

 26 000

 278 000

 343 000

 288 000

(8.4)

(9.4)

(35.0)

(14.0)

(6.4)

(6.1)

(7.0)

(23.0)

(5.5)

(9.0)

(5.7)

(5.5)

(14.0)

(3.5)

(8.5)

(5.9)

(53.0)

–

(62.0)

(9.7)

(11.0)

(6.3)

(7.9)

(21.0)

(27.0)

(92.0)

(6.8)

(7.5)

(14.0)

(7.1)

(14.6)

(16.0)

(13.0)

(53.0)

(86.0)

(63.0)

(49.0)

(119.0)

(7.6)

(122.0)

(127.0)

(1.1)

(18.0)

(21.0)

(124.0)

(77.0)

(0.0)

(24.0)

(6.0)

(108.0)

(22.0)

(70.0)

(101.0)

(14.0)

(89.0)

(60.8)

(38.0)

(73.3)

		720

	1	000

 2 400

		590

		47

		540

		380

  300

		310

	5	700

	4	800

		570

	1	200

		13

		410

	3	500

 1 000

–	

 1 800

		44

		58

		960

		420

	8	100

	2	700

 18 000

		460

		160

	6	000

		700

 62 900

		550

		6

 1 700

 7 300

 5 600

	1	600

 4 700

		350

 18 000

 8 100

		0

		140

		400

 5 200

 106 000

		0

	2	400

		540

 8 000

 15 000

 3 800

 44 000

	8	300

 26 000

 268 000

 331 000

 277 000

(8.4)

(9.3)

(33.0)

(14.0)

(4.1)

(5.1)

(6.7)

(23.0)

(5.6)

(8.9)

(5.9)

(5.3)

(12.0)

(3.9)

(8.9)

(5.8)

(49.0)

–

(60.0)

(8.1)

(13.0)

(5.7)

(8.2)

(21.0)

(26.0)

(89.0)

(8.4)

(7.7)

(13.0)

(7.3)

(14.1)

(19.0)

(7.1)

(60.0)

(78.0)

(59.0)

(44.0)

(116.0)

(4.6)

(106.0)

(142.0)

(1.1)

(22.0)

(19.0)

(127.0)

(73.0)

(0.0)

(27.0)

(6.6)

(100.0)

(20.0)

(71.0)

(96.0)

(13.0)

(86.0)

(58.2)

(36.5)

(70.0)

		650

	1	000

 2 300

		570

		45

		550

		340

  270

		290

	5	500

	5	000

		560

		920

		9

		340

	4	000

  850

–

 1 700

		28

		52

		940

		350

	7	500

	2	500

 17 000

		370

		160

	5	500

		730

 60 000

		470

		7

 1 700

 7 200

 4 800

	1	500

 4 300

		420

 16 000

 7 300

		0

		130

		350

 4 700

 101 000

		0

	2	100

		490

 7 500

 15 000

 3 200

 43 000

	7	400

 25 000

 254 000

 314 000

 263 000

		650

	1	100

 2 000

		560

		72

		580

		370

  240

		310

	5	400

	6	500

		500

		990

		8

		340

	4	000

  800

–

 1 600

		34

		37

		980

		330

	7	200

	2	400

 16 000

		350

		150

	4	600

		900

 59 000

		480

		5

 1 500

 6 800

 4 700

	1	400

 4 000

		320

 14 000

 8 100

		0

		92

		350

 4 100

 97 000

		0

	1	900

		610

 7 300

 14 000

 2 700

 41 000

	6	600

 25 000

(7.5)

(9.1)

(31.0)

(13.0)

(3.9)

(5.1)

(5.9)

(21.0)

(5.3)

(8.5)

(6.1)

(5.2)

(9.4)

(2.8)

(7.4)

(6.6)

(42.0)

–

(57.0)

(5.0)

(12.0)

(5.5)

(6.8)

(20.0)

(24.0)

(85.0)

(6.8)

(7.9)

(12.0)

(7.5)

(13.4)

(16.0)

(8.7)

(57.0)

(76.0)

(51.0)

(43.0)

(106.0)

(5.3)

(91.0)

(126.0)

(0.0)

(21.0)

(17.0)

(115.0)

(70.0)

(0.0)

(23.0)

(5.9)

(91.0)

(20.0)

(58.0)

(94.0)

(11.0)

(82.0)

(54.8)

(34.5)

(66.1)

		710

	1	100

 1 900

		520

		66

		590

		340

  220

		260

	5	700

	6	600

		470

		850

		7

		340

	4	300

  740

–

 1 500

		33

		58

	1	000

		320

	7	100

	2	100

 15 000

		320

		140

	5	400

		810

		480

		5

 1 300

 6 400

 4 000

	1	100

 3 700

		290

 13 000

 8 100

		2

		100

		330

 4 100

 91 000

		0

	1	700

		660

 7 400

 14 000

 2 600

 39 000

	6	500

 24 000

(7.5)

(9.5)

(28.0)

(13.0)

(6.2)

(5.5)

(6.5)

(18.0)

(5.6)

(8.4)

(8.0)

(4.7)

(10.0)

(2.4)

(7.3)

(6.6)

(40.0)

–

(55.0)

(6.1)

(8.5)

(5.8)

(6.3)

(19.0)

(23.0)

(82.0)

(6.5)

(7.2)

(9.9)

(9.2)

(17.0)

(5.9)

(50.0)

(71.0)

(50.0)

(40.0)

(99.0)

(4.0)

(81.0)

(136.0)

(0.0)

(15.0)

(17.0)

(102.0)

(67.0)

(0.0)

(21.0)

(7.4)

(86.0)

(18.0)

(49.0)

(91.0)

(10.0)

(79.0)

(51.8)

(32.9)

(62.7)

(13.2)

 58 500

 242 000

 301 000

 251 000

 230 000

 289 000

 238 000

(8.1)

(10.0)

(27.0)

(12.0)

(5.6)

(5.5)

(5.9)

(16.0)

(4.7)

(8.7)

(8.0)

(4.4)

(8.7)

(2.1)

(7.2)

(7.2)

(37.0)

–

(54.0)

(5.8)

(13.0)

(5.9)

(6.1)

(19.0)

(20.0)

(74.0)

(5.9)

(6.5)

(12.0)

(8.2)

(13.1)

(17.0)

(6.0)

(44.0)

(66.0)

(42.0)

(33.0)

(92.0)

(3.5)

(73.0)

(133.0)

(6.0)

(16.0)

(16.0)

(101.0)

(63.0)

(0.0)

(19.0)

(7.9)

(85.0)

(18.0)

(46.0)

(87.0)

(9.8)

(76.0)

(48.9)

(31.5)

(59.0)

Note: European Region comprises the 53 countries of the WHO European Region and Liechtenstein. WHO European Region 18 TB HPCs are presented in italics.

HPCs: high-priority countries. 

Table II. Estimated TB incidence per 100 000 population, European Region, 2011–2020

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

N

Rate per 

100 000

N

Rate per 

100 000

N

Rate per 

100 000

N

Rate per 

100 000

N

Rate per 

100 000

N

Rate per 

100 000

N

Rate per 
100 000

N

Rate per 
100 000

N

Rate per 
100 000

N

Rate per 
100 000

Mean annual 
% change 
in rate,  
2016–2020

Mean annual 
% change 
in rate,  
2011–2020

Country

		650
	1	100
 1 800
		420
		60
		570
		290
  200
		270
	5	900
	6	200
		500
		750
		15
		350
	4	400
  620
–
 1 500
		37
		48
		890
		270
	6	400
	2	000
 14 000
		260
		130
	5	000
		560
 55 200

		580
		1
 1 100
 6 500
 3 500
		960
 3 400
		270
 12 000
 7 700
		0
		86
		270
 3 900
 86 000
		0
	1	700
		610
 7 500
 14 000
 2 500
 37 000
	5	900
 23 000
 218 000
 273 000
 226 000

(7.3)
(9.2)
(25.0)
(10.0)
(5.1)
(5.4)
(5.1)
(15.0)
(4.9)
(9.0)
(7.4)
(4.7)
(7.7)
(4.5)
(7.3)
(7.3)
(32.0)
–
(51.0)
(6.2)
(11.0)
(5.2)
(5.1)
(17.0)
(20.0)
(72.0)
(4.8)
(6.2)
(11.0)
(5.7)
(12.3)

(20.0)
(1.5)
(36.0)
(66.0)
(37.0)
(29.0)
(86.0)
(3.3)
(69.0)
(124.0)
(0.0)
(14.0)
(13.0)
(95.0)
(59.0)
(0.0)
(19.0)
(7.2)
(85.0)
(17.0)
(43.0)
(84.0)
(8.8)
(73.0)
(46.0)
(29.6)
(55.7)

		540
	1	000
 1 600
		420
		59
		500
		310
  170
		260
	5	800
	6	100
		470
		690
		9
		340
	4	300
  560
–
 1 200
		48
		63
		910
		220
	6	000
	2	100
 13 000
		310
		110
	5	200
		550
 52 800

		510
		2
  920
 6 300
 2 900
		830
 3 200
		340
 12 000
 7 300
		1
		97
		270
 3 500
 79 000
		0
	1	500
		540
 7 600
 13 000
 2 700
 36 000
	5	400
 23 000
 207 000
 260 000
 214 000

(6.1)
(9.1)
(23.0)
(10.0)
(4.9)
(4.7)
(5.4)
(13.0)
(4.8)
(8.9)
(7.3)
(4.4)
(7.1)
(2.7)
(7.0)
(7.2)
(29.0)
–
(44.0)
(8.0)
(14.0)
(5.3)
(4.1)
(16.0)
(21.0)
(68.0)
(5.8)
(5.4)
(11.0)
(5.5)
(11.7)

(18.0)
(3.0)
(31.0)
(63.0)
(31.0)
(25.0)
(80.0)
(4.0)
(67.0)
(116.0)
(3.0)
(15.0)
(13.0)
(86.0)
(54.0)
(0.0)
(17.0)
(6.4)
(84.0)
(16.0)
(46.0)
(80.0)
(8.0)
(70.0)
(43.4)
(28.1)
(52.5)

		530
	1	000
 1 400
		340
		76
		530
		300
  170
		260
	5	900
	5	300
		500
		610
		15
		280
	3	700
  490
–
 1 200
		55
		110
		860
		180
	5	700
	2	000
 13 000
		250
		110
	4	700
		550
 50 100

		470
		6
  780
 6 000
 2 800
		900
 3 000
		250
 13 000
 7 100
		0
		92
		250
 3 200
 73 000
		0
	1	300
		460
 7 700
 13 000
 2 600
 34 000
	5	400
 22 000
 197 000
 247 000
 204 000

(6.0)
(8.9)
(21.0)
(8.3)
(6.3)
(4.9)
(5.2)
(13.0)
(4.7)
(9.0)
(6.4)
(4.8)
(6.3)
(4.4)
(5.8)
(6.0)
(26.0)
–
(42.0)
(9.0)
(26.0)
(5.0)
(3.3)
(15.0)
(19.0)
(66.0)
(4.5)
(5.4)
(10.0)
(5.5)
(11.1)

(16.0)
(7.5)
(26.0)
(60.0)
(29.0)
(27.0)
(74.0)
(2.9)
(68.0)
(110.0)
(0.0)
(15.0)
(12.0)
(80.0)
(50.0)
(0.0)
(14.0)
(5.4)
(83.0)
(16.0)
(45.0)
(77.0)
(8.0)
(67.0)
(41.1)
(26.6)
(49.8)

		440
		890
 1 300
		270
		69
		410
		280
  140
		200
	5	300
	4	600
		470
		440
		10
		260
	4	000
  430
–
  790
		37
		160
		710
		170
	3	600
	1	600
 12 000
		180
		86
	3	400
		360
 42 600

		430
		2
  680
 5 900
 2 500
		850
 2 800
		180
 13 000
 6 900
		0
		99
		250
 3 000
 68 000
		0
	1	200
		400
 8 000
 13 000
 2 800
 32 000
	4	700
 22 000
 189 000
 232 000
 195 000

(4.9)
(7.7)
(19.0)
(6.6)
(5.7)
(3.9)
(4.9)
(10.0)
(3.6)
(8.2)
(5.5)
(4.5)
(4.6)
(2.8)
(5.3)
(6.6)
(23.0)
–
(29.0)
(5.9)
(36.0)
(4.1)
(3.1)
(9.6)
(16.0)
(64.0)
(3.2)
(4.1)
(7.3)
(3.6)
(9.5)

(15.0)
(3.0)
(23.0)
(58.0)
(26.0)
(26.0)
(70.0)
(2.1)
(69.0)
(105.0)
(0.0)
(16.0)
(12.0)
(74.0)
(46.0)
(0.0)
(13.0)
(4.7)
(84.0)
(15.0)
(47.0)
(73.0)
(6.9)
(66.0)
(39.2)
(24.9)
(47.4)

−11.8
−6.3
−8.4
−13.9
0.4
−8.2
−4.5
−11.1
−6.4
−1.5
−8.9
0.6
−14.7
7.5
−7.4
−2.2
−11.2
–
−14.4
0.4
29.0
−8.7
−15.6
−15.7
−5.4
−3.6
−14.2
−10.9
−11.7
−18.6
−7.8

−3.1
−15.9
−15.0
−3.2
−11.3
−5.8
−6.6
−12.0
−1.4
−5.7
0.0
0.0
−6.9
−7.5
−7.6
0.0
−9.1
−12.2
−0.3
−4.5
0.5
−4.3
−8.4
−3.5
−5.4
−5.7
−5.3

EU/EEA
−6.8 Austria
−2.9 Belgium
−7.1 Bulgaria
−10.0 Croatia
1.0 Cyprus
−5.0 Czechia
−4.5 Denmark
−9.7 Estonia
−6.7 Finland
−1.0 France
−0.6 Germany
−0.7 Greece
−12.3 Hungary
0.0 Iceland
−6.5 Ireland
0.0 Italy
−7.6 Latvia

– Liechtenstein

−8.6 Lithuania
0.8 Luxembourg
17.7 Malta
−5.3 Netherlands
−9.2 Norway
−9.7 Poland
−5.6 Portugal
−4.4 Romania
−9.7 Slovakia
−9.4 Slovenia
−8.3 Spain
−6.4 Sweden
−5.4 Subtotal EU/EEA 
Non-EU/EEA 

−1.4 Albania
−3.4 Andorra
−9.2 Armenia
−8.2 Azerbaijan
−9.2 Belarus
−6.1 Bosnia and Herzegovina
−6.0 Georgia
−11.5 Israel
−7.2 Kazakhstan
−1.9 Kyrgyzstan

−100.0 Monaco

−2.4 Montenegro
−5.5 North Macedonia
−5.1 Republic of Moldova
−6.1 Russian Federation
0.0 San Marino
−8.2 Serbia
−5.2 Switzerland
−3.6 Tajikistan
−5.1 Turkey
−3.7 Turkmenistan
−4.0 Ukraine
−8.3 United Kingdom
−3.7 Uzbekistan
−5.4 Subtotal non-EU/EEA
−5.2 Total European Region
−5.4 Subtotal 18 HPCs

105

Tuberculosis surveillance and monitoring in Europe 2022SURVEILLANCE REPORT 
 
 
 
 
 
 
Table III. New and relapse TB cases,a notification rates per 100 000 population and mean annual change in rates, 
European Region, 2011–2020

Country

EU/EEA
Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
Subtotal EU/EEA 
Non-EU/EEA 
Albania
Andorra
Armenia
Azerbaijan
Belarus
Bosnia and Herzegovina
Georgia
Israel
Kazakhstan
Kyrgyzstan
Monaco
Montenegro
North Macedonia
Republic of Moldova
Russian Federation
San Marino
Serbia

Serbia excluding Kosovo1
Kosovo1
Switzerland
Tajikistan
Turkey
Turkmenistan
Ukraine
United Kingdom
Uzbekistan
Subtotal non-EU/EEA
Total European Region
Subtotal 18 HPCs

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

N

Rate per 
100 000

N

Rate per 
100 000

N

Rate per 
100 000

N

Rate per 
100 000

N

Rate per 
100 000

N

Rate per 
100 000

N

Rate per 

100 000

N

Rate per 

100 000

N

Rate per 

100 000

N

Rate per 

100 000

Mean annual 

Mean annual 

% change 

in rate,  

2016–2020

% change 

in rate,  

2011–2020

Country

		671
		963
 2 313
-
		52
		568
		359
  316
		318
	5	000
	4	176
		454
	1	445
		9
		387
	4	140
  871
		1
 1 751
		25
		32
		985
		320
	8	175
	2	551
 17 672
		397
		190
	6	410
		542
 61 093

		422
		3
 1 261
 9 146
 4 697
	1	360
 4 547
		412
 25 074
 5 980
		0
		110
		335
 4 233
 112 910
		0
	2	174
	1	320
		854
		524
 7 035
 15 054
	2	731
 34 237
 8 407
 15 345
 255 997
 317 090
 265 173

(8.0)
(8.8)
(31.4)
-
(6.2)
(5.4)
(6.5)
(23.8)
(5.9)
(7.7)
(5.2)
(4.1)
(14.5)
(2.8)
(8.5)
(7.0)
(42.0)
(2.8)
(57.4)
(4.9)
(7.7)
(5.9)
(6.5)
(21.5)
(24.1)
(87.5)
(7.4)
(9.3)
(13.7)
(5.8)
(13.7)

(14.4)
(3.6)
(43.8)
(100.0)
(49.9)
(37.1)
(111.4)
(5.5)
(152.0)
(108.4)
(0.0)
(17.6)
(16.2)
(103.8)
(78.6)
(0.0)
(24.3)
(17.9)
(48.6)
(6.6)
(91.4)
(20.5)
(52.8)
(75.0)
(13.1)
(53.0)
(56.4)
(35.3)
(67.9)

		623
		898
 2 212
		539
		65
		557
		342
  269
		269
	5	003
	4	038
		520
	1	182
		11
		333
	3	512
  971
		2
 1 640
		45
		41
		934
		340
	7	285
	2	558
 16 764
		344
		138
	5	738
		591
 57 764

		408
		9
 1 213
 6 363
 4 783
	1	409
 3 940
		506
 18 006
 6 195
		0
		98
		346
 4 409
 105 753
		0
	1	872
	1	168
		704
		416
 6 508
 14 139
	2	937
 40 990
 8 269
 14 832
 243 401
 301 165
 251 924

(7.4)
(8.1)
(30.2)
(12.6)
(7.5)
(5.3)
(6.1)
(20.3)
(5.0)
(7.7)
(5.0)
(4.7)
(11.9)
(3.4)
(7.3)
(5.9)
(47.5)
(5.5)
(54.6)
(8.6)
(9.8)
(5.6)
(6.8)
(19.1)
(24.3)
(83.4)
(6.4)
(6.7)
(12.3)
(6.2)
(13.0)

(14.0)
(10.9)
(42.1)
(68.7)
(50.8)
(39.1)
(96.9)
(6.6)
(107.5)
(110.2)
(0.0)
(15.7)
(16.7)
(108.2)
(73.4)
(0.0)
(20.9)
(16.2)
(38.7)
(5.2)
(82.6)
(18.9)
(55.8)
(90.2)
(12.8)
(50.4)
(53.2)
(33.4)
(64.1)

		628
		890
 1 930
		510
		41
		468
		330
  265
		263
	4	947
	4	094
		494
	1	040
		11
		350
	3	435
  872
		0
 1 573
		38
		50
		828
		354
	7	043
	2	356
 15 505
		398
		139
	5	328
		603
 54 783

		474
		5
 1 397
 5 860
 4 470
	1	261
 3 434
		308
 18 958
 7 075
		0
		119
		318
 4 485
 106 053
		0
	2	106
	1	184
		922
		466
 5 576
 13 170
	3	047
 36 510
 7 384
 20 812
 243 288
 298 071
 250 992

(7.4)
(8.0)
(26.5)
(12.0)
(4.7)
(4.5)
(5.9)
(20.1)
(4.8)
(7.5)
(5.1)
(4.5)
(10.5)
(3.4)
(7.6)
(5.8)
(43.1)
(0.0)
(52.9)
(7.1)
(11.8)
(4.9)
(7.0)
(18.5)
(22.5)
(77.4)
(7.4)
(6.8)
(11.4)
(6.3)
(12.3)

(16.3)
(6.2)
(48.2)
(62.4)
(47.4)
(35.6)
(84.8)
(4.0)
(111.3)
(123.4)
(0.0)
(19.0)
(15.3)
(110.1)
(73.5)
(0.0)
(23.6)
(16.2)
(54.0)
(5.7)
(69.2)
(17.3)
(56.8)
(80.6)
(11.4)
(69.5)
(52.8)
(32.9)
(63.5)

		567
		878
 1 825
		498
		39
		472
		293
  237
		257
	4	888
	4	350
		484
		799
		9
		290
	3	663
  738
		0
 1 481
		24
		45
		805
		299
	6	539
	2	223
 14 834
		320
		142
	4	685
		625
 52 309

		408
		6
 1 329
 5 788
 3 858
	1	196
 3 200
		361
 15 244
 6 390
		0
		113
		284
 4 058
 102 340
		0
	1	818
		984
		834
		423
 5 807
 13 108
	2	537
 31 701
 6 622
 18 345
 224 936
 277 245
 232 820

(6.7)
(7.9)
(25.2)
(11.7)
(4.5)
(4.5)
(5.2)
(18.0)
(4.7)
(7.4)
(5.4)
(4.4)
(8.1)
(2.8)
(6.3)
(6.0)
(36.9)
(0.0)
(50.3)
(4.4)
(10.5)
(4.8)
(5.9)
(17.2)
(21.3)
(74.4)
(5.9)
(6.9)
(10.1)
(6.5)
(11.7)

(14.1)
(7.6)
(45.6)
(60.9)
(40.9)
(34.3)
(79.3)
(4.6)
(88.1)
(109.3)
(0.0)
(18.0)
(13.7)
(99.6)
(70.7)
(0.0)
(20.4)
(13.8)
(44.8)
(5.2)
(70.4)
(17.0)
(46.4)
(70.3)
(10.1)
(60.3)
(48.5)
(30.4)
(58.5)

		564
		919
 1 619
		485
		63
		507
		320
  206
		270
	4	457
	5	626
		438
		858
		7
		266
	3	476
  697
		1
 1 395
		30
		32
		846
		282
	6	237
	2	154
 14 215
		308
		129
	4	818
		776
 52 001

		415
		4
 1 171
 5 456
 3 765
	1	092
 3 152
		280
 14 006
 7 027
		0
		80
		282
 3 608
 99 590
		0
	1	649
		879
		770
		531
 5 894
 12 550
	2	191
 30 151
 5 854
 16 315
 215 063
 267 064
 223 008

(6.6)
(8.2)
(22.5)
(11.5)
(7.4)
(4.8)
(5.7)
(15.7)
(4.9)
(6.7)
(6.9)
(4.0)
(8.7)
(2.1)
(5.7)
(5.7)
(35.1)
(2.7)
(47.8)
(5.3)
(7.3)
(5.0)
(5.5)
(16.4)
(20.8)
(71.5)
(5.7)
(6.3)
(10.4)
(8.0)
(11.6)

(14.4)
(5.1)
(40.0)
(56.7)
(39.9)
(31.8)
(78.3)
(3.5)
(79.7)
(117.9)
(0.0)
(12.8)
(13.6)
(88.6)
(68.7)
(0.0)
(18.6)
12.4
43.5
(6.4)
(69.7)
(16.0)
(39.4)
(67.1)
(8.9)
(52.7)
(46.0)
(29.2)
(55.7)

		619
		982
 1 525
		452
		57
		511
		292
  188
		223
	5	446
	5	739
		417
		737
		6
		290
	3	778
  641
		2
 1 347
		29
		50
		875
		273
	6	143
	1	891
 12 774
		281
		118
	3	973
		691
 50 350

		415
		4
 1 027
 5 159
 3 211
		907
 2 983
		250
 12 322
 7 026
		2
		87
		263
 3 571
 92 407
		0
	1	472
		755
		717
		573
 5 965
 12 186
	2	068
 29 052
 5 793
 16 050
 202 793
 253 143
 209 502

(7.1)
(8.7)
(21.3)
(10.8)
(6.7)
(4.8)
(5.1)
(14.3)
(4.1)
(8.2)
(7.0)
(3.9)
(7.5)
(1.8)
(6.1)
(6.2)
(32.6)
(5.3)
(46.6)
(5.0)
(11.1)
(5.2)
(5.2)
(16.2)
(18.3)
(64.6)
(5.2)
(5.7)
(8.6)
(7.0)
(11.2)

(14.4)
(5.2)
(35.0)
(53.0)
(34.0)
(26.8)
(74.3)
(3.1)
(69.1)
(115.7)
(5.3)
(13.9)
(12.6)
(87.8)
(63.6)
(0.0)
(16.6)
10.7
40.4
(6.8)
(68.9)
(15.3)
(36.5)
(65.0)
(8.7)
(51.0)
(43.1)
(27.6)
(52.0)

		561

		911

 1 408

		372

		52

		495

		253

  172

		242

	5	015

	5	371

		434

		650

		13

		283

	3	828

  543

		1

 1 268

		32

		42

		772

		237

	5	535

	1	870

 12 303

		228

		112

	4	522

		487

 48 012

		503

		1

  841

 5 231

 2 781

		766

 2 597

		234

 12 449

 6 687

–

		75

		216

 3 358

 84 510

		0

	1	450

		738

		712

		529

 5 895

 11 821

	1	968

 27 229

 5 248

 16 842

 191 231

 239 243

 197 903

(6.4)

(8.0)

(19.8)

(9.0)

(6.1)

(4.7)

(4.4)

(13.1)

(4.4)

(7.5)

(6.5)

(4.0)

(6.6)

(3.8)

(5.9)

(6.3)

(27.8)

(2.6)

(44.5)

(5.4)

(9.1)

(4.5)

(4.5)

(14.6)

(18.1)

(62.6)

(4.2)

(5.4)

(9.7)

(4.9)

(17.4)

(1.3)

(28.6)

(53.1)

(29.4)

(22.9)

(64.8)

(2.8)

(68.9)

(108.0)

–

(12.0)

(10.4)

(82.7)

(58.1)

(0.0)

(16.4)

10.5

39.9

(6.3)

(66.4)

(14.6)

(34.2)

(61.2)

(7.9)

(52.7)

(40.4)

(25.9)

(48.8)

		470

		910

 1 290

		364

		51

		434

		270

  145

		226

	4	779

	5	326

		406

		602

		8

		290

	3	777

–

		1

 1 063

		42

		55

		780

		188

	5	196

	1	887

 11 581

		273

		98

	4	614

		474

		440

		2

  734

 5 038

 2 359

		666

 2 316

		292

 12 832

 6 338

		1

		84

		217

 3 022

 78 258

		0

	1	330

		641

		689

		473

 5 726

 11 576

	2	157

 26 512

 4 775

 16 413

 181 561

 227 161

187360

(10.6)

 45 600

		464

		890

 1 288

		297

		66

		455

		260

  147

		225

	4	869

	4	648

		434

		528

		13

		247

	3	185

–

–

 1 006

		48

		98

		739

		150

	4	983

	1	872

 11 070

		214

		98

	4	406

		478

 43 178

		412

		5

  621

 4 823

 2 207

		580

 2 169

		217

 12 501

 6 138

–

		80

		199

 2 809

 73 328

		0

	1	106

		501

		605

		402

 5 755

 11 247

	2	117

 25 379

 4 803

 16 272

(5.3)

(8.0)

(18.3)

(8.9)

(5.9)

(4.1)

(4.7)

(11.0)

(4.1)

(7.1)

(6.4)

(3.8)

(6.2)

(2.3)

(6.0)

(6.2)

–

(2.6)

(37.8)

(7.0)

(11.6)

(4.5)

(3.6)

(13.7)

(18.3)

(59.3)

(5.0)

(4.7)

(9.9)

(4.7)

(10.1)

(15.3)

(2.6)

(24.9)

(50.6)

(25.0)

(20.0)

(57.9)

(3.5)

(70.0)

(100.5)

(2.6)

(13.4)

(10.4)

(74.6)

(53.7)

(0.0)

(15.1)

9.1

38.5

(5.5)

(62.9)

(14.1)

(36.9)

(59.9)

(7.1)

(50.5)

(38.1)

(24.5)

(46.0)

		382

		778

  887

		177

		34

		360

		205

  120

		174

	4	398

	4	010

		380

		384

		12

		229

	2	163

–

		2

  688

		32

		140

		614

		144

	3	150

	1	402

 7 193

		153

		75

	2	949

		316

 31 551

		240

		2

  394

 3 683

 1 514

		357

 1 671

		158

 9 603

 4 241

		0

		40

		143

 1 767

 58 723

		439

–

–

		439

		351

 4 148

 8 830

	1	918

 17 533

 4 185

 12 111

(5.2)

(7.8)

(18.4)

(7.3)

(7.5)

(4.3)

(4.5)

(11.1)

(4.1)

(7.2)

(5.6)

(4.0)

(5.4)

(3.6)

(5.0)

(5.3)

–

–

(36.0)

(7.8)

(19.9)

(4.3)

(2.8)

(13.1)

(18.2)

(57.0)

(3.9)

(4.7)

(9.4)

(4.7)

(9.6)

(14.3)

(6.5)

(21.0)

(48.0)

(23.3)

(17.6)

(54.3)

(2.5)

(67.4)

(95.7)

–

(12.7)

(9.6)

(69.5)

(50.3)

(0.0)

(12.6)

7.2

33.8

(4.7)

(61.7)

(13.5)

(35.6)

(57.7)

(7.1)

(49.3)

(36.1)

(23.3)

(43.7)

(4.3)

(6.8)

(12.8)

(4.4)

(3.8)

(3.4)

(3.5)

(9.0)

(3.1)

(6.5)

(4.8)

(3.5)

(3.9)

(3.3)

(4.6)

(3.6)

–

(5.2)

(24.6)

(5.1)

(27.2)

(3.5)

(2.7)

(8.3)

(13.6)

(37.2)

(2.8)

(3.6)

(6.2)

(3.1)

(7.0)

(8.3)

(2.6)

(13.3)

(36.3)

(16.0)

(10.9)

(41.9)

(1.8)

(51.1)

(65.0)

(0.0)

(6.4)

(6.9)

(43.8)

(40.2)

(5.0)

–

–

(23.4)

(4.1)

(43.5)

(10.5)

(31.8)

(40.1)

(6.2)

(36.2)

(27.4)

(17.5)

(32.8)

−11.9

−6.1

−12.0

−20.3

−13.1

−8.7

−8.9

−10.8

−6.2

−5.4

−8.8

−2.1

−14.9

16.3

−6.9

−12.6

–

−0.7

−14.8

0.4

25.1

−9.0

−15.4

−15.4

−7.1

−12.9

−14.2

−11.1

−7.6

−18.7

−11.1

−12.7

−15.9

−21.5

−9.0

−17.1

−20.2

−13.3

−12.3

−7.2

−13.4

−100.0

−17.7

−14.2

−16.0

−10.8

−25.9

–

–

−12.7

−12.2

−10.9

−9.0

−3.4

−11.4

−8.4

−8.2

−10.7

−10.7

-10.9

 173 170

 216 348

 178 877

 132 051

 163 602

 135 024

EU/EEA

−6.7 Austria

−2.8 Belgium

−9.5 Bulgaria

−9.5 Croatia

−5.2 Cyprus

−5.1 Czechia

−6.5 Denmark

−10.2 Estonia

−6.8 Finland

−1.8 France

−0.8 Germany

−1.6 Greece

−13.5 Hungary

1.7 Iceland

−6.5 Ireland

−7.0 Italy

– Latvia

7.2 Liechtenstein

−9.0 Lithuania

0.5 Luxembourg

15.0 Malta

−5.6 Netherlands

−9.4 Norway

−10.0 Poland

−6.2 Portugal

−9.1 Romania

−10.2 Slovakia

−10.0 Slovenia

−8.4 Spain

−6.8 Sweden

−7.2 Subtotal EU/EEA 

Non-EU/EEA 

−5.9 Albania

−3.5 Andorra

−12.4 Armenia

−10.6 Azerbaijan

−11.9 Belarus

−10.3 Georgia

−11.5 Israel

−11.4 Kazakhstan

−5.5 Kyrgyzstan

– Monaco

−10.7 Montenegro

−12.8 Bosnia and Herzegovina

Serbia excluding Kosovo1

−9.1 North Macedonia

−9.1 Republic of Moldova

−7.2 Russian Federation

0.0 San Marino

−16.0 Serbia

–

−7.8

Kosovo1

−5.3 Switzerland

−7.9 Tajikistan

−7.2 Turkey

−5.5 Turkmenistan

−6.7 Ukraine

−8.1 United Kingdom

−4.1 Uzbekistan

−7.7 Subtotal non-EU/EEA

−7.5 Total European Region

-7.8 Subtotal 18 HPCs

Note: European Region comprises the 53 countries of the WHO European Region and Liechtenstein. WHO European Region 18 TB HPCs are presented in italics.
HPCs: high-priority countries.
1 All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999). 

106

SURVEILLANCE REPORTTuberculosis surveillance and monitoring in Europe 2022 
 
 
 
 
 
Table III. New and relapse TB cases,a notification rates per 100 000 population and mean annual change in rates, 

European Region, 2011–2020

Country

EU/EEA

Austria

Belgium

Bulgaria

Croatia

Cyprus

Czechia

Denmark

Estonia

Finland

France

Germany

Greece

Hungary

Iceland

Ireland

Italy

Latvia

Liechtenstein

Lithuania

Luxembourg

Malta

Netherlands

Norway

Poland

Portugal

Romania

Slovakia

Slovenia

Spain

Sweden

Albania

Andorra

Armenia

Azerbaijan

Belarus

Georgia

Israel

Kazakhstan

Kyrgyzstan

Monaco

Montenegro

Subtotal EU/EEA 

Non-EU/EEA 

North Macedonia

Republic of Moldova

Russian Federation

San Marino

Serbia

Kosovo1

Switzerland

Tajikistan

Turkey

Turkmenistan

Ukraine

United Kingdom

Uzbekistan

Bosnia and Herzegovina

Serbia excluding Kosovo1

		671

		963

 2 313

-

		52

		568

		359

  316

		318

	5	000

	4	176

		454

	1	445

		9

		387

	4	140

  871

		1

 1 751

		25

		32

		985

		320

	8	175

	2	551

 17 672

		397

		190

	6	410

		542

 61 093

		422

		3

 1 261

 9 146

 4 697

	1	360

 4 547

		412

 25 074

 5 980

		0

		110

		335

 4 233

 112 910

		0

	2	174

	1	320

		854

		524

 7 035

 15 054

	2	731

 34 237

 8 407

 15 345

(8.0)

(8.8)

(31.4)

-

(6.2)

(5.4)

(6.5)

(23.8)

(5.9)

(7.7)

(5.2)

(4.1)

(14.5)

(2.8)

(8.5)

(7.0)

(42.0)

(2.8)

(57.4)

(4.9)

(7.7)

(5.9)

(6.5)

(21.5)

(24.1)

(87.5)

(7.4)

(9.3)

(13.7)

(5.8)

(13.7)

(14.4)

(3.6)

(43.8)

(100.0)

(49.9)

(37.1)

(111.4)

(5.5)

(152.0)

(108.4)

(0.0)

(17.6)

(16.2)

(103.8)

(78.6)

(0.0)

(24.3)

(17.9)

(48.6)

(6.6)

(91.4)

(20.5)

(52.8)

(75.0)

(13.1)

(53.0)

(56.4)

(35.3)

(67.9)

		623

		898

 2 212

		539

		65

		557

		342

  269

		269

	5	003

	4	038

		520

	1	182

		11

		333

	3	512

  971

		2

 1 640

		45

		41

		934

		340

	7	285

	2	558

 16 764

		344

		138

	5	738

		591

 57 764

		408

		9

 1 213

 6 363

 4 783

	1	409

 3 940

		506

 18 006

 6 195

		0

		98

		346

 4 409

 105 753

		0

	1	872

	1	168

		704

		416

 6 508

 14 139

	2	937

 40 990

 8 269

 14 832

 243 401

 301 165

 251 924

(7.4)

(8.1)

(30.2)

(12.6)

(7.5)

(5.3)

(6.1)

(20.3)

(5.0)

(7.7)

(5.0)

(4.7)

(11.9)

(3.4)

(7.3)

(5.9)

(47.5)

(5.5)

(54.6)

(8.6)

(9.8)

(5.6)

(6.8)

(19.1)

(24.3)

(83.4)

(6.4)

(6.7)

(12.3)

(6.2)

(13.0)

(14.0)

(10.9)

(42.1)

(68.7)

(50.8)

(39.1)

(96.9)

(6.6)

(107.5)

(110.2)

(0.0)

(15.7)

(16.7)

(108.2)

(73.4)

(0.0)

(20.9)

(16.2)

(38.7)

(5.2)

(82.6)

(18.9)

(55.8)

(90.2)

(12.8)

(50.4)

(53.2)

(33.4)

(64.1)

		628

		890

 1 930

		510

		41

		468

		330

  265

		263

	4	947

	4	094

		494

	1	040

		11

		350

	3	435

  872

		0

 1 573

		38

		50

		828

		354

	7	043

	2	356

 15 505

		398

		139

	5	328

		603

 54 783

		474

		5

 1 397

 5 860

 4 470

	1	261

 3 434

		308

 18 958

 7 075

		0

		119

		318

 4 485

 106 053

		0

	2	106

	1	184

		922

		466

 5 576

 13 170

	3	047

 36 510

 7 384

 20 812

 243 288

 298 071

 250 992

(7.4)

(8.0)

(26.5)

(12.0)

(4.7)

(4.5)

(5.9)

(20.1)

(4.8)

(7.5)

(5.1)

(4.5)

(10.5)

(3.4)

(7.6)

(5.8)

(43.1)

(0.0)

(52.9)

(7.1)

(11.8)

(4.9)

(7.0)

(18.5)

(22.5)

(77.4)

(7.4)

(6.8)

(11.4)

(6.3)

(12.3)

(16.3)

(6.2)

(48.2)

(62.4)

(47.4)

(35.6)

(84.8)

(4.0)

(111.3)

(123.4)

(0.0)

(19.0)

(15.3)

(110.1)

(73.5)

(0.0)

(23.6)

(16.2)

(54.0)

(5.7)

(69.2)

(17.3)

(56.8)

(80.6)

(11.4)

(69.5)

(52.8)

(32.9)

(63.5)

		567

		878

 1 825

		498

		39

		472

		293

  237

		257

	4	888

	4	350

		484

		799

		9

		290

	3	663

  738

		0

 1 481

		24

		45

		805

		299

	6	539

	2	223

 14 834

		320

		142

	4	685

		625

 52 309

		408

		6

 1 329

 5 788

 3 858

	1	196

 3 200

		361

 15 244

 6 390

		0

		113

		284

 4 058

		0

	1	818

		984

		834

		423

 5 807

 13 108

	2	537

 31 701

 6 622

 18 345

 102 340

 224 936

 277 245

 232 820

		564

		919

 1 619

		485

		63

		507

		320

  206

		270

	4	457

	5	626

		438

		858

		7

		266

	3	476

  697

		1

 1 395

		30

		32

		846

		282

	6	237

	2	154

 14 215

		308

		129

	4	818

		776

 52 001

		415

		4

 1 171

 5 456

 3 765

	1	092

 3 152

		280

 14 006

 7 027

		0

		80

		282

 3 608

 99 590

		0

	1	649

		879

		770

		531

 5 894

 12 550

	2	191

 30 151

 5 854

 16 315

(6.7)

(7.9)

(25.2)

(11.7)

(4.5)

(4.5)

(5.2)

(18.0)

(4.7)

(7.4)

(5.4)

(4.4)

(8.1)

(2.8)

(6.3)

(6.0)

(36.9)

(0.0)

(50.3)

(4.4)

(10.5)

(4.8)

(5.9)

(17.2)

(21.3)

(74.4)

(5.9)

(6.9)

(10.1)

(6.5)

(11.7)

(14.1)

(7.6)

(45.6)

(60.9)

(40.9)

(34.3)

(79.3)

(4.6)

(88.1)

(0.0)

(18.0)

(13.7)

(99.6)

(70.7)

(0.0)

(20.4)

(13.8)

(44.8)

(5.2)

(70.4)

(17.0)

(46.4)

(70.3)

(10.1)

(60.3)

(48.5)

(30.4)

(58.5)

(109.3)

		619

		982

 1 525

		452

		57

		511

		292

  188

		223

	5	446

	5	739

		417

		737

		6

		290

	3	778

  641

		2

 1 347

		29

		50

		875

		273

	6	143

	1	891

 12 774

		281

		118

	3	973

		691

 50 350

		415

		4

 1 027

 5 159

 3 211

		907

 2 983

		250

 12 322

 7 026

		2

		87

		263

 3 571

 92 407

		0

	1	472

		755

		717

		573

 5 965

 12 186

	2	068

 29 052

 5 793

 16 050

(6.6)

(8.2)

(22.5)

(11.5)

(7.4)

(4.8)

(5.7)

(15.7)

(4.9)

(6.7)

(6.9)

(4.0)

(8.7)

(2.1)

(5.7)

(5.7)

(35.1)

(2.7)

(47.8)

(5.3)

(7.3)

(5.0)

(5.5)

(16.4)

(20.8)

(71.5)

(5.7)

(6.3)

(10.4)

(8.0)

(11.6)

(14.4)

(5.1)

(40.0)

(56.7)

(39.9)

(31.8)

(78.3)

(3.5)

(79.7)

(117.9)

(0.0)

(12.8)

(13.6)

(88.6)

(68.7)

(0.0)

(18.6)

12.4

43.5

(6.4)

(69.7)

(16.0)

(39.4)

(67.1)

(8.9)

(52.7)

(46.0)

(29.2)

(55.7)

(7.1)

(8.7)

(21.3)

(10.8)

(6.7)

(4.8)

(5.1)

(14.3)

(4.1)

(8.2)

(7.0)

(3.9)

(7.5)

(1.8)

(6.1)

(6.2)

(32.6)

(5.3)

(46.6)

(5.0)

(11.1)

(5.2)

(5.2)

(16.2)

(18.3)

(64.6)

(5.2)

(5.7)

(8.6)

(7.0)

(11.2)

(14.4)

(5.2)

(35.0)

(53.0)

(34.0)

(26.8)

(74.3)

(3.1)

(69.1)

(115.7)

(5.3)

(13.9)

(12.6)

(87.8)

(63.6)

(0.0)

(16.6)

10.7

40.4

(6.8)

(68.9)

(15.3)

(36.5)

(65.0)

(8.7)

(51.0)

(43.1)

(27.6)

(52.0)

 215 063

 267 064

 223 008

 202 793

 253 143

 209 502

Subtotal non-EU/EEA

Total European Region

Subtotal 18 HPCs

 255 997

 317 090

 265 173

HPCs: high-priority countries.

Note: European Region comprises the 53 countries of the WHO European Region and Liechtenstein. WHO European Region 18 TB HPCs are presented in italics.

1 All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999). 

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

N

Rate per 

100 000

N

Rate per 

100 000

N

Rate per 

100 000

N

Rate per 

100 000

N

Rate per 

100 000

N

Rate per 

100 000

N

Rate per 
100 000

N

Rate per 
100 000

N

Rate per 
100 000

N

Rate per 
100 000

Mean annual 
% change 
in rate,  
2016–2020

Mean annual 
% change 
in rate,  
2011–2020

Country

		561
		911
 1 408
		372
		52
		495
		253
  172
		242
	5	015
	5	371
		434
		650
		13
		283
	3	828
  543
		1
 1 268
		32
		42
		772
		237
	5	535
	1	870
 12 303
		228
		112
	4	522
		487
 48 012

		503
		1
  841
 5 231
 2 781
		766
 2 597
		234
 12 449
 6 687
–
		75
		216
 3 358
 84 510
		0
	1	450
		738
		712
		529
 5 895
 11 821
	1	968
 27 229
 5 248
 16 842
 191 231
 239 243
 197 903

(6.4)
(8.0)
(19.8)
(9.0)
(6.1)
(4.7)
(4.4)
(13.1)
(4.4)
(7.5)
(6.5)
(4.0)
(6.6)
(3.8)
(5.9)
(6.3)
(27.8)
(2.6)
(44.5)
(5.4)
(9.1)
(4.5)
(4.5)
(14.6)
(18.1)
(62.6)
(4.2)
(5.4)
(9.7)
(4.9)
(10.6)

(17.4)
(1.3)
(28.6)
(53.1)
(29.4)
(22.9)
(64.8)
(2.8)
(68.9)
(108.0)
–
(12.0)
(10.4)
(82.7)
(58.1)
(0.0)
(16.4)
10.5
39.9
(6.3)
(66.4)
(14.6)
(34.2)
(61.2)
(7.9)
(52.7)
(40.4)
(25.9)
(48.8)

		470
		910
 1 290
		364
		51
		434
		270
  145
		226
	4	779
	5	326
		406
		602
		8
		290
	3	777
–
		1
 1 063
		42
		55
		780
		188
	5	196
	1	887
 11 581
		273
		98
	4	614
		474
 45 600

		440
		2
  734
 5 038
 2 359
		666
 2 316
		292
 12 832
 6 338
		1
		84
		217
 3 022
 78 258
		0
	1	330
		641
		689
		473
 5 726
 11 576
	2	157
 26 512
 4 775
 16 413
 181 561
 227 161
187360

(5.3)
(8.0)
(18.3)
(8.9)
(5.9)
(4.1)
(4.7)
(11.0)
(4.1)
(7.1)
(6.4)
(3.8)
(6.2)
(2.3)
(6.0)
(6.2)
–
(2.6)
(37.8)
(7.0)
(11.6)
(4.5)
(3.6)
(13.7)
(18.3)
(59.3)
(5.0)
(4.7)
(9.9)
(4.7)
(10.1)

(15.3)
(2.6)
(24.9)
(50.6)
(25.0)
(20.0)
(57.9)
(3.5)
(70.0)
(100.5)
(2.6)
(13.4)
(10.4)
(74.6)
(53.7)
(0.0)
(15.1)
9.1
38.5
(5.5)
(62.9)
(14.1)
(36.9)
(59.9)
(7.1)
(50.5)
(38.1)
(24.5)
(46.0)

		464
		890
 1 288
		297
		66
		455
		260
  147
		225
	4	869
	4	648
		434
		528
		13
		247
	3	185
–
–
 1 006
		48
		98
		739
		150
	4	983
	1	872
 11 070
		214
		98
	4	406
		478
 43 178

		412
		5
  621
 4 823
 2 207
		580
 2 169
		217
 12 501
 6 138
–
		80
		199
 2 809
 73 328
		0
	1	106
		501
		605
		402
 5 755
 11 247
	2	117
 25 379
 4 803
 16 272
 173 170
 216 348
 178 877

(5.2)
(7.8)
(18.4)
(7.3)
(7.5)
(4.3)
(4.5)
(11.1)
(4.1)
(7.2)
(5.6)
(4.0)
(5.4)
(3.6)
(5.0)
(5.3)
–
–
(36.0)
(7.8)
(19.9)
(4.3)
(2.8)
(13.1)
(18.2)
(57.0)
(3.9)
(4.7)
(9.4)
(4.7)
(9.6)

(14.3)
(6.5)
(21.0)
(48.0)
(23.3)
(17.6)
(54.3)
(2.5)
(67.4)
(95.7)
–
(12.7)
(9.6)
(69.5)
(50.3)
(0.0)
(12.6)
7.2
33.8
(4.7)
(61.7)
(13.5)
(35.6)
(57.7)
(7.1)
(49.3)
(36.1)
(23.3)
(43.7)

		382
		778
  887
		177
		34
		360
		205
  120
		174
	4	398
	4	010
		380
		384
		12
		229
	2	163
–
		2
  688
		32
		140
		614
		144
	3	150
	1	402
 7 193
		153
		75
	2	949
		316
 31 551

		240
		2
  394
 3 683
 1 514
		357
 1 671
		158
 9 603
 4 241
		0
		40
		143
 1 767
 58 723
–
		439
–
		439
		351
 4 148
 8 830
	1	918
 17 533
 4 185
 12 111
 132 051
 163 602
 135 024

(4.3)
(6.8)
(12.8)
(4.4)
(3.8)
(3.4)
(3.5)
(9.0)
(3.1)
(6.5)
(4.8)
(3.5)
(3.9)
(3.3)
(4.6)
(3.6)
–
(5.2)
(24.6)
(5.1)
(27.2)
(3.5)
(2.7)
(8.3)
(13.6)
(37.2)
(2.8)
(3.6)
(6.2)
(3.1)
(7.0)

(8.3)
(2.6)
(13.3)
(36.3)
(16.0)
(10.9)
(41.9)
(1.8)
(51.1)
(65.0)
(0.0)
(6.4)
(6.9)
(43.8)
(40.2)
–
(5.0)
–
(23.4)
(4.1)
(43.5)
(10.5)
(31.8)
(40.1)
(6.2)
(36.2)
(27.4)
(17.5)
(32.8)

−11.9
−6.1
−12.0
−20.3
−13.1
−8.7
−8.9
−10.8
−6.2
−5.4
−8.8
−2.1
−14.9
16.3
−6.9
−12.6
–
−0.7
−14.8
0.4
25.1
−9.0
−15.4
−15.4
−7.1
−12.9
−14.2
−11.1
−7.6
−18.7
−11.1

−12.7
−15.9
−21.5
−9.0
−17.1
−20.2
−13.3
−12.3
−7.2
−13.4
−100.0
−17.7
−14.2
−16.0
−10.8
–
−25.9
–
−12.7
−12.2
−10.9
−9.0
−3.4
−11.4
−8.4
−8.2
−10.7
−10.7
-10.9

EU/EEA
−6.7 Austria
−2.8 Belgium
−9.5 Bulgaria
−9.5 Croatia
−5.2 Cyprus
−5.1 Czechia
−6.5 Denmark
−10.2 Estonia
−6.8 Finland
−1.8 France
−0.8 Germany
−1.6 Greece
−13.5 Hungary
1.7 Iceland
−6.5 Ireland
−7.0 Italy

– Latvia

7.2 Liechtenstein

−9.0 Lithuania
0.5 Luxembourg
15.0 Malta
−5.6 Netherlands
−9.4 Norway
−10.0 Poland
−6.2 Portugal
−9.1 Romania
−10.2 Slovakia
−10.0 Slovenia
−8.4 Spain
−6.8 Sweden
−7.2 Subtotal EU/EEA 
Non-EU/EEA 

−5.9 Albania
−3.5 Andorra
−12.4 Armenia
−10.6 Azerbaijan
−11.9 Belarus
−12.8 Bosnia and Herzegovina
−10.3 Georgia
−11.5 Israel
−11.4 Kazakhstan
−5.5 Kyrgyzstan
– Monaco
−10.7 Montenegro
−9.1 North Macedonia
−9.1 Republic of Moldova
−7.2 Russian Federation
0.0 San Marino

−16.0 Serbia

Serbia excluding Kosovo1
Kosovo1

–
−7.8
−5.3 Switzerland
−7.9 Tajikistan
−7.2 Turkey
−5.5 Turkmenistan
−6.7 Ukraine
−8.1 United Kingdom
−4.1 Uzbekistan
−7.7 Subtotal non-EU/EEA
−7.5 Total European Region
-7.8 Subtotal 18 HPCs

107

Tuberculosis surveillance and monitoring in Europe 2022SURVEILLANCE REPORT 
 
 
 
 
 
Table IV. TB cases in children under 15 years, European Region, 2016–2020a

Country/area

EU/EEA
Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
Subtotal EU/EEA 
Non−EU/EEA 
Albania
Andorra
Armenia
Azerbaijan
Belarus
Bosnia and Herzegovina
Georgia
Israel
Kazakhstan
Kyrgyzstan
Monaco
Montenegro
North Macedonia
Republic of Moldova
Russian Federation
San Marino
Serbia

Serbia excluding 
Kosovo1
Kosovo1
Switzerland
Tajikistan
Turkey
Turkmenistan
Ukraine
United Kingdom
Uzbekistan
Subtotal non−EU/EEA
Total European Region
Subtotal 18 HPCs

N

		30
		59
  126
		5
		0
		10
		18
  4
		6
	1	153
		226
		21
		6
		0
		17
		158
  23
		0
  47
		1
		0
		49
		13
		103
		36
  596
		61
		3
		321
		58
 3 150

		13
		0
  21
  175
  13
		10
  123
		13
  326
  407
		1
		0
		25
  103
 2 876
0
		17

		0

		17
		30
  389
  628
		5
  571
		224
 2 010
 7 980
 11 130
 8 443

2016

2017

2018

2019

2020

g
n
o
m
a
e
g
a
t
n
e
c
r
e
P

B Rate per 
100 000

T
l
l
a

N

g
n
o
m
a
e
g
a
t
n
e
c
r
e
P

B Rate per 
100 000

T
l
l
a

N

g
n
o
m
a
e
g
a
t
n
e
c
r
e
P

B Rate per 
100 000

T
l
l
a

N

g
n
o
m
a
e
g
a
t
n
e
c
r
e
P

B Rate per 
100 000

T
l
l
a

N

g
n
o
m
a
e
g
a
t
n
e
c
r
e
P

B Rate per 
100 000

T
l
l
a

(4.7)
(5.7)
(7.9)
(1.1)
(0.0)
(1.9)
(5.5)
(2.1)
(2.6)
(20.1)
(3.8)
(4.8)
(0.8)
(0.0)
(5.4)
(3.9)
(3.5)
(0.0)
(3.3)
(3.4)
(0.0)
(5.5)
(4.4)
(1.6)
(1.9)
(4.4)
(20.6)
(2.5)
(6.3)
(8.1)
(5.8)

(3.1)
(0.0)
(2.0)
(3.4)
(0.4)
(1.1)
(4.1)
(5.2)
(2.6)
(5.8)
(0.0)
(0.0)
(9.5)
(2.9)
(3.1)
–
(1.2)

(0.0)

(2.4)
(5.2)
(6.5)
(5.2)
(0.2)
(2.0)
(3.9)
(12.5)
(3.9)
(4.4)
(4.0)

2.4
3.1
12.6
0.8
0.0
0.6
1.9
1.9
0.7
9.4
2.1
1.3
0.4
0.0
1.7
1.9
7.7
0.0
11.1
1.1
0.0
1.8
1.4
1.8
2.5
19.4
7.3
1.0
4.6
3.4
4.6

2.4
0.0
3.5
7.8
0.8
2.0
15.9
0.6
6.7
21.0
0.0
0.0
7.2
16.0
11.4
–
1.2

0.0

3.7
2.4
12.4
3.1
0.3
8.3
1.9
22.5
8.2
6.7
10.1

		21
		68
  108
		3
		3
		6
		12
  0
		6
		343
		242
		11
		6
		0
		6
		168
  10
		0
  44
		1
		0
		34
		17
		68
		45
  533
		46
		2
		347
		26
 2 176

		14
		0
  20
  166
  13
		11
  94
		16
  404
  436
		0
		0
		10
  123
 2 494
0
		22

		7

		15
		23
  353
  551
  39
  611
		195
 1 989
 7 584
 9 760
 7 988

(3.7)
(7.0)
(7.4)
(0.8)
(5.7)
(1.2)
(4.4)
(0.0)
(2.4)
(6.8)
(4.4)
(2.4)
(0.9)
(0.0)
(2.0)
(4.3)
(1.8)
(0.0)
(3.2)
(3.1)
(0.0)
(4.3)
(6.5)
(1.2)
(2.4)
(4.1)
(18.5)
(1.8)
(6.1)
(5.0)
(4.3)

(2.8)
(0.0)
(2.4)
(3.2)
(0.5)
(1.4)
(3.6)
(6.8)
(3.2)
(6.5)
–
(0.0)
(4.6)
(3.7)
(3.0)
(0.0)
(1.5)

(0.9)

(2.1)
(4.3)
(6.0)
(4.7)
(2.0)
(2.2)
(3.7)
(11.8)
(4.0)
(4.1)
(4.0)

1.7
3.5
10.8
0.5
2.2
0.4
1.2
0.0
0.7
2.8
2.2
0.7
0.4
0.0
0.6
2.1
3.3
0.0
10.4
1.0
0.0
1.2
1.8
1.2
3.1
17.4
5.5
0.6
5.0
1.5
3.2

2.7
0.0
3.3
7.2
0.8
2.2
12.0
0.7
8.0
21.9
–
0.0
2.9
19.2
9.7
0.0
1.6

0.7

3.3
1.8
10.9
2.7
2.2
8.8
1.7
21.8
7.7
5.9
9.4

		28
		60
  72
		8
		1
		5
		11
  2
		2
		244
		213
		6
		3
		0
		7
		164
–
		0
  19
		0
		1
		21
		7
		52
		50
  542
		40
		1
		302
		31
 1 892

		4
		0
  37
  200
  12
		5
  77
		16
  362
  310
0
		2
		12
  95
 2 169
		0
		29

		6

		23
		26
  346
  599
  37
  580
159
 2 029
 7 106
 8 998
 7 488

(5.8)
(6.1)
(5.3)
(2.2)
(1.9)
(1.1)
(3.8)
(1.4)
(0.9)
(4.8)
(3.9)
(1.4)
(0.5)
(0.0)
(2.3)
(4.2)
–
(0.0)
(1.7)
(0.0)
(1.8)
(2.6)
(3.4)
(0.9)
(2.6)
(4.4)
(14.2)
(1.0)
(6.3)
(6.4)
(4.0)

(0.9)
(0.0)
(5.0)
(4.0)
(0.5)
(0.8)
(3.3)
(5.5)
(2.8)
(4.9)
–
(2.4)
(5.5)
(3.1)
(2.8)
(0.0)
(2.1)

(0.9)

(3.3)
(5.5)
(6.0)
(5.2)
(1.7)
(2.2)
(3.3)
(12.4)
(3.9)
(4.0)
(4.0)

2.2
3.1
7.2
1.3
0.7
0.3
1.1
0.9
0.2
2.0
1.9
0.4
0.2
0.0
0.7
2.0
–
0.0
4.5
0.0
1.5
0.8
0.7
0.9
3.5
17.7
4.7
0.3
4.3
1.7
2.8

0.8
0.0
6.1
8.6
0.8
1.0
9.7
0.7
6.9
15.2
–
1.7
3.5
14.8
8.3
0.0
2.1

0.6

5.2
2.0
10.3
3.0
2.1
8.3
1.3
21.8
7.1
5.4
8.7

		22
		50
  59
		1
		2
		4
		16
  1
		9
		226
		195
		17
		10
		0
		10
		180
–
–
  27
		0
		2
		48
		4
		81
		71
  390
		35
		2
		319
		19
 1 800

		11
		0
  38
  179
  8
		3
  72
		7
  351
  305
0
		1
		12
  101
 2 028
		0
		15

		4

		11
		15
  404
  496
		44
  585
182
 2 190
 7 047
 8 847
 7 278

(4.6)
(5.2)
(4.4)
(0.3)
(2.9)
(0.9)
(5.7)
(0.7)
(4.0)
(4.4)
(4.1)
(3.7)
(1.8)
(0.0)
(3.8)
(5.4)
–
–
(2.6)
(0.0)
(2.0)
(6.4)
(2.5)
(1.5)
(3.7)
(3.4)
(16.4)
(2.0)
(7.0)
(4.0)
(4.0)

(2.7)
(0.0)
(6.1)
(3.7)
(0.4)
(0.5)
(3.3)
(3.2)
(2.8)
(5.0)
–
(1.3)
(6.0)
(3.6)
(2.8)
(0.0)
(1.3)

(0.7)

(1.8)
(3.7)
(7.0)
(4.4)
(2.1)
(2.3)
(3.8)
(13.5)
(4.1)
(4.1)
(4.1)

1.7
2.6
5.9
0.2
1.4
0.2
1.7
0.5
1.0
1.9
1.7
1.1
0.7
0.0
1.0
2.3
–
–
6.4
0.0
3.0
1.8
0.4
1.4
5.0
12.8
4.1
0.6
4.6
1.0
2.6

2.2
0.0
6.2
7.6
0.5
0.6
9.0
0.3
6.6
14.6
–
0.9
3.5
15.7
7.7
0.0
1.1

0.4

2.5
1.2
11.7
2.4
2.4
8.3
1.5
23.1
7.0
5.3
8.4

		12
		48
  24
		2
		0
		2
		10
  1
		5
		196
		163
		17
		5
		2
		6
		104
–
		0
  13
		0
		7
		19
		11
		39
		43
  262
		35
		0
		188
		16
 1 230

		3
		0
  23
  91
  4
		1
  48
		4
  303
  180
0
		0
		10
  56
 1 627
		0
		11

–

		11
		16
		240
  391
  50
  382
153
 1 733
 5 326
 6 556
 5 428

(3.1)
(5.8)
(2.6)
(1.1)
(0.0)
(0.5)
(4.6)
(0.8)
(2.9)
(4.3)
(3.9)
(4.3)
(1.2)
(16.7)
(2.5)
(4.5)
–
(0.0)
(1.8)
(0.0)
(5.0)
(3.0)
(6.9)
(1.2)
(3.0)
(3.4)
(22.2)
(0.0)
(6.2)
(4.9)
(3.7)

(1.3)
(0.0)
(5.8)
(2.5)
(0.3)
(0.3)
(2.9)
(2.5)
(3.2)
(4.2)
–
(0.0)
(7.0)
(3.2)
(2.8)
(0.0)
(2.5)

–

(2.5)
(4.6)
(5.8)
(4.4)
(2.6)
(2.2)
(3.7)
(14.3)
(4.0)
(4.0)
(4.0)

0.9
2.5
2.4
0.3
0.0
0.1
1.0
0.5
0.6
1.6
1.4
1.1
0.4
2.9
0.6
1.3
–
0.0
3.1
0.0
10.1
0.7
1.2
0.7
3.1
8.6
4.1
0.0
2.7
0.9
1.8

0.6
0.0
3.7
3.8
0.2
0.2
6.0
0.2
5.5
8.5
–
0.0
2.9
8.7
6.1
0.0
0.8

–

2.5
1.2
6.8
1.9
2.7
5.5
1.3
18.0
5.3
3.9
6.2

Note: European Region comprises the 53 countries of the WHO European Region and Liechtenstein. WHO European Region 18 TB HPCs are presented in italics.
HPCs: high-priority countries.
a For non-EU/EEA countries, new and relapse cases are included; for EU/EEA countries, all TB cases under 15 years of age are included.
1 All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999). 

108

SURVEILLANCE REPORTTuberculosis surveillance and monitoring in Europe 2022 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     
    
SURVEILLANCE REPORT

Tuberculosis surveillance and monitoring in Europe 2022

Table V. RR/MDR-TBa  notification among new bacteriologically confirmedb pulmonary TB cases with available DST 
results, European Region, 2016–2020

2016

2017

2018

2019

2020

Country/area

N

% 

Rate 
per 
100 000

N

% 

Rate 
per 
100 000

N

% 

Rate 
per 
100 000

N

% 

Rate 
per 
100 000

N

% 

Rate 
per 
100 000

EU/EEA
Austria
Belgiumc
Bulgaria
Croatia
Cyprus
Czechia
Denmarkc
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Irelandc
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norwayc
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
Subtotal EU/EEA 
Non-EU/EEA 
Albania
Andorra
Armenia
Azerbaijan
Belarus
Bosnia and Herzegovina
Georgia
Israel
Kazakhstan
Kyrgyzstan
Monaco
Montenegro
North Macedonia
Republic of Moldova
Russian Federation
San Marino
Serbia

Serbia excluding Kosovo1
Kosovo1
Switzerland
Tajikistan
Turkey
Turkmenistan
Ukraine
United Kingdomc
Uzbekistan
Subtotal non-EU/EEA
Total European Region
Subtotal 18 HPCs

8
6
7
0
0
4
4
18
2
33
56
3
12
0
4
24
32
0
126
0
0
6
8
31
14
178
2
0
7
12
597

		2
		0
  61
  219
  677
		0
		172
  9
 1 869
  597
0
  0
		2
  387
 8 463
0
		5
		5
0
		13
  576
  148
–
 3 687
38
  757
 17 682
 18 279
 17 974

(3.0)
(1.4)
(1.2)
(0.0)
(0.0)
(1.3)
(2.2)
(13.5)
(1.6)
(1.4)
(2.6)
(3.1)
(4.0)
(0.0)
(3.1)
(3.1)
(7.6)
(0.0)
(14.3)
(0.0)
(0.0)
(1.8)
(5.4)
(0.8)
(1.6)
(2.9)
(2.2)
(0.0)
(2.2)
(3.3)
(2.8)

(5.3)
(0.0)
(17.1)
(18.8)
(38.0)
(0.0)
(10.8)
(7.4)
(57.3)
(27.3)
–
(0.0)
(1.3)
(25.7)
(27.3)
–
(1.4)
(1.4)
–
(4.6)
(22.5)
(2.9)
–
(26.6)
(1.7)
(100.0)
(25.7)
(20.6)
(24.6)

0.1
0.1
0.1
0.0
0.0
0.0
0.1
1.4
0.0
0.0
0.1
0.0
0.1
0.0
0.1
0.0
1.6
0.0
4.4
0.0
0.0
0.0
0.2
0.1
0.1
0.9
0.0
0.0
0.0
0.1
0.1

11
2
14
0
1
3
1
26
4
48
57
6
9
0
2
60
29
0
118
0
0
6
6
37
11
152
4
1
19
8
635

		2
0.1
		0
0.0
  51
2.1
  245
2.2
  649
7.2
		0
0.0
		163
4.3
  7
0.1
 1 406
10.5
  584
9.8
–
–
  0
0.0
		0
0.1
  399
9.5
 9 312
5.8
0
–
		1
0.1
		1
0.1
0
–
		7
0.2
  490
6.6
  162
0.2
–
–
 3 388
8.2
28
0.1
  657
2.4
3.8
 17 551
2.0  18 186
4.5  17 845

(4.2)
(0.5)
(2.7)
(0.0)
(3.0)
(1.0)
(0.6)
(21.7)
(2.9)
(1.8)
(2.6)
(4.0)
(3.1)
(0.0)
(1.9)
(3.1)
(8.0)
(0.0)
(13.8)
(0.0)
(0.0)
(1.7)
(4.4)
(1.1)
(1.2)
(2.5)
(4.1)
(1.2)
(2.2)
(3.2)
(2.8)

(2.9)
(0.0)
(15.9)
(12.4)
(38.4)
(0.0)
(11.3)
(5.4)
(36.7)
(25.6)
–
(0.0)
(0.0)
(27.6)
(32.0)
(0.0)
(0.3)
(0.3)
–
(2.6)
(20.1)
(3.3)
–
(27.9)
(1.4)
(14.8)
(25.3)
(20.3)
(24.2)

0.1
0.0
0.2
0.0
0.1
0.0
0.0
2.0
0.1
0.1
0.1
0.1
0.1
0.0
0.0
0.1
1.5
0.0
4.1
0.0
0.0
0.0
0.1
0.1
0.1
0.8
0.1
0.0
0.0
0.1
0.1

10
5
12
1
0
10
4
22
4
46
62
5
8
0
4
37
–
0
96
0
0
3
6
37
6
166
1
0
14
5
564

		3
0.1
		0
0.0
  51
1.7
  237
2.5
  559
6.9
		2
0.0
		160
4.1
  15
0.1
 1 706
7.8
  663
9.4
0
–
  0
0.0
		0
0.0
  402
9.8
 9 654
6.4
0
0.0
		2
0.0
		2
0.0
0
–
		3
0.1
  696
5.5
  163
0.2
–
–
 3 587
7.6
24
0.0
2.1
  735
3.8  18 662
2.1
 19 226
4.5  18 909

(4.8)
(1.2)
(2.5)
(0.4)
(0.0)
(3.6)
(2.5)
(21.6)
(3.1)
(1.7)
(2.8)
(4.3)
(2.6)
(0.0)
(4.2)
(2.1)
–
(0.0)
(12.8)
(0.0)
(0.0)
(0.9)
(6.1)
(1.2)
(0.7)
(2.8)
(0.9)
(0.0)
(1.7)
(1.8)
(2.6)

(5.1)
(0.0)
(20.4)
(12.0)
(36.6)
(0.5)
(12.2)
(9.7)
(27.1)
(28.9)
–
(0.0)
(0.0)
(28.8)
(34.5)
(0.0)
(0.7)
(0.7)
–
(1.1)
(28.0)
(3.5)
–
(29.0)
(1.2)
(15.2)
(26.4)
(21.0)
(25.3)

0.1
0.0
0.2
0.0
0.0
0.1
0.1
1.7
0.1
0.1
0.1
0.0
0.1
0.0
0.1
0.1
–
0.0
3.4
0.0
0.0
0.0
0.1
0.1
0.1
0.8
0.0
0.0
0.0
0.0
0.1

(1.0)
2
(2.1)
9
(1.7)
7
(0.0)
0
(0.0)
0
(2.6)
8
(1.8)
3
(17.0)
17
2
(1.6)
20 (100.0)
(2.0)
39
(3.4)
6
(3.3)
8
(0.0)
0
(1.1)
1
(2.4)
41
–
–
–
–
(13.8)
100
(0.0)
0
(0.0)
0
(2.3)
7
(1.2)
1
(1.0)
32
(1.2)
9
(2.7)
159
(1.3)
1
(0.0)
0
(1.7)
17
(2.1)
5
(2.7)
494

0.0
0.1
0.1
0.0
0.0
0.1
0.1
1.3
0.0
0.0
0.0
0.1
0.1
0.0
0.0
0.1
–
–
3.6
0.0
0.0
0.0
0.0
0.1
0.1
0.8
0.0
0.0
0.0
0.0
0.1

(0.6)
1
(0.9)
3
(3.9)
8
(0.0)
0
(0.0)
0
(3.6)
8
(0.8)
1
(18.0)
16
0
(0.0)
20 (100.0)
(2.1)
33
(2.0)
5
(3.8)
6
–
0
(0.0)
0
(3.4)
33
–
–
(0.0)
0
(12.6)
61
(0.0)
0
(0.0)
0
(1.6)
4
(2.6)
2
(1.4)
29
(0.9)
4
(2.4)
85
(0.0)
0
(1.8)
1
(1.8)
11
(2.4)
4
(2.8)
335

		2
0.1
		0
0.0
  38
1.7
  219
2.4
  561
5.9
		1
0.1
		165
4.0
  9
0.2
 1 534
9.3
  700
10.5
–
–
  0
0.0
		1
0.0
  441
9.9
 9 246
6.6
0
0.0
		2
0.0
		2
0.0
0
–
		5
0.0
  672
7.6
  113
0.2
–
–
 3 438
8.1
27
0.0
2.3
  615
4.0  17 789
 18 283
2.1
 18 025
4.7

(7.7)
(0.0)
(16.3)
(11.5)
(37.7)
(0.3)
(12.1)
(8.6)
(27.0)
(29.5)
–
(0.0)
(0.8)
(32.9)
(35.3)
(0.0)
(0.9)
(0.9)
–
(2.6)
(29.0)
(2.4)
–
(27.2)
(1.4)
(11.7)
(26.0)
(21.3)
(24.8)

0.1
0.0
1.3
2.2
5.9
0.0
4.1
0.1
8.3
10.9
–
0.0
0.0
10.9
6.3
0.0
0.0
0.0
–
0.1
7.2
0.1
–
7.8

		1
		0
  28
  149
  401
		0
		114
  5
 1 758
  493
0
  0
		1
  218
 7 657
–
–
–
–
		4
  408
  94
–
 2 515
31
1.9
  721
3.8  14 598
2.0  14 933
 14 726
4.5

(0.8)
(0.0)
(14.1)
(12.0)
(39.5)
(0.0)
(10.7)
(5.6)
(36.2)
(28.3)
–
(0.0)
(1.2)
(26.0)
(36.3)
–
–
–
–
(2.3)
(24.2)
(2.5)
–
(28.6)
(2.0)
(18.3)
(27.8)
(23.1)
(26.9)

0.0
0.0
0.1
0.0
0.0
0.1
0.0
1.2
0.0
0.0
0.0
0.0
0.1
0.0
0.0
0.1
–
0.0
2.2
0.0
0.0
0.0
0.0
0.1
0.0
0.4
0.0
0.0
0.0
0.0
0.1

0.0
0.0
0.9
1.5
4.2
0.0
2.9
0.1
9.4
7.6
–
0.0
0.0
5.4
5.2
–
–
–
–
0.0
4.3
0.1
–
5.8
0.0
2.2
3.1
1.6
3.7

Mean 
annual 
% 
change 
in rate, 
2016–
2020

−40.9
−16.3
4.1
–
–
18.5
−29.6
−3.1
−100.0
−12.0
−12.6
13.8
−15.8
–
−100.0
8.7
–
–
−15.9
–
–
−10.2
−29.8
−1.6
−26.8
−16.4
−100.0
–
11.4
−24.9
−13.5

−15.8
0.0
−17.9
−10.1
−12.3
0.0
−9.6
−15.1
−2.8
−6.4
0.0
0.0
−15.9
−13.2
−2.6
–
–
–
–
−26.1
−10.4
−11.9
–
−8.6
−5.5
−2.7
−4.8
−4.9
−5.2

Note: European Region comprises the 53 countries of the WHO European Region and Liechtenstein. WHO European Region 18 TB HPCs are presented in italics. The 
resistance pattern at the initiation of treatment is reported to TESSy irrespective of the method used for DST or resistance prediction.
DST: drug-susceptibility testing.
HPCs: high-priority countries.
RR/MDR-TB: rifampicin-resistant or multidrug-resistant tuberculosis.
TESSy: the European Surveillance System. 
a Includes cases that are RR/MDR but that also meet the pre-XDR or XDR case definitions (pre-XDR and XDR cases have not been excluded).
b Bacteriologically confirmed cases – cases with positive identification for Mycobacterium tuberculosis complex confirmed by culture and/or line probe assay for non-
EU/EEA countries, culture-positive OR microscopy-positive and nucleic acid amplification test-positive cases for EU/EEA countries.
c Previous TB history is defined as previous diagnosis.
1 All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999).

109

Table VI. RR/MDR-TBa notification among previously treated bacteriologically confirmedb pulmonary TB cases with 
available DST results, European Region, 2016–2020

2016

2017

2018

2019

2020

Country/area

N

% 

Rate 
per 
100 000

N

% 

Rate 
per 
100 000

N

% 

Rate 
per 
100 000

N

% 

Rate 
per 
100 000

N

% 

Rate 
per 
100 000

EU/EEA
Austria
Belgiumc
Bulgaria
Croatia
Cyprus
Czechia
Denmarkc
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Irelandc
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norwayc
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
Subtotal EU/EEA 
Non-EU/EEA 
Albania
Andorra
Armenia
Azerbaijan
Belarus
Bosnia and Herzegovina
Georgia
Israel
Kazakhstan
Kyrgyzstan
Monaco
Montenegro
North Macedonia
Republic of Moldova
Russian Federation
San Marino
Serbia

Serbia excluding Kosovo1
Kosovo1
Switzerland
Tajikistan
Turkey
Turkmenistan
Ukraine
United Kingdomc
Uzbekistan

3
3
15
0
0
2
0
7
0
18
18
2
8
0
2
9
21
0
127
0
0
5
0
20
3
365
1
0
4
3
636

	2	
		0
  67
  706
  569
		0
		192
  0
 1 050
  619
0
  0
		0
  295
 17 508
0
		5
		3
2
		1
  172
  92
–
 3 654
8
 1 199

(17.6)
(8.6)
(18.5)
(0.0)
(0.0)
(16.7)
(0.0)
(53.8)
(0.0)
(6.8)
(12.8)
(20.0)
(21.6)
(0.0)
(16.7)
(9.3)
(23.3)
(0.0)
(43.6)
(0.0)
(0.0)
(38.5)
(0.0)
(4.4)
(4.3)
(16.9)
(5.6)
(0.0)
(0.8)
(15.8)
(14.5)

(100.0)
(0.0)
(64.4)
(39.5)
(71.7)
(0.0)
(30.8)
(0.0)
(53.9)
(60.2)
–
(0.0)
(0.0)
(55.7)
(65.2)
–
(12.5)
(7.5)
(6.3)
(7.1)
(44.9)
(15.7)
–
(47.0)
(5.4)
(97.6)

Subtotal non-EU/EEA

 26 139

(59.5)

Total European Region
Subtotal 18 HPCs

 26 775
 26 658

(55.4)
(57.6)

0.0
0.0
0.2
0.0
0.0
0.0
0.0
0.5
0.0
0.0
0.0
0.0
0.1
0.0
0.0
0.0
1.1
0.0
4.4
0.0
0.0
0.0
0.0
0.1
0.0
1.8
0.0
0.0
0.0
0.0
0.1

3
2
15
0
0
3
0
11
2
33
25
1
4
0
0
13
18
0
145
0
0
1
0
15
2
291
2
0
13
2
601

0.1
0.0
2.3
7.3
6.0
0.0
4.8
0.0
5.9
10.2
–
0.0
0.0
7.3
12.1
–
0.1
0.0
0.1
0.0
2.0
0.1
–
8.2
0.0
3.8

		2
		0
  48
  762
  468
		0
		161
  1
 1 557
  666
–
  1
		0
  280
 16 567
  0
		4
		4
		0
		2
  153
  77
–
 3 113
6
 1 200
 25 
068
2.9  25 669
 25 532
6.7

5.6

(20.0)
(5.1)
(18.1)
(0.0)
(0.0)
(18.8)
(0.0)
(52.4)
(66.7)
(13.9)
(20.8)
(5.9)
(14.8)
(0.0)
(0.0)
(17.3)
(30.5)
(0.0)
(54.1)
(0.0)
(0.0)
(7.1)
(0.0)
(3.9)
(2.9)
(15.0)
(7.7)
(0.0)
(2.3)
(9.5)
(14.8)

(20.0)
(0.0)
(44.4)
(28.3)
(66.9)
(0.0)
(30.0)
(50.0)
(60.3)
(60.9)
–
(11.1)
(0.0)
(55.0)
(66.8)
–
(13.3)
(13.3)
(0.0)
(22.2)
(23.5)
(14.1)
–
(47.9)
(4.7)
(57.5)

(58.2)

(54.5)
(56.5)

0.0
0.0
0.2
0.0
0.0
0.0
0.0
0.8
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.9
0.0
5.1
0.0
0.0
0.0
0.0
0.0
0.0
1.5
0.0
0.0
0.0
0.0
0.1

0.1
0.0
1.6
7.7
5.0
0.0
4.0
0.0
8.6
10.8
–
0.2
0.0
6.9
11.4
0.0
0.0
0.0
0.0
0.0
1.7
0.1
–
7.0
0.0
3.8

3
1
16
1
0
0
0
10
0
36
23
0
5
0
0
12
–
0
92
0
0
0
0
18
2
270
2
0
4
2
497

		1
		0
  34
  701
  425
		0
		137
  0
 2 337
  850
0
  1
		0
  359
 17 011
  0
		1
		1
		0
		1
  208
  53
–
 2 888
8
  687

(21.4)
(2.9)
(22.2)
(6.3)
(0.0)
(0.0)
(0.0)
(55.6)
(0.0)
(14.8)
(17.2)
(0.0)
(14.7)
(0.0)
(0.0)
(17.9)
–
(0.0)
(42.2)
(0.0)
(0.0)
(0.0)
(0.0)
(4.1)
(3.9)
(14.8)
(13.3)
(0.0)
(9.3)
(18.2)
(15.0)

(25.0)
(0.0)
(41.5)
(25.6)
(69.4)
(0.0)
(30.9)
(0.0)
(64.3)
(68.3)
–
(33.3)
(0.0)
(59.6)
(70.6)
–
(3.7)
(3.7)
(0.0)
(6.7)
(37.8)
(11.9)
–
(46.4)
(5.3)
(34.1)

0.0
0.0
0.2
0.0
0.0
0.0
0.0
0.8
0.0
0.1
0.0
0.0
0.1
0.0
0.0
0.0
–
0.0
3.3
0.0
0.0
0.0
0.0
0.0
0.0
1.4
0.0
0.0
0.0
0.0
0.1

0.0
0.0
1.2
7.0
4.5
0.0
3.4
0.0
12.8
13.5
–
0.2
0.0
8.9
11.7
0.0
0.0
0.0
0.0
0.0
2.3
0.1
–
6.5
0.0
2.1

(8.3)
1
(10.0)
4
(14.0)
7
(7.7)
1
(0.0)
0
(0.0)
0
(0.0)
0
(47.6)
10
1
(25.0)
18 (100.0)
(15.0)
18
(5.9)
1
(22.7)
5
(0.0)
0
(11.1)
1
(12.9)
4
–
–
–
–
(38.9)
70
(0.0)
0
(0.0)
0
(0.0)
0
(14.3)
1
(3.0)
12
(7.7)
5
(12.7)
216
(19.0)
4
(0.0)
0
(1.7)
1
(0.0)
0
(13.4)
380

		2
		0
  27
  533
  313
		0
		139
  0
 1 446
  603
0
  0
		0
  118
 17 199
  0
		0
		0
–
		4
  206
  37
–
 2 498
4
  467

(66.7)
(0.0)
(40.9)
(24.4)
(59.8)
(0.0)
(32.1)
(0.0)
(44.5)
(60.1)
–
(0.0)
(0.0)
(34.2)
(70.8)
–
(0.0)
(0.0)
–
(16.7)
(40.4)
(9.7)
–
(42.9)
(3.3)
(21.8)

0.0
0.0
0.1
0.0
0.0
0.0
0.0
0.8
0.0
0.0
0.0
0.0
0.1
0.0
0.0
0.0
–
–
2.5
0.0
0.0
0.0
0.0
0.0
0.0
1.1
0.1
0.0
0.0
0.0
0.1

0.1
0.0
0.9
5.3
3.3
0.0
3.5
0.0
7.8
9.4
–
0.0
0.0
2.9
11.8
0.0
0.0
0.0
–
0.0
2.2
0.0
–
5.7
0.0
1.4

1
0
4
1
0
3
1
3
0
11
5
1
5
0
0
6
–
0
43
0
0
0
0
11
3
159
1
0
1
1
260

		3
		0
  24
  552
  424
		0
		77
  0
 1 101
  377
–
  0
		1
  195
 14 306
  0
–
–
–
		0
  147
  33
–
 1 662
		4
  679

(20.0)
(0.0)
(11.1)
(16.7)
(0.0)
(30.0)
(14.3)
(30.0)
(0.0)
(100.0)
(5.3)
(7.1)
(23.8)
(0.0)
(0.0)
(23.1)
–
(0.0)
(32.1)
(0.0)
(0.0)
(0.0)
(0.0)
(3.3)
(10.7)
(13.4)
(9.1)
(0.0)
(3.3)
(10.0)
(12.8)

(23.1)
(0.0)
(50.0)
(24.4)
(74.5)
(0.0)
(26.5)
(0.0)
(49.7)
(54.0)
–
(0.0)
(10.0)
(53.1)
(68.4)
–
–
–
–
(0.0)
(43.2)
(11.1)
–
(41.3)
(5.3)
(38.4)

5.4  25 702

(59.9)

5.5  23 596

(57.3)

5.0  19 585

(57.7)

3.0  26 199
6.4  26 078

(56.7)
(58.2)

2.8  23 976
6.5  23 889

(54.5)
(55.7)

2.6  19 845
5.9  19 786

(55.2)
(56.2)

0.0
0.0
0.1
0.0
0.0
0.0
0.0
0.2
0.0
0.0
0.0
0.0
0.1
0.0
0.0
0.0
–
0.0
1.5
0
0.0
0.0
0.0
0.0
0.0
0.8
0.0
0.0
0.0
0.0
0.1

0.1
0.0
0.8
5.4
4.5
0.0
1.9
0.0
5.9
5.8
–
0.0
0.0
4.8
9.8
0.0
–
–
–
0.0
1.5
0.0
–
3.8
0.0
2.0

4.2

2.2
4.9

Mean 
annual 
% 
change 
in rate, 
2016–
2020

−24.4
−100.0
−27.6
–
–
10.3
–
−19.3
–
−11.8
−27.6
−15.8
−10.9
–
−100.0
−9.3
–
–
−23.1
–
–
−100.0
–
−13.9
0.1
−18.3
−0.1
–
−29.6
−24.9
−20.1

10.8
0.0
−22.8
−6.9
−7.1
–
−20.3
–
−0.1
−13.2
–
–
–
−9.7
−5.0
0.0
–
–
–
−100.0
−6.1
−23.7
–
−17.4
−16.4
−14.6

−7.1

−7.3
−7.5

Note: European Region comprises the 53 countries of the WHO European Region and Liechtenstein. WHO European Region 18 TB HPCs are presented in italics. The 
resistance pattern at the initiation of treatment is reported to TESSy irrespective of the method used for DST or resistance prediction.
DST: drug-susceptibility testing.
HPCs: high-priority countries.
RR/MDR-TB: rifampicin-resistant or multidrug-resistant tuberculosis.
TESSy: the European Surveillance System.  
a Includes cases that are RR/MDR but that also meet the pre-XDR or XDR case definitions (pre-XDR and XDR cases have not been excluded).
b Bacteriologically confirmed cases – cases with positive identification for Mycobacterium tuberculosis complex confirmed by culture and/or line probe assay for non-
EU/EEA countries, culture-positive OR microscopy-positive and nucleic acid amplification test-positive cases for EU/EEA countries.
c Previous TB history is defined as previous diagnosis.
1 All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999).
110

SURVEILLANCE REPORTTuberculosis surveillance and monitoring in Europe 2022 
  
Table VII. RR/MDR-TBa notification among all bacteriologically confirmedb TB cases with available DST results  EU/EEA  
2016–2020

Country

EU/EEA
Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
Total EU/EEA 

2016

2017

2018

2019

2020

N

% 

Rate 
per 
100 000

N

% 

Rate 
per 
100 000

N

% 

Rate 
per 
100 000

N

% 

Rate 
per 
100 000

N

% 

Mean 
annual % 
change 
in rate  
2016–
2020

Rate 
per 
100 000

17
12
22
0
1
7
5
26
6
51
116
5
20
0
7
33
56
0
255
1
0
15
11
52
19
550
3
0
15
25
1 330

(3.6)
(1.6)
(3.3)
(0.0)
(2.4)
(1.9)
(2.0)
(17.1)
(3.3)
(1.9)
(2.9)
(4.2)
(5.9)
(0.0)
(3.0)
(3.8)
(10.4)
(0.0)
(21.2)
(4.0)
(0.0)
(2.7)
(4.8)
(1.2)
(1.7)
(6.4)
(2.7)
(0.0)
(1.4)
(4.2)
(4.5)

0.2
0.1
0.3
0.0
0.1
0.1
0.1
2.0
0.1
0.1
0.1
0.0
0.2
0.0
0.1
0.1
2.8
0.0
8.8
0.2
0.0
0.1
0.2
0.1
0.2
2.8
0.1
0.0
0.0
0.3
0.3

19
8
29
0
1
8
2
37
6
81
134
9
13
0
6
73
48
0
264
1
0
10
9
52
13
454
7
1
35
12
1 332

(4.5)
(1.1)
(4.8)
(0.0)
(2.6)
(2.3)
(0.9)
(26.1)
(3.1)
(2.8)
(3.4)
(4.7)
(4.1)
(0.0)
(3.0)
(3.7)
(11.1)
(0.0)
(23.0)
(4.3)
(0.0)
(1.9)
(4.2)
(1.4)
(1.2)
(5.5)
(5.2)
(0.9)
(2.0)
(2.8)
(4.4)

0.2
0.1
0.4
0.0
0.1
0.1
0.0
2.8
0.1
0.1
0.2
0.1
0.1
0.0
0.1
0.1
2.5
0.0
9.3
0.2
0.0
0.1
0.2
0.1
0.1
2.3
0.1
0.0
0.1
0.1
0.3

18
9
28
2
0
12
4
32
4
82
130
6
13
0
7
49
–
0
189
1
0
6
6
58
11
442
3
0
23
13
1 148

(5.2)
(1.3)
(5.1)
(0.7)
(0.0)
(3.7)
(1.8)
(26.2)
(2.2)
(2.7)
(3.3)
(3.9)
(3.9)
(0.0)
(3.4)
(2.7)
–
(0.0)
(19.1)
(2.9)
(0.0)
(1.1)
(3.6)
(1.5)
(1.0)
(5.5)
(2.1)
(0.0)
(2.1)
(3.2)
(4.0)

0.2
0.1
0.4
0.0
0.0
0.1
0.1
2.4
0.1
0.1
0.2
0.1
0.1
0.0
0.1
0.1
–
0.0
6.7
0.2
0.0
0.0
0.1
0.2
0.1
2.3
0.1
0.0
0.0
0.1
0.3

6
17
14
2
1
8
4
27
3
75
100
7
13
0
6
45
–
–
173
1
0
9
2
45
15
381
5
0
19
10
988

(1.8)
(2.4)
(3.1)
(0.8)
(1.9)
(2.4)
(1.8)
(21.3)
(1.7)
(100.0)
(2.9)
(3.1)
(5.0)
(0.0)
(3.4)
(2.6)
–
–
(18.5)
(3.1)
(0.0)
(1.9)
(1.5)
(1.2)
(1.7)
(4.9)
(4.4)
(0.0)
(1.4)
(2.5)
(4.0)

0.1
0.1
0.2
0.0
0.1
0.1
0.1
2.0
0.1
0.1
0.1
0.1
0.1
0.0
0.1
0.1
–
–
6.2
0.2
0.0
0.1
0.0
0.1
0.1
2.0
0.1
0.0
0.0
0.1
0.2

2
17
10
1
0
11
2
19
1
67
91
12
11
0
1
39
–
0
105
0
2
12
2
42
9
252
1
1
15
6
731

(0.7)
(2.8)
(4.1)
(0.8)
(0.0)
(4.3)
(1.1)
(18.1)
(0.7)
(100.0)
(3.2)
(3.4)
(6.2)
(0.0)
(1.0)
(3.3)
–
(0.0)
(16.5)
(0.0)
(5.0)
(3.0)
(1.5)
(1.7)
(1.7)
(5.1)
(1.5)
(1.4)
(1.8)
(2.3)
(4.3)

0.0
0.1
0.1
0.0
0.0
0.1
0.0
1.4
0.0
0.1
0.1
0.1
0.1
0.0
0.0
0.1
–
0.0
3.8
0.0
0.4
0.1
0.0
0.1
0.1
1.3
0.0
0.0
0.0
0.1
0.2

−41.8
8.6
−17.3
–
−100.0
11.6
−20.9
−7.8
−36.2
6.8
−6.2
24.7
−13.7
–
−39.3
4.7
–
–
−19.2
−100.0
–
−6.0
−35.2
−5.2
−16.9
−17.3
−24.1
–
−0.5
−30.8
−13.9

Note: European Region comprises the 53 countries of the WHO European Region and Liechtenstein. WHO European Region 18 TB high-priority countries are presented 
in italics. The resistance pattern at the initiation of treatment is reported to TESSy irrespective of the method used for DST or resistance prediction.
DST: drug-susceptibility testing.
RR/MDR-TB: rifampicin-resistant or multidrug-resistant tuberculosis.
TESSy: the European Surveillance System. 
a Includes cases that are RR/MDR but that also meet the pre-XDR or XDR case definitions (pre-XDR and XDR cases have not been excluded).
b Culture-positive OR microscopy-positive and nucleic acid amplification test-positive cases. 

111

Tuberculosis surveillance and monitoring in Europe 2022SURVEILLANCE REPORT  
Table VIII. Pre-XDR-TB notification among pulmonary RR/MDR-TBa cases with DST results to fluoroquinolones, 
European Region, 2016–2020b

Country/area

EU/EEA
Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia 
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
Subtotal EU/EEA 
Non-EU/EEA 
Albania
Andorra
Armenia
Azerbaijan
Belarus
Bosnia and Herzegovina
Georgia
Israel
Kazakhstan
Kyrgyzstan
Monaco
Montenegro
North Macedonia
Republic of Moldova
Russian Federation
San Marino
Serbia

Serbia excluding Kosovo1
Kosovo1
Switzerland
Tajikistan
Turkey
Turkmenistan
Ukraine
United Kingdom
Uzbekistan
Subtotal non-EU/EEA
Total European Region
Subtotal 18 HPCs

2016

B
T
-
R
D
X
-
e
r
P

)
N
(

s
e
s
a
c

s
e
s
a
c
B
T
-
R
D
M
/
R
R

)
N
(

L
Q
F

r
o
f
d
e
t
s
e
t

g
n
o
m
a
e
g
a
t
n
e
c
r
e
P

d
e
t
s
e
t

s
e
s
a
c

L
Q
F

r
o
f

s
e
s
a
c
B
T
-
R
D
M
/
R
R

)
N
(

L
Q
F

r
o
f
d
e
t
s
e
t

2017

B
T
-
R
D
X
-
e
r
P

)
N
(

s
e
s
a
c

g
n
o
m
a
e
g
a
t
n
e
c
r
e
P

d
e
t
s
e
t

s
e
s
a
c

L
Q
F

r
o
f

s
e
s
a
c
B
T
-
R
D
M
/
R
R

)
N
(

L
Q
F

r
o
f
d
e
t
s
e
t

2018

B
T
-
R
D
X
-
e
r
P

)
N
(

s
e
s
a
c

g
n
o
m
a
e
g
a
t
n
e
c
r
e
P

d
e
t
s
e
t

s
e
s
a
c

L
Q
F

r
o
f

s
e
s
a
c
B
T
-
R
D
M
/
R
R

)
N
(

L
Q
F

r
o
f
d
e
t
s
e
t

2019

B
T
-
R
D
X
-
e
r
P

)
N
(

s
e
s
a
c

g
n
o
m
a
e
g
a
t
n
e
c
r
e
P

d
e
t
s
e
t

s
e
s
a
c

L
Q
F

r
o
f

s
e
s
a
c
B
T
-
R
D
M
/
R
R

)
N
(

L
Q
F

r
o
f
d
e
t
s
e
t

2020

B
T
-
R
D
X
-
e
r
P

)
N
(

s
e
s
a
c

g
n
o
m
a
e
g
a
t
n
e
c
r
e
P

d
e
t
s
e
t

s
e
s
a
c

L
Q
F

r
o
f

15
9
22
0
0
5
4
25
3
46
72
0
17
0
6
22
53
0
253
0
0
9
8
38
12
238
3
0
5
14
879

–
0
57
535
674
0
315
9
–
407
–
0
0
603
0
0
–
–
–
13
644
156
–
10 141
44
1 802
 15 400
 16 279
 15 925

4
0
3
–
–
0
0
7
1
12
23
–
10
–
2
13
22
–
88
–
–
0
0
13
3
95
1
–
2
5
304

–
–
12
209
218
–
106
3
–
114
–
–
–
108
–
–
–
–
–
1
331
23
–
3 464
8
211
 4 808
 5 112
 5 011

(26.7)
(0.0)
(13.6)
–
–
(0.0)
(0.0)
(28.0)
(33.3)
(26.1)
(31.9)
–
(58.8)
–
(33.3)
(59.1)
(41.5)
–
(34.8)
–
–
(0.0)
(0.0)
(34.2)
(25.0)
(39.9)
(33.3)
–
(40.0)
(35.7)
(34.6)

–
–
(21.1)
(39.1)
(32.3)
–
(33.7)
(33.3)
–
(28.0)
–
–
–
(17.9)
–
–
–
–
–
(7.7)
(51.4)
(14.7)
–
(34.2)
(18.2)
(11.7)
(31.2)
(31.4)
(31.5)

16
3
27
0
1
6
1
35
6
57
85
6
12
0
5
28
47
0
263
0
0
6
6
36
8
225
5
1
9
10
904

		0
0
  98
  812
 1 117
–
  266
		8
2 187
  659
–
		1
0
  533
22 528
0
0
0
0
–
  464
  121
–
6 501
31
540
 35 866
 36 770
 36 423

4
0
4
–
1
2
0
11
1
14
14
1
5
–
1
11
18
–
108
–
–
0
1
11
2
76
2
0
1
0
288

0
–
20
208
464
–
93
1
278
220
–
1
–
89
5 672
–
–
–
–
–
55
9
–
1 965
10
51
 9 136
 9 424
 9 341

(25.0)
(0.0)
(14.8)
–
(100.0)
(33.3)
(0.0)
(31.4)
(16.7)
(24.6)
(16.5)
(16.7)
(41.7)
–
(20.0)
(39.3)
(38.3)
–
(41.1)
–
–
(0.0)
(16.7)
(30.6)
(25.0)
(33.8)
(40.0)
(0.0)
(11.1)
(0.0)
(31.9)

–
–
(20.4)
(25.6)
(41.5)
–
(35.0)
(12.5)
(12.7)
(33.4)
–
(100.0)
–
(16.7)
(25.2)
–
–
–
–
–
(11.9)
(7.4)
–
(30.2)
(32.3)
(9.4)
(25.5)
(25.6)
(25.6)

15
7
28
1
0
10
4
32
4
61
87
6
12
0
5
17
–
0
188
0
0
3
6
41
1
265
2
0
10
7
812

4
5
5
0
–
1
0
10
1
16
26
1
6
–
0
14
–
–
76
–
–
1
1
18
0
70
1
–
2
0
258

–
0
85
  864
984
–
211
15
3 577
666
–
1
0
658
23 919
0
–
–
–
4
583
142
–
6 475
25
1 422
 39 631
 40 443
 40 099

–
–
18
148
272
–
75
3
349
117
–
0
–
157
7 737
–
–
–
–
1
197
16
–
2 498
6
11
 11 605
 11 863
 11 756

(26.7)
(71.4)
(17.9)
(0.0)
–
(10.0)
(0.0)
(31.3)
(25.0)
(26.2)
(29.9)
(16.7)
(50.0)
–
(0.0)
(82.4)
–
–
(40.4)
–
–
(33.3)
(16.7)
(43.9)
(0.0)
(26.4)
(50.0)
–
(20.0)
(0.0)
(31.8)

–
–
(21.2)
(17.1)
(27.6)
–
(35.5)
(20.0)
(9.8)
(17.6)
–
(0.0)
–
(23.9)
(32.3)
–
–
–
–
(25.0)
(33.8)
(11.3)
–
(38.6)
(24.0)
(0.8)
(29.3)
(29.3)
(29.3)

3
11
14
1
1
2
3
25
2
60
59
4
13
0
3
34
–
0
159
0
0
7
2
31
5
147
5
0
5
6
602

–
0
  63
  704
  874
–
  242
		9
2 460
  909
–
		0
0
  559
 25 331
0
–
–
–
9
  362
  90
–
 5 936
29
466
 38 043
 38 645
 38 341

2
2
4
1
0
0
0
5
0
15
15
0
6
–
0
12
–
–
75
–
–
2
1
7
0
51
0
–
0
0
198

–
–
  19
153
  277
–
  65
		1
635
  97
–
–
–
121
 9 077
–
–
–
–
0
  16
  22
–
  890
5
209
 11 587
 11 785
 11 716

(66.7)
(18.2)
(28.6)
(100.0)
(0.0)
(0.0)
(0.0)
(20.0)
(0.0)
(25.0)
(25.4)
(0.0)
(46.2)
–
(0.0)
(35.3)
–
–
(47.2)
–
–
(28.6)
(50.0)
(22.6)
(0.0)
(34.7)
(0.0)
–
(0.0)
(0.0)
(32.9)

–
–
(30.2)
(21.7)
(31.7)
–
(26.9)
(11.1)
(25.8)
(10.7)
–
–
–
(21.6)
(35.8)
–
–
–
–
(0.0)
(4.4)
(24.4)
–
(15.0)
(17.2)
(44.8)
(30.5)
(30.5)
(30.6)

2
5
10
0
0
7
2
19
0
41
51
3
10
0
0
34
–
0
104
0
0
4
2
14
3
96
1
1
3
5
417

0
1
2
–
–
4
0
6
–
8
10
0
0
–
–
8
–
–
34
–
–
0
0
12
0
27
0
0
1
2
115

–
–
  52
576
  825
–
  173
		5
2 848
  869
–
		0
0
  413
 20 449
–
–
–
–
		4
  512
  99
0
 4 177
32
 1 400
 32 434
 32 851
 32 622

–
–
  11
87
  354
–
  50
		1
399
  149
–
–
–
188
 7 822
–
–
–
–
		2
  121
  14
–
 1 120
8
  378
 10 704
 10 819
 10 762

(0.0)
(20.0)
(20.0)
–
–
(57.1)
(0.0)
(31.6)
–
(19.5)
(19.6)
(0.0)
(0.0)
–
–
(23.5)
–
–
(32.7)
–
–
(0.0)
(0.0)
(85.7)
(0.0)
(28.1)
(0.0)
(0.0)
(33.3)
(40.0)
(27.6)

–
–
(21.2)
(15.1)
(42.9)
–
(28.9)
(20.0)
(14.0)
(17.1)
–
–
–
(45.5)
(38.3)
–
–
–
–
(50.0)
(23.6)
(14.1)
–
(26.8)
(25.0)
(27.0)
(33.0)
(32.9)
(33.0)

Note: European Region comprises the 53 countries of the WHO European Region and Liechtenstein. WHO European Region 18 TB HPCs are presented in italics.  
DST: drug-susceptibility testing.
FQL:	fluroquinolones.
HPCs: high-priority countries.
RR/MDR-TB: rifampicin-resistant or multidrug-resistant tuberculosis.
XDR-TB: extensively drug-resistant tuberculosis.
a Includes cases that are RR/MDR but that also meet the pre-XDR or XDR case definitions (pre-XDR and XDR cases have not been excluded).
b Includes only countries reporting second-line anti-TB drug susceptibility testing for at least one fluoroquinolone (ciprofloxacin, gatifloxacin, levofloxacin, 
moxifloxacin and ofloxacin) and one injectable drug (amikacin, capreomycin and kanamycin).
1 All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999).

112

SURVEILLANCE REPORTTuberculosis surveillance and monitoring in Europe 2022 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N

%

N

%b

N

%

N

%b

N

%

N

%b

N

%

N

%b

2017

2018

) Cases with known 
N
(

HIV status

HIV positive

) Cases with known 
N
(

HIV status

HIV positive

Table IX. TB cases with HIV infection, European Region, 2016–2020a

Country/area

EU/EEA
Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
Subtotal EU/EEA
Non-EU/EEA
Albania
Andorra
Armenia
Azerbaijan
Belarus
Bosnia and Herzegovina
Georgia
Israel
Kazakhstan
Kyrgyzstan
Monaco
Montenegro
North Macedonia
Republic of Moldova
Russian Federation
San Marino
Serbia

Serbia excluding Kosovo1
Kosovo1
Switzerland
Tajikistan
Turkey
Turkmenistan
Ukraine
United Kingdom
Uzbekistan
Subtotal non-EU/EEA
Total European Region
Subtotal 18 HPCs

)
N
(

s
e
s
a
c
B
T
l
l

A

–
	1	042
 1 603
		464
		60
		516
		330
  192
–
–
–
		440
		786
		6
		315
–
  660
–
 1 442
		29
		50
		887
		295
–
	1	936
 13 601
		296
		118
	5	070
–
 30 138

		415
		4
 1 027
 5 159
 3 211
		907
 2 983
  250
 12 322
 7 026
–
		87
		263
 3 571
 92 407
0
		755
		755
–
–
 5 965
 12 186
–
 29 052
–
 16 050
 193 640
 223 778
 208 457

2016

Cases with known 
HIV status

HIV positive

N

%

N

%b

–
		477
 1 260
		4
		48
		205
		150
  185
–
–
–
		296
		19
		6
		139
–
  507
–
 1 138
		5
		46
		646
		255
–
	1	697
 10 844
		132
		95
	3	021
–
 21 175

		223
		0
 1 027
 4 722
 3 148
		1
 2 866
  250
 10 616
 6 254
–
		60
		207
 3 366
 79 935
–
84
84
–
–
 5 850
 8 549
–
 28 194
–
 18 441
 173 793
 194 968
 186 902

–
(45.8)
(78.6)
(0.9)
(80.0)
(39.7)
(45.5)
(96.4)
–
–
–
(67.3)
(2.4)
(100.0)
(44.1)
–
(76.8)
–
(78.9)
(17.2)
(92.0)
(72.8)
(86.4)
–
(87.7)
(79.7)
(44.6)
(80.5)
(59.6)
–
(70.3)

(53.7)
(0.0)
(100.0)
(91.5)
(98.0)
(0.1)
(96.1)
(100.0)
(86.2)
(89.0)
–
(69.0)
(78.7)
(94.3)
(86.5)
–
(11.1)
(11.1)
–
–
(98.1)
(70.2)
–
(97.0)
–
(114.9)
(89.8)
(87.1)
(89.7)

–
		33
  0
		0
		0
		5
		9
  22
–
–
–
		8
		1
		0
		4
–
  57
–
  41
		2
		8
		20
		10
–
		183
  305
		0
		1
		243
–
  952

		6
–
  57
  99
  275
		1
  61
  18
  576
  210
–
		0
		0
  293
 16 570
–
		5
		5
–
–
  201
  56
–
 5 832
–
  758
 25 018
 25 970
 25 413

–
(6.9)
(0.0)
(0.0)
(0.0)
(2.4)
(6.0)
(11.9)
–
–
–
(2.7)
(5.3)
(0.0)
(2.9)
–
(11.2)
–
(3.6)
(40.0)
(17.4)
(3.1)
(3.9)
–
(10.8)
(2.8)
(0.0)
(1.1)
(8.0)
–
(4.5)

(2.7)
–
(5.6)
(2.1)
(8.7)
(100.0)
(2.1)
(7.2)
(5.4)
(3.4)
–
(0.0)
(0.0)
(8.7)
(20.7)
–
(6.0)
(6.0)
–
–
(3.4)
(0.7)
–
(20.7)
–
(4.1)
(14.4)
(13.3)
(13.6)

s
e
s
a
c
B
T
l
l

A

–
		967
 1 463
		378
		53
		501
		275
  176
–
–
–
		467
		685
		14
		300
–
  552
–
 1 387
		32
		42
		783
		261
–
	1	914
 12 997
		249
		112
	5	660
–
 29 268

–
		514
 1 204
		3
		49
		195
		211
  164
–
–
–
		389
		18
		13
		156
–
  471
–
 1 125
		3
		37
		602
		228
–
	1	744
 10 890
		227
		80
	2	845
–
 21 168

		503
		1
  841
 5 231
 2 781
–
 2 597
  234
 12 449
 6 687
–
		75
		216
 3 358
 84 510
  0
	1	450
		738
712
–
 5 895
 11 821
–
 27 229
	5	248
 16 842

235
0
 838
5 889
2 781
–
2 442
234
11 056
5 966
–
63
178
3 352
81 443
–
	71
	91
0
–
5 937
8 423
–
26 623
	4	407
16 842
 187 968  176 780
 217 236  197 948
 196 816  185 446

s
e
s
a
c
B
T
l
l

A

–
		977
 1 358
		372
		52
		443
		291
  147
–
–
–
		432
		640
		8
		310
–
–
–
 1 142
		42
–
		795
		208
–
	1	936
 12 199
		281
		99
	4	766
–
 26 498

–
		502
 1 118
		2
		41
		190
		234
  137
–
–
–
		362
		23
		8
		160
–
–
–
  954
		7
–
		624
		184
–
	1	698
 10 355
		238
		80
		76
–
 16 993

		440
		2
  734
 5 038
 2 359
–
 2 316
  292
 12 832
 6 338
–
		84
		217
 3 022
 78 258
  0
		641
		641
–
–
 5 726
 11 576
–
 26 512
	4	775
16 413

	215
	0
 699
6 483
2 359
–
2 174
 292
12 236
5 771
–
	43
	126
2 893
74 075
–
56	
56	
–
–
5 545
8 234
–
26 312
	4	060
16 413
 177 575  167 986
 204 073  184 979
 175 758
 185 970

–
(53.2)
(82.3)
(0.8)
(92.5)
(38.9)
(76.7)
(93.2)
–
–
–
(83.3)
(2.6)
(92.9)
(52.0)
–
(85.3)
–
(81.1)
(9.4)
(88.1)
(76.9)
(87.4)
–
(91.1)
(83.8)
(91.2)
(71.4)
(50.3)
–
(72.3)

(46.7)
(0.0)
(99.6)
(112.6)
(100.0)
–
(94.0)
(100.0)
(88.8)
(89.2)
–
(84.0)
(82.4)
(99.8)
(96.4)
–
(4.9)
(12.3)
(0.0)
–
(100.7)
(71.3)
–
(97.8)
(84.0)
(100.0)
(94.0)
(91.1)
(94.2)

–
		43
  3
		0
		0
		8
		3
  14
–
–
–
		13
		1
		0
		14
–
  52
–
  42
		1
		0
		23
		7
–
		149
  232
		0
		0
		266
–
  871

		4
		0
  66
  95
  202
–
  43
  12
  443
  216
–
		0
		0
  277
 15 695
–
8
8
–
–
  219
  65
–
 5 955
		128
  935
 24 363
 25 234
 24 554

–
(8.4)
(0.2)
(0.0)
(0.0)
(4.1)
(1.4)
(8.5)
–
–
–
(3.3)
(5.6)
(0.0)
(9.0)
–
(11.0)
–
(3.7)
(33.3)
(0.0)
(3.8)
(3.1)
–
(8.5)
(2.1)
(0.0)
(0.0)
(9.3)
–
(4.1)

(1.7)
(0.0)
(7.9)
(1.6)
(7.3)
–
(1.8)
(5.1)
(4.0)
(3.6)
–
(0.0)
(0.0)
(8.3)
(19.3)
–
(11.3)
(8.8)
–
–
(3.7)
(0.8)
–
(22.4)
(2.9)
(5.6)
(13.8)
(12.7)
(13.2)

–
(51.4)
(82.3)
(0.5)
(78.8)
(42.9)
(80.4)
(93.2)
–
–
–
(83.8)
(3.6)
(100.0)
(51.6)
–
–
–
(83.5)
(16.7)
–
(78.5)
(88.5)
–
(87.7)
(84.9)
(84.7)
(80.8)
(1.6)
–
(64.1)

(48.9)
(0.0)
(95.2)
(128.7)
(100.0)
–
(93.9)
(100.0)
(95.4)
(91.1)
–
(51.2)
(58.1)
(95.7)
(94.7)
–
(8.7)
(8.7)
–
–
(96.8)
(71.1)
–
(99.2)
(85.0)
(100.0)
(94.6)
(90.6)
(94.5)

–
		35
  0
		0
		1
		4
		3
  13
–
–
–
		11
		3
		1
		13
–
–
–
  32
		0
–
		21
		7
–
		161
  255
		2
		0
		35
–
  597

6
		0
72
87
182
–
45
12
717
187
–
0
3
248
14797
–
	8
	8
–
–
227
67
–
6053
		115
736
 23 562
 24 159
 23 718

–
(7.0)
(0.0)
(0.0)
(2.4)
(2.1)
(1.3)
(9.5)
–
–
–
(3.0)
(13.0)
(12.5)
(8.1)
–
–
–
(3.4)
(0.0)
–
(3.4)
(3.8)
–
(9.5)
(2.5)
(0.8)
(0.0)
(46.1)
–
(3.5)

(2.8)
(0.0)
(10.3)
(1.3)
(7.7)
–
(2.1)
(4.1)
(5.9)
(3.2)
–
(0.0)
(2.4)
(8.6)
(20.0)
–
(14.3)
(14.3)
–
–
(4.1)
(0.8)
–
(23.0)
(2.8)
(4.5)
(14.0)
(13.1)
(13.5)

  16

(11.3)

  13

(11.2) Estonia

2019

2020

Cases with known HIV 

status

HIV positive

) Cases with known 

N

HIV status

HIV positive

All TB 

cases (N)

Country/area

EU/EEA

– Austria

(8.5) Belgium

(0.1) Bulgaria

(0.0) Croatia

(6.7) Cyprus

(3.5) Czechia

(2.4) Denmark

– Finland

– France

– Germany

(4.3) Greece

(11.1) Hungary

– Iceland

(3.6)

Ireland

– Italy

– Latvia

– Liechtenstein

(2.8) Lithuania

(0.0) Luxembourg

– Malta

(2.9) Netherlands

(1.6) Norway

– Poland

(10.2) Portugal

(2.3) Romania

(2.4) Slovakia

(0.0) Slovenia

(9.8) Spain

– Sweden

Non-EU/EEA

(1.0) Albania

	–			 Andorra

(10.6) Armenia

(2.3) Azerbaijan

(8.9) Belarus

(1.9) Georgia

(9.5)

Israel

(6.5) Kazakhstan

(3.3) Kyrgyzstan

 –    Monaco

(0.0) Montenegro

– San Marino

– Serbia

–

–

Kosovo1

– Switzerland

(2.9) Tajikistan

(1.2) Turkey

 –    Turkmenistan

(

s

e

s

a

c

B

T

l

l

A

–

		830

  930

		183

		36

		367

		219

  124

–

–

–

–

–

–

–

–

–

  726

		34

		623

		160

	1	445

 7 698

		158

		77

	3	044

–

		240

		2

  394

 3 683

 1 514

–

 1 669

  158

 9 603

 4 241

–

		40

		143

 1 767

  0

–

–

–

–

–

–

–

		389

  781

		4

		30

		201

		166

  116

–

(46.9)

(84.0)

(2.2)

(83.3)

(54.8)

(75.8)

(93.5)

		396

		406

		396

		18

(100.0)

(4.4)

		240

		84

(35.0)

–

–

–

–

–

–

–

–

–

  714

		28

		489

		122

	1	087

 6 513

		82

		58

	1	759

–

			199

			0

   369

  3 683

  1 514

  1 490

   158

  9 440

  4 007

 –   

			35

			69

  1 693

–

–

–

–

–

 –   

	–			

–

–

–

–

–

–

–

–

–

(98.3)

(82.4)

(78.5)

(76.3)

(75.2)

(84.6)

(51.9)

(75.3)

(57.8)

–

(82.9)

(0.0)

(93.7)

(100.0)

(100.0)

(89.3)

(100.0)

(98.3)

(94.5)

 –   

(87.5)

(48.3)

(95.8)

(95.1)

–

–

–

–

–

 –   

	–			

–

		33

  1

		0

		2

		7

		4

		17

		2

–

		3

–

–

–

–

–

–

  20

		0

–

		14

		2

–

		111

  150

		2

		0

		173

–

  554

			2

		0

   39

   83

   135

	–			

   29

   15

   614

   131

 –   

			0

			1

–

–

–

–

–

   118

   83

 –   

	–			

   379

 19 148

 19 702

 19 314

 1 058

 1 020

–

		963

 1 344

		305

		69

		461

		281

  150

		459

		552

		13

		266

–

–

–

–

–

–

		50

–

		754

		162

–

	1	932

 11 618

		214

		101

	4	543

–

		412

		5

  621

 4 823

 2 207

–

 2 169

  217

 12 501

 6 138

–

		80

		199

 2 809

 73 328

  0

		501

		501

–

–

–

–

–

		502

 1 104

		5

		43

		270

		227

  141

		408

		32

		11

		106

–

–

–

–

–

–

		37

–

		596

		133

–

	1	641

 10 218

		148

		73

	2	597

–

368	

0	

591 

4 534

2 207

–

1 841

217 

12 375

5 810

–

76	

152	

2 792

70 610

–

–

–

–

–

–

(52.1)

(82.1)

(1.6)

(62.3)

(58.6)

(80.8)

(94.0)

(88.9)

(5.8)

(84.6)

(39.8)

(96.4)

(74.0)

(79.0)

(82.1)

(84.9)

(87.9)

(69.2)

(72.3)

(57.2)

–

–

–

–

–

–

–

–

–

(89.3)

(0.0)

(95.2)

(94.0)

(100.0)

–

(84.9)

(100.0)

(99.0)

(94.7)

–

(95.0)

(76.4)

(99.4)

(96.3)

–

–

–

–

–

–

		43

  1

		0

		2

		8

		7

		19

		3

		0

		10

–

–

–

–

–

–

  27

		0

–

		21

		6

–

		153

  200

		4

		1

–

		233

	8

		0

 62

 71

 157

–

 33

 8

 666

 131

–

	0

	1

 295

16 453

–

			3

			3

–

–

–

–

–

(8.6)

(0.1)

(0.0)

(4.7)

(3.0)

(3.1)

–

–

–

–

–

–

–

–

(4.7)

(9.4)

(0.0)

(9.4)

(2.6)

(0.0)

(3.5)

(4.5)

(9.3)

(2.0)

(2.7)

(1.4)

(9.0)

–

(2.2)

(0.0)

(10.5)

(1.6)

(7.1)

–

(1.8)

(3.7)

(5.4)

(2.3)

–

(0.0)

(0.7)

(10.6)

(23.3)

(7.7)

(7.7)

–

–

–

–

–

(4.0)

(15.6)

(14.3)

(14.7)

 58 723

  55 838

  13 506

(24.2) Russian Federation

(1.4) North Macedonia

   219

(12.9) Republic of Moldova

			39

			39

(7.8)

(7.8)

Serbia excluding Kosovo1

 5 755

 11 247

5 660

8 814

(98.3)

(78.4)

 167

 104

(3.0)

(1.2)

 4 148

 8 830

  4 043

  7 062

(97.5)

(80.0)

 25 379

25 210

(99.3)

5 800

(23.0)

 17 533

  17 375

(99.1)

  3 794

(21.8) Ukraine

 16 272

 164 663

 189 958

 177 419

16 272

(100.0)

 647

 12 111

  12 111

(100.0)

 157 568

 176 880

 169 199

(95.7)

(93.1)

(95.4)

 24 606

 25 360

 24 830

 124 799  119 086

 142 495

 133 694

 132 123

 126 749

(95.4)

(92.7)

(94.8)

	–			 United Kingdom

(3.1) Uzbekistan

(16.1) Subtotal non-EU/EEA

(14.9) Total European Region

(15.2) Subtotal 18 HPCs

 25 295

 19 312

(76.3)

  754

(3.9)

 17 696

 13 037

(73.7)

(4.2) Subtotal EU/EEA

	–			

	–			

	–			 Bosnia and Herzegovina

Note: European Region comprises the 53 countries of the WHO European Region and Liechtenstein. WHO European Region 18 TB HPCs are presented in italics. 
HPCs: high-priority countries.
a HIV prevalence may be underestimated due to incomplete HIV testing and/or reporting of HIV serostatus. Countries/areas were only included in this analysis if the 
total number of cases tested for HIV and test results were provided.
b Proportion calculated from TB cases with known HIV test results.
1 All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999). 

114

SURVEILLANCE REPORTTuberculosis surveillance and monitoring in Europe 2022 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  660

  507

(76.8)

(11.2)

  552

  471

(85.3)

Table IX. TB cases with HIV infection, European Region, 2016–2020a

2016

Cases with known 

HIV status

HIV positive

) Cases with known 

N

HIV status

HIV positive

) Cases with known 

N

HIV status

HIV positive

2017

2018

N

%

N

%b

N

%

N

%b

N

%

N

%b

)

N

(

s

e

s

a

c

B

T

l

l

A

–

	1	042

 1 603

		464

		60

		516

		330

  192

		440

		786

		6

		315

–

–

–

–

–

 1 442

		29

		50

		887

		295

–

	1	936

 13 601

		296

		118

	5	070

–

		415

		4

 1 027

 5 159

 3 211

		907

 2 983

  250

 12 322

 7 026

–

		87

		263

 3 571

 92 407

		755

		755

0

–

–

–

–

Country/area

EU/EEA

Austria

Belgium

Bulgaria

Croatia

Cyprus

Czechia

Denmark

Estonia

Finland

France

Germany

Greece

Hungary

Iceland

Ireland

Italy

Latvia

Liechtenstein

Lithuania

Luxembourg

Malta

Netherlands

Norway

Poland

Portugal

Romania

Slovakia

Slovenia

Spain

Sweden

Albania

Andorra

Armenia

Azerbaijan

Belarus

Georgia

Israel

Kazakhstan

Kyrgyzstan

Monaco

Montenegro

Subtotal EU/EEA

Non-EU/EEA

Bosnia and Herzegovina

Serbia excluding Kosovo1

North Macedonia

Republic of Moldova

Russian Federation

San Marino

Serbia

Kosovo1

Switzerland

Tajikistan

Turkey

Turkmenistan

Ukraine

United Kingdom

Uzbekistan

Subtotal non-EU/EEA

Total European Region

Subtotal 18 HPCs

–

		477

 1 260

		4

		48

		205

		150

  185

–

(45.8)

(78.6)

(0.9)

(80.0)

(39.7)

(45.5)

(96.4)

		296

		19

		6

		139

(67.3)

(2.4)

(100.0)

(44.1)

–

–

–

–

–

–

–

–

–

–

 1 138

		5

		46

		646

		255

–

	1	697

 10 844

		132

		95

	3	021

–

		223

		0

 1 027

 4 722

 3 148

		1

 2 866

  250

 10 616

 6 254

–

		60

		207

 3 366

 79 935

–

84

84

–

–

–

–

(78.9)

(17.2)

(92.0)

(72.8)

(86.4)

–

(87.7)

(79.7)

(44.6)

(80.5)

(59.6)

–

(53.7)

(0.0)

(100.0)

(91.5)

(98.0)

(0.1)

(96.1)

(100.0)

(86.2)

(89.0)

–

(69.0)

(78.7)

(94.3)

(86.5)

(11.1)

(11.1)

–

–

–

–

–

  22

(11.9)

–

		33

  0

		0

		0

		5

		9

–

–

–

		8

		1

		0

		4

–

  57

–

  41

		2

		8

		20

		10

–

		183

  305

		0

		1

		243

–

  952

		6

–

  57

  99

  275

		1

  61

  18

  576

  210

–

		0

		0

–

		5

		5

–

–

–

–

  293

 16 570

–

(6.9)

(0.0)

(0.0)

(0.0)

(2.4)

(6.0)

(2.7)

(5.3)

(0.0)

(2.9)

–

–

–

–

–

(3.6)

(40.0)

(17.4)

(3.1)

(3.9)

–

(10.8)

(2.8)

(0.0)

(1.1)

(8.0)

–

(100.0)

(2.7)

–

(5.6)

(2.1)

(8.7)

(2.1)

(7.2)

(5.4)

(3.4)

–

(0.0)

(0.0)

(8.7)

(20.7)

(6.0)

(6.0)

–

–

–

–

–

(

s

e

s

a

c

B

T

l

l

A

–

		967

 1 463

		378

		53

		501

		275

  176

		467

		685

		14

		300

–

–

–

–

–

 1 387

		32

		42

		783

		261

–

	1	914

 12 997

		249

		112

	5	660

–

		503

		1

  841

 5 231

 2 781

–

 2 597

  234

 12 449

 6 687

–

		75

		216

 3 358

 84 510

  0

	1	450

		738

712

–

 5 895

 11 821

–

 27 229

	5	248

 16 842

–

(8.4)

(0.2)

(0.0)

(0.0)

(4.1)

(1.4)

(8.5)

–

–

–

–

–

(3.3)

(5.6)

(0.0)

(9.0)

(11.0)

(3.7)

(33.3)

(0.0)

(3.8)

(3.1)

–

(8.5)

(2.1)

(0.0)

(0.0)

(9.3)

–

(1.7)

(0.0)

(7.9)

(1.6)

(7.3)

–

(1.8)

(5.1)

(4.0)

(3.6)

–

(0.0)

(0.0)

(8.3)

(19.3)

(11.3)

(8.8)

–

–

–

–

–

		514

 1 204

		3

		49

		195

		211

  164

–

(53.2)

(82.3)

(0.8)

(92.5)

(38.9)

(76.7)

(93.2)

		389

		18

		13

		156

(83.3)

(2.6)

(92.9)

(52.0)

–

–

–

–

–

–

–

–

–

–

 1 125

		3

		37

		602

		228

–

	1	744

 10 890

		227

		80

	2	845

–

235

0

 838

5 889

2 781

–

2 442

234

11 056

5 966

–

63

178

3 352

81 443

–

	71

	91

0

–

–

(81.1)

(9.4)

(88.1)

(76.9)

(87.4)

–

(91.1)

(83.8)

(91.2)

(71.4)

(50.3)

–

(46.7)

(0.0)

(99.6)

(112.6)

(100.0)

–

(94.0)

(100.0)

(88.8)

(89.2)

–

(84.0)

(82.4)

(99.8)

(96.4)

(4.9)

(12.3)

(0.0)

–

–

–

5 937

8 423

(100.7)

(71.3)

26 623

	4	407

16 842

(97.8)

(84.0)

(100.0)

–

		43

  3

		0

		0

		8

		3

  14

–

–

–

		13

		1

		0

		14

  52

–

–

  42

		1

		0

		23

		7

–

		149

  232

		0

		0

–

		266

		4

		0

  66

  95

  202

–

  43

  12

  443

  216

–

		0

		0

  277

 15 695

–

8

8

–

–

–

  219

  65

 5 955

		128

  935

(

s

e

s

a

c

B

T

l

l

A

–

		977

 1 358

		372

		52

		443

		291

  147

		432

		640

		8

		310

–

–

–

–

–

–

–

–

 1 142

		42

		795

		208

	1	936

 12 199

		281

		99

	4	766

–

		440

		2

  734

 5 038

 2 359

–

 2 316

  292

 12 832

 6 338

–

		84

		217

  0

		641

		641

–

–

–

–

		502

 1 118

		2

		41

		190

		234

  137

–

–

–

		362

		23

		8

		160

–

–

–

		7

–

  954

		624

		184

–

	1	698

 10 355

		238

		80

		76

–

	215

	0

 699

6 483

2 359

–

2 174

 292

12 236

5 771

–

	43

	126

–

56	

56	

–

–

–

–

(51.4)

(82.3)

(0.5)

(78.8)

(42.9)

(80.4)

(93.2)

–

–

–

–

–

–

–

–

(83.8)

(3.6)

(100.0)

(51.6)

(83.5)

(16.7)

(78.5)

(88.5)

(87.7)

(84.9)

(84.7)

(80.8)

(1.6)

–

(48.9)

(0.0)

(95.2)

(128.7)

(100.0)

–

(93.9)

(100.0)

(95.4)

(91.1)

–

(51.2)

(58.1)

(95.7)

(94.7)

(8.7)

(8.7)

–

–

–

–

 3 022

 78 258

2 893

74 075

248

14797

(3.7)

(0.8)

 5 726

 11 576

5 545

8 234

(96.8)

(71.1)

(22.4)

(2.9)

(5.6)

(13.8)

(12.7)

(13.2)

 26 512

	4	775

16 413

26 312

	4	060

16 413

 177 575  167 986

 204 073  184 979

 185 970

 175 758

(99.2)

(85.0)

(100.0)

(94.6)

(90.6)

(94.5)

227

67

–

6053

		115

736

 23 562

 24 159

 23 718

–

		35

  0

		0

		1

		4

		3

  13

		11

		3

		1

		13

–

–

–

–

–

–

  32

		0

–

		21

		7

–

		161

  255

		2

		0

		35

–

6

		0

72

87

–

45

12

182

717

187

–

0

3

–

	8

	8

–

–

–

(7.0)

(0.0)

(0.0)

(2.4)

(2.1)

(1.3)

(9.5)

–

–

–

–

–

–

–

–

(3.0)

(13.0)

(12.5)

(8.1)

(3.4)

(0.0)

(3.4)

(3.8)

(9.5)

(2.5)

(0.8)

(0.0)

(46.1)

–

(3.5)

(2.8)

(0.0)

(10.3)

(1.3)

(7.7)

–

(2.1)

(4.1)

(5.9)

(3.2)

–

(0.0)

(2.4)

(8.6)

(20.0)

(14.3)

(14.3)

(4.1)

(0.8)

(23.0)

(2.8)

(4.5)

(14.0)

(13.1)

(13.5)

–

–

–

–

 5 965

 12 186

 5 850

 8 549

(98.1)

(70.2)

  201

  56

(3.4)

(0.7)

 29 052

 28 194

(97.0)

 5 832

(20.7)

 16 050

 193 640

 223 778

 208 457

 18 441

 173 793

 194 968

 186 902

(114.9)

(89.8)

(87.1)

(89.7)

  758

 25 018

 25 970

 25 413

(4.1)

(14.4)

(13.3)

(13.6)

 187 968  176 780

(94.0)

 24 363

 217 236  197 948

 196 816  185 446

(91.1)

(94.2)

 25 234

 24 554

 30 138

 21 175

(70.3)

(4.5)

 29 268

 21 168

(72.3)

  871

(4.1)

 26 498

 16 993

(64.1)

  597

Note: European Region comprises the 53 countries of the WHO European Region and Liechtenstein. WHO European Region 18 TB HPCs are presented in italics. 

a HIV prevalence may be underestimated due to incomplete HIV testing and/or reporting of HIV serostatus. Countries/areas were only included in this analysis if the 

HPCs: high-priority countries.

total number of cases tested for HIV and test results were provided.

b Proportion calculated from TB cases with known HIV test results.

1 All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999). 

2019

Cases with known HIV 
status

HIV positive

N

%

N

%b

All TB 
cases (N)

–
		963
 1 344
		305
		69
		461
		281
  150
–
–
–
		459
		552
		13
		266
–
–
–
 1 058
		50
–
		754
		162
–
	1	932
 11 618
		214
		101
	4	543
–
 25 295

		412
		5
  621
 4 823
 2 207
–
 2 169
  217
 12 501
 6 138
–
		80
		199
 2 809
 73 328
  0
		501
		501
–
–
 5 755
 11 247
–
 25 379
–
 16 272
 164 663
 189 958
 177 419

–
		502
 1 104
		5
		43
		270
		227
  141
–
–
–
		408
		32
		11
		106
–
–
–
 1 020
		37
–
		596
		133
–
	1	641
 10 218
		148
		73
	2	597
–
 19 312

368	
0	
591 
4 534
2 207
–
1 841
217 
12 375
5 810
–
76	
152	
2 792
70 610
–
			39
			39
–
–
5 660
8 814
–
25 210
–
16 272
 157 568
 176 880
 169 199

–
(52.1)
(82.1)
(1.6)
(62.3)
(58.6)
(80.8)
(94.0)
–
–
–
(88.9)
(5.8)
(84.6)
(39.8)
–
–
–
(96.4)
(74.0)
–
(79.0)
(82.1)
–
(84.9)
(87.9)
(69.2)
(72.3)
(57.2)
–
(76.3)

(89.3)
(0.0)
(95.2)
(94.0)
(100.0)
–
(84.9)
(100.0)
(99.0)
(94.7)
–
(95.0)
(76.4)
(99.4)
(96.3)
–
(7.8)
(7.8)
–
–
(98.3)
(78.4)
–
(99.3)
–
(100.0)
(95.7)
(93.1)
(95.4)

–
		43
  1
		0
		2
		8
		7
  16
–
–
–
		19
		3
		0
		10
–
–
–
  27
		0
–
		21
		6
–
		153
  200
		4
		1
		233
–
  754

	8
		0
 62
 71
 157
–
 33
 8
 666
 131
–
	0
	1
 295
16 453
–
			3
			3
–
–
 167
 104
–
5 800
–
 647
 24 606
 25 360
 24 830

–
(8.6)
(0.1)
(0.0)
(4.7)
(3.0)
(3.1)
(11.3)
–
–
–
(4.7)
(9.4)
(0.0)
(9.4)
–
–
–
(2.6)
(0.0)
–
(3.5)
(4.5)
–
(9.3)
(2.0)
(2.7)
(1.4)
(9.0)
–
(3.9)

(2.2)
(0.0)
(10.5)
(1.6)
(7.1)
–
(1.8)
(3.7)
(5.4)
(2.3)
–
(0.0)
(0.7)
(10.6)
(23.3)
–
(7.7)
(7.7)
–
–
(3.0)
(1.2)
–
(23.0)
–
(4.0)
(15.6)
(14.3)
(14.7)

s
e
s
a
c
B
T
l
l

A

–
		830
  930
		183
		36
		367
		219
  124
–
–
–
		396
		406
–
		240
–
–
–
  726
		34
–
		623
		160
–
	1	445
 7 698
		158
		77
	3	044
–
 17 696

–
		389
  781
		4
		30
		201
		166
  116
–
–
–
		396
		18
–
		84
–
–
–
  714
		28
–
		489
		122
–
	1	087
 6 513
		82
		58
	1	759
–
 13 037

		240
		2
  394
 3 683
 1 514
–
 1 669
  158
 9 603
 4 241
–
		40
		143
 1 767
 58 723
  0
–
–
–
–
 4 148
 8 830
–
 17 533
–
 12 111

			199
			0
   369
  3 683
  1 514
	–			
  1 490
   158
  9 440
  4 007
 –   
			35
			69
  1 693
  55 838
–
–
–
–
–
  4 043
  7 062
 –   
  17 375
	–			
  12 111
 124 799  119 086
 132 123
 142 495
 126 749
 133 694

2020

) Cases with known 
N
(

HIV status

HIV positive

Country/area

N

%

N

%b

–
(46.9)
(84.0)
(2.2)
(83.3)
(54.8)
(75.8)
(93.5)
–
–
–
(100.0)
(4.4)
–
(35.0)
–
–
–
(98.3)
(82.4)
–
(78.5)
(76.3)
–
(75.2)
(84.6)
(51.9)
(75.3)
(57.8)
–
(73.7)

(82.9)
(0.0)
(93.7)
(100.0)
(100.0)
	–			
(89.3)
(100.0)
(98.3)
(94.5)
 –   
(87.5)
(48.3)
(95.8)
(95.1)
–
–
–
–
–
(97.5)
(80.0)
 –   
(99.1)
	–			
(100.0)
(95.4)
(92.7)
(94.8)

–
		33
  1
		0
		2
		7
		4
  13
–
–
–
		17
		2
–
		3
–
–
–
  20
		0
–
		14
		2
–
		111
  150
		2
		0
		173
–
  554

			2
		0
   39
   83
   135
	–			
   29
   15
   614
   131
 –   
			0
			1
   219
  13 506
–
–
–
–
–
   118
   83
 –   
  3 794
	–			
   379
 19 148
 19 702
 19 314

EU/EEA
– Austria
(8.5) Belgium
(0.1) Bulgaria
(0.0) Croatia
(6.7) Cyprus
(3.5) Czechia
(2.4) Denmark
(11.2) Estonia
– Finland
– France
– Germany

(4.3) Greece
(11.1) Hungary
– Iceland
Ireland

(3.6)

– Italy
– Latvia
– Liechtenstein

(2.8) Lithuania
(0.0) Luxembourg

– Malta

(2.9) Netherlands
(1.6) Norway
– Poland
(10.2) Portugal
(2.3) Romania
(2.4) Slovakia
(0.0) Slovenia
(9.8) Spain

– Sweden

(4.2) Subtotal EU/EEA
Non-EU/EEA

(1.0) Albania
	–			 Andorra
(10.6) Armenia
(2.3) Azerbaijan
(8.9) Belarus

	–			 Bosnia and Herzegovina

(1.9) Georgia
(9.5)
Israel
(6.5) Kazakhstan
(3.3) Kyrgyzstan
 –    Monaco
(0.0) Montenegro
(1.4) North Macedonia
(12.9) Republic of Moldova
(24.2) Russian Federation

– San Marino
– Serbia
–
–
– Switzerland

Serbia excluding Kosovo1
Kosovo1

(2.9) Tajikistan
(1.2) Turkey

 –    Turkmenistan

(21.8) Ukraine

	–			 United Kingdom

(3.1) Uzbekistan
(16.1) Subtotal non-EU/EEA
(14.9) Total European Region
(15.2) Subtotal 18 HPCs

115

Tuberculosis surveillance and monitoring in Europe 2022SURVEILLANCE REPORT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table X. Treatment success after 12 months for newa and relapse TB cases, European Region, 2015–2019b

Country/area

EU/EEA
Austria
Belgiumc
Bulgaria
Croatia
Cyprus
Czechia
Denmarkc
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Irelandc
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norwayc
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
Subtotal EU/EEA
Non-EU/EEA
Albania
Andorra
Armenia
Azerbaijan
Belarus
Bosnia and Herzegovina
Georgia
Israel
Kazakhstan
Kyrgyzstan
Monaco
Montenegro
North Macedonia
Republic of Moldova
Russian Federation
San Marino
Serbia

Serbia excluding Kosovo1
Kosovo1
Switzerland
Tajikistan
Turkey
Turkmenistan
Ukraine
United Kingdomc
Uzbekistan
Subtotal non-EU/EEA
Total European Region
Subtotal 18 HPCs

2015

2016

2017

2018

2019

Cases 
reported 

Success
N

Cases 
reported

(%)

Success
N

Cases 
reported

(%)

Success
N

(%)

Cases 
reported

Success
N

Cases 
reported

(%)

Success

N

(%)

	553
	905
1 598
	484
	63
	499
	314
 172
	261
–
5	525
–
	851
	7
	265
–
 642
	1
1 219
–
–
	838
	277
6	196
2	130
13 908
	305
	129
4	798
	754
42 694

		409
		4
  910
 1 475
 2 525
	1	092
 2 841
		263
 14 006
 6 139
–
		80
		282
 2 992
 80 424
0
	1	647
		882
		765
–
 5 298
 12 362
 1 669
 23 892
	5	802
 15 220
 179 332
 222 026
 187 292

	404
	719
1 350
	275
	35
	343
	157
 143
	100
–
3	590
–
	600
	7
	191
–
 540
	0
 975
–
–
	732
	244
3	293
1	556
11 834
	263
	105
3	454
	659
31 569

		354
		4
  721
 1 221
 2 243
		707
 2 386
		218
 12 691
 5 063
–
		74
		243
 2 379
 57 060
–
	1	471
		733
		738
–
 4 734
 10 735
 1 451
 17 939
	4	594
 13 536
 139 824
 171 393
 147 001

(73.1)
(79.4)
(84.5)
(56.8)
(55.6)
(68.7)
(50.0)
(83.1)
(38.3)
–
(65.0)
–
(70.5)
(100.0)
(72.1)
–
(84.1)
(0.0)
(80.0)
–
–
(87.4)
(88.1)
(53.1)
(73.1)
(85.1)
(86.2)
(81.4)
(72.0)
(87.4)
(73.9)

(86.6)
(100.0)
(79.2)
(82.8)
(88.8)
(64.7)
(84.0)
(82.9)
(90.6)
(82.5)
–
(92.5)
(86.2)
(79.5)
(70.9)
–
(89.3)
(83.1)
(96.5)
–
(89.4)
(86.8)
(86.9)
(75.1)
(79.2)
(88.9)
(78.0)
(77.2)
(78.5)

	604
	973
1 510
	452
	56
	505
	288
 165
	217
–
5	635
–
	722
	6
	285
–
 592
	2
1 152
–
–
	864
	262
6	099
1	872
12 458
	279
	118
3	964
	669
39 749

		409
		4
  869
 1 464
 2 123
		907
 2 715
		250
 6 775
 6 072
2
		87
		263
 3 048
 73 137
0
	1	443
		733
		710
565
 5 324
 12 017
 2 068
 22 615
	5	675
 14 743
 162 575
 202 324
 168 847

	452
	793
1 291
	264
	37
	346
	113
 132
	69
–
3	926
–
	511
	5
	168
–
 505
	2
 958
–
–
	758
	226
3	300
1	316
10 729
	241
	84
2	669
	607
29 502

		357
		3
  703
 1 225
 1 894
		505
 2 263
		198
 5 962
 4 968
		0
		70
		232
 2 515
 52 335
–
	1	191
		590
		601
384
 4 751
 10 462
 1 738
 17 234
	4	570
 12 906
 126 466
 155 968
 132 571

(74.8)
(81.5)
(85.5)
(58.4)
(66.1)
(68.5)
(39.2)
(80.0)
(31.8)
–
(69.7)
–
(70.8)
(83.3)
(58.9)
–
(85.3)
(100.0)
(83.2)
–
–
(87.7)
(86.3)
(54.1)
(70.3)
(86.1)
(86.4)
(71.2)
(67.3)
(90.7)
(74.2)

(87.3)
(75.0)
(80.9)
(83.7)
(89.2)
(55.7)
(83.4)
(79.2)
(88.0)
(81.8)
(0.0)
(80.5)
(88.2)
(82.5)
(71.6)
–
(82.5)
(80.5)
(84.6)
(68.0)
(89.2)
(87.1)
(84.0)
(76.2)
(80.5)
(87.5)
(77.8)
(77.1)
(78.5)

	543
	905
1 386
	372
	51
	489
	251
 139
	236
–
5	253
–
	639
	13
	277
–
–
	1
1 086
–
–
	762
	228
–
1	859
12 007
	222
	111
4	499
	477
31 806

		499
		1
  710
 1 777
 1 792
		766
 2 351
		225
 8 589
 5 752
–
		75
		219
 2 715
 67 593
		0
	1	440
		738
		702
518
 5 259
 11 638
 1 968
 21 165
	5	176
 15 167
 155 395
 187 201
 161 094

	375
	718
1 167
	245
	34
	337
	99
 112
	85
–
3	716
–
	429
	12
	163
–
–
	1
 905
–
–
	665
	214
–
1	350
10 348
	204
	85
2	721
	413
24 398

		435
		1
  563
 1 492
 1 587
		343
 1 977
		196
 7 826
 4 728
–
		65
		193
 2 187
 46 938
–
	1	239
		616
		623
406
 4 789
 10 014
 1 676
 16 189
	4	216
 13 554
 120 614
 145 012
 126 052

(69.1)
(79.3)
(84.2)
(65.9)
(66.7)
(68.9)
(39.4)
(80.6)
(36.0)
–
(70.7)
–
(67.1)
(92.3)
(58.8)
–
–
(100.0)
(83.3)
–
–
(87.3)
(93.9)
–
(72.6)
(86.2)
(91.9)
(76.6)
(60.5)
(86.6)
(76.7)

(87.2)
(100.0)
(79.3)
(84.0)
(88.6)
(44.8)
(84.1)
(87.1)
(91.1)
(82.2)
–
(86.7)
(88.1)
(80.6)
(69.4)
–
(86.0)
(83.5)
(88.7)
(78.4)
(91.1)
(86.0)
(85.2)
(76.5)
(81.5)
(89.4)
(77.6)
(77.5)
(78.2)

	455
	902
1 268
	363
	51
	422
	266
 115
	222
–
5	214
–
	591
	8
	284
–
–
–
 926
–
–
	774
	182
–
1	877
11 271
	271
	98
4	596
	462
30 618

		434
		2
  615
 1 751
 1 418
		666
 2 071
		292
 7 859
 5 333
		1
		81
		214
 2 312
 59 850
		0
	1	265
		579
		686
		376
 4 995
 11 407
 2 157
 20 221
	4	684
 14 423
 142 427
 173 045
 147 992

	334
	737
1 085
	107
	30
	290
	48
 96
	51
–
3	721
–
	388
	8
	110
–
–
–
 806
–
–
	668
	160
–
1	365
9 483
	249
	77
2	065
	361
22 239

		386
		2
  497
 1 471
 1 250
		189
 1 735
		227
 7 093
 4 321
0
		77
		187
 1 954
 41 154
–
	1	032
		459
		573
		309
 4 452
 9 691
 1 780
 15 607
	3	724
 13 217
 110 355
 132 594
 115 692

(73.4)
(81.7)
(85.6)
(29.5)
(58.8)
(68.7)
(18.0)
(83.5)
(23.0)
–
(71.4)
–
(65.7)
(100.0)
(38.7)
–
–
–
(87.0)
–
–
(86.3)
(87.9)
–
(72.7)
(84.1)
(91.9)
(78.6)
(44.9)
(78.1)
(72.6)

(88.9)
(100.0)
(80.8)
(84.0)
(88.2)
(28.4)
(83.8)
(77.7)
(90.3)
(81.0)
(0.0)
(95.1)
(87.4)
(84.5)
(68.8)
–
(81.6)
(79.3)
(83.5)
(82.2)
(89.1)
(85.0)
(82.5)
(77.2)
(79.5)
(91.6)
(77.5)
(76.6)
(78.2)

	459
	877
1 278
	295
	65
	447
	259
 120
	222
–
4	566
–
	517
	13
	243
–
–
–
 866
	47
–
	730
	149
–
1	859
10 812
	209
	98
4	386
	468
28 985

	341
	709
1 045
	72
	18
	330
	117
 91
	85
–
3	130
–
	336
	13
	9
–
–
–
 754
	17
–
	630
	126
–
1	327
9 051
	196
	69
2	045
	286
20 797

		412
		5
  485
 1 702
 1 302
		580
 1 947
		217
 7 429
 5 110
–
		82
		199
 2 215
 54 589
–
		602
–
		602
		391
 5 114
 11 095
 2 117
 19 414
	4	739
 14 224

		364
		3
  399
 1 429
 1 153
		185
 1 659
		182
 6 704
 4 155
–
		78
		177
 1 854
 37 208
–
		513
–
		513
		267
 4 643
 9 231
 1 749
 15 381
	3	675
 12 820
 133 970  103 829
 162 955  124 626
 139 819  109 326

(74.3)
(80.8)
(81.8)
(24.4)
(27.7)
(73.8)
(45.2)
(75.8)
(38.3)
–
(68.6)
–
(65.0)
(100.0)
(3.7)
–
–
–
(87.1)
(36.2)
–
(86.3)
(84.6)
–
(71.4)
(83.7)
(93.8)
(70.4)
(46.6)
(61.1)
(71.8)

(88.3)
(60.0)
(82.3)
(84.0)
(88.6)
(31.9)
(85.2)
(83.9)
(90.2)
(81.3)
–
(95.1)
(88.9)
(83.7)
(68.2)
–
(85.2)
–
(85.2)
(68.3)
(90.8)
(83.2)
(82.6)
(79.2)
(77.5)
(90.1)
(77.5)
(76.5)
(78.2)

Note: European Region comprises the 53 countries of the WHO European Region and Liechtenstein. WHO European Region 18 TB HPCs are presented in italics. EU/EEA: 
country data are shown as missing (–) when data on treatment outcome are not reported. For inclusion in the cohort, drug-susceptibility data are also required.
HPCs: high-priority countries.
a For EU/EEA countries, cases with unknown TB history are considered as new cases.
b Excluding rifampicin-resistant cases.
c Previous TB history is defined as previous diagnosis.
1 All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999). 

116

SURVEILLANCE REPORTTuberculosis surveillance and monitoring in Europe 2022 
 
 
Table XI. Treatment success after 24 months of RR/MDR-TBa cases started on treatmentb, European Region, 2014–2018

Country/area

EU/EEA
Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
Subtotal EU/EEA 
Non-EU/EEA
Albania
Andorra
Armenia
Azerbaijan
Belarus
Bosnia and Herzegovina
Georgia
Israel
Kazakhstan
Kyrgyzstan
Monaco
Montenegro
North Macedonia
Republic of Moldova
Russian Federation
San Marino
Serbia

Serbia excluding Kosovo1
Kosovo1
Switzerland
Tajikistan
Turkey
Turkmenistan
Ukraine
United Kingdom
Uzbekistan
Subtotal non-EU/EEA
Total European Region
Subtotal 18 HPCs

2014

2015

2016

2017

2018

Cases 
reported 

Success
N

Cases 
reported

(%)

Success
N

(%)

Cases 
reported

Success
N

(%)

Cases 
reported

Success
N

Cases 
reported

(%)

Success

N

(%)

21
13
44
1
0
7
2
51
7
–
105
–
4
0
2
–
71
0
279
–
–
7
11
49
28
597
4
0
0
17
1 320

–
		0
  118
  745
 1 472
		3
  411
		16
 6 320
 1 157
–
		2
		3
  919
 20 089
0
		19
		13
		6
12
  804
  257
213
 7 174
53
 3 602
 43 389
 44 709
 44 323

13
7
22
0
–
3
1
32
2
–
35
–
4
–
1
–
52
–
91
–
–
6
9
9
15
246
2
–
–
15
565

–
–
  68
  441
  872
		2
  201
		12
 4 813
  650
–
0
		1
  457
 10 170
–
		12
		7
		5
9
  398
  163
143
 3 297
32
 2 216
 23 957
 24 522
 24 332

(61.9)
(53.8)
(50.0)
(0.0)
–
(42.9)
(50.0)
(62.7)
(28.6)
–
(33.3)
–
(100.0)
–
(50.0)
–
(73.2)
–
(32.6)
–
–
(85.7)
(81.8)
(18.4)
(53.6)
(41.2)
(50.0)
–
–
(88.2)
(42.8)

–
–
(57.6)
(59.2)
(59.2)
(66.7)
(48.9)
(75.0)
(76.2)
(56.2)
–
(0.0)
(33.3)
(49.7)
(50.6)
–
(63.2)
(53.8)
(83.3)
(75.0)
(49.5)
(63.4)
(67.1)
(46.0)
(60.4)
(61.5)
(55.2)
(54.8)
(54.9)

13
16
28
1
0
9
7
40
9
–
131
–
9
0
1
–
63
0
248
–
–
10
6
45
26
589
3
0
–
26
1 280

3
		0
  95
  800
 1 400
		1
  412
		10
 6 482
 1 162
–
		1
		5
  996
 22 607
0
		10
		5
		5
16
  682
  230
210
 7 592
45
 2 149
 44 908
 46 188
 45 785

12
16
17
1
–
3
0
25
4
–
54
–
2
–
0
–
39
–
99
–
–
6
6
16
9
259
1
–
–
24
593

3
–
  40
  473
  899
		1
  231
		8
 5 063
  624
–
1
		2
  487
 12 117
–
		9
		4
		5
7
  398
  156
142
 3 855
32
 1 259
 25 807
 26 400
 26 183

(92.3)
(100.0)
(60.7)
(100.0)
–
(33.3)
(0.0)
(62.5)
(44.4)
–
(41.2)
–
(22.2)
–
(0.0)
–
(61.9)
–
(39.9)
–
–
(60.0)
(100.0)
(35.6)
(34.6)
(44.0)
(33.3)
–
–
(92.3)
(46.3)

(100.0)
–
(42.1)
(59.1)
(64.2)
(100.0)
(56.1)
(80.0)
(78.1)
(53.7)
–
(100.0)
(40.0)
(48.9)
(53.6)
–
(90.0)
(80.0)
(100.0)
(43.8)
(58.4)
(67.8)
(67.6)
(50.8)
(71.1)
(58.6)
(57.5)
(57.2)
(57.2)

17
12
22
0
–
5
5
25
6
–
121
–
20
0
7
–
–
0
255
–
–
15
11
–
19
547
3
0
–
25
 1 115

1
		0
  118
  798
 1 180
		0
  339
		9
 6 260
 1 232
–
		0
		2
  979
 22 593
0
		12
		10
		2
		17
  681
  211
  557
 7 277
59
 1 986
 44 311
 45 426
 45 060

11
10
12
–
–
2
3
18
4
–
45
–
8
–
5
–
–
–
110
–
–
11
10
–
5
271
0
–
–
23
548

1
–
  58
  480
  796
–
  222
		6
 4 979
  655
–
–
		1
  518
 12 141
–
		9
		7
		2
		8
  440
  131
  303
 3 590
39
 1 140
 25 517
 26 065
 25 864

(64.7)
(83.3)
(54.5)
–
–
(40.0)
(60.0)
(72.0)
(66.7)
–
(37.2)
–
(40.0)
–
(71.4)
–
–
–
(43.1)
–
–
(73.3)
(90.9)
–
(26.3)
(49.5)
(0.0)
–
–
(92.0)
(49.1)

(100.0)
–
(49.2)
(60.2)
(67.5)
–
(65.5)
(66.7)
(79.5)
(53.2)
–
–
(50.0)
(52.9)
(53.7)
–
(75.0)
(70.0)
(100.0)
(47.1)
(64.6)
(62.1)
(54.4)
(49.3)
(66.1)
(57.4)
(57.6)
(57.4)
(57.4)

19
8
29
0
–
8
2
35
5
–
138
–
13
0
6
–
–
0
264
–
–
10
9
–
13
455
7
1
–
12
 1 034

		0
		0
  104
  858
 1 067
–
  316
		7
 5 338
 1 166
–
		0
		1
  962
 22 901
0
		10
		6
		4
		12
  546
  202
  343
 6 685
56
 2 265
 42 839
 43 873
 43 536

10
6
18
–
–
3
1
28
2
–
75
–
6
–
2
–
–
–
111
–
–
8
8
0
10
183
2
0
–
10
483

–
–
  52
  509
  752
–
  203
		5
 4 340
  643
–
–
		0
  537
 12 629
–
		7
		4
		3
		10
  352
  139
  226
 3 407
35
 1 372
 25 218
 25 701
 25 501

(52.6)
(75.0)
(62.1)
–
–
(37.5)
(50.0)
(80.0)
(40.0)
–
(54.3)
–
(46.2)
–
(33.3)
–
–
–
(42.0)
–
–
(80.0)
(88.9)
–
(76.9)
(40.2)
(28.6)
(0.0)
–
(83.3)
(46.7)

–
–
(50.0)
(59.3)
(70.5)
–
(64.2)
(71.4)
(81.3)
(55.1)
–
–
(0.0)
(55.8)
(55.1)
–
(70.0)
(66.7)
(75.0)
(83.3)
(64.5)
(68.8)
(65.9)
(51.0)
(62.5)
(60.6)
(58.9)
(58.6)
(58.6)

18
9
28
2
0
12
4
31
3
–
131
–
13
0
8
–
–
0
189
–
–
6
6
–
11
439
3
0
–
14
927

15
7
17
0
–
4
0
23
2
–
83
–
6
–
1
–
–
–
103
–
–
5
5
0
7
192
2
–
–
14
486

		4
0
  85
  821
  919
–
  230
		14
 4 336
 1 244
–
		1
		2
  921
 28 706
–
–
–
–
		9
  727
  180
  549
 5 953
40
 2 039
 46 780
 47 707
 47 397

3
–
  39
  471
  670
–
  155
		9
 3 499
  775
–
1
		1
  541
 14 757
–
–
–
–
		6
  510
  99
  248
 3 006
30
 1 375
 26 195
 26 681
 26 480

(83.3)
(77.8)
(60.7)
(0.0)
–
(33.3)
(0.0)
(74.2)
(66.7)
–
(63.4)
–
(46.2)
–
(12.5)
–
–
–
(54.5)
–
–
(83.3)
(83.3)
–
(63.6)
(43.7)
(66.7)
–
–
(100.0)
(52.4)

(75.0)
–
(45.9)
(57.4)
(72.9)
–
(67.4)
(64.3)
(80.7)
(62.3)
–
(100.0)
(50.0)
(58.7)
(51.4)
–
–
–
–
(66.7)
(70.2)
(55.0)
(45.2)
(50.5)
(75.0)
(67.4)
(56.0)
(55.9)
(55.9)

Note: European Region comprises the 53 countries of the WHO European Region and Liechtenstein. WHO European Region 18 TB HPCs are presented in italics. EU/EEA: 
country data are shown as missing (–) when data on treatment outcome are not reported. For inclusion in the cohort, drug-susceptibility data are also required.
HPCs: high-priority countries.
RR/MDR-TB: rifampicin-resistant/multidrug-resistant tuberculosis.
a Includes cases that are RR/MDR but that also meet the pre-XDR or XDR case definitions (pre-XDR and XDR cases have not been excluded).
b For EU/EEA countries, cases diagnosed postmortem were excluded, and cases with no data on treatment enrolment were assumed to be enrolled in treatment.
1 All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999).

117

Tuberculosis surveillance and monitoring in Europe 2022SURVEILLANCE REPORTTable XII. Treatment success after 24 months of pre-XDR-TBa cases started on treatment,b European Region, 2014–2018

Country/area

EU/EEA
Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
Subtotal EU/EEA 
Non-EU/EEA
Albania
Andorra
Armenia
Azerbaijan
Belarus
Bosnia and Herzegovina
Georgia
Israel
Kazakhstan
Kyrgyzstan
Monaco
Montenegro
North Macedonia
Republic of Moldova
Russian Federation
San Marino
Serbia

Serbia excluding Kosovo1
Kosovo1
Switzerland
Tajikistan
Turkey
Turkmenistan
Ukraine
United Kingdom
Uzbekistan
Subtotal non-EU/EEA
Total European Region
Subtotal 18 HPCs

2014

Success

N

(%)

2015

Success

N

(%)

s
e
s
a
c
B
T
R
D
X
-
e
r
P

)
N
(

s
e
s
a
c
B
T
R
D
X
-
e
r
P

)
N
(

2016

Success

N

(%)

2017

Success

N

(%)

s
e
s
a
c
B
T
R
D
X
-
e
r
P

)
N
(

s
e
s
a
c
B
T
R
D
X
-
e
r
P

)
N
(

2018

Success

N

(%)

s
e
s
a
c
B
T
R
D
X
-
e
r
P

)
N
(

2
3
10
0
0
1
0
16
1
–
18
–
1
0
0
–
17
0
106
–
–
0
2
10
3
105
1
0
–
1
297

–
0
10
69
431
0
56
2
318
32
–
0
0
9
 2 209
0
0
–
–
1
0
2
–
 1 097
3
–
 4 239
 4 536
 4 487

1
1
4
–
–
0
–
5
0
–
6
–
1
–
–
–
12
–
12
–
–
–
1
1
2
22
1
–
–
0
69

–
–
4
16
157
–
18
1
98
5
–
–
–
3
687
–

–
–
0
–
0
–
278
1
–
 1 268
 1 337
 1 321

(50.0)
(33.3)
(40.0)
–
–
(0.0)
–
(31.3)
(0.0)
–
(33.3)
–
(100.0)
–
–
–
(70.6)
–
(11.3)
–
–
–
(50.0)
(10.0)
(66.7)
(21.0)
(100.0)
–
–
(0.0)
(23.2)

–
–
(40.0)
(23.2)
(36.4)
–
(32.1)
(50.0)
(30.8)
(15.6)
–
–
–
(33.3)
(31.1)
–
–
–
–
(0.0)
–
(0.0)
–
(25.3)
(33.3)
–
(29.9)
(29.5)
(29.4)

2
4
6
1
0
5
2
14
1
–
24
–
3
0
0
–
18
0
100
–
–
0
0
9
6
123
0
0
–
2
320

–
0
8
–
508
–
62
1
391
51
–
0
0
32
 2 882
0
0
–
–
0

3
–
 1 206
8
147
 5 299
 5 619
 5 551

1
4
3
1
–
1
0
7
0
–
8
–
1
–
–
–
10
–
19
–
–
–
–
4
1
48
–
–
–
1
109

–
–
4
–
268
–
35
1
126
9
–
–
–
5
960
–
–
–
–
–

2
–
  424
2
34
 1 870
 1 979
 1 954

(50.0)
(100.0)
(50.0)
(100.0)
–
(20.0)
(0.0)
(50.0)
(0.0)
–
(33.3)
–
(33.3)
–
–
–
(55.6)
–
(19.0)
–
–
–
–
(44.4)
(16.7)
(39.0)
–
–
–
(50.0)
(34.1)

–
–
(50.0)
–
(52.8)
–
(56.5)
(100.0)
(32.2)
(17.6)
–
–
–
(15.6)
(33.3)
–
–
–
–
–
–
(66.7)
–
(35.2)
(25.0)
(23.1)
(35.3)
(35.2)
(35.2)

5
0
3
0
–
0
0
6
2
–
24
–
10
0
2
–
–
0
88
–
–
0
0
–
4
96
1
0
–
6
247

0
0
10
–
393
–
55
2
435
68
–
1
0
65
 2 909
0
1
–
–
0
43
9
–
 1 353
7
184
 5 535
 5 782
 5 717

4
–
0
–
–
–
–
3
1
–
8
–
5
–
1
–
–
–
11
–
–
–
–
–
0
34
0
–
–
4
71

–
–
3
–
207
–
31
2
207
10
–
1
–
17
 1 094
–
0
–
–
–
20
5
–
  501
3
91
 2 192
 2 263
 2 234

(80.0)
–
(0.0)
–
–
–
–
(50.0)
(50.0)
–
(33.3)
–
(50.0)
–
(50.0)
–
–
–
(12.5)
–
–
–
–
–
(0.0)
(35.4)
(0.0)
–
–
(66.7)
(28.7)

–
–
(30.0)
–
(52.7)
–
(56.4)
(100.0)
(47.6)
(14.7)
–
(100.0)
–
(26.2)
(37.6)
–
(0.0)
–
–
–
–
(55.6)
–
(37.0)
(42.9)
(49.5)
(39.6)
(39.1)
(39.1)

6
0
4
0
–
2
0
11
0
–
15
–
5
0
1
–
–
0
108
–
–
1
2
–
2
76
2
0
–
1
247

0
0
16
182
419
–
47
1
300
157
–
1
0
62
 4 140
0
0
0
0
0
250
2
5
 1 376
3
258
 7 219
 7 466
 7 413

3
–
2
–
–
1
–
6
–
–
7
–
2
–
1
–
–
–
12
–
–
0
2
–
2
8
0
–
–
0
46

–
–
7
115
256
–
28
0
145
91
–
1
–
20
 1 710
–
–
–
–
–
155
0
2
  473
1
162
 3 166
 3 212
 3 192

(50.0)
–
(50.0)
–
–
(50.0)
–
(54.5)
–
–
(46.7)
–
(40.0)
–
(100.0)
–
–
–
(11.1)
–
–
(0.0)
(100.0)
–
(100.0)
(10.5)
(0.0)
–
–
(0.0)
(18.6)

–
–
(43.8)
(63.2)
(61.1)
–
(59.6)
(0.0)
(48.3)
(58.0)
–
(100.0)
–
(32.3)
(41.3)
–
–
–
–
–
(62.0)
(0.0)
(40.0)
(34.4)
(33.3)
(62.8)
(43.9)
(43.0)
(43.1)

5
5
5
0
0
3
0
10
1
–
27
–
6
0
0
–
–
0
76
–
–
2
1
–
0
69
1
0
–
0
211

0
0
14
189
383
–
54
2
386
105
–
0
0
62
27
–
–
–
–
1
63
8
28
 1 479
5
404
 3 210
 3 421
 3 362

3
4
2
–
–
0
–
9
1
–
14
–
1
–
–
–
–
–
23
–
–
2
1
–
–
10
0
–
–
–
70

–
–
3
116
293
–
29
1
293
55
–
–
–
32
11
–
–
–
–
1
42
1
8
  505
2
280
 1 672
 1 742
 1 712

(60.0)
(80.0)
(40.0)
–
–
(0.0)
–
(90.0)
(100.0)
–
(51.9)
–
(16.7)
–
–
–
–
–
(30.3)
–
–
(100.0)
(100.0)
–
–
(14.5)
(0.0)
–
–
–
(33.2)

–
–
(21.4)
(61.4)
(76.5)
–
(53.7)
(50.0)
(75.9)
(52.4)
–
–
–
(51.6)
(40.7)
–
–
–
–
(100.0)
(66.7)
(12.5)
(28.6)
(34.1)
(40.0)
(69.3)
(52.1)
(50.9)
(50.9)

Note: European Region comprises the 53 countries of the WHO European Region and Liechtenstein. WHO European Region 18 TB HPCs are presented in italics. EU/EEA: 
country data are shown as missing (–) when data on treatment outcome are not reported. For inclusion in the cohort, drug-susceptibility data are also required.
HPCs: high-priority countries. 
Pre-XDR-TB: pre-extensively drug-resistant tuberculosis.
a Pre-XDR-TB defined as resistance to rifampicin (RR/MDR-TB) as well as resistance to any fluoroquinolone. Includes cases that are pre-XDR-TB but that also meet the 
XDR case definition (XDR cases have not been excluded).
b For EU/EEA countries, cases diagnosed postmortem are excluded, and cases with no treatment enrolment data reported are assumed to be enrolled in treatment.
1 All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999).

118

SURVEILLANCE REPORTTuberculosis surveillance and monitoring in Europe 2022 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table XIII. Treatment success after 36 months of XDR-TBa cases notified in EU/EEA, 2013–2017

Country/area

EU/EEA
Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
Total EU/EEA 

2013

Success

N

(%)

s
e
s
a
c
B
T
-
R
D
X

)
N
(

s
e
s
a
c
B
T
-
R
D
X

)
N
(

2014

Success

N

(%)

2015

Success

N

(%)

s
e
s
a
c
B
T
-
R
D
X

)
N
(

s
e
s
a
c
B
T
-
R
D
X

)
N
(

2016

Success

N

(%)

s
e
s
a
c
B
T
-
R
D
X

)
N
(

2017

Success

N

(%)

7
4
7
0
0
0
1
4
0
–
11
–
0
0
–
–
0
0
0
0
–
0
0
0
2
0
0
0
–
1
37

4
3
2
–
–
–
1
1
–
–
1
–
–
–
–
–
–
–
–
–
–
–
–
–
2
–
–
–
–
1
15

(57.1)
(75.0)
(28.6)
–
–
–
(100.0)
(25.0)
–
–
(9.1)
–
–
–
–
–
–
–
–
–
–
–
–
–
(100.0)
–
–
–
–
(100.0)
(40.5)

2
3
5
0
0
0
0
6
0
–
11
–
0
0
0
–
8
0
0
0
–
0
0
0
1
0
0
0
–
1
37

2
3
2
–
–
–
–
3
–
–
3
–
–
–
–
–
7
–
–
–
–
–
–
–
0
–
–
–
–
0
20

(100.0)
(100.0)
(40.0)
–
–
–
–
(50.0)
–
–
(27.3)
–
–
–
–
–
(87.5)
–
–
–
–
–
–
–
(0.0)
–
–
–
–
(0.0)
(54.1)

1
4
1
0
0
0
2
6
0
–
16
–
0
0
0
–
–
0
0
0
–
0
0
0
2
0
0
0
–
1
33

1
4
1
–
–
–
0
3
–
–
6
–
–
–
–
–
–
–
–
–
–
–
–
–
0
–
–
–
–
1
16

(100.0)
(100.0)
(100.0)
–
–
–
(0.0)
(50.0)
–
–
(37.5)
–
–
–
–
–
–
–
–
–
–
–
–
–
(0.0)
–
–
–
–
(100.0)
(48.5)

2
0
1
0
–
0
0
0
0
–
19
–
0
0
–
–
–
0
0
0
–
0
0
0
2
0
0
0
–
3
27

2
–
0
–
–
–
–
–
–
–
6
–
–
–
–
–
–
–
–
–
–
–
–
–
0
–
–
–
–
1
9

(100.0)
–
(0.0)
–
–
–
–
–
–
–
(31.6)
–
–
–
–
–
–
–
–
–
–
–
–
–
(0.0)
–
–
–
–
(33.3)
(33.3)

2
0
4
0
0
0
0
3
0
–
13
–
0
0
–
–
–
0
1
0
–
0
0
0
2
1
0
0
–
0
26

0
–
2
–
–
–
–
1
–
–
5
–
–
–
–
–
–
–
0
–
–
–
–
–
2
0
–
–
–
–
10

(0.0)
–
(50.0)
–
–
–
–
(33.3)
–
–
(38.5)
–
–
–
–
–
–
–
(0.0)
–
–
–
–
–
(100.0)
(0.0)
–
–
–
–
(38.5)

Note: WHO European Region 18 TB high-priority countries presented in italics. EU/EEA: country data are shown as missing (–) when data on treatment outcome are not 
reported. For inclusion in the cohort, drug-susceptibility data are also required.
TESSy: the European Surveillance System. 
XDR TB: extensively drug-resistant tuberculosis.
a XDR-TB defined as resistance to rifampicin and to at least one fluoroquinolone (pre-XDR-TB) as well as resistance to at least one additional Group A drug. Group 
A drugs include levofloxacin, moxifloxacin, bedaquiline and linezolid. For EU/EEA countries, linezolid resistance is not yet reported to TESSy, therefore XDR-TB is 
assessed on resistance to levofloxacin, moxifloxacin and/or bedaquiline (in addition to meeting pre-XDR-TB criteria).    

119

Tuberculosis surveillance and monitoring in Europe 2022SURVEILLANCE REPORT 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table XIV.  New and relapsed TB cases tested using WHO-recommended rapid diagnostics such as Xpert MTB/RIF,a 
European Region, 2016–2020

Country/area

EU/EEA
Austria
Belgiumd
Bulgaria
Croatia
Cyprus
Czechia
Denmarkd
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Irelandd
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norwayd
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
Subtotal EU/EEA
Non-EU/EEA
Albania
Andorra
Armenia
Azerbaijan
Belarus
Bosnia and Herzegovina
Georgia
Israel
Kazakhstan
Kyrgyzstan
Monaco
Montenegro
North Macedonia
Republic of Moldova
Russian Federation
San Marino
Serbia

Serbia excluding Kosovo1
Kosovo1
Switzerland
Tajikistan
Turkey
Turkmenistan
Ukraine
United Kingdom
Uzbekistan
Subtotal non-EU/EEA
Total European Region
Subtotal 18 HPCs

2016

2017

New and 
relapse 
TB 
casesb
N

Cases tested using 
WHO recommended 
rapid diagnosticsc

N

(%)

New and 
relapse 
TB 
casesb
N

Cases tested using 
WHO recommended 
rapid diagnosticsc

N

(%)

New and 
relapse 
TB 
casesb
N

2018
Cases tested 
using WHO 
recommended 
rapid diagnosticsc
(%)
N

2019

2020

New and 
relapse 
TB 
casesb
N

Cases tested using 
WHO recommended 
rapid diagnosticsc

N

(%)

New and 
relapse 
TB 
casesb
N

Cases tested using 
WHO recommended 
rapid diagnosticsc

N

(%)

		619
		982
 1 525
		452
		57
		511
		292
  188
		223
	5	446
	5	739
		417
		737
		6
		290
	3	778
  641
		2
 1 347
		29
		50
		875
		273
	6	143
	1	891
 12 774
		281
		118
	3	973
		691
 50 350

	–			
		4
 1 027
 5 159
 3 211
	–			
 2 983
	–			
 12 322
 7 026
	–			
		87
	–			
 3 571
 92 407
		0
	–			
	–			
	–			
	–			
 5 965
 –   
 –   
 –   
	5	793
 16 050
 155 605
 205 955
 166 196

		490
		473
  6
		0
		4
		252
		209
  144
		62
		0
	4	454
		168
		0
		5
		118
–
  0
		0
  0
		0
		17
		588
		204
		888
		349
  846
		58
		96
		976
		461
 10 868

	–			
		4
  57
 2 025
 2 555
	–			
 2 421
	–			
 10 505
 2 533
	–			
		25
	–			
 1 813
 64 512
	–			
	–			
	–			
	–			
	–			
 4 368
 –   
 –   
 –   
381
 12 270
 103 469
 114 337
 104 055

(79.2)
(48.2)
(0.4)
(0.0)
(7.0)
(49.3)
(71.6)
(76.6)
(27.8)
(0.0)
(77.6)
(40.3)
(0.0)
(83.3)
(40.7)
–
(0.0)
(0.0)
(0.0)
(0.0)
(34.0)
(67.2)
(74.7)
(14.5)
(18.5)
(6.6)
(20.6)
(81.4)
(24.6)
(66.7)
(21.6)

		561
		911
 1 408
		372
		52
		495
		253
  172
		242
	5	015
	5	371
		434
		650
		13
		283
	3	828
  543
		1
 1 268
		32
		42
		772
		237
	5	535
	1	870
 12 303
		228
		112
	4	522
		487
 48 012

	–			
(100.0)
(5.6)
(39.3)
(79.6)
	–			
(81.2)
	–			
(85.3)
(36.1)
	–			
(28.7)
	–			
(50.8)
(69.8)
	–			
	–			
	–			
	–			
	–			
(73.2)
 –   
 –   
 –   
(6.6)
(76.4)
(66.5)
(55.5)
(62.6)

	–			
		1
  841
 5 231
 2 781
	–			
 2 597
	–			
 12 449
 6 687
	–			
		75
		216
 3 358
 84 510
		0
	1	450
		738
		712
	529	
 5 895
 –   
 1 968
 –   
	5	248
 16 842
 150 678
 198 690
 158 853

		444
		484
  5
		0
		14
		334
		198
  138
		91
		0
	4	328
		204
		0
		12
		124
–
  178
		1
  0
		0
		13
		576
		183
	1	037
		404
 3 214
		56
		95
	1	228
		412
 13 773

	–			
		1
  631
 2 869
 2 452
	–			
 2 099
	–			
 10 226
 4 330
	–			
		48
		152
 3 129
 65 843
	–			
	275	
		0
		275
	354	
 3 075
 –   
 1,488 
 –   
397
 11 368
 108 737
 122 510
 111 045

(79.1)
(53.1)
(0.4)
(0.0)
(26.9)
(67.5)
(78.3)
(80.2)
(37.6)
(0.0)
(80.6)
(47.0)
(0.0)
(92.3)
(43.8)
–
(32.8)
(100.0)
(0.0)
(0.0)
(31.0)
(74.6)
(77.2)
(18.7)
(21.6)
(26.1)
(24.6)
(84.8)
(27.2)
(84.6)
(28.7)

	–			
(100.0)
(75.0)
(54.8)
(88.2)
	–			
(80.8)
	–			
(82.1)
(64.8)
	–			
(64.0)
(70.4)
(93.2)
(77.9)
	–			
(19.0)
(0.0)
(38.6)
(66.9)
(52.2)
 –   
(75.6)
 –   
(7.6)
(67.5)
(72.2)
(61.7)
(69.9)

		470
		910
 1 290
		364
		51
		434
		270
  145
		226
	4	779
	5	326
		406
		602
		8
		290
	3	777
–
		1
 1 063
		42
		55
		780
		188
	5	196
	1	887
 11 581
		273
		98
	4	614
		474
 45 600

	–			
		2
  734
 5 038
 2 359
	–			
 2 316
	–			
 12 832
 6 338
	–			
		84
		217
 3 022
 78 258
		0
	1	330
		641
		689
	–			
 5 726
 –   
 2 157
 26 512
	4	775
 16 413
 168 113
 213 713
 175 784

		376
		522
  7
		0
		17
		274
		262
  127
		105
		0
	4	497
		181
		0
		8
		140
–
–
		1
  0
		0
		0
		582
		150
	1	054
		481
 2 757
		66
		81
	1	181
		326
 13 195

	–			
		2
  619
 3 472
 2 201
	–			
 1 940
	–			
 11 454
 3 910
	–			
		64
		147
 2 857
 57 344
	–			
		399
		0
		399
	–			
 4 235
 –   
 1 611
 23,093 
367
 14 390
 128 105
 141 300
 130 017

(80.0)
(57.4)
(0.5)
(0.0)
(33.3)
(63.1)
(97.0)
(87.6)
(46.5)
(0.0)
(84.4)
(44.6)
(0.0)
(100.0)
(48.3)
–
–
(100.0)
(0.0)
(0.0)
(0.0)
(74.6)
(79.8)
(20.3)
(25.5)
(23.8)
(24.2)
(82.7)
(25.6)
(68.8)
(28.9)

	–			
(100.0)
(84.3)
(68.9)
(93.3)
	–			
(83.8)
	–			
(89.3)
(61.7)
	–			
(76.2)
(67.7)
(94.5)
(73.3)
	–			
(30.0)
(0.0)
(57.9)
	–			
(74.0)
 –   
(74.7)
(87.1)
(7.7)
(87.7)
(76.2)
(66.1)
(74.0)

		464
		890
 1 288
		297
		66
		455
		260
  147
		225
	4	869
	4	648
		434
		528
		13
		247
	3	185
–
–
 1 006
		48
		98
		739
		150
	4	983
	1	872
 11 070
		214
		98
	4	406
		478
 43 178

	412	
		5
  621
 4 823
 2 207
 –   
 2 169
	–			
 12 501
 6 138
	–			
		80
	–			
 2 809
 73 328
		0
	1	106
		501
		605
	402	
 5 755
 –   
 2 117
 25 379
	4	803
 16 272
 160 927
 204 105
 167 630

		366
		613
  17
		0
		30
		313
		238
  132
		130
		0
	4	005
		219
		0
		12
		114
–
–
–
  0
		0
		0
		573
		128
	1	094
		543
 2 840
		60
		84
	1	261
		386
 13 158

	135	
		5
  512
 4 096
 2 035
 –   
 1 824
	–			
 11 513
 4 575
	–			
		57
	–			
 2 809
 58 300
	–			
		414
		0
		414
	304	
 4 915
 –   
 1 650
 22 537
492
 12 074
 128 247
 141 405
 129 829

(78.9)
(68.9)
(1.3)
(0.0)
(45.5)
(68.8)
(91.5)
(89.8)
(57.8)
(0.0)
(86.2)
(50.5)
(0.0)
(92.3)
(46.2)
–
–
–
(0.0)
(0.0)
(0.0)
(77.5)
(85.3)
(22.0)
(29.0)
(25.7)
(28.0)
(85.7)
(28.6)
(80.8)
(30.5)

(32.8)
(100.0)
(82.4)
(84.9)
(92.2)
 –   
(84.1)
	–			
(92.1)
(74.5)
	–			
(71.3)
	–			
(100.0)
(79.5)
	–			
(37.4)
(0.0)
(68.4)
(75.6)
(85.4)
 –   
(77.9)
(88.8)
(10.2)
(74.2)
(79.7)
(69.3)
(77.4)

		382
		778
  887
		177
		34
		360
		205
  120
		174
	4	398
	4	010
		380
		384
		12
		229
	2	163
–
		2
  688
		32
		140
		614
		144
	3	150
	1	402
 7 193
		153
		75
	2	949
		316
 31 551

		240
		2
  394
 3 683
 1 514
 –   
 1 669
	–			
 9 603
 4 241
	–			
		40
	–			
 1 767
 58 723
	–			
	–			
	–			
	–			
	–			
 4 148
 –   
 1 918
 17 533
	4	185
 12 111
 121 771
 153 322
 126 192

		263
		533
  2
		0
		12
		257
		197
  105
		107
		0
	3	428
		96
		0
		5
		176
–
–
		2
  0
		0
		0
		494
		123
		876
		434
 2 211
		45
		62
		940
		274
 10 642

	138	
		2
  326
 3 033
 1 426
 –   
 1 464
	–			
 9 219
 2 495
	–			
		35
	–			
 1 664
 47 901
	–			
	–			
	–			
	–			
	–			
 3 502
 –   
  711
 16 774
475
 11 062
 100 227
 110 869
 101 895

(68.8)
(68.5)
(0.2)
(0.0)
(35.3)
(71.4)
(96.1)
(87.5)
(61.5)
(0.0)
(85.5)
(25.3)
(0.0)
(41.7)
(76.9)
–
–
(100.0)
(0.0)
(0.0)
(0.0)
(80.5)
(85.4)
(27.8)
(31.0)
(30.7)
(29.4)
(82.7)
(31.9)
(86.7)
(33.7)

(57.5)
(100.0)
(82.7)
(82.4)
(94.2)
 –   
(87.7)
	–			
(96.0)
(58.8)
	–			
(87.5)
	–			
(94.2)
(81.6)
	–			
	–			
	–			
	–			
	–			
(84.4)
 –   
(37.1)
(95.7)
(11.4)
(91.3)
(82.3)
(72.3)
(80.7)

Note: European Region comprises the 53 countries of the WHO European Region and Liechtenstein. WHO European Region 18 TB HPCs are presented in italics. 
HPCs: high-priority countries.
a See:WHO (2013). Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance. Policy 
update. Geneva: World Health Organization (WHOWHO/HTM/TB/2013.16; https://apps.who.int/iris/handle/10665/112472, accessed 7 February 2022). 
b Cases with unknown previous TB history are included among new TB cases.
c All nucleic acid amplification tests are counted as "tested using WHO-recommended rapid diagnostics" for EU/EEA countries.
d Previous TB history is defined as previous diagnosis.
1 All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999).

120

SURVEILLANCE REPORTTuberculosis surveillance and monitoring in Europe 20228. Country profiles

121
121

Abbreviations used in country profiles

ART

C+

DR-TB

DRS

DST

antiretroviral therapy

culture-positive

drug-resistant tuberculosis

drug-resistance surveillance

drug-susceptibility testing

MDR-TB

multidrug-resistant tuberculosis

EQA

external quality assessment

pre-XDR-TB 

pre-extensively drug-resistant tuberculosis

RR/MDR-TB 

rifampicin-resistant or multidrug-resistant tuberculosis 

RR-TB

TB

rifampicin-resistant tuberculosis

tuberculosis

122

SURVEILLANCE REPORTTuberculosis surveillance and monitoring in Europe 2022Albania

Population estimate 2020 by United Nations Statistical Database: 2 877 800

TB cases, 2020

Notifications

Total number of cases
Notification rate per 100 000
Newa and relapse
Newa and relapse notification rate 
per 100 000
Pulmonary
  of which microscopy-positive
  of which laboratory-confirmed
Laboratory-confirmed TB cases
Mean age of new native TB cases
Mean age of new foreign TB cases
Foreign origin of all TB cases
New (not previously treated)
Estimates
Estimated new and relapse cases N, best 
[low–high]

  240
8.3
  240

8.3

  201
–
  147
–

–
0
  223

(83.8%)
–
(73.1%)
–
45.4 years
–
(0.0%)
(92.9%)

430

[370–500]

a Cases with unknown previous TB history included in new cases.

Drug-resistance surveillance and  
TB/HIV coinfection, 2020

Completeness of DRS dataa
Completeness of HIV datab
Case-linked data-reporting
Cases with DST results
Estimated RR-TB among notified 
bacteriologically confirmed 
pulmonary cases N, best [low–high]
Pulmonary RR/MDR-TB cases 
notified
  of which pre-XDR-TB cases
Notified RR/MDR-TB
  of which pre-XDR-TB cases
TB cases tested for HIV
HIV-positive TB cases
  of these on ART

Yes
Yes
Yes

138

(93.9%)

4

4

0
4
0
199
2
2

[0–8]

(2.9%)

(0.0%)
–
(0.0%)
(82.9%)
(1.0%)
(100.0%)

a National coverage 100% or culturing ≥ 90%, C+/all TB 
cases > 50%, DST done for C+ > 75%, EQA ≥ 95%.
b More than 50% of TB cases with reported HIV status.

Treatment outcome monitoring

Geographical 
coverage

Outcome cohort

Case-linked 
data-reporting
Cases notified
Success
Died
Failed
Lost to follow-up
Not evaluated

National

New and relapse 
TB cases notified 
in 2019a

RR/MDR-TB cases 
enrolled into DR-TB 
treatment in  2018b

Yes

412
364
19
0
18
11

(88.3%)
(4.6%)
(0.0%)
(4.4%)
(2.7%)

3
1
0
0
0

–

4

(75.0%)
(25.0%)
(0.0%)
(0.0%)
(0.0%)

a Treatment outcome as presented is treatment outcome after 12 months.
b Treatment outcome as presented is treatment outcome after 24 months.

TB notification rates by previous treatment history, 2011–2020

New and relapse
Other 

Unknown
Total

New and relapse TB cases – notification rates by age group, 
2011–2020

0–14

15–44

45–64

> 64

0
0
0
0
0
1
/
s
e
s
a
C

20

15

10

5

0

2012

2014

2016

2018

2020

0
0
0
0
0
1
/
s
e
s
a
C

35

30

25

20

15

10

5

0

2012

2014

2016

2018

2020

Note: starting from 2013 onward, cases with unknown history are included in new and 
relapses. 

Note: data up to 2012 include new TB cases only. 

TB cases by geographical origin, 2011–2020

TB/HIV coinfection, 2011–2020

Native

Foreign origin

Unknown

HIV testing coverage
Proportion of HIV-positive TB cases among tested

All TB cases

s
e
s
a
C

600

500

400

300

200

100

0

2012

2014

2016

2018

2020

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

600

500

400

300

200

100

C
a
s
e
s

2012

2014

2016

2018

0

2020

RR/MDR-TB cases and percentage of RR/MDR-TB cases by previous 
treatment history among all TB cases, 2011–2020

Treatment outcome, new and relapse TB cases, 2010–2019

New
Retreatment
Total number of RR/MDR-TB

Unknown

Success
Died

Failed
Lost to follow-up

Not evaluated

Note: data up to 2014 include all TB cases.

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

12

10

8

6

4

2

0

C
a
s
e
s

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

2012

2014

2016

2018

2020

2011

2013

2015

2017

2019

Note: 2010–2011 cohorts include new cases only.

123

Tuberculosis surveillance and monitoring in Europe 2022SURVEILLANCE REPORT 
Andorra

Total population estimate 2020 by United Nations Statistical Database: 77 267

TB cases, 2020

Notifications

Total number of cases
Notification rate per 100 000
Newa and relapse
Newa and relapse notification rate 
per 100 000
Pulmonary
  of which microscopy-positive
  of which laboratory-confirmed
Laboratory-confirmed TB cases
Mean age of new native TB cases
Mean age of new foreign TB cases
Foreign origin of all TB cases
New (not previously treated)
Estimates
Estimated new and relapse cases N, best 
[low–high]

  2
2.6
  2

2.6

(50.0%)
  1
–
–
(100.0%)
  1
–
–
40.0 years
–
–
(0.0%)
0
(100.0%)
  2

2

[2–3]

Drug resistance surveillance and TB/HIV 
coinfection, 2020 

Completeness of DRS dataa
Completeness of HIV datab
Case-linked data-reporting
Cases with DST results
Estimated RR-TB among notified 
bacteriologically confirmed 
pulmonary TB cases N, best 
[low–high]
Pulmonary RR/MDR-TB cases 
notified
  of which pre-XDR-TB cases
Notified RR/MDR-TB
  of which pre-XDR-TB cases
TB cases tested for HIV
HIV-positive TB cases
  of these on ART

Yes
No
Yes

(100.0%)

[0–1]

(0.0%)

(0.0%)
–
(0.0%)
(0.0%)
–
–

1

0

0

0
0
0
0
–
–

a Cases with unknown previous TB history included in new cases.

a National coverage 100% or culturing ≥ 90%, C+/all TB 
cases > 50%, DST done for C+ > 75%, EQA ≥ 95%.
b More than 50% of TB cases with reported HIV status.

Treatment outcome monitoring

Geographical 
coverage

Outcome cohort

Case-linked 
data-reporting
Cases notified
Success
Died
Failed
Lost to follow-up
Not evaluated

National

New and relapse 
TB cases notified 
in 2019a

RR/MDR-TB cases 
enrolled into DR-TB 
treatment in  2018b

Yes

5

3
1
0
1
0

(60.0%)
(20.0%)
(0.0%)
(20.0%)
(0.0%)

0
0
0
0
0

–

0

–
–
–
–
–

a Treatment outcome as presented is treatment outcome after 12 months.
b Treatment outcome as presented is treatment outcome after 24 months.

TB notification rates by previous treatment history, 2011–2020

New and relapse
Other 

Unknown
Total

New and relapse TB cases – notification rates by age group, 
2011–2020

0–14

15–44

45–64

> 64

0
0
0
0
0
1
/
s
e
s
a
C

12

10

8

6

4

2

0

2012

2014

2016

2018

2020

0
0
0
0
0
1
/
s
e
s
a
C

25

20

15

10

5

0

2012

2014

2016

2018

2020

Note: starting from 2013 onward, cases with unknown history are included in new and relapses.

Note: data up to 2012 include new TB cases only. 

TB cases by geographical origin, 2011–2020

TB/HIV coinfection, 2011–2020

Native

Foreign origin

Unknown

HIV testing coverage
Proportion of HIV-positive TB cases among tested

TB cases

s
e
s
a
C

10

8

6

4

2

0

2012

2014

2016

2018

2020

100

80

60

40

20

e
g
a
t
n
e
c
r
e
P

0

2014
Note: data up to 2014 include all TB cases.

2012

10

8

6

4

2

0

C
a
s
e
s

2016

2018

2020

RR/MDR-TB cases and percentage of RR/MDR-TB cases by previous 
treatment history among all TB cases, 2011–2020

Treatment outcome, new and relapse TB cases, 2010–2019

New
Retreatment
Total number of RR/MDR-TB

Unknown

Success
Died

Failed
Lost to follow-up

Not evaluated

3

2

1

0

C
a
s
e
s

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

2012

2014

2016

2018

2020

2011

2013

2015

2017

2019

Note: 2010–2011 cohorts include new cases only.

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

124

SURVEILLANCE REPORTTuberculosis surveillance and monitoring in Europe 2022 
 
Armenia

Total population estimate 2020 by United Nations Statistical Database: 2 963 234

TB cases, 2020

Notifications

Total number of cases
Notification rate per 100 000
Newa and relapse
Newa and relapse notification rate 
per 100 000
Pulmonary
  of which microscopy-positive
  of which laboratory-confirmed
Laboratory-confirmed TB cases
Mean age of new native TB cases
Mean age of new foreign TB cases
Foreign origin of all TB cases
New (not previously treated)
Estimates
Estimated new and relapse cases N, best 
[low–high]

  444
15.0
  394

13.3

  337
–
  251
–

–
4
  369

(75.9%)
– 
(74.5%)
–
44.0 years
–
(0.9%)
(83.1%)

680

[520–870]

Drug resistance surveillance and TB/HIV 
coinfection, 2020

Completeness of DRS dataa
Completeness of HIV datab
Case-linked data-reporting
Cases with DST results
Estimated RR-TB among notified 
bacteriologically confirmed 
pulmonary TB cases N, best 
[low–high]
Pulmonary RR/MDR-TB cases 
notified
  of which pre-XDR-TB cases
Notified RR/MDR-TB
  of which pre-XDR-TB cases
TB cases tested for HIV
HIV-positive TB cases
  of these on ART

Yes
Yes
Yes

246

(98.0%)

54

[42–66]

52

11
52
7
369
39
0

(21.1%)

(21.2%)
–
(13.5%)
(93.7%)
(10.6%)
(0.0%)

Treatment outcome monitoring

Geographical 
coverage

Outcome cohort

Case-linked 
data-reporting
Cases notified
Success
Died
Failed
Lost to follow-up
Not evaluated

National

New and relapse 
TB cases notified 
in 2019a

RR/MDR-TB cases 
enrolled into DR-TB 
treatment in  2018b

Yes

485

–

85

399
36
19
29
2

(82.3%)
(7.4%)
(3.9%)
(6.0%)
(0.4%)

39
13
11
22
0

(45.9%)
(15.3%)
(12.9%)
(25.9%)
(0.0%)

a Treatment outcome as presented is treatment outcome after 12 months.
b Treatment outcome as presented is treatment outcome after 24 months.

a Cases with unknown previous TB history included in new cases.

a National coverage 100% or culturing ≥ 90%, C+/all TB 
cases > 50%, DST done for C+ > 75%, EQA ≥ 95%.
b More than 50% of TB cases with reported HIV status.

TB notification rates by previous treatment history, 2011–2020

New and relapse
Other

Unknown
Total

New and relapse TB cases – notification rates by age group, 
2011–2020

0–14

15–44

45–64

> 64

0
0
0
0
0
1
/
s
e
s
a
C

70

60

50

40

30

20

10

0

2012

2014

2016

2018

2020

0
0
0
0
0
1
/
s
e
s
a
C

90
80
70
60
50
40
30
20
10
0

2012

2014

2016

2018

2020

Note: starting from 2013 onward, cases with unknown history are included in new and relapses.

Note: data up to 2012 include new TB cases only. 

TB cases by geographical origin, 2011–2020

TB/HIV coinfection, 2011–2020

s
e
s
a
C

1800
1600
1400
1200
1000
800
600
400
200
0

Native

Foreign origin

Unknown

2012

2014

2016

2018

2020

100

80

60

40

20

e
g
a
t
n
e
c
r
e
P

HIV testing coverage
Proportion of HIV-positive TB cases among tested
2000

TB cases

1500

1000

500

C
a
s
e
s

2016

2018

0

2020

0

2014
Note: data up to 2014 include all TB cases.

2012

RR/MDR-TB cases and percentage of RR/MDR-TB cases by previous 
treatment history among all TB cases, 2011–2020

Treatment outcome, new and relapse TB cases, 2010–2019

New
Retreatment
Total number of RR/MDR-TB

Unknown

Success
Died

Failed
Lost to follow-up

Not evaluated

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

140

120

100

80

60

40

20

0

C
a
s
e
s

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

2012

2014

2016

2018

2020

2011

2013

2015

2017

2019

Note: 2010–2011 cohorts include new cases only.

125

Tuberculosis surveillance and monitoring in Europe 2022SURVEILLANCE REPORT 
 
Austria

Total population at 9 April 2021 by EUROSTAT: 8 901 064

TB cases, 2020

Notifications

Total number of cases
Notification rate per 100 000
Newa and relapse
Newa and relapse notification rate 
per 100 000
Pulmonary
  of which microscopy-positive
  of which laboratory-confirmed
Laboratory-confirmed TB cases
Mean age of new native TB cases
Mean age of new foreign TB cases
Foreign origin of all TB cases
New (not previously treated)
Estimates
Estimated new and relapse cases N, best 
[low–high]

388
4.4
382

4.3

295
65
227
281

(76.0%)
(22.0%)
(76.9%)
(72.4%)

53.3 years
40.3 years

215
296

(55.4%)
(76.3%)

440

[380–510]

a Cases with unknown previous TB history included in new cases.

Drug resistance surveillance and TB/HIV 
coinfection, 2020

Completeness of DRS dataa
Completeness of HIV datab
Case-linked data-reporting
Cases with DST results
Estimated RR-TB among notified 
bacteriologically confirmed 
pulmonary TB cases N, best 
[low–high]
Pulmonary RR/MDR-TB cases notified
  of which pre-XDR-TB cases
Notified RR/MDR-TB
  of which pre-XDR-TB cases
TB cases tested for HIV
HIV-positive TB cases
  of these on ART

Yes
No
Yes

269

(95.7%)

8

1
0
1
0
–
–
–

[3–13]

(0.5%)
(0.0%)
–
(0.0%)
–
–
–

a National coverage 100% or culturing ≥ 90%, C+/all TB 
cases > 50%, DST done for C+ > 75%, EQA ≥ 95%.
b More than 50% of TB cases with reported HIV status.

Treatment outcome monitoring

Geographical 
coverage

Outcome cohort

Case-linked 
data-reporting
Cases notified
Success
Died
Failed
Lost to follow-up
Still on treatment
Not evaluated

National

New culture-positive 
pulmonary TB cases 
notified in 2019a

All RR/MDR-TB cases 
notified in 2018b

Yes

195

149
15
0
1
18
12

(76.4%)
(7.7%)
(0.0%)
(0.5%)
(9.2%)
(6.2%)

–

18

(83.3%)
(5.6%)
(0.0%)
(0.0%)
(5.6%)
(5.6%)

15
1
0
0
1
1

a Treatment outcome as presented is treatment outcome after 12 months.
b Treatment outcome as presented is treatment outcome after 24 months.

TB notification rates by previous treatment history, 2011–2020

New and relapse
Other

Unknown
Total

New and relapse TB cases – notification rates by age group, 
2011–2020

0–14

15–44

45–64

> 64

0
0
0
0
0
1
/
s
e
s
a
C

9
8
7
6
5
4
3
2
1
0

2012

2014

2016

2018

2020

0
0
0
0
0
1
/
s
e
s
a
C

9
8
7
6
5
4
3
2
1
0

2012

2014

2016

2018

2020

TB cases by geographical origin, 2011–2020

TB/HIV coinfection, 2011–2020

Native

Foreign origin

Unknown

Data not reported

s
e
s
a
C

450
400
350
300
250
200
150
100
50
0

2012

2014

2016

2018

2020

RR/MDR-TB cases and percentage of RR/MDR-TB cases by previous 
treatment history among all TB cases, 2011–2020

Treatment outcome, new culture-confirmed pulmonary TB cases, 
2010–2019

New
Retreatment
Total number of RR/MDR-TB

Unknown

Success
Died

Still on treatment
Lost to follow-up

Failed
Not evaluated

30

25

20

15

10

5

0

C
a
s
e
s

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

2012

2014

2016

2018

2020

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

126

2011

2013

2015

2017

2019

SURVEILLANCE REPORTTuberculosis surveillance and monitoring in Europe 2022 
 
Azerbaijan

Total population estimate 2020 by United Nations Statistical Database: 10 139 175

TB cases, 2020

Notifications

Total number of cases
Notification rate per 100 000
Newa and relapse
Newa and relapse notification rate 
per 100 000
Pulmonary
  of which microscopy-positive
  of which laboratory-confirmed
Laboratory-confirmed TB cases
Mean age of new native TB cases
Mean age of new foreign TB cases
Foreign origin of all TB cases
New (not previously treated)
Estimates
Estimated new and relapse cases N, 
best [low–high]

 4 991
49.2
 3 683

36.3

 4 380
–
 3 617
–

–
–
 2 558

(87.8%)
–
(82.6%)
–
26.9 years
–
–
(51.3%)

5 900

[4 500–7 500]

a Cases with unknown previous TB history included in new cases.

Drug resistance surveillance and TB/HIV 
coinfection, 2020

Completeness of DRS dataa
Completeness of HIV datab
Case-linked data-reporting
Cases with DST results
Estimated RR-TB among notified 
bacteriologically confirmed 
pulmonary TB cases N, best 
[low–high]
Pulmonary RR/MDR-TB cases 
notified
  of which pre-XDR-TB cases
Notified RR/MDR-TB
  of which pre-XDR-TB cases
TB cases tested for HIV
HIV-positive TB cases
  of these on ART

Yes
Yes
Yes

3 505

(96.9%)

720

[670–760]

701

(20.0%)

87
764
108
3 683
83
77

(15.1%)
–
(14.1%)
(100%)
(1.9%)
(92.8%)

a National coverage 100% or culturing 90%, C+/all TB 
cases > 50%, DST done for C+ > 75%, EQA ≥ 95%.
b More than 50% of TB cases with reported HIV status.

Treatment outcome monitoring

Geographical 
coverage

Outcome cohort

Case-linked 
data-reporting
Cases notified
Success
Died
Failed
Lost to follow-up
Not evaluated

National

New and relapse 
TB cases notified 
in 2019a

RR/MDR-TB cases 
enrolled into DR-TB 
treatment in  2018b

Yes

1 702

–

821

1 429
66
53
134
20

(84.0%)
(3.9%)
(3.1%)
(7.9%)
(1.2%)

471
94
142
114
0

(57.4%)
(11.4%)
(17.3%)
(13.9%)
(0.0%)

a Treatment outcome as presented is treatment outcome after 12 months.
b Treatment outcome as presented is treatment outcome after 24 months.

TB notification rates by previous treatment history, 2011–2020

New and relapse
Other 

Unknown
Total

New and relapse TB cases – notification rates by age group, 
2011–2020

0–14

15–44

45–64

> 64

0
0
0
0
0
1
/
s
e
s
a
C

120

100

80

60

40

20

0

2012

2014

2016

2018

2020

0
0
0
0
0
1
/
s
e
s
a
C

80

70

60

50

40

30

20

10

0

2012

2014

2016

2018

2020

Note: starting from 2013 onward, cases with unknown history are included in new and relapse.

Note: data up to 2012 include new TB cases only. 

TB cases by geographical origin, 2011–2020

TB/HIV coinfection, 2011–2020

Native

Foreign origin

Unknown

HIV testing coverage
Proportion of HIV-positive TB cases among tested

TB cases

12 000

10 000

s
e
s
a
C

8000

6000

4000

2000

0

2012

2014

2016

2018

2020

150

120

90

60

30

e
g
a
t
n
e
c
r
e
P

0

2014
Note: data up to 2018 include all TB cases.

2012

12 000

10 000

C
a
s
e
s

8000

6000

4000

2000

2016

2018

0

2020

RR/MDR-TB cases and percentage of RR/MDR-TB cases by previous 
treatment history among all TB cases, 2011–2020

Treatment outcome, new and relapse TB cases, 2010–2019

New
Retreatment
Total number of RR/MDR-TB

Unknown

Success
Died

Failed
Lost to follow-up

Not evaluated

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

1200

1000

800

600

400

200

C
a
s
e
s

2012

2014

2016

2018

0

2020

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

2011

2013

2015

2017

2019

Note: 2010–2011 cohorts include new cases only.

127

Tuberculosis surveillance and monitoring in Europe 2022SURVEILLANCE REPORT 
 
 
  
Belarus

Total population estimate 2020 by United Nations Statistical Database: 9 449 321

TB cases, 2020

Notifications

Total number of cases
Notification rate per 100 000
Newa and relapse
Newa and relapse notification rate 
per 100 000
Pulmonary
  of which microscopy-positive
  of which laboratory-confirmed
Laboratory-confirmed TB cases
Mean age of new native TB cases
Mean age of new foreign TB cases
Foreign origin of all TB cases
New (not previously treated)
Estimates
Estimated new and relapse cases N, 
best [low–high]

 1 778
18.8
 1 514

16.0

 1 658
–
 1 584
–

–
0
 1 171

(93.3%)
–
(95.5%)
–
48.6 years
–
(0.0%)
(65.9%)

2 500

[1 900–3 100]

a Cases with unknown previous TB history included in new cases.

Drug-resistance surveillance and  
TB/HIV coinfection, 2020

Completeness of DRS dataa
Completeness of HIV datab
Case-linked data-reporting
Cases with DST results
Estimated RR-TB among notified 
bacteriologically confirmed 
pulmonary TB cases N, best 
[low–high]
Pulmonary RR/MDR-TB cases 
notified
  of which pre-XDR-TB cases
Notified RR/MDR-TB
  of which pre-XDR-TB cases
TB cases tested for HIV
HIV-positive TB cases
  of these on ART

Yes
Yes
Yes

1 584

(100.0%)

820

[790–860]

825

354
874
354
1 514
135
124

(52.1%)

(42.9%)
–
(40.5%)
(100.0%)
(8.9%)
(91.9%)

a National coverage 100% or culturing ≥ 90%, C+/all TB 
cases > 50%, DST done for C+ > 75%, EQA ≥ 95%.
b More than 50% of TB cases with reported HIV status.

Treatment outcome monitoring

Geographical 
coverage

Outcome cohort

Case-linked 
data-reporting
Cases notified
Success
Died
Failed
Lost to follow-up
Not evaluated

National

New and relapse 
TB cases notified 
in 2019a

RR/MDR-TB cases 
enrolled into DR-TB 
treatment in  2018b

Yes

1 302

–

919

1 153
93
28
28
0

(88.6%)
(7.1%)
(2.2%)
(2.2%)
(0.0%)

670
87
60
95
7

(72.9%)
(9.5%)
(6.5%)
(10.3%)
(0.8%)

a Treatment outcome as presented is treatment outcome after 12 months.
b Treatment outcome as presented is treatment outcome after 24 months.

TB notification rates by previous treatment history, 2011–2020

New and relapse
Other

Unknown
Total

New and relapse TB cases – notification rates by age group, 
2011–2020

0–14

15–44

45–64

> 64

0
0
0
0
0
1
/
s
e
s
a
C

70

60

50

40

30

20

10

0

2012

2014

2016

2018

2020

0
0
0
0
0
1
/
s
e
s
a
C

80

70

60

50

40

30

20

10

0

2012

2014

2016

2018

2020

Note: starting from 2013 onward, cases with unknown history are included in new and 
relapses. 

Note: data up to 2012 include new TB cases only. 

TB cases by geographical origin, 2011–2020

TB/HIV coinfection, 2011–2020

s
e
s
a
C

6000

5000

4000

3000

2000

1000

0

Native

Foreign origin

Unknown

2012

2014

2016

2018

2020

100

80

60

40

20

e
g
a
t
n
e
c
r
e
P

HIV testing coverage
Proportion of HIV-positive TB cases among tested
6000

TB cases

5000

4000

3000

2000

1000

C
a
s
e
s

2016

2018

0

2020

0

2014
Note: data up to 2014 include all TB cases.

2012

RR/MDR-TB cases and percentage of RR/MDR-TB cases by previous 
treatment history among all TB cases, 2011–2020

Treatment outcome, new and relapse TB cases, 2010–2019a

New
Retreatment
Total number of RR/MDR-TB

Unknown

Success
Died

Failed
Lost to follow-up

Not evaluated

1800
1600
1400
1200
1000
800
600
400
200
0

C
a
s
e
s

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

2012

2014

2016

2018

2020

2011

2013

2015

2017

2019

Note: 2010–2011 cohorts include new cases only.

80

70

60

50

40

30

20

10

0

e
g
a
t
n
e
c
r
e
P

128

SURVEILLANCE REPORTTuberculosis surveillance and monitoring in Europe 2022 
 
Belgium

Total population at 9 April 2021 by EUROSTAT: 11 522 440

TB cases, 2020

Notifications

Total number of cases
Notification rate per 100 000
Newa and relapse
Newa and relapse notification rate 
per 100 000
Pulmonary
  of which microscopy-positive
  of which laboratory-confirmed
Laboratory-confirmed TB cases
Mean age of new native TB cases
Mean age of new foreign TB cases
Foreign origin of all TB cases
New (not previously treated)
Estimates
Estimated new and relapse cases N, 
best [low–high]

  830
7.2
  778

6.8

  574
  271
  461
  637

(69.2%)
(47.2%)
(80.3%)
(76.7%)

45.6 years
34.7 years

472
607

(56.9%)
(73.1%)

Drug resistance surveillance and TB/HIV 
coinfection, 2020

Completeness of DRS dataa
Completeness of HIV datab
Case-linked data-reporting
Cases with DST results
Estimated RR-TB among notified 
bacteriologically confirmed pulmonary 
TB cases N, best [low–high]
Pulmonary RR/MDR-TB cases notified
  of which pre-XDR-TB cases
Notified RR/MDR-TB
  of which pre-XDR-TB cases
TB cases tested for HIV
HIV-positive TB cases
  of these on ART

Yes
No
Yes

613

(96.2%)

13

[6–20]

9
1
17
3
389
33
–

(2.0%)
(20.0%)
–
(17.6%)
(46.9%)
(8.5%)
–

Treatment outcome monitoring

Geographical 
coverage

Outcome cohort

Case-linked 
data-reporting
Cases notified
Success
Died
Failed
Lost to follow-up
Still on treatment
Not evaluated

National

New culture-positive 
pulmonary TB cases 
notified in 2019a

All MDR-TB cases 
notified in 2018b

Yes

445

353
34
4
33
13
8

(79.3%)
(7.6%)
(0.9%)
(7.4%)
(2.9%)
(1.8%)

–

9

(77.8%)
(11.1%)
(0.0%)
(11.1%)
(0.0%)
(0.0%)

7
1
0
1
0
0

a Treatment outcome as presented is treatment outcome after 12 months.
b Treatment outcome as presented is treatment outcome after 24 months.

890

[770–1000]

a National coverage 100% or culturing ≥ 90%, C+/all TB 
cases > 50%, DST done for C+ > 75%, EQA ≥ 95%.
b More than 50% of TB cases with reported HIV status.

a Cases with unknown previous TB history included in new cases.

TB notification rates by previous treatment history, 2011–2020

New and relapse
Other 

Unknown
Total

New and relapse TB cases – notification rates by age group, 
2011–2020

0–14

15–44

45–64

> 64

0
0
0
0
0
1
/
s
e
s
a
C

10

8

6

4

2

0

2012

2014

2016

2018

2020

0
0
0
0
0
1
/
s
e
s
a
C

12

10

8

6

4

2

0

2012

2014

2016

2018

2020

TB cases by geographical origin, 2011–2020

TB/HIV coinfection, 2011–2020

s
e
s
a
C

700

600

500

400

300

200

100

0

Native

Foreign origin

Unknown

2012

2014

2016

2018

2020

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

HIV testing coverage
Proportion of HIV-positive TB cases among tested
1200

All TB cases

1000

800

600

400

200

C
a
s
e
s

2012

2014

2016

2018

0

2020

RR/MDR-TB cases and percentage of RR/MDR-TB cases by previous 
treatment history among all TB cases, 2011–2020

Treatment outcome, new culture-confirmed pulmonary TB cases, 
2010–2019

New
Retreatment
Total number of RR/MDR-TB

Unknown

Success
Died

Still on treatment
Lost to follow-up

Failed
Not evaluated

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

25

20

15

10

5

0

C
a
s
e
s

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

2012

2014

2016

2018

2020

2011

2013

2015

2017

2019

129

Tuberculosis surveillance and monitoring in Europe 2022SURVEILLANCE REPORT 
 
  
Bosnia and Herzegovina

Total population estimate 2020 by United Nations Statistical Database: 3 280 815

TB cases, 2020

Notifications

Total number of cases
Notification rate per 100 000
Newa and relapse
Newa and relapse notification rate 
per 100 000
Pulmonary
  of which microscopy-positive
  of which laboratory-confirmed
Laboratory-confirmed TB cases
Mean age of new native TB cases
Mean age of new foreign TB cases
Foreign origin of all TB cases
New (not previously treated)
Estimates
Estimated new and relapse cases N, 
best [low–high]

  357
10.9
  357

10.9

  332
–
  240
–

–
5
  322

(93.0%)
–
(72.3%)
–
51.3 years
–
(1.4%)
(90.2%)

850

[650–1 100]

a Cases with unknown previous TB history included in new cases.

Drug resistance surveillance and TB/HIV 
coinfection, 2020

Completeness of DRS dataa
Completeness of HIV datab
Case-linked data-reporting
Cases with DST results
Estimated RR-TB among notified 
bacteriologically confirmed 
pulmonary cases N, best [low–high]
Pulmonary RR/MDR-TB cases 
notified
  of which pre-XDR-TB cases
Notified RR/MDR-TB
  of which pre-XDR-TB cases
TB cases tested for HIV
HIV-positive TB cases
  of these on ART

Yes
No
Yes

231

(96.3%)

0

0

–
0
–
15
0
–

[0–3]

(0.0%)

–
–
–
(4.2%)
(0.0%)
–

a National coverage 100% or culturing ≥ 90%, C+/all TB cases 
> 50%, DST done for C+ > 75%, EQA ≥ 95%.
b More than 50% of TB cases with reported HIV status.

Treatment outcome monitoring

Geographical 
coverage

Outcome cohort

Case-linked 
data-reporting
Cases notified
Success
Died
Failed
Lost to follow-up
Not evaluated

National

New and relapse 
TB cases notified 
in 2019a

RR/MDR-TB cases 
enrolled into DR-TB 
treatment in  2018b

Yes

580

185
28
10
3
354

(31.9%)
(4.8%)
(1.7%)
(0.5%)
(61.0%)

–

0

–
–
–
–
–

0
0
0
0
0

a Treatment outcome as presented is treatment outcome after 12 months.
b Treatment outcome as presented is treatment outcome after 24 months.

TB notification rates by previous treatment history, 2011–2020

New and relapse
Other 

Unknown
Total

New and relapse TB cases – notification rates by age group, 
2011–2020

0–14

15–44

45–64

> 64

0
0
0
0
0
1
/
s
e
s
a
C

45
40
35
30
25
20
15
10
5
0

2012

2014

2016

2018

2020

0
0
0
0
0
1
/
s
e
s
a
C

120

100

80

60

40

20

0

2012

2014

2016

2018

2020

Note: starting from 2013 onward, cases with unknown history are included in new and 
relapses. 

Note: data up to 2012 include new TB cases only. 

TB cases by geographical origin, 2011–2020

TB/HIV coinfection, 2011–2020

s
e
s
a
C

1600

1400

1200

1000

800

600

400

200

0

Native

Foreign origin

Unknown

2012

2014

2016

2018

2020

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

HIV testing coverage
Proportion of HIV-positive TB cases among tested
1500

TB cases

1200

900

600

300

C
a
s
e
s

2012

2014

2016

2018

0

2020

RR/MDR-TB cases and percentage of RR/MDR-TB cases by previous 
treatment history among all TB cases, 2011–2020

Treatment outcome, new and relapse TB cases, 2010–2019

New
Retreatment
Total number of RR/MDR-TB

Unknown

Success
Died

Failed
Lost to follow-up

Not evaluated

Note: data up to 2014 include all TB cases.

8
7
6
5
4
3
2
1
0

C
a
s
e
s

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

2012

2014

2016

2018

2020

2011

2013

2015

2017

2019

Note: 2010–2011 cohorts include new cases only.

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

130

SURVEILLANCE REPORTTuberculosis surveillance and monitoring in Europe 2022 
 
Bulgaria

Total population at 9 April 2021 by EUROSTAT: 6 951 482

TB cases, 2020

Notifications

Total number of cases
Notification rate per 100 000
Newa and relapse
Newa and relapse notification rate 
per 100 000
Pulmonary
  of which microscopy-positive
  of which laboratory-confirmed
Laboratory-confirmed TB cases
Mean age of new native TB cases
Mean age of new foreign TB cases
Foreign origin of all TB cases
New (not previously treated)
Estimates
Estimated new and relapse cases N, 
best [low–high]

930
13.4
887

12.8

  746
  377
  424
  433

(80.2%)
(50.5%)
(56.8%)
(46.6%)

51.5 years
37.5 years

2
  820

(0.2%)
(88.2%)

1 300

[1 000–1 700]

a Cases with unknown previous TB history included in new cases.

Drug resistance surveillance and TB/HIV 
coinfection, 2020

Completeness of DRS dataa
Completeness of HIV datab
Case-linked data-reporting
Cases with DST results
Estimated RR-TB among notified 
bacteriologically confirmed 
pulmonary TB cases N, best 
[low–high]
Pulmonary RR/MDR-TB cases notified
  of which pre-XDR-TB cases
Notified RR/MDR-TB
  of which pre-XDR-TB cases
TB cases tested for HIV
HIV-positive TB cases
  of these on ART

Yes
Yes
Yes

  246

(56.8%)

24

[16–32]

12
2
12
2
  781
1
1

(5.0%)
(22.2%)
–
(22.2%)
(84.0%)
(0.1%)
(100.0%)

a National coverage 100% or culturing ≥ 90%, C+/all TB cases  
> 50%, DST done for C+ > 75%, EQA ≥ 95%.
b More than 50% of TB cases with reported HIV status.

Treatment outcome monitoring

Geographical 
coverage

Outcome cohort

Case-linked 
data-reporting
Cases notified
Success
Died
Failed
Lost to follow-up
Still on treatment
Not evaluated

National

New culture-positive 
pulmonary TB cases 
notified in 2019a

All RR/MDR-TB cases 
notified in 2018b

Yes

  549

  449
  44
  7
  34
0
15

(81.8%)
(8.0%)
(1.3%)
(6.2%)
(0.0%)
(2.7%)

–

28

(60.7%)
(14.3%)
(3.6%)
(17.9%)
(0.0%)
(3.6%)

17
4
1
5
0
1

a Treatment outcome as presented is treatment outcome after 12 months.
b Treatment outcome as presented is treatment outcome after 24 months.

TB notification rates by previous treatment history, 2011–2020

New and relapse TB cases – notification rates by age group, 
2011–2020

New and relapse
Other

Unknown
Total

0–14

15–44

45–64

> 64

0
0
0
0
0
1
/
s
e
s
a
C

40

35

30

25

20

15

10

5

0

2012

2014

2016

2018

2020

0
0
0
0
0
1
/
s
e
s
a
C

40

35

30

25

20

15

10

5

0

2012

2014

2016

2018

2020

TB cases by geographical origin, 2011–2020

TB/HIV coinfection, 2011–2020

s
e
s
a
C

3000

2500

2000

1500

1000

500

0

Native

Foreign origin

Unknown

2012

2014

2016

2018

2020

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

HIV testing coverage
Proportion of HIV-positive TB cases among tested
3500

All TB cases

3000

2500

2000

1500

1000

500

C
a
s
e
s

2012

2014

2016

2018

0

2020

RR/MDR-TB cases and percentage of RR/MDR-TB cases by previous 
treatment history among all TB cases, 2011–2020

Treatment outcome, new culture-confirmed pulmonary TB cases, 
2010–2019

New
Retreatment
Total number of RR/MDR-TB

Unknown

Success
Died

Still on treatment
Lost to follow-up

Failed
Not evaluated

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

60

50

40

30

20

10

0

C
a
s
e
s

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

2012

2014

2016

2018

2020

2011

2013

2015

2017

2019

131

Tuberculosis surveillance and monitoring in Europe 2022SURVEILLANCE REPORT 
 
Croatia

Total population at 9 April 2021 by EUROSTAT: 4 058 165

TB cases, 2020

Notifications

Total number of cases
Notification rate per 100 000
Newa and relapse
Newa and relapse notification rate 
per 100 000
Pulmonary
  of which microscopy-positive
  of which laboratory-confirmed
Laboratory-confirmed TB cases
Mean age of new native TB cases
Mean age of new foreign TB cases
Foreign origin of all TB cases
New (not previously treated)
Estimates
Estimated new and relapse cases N, best 
[low–high]

183
4.5
177

4.4

104
67
99
146

(56.8%)
(64.4%)
(95.2%)
(79.8%)

86.0 years
–

0
1

(0.0%)
(0.5%)

270

[230–310]

a Cases with unknown previous TB history included in new cases.

Drug resistance surveillance and TB/HIV 
coinfection, 2020

Completeness of DRS dataa
Completeness of HIV datab
Case-linked data-reporting
Cases with DST results
Estimated RR-TB among notified 
bacteriologically confirmed 
pulmonary TB cases N, best 
[low–high]
Pulmonary RR/MDR-TB cases notified
  of which pre-XDR-TB cases
Notified RR/MDR-TB
  of which pre-XDR-TB cases
TB cases tested for HIV
HIV-positive TB cases
  of these on ART

Yes
No
Yes

131

(89.7%)

1

1
0
1
0
4
0
–

[0–3]

(1.2%)
–
–
–
(2.2%)
(0.0%)
–

a National coverage 100% or culturing ≥ 90%, C+/all TB cases  
> 50%, DST done for C+ > 75%, EQA ≥ 95%.
b More than 50% of TB cases with reported HIV status.

Treatment outcome monitoring

Geographical 
coverage

Outcome cohort

Case-linked 
data-reporting
Cases notified
Success
Died
Failed
Lost to follow-up
Still on treatment
Not evaluated

National

Newa culture-positive 
pulmonary TB cases 
notified in 2019b

All RR/MDR-TB cases 
notified in 2018c

Yes

2

(100%)
(0.0%)
(0.0%)
(0.0%)
(0.0%)
(0.0%)

2
0
0
0
0
0

–

2

(0.0%)
(50.0%)
(0.0%)
(0.0%)
(0.0%)
(50.0%)

0
1
0
0
0
1

a For 2019, cases with unknown treatment history included in new cases. 
b Treatment outcome as presented is treatment outcome after 12 months.  
c Treatment outcome as presented is treatment outcome after 24 months."

TB notification rates by previous treatment history, 2011–2020

New and relapse
Other 

Unknown
Total

New and relapse TB cases – notification rates by age group, 
2011–2020

0–14

15–44

45–64

> 64

0
0
0
0
0
1
/
s
e
s
a
C

20

15

10

5

0

2012

2014

2016

2018

2020

0
0
0
0
0
1
/
s
e
s
a
C

40

35

30

25

20

15

10

5

0

2012

2014

2016

2018

2020

TB cases by geographical origin, 2011–2020

TB/HIV coinfection, 2011–2020

Note: for 2019, cases with unknown treatment history included in new cases.

Native

Foreign origin

Unknown

HIV testing coverage
Proportion of HIV-positive TB cases among tested

All TB cases

s
e
s
a
C

800

700

600

500

400

300

200

100

0

2012

2014

2016

2018

2020

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

700

600

500

400

300

200

100

C
a
s
e
s

2012

2014

2016

2018

0

2020

RR/MDR-TB cases and percentage of RR/MDR-TB cases by previous 
treatment history among all TB cases, 2011–2020

Treatment outcome, new culture-confirmed pulmonary TB cases, 
2010–2019

New
Retreatment
Total number of RR/MDR-TB

Unknown

Success
Died

Still on treatment
Lost to follow-up

Failed
Not evaluated

3

2

1

0

C
a
s
e
s

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

2012

2014

2016

2018

2020

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

132

2011

2013

2015

2017

2019

SURVEILLANCE REPORTTuberculosis surveillance and monitoring in Europe 2022 
 
Cyprus

Total population at 9 April 2021 by EUROSTAT: 888 005

TB cases, 2020

Notifications

Total number of cases
Notification rate per 100 000
Newa and relapse
Newa and relapse notification rate 
per 100 000
Pulmonary
  of which microscopy-positive
  of which laboratory-confirmed
Laboratory-confirmed TB cases
Mean age of new native TB cases
Mean age of new foreign TB cases
Foreign origin of all TB cases
New (not previously treated)
Estimates
Estimated new and relapse cases N, best 
[low–high]

36
4.1
34

3.8

30
10
27
28

(83.3%)
(33.3%)
(90.0%)
(77.8%)

55.4 years
32.9 years
31
34

(86.1%)
(94.4%)

69

[59–80]

a Cases with unknown previous TB history included in new cases.

Drug resistance surveillance and TB/HIV 
coinfection, 2020

Completeness of DRS dataa
Completeness of HIV datab
Case-linked data-reporting
Cases with DST results
Estimated RR-TB among notified 
bacteriologically confirmed 
pulmonary TB cases N, best 
[low–high]
Pulmonary RR/MDR-TB cases notified
  of which pre-XDR-TB cases
Notified RR/MDR-TB
  of which pre-XDR-TB cases
TB cases tested for HIV
HIV-positive TB cases
  of these on ART

Yes
Yes
Yes

28

(100.0%)

0

0
0
0
0
30
2
–

[0–1]

–
–
–
–
(83.3%)
(6.7%)
–

a National coverage 100% or culturing ≥ 90%, C+/all TB cases  
> 50%, DST done for C+ > 75%, EQA ≥ 95%.
b More than 50% of TB cases with reported HIV status.

Treatment outcome monitoring

Geographical 
coverage

Outcome cohort

Case-linked 
data-reporting
Cases notified
Success
Died
Failed
Lost to follow-up
Still on treatment
Not evaluated

National

New culture-positive 
pulmonary TB cases 
notified in 2019a

All RR/MDR-TB cases 
notified in 2018b

Yes

47

12
0
0
6
7
22

(25.5%)
(0.0%)
(0.0%)
(12.8%)
(14.9%)
(46.8%)

–

0

–
–
–
–
–
–

0
0
0
0
0
0

a Treatment outcome as presented is treatment outcome after 12 months.
b Treatment outcome as presented is treatment outcome after 24 months.

TB notification rates by previous treatment history, 2011–2020

New and relapse
Other

Unknown
Total

New and relapse TB cases – notification rates by age group, 
2011–2020

0–14

15–44

45–64

> 64

0
0
0
0
0
1
/
s
e
s
a
C

8

7

6

5

4

3

2

1

0

2012

2014

2016

2018

2020

0
0
0
0
0
1
/
s
e
s
a
C

14

12

10

8

6

4

2

0

2012

2014

2016

2018

2020

TB cases by geographical origin, 2011–2020

TB/HIV coinfection, 2011–2020

Native

Foreign origin

Unknown

HIV testing coverage
Proportion of HIV-positive TB cases among tested

All TB cases

s
e
s
a
C

80

70

60

50

40

30

20

10

0

2012

2014

2016

2018

2020

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

80

70

60

50

40

30

20

10

0

C
a
s
e
s

2012

2014

2016

2018

2020

RR/MDR-TB cases and percentage of RR/MDR-TB cases by previous 
treatment history among all TB cases, 2011–2020

Treatment outcome, new culture-confirmed pulmonary TB cases, 
2010–2019

New
Retreatment
Total number of RR/MDR-TB

Unknown

Success
Died

Still on treatment
Lost to follow-up

Failed
Not evaluated

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

2

1

C
a
s
e
s

2012

2014

2016

2018

0

2020

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

2011

2013

2015

2017

2019

133

Tuberculosis surveillance and monitoring in Europe 2022SURVEILLANCE REPORT 
 
Czechia

Total population at 9 April 2021 by EUROSTAT: 10 693 939

TB cases, 2020

Notifications

Total number of cases
Notification rate per 100 000
Newa and relapse
Newa and relapse notification rate 
per 100 000
Pulmonary
  of which microscopy-positive
  of which laboratory-confirmed
Laboratory-confirmed TB cases
Mean age of new native TB cases
Mean age of new foreign TB cases
Foreign origin of all TB cases
New (not previously treated)

Drug resistance surveillance and TB/HIV 
coinfection, 2020

Completeness of DRS dataa
Completeness of HIV datab
Case-linked data-reporting
Cases with DST results
Estimated RR-TB among notified 
bacteriologically confirmed pulmonary 
TB cases N, best [low–high]
Pulmonary RR/MDR-TB cases notified
  of which pre-XDR-TB cases
Notified RR/MDR-TB
  of which pre-XDR-TB cases
TB cases tested for HIV
HIV-positive TB cases
  of these on ART

Yes
Yes
Yes

  257

(90.2%)

13

[6–20]

11
4
11
4
  201
7
–

(4.7%)
(57.1%)
–
(36.4%)
(54.8%)
(3.5%)
–

 367
3.4
360

3.4

  321
  166
  254
  285

(87.5%)
(51.7%)
(79.1%)
(77.7%)

57.1 years
40.2 years

  126
  351

(34.3%)
(95.6%)

Estimates
Estimated new and relapse cases N, best 
[low–high]

410

[350–480]

a National coverage 100% or culturing ≥ 90%, C+/all TB 
cases > 50%, DST done for C+ > 75%, EQA ≥ 95%.
b More than 50% of TB cases with reported HIV status.

a Cases with unknown previous TB history included in new cases.

Treatment outcome monitoring

Geographical 
coverage

Outcome cohort

Case-linked 
data-reporting
Cases notified
Success
Died
Failed
Lost to follow-up
Still on treatment
Not evaluated

National

New culture-positive 
pulmonary TB cases 
notified in 2019a

All RR/MDR-TB cases 
notified in 2018b

Yes

  335

  235
40
1
40
12
7

(70.1%)
(11.9%)
(0.3%)
(11.9%)
(3.6%)
(2.1%)

–

12

(33.3%)
(8.3%)
(0.0%)
(33.3%)
(8.3%)
(16.7%)

4
1
0
4
1
2

a Treatment outcome as presented is treatment outcome after 12 months.
b Treatment outcome as presented is treatment outcome after 24 months.

TB notification rates by previous treatment history, 2011–2020

New and relapse
Other 

Unknown
Total

New and relapse TB cases – notification rates by age group, 
2011–2020

0–14

15–44

45–64

> 64

0
0
0
0
0
1
/
s
e
s
a
C

7

6

5

4

3

2

1

0

2012

2014

2016

2018

2020

0
0
0
0
0
1
/
s
e
s
a
C

14

12

10

8

6

4

2

0

2012

2014

2016

2018

2020

TB cases by geographical origin, 2011–2020

TB/HIV coinfection, 2011–2020

Native

Foreign origin

Unknown

HIV testing coverage
Proportion of HIV-positive TB cases among tested

All TB cases

s
e
s
a
C

600

500

400

300

200

100

0

2012

2014

2016

2018

2020

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

700

600

500

400

300

200

100

C
a
s
e
s

2012

2014

2016

2018

0

2020

RR/MDR-TB cases and percentage of RR/MDR-TB cases by previous 
treatment history among all TB cases, 2011–2020

Treatment outcome, new culture-confirmed pulmonary TB cases, 
2010–2019

New
Retreatment
Total number of RR/MDR-TB

Unknown

Success
Died

Still on treatment
Lost to follow-up

Failed
Not evaluated

14

12

10

8

6

4

2

0

C
a
s
e
s

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

2012

2014

2016

2018

2020

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

134

2011

2013

2015

2017

2019

SURVEILLANCE REPORTTuberculosis surveillance and monitoring in Europe 2022 
 
Denmark

Total population at 9 April 2021 by EUROSTAT: 5 822 763

TB cases, 2020

Notifications

Total number of cases
Notification rate per 100 000
Newa and relapse
Newa and relapse notification rate 
per 100 000
Pulmonary
  of which microscopy-positive
  of which laboratory-confirmed
Laboratory-confirmed TB cases
Mean age of new native TB cases
Mean age of new foreign TB cases
Foreign origin of all TB cases
New (not previously treated)
Estimates
Estimated new and relapse cases N, best 
[low–high]

221
3.8
207

3.6

160
76
134
180

(72.4%)
(47.5%)
(83.8%)
(81.4%)

48.7 years
40.6 years

159
207

(71.9%)
(93.7%)

280

[240–320]

a Cases with unknown previous TB history included in new cases.

Drug resistance surveillance and TB/HIV 
coinfection, 2020

Completeness of DRS dataa
Completeness of HIV datab
Case-linked data-reporting
Cases with DST results
Estimated RR-TB among notified 
bacteriologically confirmed 
pulmonary TB cases N, best 
[low–high]
Pulmonary RR/MDR-TB cases notified
  of which pre-XDR-TB cases
Notified RR/MDR-TB
  of which pre-XDR-TB cases
TB cases tested for HIV
HIV-positive TB cases
  of these on ART

Yes
Yes
Yes

179

(99.4%)

2

[0–5]

2
0
2
0
168
4
–

(1.5%)
(0.0%)
–
(0.0%)
(76.0%)
(2.4%)
–

a National coverage 100% or culturing ≥ 90%, C+/all TB cases  
> 50%, DST done for C+ > 75%, EQA ≥ 95%.
b More than 50% of TB cases with reported HIV status.

Treatment outcome monitoring

Geographical 
coverage

Outcome cohort

Case-linked 
data-reporting
Cases notified
Success
Died
Failed
Lost to follow-up
Still on treatment
Not evaluated

National

New culture-positive 
pulmonary TB cases 
notified in 2019a

All RR/MDR-TB cases 
notified in 2018b

Yes

170

77
1
0
1
3
88

(45.3%)
(0.6%)
(0.0%)
(0.6%)
(1.8%)
(51.8%)

–

4

(0.0%)
(0.0%)
(0.0%)
(0.0%)
(0.0%)
(100.0%)

0
0
0
0
0
4

a Treatment outcome as presented is treatment outcome after 12 months.
b Treatment outcome as presented is treatment outcome after 24 months.

TB notification rates by previous treatment history, 2011–2020

New and relapse
Other

Unknown
Total

New and relapse TB cases – notification rates by age group, 
2011–2020

0–14

15–44

45–64

> 64

0
0
0
0
0
1
/
s
e
s
a
C

8

7

6

5

4

3

2

1

0

2012

2014

2016

2018

2020

0
0
0
0
0
1
/
s
e
s
a
C

10

8

6

4

2

0

2012

2014

2016

2018

2020

TB cases by geographical origin, 2011–2020

TB/HIV coinfection, 2011–2020

Native

Foreign origin

Unknown

HIV testing coverage
Proportion of HIV-positive TB cases among tested

All TB cases

s
e
s
a
C

300

250

200

150

100

50

0

2012

2014

2016

2018

2020

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

450
400
350
300
250
200
150
100
50
0

C
a
s
e
s

2012

2014

2016

2018

2020

RR/MDR-TB cases and percentage of RR/MDR-TB cases by previous 
treatment history among all TB cases, 2011–2020

Treatment outcome, new culture-confirmed pulmonary TB cases, 
2010–2019

New
Retreatment
Total number of RR/MDR-TB

Unknown

Success
Died

Still on treatment
Lost to follow-up

Failed
Not evaluated

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

7

6

5

4

3

2

1

0

C
a
s
e
s

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

2012

2014

2016

2018

2020

2011

2013

2015

2017

2019

135

Tuberculosis surveillance and monitoring in Europe 2022SURVEILLANCE REPORT 
 
Estonia

Total population at 9 April 2021 by EUROSTAT: 1 328 976

TB cases, 2020

Notifications

Total number of cases
Notification rate per 100 000
Newa and relapse
Newa and relapse notification rate 
per 100 000
Pulmonary
  of which microscopy-positive
  of which laboratory-confirmed
Laboratory-confirmed TB cases
Mean age of new native TB cases
Mean age of new foreign TB cases
Foreign origin of all TB cases
New (not previously treated)
Estimates
Estimated new and relapse cases N, best 
[low–high]

124
9.3
120

9.0

115
54
100
107

(92.7%)
(47.0%)
(87.0%)
(86.3%)

53.9 years
60.1 years

36
109

(29.0%)
(87.9%)

140

[120–160]

a Cases with unknown previous TB history included in new cases.

Drug resistance surveillance and TB/HIV 
coinfection, 2020

Completeness of DRS dataa
Completeness of HIV datab
Case-linked data-reporting
Cases with DST results
Estimated RR-TB among notified 
bacteriologically confirmed 
pulmonary TB cases N, best 
[low–high]
Pulmonary RR/MDR-TB cases notified
  of which pre-XDR-TB cases
Notified RR/MDR-TB
  of which pre-XDR-TB cases
TB cases tested for HIV
HIV-positive TB cases
  of these on ART

Yes
Yes
Yes

105

(98.1%)

22

[14–30]

19
6
19
6
116
13
11

(19.4%)
(31.6%)
–
(31.6%)
(93.5%)
(11.2%)
(84.6%)

a National coverage 100% or culturing ≥ 90%, C+/all TB cases  
> 50%, DST done for C+ > 75%, EQA ≥ 95%.
b More than 50% of TB cases with reported HIV status.

Treatment outcome monitoring

Geographical 
coverage

Outcome cohort

Case-linked 
data-reporting
Cases notified
Success
Died
Failed
Lost to follow-up
Still on treatment
Not evaluated

National

New culture-positive 
pulmonary TB cases 
notified in 2019a

All RR/MDR-TB cases 
notified in 2018b

Yes

100

68
15
0
1
14
2

(68.0%)
(15.0%)
(0.0%)
(1.0%)
(14.0%)
(2.0%)

–

32

23
5
0
1
1
2

(71.9%)
(15.6%)
(0.0%)
(3.1%)
(3.1%)
(6.3%)

a Treatment outcome as presented is treatment outcome after 12 months.
b Treatment outcome as presented is treatment outcome after 24 months.

TB notification rates by previous treatment history, 2011–2020

New and relapse
Other

Unknown
Total

New and relapse TB cases – notification rates by age group, 
2011–2020

0–14

15–44

45–64

> 64

0
0
0
0
0
1
/
s
e
s
a
C

30

25

20

15

10

5

0

2012

2014

2016

2018

2020

0
0
0
0
0
1
/
s
e
s
a
C

50

40

30

20

10

0

2012

2014

2016

2018

2020

TB cases by geographical origin, 2011–2020

TB/HIV coinfection, 2011–2020

Native

Foreign origin

Unknown

HIV testing coverage
Proportion of HIV-positive TB cases among tested

All TB cases

s
e
s
a
C

350

300

250

200

150

100

50

0

2012

2014

2016

2018

2020

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

500

400

300

200

100

C
a
s
e
s

2012

2014

2016

2018

0

2020

RR/MDR-TB cases and percentage of RR/MDR-TB cases by previous 
treatment history among all TB cases, 2011–2020

Treatment outcome, new culture-confirmed pulmonary TB cases, 
2010–2019

New
Retreatment
Total number of RR/MDR-TB

Unknown

Success
Died

Still on treatment
Lost to follow-up

Failed
Not evaluated

90

60

30

C
a
s
e
s

2012

2014

2016

2018

0

2020

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

136

2011

2013

2015

2017

2019

SURVEILLANCE REPORTTuberculosis surveillance and monitoring in Europe 2022 
 
Finland

Total population at 9 April 2021 by EUROSTAT: 5 525 292

TB cases, 2020

Notifications

Total number of cases
Notification rate per 100 000
Newa and relapse
Newa and relapse notification rate 
per 100 000
Pulmonary
  of which microscopy-positive
  of which laboratory-confirmed
Laboratory-confirmed TB cases
Mean age of new native TB cases
Mean age of new foreign TB cases
Foreign origin of all TB cases
New (not previously treated)
Estimates
Estimated new and relapse cases N, best 
[low–high]

174
3.1
174

3.1

118
32
103
141

(67.8%)
(27.1%)
(87.3%)
(81.0%)

71.1 years
40.7 years

66
169

(37.9%)
(97.1%)

200

[170–230]

a Cases with unknown previous TB history included in new cases.

Drug resistance surveillance and TB/HIV 
coinfection, 2020

Completeness of DRS dataa
Completeness of HIV datab
Case-linked data-reporting
Cases with DST results
Estimated RR-TB among notified 
bacteriologically confirmed 
pulmonary TB cases N, best 
[low–high]
Pulmonary RR/MDR-TB cases notified
  of which pre-XDR-TB cases
Notified RR/MDR-TB
  of which pre-XDR-TB cases
TB cases tested for HIV
HIV-positive TB cases
  of these on ART

Yes
No
Yes

  138

(97.9%)

2

0
0
1
0
–
–
–

[0–4]

(0.0%)
(0.0%)
–
(0.0%)
–
–
–

a National coverage 100% or culturing ≥ 90%, C+/all TB cases  
> 50%, DST done for C+ > 75%, EQA ≥ 95%.
b More than 50% of TB cases with reported HIV status.

Treatment outcome monitoring

Geographical 
coverage

Outcome cohort

Case-linked 
data-reporting
Cases notified
Success
Died
Failed
Lost to follow-up
Still on treatment
Not evaluated

National

New culture-positive 
pulmonary TB cases 
notified in 2019a

All RR/MDR-TB cases 
notified in 2018b

Yes

  126

73
0
0
3
4
46

(57.9%)
(0.0%)
(0.0%)
(2.4%)
(3.2%)
(36.5%)

–

4

(50.0%)
(0.0%)
(0.0%)
(0.0%)
(0.0%)
(50.0%)

2
0
0
0
0
2

a Treatment outcome as presented is treatment outcome after 12 months.
b Treatment outcome as presented is treatment outcome after 24 months.

TB notification rates by previous treatment history, 2011–2020

New and relapse
Other

Unknown
Total

New and relapse TB cases – notification rates by age group, 
2011–2020

0–14

15–44

45–64

> 64

0
0
0
0
0
1
/
s
e
s
a
C

7

6

5

4

3

2

1

0

2012

2014

2016

2018

2020

0
0
0
0
0
1
/
s
e
s
a
C

18
16
14
12
10
8
6
4
2
0

2012

2014

2016

2018

2020

TB cases by geographical origin, 2011–2020

TB/HIV coinfection, 2011–2020

Native

Foreign origin

Unknown

Data not reported

s
e
s
a
C

250

200

150

100

50

0

2012

2014

2016

2018

2020

RR/MDR-TB cases and percentage of RR/MDR-TB cases by previous 
treatment history among all TB cases, 2011–2020

Treatment outcome, new culture-confirmed pulmonary TB cases, 
2010–2019

New
Retreatment
Total number of RR/MDR-TB

Unknown

Success
Died

Still on treatment
Lost to follow-up

Failed
Not evaluated

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

9
8
7
6
5
4
3
2
1
0

C
a
s
e
s

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

2012

2014

2016

2018

2020

2011

2013

2015

2017

2019

137

Tuberculosis surveillance and monitoring in Europe 2022SURVEILLANCE REPORT 
 
France

Total population at 9 April 2021 by EUROSTAT: 67 320 216

TB cases, 2020

Notifications

Total number of cases
Notification rate per 100 000
Newa and relapse
Newa and relapse notification rate 
per 100 000
Pulmonary
  of which microscopy-positive
  of which laboratory-confirmed
Laboratory-confirmed TB cases
Mean age of new native TB cases
Mean age of new foreign TB cases
Foreign origin of all TB cases
New (not previously treated)
Estimates
Estimated new and relapse cases N, 
best [low–high]

4 606
6.8
4 398

6.5

3 140
1 439
1 388
1 879

(68.2%)
–
(44.2%)
(40.8%)

46.3 years
37.4 years

2 719
2 288

(59.0%)
(49.7%)

5 300

[4 700–6 000]

a Cases with unknown previous TB history included in new cases.

Drug resistance surveillance and TB/HIV 
coinfection, 2020

Completeness of DRS dataa
Completeness of HIV datab
Case-linked data-reporting
Cases with DST results
Estimated RR-TB among notified 
bacteriologically confirmed 
pulmonary TB cases N, best 
[low–high]
Pulmonary RR/MDR-TB cases notified
  of which pre-XDR-TB cases
Notified RR/MDR-TB
  of which pre-XDR-TB cases
TB cases tested for HIV
HIV-positive TB cases
  of these on ART

Yes
No
No

67

32

47
8
66
8
–
–
–

(1.5%)

[23–41]

(100.0%)
(19.5%)
–
(12.1%)
–
–
–

a National coverage 100% or culturing ≥ 90%, C+/all TB cases  
> 50%, DST done for C+ > 75%, EQA ≥ 95%.
b More than 50% of TB cases with reported HIV status.

Treatment outcome monitoring

Geographical 
coverage

Outcome cohort

Case-linked 
data-reporting
Cases notified
Success
Died
Failed
Lost to follow-up
Still on treatment
Not evaluated

National

New culture-positive 
pulmonary TB cases 
notified in 2019a

All RR/MDR-TB cases 
notified in 2018b

Yes

  726

  129
  15
0
6
4
572

(17.8%)
(2.1%)
(0.0%)
(0.8%)
(0.6%)
(78.8%)

–

82

3
1
0
1
0
77

(3.7%)
(1.2%)
(0.0%)
(1.2%)
(0.0%)
(93.9%)

a Treatment outcome as presented is treatment outcome after 12 months.
b Treatment outcome as presented is treatment outcome after 24 months.

TB notification rates by previous treatment history, 2011–2020

New and relapse
Other

Unknown
Total

New and relapse TB cases – notification rates by age group, 
2011–2020

0–14

15–44

45–64

> 64

0
0
0
0
0
1
/
s
e
s
a
C

10

8

6

4

2

0

2012

2014

2016

2018

2020

0
0
0
0
0
1
/
s
e
s
a
C

8

7

6

5

4

3

2

1

0

2012

2014

2016

2018

2020

TB cases by geographical origin, 2011–2020

TB/HIV coinfection, 2011–2020

s
e
s
a
C

3500

3000

2500

2000

1500

1000

500

0

Native

Foreign origin

Unknown

2012

2014

2016

2018

2020

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

HIV testing coverage
Proportion of HIV-positive TB cases among tested
7000

All TB cases

6000

5000

4000

3000

2000

1000

C
a
s
e
s

2012

2014

2016

2018

0

2020

RR/MDR-TB cases and percentage of RR/MDR-TB cases by previous 
treatment history among all TB cases, 2011–2020

Treatment outcome, new culture-confirmed pulmonary TB cases, 
2010–2019

New
Retreatment
Total number of RR/MDR-TB

Unknown

Success
Died

Still on treatment
Lost to follow-up

Failed
Not evaluated

120

100

80

60

40

20

0

C
a
s
e
s

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

2012

2014

2016

2018

2020

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

138

2011

2013

2015

2017

2019

SURVEILLANCE REPORTTuberculosis surveillance and monitoring in Europe 2022 
 
Georgia

Total population estimate 2020 by United Nations Statistical Database: 3 989 175

TB cases, 2020

Notifications

Total number of cases
Notification rate per 100 000
Newa and relapse
Newa and relapse notification rate 
per 100 000
Pulmonary
  of which microscopy-positive
  of which laboratory-confirmed
Laboratory-confirmed TB cases
Mean age of new native TB cases
Mean age of new foreign TB cases
Foreign origin of all TB cases
New (not previously treated)
Estimates
Estimated new and relapse cases 
N, best [low–high]

 1 842
46.2
 1 671

41.9

 1 475

(80.1%)

 1 370
–

–
–
 1 484

(92.9%)
–
42.9 years
–
–
(80.6%)

2 800

[2 300–3 300]

a Cases with unknown previous TB history included in new cases.

Drug resistance surveillance and TB/HIV 
coinfection, 2020

Completeness of DRS dataa
Completeness of HIV datab
Case-linked data-reporting
Cases with DST results
Estimated RR-TB among notified 
bacteriologically confirmed 
pulmonary TB cases N, best 
[low–high]
Pulmonary RR/MDR-TB cases 
notified
  of which pre-XDR-TB cases
Notified RR/MDR-TB
  of which pre-XDR-TB cases
TB cases tested for HIV
HIV-positive TB cases
  of these on ART

Yes
Yes
Yes

1 355

(98.9%)

190

[170–220]

191

(14.1%)

50
202
52
1 493
29
29

(28.9%)
–
(25.7%)
(89.3%)
(1.9%)
(100.0%)

a National coverage 100% or culturing ≥ 90%, C+/all TB 
cases > 50%, DST done for C+ > 75%, EQA ≥ 95%.
b More than 50% of TB cases with reported HIV status.

Treatment outcome monitoring

Geographical 
coverage

Outcome cohort

Case-linked 
data-reporting
Cases notified
Success
Died
Failed
Lost to follow-up
Not evaluated

National

New and relapse 
TB cases notified 
in 2019a

RR/MDR-TB cases 
enrolled into DR-TB 
treatment in  2018b

Yes

1 947

–

230

1 659
74
46
97
71

(85.2%)
(3.8%)
(2.4%)
(5.0%)
(3.6%)

155
13
13
34
15

(67.4%)
(5.7%)
(5.7%)
(14.8%)
(6.5%)

a Treatment outcome as presented is treatment outcome after 12 months.
b Treatment outcome as presented is treatment outcome after 24 months.

TB notification rates by previous treatment history, 2011–2020

New and relapse
Other

Unknown
Total

New and relapse TB cases – notification rates by age group, 
2011–2020 

0–14

15–44

45–64

> 64

0
0
0
0
0
1
/
s
e
s
a
C

160

140

120

100

80

60

40

20

0

2012

2014

2016

2018

2020

0
0
0
0
0
1
/
s
e
s
a
C

180
160
140
120
100
80
60
40
20
0

2012

2014

2016

2018

2020

Note: starting from 2013 onward, cases with unknown history are included in new and 
relapses. 

Note: data up to 2012 include new TB cases only. 

TB cases by geographical origin, 2011–2020

TB/HIV coinfection, 2011–2020

s
e
s
a
C

7000

6000

5000

4000

3000

2000

1000

0

Native

Foreign origin

Unknown

2012

2014

2016

2018

2020

e
g
a
t
n
e
c
r
e
P

100
90
80
70
60
50
40
30
20
10
0

HIV testing coverage
Proportion of HIV-positive TB cases among tested
7000

TB cases

6000

5000

4000

3000

2000

1000

C
a
s
e
s

2012

2014

2016

2018

0

2020

RR/MDR-TB cases and percentage of RR/MDR-TB cases by previous 
treatment history among all TB cases, 2011–2020

Treatment outcome, new and relapse TB cases, 2010–2019

New
Retreatment
Total number of RR/MDR-TB

Unknown

Success
Died

Failed
Lost to follow-up

Not evaluated

Note: data up to 2014 include all TB cases.

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

500
450
400
350
300
250
200
150
100
50
0

C
a
s
e
s

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

2012

2014

2016

2018

2020

2011

2013

2015

2017

2019

Note: 2010–2011 cohorts include new cases only.

139

Tuberculosis surveillance and monitoring in Europe 2022SURVEILLANCE REPORT 
 
Germany

Total population at 9 April 2021 by EUROSTAT: 83 166 711

TB cases, 2020

Notifications

Total number of cases
Notification rate per 100 000
Newa and relapse
Newa and relapse notification rate 
per 100 000
Pulmonary
  of which microscopy-positive
  of which laboratory-confirmed
Laboratory-confirmed TB cases
Mean age of new native TB cases
Mean age of new foreign TB cases
Foreign origin of all TB cases
New (not previously treated)
Estimates
Estimated new and relapse cases N, 
best [low–high]

 4 127
5.0
 4 010

4.8

 2 903
 1 547
 2 468
 3 259

(70.3%)
(53.3%)
(85.0%)
(79.0%)

52.0 years
37.6 years

 2 817
 2 725

(68.3%)
(66.0%)

4 600

[3 900–5 300]

a Cases with unknown previous TB history included in new cases.

Drug resistance surveillance and TB/HIV 
coinfection, 2020

Completeness of DRS dataa
Completeness of HIV datab
Case-linked data-reporting
Cases with DST results
Estimated RR-TB among notified 
bacteriologically confirmed 
pulmonary TB cases N, best 
[low–high]
Pulmonary RR/MDR-TB cases notified
  of which pre-XDR-TB cases
Notified RR/MDR-TB
  of which pre-XDR-TB cases
TB cases tested for HIV
HIV-positive TB cases
  of these on ART

Yes
No
Yes

2 865

–

92

[46–140]

69
10
94
13
–
–
–

(3.1%)
(21.3%)
–
(13.8%) 
–
–
–

a National coverage 100% or culturing ≥ 90%, C+/all TB cases  
> 50%, DST done for C+ > 75%, EQA ≥ 95%.
b More than 50% of TB cases with reported HIV status.

Treatment outcome monitoring

Geographical 
coverage

Outcome cohort

Case-linked 
data-reporting
Cases notified
Success
Died
Failed
Lost to follow-up
Still on treatment
Not evaluated

National

New culture-positive 
pulmonary TB cases 
notified in 2019a

All RR/MDR-TB cases 
notified in 2018b

Yes

2 009

1 426
174
2
39
63
305

(71.0%)
(8.7%)
(0.1%)
(1.9%)
(3.1%)
(15.2%)

–

134

83
4
1
4
12
30

(61.9%)
(3.0%)
(0.7%)
(3.0%)
(9.0%)
(22.4%)

a Treatment outcome as presented is treatment outcome after 12 months.
b Treatment outcome as presented is treatment outcome after 24 months.

TB notification rates by previous treatment history, 2011–2020

New and relapse
Other 

Unknown
Total

New and relapse TB cases – notification rates by age group, 
2011–2020

0–14

15–44

45–64

> 64

0
0
0
0
0
1
/
s
e
s
a
C

8

7

6

5

4

3

2

1

0

2012

2014

2016

2018

2020

0
0
0
0
0
1
/
s
e
s
a
C

9
8
7
6
5
4
3
2
1
0

2012

2014

2016

2018

2020

TB cases by geographical origin, 2011–2020

TB/HIV coinfection, 2011–2020

Native

Foreign origin

Unknown

Data not reported

5000

4000

s
e
s
a
C

3000

2000

1000

0

2012

2014

2016

2018

2020

RR/MDR-TB cases and percentage of RR/MDR-TB cases by previous 
treatment history among all TB cases, 2011–2020

Treatment outcome, new culture-confirmed pulmonary TB cases, 
2010–2019

New
Retreatment
Total number of RR/MDR-TB

Unknown

Success
Died

Still on treatment
Lost to follow-up

Failed
Not evaluated

140

120

100

80

60

40

20

0

C
a
s
e
s

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

2012

2014

2016

2018

2020

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

140

2011

2013

2015

2017

2019

SURVEILLANCE REPORTTuberculosis surveillance and monitoring in Europe 2022 
 
Greece

Total population at 9 April 2021 by EUROSTAT: 10 718 565

TB cases, 2020

Notifications

Total number of cases
Notification rate per 100 000
Newa and relapse
Newa and relapse notification rate 
per 100 000
Pulmonary
  of which microscopy-positive
  of which laboratory-confirmed
Laboratory-confirmed TB cases
Mean age of new native TB cases
Mean age of new foreign TB cases
Foreign origin of all TB cases
New (not previously treated)
Estimates
Estimated new and relapse cases N, 
best [low–high]

396
3.7
380

3.5

324
206
299
361

240
338

(81.8%)
(63.6%)
(92.3%)
(91.2%)

58.0 years
31.2 years

(60.6%)
(85.4%)

470

[400–550]

a Cases with unknown previous TB history included in new cases.

Drug resistance surveillance and TB/HIV 
coinfection, 2020

Completeness of DRS dataa
Completeness of HIV datab
Case-linked data-reporting
Cases with DST results
Estimated RR-TB among notified 
bacteriologically confirmed 
pulmonary TB cases N, best 
[low–high]
Pulmonary RR/MDR-TB cases notified
  of which pre-XDR-TB cases
Notified RR/MDR-TB
  of which pre-XDR-TB cases
TB cases tested for HIV
HIV-positive TB cases
  of these on ART

Yes
Yes
Yes

348

(96.4%)

6

[0–16]

7
0
12
0
396
17
–

(2.4%)
– 
–
–
(100.0%)
(4.3%)
–

a National coverage 100% or culturing ≥ 90%, C+/all TB cases  
> 50%, DST done for C+ > 75%, EQA ≥ 95%.
b More than 50% of TB cases with reported HIV status.

Treatment outcome monitoring

Geographical 
coverage

Outcome cohort

Case-linked 
data-reporting
Cases notified
Success
Died
Failed
Lost to follow-up
Still on treatment
Not evaluated

National

New culture-positive 
pulmonary TB cases 
notified in 2019a

All RR/MDR-TB cases 
notified in 2018b

Yes

212

–

6

–
–
–
–
–
–

–
–
–
–
–
–

–
–
–
–
–
–

–
–
–
–
–
–

a Treatment outcome as presented is treatment outcome after 12 months.
b Treatment outcome as presented is treatment outcome after 24 months.

TB notification rates by previous treatment history, 2011–2020

New and relapse
Other 

Unknown
Total

New and relapse TB cases – notification rates by age group, 
2011–2020

0–14

15–44

45–64

> 64

0
0
0
0
0
1
/
s
e
s
a
C

6

5

4

3

2

1

0

2012

2014

2016

2018

2020

0
0
0
0
0
1
/
s
e
s
a
C

7

6

5

4

3

2

1

0

2012

2014

2016

2018

2020

TB cases by geographical origin, 2011–2020

TB/HIV coinfection, 2011–2020

Native

Foreign origin

Unknown

HIV testing coverage
Proportion of HIV-positive TB cases among tested

All TB cases

s
e
s
a
C

400

300

200

100

0

2012

2014

2016

2018

2020

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

700

600

500

400

300

200

100

C
a
s
e
s

2012

2014

2016

2018

0

2020

RR/MDR-TB cases and percentage of RR/MDR-TB cases by previous 
treatment history among all TB cases, 2011–2020

Treatment outcome, new culture-confirmed pulmonary TB cases, 
2010–2019

New
Retreatment
Total number of RR/MDR-TB

Unknown

Data not reported

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

14

12

10

8

6

4

2

0

C
a
s
e
s

2012

2014

2016

2018

2020

141

Tuberculosis surveillance and monitoring in Europe 2022SURVEILLANCE REPORT 
 
Hungary

Total population at 9 April 2021 by EUROSTAT: 9 769 526

TB cases, 2020

Notifications

Total number of cases
Notification rate per 100 000
Newa and relapse
Newa and relapse notification rate 
per 100 000
Pulmonary
  of which microscopy-positive
  of which laboratory-confirmed
Laboratory-confirmed TB cases
Mean age of new native TB cases
Mean age of new foreign TB cases
Foreign origin of all TB cases
New (not previously treated)
Estimates
Estimated new and relapse cases N, 
best [low–high]

406
4.2
384

3.9

388
125
196
197

19
359

(95.6%)
(32.2%)
(50.5%)
(48.5%)

52.6 years
34.4 years

(4.7%)
(88.4%)

440

[380–510]

a Cases with unknown previous TB history included in new cases.

Drug resistance surveillance and TB/HIV 
coinfection, 2020

Completeness of DRS dataa
Completeness of HIV datab
Case-linked data-reporting
Cases with DST results
Estimated RR-TB among notified 
bacteriologically confirmed 
pulmonary TB cases N, best 
[low–high]
Pulmonary RR/MDR-TB cases notified
  of which pre-XDR-TB cases
Notified RR/MDR-TB
  of which pre-XDR-TB cases
TB cases tested for HIV
HIV-positive TB cases
  of these on ART

Yes
No
Yes

177

(89.8%)

13

11
0
11
0
18
2
–

[6–21]

(6.3%)
–
– 
–
(4.4%)
(11.1%)
–

a National coverage 100% or culturing ≥ 90%, C+/all TB cases  
> 50%, DST done for C+ > 75%, EQA ≥ 95%.
b More than 50% of TB cases with reported HIV status.

Treatment outcome monitoring

Geographical 
coverage

Outcome cohort

Case-linked 
data-reporting
Cases notified
Success
Died
Failed
Lost to follow-up
Still on treatment
Not evaluated

National

New culture-positive 
pulmonary TB cases 
notified in 2019a

All RR/MDR-TB cases 
notified in 2018b

Yes

255

151
42
6
33
10
13

(59.2%)
(16.5%)
(2.4%)
(12.9%)
(3.9%)
(5.1%)

–

13

(46.2%)
(23.1%)
(0.0%)
(0.0%)
(7.7%)
(23.1%)

6
3
0
0
1
3

a Treatment outcome as presented is treatment outcome after 12 months.
b Treatment outcome as presented is treatment outcome after 24 months.

TB notification rates by previous treatment history, 2011–2020

New and relapse
Other

Unknown
Total

New and relapse TB cases – notification rates by age group, 
2011–2020

0–14

15–44

45–64

> 64

0
0
0
0
0
1
/
s
e
s
a
C

15

12

9

6

3

0

2012

2014

2016

2018

2020

0
0
0
0
0
1
/
s
e
s
a
C

25

20

15

10

5

0

2012

2014

2016

2018

2020

TB cases by geographical origin, 2011–2020

TB/HIV coinfection, 2011–2020

s
e
s
a
C

1500

1200

900

600

300

0

Native

Foreign origin

Unknown

2012

2014

2016

2018

2020

HIV testing coverage
Proportion of HIV-positive TB cases among tested
2000

All TB cases

1600

1200

800

400

C
a
s
e
s

2012

2014

2016

2018

0

2020

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

RR/MDR-TB cases and percentage of RR/MDR-TB cases by previous 
treatment history among all TB cases, 2011–2020

Treatment outcome, new culture-confirmed pulmonary TB cases, 
2010–2019

New
Retreatment
Total number of RR/MDR-TB

Unknown

Success
Died

Still on treatment
Lost to follow-up

Failed
Not evaluated

25

20

15

10

5

0

C
a
s
e
s

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

2012

2014

2016

2018

2020

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

142

2011

2013

2015

2017

2019

SURVEILLANCE REPORTTuberculosis surveillance and monitoring in Europe 2022 
 
Iceland

Total population at 9 April 2021 by EUROSTAT: 364 134

TB cases, 2020

Notifications

Total number of cases
Notification rate per 100 000
Newa and relapse
Newa and relapse notification rate 
per 100 000
Pulmonary
  of which microscopy-positive
  of which laboratory-confirmed
Laboratory-confirmed TB cases
Mean age of new native TB cases
Mean age of new foreign TB cases
Foreign origin of all TB cases
New (not previously treated)
Estimates
Estimated new and relapse cases N, 
best [low–high]

  12
3.3
  12

3.3

(66.7%)
(25.0%)
(62.5%)
(50.0%)

–
–

(91.7%)
(100.0%)

[8–11]

8
2
5
6

11
12

10

a Cases with unknown previous TB history included in new cases.

Drug resistance surveillance and TB/HIV 
coinfection, 2020

Completeness of DRS dataa
Completeness of HIV datab
Case-linked data-reporting
Cases with DST results
Estimated RR-TB among notified 
bacteriologically confirmed 
pulmonary TB cases N, best 
[low–high]
Pulmonary RR/MDR-TB cases notified
  of which pre-XDR-TB cases
Notified RR/MDR-TB
  of which pre-XDR-TB cases
TB cases tested for HIV
HIV-positive TB cases
  of these on ART

Yes
No
Yes

(100.0%)

[0–3]

(0.0%)
–
–
–
–
–
–

6

0

0
0
0
0
–
–
–

a National coverage 100% or culturing ≥ 90%, C+/all TB cases  
> 50%, DST done for C+ > 75%, EQA ≥ 95%.
b More than 50% of TB cases with reported HIV status.

Treatment outcome monitoring

Geographical 
coverage

Outcome cohort

Case-linked 
data-reporting
Cases notified
Success
Died
Failed
Lost to follow-up
Still on treatment
Not evaluated

National

New culture-positive 
pulmonary TB cases 
notified in 2019a

All RR/MDR-TB cases 
notified in 2018b

Yes

4

–

0

4
0
0
0
0
0

(100.0%)
(0.0%)
(0.0%)
(0.0%)
(0.0%)
(0.0%)

–
–
–
–
–
–

–
–
–
–
–
–

a Treatment outcome as presented is treatment outcome after 12 months.
b Treatment outcome as presented is treatment outcome after 24 months.

TB notification rates by previous treatment history, 2011–2020

New and relapse
Other

Unknown
Total

New and relapse TB cases – notification rates by age group, 
2011–2020

0–14

15–44

45–64

> 64

0
0
0
0
0
1
/
s
e
s
a
C

5

4

3

2

1

0

2012

2014

2016

2018

2020

0
0
0
0
0
1
/
s
e
s
a
C

9
8
7
6
5
4
3
2
1
0

2012

2014

2016

2018

2020

TB cases by geographical origin, 2011–2020

TB/HIV coinfection, 2011–2020

Native

Foreign origin

Unknown

HIV testing coverage
Proportion of HIV-positive TB cases among tested

All TB cases

s
e
s
a
C

12

10

8

6

4

2

0

2012

2014

2016

2018

2020

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

15

12

9

6

3

0

C
a
s
e
s

2012

2014

2016

2018

2020

RR/MDR-TB cases and percentage of RR/MDR-TB cases by previous 
treatment history among all TB cases, 2011–2020

Treatment outcome, new culture-confirmed pulmonary TB cases, 
2010–2019

New
Retreatment
Total number of RR/MDR-TB

Unknown

Success
Died

Still on treatment
Lost to follow-up

Failed
Not evaluated

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

2

1

C
a
s
e
s

2012

2014

2016

2018

0

2020

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

2011

2013

2015

2017

2019

143

Tuberculosis surveillance and monitoring in Europe 2022SURVEILLANCE REPORT 
 
Ireland

Total population at 9 April 2021 by EUROSTAT: 4 964 440

TB cases, 2020

Notifications

Total number of cases
Notification rate per 100 000
Newa and relapse
Newa and relapse notification rate 
per 100 000
Pulmonary
  of which microscopy-positive
  of which laboratory-confirmed
Laboratory-confirmed TB cases
Mean age of new native TB cases
Mean age of new foreign TB cases
Foreign origin of all TB cases
New (not previously treated)
Estimates
Estimated new and relapse cases N, 
best [low–high]

240
4.8
229

4.6

126
51
103
170

108
114

(52.5%)
(40.5%)
(81.7%)
(70.8%)

57.8 years
35.6 years

(45.0%)
(47.5%)

260

[230–300]

a Cases with unknown previous TB history included in new cases.

Drug resistance surveillance and TB/HIV 
coinfection, 2020

Completeness of DRS dataa
Completeness of HIV datab
Case-linked data-reporting
Cases with DST results
Estimated RR-TB among notified 
bacteriologically confirmed 
pulmonary TB cases N, best 
[low–high]
Pulmonary RR/MDR-TB cases notified
  of which pre-XDR-TB cases
Notified RR/MDR-TB
  of which pre-XDR-TB cases
TB cases tested for HIV
HIV-positive TB cases
  of these on ART

Yes
No
Yes

101

(59.4%)

1

0
0
1
0
84
3
–

[0–5]

(0.0%)
–
– 
(0.0%)
(35.0%)
(3.6%)
–

a National coverage 100% or culturing ≥ 90%, C+/all TB cases  
> 50%, DST done for C+ > 75%, EQA ≥ 95%.
b More than 50% of TB cases with reported HIV status.

Treatment outcome monitoring

Geographical 
coverage

Outcome cohort

Case-linked 
data-reporting
Cases notified
Success
Died
Failed
Lost to follow-up
Still on treatment
Not evaluated

National

New culture-positive 
pulmonary TB cases 
notified in 2019a

All RR/MDR-TB cases 
notified in 2018b

Yes

98

5
3
0
0
0
90

(5.1%)
(3.1%)
(0.0%)
(0.0%)
(0.0%)
(91.8%)

–

8

(12.5%)
(12.5%)
(0.0%)
(12.5%)
(0.0%)
(62.5%)

1
1
0
1
0
5

a Treatment outcome as presented is treatment outcome after 12 months.
b Treatment outcome as presented is treatment outcome after 24 months.

TB notification rates by previous treatment history, 2011–2020

New and relapse
Other

Unknown
Total

New and relapse TB cases – notification rates by age group, 
2011–2020

0–14

15–44

45–64

> 64

0
0
0
0
0
1
/
s
e
s
a
C

10

8

6

4

2

0

2012

2014

2016

2018

2020

0
0
0
0
0
1
/
s
e
s
a
C

10

8

6

4

2

0

2012

2014

2016

2018

2020

TB cases by geographical origin, 2011–2020

TB/HIV coinfection, 2011–2020

Native

Foreign origin

Unknown

HIV testing coverage
Proportion of HIV-positive TB cases among tested

All TB cases

s
e
s
a
C

250

200

150

100

50

0

2012

2014

2016

2018

2020

e
g
a
t
n
e
c
r
e
P

100

75

50

25

0

450
400
350
300
250
200
150
100
50
0

C
a
s
e
s

2012

2014

2016

2018

2020

RR/MDR-TB cases and percentage of RR/MDR-TB cases by previous 
treatment history among all TB cases, 2011–2020

Treatment outcome, new culture-confirmed pulmonary TB cases, 
2010–2019

New
Retreatment
Total number of RR/MDR-TB

Unknown

Success
Died

Still on treatment
Lost to follow-up

Failed
Not evaluated

8
7
6
5
4
3
2
1
0

C
a
s
e
s

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

2012

2014

2016

2018

2020

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

144

2011

2013

2015

2017

2019

SURVEILLANCE REPORTTuberculosis surveillance and monitoring in Europe 2022 
 
Israel

Total population estimate 2020 by United Nations Statistical Database: 8 655 541

TB cases, 2020

Notifications

Total number of cases
Notification rate per 100 000
Newa and relapse
Newa and relapse notification rate 
per 100 000
Pulmonary
  of which microscopy-positive
  of which laboratory-confirmed
Laboratory-confirmed TB cases
Mean age of new native TB cases
Mean age of new foreign TB cases
Foreign origin of all TB cases
New (not previously treated)
Estimates
Estimated new and relapse cases N, 
best [low–high]

  158
1.8
  158

1.8

113

90
–

134
156

(71.5%)

(79.6%)
–
44.6 years
–

(84.8%)
(98.7%)

180

[160–210]

Drug resistance surveillance and TB/HIV 
coinfection, 2020

Completeness of DRS dataa
Completeness of HIV datab
Case-linked data-reporting
Cases with DST results
Estimated RR-TB among notified 
bacteriologically confirmed 
pulmonary TB cases N, best 
[low–high]
Pulmonary RR/MDR-TB cases 
notified
  of which pre-XDR-TB cases
Notified RR/MDR-TB
  of which pre-XDR-TB cases
TB cases tested for HIV
HIV-positive TB cases
  of these on ART

Yes
Yes
Yes

90

(100.0%)

5

5

1
5
1
158
15
15

[1–9]

(5.6%)

(20.0%)
–
(20.0%)
(100.0%)
(9.5%)
(100.0%)

Treatment outcome monitoring

Geographical 
coverage

Outcome cohort

Case-linked 
data-reporting
Cases notified
Success
Died
Failed
Lost to follow-up
Not evaluated

National

New and relapse 
TB cases notified 
in 2019a

RR/MDR-TB cases 
enrolled into DR-TB 
treatment in  2018b

Yes

217

182
14
2
6
13

(83.9%)
(6.5%)
(0.9%)
(2.8%)
(6.0%)

–

14

9
2
0
2
1

(64.3%)
(14.3%)
(0.0%)
(14.3%)
(7.1%)

a Treatment outcome as presented is treatment outcome after 12 months.
b Treatment outcome as presented is treatment outcome after 24 months.

a Cases with unknown previous TB history included in new cases.

a National coverage 100% or culturing ≥ 90%, C+/all TB 
cases > 50%, DST done for C+ > 75%, EQA ≥ 95%.
b More than 50% of TB cases with reported HIV status.

TB notification rates by previous treatment history, 2011–2020

New and relapse
Other

Unknown
Total

New and relapse TB cases – notification rates by age group, 
2011–2020

0–14

15–44

45–64

> 64

0
0
0
0
0
1
/
s
e
s
a
C

8

7

6

5

4

3

2

1

0

2012

2014

2016

2018

2020

0
0
0
0
0
1
/
s
e
s
a
C

12

10

8

6

4

2

0

2012

2014

2016

2018

2020

Note: cases with unknown previous treatment included with new and relapse cases.

Note: data up to 2012 include new TB cases only. 

TB cases by geographical origin, 2011–2020

TB/HIV coinfection, 2011–2020

Native

Foreign origin

Unknown

HIV testing coverage
Proportion of HIV-positive TB cases among tested

TB cases

s
e
s
a
C

500

400

300

200

100

0

2012

2014

2016

2018

2020

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

600

500

400

300

200

100

C
a
s
e
s

2012

2014

2016

2018

0

2020

RR/MDR-TB cases and percentage of RR/MDR-TB cases by previous 
treatment history among all TB cases, 2011–2020

Treatment outcome, new and relapse TB cases, 2010–2019

New
Retreatment
Total number of RR/MDR-TB

Unknown

Success
Died

Failed
Lost to follow-up

Not evaluated

Note: data up to 2014 includes all TB cases.

e
g
a
t
n
e
c
r
e
P

120

100

80

60

40

20

0

18
16
14
12
10
8
6
4
2
0

C
a
s
e
s

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

2012

2014

2016

2018

2020

2011

2013

2015

2017

2019

Note: 2010–2011 cohorts include new cases only.

145

Tuberculosis surveillance and monitoring in Europe 2022SURVEILLANCE REPORT 
 
Italy

Total population at 9 April 2021 by EUROSTAT: 59 641 488

TB cases, 2020

Notifications

Total number of cases
Notification rate per 100 000
Newa and relapse
Newa and relapse notification rate 
per 100 000
Pulmonary
  of which microscopy-positive
  of which laboratory-confirmed
Laboratory-confirmed TB cases
Mean age of new native TB cases
Mean age of new foreign TB cases
Foreign origin of all TB cases
New (not previously treated)
Estimates
Estimated new and relapse cases N, 
best [low–high]

 2 287
3.8
 2 163

3.6

 1 643
  725
  0
 1 490

(71.8%)
(44.1%)
(0.0%)
(65.2%)

53.3 years
36.9 years

 1 273
 1 597

(55.7%)
(69.8%)

4 000

[3 400–4 600]

a Cases with unknown previous TB history included in new cases.

Drug resistance surveillance and TB/HIV 
coinfection, 2020

Completeness of DRS dataa
Completeness of HIV datab
Case-linked data-reporting
Cases with DST results
Estimated RR-TB among notified 
bacteriologically confirmed 
pulmonary TB cases N, best 
[low–high]
Pulmonary RR/MDR-TB cases notified
  of which pre-XDR-TB cases
Notified RR/MDR-TB
  of which pre-XDR-TB cases
TB cases tested for HIV
HIV-positive TB cases
  of these on ART

No
No
No

 1 009

(67.7%)

42

[31–53]

  39
  8
  39
–
–
–
–

(3.3%)
(21.6%)
–
–
–
–
–

a National coverage 100% or culturing ≥ 90%, C+/all TB cases  
> 50%, DST done for C+ > 75%, EQA ≥ 95%.
b More than 50% of TB cases with reported HIV status.
c Cases with unknown previous TB treatment history included 
in new cases.

Treatment outcome monitoring

Geographical 
coverage

Outcome cohort

Case-linked 
data-reporting
Cases notified
Success
Died
Failed
Lost to follow-up
Still on treatment
Not evaluated

National

New culture-positive 
pulmonary TB cases 
notified in 2019a

All RR/MDR-TB cases 
notified in 2018b

Yes

1 534

–

49

–
–
–
–
–
–

–
–
–
–
–
–

–
–
–
–
–
–

–
–
–
–
–
–

a Treatment outcome as presented is treatment outcome after 12 months.
b Treatment outcome as presented is treatment outcome after 24 months.

TB notification rates by previous treatment history, 2011–2020

New and relapse
Other

Unknown
Total

New and relapse TB cases – notification rates by age group, 
2011–2020

0–14

15–44

45–64

> 64

0
0
0
0
0
1
/
s
e
s
a
C

9
8
7
6
5
4
3
2
1
0

2012

2014

2016

2018

2020

0
0
0
0
0
1
/
s
e
s
a
C

4

3

2

1

0

2012

2014

2016

2018

2020

TB cases by geographical origin, 2011–2020

TB/HIV coinfection, 2011–2020

Native

Foreign origin

Unknown

Data not reported

s
e
s
a
C

3000

2500

2000

1500

1000

500

0

2012

2014

2016

2018

2020

RR/MDR-TB cases and percentage of RR/MDR-TB cases by previous 
treatment history among all TB cases, 2011–2020

Treatment outcome, new culture-confirmed pulmonary TB cases, 
2010–2019

New
Retreatment
Total number of RR/MDR-TB

Unknown

Data not reported

100

80

60

40

20

C
a
s
e
s

2012

2014

2016

2018

0

2020

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

146

SURVEILLANCE REPORTTuberculosis surveillance and monitoring in Europe 2022 
 
Kazakhstan

Total population estimate 2020 by United Nations Statistical Database: 18 776 707

TB cases, 2020

Notifications

Total number of cases
Notification rate per 100 000
Newa and relapse
Newa and relapse notification rate 
per 100 000
Pulmonary
  of which microscopy-positive
  of which laboratory-confirmed
Laboratory-confirmed TB cases
Mean age of new native TB cases
Mean age of new foreign TB cases
Foreign origin of all TB cases
New (not previously treated)
Estimates
Estimated new and relapse cases N, 
best [low–high]

 10 020
53.4
 9 603

51.1

 9 051
–
 7 084
–

(90.3%)
–
(78.3%)
–
42.9 years
–

178
 6 934

(1.8%)
(69.2%)

13 000

[8 400–19 000]

a Cases with unknown previous TB history included in new cases.

Drug resistance surveillance and TB/HIV 
coinfection, 2020

Completeness of DRS dataa
Completeness of HIV datab
Case-linked data-reporting
Cases with DST results
Estimated RR-TB among notified 
bacteriologically confirmed 
pulmonary TB cases N, best 
[low–high]
Pulmonary RR/MDR-TB cases 
notified
  of which pre-XDR-TB cases
Notified RR/MDR-TB
  of which pre-XDR-TB cases
TB cases tested for HIV
HIV-positive TB cases
  of these on ART

No
Yes
Yes

7 074

(99.9%)

2 900

[2 800–2 900]

2 859

399
4 307
1193
9 440
614
592

(40.4%)

(14.0%)
–
(27.7%)
(98.3%)
(6.5%)
(96.4%)

a National coverage 100% or culturing ≥ 90%, C+/all TB 
cases > 50%, DST done for C+ > 75%, EQA ≥ 95%.
b More than 50% of TB cases with reported HIV status.

Treatment outcome monitoring

Geographical 
coverage

Outcome cohort

Case-linked 
data-reporting
Cases notified
Success
Died
Failed
Lost to follow-up
Not evaluated

National

New and relapse 
TB cases notified 
in 2019a

RR/MDR TB cases 
enrolled into DR-TB 
treatment in 2018b

Yes

7 429

–

4 336

6 704
432
186
107
0

(90.2%)
(5.8%)
(2.5%)
(1.4%)
(0.0%)

3 499
408
182
216
31

(80.7%)
(9.4%)
(4.2%)
(5.0%)
(0.7%)

a Treatment outcome as presented is treatment outcome after 12 months.
b Treatment outcome as presented is treatment outcome after 24 months.

TB notification rates by previous treatment history, 2011–2020

New and relapse
Other

Unknown
Total

New and relapse TB cases – notification rates by age group, 
2011–2020

0–14

15–44

45–64

> 64

0
0
0
0
0
1
/
s
e
s
a
C

200

150

100

50

0

2012

2014

2016

2018

2020

0
0
0
0
0
1
/
s
e
s
a
C

180
160
140
120
100
80
60
40
20
0

2012

2014

2016

2018

2020

Note: starting from 2013 onward, cases with unknown history are included in new and relapses. 

Note: data up to 2012 include new TB cases only. 

TB cases by geographical origin, 2011–2020

TB/HIV coinfection, 2011–2020

Native

Foreign origin

Unknown

HIV testing coverage
Proportion of HIV-positive TB cases among tested

TB cases

s
e
s
a
C

30 000

25 000

20 000

15 000

10 000

5000

0

2012

2014

2016

2018

2020

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

30 000

25 000

20 000

15 000

10 000

5000

C
a
s
e
s

2012

2014

2016

2018

0

2020

RR/MDR-TB cases and percentage of RR/MDR-TB cases by previous 
treatment history among all TB cases, 2011–2020

Treatment outcome, new and relapse TB cases 2010–2019

New
Retreatment
Total number of RR/MDR-TB

Unknown

Success
Died

Failed
Lost to follow-up

Not evaluated

Note: data up to 2014 include all TB cases.

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

8000
7000
6000
5000
4000
3000
2000
1000
0

C
a
s
e
s

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

2012

2014

2016

2018

2020

2011

2013

2015

2017

2019

Note: 2010–2011 cohorts include new cases only.

147

Tuberculosis surveillance and monitoring in Europe 2022SURVEILLANCE REPORT 
 
 
Kyrgyzstan

Total population estimate 2020 by United Nations Statistical Database: 6 524 191

TB cases, 2020

Notifications

Total number of cases
Notification rate per 100 000
Newa and relapse
Newa and relapse notification rate 
per 100 000
Pulmonary
  of which microscopy-positive
  of which laboratory-confirmed
Laboratory-confirmed TB cases
Mean age of new native TB cases
Mean age of new foreign TB cases
Foreign origin of all TB cases
New (not previously treated)
Estimates
Estimated new and relapse cases N, 
best [low–high]

 4 885
74.9
 4 241

65.0

 3 992
–
 2 635
–

(81.7%)
–
(66.0%)
–
41.6 years
–

0
 3 534

(0.0%)
(72.3%)

6 900

[5 800–8 000]

a Cases with unknown previous TB history included in new cases.

Drug resistance surveillance and TB/HIV 
coinfection, 2020

Completeness of DRS dataa
Completeness of HIV datab
Case-linked data-reporting
Cases with DST results
Estimated RR-TB among notified 
bacteriologically confirmed 
pulmonary TB cases N, best 
[low–high]
Pulmonary RR/MDR-TB cases 
notified
  of which pre-XDR-TB cases
Notified RR/MDR-TB
  of which pre-XDR-TB cases
TB cases tested for HIV
HIV-positive TB cases
  of these on ART

Yes
Yes
Yes

2 439

(92.6%)

940

[890–990]

870

(35.7%)

149
1 038
149
4 007
131
88

(17.1%)
–
(14.4%)
(94.5%)
(3.3%)
(67.2%)

a National coverage 100% or culturing ≥ 90%, C+/all TB 
cases > 50%, DST done for C+ > 75%, EQA ≥ 95%.
b More than 50% of TB cases with reported HIV status.

Treatment outcome monitoring

Geographical 
coverage

Outcome cohort

Case-linked 
data-reporting
Cases notified
Success
Died
Failed
Lost to follow-up
Not evaluated

National

New and relapse 
TB cases notified 
in 2019a

RR/MDR TB cases 
enrolled into DR-TB 
treatment in 2018b

Yes

5 110

–

1 244

4 155
328
112
481
34

(81.3%)
(6.4%)
(2.2%)
(9.4%)
(0.7%)

775
122
97
249
1

(62.3%)
(9.8%)
(7.8%)
(20.0%)
(0.1%)

a Treatment outcome as presented is treatment outcome after 12 months.
b Treatment outcome as presented is treatment outcome after 24 months.

TB notification rates by previous treatment history, 2011–2020

New and relapse
Other retreatment

Unknown
Total

New and relapse TB cases - notification rates by age group, 
2011–2020

0–14

15–44

45–64

> 64

0
0
0
0
0
1
/
s
e
s
a
C

140

120

100

80

60

40

20

0

2012

2014

2016

2018

2020

0
0
0
0
0
1
/
s
e
s
a
C

300

250

200

150

100

50

0

2012

2014

2016

2018

2020

Note: starting from 2013 onward, cases with unknown history are included in new and 
relapses. 

Note: data up to 2012 include new TB cases only. 

TB cases by geographical origin, 2011–2020

TB/HIV coinfection, 2011–2020

s
e
s
a
C

9000
8000
7000
6000
5000
4000
3000
2000
1000
0

Native

Foreign origin

Unknown

2012

2014

2016

2018

2020

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

HIV testing coverage
Proportion of HIV-positive TB cases among tested
8000

TB cases

7000

6000

5000

4000

3000

2000

1000

C
a
s
e
s

2012

2014

2016

2018

0

2020

RR/MDR-TB cases and percentage of RR/MDR-TB cases by previous 
treatment history among all TB cases, 2011–2020

Treatment outcome, new and relapse TB cases, 2010–2019

New
Retreatment
Total number of RR/MDR-TB

Unknown

Success
Died

Failed
Lost to follow-up

Not evaluated

Note: data up to 2014 include all TB cases.

1400

1200

1000

800

600

400

200

C
a
s
e
s

2012

2014

2016

2018

0

2020

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

2011

2013

2015

2017

2019

Note: 2010–2011 cohorts include new cases only.

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

148

SURVEILLANCE REPORTTuberculosis surveillance and monitoring in Europe 2022 
 
Latvia

Total population at 9 April 2021 by EUROSTAT: 1 907 675

TB cases, 2020

Notifications

Total number of cases
Notification rate per 100 000
Newa and relapse
Newa and relapse notification rate 
per 100 000
Pulmonary
  of which microscopy-positive
  of which laboratory-confirmed
Laboratory-confirmed TB cases
Mean age of new native TB cases
Mean age of new foreign TB cases
Foreign origin of all TB cases
New (not previously treated)
Estimates
Estimated new and relapse cases N, 
best [low–high]

–
–
–

–

–
–

–
–
–
–

–
–

–
–
–
–

–
–

430

[370–500]

a Cases with unknown previous TB history included in new cases.

Drug resistance surveillance and TB/HIV 
coinfection, 2020

Completeness of DRS dataa
Completeness of HIV datab
Case-linked data-reporting
Cases with DST results
Estimated RR-TB among notified 
bacteriologically confirmed 
pulmonary TB cases N, best 
[low–high]
Pulmonary RR/MDR-TB cases notified
  of which pre-XDR-TB cases
Notified RR/MDR-TB
  of which pre-XDR-TB cases
TB cases tested for HIV
HIV-positive TB cases
  of these on ART

No
No
No

–

–

–
–
–
–
–
–
–

–

–

–
–
–
–
–
–
–

a National coverage 100% or culturing ≥ 90%, C+/all TB cases  
> 50%, DST done for C+ > 75%, EQA ≥ 95%.
b More than 50% of TB cases with reported HIV status.

Treatment outcome monitoring

Geographical 
coverage

Outcome cohort

Case-linked 
data-reporting
Cases notified
Success
Died
Failed
Lost to follow-up
Still on treatment
Not evaluated

National

New culture-positive 
pulmonary TB cases 
notified in 2019a

All RR/MDR-TB cases 
notified in 2018b

No

0

–

0

–
–
–
–
–
–

–
–
–
–
–
–

–
–
–
–
–
–

–
–
–
–
–
–

a Treatment outcome as presented is treatment outcome after 12 months.
b Treatment outcome as presented is treatment outcome after 24 months.

TB notification rates by previous treatment history, 2011–2020

New and relapse
Other

Unknown
Total

New and relapse TB cases – notification rates by age group, 
2011–2020

0–14

15–44

45–64

> 64

0
0
0
0
0
1
/
s
e
s
a
C

60

50

40

30

20

10

0

2012

2014

2016

2018

2020

0
0
0
0
0
1
/
s
e
s
a
C

70

60

50

40

30

20

10

0

2012

2014

2016

2018

2020

TB cases by geographical origin, 2011–2020

TB/HIV coinfection, 2011–2020

s
e
s
a
C

1000
900
800
700
600
500
400
300
200
100
0

Native

Foreign origin

Unknown

2012

2014

2016

2018

2020

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

HIV testing coverage
Proportion of HIV-positive TB cases among tested
1200

All TB cases

1000

800

600

400

200

C
a
s
e
s

2012

2014

2016

2018

0

2020

RR/MDR-TB cases and percentage of RR/MDR-TB cases by previous 
treatment history among all TB cases, 2011–2020

Treatment outcome, new culture-confirmed pulmonary TB cases, 
2010–2019

New
Retreatment
Total number of RR/MDR-TB

Unknown

Success
Died

Still on treatment
Lost to follow-up

Failed
Not evaluated

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

140

120

100

80

60

40

20

0

C
a
s
e
s

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

2012

2014

2016

2018

2020

2011

2013

2015

2017

2019

149

Tuberculosis surveillance and monitoring in Europe 2022SURVEILLANCE REPORT 
 
Liechtenstein

Total population at 9 April 2021 by EUROSTAT: 38 747

TB cases, 2020

Notifications

Total number of cases
Notification rate per 100 000
Newa and relapse
Newa and relapse notification rate 
per 100 000
Pulmonary
  of which microscopy-positive
  of which laboratory-confirmed
Laboratory-confirmed TB cases
Mean age of new native TB cases
Mean age of new foreign TB cases
Foreign origin of all TB cases
New (not previously treated)
Estimates
Estimated new and relapse cases N, 
best [low–high]

2
5.2
2

5.2

0
0
0
1

2
1

–

(0.0%)
–
–
(50.0%)

–
76.0 years

(100.0%)
(50.0%)

–

a Cases with unknown previous TB history included in new cases.

Drug resistance surveillance and TB/HIV 
coinfection, 2020

Completeness of DRS dataa
Completeness of HIV datab
Case-linked data-reporting
Cases with DST results
Estimated RR-TB among notified 
bacteriologically confirmed 
pulmonary TB cases N, best 
[low–high]
Pulmonary RR/MDR-TB cases notified
  of which pre-XDR-TB cases
Notified RR/MDR-TB
  of which pre-XDR-TB cases
TB cases tested for HIV
HIV-positive TB cases
  of these on ART

Yes
No
Yes

(0.0%)

–

–
–
–
–
–
–
–

0

–

0
0
0
0
–
–
–

a National coverage 100% or culturing ≥ 90%, C+/all TB cases  
> 50%, DST done for C+ > 75%, EQA ≥ 95%.
b More than 50% of TB cases with reported HIV status.

Treatment outcome monitoring

Geographical 
coverage

Outcome cohort

Case-linked 
data-reporting
Cases notified
Success
Died
Failed
Lost to follow-up
Still on treatment
Not evaluated

National

New culture-positive 
pulmonary TB cases 
notified in 2019a

All RR/MDR-TB cases 
notified in 2018b

Yes

0

–

0

–
–
–
–
–
–

–
–
–
–
–
–

–
–
–
–
–
–

–
–
–
–
–
–

a Treatment outcome as presented is treatment outcome after 12 months.
b Treatment outcome as presented is treatment outcome after 24 months.

TB notification rates by previous treatment history, 2011–2020

New and relapse
Other

Unknown
Total

New and relapse TB cases – notification rates by age group, 
2011–2020

0–14

15–44

45–64

> 64

0
0
0
0
0
1
/
s
e
s
a
C

9
8
7
6
5
4
3
2
1
0

2012

2014

2016

2018

2020

0
0
0
0
0
1
/
s
e
s
a
C

25

20

15

10

5

0

2012

2014

2016

2018

2020

TB cases by geographical origin, 2011–2020

TB/HIV coinfection, 2011–2020

Native

Foreign origin

Unknown

Data not reported

s
e
s
a
C

2

1

0

2012

2014

2016

2018

2020

RR/MDR-TB cases and percentage of RR/MDR-TB cases by previous 
treatment history among all TB cases, 2011–2020

Treatment outcome, new culture-confirmed pulmonary TB cases, 
2010–2019 

New
Retreatment
Total number of RR/MDR-TB

Unknown

1

2012

2014

2016

2018

0

2020

C
a
s
e
s

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

150

Success
Died

Still on treatment
Lost to follow-up

Failed
Not evaluated

2011

2013

2015

2017

2019

SURVEILLANCE REPORTTuberculosis surveillance and monitoring in Europe 2022 
 
Lithuania

Total population at 9 April 2021 by EUROSTAT: 2 794 090

TB cases, 2020

Notifications

Total number of cases
Notification rate per 100 000
Newa and relapse
Newa and relapse notification rate 
per 100 000
Pulmonary
  of which microscopy-positive
  of which laboratory-confirmed
Laboratory-confirmed TB cases
Mean age of new native TB cases
Mean age of new foreign TB cases
Foreign origin of all TB cases
New (not previously treated)
Estimates
Estimated new and relapse cases N, 
best [low–high]

726
26.0
688

24.6

676
434
617
635

13
591

(93.1%)
(64.2%)
(91.3%)
(87.5%)

49.9 years
55.1 years

(1.8%)
(81.4%)

790

[680–910]

a Cases with unknown previous TB history included in new cases.

Drug resistance surveillance and TB/HIV 
coinfection, 2020

Completeness of DRS dataa
Completeness of HIV datab
Case-linked data-reporting
Cases with DST results
Estimated RR-TB among notified 
bacteriologically confirmed 
pulmonary TB cases N, best 
[low–high]
Pulmonary RR/MDR-TB cases notified
  of which pre-XDR-TB cases
Notified RR/MDR-TB
  of which pre-XDR-TB cases
TB cases tested for HIV
HIV-positive TB cases
  of these on ART

Yes
Yes
Yes

  635

(100.0%)

100

[86–120]

104
34
105
34
  714
20
–

(16.9%)
(56.7%)
–
(32.4%)
(98.3%)
(2.8%)
–

a National coverage 100% or culturing ≥ 90%, C+/all TB cases  
> 50%, DST done for C+ > 75%, EQA ≥ 95%.
b More than 50% of TB cases with reported HIV status.
c Cases with unknown previous TB treatment history included 
in new cases.

Treatment outcome monitoring

Geographical 
coverage

Outcome cohort

Case-linked 
data-reporting
Cases notified
Success
Died
Failed
Lost to follow-up
Still on treatment
Not evaluated

National

New culture-positive 
pulmonary TB cases 
notified in 2019a

All RR/MDR-TB cases 
notified in 2018b

Yes

  725

  535
  75
13
17
84
1

(73.8%)
(10.3%)
(1.8%)
(2.3%)
(11.6%)
(0.1%)

– 

189 

103
31
12
20
23
0

(54.5%)
(16.4%)
(6.3%)
(10.6%)
(12.2%)
(0.0%)

a Treatment outcome as presented is treatment outcome after 12 months.
b Treatment outcome as presented is treatment outcome after 24 months.

TB notification rates by previous treatment history, 2011–2020

New and relapse
Other

Unknown
Total

New and relapse TB cases – notification rates by age group, 
2011–2020

0–14

15–44

45–64

> 64

0
0
0
0
0
1
/
s
e
s
a
C

70

60

50

40

30

20

10

0

2012

2014

2016

2018

2020

0
0
0
0
0
1
/
s
e
s
a
C

100

80

60

40

20

0

2012

2014

2016

2018

2020

TB cases by geographical origin, 2011–2020

TB/HIV coinfection, 2011–2020

2500

2000

s
e
s
a
C

1500

1000

500

0

Native

Foreign origin

Unknown

2012

2014

2016

2018

2020

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

HIV testing coverage
Proportion of HIV-positive TB cases among tested
2500

All TB cases

2000

1500

1000

C
a
s
e
s

500

2012

2014

2016

2018

0

2020

RR/MDR-TB cases and percentage of RR/MDR-TB cases by previous 
treatment history among all TB cases, 2011–2020

Treatment outcome, new culture-confirmed pulmonary TB cases, 
2010–2019

New
Retreatment
Total number of RR/MDR-TB

Unknown

Success
Died

Still on treatment
Lost to follow-up

Failed
Not evaluated

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

350

300

250

200

150

100

50

0

C
a
s
e
s

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

2012

2014

2016

2018

2020

2011

2013

2015

2017

2019

151

Tuberculosis surveillance and monitoring in Europe 2022SURVEILLANCE REPORT 
 
Luxembourg  

Total population at 9 April 2021 by EUROSTAT: 626 108

TB cases, 2020

Notifications

Total number of cases
Notification rate per 100 000
Newa and relapse
Newa and relapse notification rate 
per 100 000
Pulmonary
  of which microscopy-positive
  of which laboratory-confirmed
Laboratory-confirmed TB cases
Mean age of new native TB cases
Mean age of new foreign TB cases
Foreign origin of all TB cases
New (not previously treated)
Estimates
Estimated new and relapse cases N, 
best [low–high]

34
5.4
32

5.1

26
19
23
28

29
28

37

(76.5%)
(73.1%)
(88.5%)
(82.4%)

43.2 years
34.4 years

(85.3%)
(82.4%)

[31–43]

a Cases with unknown previous TB history included in new cases.

Drug resistance surveillance and TB/HIV 
coinfection, 2020

Completeness of DRS dataa
Completeness of HIV datab
Case-linked data-reporting
Cases with DST results
Estimated RR-TB among notified 
bacteriologically confirmed 
pulmonary TB cases N, best 
[low–high]
Pulmonary RR/MDR-TB cases notified
  of which pre-XDR-TB cases
Notified RR/MDR-TB
  of which pre-XDR-TB cases
TB cases tested for HIV
HIV-positive TB cases
  of these on ART

Yes
Yes
Yes

27

(96.4%)

0

0
0
0
0
28
0
0

[0–2]

(0.0%)
–
–
–
(82.4%)
(0.0%)
–

a National coverage 100% or culturing ≥ 90%, C+/all TB cases  
> 50%, DST done for C+ > 75%, EQA ≥ 95%.
b More than 50% of TB cases with reported HIV status.

Treatment outcome monitoring

Geographical 
coverage

Outcome cohort

Case-linked 
data-reporting
Cases notified
Success
Died
Failed
Lost to follow-up
Still on treatment
Not evaluated

National

New culture-positive 
pulmonary TB cases 
notified in 2019a

All RR/MDR-TB cases 
notified in 2018b

Yes

21

8
0
0
3
0
10

(38.1%)
(0.0%)
(0.0%)
(14.3%)
(0.0%)
(47.6%)

–

1

(0.0%)
(0.0%)
(0.0%)
(0.0%)
(0.0%)
(100.0%)

0
0
0
0
0
1

a Treatment outcome as presented is treatment outcome after 12 months.
b Treatment outcome as presented is treatment outcome after 24 months.

TB notification rates by previous treatment history, 2011–2020

New and relapse
Other

Unknown
Total

New and relapse TB cases – notification rates by age group, 
2011–2020

0–14

15–44

45–64

> 64

0
0
0
0
0
1
/
s
e
s
a
C

10

8

6

4

2

0

2012

2014

2016

2018

2020

0
0
0
0
0
1
/
s
e
s
a
C

8

7

6

5

4

3

2

1

0

2012

2014

2016

2018

2020

TB cases by geographical origin, 2011–2020

TB/HIV coinfection, 2011–2020

Native

Foreign origin

Unknown

HIV testing coverage
Proportion of HIV-positive TB cases among tested

All TB cases

s
e
s
a
C

50

40

30

20

10

0

2012

2014

2016

2018

2020

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

50

40

30

20

10

C
a
s
e
s

2012

2014

2016

2018

0

2020

RR/MDR-TB cases and percentage of RR/MDR-TB cases by previous 
treatment history among all TB cases, 2011–2020

Treatment outcome, new culture-confirmed pulmonary TB cases, 
2010–2019

New
Retreatment
Total number of RR/MDR-TB

Unknown

3

2

1

0

C
a
s
e
s

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

2012

2014

2016

2018

2020

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

152

Success
Died

Still on treatment
Lost to follow-up

Failed
Not evaluated

2011

2013

2015

2017

2019

SURVEILLANCE REPORTTuberculosis surveillance and monitoring in Europe 2022 
 
Malta

Total population at 9 April 2021 by EUROSTAT: 514 564

TB cases, 2020

Notifications

Total number of cases
Notification rate per 100 000
Newa and relapse
Newa and relapse notification rate 
per 100 000
Pulmonary
  of which microscopy-positive
  of which laboratory-confirmed
Laboratory-confirmed TB cases
Mean age of new native TB cases
Mean age of new foreign TB cases
Foreign origin of all TB cases
New (not previously treated)
Estimates
Estimated new and relapse cases N, 
best [low–high]

140
27.2
140

27.2

99
29
27
43

137
98

(70.7%)
(29.3%)
(27.3%)
(30.7%)

31.3 years
25.1 years

(97.9%)
(70.0%)

160

[140–190]

a Cases with unknown previous TB history included in new cases.

Drug resistance surveillance and TB/HIV 
coinfection, 2020

Completeness of DRS dataa
Completeness of HIV datab
Case-linked data-reporting
Cases with DST results
Estimated RR-TB among notified 
bacteriologically confirmed 
pulmonary TB cases N, best 
[low–high]
Pulmonary RR/MDR-TB cases notified
  of which pre-XDR-TB cases
Notified RR/MDR-TB
  of which pre-XDR-TB cases
TB cases tested for HIV
HIV-positive TB cases
  of these on ART

Yes
No
Yes

40

(93.0%)

0

0
0
0
0
–
–
–

[0–5]

(0.0%)
–
–
–
–
–
–

a National coverage 100% or culturing ≥ 90%, C+/all TB cases  
> 50%, DST done for C+ > 75%, EQA ≥ 95%.
b More than 50% of TB cases with reported HIV status.

Treatment outcome monitoring

Geographical 
coverage

Outcome cohort

Case-linked 
data-reporting
Cases notified
Success
Died
Failed
Lost to follow-up
Still on treatment
Not evaluated

National

New culture-positive 
pulmonary TB cases 
notified in 2019a

All RR/MDR-TB cases 
notified in 2018b

Yes

37

–

0

–
–
–
–
–
–

–
–
–
–
–
–

–
–
–
–
–
–

–
–
–
–
–
–

a Treatment outcome as presented is treatment outcome after 12 months.
b Treatment outcome as presented is treatment outcome after 24 months.

TB notification rates by previous treatment history, 2011–2020

New and relapse
Other

Unknown
Total

New and relapse TB cases – notification rates by age group, 
2011–2020

0–14

15–44

45–64

> 64

0
0
0
0
0
1
/
s
e
s
a
C

25

20

15

10

5

0

2012

2014

2016

2018

2020

0
0
0
0
0
1
/
s
e
s
a
C

45
40
35
30
25
20
15
10
5
0

2012

2014

2016

2018

2020

TB cases by geographical origin, 2011–2020

TB/HIV coinfection, 2011–2020

Native

Foreign origin

Unknown

HIV testing coverage
Proportion of HIV-positive TB cases among tested

All TB cases

s
e
s
a
C

160

140

120

100

80

60

40

20

0

2012

2014

2016

2018

2020

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

150

120

90

60

30

C
a
s
e
s

2012

2014

2016

2018

0

2020

Note: by nationality for 2000–2006.

RR/MDR-TB cases and percentage of RR/MDR-TB cases by previous 
treatment history among all TB cases, 2011–2020

Treatment outcome, new culture-confirmed pulmonary TB cases, 
2010–2019

New
Retreatment
Total number of RR/MDR-TB

Unknown

Success
Died

Still on treatment
Lost to follow-up

Failed
Not evaluated

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

3

2

1

0

C
a
s
e
s

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

2012

2014

2016

2018

2020

2011

2013

2015

2017

2019

153

Tuberculosis surveillance and monitoring in Europe 2022SURVEILLANCE REPORT 
 
Monaco

Total population estimate 2020 by United Nations Statistical Database: 39 244

TB cases, 2020

Notifications

Total number of cases
Notification rate per 100 000
Newa and relapse
Newa and relapse notification rate 
per 100 000
Pulmonary
  of which microscopy-positive
  of which laboratory-confirmed
Laboratory-confirmed TB cases
Mean age of new native TB cases
Mean age of new foreign TB cases
Foreign origin of all TB cases
New (not previously treated)
Estimates
Estimated new and relapse cases N, 
best [low–high]

0
–
–

–

–
–

–
–
–

–
–

[0–0]

–
–
–

–
–

0

a Cases with unknown previous TB history included in new cases.

Drug resistance surveillance and TB/HIV 
coinfection, 2020

Completeness of DRS dataa
Completeness of HIV datab
Case-linked data-reporting
Cases with DST results
Estimated RR-TB among notified 
bacteriologically confirmed 
pulmonary TB cases N, best 
[low–high]
Pulmonary RR/MDR-TB cases 
notified
  of which pre-XDR-TB cases
Notified RR/MDR-TB
  of which pre-XDR-TB cases
TB cases tested for HIV
HIV-positive TB cases
  of these on ART

No
No
No

–

[0–0]

–

–
–
–
–
–
–

–

0

–

–
–
–
–
–
–

a National coverage 100% or culturing ≥ 90%, C+/all TB cases 
> 50%, DST done for C+ > 75%, EQA ≥ 95%.
b More than 50% of TB cases with reported HIV status.

Treatment outcome monitoring

Geographical 
coverage

Outcome cohort

Case-linked 
data-reporting
Cases notified
Success
Died
Failed
Lost to follow-up
Not evaluated

National

New and relapse 
TB cases notified 
in 2019a

RR/MDR-TB cases 
enrolled into DR-TB 
treatment in  2018b

Yes

0
–
–
–
–
–

–

0
–
–
–
–
–

a Treatment outcome as presented is treatment outcome after 12 months.
b Treatment outcome as presented is treatment outcome after 24 months.

TB notification rates by previous treatment history, 2011–2020

New and relapse
Other

Unknown
Total

New and relapse TB cases – notification rates by age group, 
2011–2020

0–14

15–44

45–64

> 64

0
0
0
0
0
1
/
s
e
s
a
C

1

0

2012

2014

2016

2018

2020

0
0
0
0
0
1
/
s
e
s
a
C

1

0

2012

2014

2016

2018

2020

Note: starting from 2013 onward, cases with unknown history are included in new and 
relapses. 

Note: data up to 2012 include new TB cases only. 

TB cases by geographical origin, 2011–2020

TB/HIV coinfection, 2011–2020

Native

Foreign origin

Unknown

HIV testing coverage
Proportion of HIV-positive TB cases among tested

TB cases

s
e
s
a
C

3

2

1

0

2012

2014

2016

2018

2020

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

3

2

1

0

C
a
s
e
s

2012

2014

2016

2018

2020

Note: data up to 2014 include all TB cases.

RR/MDR-TB cases and percentage of RR/MDR-TB cases by previous 
treatment history among all TB cases, 2011–2020

Treatment outcome, new and relapse TB cases, 2010–2019

New
Retreatment
Total number of RR/MDR-TB

Unknown

Success
Died

Failed
Lost to follow-up

Not evaluated

3

2

1

0

C
a
s
e
s

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

2012

2014

2016

2018

2020

2011

2013

2015

2017

2019

Note: 2010–2011 cohorts include new cases only.

45
40
35
30
25
20
15
10
5
0

e
g
a
t
n
e
c
r
e
P

154

SURVEILLANCE REPORTTuberculosis surveillance and monitoring in Europe 2022 
 
  
Montenegro

Total population estimate 2020 by United Nations Statistical Database: 628 062

TB cases, 2020

Notifications

Total number of cases
Notification rate per 100 000
Newa and relapse
Newa and relapse notification rate 
per 100 000
Pulmonary
  of which microscopy-positive
  of which laboratory-confirmed
Laboratory-confirmed TB cases
Mean age of new native TB cases
Mean age of new foreign TB cases
Foreign origin of all TB cases
New (not previously treated)
Estimates
Estimated new and relapse cases N, 
best [low–high]

  40
6.4
  40

6.4

  38
–
  31
–

4
  38

(95.0%)
–
(81.6%)
–
48.0 years
–

(10.0%)
(95.0%)

99

[84–120]

a Cases with unknown previous TB history included in new cases.

Drug resistance surveillance and TB/HIV 
coinfection, 2020

Completeness of DRS dataa
Completeness of HIV datab
Case-linked data-reporting
Cases with DST results
Estimated RR-TB among notified 
bacteriologically confirmed 
pulmonary TB cases N, best 
[low–high]
Pulmonary RR/MDR-TB cases 
notified
  of which pre-XDR-TB cases
Notified RR/MDR-TB
  of which pre-XDR-TB cases
TB cases tested for HIV
HIV-positive TB cases
  of these on ART

Yes
Yes
Yes

(100.0%)

[0–2]

(0.0%)

–
–
–
(87.5%)
(0.0%)
–

31

0

0

–
0
–
35
0
–

a National coverage 100% or culturing ≥ 90%, C+/all TB cases 
> 50%, DST done for C+ > 75%, EQA ≥ 95%.
b More than 50% of TB cases with reported HIV status.

Treatment outcome monitoring

Geographical 
coverage

Outcome cohort

Case-linked 
data-reporting
Cases notified
Success
Died
Failed
Lost to follow-up
Not evaluated

National

New and relapse 
TB cases notified 
in 2019a

RR/MDR-TB cases 
enrolled into DR-TB 
treatment in  2018b

Yes

82

78
4
0
0
0

(95.1%)
(4.9%)
(0.0%)
(0.0%)
(0.0%)

–

1

1
0
0
0
0

(100.0%)
(0.0%)
(0.0%)
(0.0%)
(0.0%)

a Treatment outcome as presented is treatment outcome after 12 months.
b Treatment outcome as presented is treatment outcome after 24 months.

TB notification rates by previous treatment history, 2011–2020

New and relapse
Other

Unknown
Total

New and relapse TB cases – notification rates by age group, 
2011–2020

0–14

15–44

45–64

> 64

0
0
0
0
0
1
/
s
e
s
a
C

20

15

10

5

0

2012

2014

2016

2018

2020

0
0
0
0
0
1
/
s
e
s
a
C

45
40
35
30
25
20
15
10
5
0

2012

2014

2016

2018

2020

Note: starting from 2013 onward, cases with unknown history are included in new and 
relapses. 

Note: data up to 2012 include new TB cases only. 

TB cases by geographical origin, 2011–2020

TB/HIV coinfection, 2011–2020

Native

Foreign origin

Unknown

HIV testing coverage
Proportion of HIV-positive TB cases among tested

TB cases

s
e
s
a
C

140

120

100

80

60

40

20

0

2012

2014

2016

2018

2020

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

140

120

100

80

60

40

20

0

C
a
s
e
s

2012

2014

2016

2018

2020

Note: data up to 2014 include all TB cases.

RR/MDR-TB cases and percentage of RR/MDR-TB cases by previous 
treatment history among all TB cases, 2011–2020

Treatment outcome, new and relapse TB cases, 2010–2019

New
Retreatment
Total number of RR/MDR-TB

Unknown

Success
Died

Failed
Lost to follow-up

Not evaluated

e
g
a
t
n
e
c
r
e
P

45
40
35
30
25
20
15
10
5
0

3

2

1

0

C
a
s
e
s

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

2012

2014

2016

2018

2020

2011

2013

2015

2017

2019

Note: 2010–2011 cohorts include new cases only.

155

Tuberculosis surveillance and monitoring in Europe 2022SURVEILLANCE REPORT 
 
Netherlands

Total population at 9 April 2021 by EUROSTAT: 17 407 585

TB cases, 2020

Notifications

Total number of cases
Notification rate per 100 000
Newa and relapse
Newa and relapse notification rate 
per 100 000
Pulmonary
  of which microscopy-positive
  of which laboratory-confirmed
Laboratory-confirmed TB cases
Mean age of new native TB cases
Mean age of new foreign TB cases
Foreign origin of all TB cases
New (not previously treated)
Estimates
Estimated new and relapse cases N. 
best [low–high]

623
3.6
614

3.5

334
166
264
431

451
593

(53.6%)
(49.7%)
(79.0%)
(69.2%)

45.8 years
39.1 years

(72.4%)
(95.2%)

710

[600–820]

a Cases with unknown previous TB history included in new cases.

Drug-resistance surveillance and TB/HIV 
coinfection, 2020

Completeness of DRS dataa
Completeness of HIV datab
Case-linked data-reporting
Cases with DST results
Estimated RR-TB among notified 
bacteriologically confirmed pulmonary 
TB cases N, best [low–high]
Pulmonary RR/MDR-TB cases notified
  of which pre-XDR-TB cases
Notified RR/MDR-TB
  of which pre-XDR-TB cases
TB cases tested for HIV
HIV-positive TB cases
  of these on ART

Yes
Yes
Yes

401

(93.0%)

5

[0–9]

4
0
12
0
489
14
0

(1.6%)
(0.0%)
–
(0.0%)
(78.5%)
(2.9%)
(0.0%)

a National coverage 100% or culturing ≥ 90%. C+/all TB cases  
> 50%. DST done for C+ > 75%. EQA ≥ 95%.
b More than 50% of TB cases with reported HIV status.
c Cases with unknown previous TB treatment history included 
in new cases.

Treatment outcome monitoring

Geographical 
coverage

Outcome cohort

Case-linked 
data-reporting
Cases notified
Success
Died
Failed
Lost to follow-up
Still on treatment
Not evaluated

National

New culture-positive 
pulmonary TB cases 
notified in 2019a

All RR/MDR-TB cases 
notified in 2018b

Yes

321

265
18
0
12
7
19

(82.6%)
(5.6%)
(0.0%)
(3.7%)
(2.2%)
(5.9%)

–

6

(83.3%)
(16.7%)
(0.0%)
(0.0%)
(0.0%)
(0.0%)

5
1
0
0
0
0

a Treatment outcome as presented is treatment outcome after 12 months.
b Treatment outcome as presented is treatment outcome after 24 months.

TB notification rates by previous treatment history, 2011–2020

New and relapse
Other

Unknown
Total

New and relapse TB cases – notification rates by age group, 
2011–2020

0–14

15–44

45–64

> 64

0
0
0
0
0
1
/
s
e
s
a
C

8

7

6

5

4

3

2

1

0

2012

2014

2016

2018

2020

0
0
0
0
0
1
/
s
e
s
a
C

12

10

8

6

4

2

0

2012

2014

2016

2018

2020

TB cases by geographical origin, 2011–2020

TB/HIV coinfection, 2011–2020

s
e
s
a
C

900
800
700
600
500
400
300
200
100
0

Native

Foreign origin

Unknown

2012

2014

2016

2018

2020

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

HIV testing coverage
Proportion of HIV-positive TB cases among tested
1400

All TB cases

1200

1000

800

600

400

200

C
a
s
e
s

2012

2014

2016

2018

0

2020

RR/MDR-TB cases and percentage of RR/MDR-TB cases by previous 
treatment history among all TB cases, 2011–2020

Treatment outcome, new culture-confirmed pulmonary TB cases, 
2010–2019

New
Retreatment
Total number of RR/MDR-TB

Unknown

Success
Died

Still on treatment
Lost to follow-up

Failed
Defaulted

20

15

10

5

0

C
a
s
e
s

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

2012

2014

2016

2018

2020

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

156

2011

2013

2015

2017

2019

SURVEILLANCE REPORTTuberculosis surveillance and monitoring in Europe 2022 
 
North Macedonia

Total population estimate 2020 by United Nations Statistical Database: 2 083 380

TB cases, 2020

Notifications

Total number of cases
Notification rate per 100 000
Newa and relapse
Newa and relapse notification rate 
per 100 000
Pulmonary
  of which microscopy-positive
  of which laboratory-confirmed
Laboratory-confirmed TB cases
Mean age of new native TB cases
Mean age of new foreign TB cases
Foreign origin of all TB cases
New (not previously treated)
Estimates
Estimated new and relapse cases N, 
best [low–high]

  148
7.1
  143

6.9

  126
–
  105
–

7
  130

(85.1%)
–
(83.3%)
–
42.9 years
–

(4.7%)
(87.8%)

250

[190–310]

a Cases with unknown previous TB history included in new cases.

Drug resistance surveillance and TB/HIV 
coinfection, 2020

Completeness of DRS dataa
Completeness of HIV datab
Case-linked data-reporting
Cases with DST results
Estimated RR-TB among notified 
bacteriologically confirmed 
pulmonary TB cases N, best 
[low–high]
Pulmonary RR/MDR-TB cases 
notified
  of which pre-XDR-TB cases
Notified RR/MDR-TB
  of which pre-XDR-TB cases
TB cases tested for HIV
HIV-positive TB cases
  of these on ART

Yes
No
Yes

91

(86.7%)

2

2

–
2
0
69
1
1

[0–5]

(2.2%)

–
–
(0.0%)
(48.3%)
(1.4%)
(100.0%)

a National coverage 100% or culturing ≥ 90%, C+/all TB cases  
> 50%, DST done for C+ > 75%, EQA ≥ 95%.
b More than 50% of TB cases with reported HIV status.

Treatment outcome monitoring

Geographical 
coverage

Outcome cohort

Case-linked 
data-reporting
Cases notified
Success
Died
Failed
Lost to follow-up
Not evaluated

National

New and relapse 
TB cases notified 
in 2019a

RR/MDR TB cases 
enrolled into DR-TB 
treatment in 2018b

Yes

199

177
9
2
11
0

(88.9%)
(4.5%)
(1.0%)
(5.5%)
(0.0%)

–

2

1
0
0
1
0

(50.0%)
(0.0%)
(0.0%)
(50.0%)
(0.0%)

a Treatment outcome as presented is treatment outcome after 12 months.
b Treatment outcome as presented is treatment outcome after 24 months.

TB notification rates by previous treatment history, 2011–2020

New and relapse
Other

Unknown
Total

New and relapse TB cases – notification rates by age group, 
2011–2020

0–14

15–44

45–64

> 64

0
0
0
0
0
1
/
s
e
s
a
C

20

15

10

5

0

2012

2014

2016

2018

2020

0
0
0
0
0
1
/
s
e
s
a
C

25

20

15

10

5

0

2012

2014

2016

2018

2020

Note: starting from 2013 onward, cases with unknown history are included in new and 
relapses. 

Note: data up to 2012 include new TB cases only. 

TB cases by geographical origin, 2011–2020

TB/HIV coinfection, 2011–2020

Native

Foreign origin

Unknown

HIV testing coverage
Proportion of HIV-positive TB cases among tested

TB cases

s
e
s
a
C

500

400

300

200

100

0

2012

2014

2016

2018

2020

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

400

350

300

250

200

150

100

50

0

C
a
s
e
s

2012

2014

2016

2018

2020

RR/MDR-TB cases and percentage of RR/MDR-TB cases by previous 
treatment history among all TB cases, 2011–2020

Treatment outcome, new and relapse TB cases, 2010–2019

New
Retreatment
Total number of RR/MDR-TB

Unknown

Success
Died

Failed
Lost to follow-up

Not evaluated

Note: data up to 2014 include all TB cases.

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

8
7
6
5
4
3
2
1
0

C
a
s
e
s

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

2012

2014

2016

2018

2020

2011

2013

2015

2017

2019

Note: 2010–2011 cohorts include new cases only.

157

Tuberculosis surveillance and monitoring in Europe 2022SURVEILLANCE REPORT 
 
Norway

Total population at 9 April 2021 by EUROSTAT: 5 367 580

TB cases, 2020

Notifications

Total number of cases
Notification rate per 100 000
Newa and relapse
Newa and relapse notification rate 
per 100 000
Pulmonary
  of which microscopy-positive
  of which laboratory-confirmed
Laboratory-confirmed TB cases
Mean age of new native TB cases
Mean age of new foreign TB cases
Foreign origin of all TB cases
New (not previously treated)
Estimates
Estimated new and relapse cases N, 
best [low–high]

160
3.0
144

2.7

96
41
84
133

130
144

(60.0%)
(42.7%)
(87.5%)
(83.1%)

40.8 years
36.1 years

(81.3%)
(90.0%)

170

[140–190]

a Cases with unknown previous TB history included in new cases.

Drug resistance surveillance and TB/HIV 
coinfection, 2020

Completeness of DRS dataa
Completeness of HIV datab
Case-linked data-reporting
Cases with DST results
Estimated RR-TB among notified 
bacteriologically confirmed 
pulmonary TB cases N, best 
[low–high]
Pulmonary RR/MDR-TB cases notified
  of which pre-XDR-TB cases
Notified RR/MDR-TB
  of which pre-XDR-TB cases
TB cases tested for HIV
HIV-positive TB cases
  of these on ART

Yes
Yes
Yes

132

(99.2%)

2

[0–5]

2
0
2
0
122
2
–

(2.4%)
(0.0%)
–
(0.0%)
(76.3%)
(1.6%)
–

a National coverage 100% or culturing ≥ 90%, C+/all TB cases  
> 50%, DST done for C+ > 75%, EQA ≥ 95%.
b More than 50% of TB cases with reported HIV status.

Treatment outcome monitoring

Geographical 
coverage

Outcome cohort

Case-linked 
data-reporting
Cases notified
Success
Died
Failed
Lost to follow-up
Still on treatment
Not evaluated

National

New culture-positive 
pulmonary TB cases 
notified in 2019a

All RR/MDR-TB cases 
notified in 2018b

Yes

86

74
3
0
1
1
7

(86.0%)
(3.5%)
(0.0%)
(1.2%)
(1.2%)
(8.1%)

–

6

(83.3%)
(0.0%)
(16.7%)
(0.0%)
(0.0%)
(0.0%)

5
0
1
0
0
0

a Treatment outcome as presented is treatment outcome after 12 months.
b Treatment outcome as presented is treatment outcome after 24 months.

TB notification rates by previous treatment history, 2011–2020

New and relapse
Other

Unknown
Total

New and relapse TB cases – notification rates by age group, 
2011–2020

0–14

15–44

45–64

> 64

0
0
0
0
0
1
/
s
e
s
a
C

9
8
7
6
5
4
3
2
1
0

2012

2014

2016

2018

2020

0
0
0
0
0
1
/
s
e
s
a
C

14

12

10

8

6

4

2

0

2012

2014

2016

2018

2020

TB cases by geographical origin, 2011–2020

TB/HIV coinfection, 2011–2020

Native

Foreign origin

Unknown

HIV testing coverage
Proportion of HIV-positive TB cases among tested

All TB cases

s
e
s
a
C

400

350

300

250

200

150

100

50

0

2012

2014

2016

2018

2020

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

450
400
350
300
250
200
150
100
50
0

C
a
s
e
s

2012

2014

2016

2018

2020

RR/MDR-TB cases and percentage of RR/MDR-TB cases by previous 
treatment history among all TB cases, 2011–2020

Treatment outcome, new culture-confirmed pulmonary TB cases, 
2010–2019

New
Retreatment
Total number of RR/MDR-TB

Unknown

Success
Died

Still on treatment
Lost to follow-up

Failed
Not evaluated

12

10

8

6

4

2

0

C
a
s
e
s

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

2012

2014

2016

2018

2020

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

158

2011

2013

2015

2017

2019

SURVEILLANCE REPORTTuberculosis surveillance and monitoring in Europe 2022 
 
Poland 

Total population at 9 April 2021 by EUROSTAT: 37 958 138

TB cases, 2020

Notifications

Total number of cases
Notification rate per 100 000
Newa and relapse
Newa and relapse notification rate 
per 100 000
Pulmonary
  of which microscopy-positive
  of which laboratory-confirmed
Laboratory-confirmed TB cases
Mean age of new native TB cases
Mean age of new foreign TB cases
Foreign origin of all TB cases
New (not previously treated)
Estimates
Estimated new and relapse cases N, 
best [low–high]

 3 388
8.9
 3 150

8.3

 3 237
 1 794
 2 573
 2 655

(95.5%)
(55.4%)
(79.5%)
(78.4%)

53.9 years
36.4 years

116
 2 912

(3.4%)
(86.0%)

3 600

[3 100–4 200]

a Cases with unknown previous TB history included in new cases.

Drug resistance surveillance and TB/HIV 
coinfection, 2020

Completeness of DRS dataa
Completeness of HIV datab
Case-linked data-reporting
Cases with DST results
Estimated RR-TB among notified 
bacteriologically confirmed 
pulmonary TB cases N, best 
[low–high]
Pulmonary RR/MDR-TB cases notified
  of which pre-XDR-TB cases
Notified RR/MDR-TB
  of which pre-XDR-TB cases
TB cases tested for HIV
HIV-positive TB cases
  of these on ART

Yes
No
Yes

 2 421

(91.2%)

44

40
12
42
13
–
–
–

[30–58]

(1.7%)
(30.0%)
–
(31.0%)
–
–
–

a National coverage 100% or culturing ≥ 90%, C+/all TB cases  
> 50%, DST done for C+ > 75%, EQA ≥ 95%.
b More than 50% of TB cases with reported HIV status.

Treatment outcome monitoring

Geographical 
coverage

Outcome cohort

Case-linked 
data-reporting
Cases notified
Success
Died
Failed
Lost to follow-up
Still on treatment
Not evaluated

National

New culture-positive 
pulmonary TB cases 
notified in 2019a

All RR/MDR-TB cases 
notified in 2018b

Yes

 3 466

–

58  

–
–
–
–
–
–

–
–
–
–
–
–

–
–
–
–
–
–

–
–
–
–
–
–

a Treatment outcome as presented is treatment outcome after 12 months.
b Treatment outcome as presented is treatment outcome after 24 months.

TB notification rates by previous treatment history, 2011–2020

New and relapse
Other

Unknown
Total

New and relapse TB cases – notification rates by age group, 
2011–2020

0–14

15–44

45–64

> 64

0
0
0
0
0
1
/
s
e
s
a
C

25

20

15

10

5

0

2012

2014

2016

2018

2020

0
0
0
0
0
1
/
s
e
s
a
C

45
40
35
30
25
20
15
10
5
0

2012

2014

2016

2018

2020

TB cases by geographical origin, 2011–2020

TB/HIV coinfection, 2011–2020

Native

Foreign origin

Unknown

Data not reported

s
e
s
a
C

9000
8000
7000
6000
5000
4000
3000
2000
1000
0

2012

2014

2016

2018

2020

RR/MDR-TB cases and percentage of RR/MDR-TB cases by previous 
treatment history among all TB cases, 2011–2020

Treatment outcome, new culture-confirmed pulmonary TB cases, 
2010–2019

New
Retreatment
Total number of RR/MDR-TB

Unknown

Success
Died

Still on treatment
Lost to follow-up

Failed
Not evaluated

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

70

60

50

40

30

20

10

0

C
a
s
e
s

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

2012

2014

2016

2018

2020

2011

2013

2015

2017

2019

159

Tuberculosis surveillance and monitoring in Europe 2022SURVEILLANCE REPORT 
 
Portugal

Total population at 9 April 2021 by EUROSTAT: 10 295 909

TB cases, 2020

Notifications

Total number of cases
Notification rate per 100 000
Newa and relapse
Newa and relapse notification rate 
per 100 000
Pulmonary
  of which microscopy-positive
  of which laboratory-confirmed
Laboratory-confirmed TB cases
Mean age of new native TB cases
Mean age of new foreign TB cases
Foreign origin of all TB cases
New (not previously treated)
Estimates
Estimated new and relapse cases N, 
best [low–high]

 1 445
14.0
 1 402

13.6

 1 007
  556
  724
  864

(69.7%)
(55.2%)
(71.9%)
(59.8%)

53.1 years
38.2 years

  393
 1 351

(27.2%)
(93.5%)

1 600

[1 400–1 800]

a Cases with unknown previous TB history included in new cases.

Drug resistance surveillance and TB/HIV 
coinfection, 2020

Completeness of DRS dataa
Completeness of HIV datab
Case-linked data-reporting
Cases with DST results
Estimated RR-TB among notified 
bacteriologically confirmed 
pulmonary TB cases N, best 
[low–high]
Pulmonary RR/MDR-TB cases notified
  of which pre-XDR-TB cases
Notified RR/MDR-TB
  of which pre-XDR-TB cases
TB cases tested for HIV
HIV-positive TB cases
  of these on ART

Yes
Yes
Yes

  538

(62.3%)

12

[7–18]

7
0
9
0
 1 087
  111
–

(1.5%)
(0.0%)
– 
(0.0%)
(75.2%)
(10.2%)
–

a National coverage 100% or culturing ≥ 90%, C+/all TB cases  
> 50%, DST done for C+ > 75%, EQA ≥ 95%.
b More than 50% of TB cases with reported HIV status.

Treatment outcome monitoring

Geographical 
coverage

Outcome cohort

Case-linked 
data-reporting
Cases notified
Success
Died
Failed
Lost to follow-up
Still on treatment
Not evaluated

National

New culture-positive 
pulmonary TB cases 
notified in 2019a

All RR/MDR-TB cases 
notified in 2018b

Yes

  961

  696
66
0
27
137
35

(72.4%)
(6.9%)
(0.0%)
(2.8%)
(14.3%)
(3.6%)

–

11

(63.6%)
(0.0%)
(0.0%)
(0.0%)
(18.2%)
(18.2%)

7
0
0
0
2
2

a Treatment outcome as presented is treatment outcome after 12 months.
b Treatment outcome as presented is treatment outcome after 24 months.

TB notification rates by previous treatment history, 2011–2020

New and relapse
Other

Unknown
Total

New and relapse TB cases – notification rates by age group, 
2011–2020

0–14

15–44

45–64

> 64

0
0
0
0
0
1
/
s
e
s
a
C

25

20

15

10

5

0

2012

2014

2016

2018

2020

0
0
0
0
0
1
/
s
e
s
a
C

35

30

25

20

15

10

5

0

2012

2014

2016

2018

2020

TB cases by geographical origin, 2011–2020

TB/HIV coinfection, 2011–2020

2500

2000

s
e
s
a
C

1500

1000

500

0

Native

Foreign origin

Unknown

2012

2014

2016

2018

2020

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

HIV testing coverage
Proportion of HIV-positive TB cases among tested
3000

All TB cases

2500

2000

1500

1000

500

C
a
s
e
s

2012

2014

2016

2018

0

2020

RR/MDR-TB cases and percentage of RR/MDR-TB cases by previous 
treatment history among all TB cases, 2011–2020

Treatment outcome, new culture-confirmed pulmonary TB cases, 
2010–2019

New
Retreatment
Total number of RR/MDR-TB

Unknown

Success
Died

Still on treatment
Lost to follow-up

Failed
Not evaluated

45
40
35
30
25
20
15
10
5
0

C
a
s
e
s

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

2012

2014

2016

2018

2020

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

160

2011

2013

2015

2017

2019

SURVEILLANCE REPORTTuberculosis surveillance and monitoring in Europe 2022 
 
Republic of Moldova

Total population estimate 2020 by United Nations Statistical Database: 4 033 963

TB cases, 2020

Notifications

Total number of cases
Notification rate per 100 000
Newa and relapse
Newa and relapse notification rate 
per 100 000
Pulmonary
  of which microscopy-positive
  of which laboratory-confirmed
Laboratory-confirmed TB cases
Mean age of new native TB cases
Mean age of new foreign TB cases
Foreign origin of all TB cases
New (not previously treated)
Estimates
Estimated new and relapse cases N, 
best [low–high]

 1 906
47.2
 1 767

43.8

 1 819
–
 1 261
–

(95.4%)
–
(69.3%)
–
44.2 years
–

8
 1 386

(0.4%)
(72.7%)

3 000

[2 500–3 500]

a Cases with unknown previous TB history included in new cases.

Drug resistance surveillance and TB/HIV 
coinfection, 2020

Completeness of DRS dataa
Completeness of HIV datab
Case-linked data-reporting
Cases with DST results
Estimated RR-TB among notified 
bacteriologically confirmed 
pulmonary TB cases N, best 
[low–high]
Pulmonary RR/MDR-TB cases 
notified
  of which pre-XDR-TB cases
Notified RR/MDR-TB
  of which pre-XDR-TB cases
TB cases tested for HIV
HIV-positive TB cases
  of these on ART

No
Yes
Yes

1 207

(95.7%)

430

[400–460]

413

(34.2%)

188
444
219
1 693
219
170

(45.5%)
–
(49.3%)
(95.8%)
(12.9%)
(77.6%)

a National coverage 100% or culturing ≥ 90%, C+/all TB 
cases > 50%, DST done for C+ > 75%, EQA ≥ 95%.
b More than 50% of TB cases with reported HIV status.

Treatment outcome monitoring

Geographical 
coverage

Outcome cohort

Case-linked 
data-reporting
Cases notified
Success
Died
Failed
Lost to follow-up
Not evaluated

National

New and relapse 
TB cases notified 
in 2019a

RR/MDR TB cases 
enrolled into DR-TB 
treatment in 2018b

Yes

2 215

–

921

1 854
164
69
116
12

(83.7%)
(7.4%)
(3.1%)
(5.2%)
(0.5%)

541
98
111
169
2

(58.7%)
(10.6%)
(12.1%)
(18.3%)
(0.2%)

a Treatment outcome as presented is treatment outcome after 12 months.
b Treatment outcome as presented is treatment outcome after 24 months.

TB notification rates by previous treatment history, 2011–2020

New and relapse
Other 

Unknown
Total

New and relapse TB cases – notification rates by age group, 
2011–2020

0–14

15–44

45–64

> 64

0
0
0
0
0
1
/
s
e
s
a
C

140

120

100

80

60

40

20

0

2012

2014

2016

2018

2020

0
0
0
0
0
1
/
s
e
s
a
C

180
160
140
120
100
80
60
40
20
0

2012

2014

2016

2018

2020

Note: starting from 2013 onward, cases with unknown history are included in new and 
relapses. 

Note: data up to 2012 include new TB cases only. 

TB cases by geographical origin, 2011–2020

TB/HIV coinfection, 2011–2020

s
e
s
a
C

6000

5000

4000

3000

2000

1000

0

Native

Foreign origin

Unknown

2012

2014

2016

2018

2020

HIV testing coverage
Proportion of HIV-positive TB cases among tested
6000

TB cases

5000

4000

3000

2000

1000

C
a
s
e
s

2012

2014

2016

2018

0

2020

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

RR/MDR-TB cases and percentage of RR/MDR-TB cases by previous 
treatment history among all TB cases, 2011–2020

Treatment outcome, new and relapse TB cases, 2010–2019

New
Retreatment
Total number of RR/MDR-TB

Unknown

Success
Died

Failed
Lost to follow-up

Not evaluated

Note: data up to 2014 include all TB cases.

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

1200

1000

800

600

400

200

C
a
s
e
s

2012

2014

2016

2018

0

2020

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

2011

2013

2015

2017

2019

Note: 2010–2011 cohorts include new cases only.

161

Tuberculosis surveillance and monitoring in Europe 2022SURVEILLANCE REPORT 
 
Romania

Total population at 9 April 2021 by EUROSTAT: 19 328 838

TB cases, 2020

Notifications

Total number of cases
Notification rate per 100 000
Newa and relapse
Newa and relapse notification rate 
per 100 000
Pulmonary
  of which microscopy-positive
  of which laboratory-confirmed
Laboratory-confirmed TB cases
Mean age of new native TB cases
Mean age of new foreign TB cases
Foreign origin of all TB cases
New (not previously treated)
Estimates
Estimated new and relapse cases N, 
best [low–high]

 7 698
39.8
 7 193

37.2

 6 655
 4 409
 5 473
 5 697

(86.5%)
(66.3%)
(82.2%)
(74.0%)

45.7 years
30.5 years

32
 6 019

(0.4%)
(78.2%)

12 000

[10 000–14 000]

a Cases with unknown previous TB history included in new cases.

Drug resistance surveillance and TB/HIV 
coinfection, 2020

Completeness of DRS dataa
Completeness of HIV datab
Case-linked data-reporting
Cases with DST results
Estimated RR-TB among notified 
bacteriologically confirmed 
pulmonary TB cases N, best 
[low–high]
Pulmonary RR/MDR-TB cases notified
  of which pre-XDR-TB cases
Notified RR/MDR-TB
  of which pre-XDR-TB cases
TB cases tested for HIV
HIV-positive TB cases
  of these on ART

Yes
Yes
Yes

 4 959

(87.0%)

290

[260–330]

244
27
252
28
 6 513
150
0

(5.1%)
(11.1%)
–
(11.1%)
(84.6%)
(2.3%)
(0.0%)

a National coverage 100% or culturing ≥ 90%, C+/all TB cases  
> 50%, DST done for C+ > 75%, EQA ≥ 95%.
b More than 50% of TB cases with reported HIV status.

Treatment outcome monitoring

Geographical 
coverage

Outcome cohort

Case-linked 
data-reporting
Cases notified
Success
Died
Failed
Lost to follow-up
Still on treatment
Not evaluated

National

New culture-positive 
pulmonary TB cases 
notified in 2019a

All RR/MDR-TB cases 
notified in 2018b

Yes

 6 310

 5 232
565
108
275
127
3

(82.9%)
(9.0%)
(1.7%)
(4.4%)
(2.0%)
(0.0%)

–

447

192
87
81
75
12
0

(43.0%)
(19.5%)
(18.1%)
(16.8%)
(2.7%)
(0.0%)

a Treatment outcome as presented is treatment outcome after 12 months.
b Treatment outcome as presented is treatment outcome after 24 months.

TB notification rates by previous treatment history, 2011–2020

New and relapse
Other

Unknown
Total

New and relapse TB cases – notification rates by age group, 
2011–2020

0–14

15–44

45–64

> 64

0
0
0
0
0
1
/
s
e
s
a
C

100

80

60

40

20

0

2012

2014

2016

2018

2020

0
0
0
0
0
1
/
s
e
s
a
C

160

120

80

40

0

2012

2014

2016

2018

2020

TB cases by geographical origin, 2011–2020

TB/HIV coinfection, 2011–2020

Native

Foreign origin

Unknown

HIV testing coverage
Proportion of HIV-positive TB cases among tested

All TB cases

20 000

15 000

s
e
s
a
C

10 000

5000

0

2012

2014

2016

2018

2020

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

20 000

15 000

10 000

C
a
s
e
s

5000

2012

2014

2016

2018

0

2020

RR/MDR-TB cases and percentage of RR/MDR-TB cases by previous 
treatment history among all TB cases, 2011–2020

Treatment outcome, new culture-confirmed pulmonary TB cases, 
2010–2019

New
Retreatment
Total number of RR/MDR-TB

Unknown

Success
Died

Still on treatment
Lost to follow-up

Failed
Not evaluated

800
700
600
500
400
300
200
100
0

C
a
s
e
s

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

2012

2014

2016

2018

2020

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

162

2011

2013

2015

2017

2019

SURVEILLANCE REPORTTuberculosis surveillance and monitoring in Europe 2022 
 
Russian Federation

Total population estimate 2020 by United Nations Statistical Database: 145 934 460

TB cases, 2020

Notifications

Total number of cases
Notification rate per 100 000
Newa and relapse
Newa and relapse notification rate 
per 100 000
Pulmonary
  of which microscopy-positive
  of which laboratory-confirmed
Laboratory-confirmed TB cases
Mean age of new native TB cases 
Mean age of new foreign TB cases
Foreign origin of all TB cases
New (not previously treated)
Estimates
Estimated new and relapse cases N,  
best [low–high]

 84 956
58.2
 58 723

40.2

 79 963
–
 45 055
–

(94.1%)
–
(56.3%)
–
42.4 years
–

1 503
 47 399

(1.8%)
(55.8%)

68 000

[43 000–98 000]

a Cases with unknown previous TB history included in new cases.

Drug resistance surveillance and TB/HIV 
coinfection, 2020

Completeness of DRS dataa
Completeness of HIV datab
Case-linked data-reporting
Cases with DST results
Estimated RR-TB among notified 
bacteriologically confirmed 
pulmonary TB cases N, best 
[low–high]
Pulmonary RR/MDR-TB cases 
notified
  of which pre-XDR-TB cases
Notified RR/MDR-TB
  of which pre-XDR-TB cases
TB cases tested for HIV
HIV-positive TB cases
  of these on ART

Yes
Yes
Yes

42 022

(93.3%)

23 000 [23 000–24 000]

21 963

7 822
21 963
7 822
55 838
13 506
9 190

(52.3%)

(38.3%)
–
(35.6%)
(95.1%)
(24.2%)
(68.0%)

a National coverage 100% or culturing ≥ 90%, C+/all TB cases  
> 50%, DST done for C+ > 75%, EQA ≥ 95%.
b More than 50% of TB cases with reported HIV status.

Treatment outcome monitoring

Geographical 
coverage

Outcome cohort

Case-linked 
data-reporting
Cases notified
Success
Died
Failed
Lost to follow-up
Not evaluated

National

New and relapse 
TB cases notified 
in 2019a

RR/MDR TB cases 
enrolled into DR-TB 
treatment in 2018b

Yes

54 589

–

28 706

37 208
5 936
3 567
3 471
4 407

(68.2%)
(10.9%)
(6.5%)
(6.4%)
(8.1%)

14 757
4 488
4 133
3 081
2 247

(51.4%)
(15.6%)
(14.4%)
(10.7%)
(7.8%)

a Treatment outcome as presented is treatment outcome after 12 months.
b Treatment outcome as presented is treatment outcome after 24 months.

TB notification rates by previous treatment history, 2011–2020

New and relapse
Other 

Unknown
Total

New and relapse TB cases – notification rates by age group, 
2011–2020

0–14

15–44

45–64

> 64

0
0
0
0
0
1
/
s
e
s
a
C

120

100

80

60

40

20

0

2012

2014

2016

2018

2020

0
0
0
0
0
1
/
s
e
s
a
C

140

120

100

80

60

40

20

0

2012

2014

2016

2018

2020

Note: starting from 2013 onward, cases with unknown history are included in new and 
relapses. 

Note: data up to 2012 include new TB cases only. 

TB cases by geographical origin, 2011–2020

TB/HIV coinfection, 2011–2020

Native

Foreign origin

Unknown

HIV testing coverage
Proportion of HIV-positive TB cases among tested

TB cases

s
e
s
a
C

180 000

160 000

140 000

120 000

100 000

80 000

60 000

40 000

20 000

0

2012

2014

2016

2018

2020

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

180 000

160 000

140 000

120 000

100 000

80 000

60 000

40 000

20 000

C
a
s
e
s

2012

2014

2016

2018

0

2020

RR/MDR-TB cases and percentage of RR/MDR-TB cases by previous 
treatment history among all TB cases, 2011–2020

Treatment outcome, new and relapse TB cases, 2010–2019

New
Retreatment
Total number of RR/MDR-TB

Unknown

Success
Died

Failed
Lost to follow-up

Not evaluated

Note: data up to 2014 include all TB cases.

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

30 000

25 000

20 000

15 000

10 000

5000

C
a
s
e
s

2012

2014

2016

2018

0

2020

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

2011

2013

2015

2017

2019

Note: 2010–2011 cohorts include new cases only.

163

Tuberculosis surveillance and monitoring in Europe 2022SURVEILLANCE REPORT 
 
San Marino

Total population estimate 2020 by United Nations Statistical Database: 33 938

TB cases, 2020

Notifications

Total number of cases
Notification rate per 100 000
Newa and relapse
Newa and relapse notification rate 
per 100 000
Pulmonary
  of which microscopy-positive
  of which laboratory-confirmed
Laboratory-confirmed TB cases
Mean age of new native TB cases
Mean age of new foreign TB cases
Foreign origin of all TB cases
New (not previously treated)
Estimates
Estimated new and relapse cases N,  
best [low–high]

–
–
–
–

–
–

0

–
–
–

–

–
–

–
–
–
–

–
–

[0–0]

a Cases with unknown previous TB history included in new cases.

Drug resistance surveillance and TB/HIV 
coinfection, 2020

Completeness of DRS dataa
Completeness of HIV datab
Case-linked data-reporting
Cases with DST results
Estimated RR-TB among notified 
bacteriologically confirmed 
pulmonary TB cases N, best 
[low–high]
Pulmonary RR/MDR-TB cases 
notified
  of which pre-XDR-TB cases
Notified RR/MDR-TB
  of which pre-XDR-TB cases
TB cases tested for HIV
HIV-positive TB cases
  of these on ART

No
No
No

–

[0–0]

–

–
–
–
–
–
–

–

0

–

–
–
–
–
–
–

a National coverage 100% or culturing ≥ 90%, C+/all TB cases 
> 50%, DST done for C+ > 75%, EQA ≥ 95%.
b More than 50% of TB cases with reported HIV status.

Treatment outcome monitoring

Geographical 
coverage

Outcome cohort

Case-linked 
data-reporting
Cases notified
Success
Died
Failed
Lost to follow-up
Not evaluated

National

New and relapse 
TB cases notified 
in 2019a

RR/MDR-TB cases 
enrolled into DR-TB 
treatment in  2018b

–

–
–
–
–
–
–

–

–
–
–
–
–
–

a Treatment outcome as presented is treatment outcome after 12 months.
b Treatment outcome as presented is treatment outcome after 24 months.

TB notification rates by previous treatment history, 2011–2020

New and relapse
Other

Unknown
Total

New and relapse TB cases – notification rates by age group, 
2011–2020

0–14

15–44

45–64

> 64

0
0
0
0
0
1
/
s
e
s
a
C

1

0

2012

2014

2016

2018

2020

0
0
0
0
0
1
/
s
e
s
a
C

1

0

2012

2014

2016

2018

2020

TB cases by geographical origin, 2011–2020

TB/HIV coinfection, 2011–2020

Native

Foreign origin

Unknown

HIV testing coverage
Proportion of HIV-positive TB cases among tested

TB cases

s
e
s
a
C

3

2

1

0

2012

2014

2016

2018

2020

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

3

2

1

0

C
a
s
e
s

2012

2014

2016

2018

2020

RR/MDR-TB cases and percentage of RR/MDR-TB cases by previous 
treatment history among all TB cases, 2011–2020

Treatment outcome, new and relapse TB cases, 2010–2019

New
Retreatment
Total number of RR/MDR-TB

Unknown

Success
Died

Failed
Lost to follow-up

Not evaluated

3

2

1

0

C
a
s
e
s

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

2012

2014

2016

2018

2020

2011

2013

2015

2017

2019

Note: 2010–2011 cohorts include new cases only.

45
40
35
30
25
20
15
10
5
0

e
g
a
t
n
e
c
r
e
P

164

SURVEILLANCE REPORTTuberculosis surveillance and monitoring in Europe 2022 
 
Serbia

Total population estimate 2020 by United Nations Statistical Database: 8 737 370

TB cases, 2020

Notifications

Total number of cases
Notification rate per 100 000
Newa and relapse
Newa and relapse notification rate 
per 100 000
Pulmonary
  of which microscopy-positive
  of which laboratory-confirmed
Laboratory-confirmed TB cases
Mean age of new native TB cases
Mean age of new foreign TB cases
Foreign origin of all TB cases
New (not previously treated)
Estimates
Estimated new and relapse cases N,  
best [low–high]

–
–
–

–

–
–

–
–
–
–

–
–

–
–
–
–

–
–

 1 200

[980–1 300]

a Cases with unknown previous TB history included in new cases.

Drug resistance surveillance and TB/HIV 
coinfection, 2020

Completeness of DRS dataa
Completeness of HIV datab
Case-linked data-reporting
Cases with DST results
Estimated RR-TB among notified 
bacteriologically confirmed 
pulmonary TB cases N, best 
[low–high]
Pulmonary RR/MDR-TB cases 
notified
  of which pre-XDR-TB cases
Notified RR/MDR-TB
  of which pre-XDR-TB cases
TB cases tested for HIV
HIV-positive TB cases
  of these on ART

No
No
No

–

[1–3]

–

–
–
–
–
–
–

–

2

–

–
–
–
–
–
–

a National coverage 100% or culturing ≥ 90%, C+/all TB cases 
> 50%, DST done for C+ > 75%, EQA ≥ 95%.
b More than 50% of TB cases with reported HIV status.

Treatment outcome monitoring

Geographical 
coverage

Outcome cohort

Case-linked 
data-reporting
Cases notified
Success
Died
Failed
Lost to follow-up
Not evaluated

National

New and relapse 
TB cases notified 
in 2019a

RR/MDR-TB cases 
enrolled into DR-TB 
treatment in  2018b

–

–
–
–
–
–
–

–

–
–
–
–
–
–

a Treatment outcome as presented is treatment outcome after 12 months.
b Treatment outcome as presented is treatment outcome after 24 months.

TB notification rates by previous treatment history, 2011–2020

New and relapse
Other 

Unknown
Total

New and relapse TB cases – notification rates by age group, 
2011–2020

0–14

15–44

45–64

> 64

0
0
0
0
0
1
/
s
e
s
a
C

30

25

20

15

10

5

0

2012

2014

2016

2018

2020

0
0
0
0
0
1
/
s
e
s
a
C

35

30

25

20

15

10

5

0

2012

2014

2016

2018

2020

Note: starting from 2013 onward, cases with unknown history are included in new and 
relapses. 

Note: data up to 2012 include new TB cases only. 

TB cases by geographical origin, 2011–2020

TB/HIV coinfection, 2011–2020

s
e
s
a
C

2500

2000

1500

1000

500

0

Native

Foreign origin

Unknown

2012

2014

2016

2018

2020

HIV testing coverage
Proportion of HIV-positive TB cases among tested
2500

TB cases

2000

1500

1000

500

C
a
s
e
s

2012

2014

2016

2018

0

2020

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

RR/MDR-TB cases and percentage of RR/MDR-TB cases by previous 
treatment history among all TB cases, 2011–2020

Treatment outcome, new and relapse TB cases, 2010–2019

New
Retreatment
Total number of RR/MDR-TB

Unknown

Success
Died

Failed
Lost to follow-up

Not evaluated

Note: data up to 2014 include all TB cases.

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

16

14

12

10

8

6

4

2

0

C
a
s
e
s

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

2012

2014

2016

2018

2020

2011

2013

2015

2017

2019

Note: 2010–2011 cohorts include new cases only.

165

Tuberculosis surveillance and monitoring in Europe 2022SURVEILLANCE REPORT 
 
Slovakia

Total population at 9 April 2021 by EUROSTAT: 5 457 873

TB cases, 2020

Notifications

Total number of cases
Notification rate per 100 000
Newa and relapse
Newa and relapse notification rate 
per 100 000
Pulmonary
  of which microscopy-positive
  of which laboratory-confirmed
Laboratory-confirmed TB cases
Mean age of new native TB cases
Mean age of new foreign TB cases
Foreign origin of all TB cases
New (not previously treated)
Estimates
Estimated new and relapse cases N, 
best [low–high]

158
2.9
153

2.8

135
37
65
67

6
133

(85.4%)
(27.4%)
(48.1%)
(42.4%)

44.2 years
37.5 years

(3.8%)
(84.2%)

180

[150–200]

a Cases with unknown previous TB history included in new cases.

Drug resistance surveillance and TB/HIV 
coinfection, 2020

Completeness of DRS dataa
Completeness of HIV datab
Case-linked data-reporting
Cases with DST results
Estimated RR-TB among notified 
bacteriologically confirmed 
pulmonary TB cases N, best 
[low–high]
Pulmonary RR/MDR-TB cases notified
  of which pre-XDR-TB cases
Notified RR/MDR-TB
  of which pre-XDR-TB cases
TB cases tested for HIV
HIV-positive TB cases
  of these on ART

Yes
Yes
Yes

66

(98.5%)

1

1
0
1
0
82
2
0

[0–4]

(1.6%)
(0.0%)
–
(0.0%)
(51.9%)
(2.4%)
(0.0%)

a National coverage 100% or culturing ≥ 90%, C+/all TB cases  
> 50%, DST done for C+ > 75%, EQA ≥ 95%.
b More than 50% of TB cases with reported HIV status.

Treatment outcome monitoring

Geographical 
coverage

Outcome cohort

Case-linked 
data-reporting
Cases notified
Success
Died
Failed
Lost to follow-up
Still on treatment
Not evaluated

National

New culture-positive 
pulmonary TB cases 
notified in 2019a

All RR/MDR-TB cases 
notified in 2018b

Yes

79

76
2
0
0
1
0

(96.2%)
(2.5%)
(0.0%)
(0.0%)
(1.3%)
(0.0%)

–

3

(66.7%)
(33.3%)
(0.0%)
(0.0%)
(0.0%)
(0.0%)

2
1
0
0
0
0

a Treatment outcome as presented is treatment outcome after 12 months.
b Treatment outcome as presented is treatment outcome after 24 months.

TB notification rates by previous treatment history, 2011–2020

New and relapse
Other 

Unknown
Total

New and relapse TB cases – notification rates by age group, 
2011–2020

0–14

15–44

45–64

> 64

0
0
0
0
0
1
/
s
e
s
a
C

10

8

6

4

2

0

2012

2014

2016

2018

2020

0
0
0
0
0
1
/
s
e
s
a
C

20

16

12

8

4

0

2012

2014

2016

2018

2020

TB cases by geographical origin, 2011–2020

TB/HIV coinfection, 2011–2020

Native

Foreign origin

Unknown

HIV testing coverage
Proportion of HIV-positive TB cases among tested

All TB cases

s
e
s
a
C

500

400

300

200

100

0

2012

2014

2016

2018

2020

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

600

500

400

300

200

100

C
a
s
e
s

2012

2014

2016

2018

0

2020

RR/MDR-TB cases and percentage of RR/MDR-TB cases by previous 
treatment history among all TB cases, 2011–2020

Treatment outcome, new culture-confirmed pulmonary TB cases, 
2010–2019

New
Retreatment
Total number of RR/MDR-TB

Unknown

Success
Died

Still on treatment
Lost to follow-up

Failed
Not evaluated

8

6

4

2

0

C
a
s
e
s

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

2012

2014

2016

2018

2020

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

166

2011

2013

2015

2017

2019

SURVEILLANCE REPORTTuberculosis surveillance and monitoring in Europe 2022 
 
Slovenia

Total population at 9 April 2021 by EUROSTAT: 22 095 861

TB cases, 2020

Notifications

Total number of cases
Notification rate per 100 000
Newa and relapse
Newa and relapse notification rate 
per 100 000
Pulmonary
  of which microscopy-positive
  of which laboratory-confirmed
Laboratory-confirmed TB cases
Mean age of new native TB cases
Mean age of new foreign TB cases
Foreign origin of all TB cases
New (not previously treated)
Estimates
Estimated new and relapse cases N, 
best [low–high]

77
3.7
75

3.6

66
25
62
73

26
70

86

(85.7%)
(37.9%)
(93.9%)
(94.8%)

67.6 years
54.0 years

(33.8%)
(90.9%)

[74–100]

a Cases with unknown previous TB history included in new cases.

Drug resistance surveillance and TB/HIV 
coinfection, 2020

Completeness of DRS dataa
Completeness of HIV datab
Case-linked data-reporting
Cases with DST results
Estimated RR-TB among notified 
bacteriologically confirmed 
pulmonary TB cases N, best 
[low–high]
Pulmonary RR/MDR-TB cases notified
  of which pre-XDR-TB cases
Notified RR/MDR-TB
  of which pre-XDR-TB cases
TB cases tested for HIV
HIV-positive TB cases
  of these on ART

Yes
Yes
Yes

73

(100.0%)

1

1
0
1
0
58
0
–

[0–3]

(1.6%)
–
–
–
(75.3%)
(0.0%)
–

a National coverage 100% or culturing ≥ 90%, C+/all TB cases  
> 50%, DST done for C+ > 75%, EQA ≥ 95%.
b More than 50% of TB cases with reported HIV status.

Treatment outcome monitoring

Geographical 
coverage

Outcome cohort

Case-linked 
data-reporting
Cases notified
Success
Died
Failed
Lost to follow-up
Still on treatment
Not evaluated

National

New culture-positive 
pulmonary TB cases 
notified in 2019a

All RR/MDR-TB cases 
notified in 2018b

Yes

78

59
15
0
3
1
0

(75.6%)
(19.2%)
(0.0%)
(3.8%)
(1.3%)
(0.0%)

–

0

–
–
–
–
–
–

–
–
–
–
–
–

a Treatment outcome as presented is treatment outcome after 12 months.
b Treatment outcome as presented is treatment outcome after 24 months.

TB notification rates by previous treatment history, 2011–2020

New and relapse
Other

Unknown
Total

New and relapse TB cases – notification rates by age group, 
2011–2020

0–14

15–44

45–64

> 64

0
0
0
0
0
1
/
s
e
s
a
C

10

8

6

4

2

0

2012

2014

2016

2018

2020

0
0
0
0
0
1
/
s
e
s
a
C

20

15

10

5

0

2012

2014

2016

2018

2020

TB cases by geographical origin, 2011–2020

TB/HIV coinfection, 2011–2020

Native

Foreign origin

Unknown

HIV testing coverage
Proportion of HIV-positive TB cases among tested

All TB cases

s
e
s
a
C

160

140

120

100

80

60

40

20

0

2012

2014

2016

2018

2020

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

200

150

100

50

C
a
s
e
s

2012

2014

2016

2018

0

2020

RR/MDR-TB cases and percentage of RR/MDR-TB cases by previous 
treatment history among all TB cases, 2011–2020

Treatment outcome, new culture-confirmed pulmonary TB cases, 
2010–2019

New
Retreatment
Total number of RR/MDR-TB

Unknown

Success
Died

Still on treatment
Lost to follow-up

Failed
Not evaluated

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

2

1

C
a
s
e
s

2012

2014

2016

2018

0

2020

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

2011

2013

2015

2017

2019

167

Tuberculosis surveillance and monitoring in Europe 2022SURVEILLANCE REPORT 
 
Spain

Total population at 9 April 2021 by EUROSTAT: 47 332 614

TB cases, 2020

Notifications

Total number of cases
Notification rate per 100 000
Newa and relapse
Newa and relapse notification rate 
per 100 000
Pulmonary
  of which microscopy-positive
  of which laboratory-confirmed
Laboratory-confirmed TB cases
Mean age of new native TB cases
Mean age of new foreign TB cases
Foreign origin of all TB cases
New (not previously treated)
Estimates
Estimated new and relapse cases N, 
best [low–high]

 3 044
6.4
 2 949

6.2

 2 225
  925
 1 420
 1 810

(73.1%)
(41.6%)
(63.8%)
(59.5%)

51.0 years
37.5 years

 1 030
 1 880

(33.8%)
(61.8%)

3 400

[2 900–3 900]

a Cases with unknown previous TB history included in new cases.

Drug resistance surveillance and TB/HIV 
coinfection, 2020

Completeness of DRS dataa
Completeness of HIV datab
Case-linked data-reporting
Cases with DST results
Estimated RR-TB among notified 
bacteriologically confirmed 
pulmonary TB cases N, best 
[low–high]
Pulmonary RR/MDR-TB cases notified
  of which pre-XDR-TB cases
Notified RR/MDR-TB
  of which pre-XDR-TB cases
TB cases tested for HIV
HIV-positive TB cases
  of these on ART

Yes
Yes
Yes

842

(46.5%)

77

[54–100]

12
1
15
1
 1 759
  173
–

(1.4%)
(33.3%)
–
(6.7%)
(57.8%)
(9.8%)
–

a National coverage 100% or culturing ≥ 90%, C+/all TB cases  
> 50%, DST done for C+ > 75%, EQA ≥ 95%.
b More than 50% of TB cases with reported HIV status.

Treatment outcome monitoring

Geographical 
coverage

Outcome cohort

Case-linked 
data-reporting
Cases notified
Success
Died
Failed
Lost to follow-up
Still on treatment
Not evaluated

National

New culture-positive 
pulmonary TB cases 
notified in 2019a

All RR/MDR-TB cases 
notified in 2018b

Yes

1 507

895
95
0
1
22
494

(59.4%)
(6.3%)
(0.0%)
(0.1%)
(1.5%)
(32.8%)

–

23

(21.7%)
(8.7%)
(0.0%)
(0.0%)
(0.0%)
(69.6%)

5
2
0
0
0
16

a Treatment outcome as presented is treatment outcome after 12 months.
b Treatment outcome as presented is treatment outcome after 24 months.

TB notification rates by previous treatment history, 2011–2020

New and relapse
Other

Unknown
Total

New and relapse TB cases – notification rates by age group, 
2011–2020

0–14

15–44

45–64

> 64

0
0
0
0
0
1
/
s
e
s
a
C

18
16
14
12
10
8
6
4
2
0

2012

2014

2016

2018

2020

0
0
0
0
0
1
/
s
e
s
a
C

18
16
14
12
10
8
6
4
2
0

2012

2014

2016

2018

2020

TB cases by geographical origin, 2011–2020

TB/HIV coinfection, 2011–2020

5000

4000

s
e
s
a
C

3000

2000

1000

0

Native

Foreign origin

Unknown

2012

2014

2016

2018

2020

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

HIV testing coverage
Proportion of HIV-positive TB cases among tested
8000

All TB cases

7000

6000

5000

4000

3000

2000

1000

C
a
s
e
s

2012

2014

2016

2018

0

2020

RR/MDR-TB cases and percentage of RR/MDR-TB cases by previous 
treatment history among all TB cases, 2011–2020

Treatment outcome, new culture-confirmed pulmonary TB cases, 
2010–2019

New
Retreatment
Total number of RR/MDR-TB

Unknown

Success
Died

Still on treatment
Lost to follow-up

Failed
Not evaluated

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

60

50

40

30

20

10

0

C
a
s
e
s

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

2012

2014

2016

2018

2020

Note: in 2013, 2015 and 2016, only pulmonary RR/MDR-TB cases were reported.

168

2011

2013

2015

2017

2019

SURVEILLANCE REPORTTuberculosis surveillance and monitoring in Europe 2022 
 
Sweden

Total population at 9 April 2021 by EUROSTAT: 10 327 589

TB cases, 2020

Notifications

Total number of cases
Notification rate per 100 000
Newa and relapse
Newa and relapse notification rate 
per 100 000
Pulmonary
  of which microscopy-positive
  of which laboratory-confirmed
Laboratory-confirmed TB cases
Mean age of new native TB cases
Mean age of new foreign TB cases
Foreign origin of all TB cases
New (not previously treated)
Estimates
Estimated new and relapse cases N, 
best [low–high]

328
3.2
316

3.1

207
76
180
264

284
306

(63.1%)
(36.7%)
(87.0%)
(80.5%)

47.3 years
37.6 years

(86.6%)
(93.3%)

360

[310–420]

a Cases with unknown previous TB history included in new cases.

Drug resistance surveillance and TB/HIV 
coinfection, 2020

Completeness of DRS dataa
Completeness of HIV datab
Case-linked data-reporting

Yes
No
Yes

Cases with DST results

264

(100.0%)

Estimated RR-TB among notified 
bacteriologically confirmed 
pulmonary TB cases N, best 
[low–high]
Pulmonary RR/MDR-TB cases notified
  of which pre-XDR-TB cases
Notified RR/MDR-TB
  of which pre-XDR-TB cases
TB cases tested for HIV
HIV-positive TB cases
  of these on ART

5

5
2
6
2
–
–
–

[1–10]

(2.8%)
(40.0%)
–
(33.3%)
–
–
–

a National coverage 100% or culturing ≥ 90%, C+/all TB cases  
> 50%, DST done for C+ > 75%, EQA ≥ 95%.
b More than 50% of TB cases with reported HIV status.

Treatment outcome monitoring

Geographical 
coverage

Outcome cohort

Case-linked 
data-reporting
Cases notified
Success
Died
Failed
Lost to follow-up
Still on treatment
Not evaluated

National

New culture-positive 
pulmonary TB cases 
notified in 2019a

All RR/MDR-TB cases 
notified in 2018b

Yes

235

138
8
0
0
4
85

(58.7%)
(3.4%)
(0.0%)
(0.0%)
(1.7%)
(36.2%)

–

14

14
0
0
0
0
0

(100.0%)
(0.0%)
(0.0%)
(0.0%)
(0.0%)
(0.0%)

a Treatment outcome as presented is treatment outcome after 12 months.
b Treatment outcome as presented is treatment outcome after 24 months.

TB notification rates by previous treatment history, 2011–2020

New and relapse
Other 

Unknown
Total

New and relapse TB cases – notification rates by age group, 
2011–2020

0–14

15–44

45–64

> 64

0
0
0
0
0
1
/
s
e
s
a
C

9
8
7
6
5
4
3
2
1
0

2012

2014

2016

2018

2020

0
0
0
0
0
1
/
s
e
s
a
C

16

14

12

10

8

6

4

2

0

2012

2014

2016

2018

2020

TB cases by geographical origin, 2011–2020

TB/HIV coinfection, 2011–2020

Native

Foreign origin

Unknown

Data not reported

s
e
s
a
C

800

700

600

500

400

300

200

100

0

2012

2014

2016

2018

2020

RR/MDR-TB cases and percentage of RR/MDR-TB cases by previous 
treatment history among all TB cases, 2011–2020

Treatment outcome, new culture-confirmed pulmonary TB cases, 
2010–2019

New
Retreatment
Total number of RR/MDR-TB

Unknown

Success
Died

Still on treatment
Lost to follow-up

Failed
Not evaluated

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

30

25

20

15

10

5

0

C
a
s
e
s

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

2012

2014

2016

2018

2020

2011

2013

2015

2017

2019

169

Tuberculosis surveillance and monitoring in Europe 2022SURVEILLANCE REPORT 
 
Switzerland

Total population estimate 2020 by United Nations Statistical Database: 8 654 618

TB cases, 2020

Notifications

Total number of cases
Notification rate per 100 000
Newa and relapse
Newa and relapse notification rate 
per 100 000
Pulmonary
  of which microscopy-positive
  of which laboratory-confirmed
Laboratory-confirmed TB cases
Mean age of new native TB cases
Mean age of new foreign TB cases
Foreign origin of all TB cases
New (not previously treated)
Estimates
Estimated new and relapse cases N,  
best [low–high]

  387
4.5
  351

4.1

  314
–
  271
–

276
  351

(81.1%)
–
(86.3%)
–
41.1 years
–

(71.3%)
(90.7%)

400

[350–470]

a Cases with unknown previous TB history included in new cases.

Drug resistance surveillance and TB/HIV 
coinfection, 2020

Completeness of DRS dataa
Completeness of HIV datab
Case-linked data-reporting
Cases with DST results
Estimated RR-TB among notified 
bacteriologically confirmed 
pulmonary TB cases N, best 
[low–high]
Pulmonary RR/MDR-TB cases 
notified
  of which pre-XDR-TB cases
Notified RR/MDR-TB
  of which pre-XDR-TB cases
TB cases tested for HIV
HIV-positive TB cases
  of these on ART

No
No
Yes

(63.1%)

[4–16]

(2.3%)

(50.0%)
–
(20.0%)
(0.0%)
–
–

171

10

4

2
5
1
0
–
–

a National coverage 100% or culturing ≥ 90%, C+/all TB cases  
> 50%, DST done for C+ > 75%, EQA ≥ 95%.
b More than 50% of TB cases with reported HIV status.

Treatment outcome monitoring

Geographical 
coverage

Outcome cohort

Case-linked 
data-reporting
Cases notified
Success
Died
Failed
Lost to follow-up
Not evaluated

National

New culture-positive 
pulmonary TB cases 
notified in 2019a

RR/MDR TB cases 
enrolled into DR-TB 
treatment in 2018b

Yes

391

267
10
0
0
114

(68.3%)
(2.6%)
(0.0%)
(0.0%)
(29.2%)

–

9

6
0
0
0
3

(66.7%)
(0.0%)
(0.0%)
(0.0%)
(33.3%)

a Treatment outcome as presented is treatment outcome after 12 months.
b Treatment outcome as presented is treatment outcome after 24 months.

TB notification rates by previous treatment history, 2011–2020

New and relapse
Other 

Unknown
Total

New and relapse TB cases – notification rates by age group, 
2011–2020

0–14

15–44

45–64

> 64

0
0
0
0
0
1
/
s
e
s
a
C

8

7

6

5

4

3

2

1

0

2012

2014

2016

2018

2020

0
0
0
0
0
1
/
s
e
s
a
C

14

12

10

8

6

4

2

0

2012

2014

2016

2018

2020

Note: starting from 2013 onward, cases with unknown history are included in new and 
relapses. 

Note: data up to 2012 include new TB cases only. 

TB cases by geographical origin, 2011–2020

TB/HIV coinfection, 2011–2020

Native

Foreign origin

Unknown

HIV testing coverage
Proportion of HIV-positive TB cases among tested

All TB cases

s
e
s
a
C

600

500

400

300

200

100

0

2012

2014

2016

2018

2020

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

700

600

500

400

300

200

100

C
a
s
e
s

2012

2014

2016

2018

0

2020

RR/MDR-TB cases and percentage of RR/MDR-TB cases by previous 
treatment history among all TB cases, 2011–2020

Treatment outcome, new and relapse TB cases, 2010–2019

New
Retreatment
Total number of RR/MDR-TB

Unknown

Success
Died

Still on treatment
Lost to follow-up

Failed
Not evaluated

16
14
12
10
8
6
4
2
0

C
a
s
e
s

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

2012

2014

2016

2018

2020

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

170

2011

2013

2015

2017

2019

SURVEILLANCE REPORTTuberculosis surveillance and monitoring in Europe 2022 
 
Tajikistan

Total population estimate 2020 by United Nations Statistical Database: 9 537 642

TB cases, 2020

Notifications

Total number of cases
Notification rate per 100 000
Newa and relapse
Newa and relapse notification rate 
per 100 000
Pulmonary
  of which microscopy-positive
  of which laboratory-confirmed
Laboratory-confirmed TB cases
Mean age of new native TB cases
Mean age of new foreign TB cases
Foreign origin of all TB cases
New (not previously treated)
Estimates
Estimated new and relapse cases N,  
best [low–high]

 4 316
45.3
 4 148

43.5

 2 925
–
 2 023
–

–
 3 759

(67.8%)
–
(69.2%)
–
37.6 years
–

–
(87.1%)

8 000

[6 100–10 000]

a Cases with unknown previous TB history included in new cases.

Drug resistance surveillance and TB/HIV 
coinfection, 2020

Completeness of DRS dataa
Completeness of HIV datab
Case-linked data-reporting
Cases with DST results
Estimated RR-TB among notified 
bacteriologically confirmed 
pulmonary TB cases N, best 
[low–high]
Pulmonary RR/MDR-TB cases 
notified
  of which pre-XDR-TB cases
Notified RR/MDR-TB
  of which pre-XDR-TB cases
TB cases tested for HIV
HIV-positive TB cases
  of these on ART

Yes
Yes
Yes

2 023

(100.0%)

560

[520–590]

555

(27.4%)

121
557
123
4 043
118
116

(23.6%)
–
(22.1%)
(97.5%)
(2.9%)
(98.3%)

a National coverage 100% or culturing ≥ 90%, C+/all TB cases  
> 50%, DST done for C+ > 75%, EQA ≥ 95%.
b More than 50% of TB cases with reported HIV status.

Treatment outcome monitoring

Geographical 
coverage

Outcome cohort

Case-linked 
data-reporting
Cases notified
Success
Died
Failed
Lost to follow-up
Not evaluated

National

New and relapse 
TB cases notified 
in 2019a

RR/MDR TB cases 
enrolled into DR-TB 
treatment in 2018b

Yes

5 114

–

727

4 643
179
60
190
42

(90.8%)
(3.5%)
(1.2%)
(3.7%)
(0.8%)

510
95
23
88
11

(70.2%)
(13.1%)
(3.2%)
(12.1%)
(1.5%)

a Treatment outcome as presented is treatment outcome after 12 months.
b Treatment outcome as presented is treatment outcome after 24 months.

TB notification rates by previous treatment history, 2011–2020

New and relapse
Other

Unknown
Total

New and relapse TB cases – notification rates by age group, 
2011–2020

0–14

15–44

45–64

> 64

0
0
0
0
0
1
/
s
e
s
a
C

100

80

60

40

20

0

2012

2014

2016

2018

2020

0
0
0
0
0
1
/
s
e
s
a
C

250

200

150

100

50

0

2012

2014

2016

2018

2020

Note: starting from 2013 onward, cases with unknown history are included in new and 
relapses. 

Note: data up to 2012 include new TB cases only. 

TB cases by geographical origin, 2011–2020

TB/HIV coinfection, 2011–2020

s
e
s
a
C

9000
8000
7000
6000
5000
4000
3000
2000
1000
0

Native

Foreign origin

Unknown

2012

2014

2016

2018

2020

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

TB cases

HIV testing coverage
Proportion of HIV-positive TB cases among tested
9000
8000
7000
6000
5000
4000
3000
2000
1000
0

2016

2018

2020

2014

2012

C
a
s
e
s

RR/MDR-TB cases and percentage of RR/MDR-TB cases by previous 
treatment history among all TB cases, 2011–2020

Treatment outcome, new and relapse TB cases, 2010–2019

New
Retreatment
Total number of RR/MDR-TB

Unknown

Success
Died

Failed
Lost to follow-up

Not evaluated

Note: data up to 2014 include all TB cases.

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

1200

1000

800

600

400

200

C
a
s
e
s

2012

2014

2016

2018

0

2020

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

2011

2013

2015

2017

2019

Note: 2010–2011 cohorts include new cases only.

171

Tuberculosis surveillance and monitoring in Europe 2022SURVEILLANCE REPORT 
 
Turkey

Total population estimate 2020 by United Nations Statistical Database: 84 339 067

TB cases, 2020

Notifications

Total number of cases
Notification rate per 100 000
Newa and relapse
Newa and relapse notification rate 
per 100 000
Pulmonary
  of which microscopy-positive
  of which laboratory-confirmed
Laboratory-confirmed TB cases
Mean age of new native TB cases
Mean age of new foreign TB cases
Foreign origin of all TB cases
New (not previously treated)
Estimates
Estimated new and relapse cases N,  
best [low–high]

 8 925
10.6
 8 830

10.5

 5 802
–
 4 523
–

(65.0%)
–
(78.0%)
–
43.6 years
–

1 420
 8 358

(15.9%)
(93.6%)

13 000

[11 000–15 000]

a Cases with unknown previous TB history included in new cases.

Drug resistance surveillance and TB/HIV 
coinfection, 2020

Completeness of DRS dataa
Completeness of HIV datab
Case-linked data-reporting
Cases with DST results
Estimated RR-TB among notified 
bacteriologically confirmed 
pulmonary TB cases N, best 
[low–high]
Pulmonary RR/MDR-TB cases 
notified
  of which pre-XDR-TB cases
Notified RR/MDR-TB
  of which pre-XDR-TB cases
TB cases tested for HIV
HIV-positive TB cases
  of these on ART

Yes
Yes
Yes

4 074

(90.1%)

140

[120–170]

127

14
149
14
7 062
83
62

(3.1%)

(14.1%)
–
(9.4%)
(80.0%)
(1.2%)
(74.7%)

a National coverage 100% or culturing ≥ 90%, C+/all TB cases 
> 50%, DST done for C+ > 75%, EQA ≥ 95%.
b More than 50% of TB cases with reported HIV status.

Treatment outcome monitoring

Geographical 
coverage

Outcome cohort

Case-linked 
data-reporting
Cases notified
Success
Died
Failed
Lost to follow-up
Not evaluated

National

New and relapse 
TB cases notified 
in 2019a

RR/MDR TB cases 
enrolled into DR-TB 
treatment in 2018b

Yes

11 095

9 231
973
22
200
669

(83.2%)
(8.8%)
(0.2%)
(1.8%)
(6.0%)

–

180

99
20
2
9
50

(55.0%)
(11.1%)
(1.1%)
(5.0%)
(27.8%)

a Treatment outcome as presented is treatment outcome after 12 months.
b Treatment outcome as presented is treatment outcome after 24 months.

TB notification rates by previous treatment history, 2011–2020

New and relapse
Other

Unknown
Total

New and relapse TB cases – notification rates by age group, 
2011–2020

0–14

15–44

45–64

> 64

0
0
0
0
0
1
/
s
e
s
a
C

30

25

20

15

10

5

0

2012

2014

2016

2018

2020

0
0
0
0
0
1
/
s
e
s
a
C

45
40
35
30
25
20
15
10
5
0

2012

2014

2016

2018

2020

Note: starting from 2013 onward, cases with unknown history are included in new and 
relapses. 

Note: data up to 2012 include new TB cases only. 

TB cases by geographical origin, 2011–2020

TB/HIV coinfection, 2011–2020

Native

Foreign origin

Unknown

HIV testing coverage
Proportion of HIV-positive TB cases among tested

TB cases

20 000

15 000

s
e
s
a
C

10 000

5000

0

2012

2014

2016

2018

2020

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

20 000

15 000

10 000

C
a
s
e
s

5000

2012

2014

2016

2018

0

2020

RR/MDR-TB cases and percentage of RR/MDR-TB cases by previous 
treatment history among all TB cases, 2011–2020

Treatment outcome, new and relapse TB cases, 2010–2019

New
Retreatment
Total number of RR/MDR-TB

Unknown

Success
Died

Still on treatment
Lost to follow-up

Failed
Not evaluated

Note: data up to 2014 include all TB cases.

400
350
300
250
200
150
100
50
0

C
a
s
e
s

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

2012

2014

2016

2018

2020

2011

2013

2015

2017

2019

Note: 2010–2011 cohorts include new cases only.

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

172

SURVEILLANCE REPORTTuberculosis surveillance and monitoring in Europe 2022 
 
Turkmenistan

Total population estimate 2020 by United Nations Statistical Database: 6 031 187

TB cases, 2020

Notifications

Total number of cases
Notification rate per 100 000
Newa and relapse
Newa and relapse notification rate 
per 100 000
Pulmonary
  of which microscopy-positive
  of which laboratory-confirmed
Laboratory-confirmed TB cases
Mean age of new native TB cases
Mean age of new foreign TB cases
Foreign origin of all TB cases
New (not previously treated)
Estimates
Estimated new and relapse cases N,  
best [low–high]

 2 610
43.3
 1 918

31.8

 2 180
–
  833
–

0
 1 603

(83.5%)
–
(38.2%)
–
40.6 years
–

(0.0%)
(61.4%)

2 800

[2 200–3 600]

a Cases with unknown previous TB history included in new cases.

Drug resistance surveillance and TB/HIV 
coinfection, 2020

Completeness of DRS dataa
Completeness of HIV datab
Case-linked data-reporting
Cases with DST results
Estimated RR-TB among notified 
bacteriologically confirmed 
pulmonary TB cases N, best 
[low–high]
Pulmonary RR/MDR-TB cases 
notified
  of which pre-XDR-TB cases
Notified RR/MDR-TB
  of which pre-XDR-TB cases
TB cases tested for HIV
HIV-positive TB cases
  of these on ART

No
No
Yes

833

(100.0%)

290

[260–310]

–

–
783
264
–
–
–

–

–
–
(33.7%)
–
–
–

a National coverage 100% or culturing ≥ 90%, C+/all TB cases 
> 50%, DST done for C+ > 75%, EQA ≥ 95%.
b More than 50% of TB cases with reported HIV status.

Treatment outcome monitoring

Geographical 
coverage

Outcome cohort

Case-linked 
data-reporting
Cases notified
Success
Died
Failed
Lost to follow-up
Not evaluated

National

New and relapse 
TB cases notified 
in 2019a

RR/MDR TB cases 
enrolled into DR-TB 
treatment in 2018b

Yes

2 117

–

549

1 749
90
135
84
59

(82.6%)
(4.3%)
(6.4%)
(4.0%)
(2.8%)

248
92
98
92
19

(45.2%)
(16.8%)
(17.9%)
(16.8%)
(3.5%)

a Treatment outcome as presented is treatment outcome after 12 months.
b Treatment outcome as presented is treatment outcome after 24 months.

TB notification rates by previous treatment history, 2011–2020

New and relapse
Other

Unknown
Total

New and relapse TB cases – notification rates by age group, 
2011–2020

0–14

15–44

45–64

> 64

0
0
0
0
0
1
/
s
e
s
a
C

80

70

60

50

40

30

20

10

0

2012

2014

2016

2018

2020

0
0
0
0
0
1
/
s
e
s
a
C

80

70

60

50

40

30

20

10

0

2012

2014

2016

2018

2020

Note: starting from 2013 onward, cases with unknown history are included in new and 
relapses. 

Note: data up to 2012 include new TB cases only. 

TB cases by geographical origin, 2011–2020

TB/HIV coinfection, 2011–2020

s
e
s
a
C

4000

3500

3000

2500

2000

1500

1000

500

0

Native

Foreign origin

Unknown

2012

2014

2016

2018

2020

HIV testing coverage
Proportion of HIV-positive TB cases among tested
4000

TB cases

3500

3000

2500

2000

1500

1000

500

C
a
s
e
s

2012

2014

2016

2018

0

2020

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

RR/MDR-TB cases and percentage of RR/MDR-TB cases by previous 
treatment history among all TB cases, 2011–2020

Treatment outcome, new and relapse TB cases, 2010–2019

New
Retreatment
Total number of RR/MDR-TB

Unknown

Success
Died

Failed
Lost to follow-up

Not evaluated

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

70

60

50

40

30

20

10

0

C
a
s
e
s

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

2012

2014

2016

2018

2020

2011

2013

2015

2017

2019

Note: 2010–2011 cohorts include new cases only.

173

Tuberculosis surveillance and monitoring in Europe 2022SURVEILLANCE REPORT 
 
Ukraine

Total population estimate 2020 by United Nations Statistical Database: 43 733 759

TB cases, 2020

Notifications

Total number of cases
Notification rate per 100 000
Newa and relapse
Newa and relapse notification rate 
per 100 000
Pulmonary
  of which microscopy-positive
  of which laboratory-confirmed
Laboratory-confirmed TB cases
Mean age of new native TB cases
Mean age of new foreign TB cases
Foreign origin of all TB cases
New (not previously treated)
Estimates
Estimated new and relapse cases N,  
best [low–high]

 19 521
44.6
 17 533

40.1

 17 915
–
 13 177
–

(91.8%)
–
(73.6%)
–
43.6 years
–

31
 14 156

(0.2%)
(72.5%)

32 000

[21 000–45 000]

a Cases with unknown previous TB history included in new cases.

Drug resistance surveillance and TB/HIV 
coinfection, 2020

Completeness of DRS dataa
Completeness of HIV datab
Case-linked data-reporting
Cases with DST results
Estimated RR-TB among notified 
bacteriologically confirmed 
pulmonary TB cases N, best 
[low–high]
Pulmonary RR/MDR-TB cases 
notified
  of which pre-XDR-TB cases
Notified RR/MDR-TB
  of which pre-XDR-TB cases
TB cases tested for HIV
HIV-positive TB cases
  of these on ART

Yes
Yes
Yes

12 818

(97.3%)

4 300

[4 200–4 400]

4 177

(32.6%)

1 120
4 257
1 172
17 375
3 794
3 460

(26.8%)
–
(27.5%)
(99.1%)
(21.8%)
(91.2%)

a National coverage 100% or culturing ≥ 90%, C+/all TB cases  
> 50%, DST done for C+ > 75%, EQA ≥ 95%.
b More than 50% of TB cases with reported HIV status.

Treatment outcome monitoring

Geographical 
coverage

Outcome cohort

Case-linked 
data-reporting
Cases notified
Success
Died
Failed
Lost to follow-up
Not evaluated

National

New and relapse 
TB cases notified 
in 2019a

RR/MDR TB cases 
enrolled into DR-TB 
treatment in 2018b

Yes

19 414

–

5 953

15 381
1 816
1 180
1 023
14

(79.2%)
(9.4%)
(6.1%)
(5.3%)
(0.1%)

3 006
970
1 033
926
18

(50.5%)
(16.3%)
(17.4%)
(15.6%)
(0.3%)

a Treatment outcome as presented is treatment outcome after 12 months.
b Treatment outcome as presented is treatment outcome after 24 months.

TB notification rates by previous treatment history, 2011–2020

New and relapse
Other

Unknown
Total

New and relapse TB cases – notification rates by age group, 
2011–2020

0–14

15–44

45–64

> 64

0
0
0
0
0
1
/
s
e
s
a
C

120

100

80

60

40

20

0

2012

2014

2016

2018

2020

0
0
0
0
0
1
/
s
e
s
a
C

120

100

80

60

40

20

0

2012

2014

2016

2018

2020

Note: starting from 2013 onward, cases with unknown history are included in new and 
relapses. 

Note: data up to 2012 include new TB cases only. 

TB cases by geographical origin, 2011–2020

TB/HIV coinfection, 2011–2020

Native

Foreign origin

Unknown

HIV testing coverage
Proportion of HIV-positive TB cases among tested

TB cases

50 000

40 000

30 000

s
e
s
a
C

20 000

10 000

0

2012

2014

2016

2018

2020

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

60 000

50 000

40 000

30 000

20 000

10 000

C
a
s
e
s

2012

2014

2016

2018

0

2020

RR/MDR-TB cases and percentage of RR/MDR-TB cases by previous 
treatment history among all TB cases, 2011–2020

Treatment outcome, new and relapse TB cases, 2010–2019

New
Retreatment
Total number of RR/MDR-TB

Unknown

Success
Died

Failed
Lost to follow -up

Not evaluated

Note: data up to 2014 include all TB cases.

9000
8000
7000
6000
5000
4000
3000
2000
1000
0

C
a
s
e
s

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

2012

2014

2016

2018

2020

2011

2013

2015

2017

2019

Note: 2010–2011 cohorts include new cases only.

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

174

SURVEILLANCE REPORTTuberculosis surveillance and monitoring in Europe 2022 
 
United Kingdom

Total population at 9 April 2021 by EUROSTAT: 67 886 004

TB cases, 2020

Notifications

Total number of cases
Notification rate per 100 000
Newa and relapse
Newa and relapse notification rate 
per 100 000
Pulmonary
  of which microscopy-positive
  of which laboratory-confirmed
Laboratory-confirmed TB cases
Mean age of new native TB cases
Mean age of new foreign TB cases
Foreign origin of all TB cases
New (not previously treated)
Estimates
Estimated new and relapse cases N, 
best [low–high]

 4 458
6.6
 4 185

6.2

 2 419
–
 1 927
–

(54.3%)
–
(79.7%)
–
42.4 years
–

3 123
 4 185

(70.1%)
(93.9%)

4 700

[4 200–5 200]

a Cases with unknown previous TB history included in new cases.

Drug resistance surveillance and TB/HIV 
coinfection, 2020

Completeness of DRS dataa
Completeness of HIV datab
Case-linked data-reporting
Cases with DST results
Estimated RR-TB among notified 
bacteriologically confirmed 
pulmonary TB cases N, best 
[low–high]
Pulmonary RR/MDR-TB cases notified
  of which pre-XDR-TB cases
Notified RR/MDR-TB
  of which pre-XDR-TB cases
TB cases tested for HIV
HIV-positive TB cases
  of these on ART

Yes
No
Yes

1 622

(84.2%)

40

[27–53]

35
8
–
–
–
–
–

(2.2%)
(25.0%)
–
–
–
–
–

a National coverage 100% or culturing ≥ 90%, C+/all TB cases  
> 50%, DST done for C+ > 75%, EQA ≥ 95%.
b More than 50% of TB cases with reported HIV status.

Treatment outcome monitoring

Geographical 
coverage

Outcome cohort

Case-linked 
data-reporting
Cases notified
Success
Died
Failed
Lost to follow-up
Still on treatment
Not evaluated

National

New culture-positive 
pulmonary TB cases 
notified in 2019a

RR/MDR TB cases 
enrolled into DR-TB 
treatment in 2018b

Yes

4 739

3 675
229
0
208
627
72

(77.5%)
(4.8%)
(0.0%)
(4.4%)
(13.2%)
(3.7%)

–

40

30
2
0
4
4
7

(75.0%)
(5.0%)
(0.0%)
(10.0%)
(10.0%)
(14.0%)

a Treatment outcome as presented is treatment outcome after 12 months.
b Treatment outcome as presented is treatment outcome after 24 months.

TB notification rates by previous treatment history, 2011–2020

New and relapse
Other 

Unknown
Total

New and relapse TB cases – notification rates by age group, 
2011–2020

0–14

15–44

45–64

> 64

0
0
0
0
0
1
/
s
e
s
a
C

16

14

12

10

8

6

4

2

0

2012

2014

2016

2018

2020

0
0
0
0
0
1
/
s
e
s
a
C

25

20

15

10

5

0

2012

2014

2016

2018

2020

TB cases by geographical origin, 2011–2020

TB/HIV coinfection, 2011–2020

s
e
s
a
C

7000

6000

5000

4000

3000

2000

1000

0

Native

Foreign origin

Unknown

2012

2014

2016

2018

2020

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

HIV testing coverage
Proportion of HIV-positive TB cases among tested
10000

All TB cases

8000

6000

4000

2000

C
a
s
e
s

2012

2014

2016

2018

0

2020

RR/MDR-TB cases and percentage of RR/MDR-TB cases by previous 
treatment history among all TB cases, 2011–2020

Treatment outcome, new culture-confirmed pulmonary TB cases, 
2010–2019

New
Retreatment
Total number of RR/MDR-TB

Unknown

Success
Died

Still on treatment
Lost to follow-up

Failed
Not evaluated

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

100

80

60

40

20

C
a
s
e
s

2012

2014

2016

2018

0

2020

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

2011

2013

2015

2017

2019

175

Tuberculosis surveillance and monitoring in Europe 2022SURVEILLANCE REPORT 
 
 
Uzbekistan

Total population estimate 2020 by United Nations Statistical Database: 33 469 199

TB cases, 2020

Notifications

Total number of cases
Notification rate per 100 000
Newa and relapse
Newa and relapse notification rate 
per 100 000
Pulmonary
  of which microscopy-positive
  of which laboratory-confirmed
Laboratory-confirmed TB cases
Mean age of new native TB cases
Mean age of new foreign TB cases
Foreign origin of all TB cases
New (not previously treated)
Estimates
Estimated new and relapse cases N,  
best [low–high]

 14 127
42.2
 12 111

36.2

 9 503
–
 5 713
–

(67.3%)
–
(60.1%)
–
40.6 years
–

0
 10 893

(0.0%)
(77.1%)

22 000

[15 000–30 000]

a Cases with unknown previous TB history included in new cases.

Drug resistance surveillance and TB/HIV 
coinfection, 2020

Completeness of DRS dataa
Completeness of HIV datab
Case-linked data-reporting
Cases with DST results
Estimated RR-TB among notified 
bacteriologically confirmed 
pulmonary TB cases N, best 
[low–high]
Pulmonary RR/MDR-TB cases 
notified
  of which pre-XDR-TB cases
Notified RR/MDR-TB
  of which pre-XDR-TB cases
TB cases tested for HIV
HIV-positive TB cases
  of these on ART

Yes
Yes
Yes

5 713

(100.0%)

1 400

[1 300–1 500]

1 400

378
1778
378
12 111
379
287

(24.5%)

(27.0%)
–
(21.3%)
(100.0%)
(3.1%)
(75.7%)

a National coverage 100% or culturing ≥ 90%, C+/all TB cases 
> 50%, DST done for C+ > 75%, EQA ≥ 95%.
b More than 50% of TB cases with reported HIV status.

Treatment outcome monitoring

Geographical 
coverage

Outcome cohort

Case-linked 
data-reporting
Cases notified
Success
Died
Failed
Lost to follow-up
Not evaluated

National

New and relapse 
TB cases notified 
in 2019a

RR/MDR TB cases 
enrolled into DR-TB 
treatment in 2018b

Yes

14 224

–

2 039

12 820
548
227
353
276

(90.1%)
(3.9%)
(1.6%)
(2.5%)
(1.9%)

1 375
278
120
173
93

(67.4%)
(13.6%)
(5.9%)
(8.5%)
(4.6%)

a Treatment outcome as presented is treatment outcome after 12 months.
b Treatment outcome as presented is treatment outcome after 24 months.

TB notification rates by previous treatment history, 2011–2020

New and relapse
Other

Unknown
Total

New and relapse TB cases – notification rates by age group, 
2011–2020

0–14

15–44

45–64

> 64

0
0
0
0
0
1
/
s
e
s
a
C

90
80
70
60
50
40
30
20
10
0

0
0
0
0
0
1
/
s
e
s
a
C

200

150

100

50

0

2012

2014

2016

2018

2020

2012

2014

2016

2018

2020

Note: starting from 2013 onward, cases with unknown history are included in new and 
relapses. 

Note: data up to 2012 include new TB cases only. 

TB cases by geographical origin, 2011–2020

TB/HIV coinfection, 2011–2020

Native

Foreign origin

Unknown

HIV testing coverage
Proportion of HIV-positive TB cases among tested

TB cases

30 000

25 000

20 000

s
e
s
a
C

15 000

10 000

5000

0

2012

2014

2016

2018

2020

e
g
a
t
n
e
c
r
e
P

120

100

80

60

40

20

0

30 000

25 000

20 000

15 000

10 000

5000

C
a
s
e
s

2012

2014

2016

2018

0

2020

RR/MDR-TB cases and percentage of RR/MDR-TB cases by previous 
treatment history among all TB cases, 2011–2020

Treatment outcome, new and relapse TB cases, 2010–2019

New
Retreatment
Total number of RR/MDR-TB

Unknown

Success
Died

Failed
Lost to follow-up

Not evaluated

Note: data up to 2014 include all TB cases. 

7000

6000

5000

4000

3000

2000

1000

C
a
s
e
s

2012

2014

2016

2018

0

2020

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

2011

2013

2015

2017

2019

Note: 2010–2011 cohorts include new cases only.

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

176

SURVEILLANCE REPORTTuberculosis surveillance and monitoring in Europe 2022 
 
EU publications
You  can  download  or  order  free  and  priced  EU  
publications at: https://publications.europa.eu/en/web/
general-publications/publications. Multiple copies of 
free publications may be obtained by contacting Europe 
Direct or your local information centre (see http://
europa.eu/contact).

Address requests about publications of 
the WHO Regional Office for Europe to:
Publications
WHO Regional Office for Europe
UN City, Marmorvej 51
DK-2100 Copenhagen Ø, Denmark

Alternatively, complete an online request 
for m  on  the  Regional  Of f ice  website  
(http://www.euro.who.int/pubrequest).

European Centre for Disease 
Prevention and Control (ECDC)

World Health Organization 
Regional Office for Europe

Gustav den III:s Boulevard 40, SE-169 73, Solna, Sweden

UN City, Marmorvej 51, DK-2100 Copenhagen Ø, Denmark

Tel. +46 858 60 10 00
Fax +46 858 60 10 01
www.ecdc.europa.eu 

Contact us 
publications@ecdc.europa.eu

 Follow us on Twitter 

@ECDC_EU

 Like our Facebook page 
www.facebook.com/ECDC.EU

Tel. +45 45 33 70 00
Fax +45 45 33 70 01
www.euro.who.int

Contact us 
eurocontact@who.int

 Follow us on Twitter 

@WHO_EUROPE

 Like our Facebook page 

www.facebook.com/WHOEurope

ECDC PDF 

ISBN 978-92-9498-567-5

WHO ISBN	

978-92-890-5782-0